<SEC-DOCUMENT>0001213900-24-028718.txt : 20240401
<SEC-HEADER>0001213900-24-028718.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401160550
ACCESSION NUMBER:		0001213900-24-028718
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		24809132

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0202277-10k_immu.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 18:01:47 UTC 2024 -->
<html xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:iccc="http://immucell.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-17757">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-17758"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-17759">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-17760">2023</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-58"><b><span style="text-decoration:underline">001-12934</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission file number)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-70"><b><span style="text-decoration:underline">ImmuCell Corporation</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center; font-weight: bold"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-84"><b>Delaware</b></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center; font-weight: bold"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center; font-weight: bold"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-89"><b>01-0382980</b></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; text-align: center"><b>(State of incorporation)</b></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: bottom; text-align: center"><b>(I.R.S. Employer <br/>
Identification No.)</b></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center; font-weight: bold"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-17761">56 Evergreen Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-17762">Portland</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-17763">Maine</ix:nonNumeric></b></td> <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center; font-weight: bold"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center; font-weight: bold"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-110"><b>04103</b></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: bottom; text-align: center"><b>(Address of principal executive offices)</b></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: bottom; text-align: center"><b>(Zip Code)</b></td></tr> </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-17764">(207)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-17765">878-2770</ix:nonNumeric></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center; font-size: 10pt"><span style="font-size: 10pt"><b>Trading symbol(s)</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center; font-size: 10pt"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-155"><span style="font-size: 10pt">Common Stock, $0.10 par value per share</span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-159"><span style="font-size: 10pt">ICCC</span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-163"><span style="font-size: 10pt">Nasdaq</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-17766">No</ix:nonNumeric> </span><span style=" font-size: 10pt">&#9745;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-17767">No</ix:nonNumeric> </span><span style=" font-size: 10pt">&#9745;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-17768">Yes</ix:nonNumeric> </span><span style=" font-size: 10pt">&#9745;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;No
&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-17769">Yes</ix:nonNumeric> </span><span style=" font-size: 10pt">&#9745;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
accelerated filer &#9744; Accelerated filer &#9744; <ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-17770">Non-accelerated filer</ix:nonNumeric> </span><span style=" font-size: 10pt">&#9745; </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span><span style=" font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-17771">&#9745;</ix:nonNumeric> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-17772">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-17773">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-17774">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that require a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No </span><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-259"><span style=" font-size: 10pt">&#9745;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates at June 30, 2023 was approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-17775">31,165,000</ix:nonFraction>
based on the closing sales price on June 30, 2023 of $5.00 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of the registrant&#8217;s common stock outstanding as of March 8, 2024 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17776">7,750,864</ix:nonFraction>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2023</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 10%">&#160;</td>
    <td style="vertical-align: bottom; width: 81%; text-align: center"><b><span style="text-decoration:underline"><a href="#a_001">PART I</a></span></b></td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 1</td>
    <td style="vertical-align: bottom"><a href="#a_002">Business</a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 1A</td>
    <td style="vertical-align: bottom"><a href="#a_003">Risk Factors</a></td>
    <td style="vertical-align: bottom; text-align: center">11</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 1B</td>
    <td style="vertical-align: bottom"><a href="#a_004">Unresolved Staff Comments</a></td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 1C</td>
    <td style="vertical-align: bottom"><a href="#a_005">Cybersecurity</a></td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 2</td>
    <td style="vertical-align: bottom"><a href="#a_006">Properties</a></td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 3</td>
    <td style="vertical-align: bottom"><a href="#a_007">Legal Proceedings</a></td>
    <td style="vertical-align: bottom; text-align: center">22</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 4</td>
    <td style="vertical-align: bottom"><a href="#a_008">Mine Safety Disclosures</a></td>
    <td style="vertical-align: bottom; text-align: center">22</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center; vertical-align: top"><a href="#a_009"><b><span style="text-decoration:underline">PART II</span></b></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 5</td>
    <td style="vertical-align: bottom"><a href="#a_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
    <td style="vertical-align: bottom; text-align: center">23</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 6</td>
    <td style="vertical-align: bottom"><a href="#a_011">[Reserved]</a></td>
    <td style="vertical-align: bottom; text-align: center">23</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 7</td>
    <td style="vertical-align: bottom"><a href="#a_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="vertical-align: bottom; text-align: center">23</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 7A</td>
    <td style="vertical-align: bottom"><a href="#a_014">Quantitative and Qualitative Disclosures about Market Risk</a></td>
    <td style="vertical-align: bottom; text-align: center">38</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 8</td>
    <td style="vertical-align: bottom"><a href="#a_015">Financial Statements and Supplementary Data</a></td>
    <td style="vertical-align: bottom; text-align: center">38</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 9</td>
    <td style="vertical-align: bottom"><a href="#a_016">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</a></td>
    <td style="vertical-align: bottom; text-align: center">38</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 9A</td>
    <td style="vertical-align: bottom"><a href="#a_017">Controls and Procedures</a></td>
    <td style="vertical-align: bottom; text-align: center">38</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 9B</td>
    <td style="vertical-align: bottom"><a href="#a_018">Other Information</a></td>
    <td style="vertical-align: bottom; text-align: center">39</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 9C</td>
    <td style="vertical-align: bottom"><a href="#a_019">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
    <td style="vertical-align: bottom; text-align: center">39</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center; vertical-align: top"><a href="#a_020"><b><span style="text-decoration:underline">PART III</span></b></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 10</td>
    <td style="vertical-align: bottom"><a href="#a_021">Directors, Executive Officers and Corporate Governance</a></td>
    <td style="vertical-align: bottom; text-align: center">40</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 11</td>
    <td style="vertical-align: bottom"><a href="#a_022">Executive Compensation</a></td>
    <td style="vertical-align: bottom; text-align: center">44</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 12</td>
    <td style="vertical-align: bottom"><a href="#a_023">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
    <td style="vertical-align: bottom; text-align: center">47</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 13</td>
    <td style="vertical-align: bottom"><a href="#a_024">Certain Relationships and Related Transactions, and Director Independence</a></td>
    <td style="vertical-align: bottom; text-align: center">48</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 14</td>
    <td style="vertical-align: bottom"><a href="#a_025">Principal Accountant Fees and Services</a></td>
    <td style="vertical-align: bottom; text-align: center">48</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center; vertical-align: top"><a href="#a_026"><b><span style="text-decoration:underline">PART IV</span></b></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 15</td>
    <td style="vertical-align: bottom"><a href="#a_027">Exhibits and Financial Statement Schedules</a></td>
    <td style="padding-left: -0.125in; vertical-align: bottom; text-align: center">51</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 16</td>
    <td style="vertical-align: bottom"><a href="#a_028">Form 10-K Summary</a></td>
    <td style="vertical-align: bottom; text-align: center">53</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="#fin_003">Audited Financial Statements</a></td>
    <td style="vertical-align: bottom; text-align: center">F-1 to F-25</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="#a_029">Signatures</a></td>
    <td style="vertical-align: bottom; text-align: center"/></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1 &#8211; BUSINESS</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cautionary Note Regarding Forward-Looking Statements (Safe Harbor
Statement):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Annual Report on Form 10-K (Annual Report) contains &#8220;forward-looking
statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can
be identified by the fact that they do not relate strictly to historical or current facts, and will often include words such as &#8220;expects&#8221;,
&#8220;may&#8221;, &#8220;anticipates&#8221;, &#8220;aims&#8221;, &#8220;intends&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;,
&#8220;will&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;targets&#8221;, &#8220;projects&#8221;,
&#8220;forecasts&#8221;, &#8220;seeks&#8221; and similar words and expressions. Such statements include, but are not limited to, any forward-looking
statements relating to: our plans and strategies for our business; projections of future financial or operational performance; the timing
and outcome of pending or anticipated applications for regulatory approvals; future demand for our products; the extent, nature and duration
of the COVID-19 pandemic and its consequences, and their direct and indirect impacts on our production activities, operating results and
financial condition and on the customers and markets that we serve; the impact of Russia&#8217;s unprovoked military invasion of Ukraine
(and attack on its people) and the war in the Middle East on the world economy including inflation and the price and availability of grain
and oil; the impact of the global supply-chain disruptions on our ability to obtain, in a timely and cost-effective fashion, all the supplies
and components we need to produce our products; the impact of inflation and rising interest rates on our operating expenses and financial
results; the scope and timing of ongoing and future product development work and commercialization of our products; future costs of product
development efforts; the estimated prevalence rate of subclinical mastitis and producers&#8217; level of interest in treating subclinical
mastitis given the current economic and market conditions; the expected efficacy of new products; estimates about the market size for
our products; future market share of and revenue generated by current products and products still in development; our ability to increase
production output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or those of third parties
with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships;
the efficacy, success and timeline to complete our contamination remediation efforts; the likelihood, severity or impact of future contamination
events; the anticipated costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds
available for these projects; the robustness of our manufacturing processes and related technical issues; estimates about our production
capacity, efficiency and yield; future regulatory requirements relating to our products; future expense ratios and margins; the efficacy
of our investments in our business; future compliance with bank debt covenants; anticipated changes in our manufacturing capabilities
and efficiencies; our effectiveness in competing against competitors within both our existing and our anticipated product markets; projections
about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical
facts. These statements are intended to provide management's current expectation of future events as of the date of this earnings release,
are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance.
Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational
performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including,
but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production
and marketing of our products (including the <b>First Defense<sup>&#174;</sup></b> product line and <b>Re-Tain<sup>&#174;</sup></b>), competition
within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our
manufacturing resources and product demand (including the consequences of backlogs), uncertainty associated with the timing and volume
of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and
supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity, and other
risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our
Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and
uncertainties and are based on our current expectations, but actual results may differ materially due to various factors, including the
risk factors summarized under <b>PART I: ITEM 1A &#8211; RISK FACTORS</b> of this Annual Report and uncertainties otherwise referred to
in this Annual Report. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those
that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from
time to time, whether as a result of new information, future developments or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>OUTLINE TO ITEM 1 &#8211; BUSINESS:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">-</td><td style="text-align: justify"><b>Summary</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Production Capacity Increase and Product Contamination</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Animal Health Products</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Sales and Markets</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Product Development</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Competition</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Intellectual Property</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Government Regulation</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Employees</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">-</td><td><b>Public Information</b></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ImmuCell Corporation was founded in 1982 and completed
an initial public offering of common stock in 1987. After achieving approval from the Center for Veterinary Biologics, U.S. Department
of Agriculture (USDA) to sell <b>First Defense</b><sup>&#174;</sup> in 1991, we focused most of our efforts during the 1990&#8217;s attempting
to develop human product applications of the underlying milk protein purification technology. Beginning in 1999, we re-focused our business
strategy on the <b>First Defense</b><sup>&#174;</sup> product line and other products that improve the health and productivity of dairy
and beef cattle. We support the dairy and beef industries&#8217; purpose to produce nutritious, protein-rich food efficiently while ensuring
food quality and safety. Our products help address the growing human health concern about using less antibiotics in food-producing animals.
We aim to capitalize on the growth in sales of the <b>First Defense</b><sup>&#174;</sup> product line (a product that provides significant
<b>Immediate Immunity<span style="font-family: Times New Roman, Times, Serif">&#8482;</span></b> to newborn dairy and beef livestock)
and to revolutionize the mastitis treatment paradigm with <b>Re-Tain</b><sup>&#174;</sup><span style="font-family: Times New Roman, Times, Serif">,
</span>a novel product we are developing to treat this most significant cause of economic loss to the dairy industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2000, we began the development of <b>Re-Tain</b><sup>&#174;</sup><span style="font-family: Times New Roman, Times, Serif">,</span>
our purified Nisin treatment for subclinical mastitis in lactating dairy cows. No sales of this product can be made without prior approval
of our New Animal Drug Application (NADA) by the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA). We have achieved
FDA approval for four out of five of the significant Technical Sections required for product approval, and we have made our third submission
of the fifth Technical Section. We expect a response to this third submission from the FDA by May of 2024. Regulatory achievements to
date have significantly reduced the product development risks in the areas of safety and effectiveness. Our primary product development
focus has now turned to completion of the manufacturing objectives required for FDA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since 2006, we have made ongoing efforts to maintain
compliance with current Good Manufacturing Practice (cGMP) regulations in all of our manufacturing operations, which requires a sustained
investment that further enhances the quality of all of our products and our operating efficiency. As we make process improvements, we
continue to invest in personnel, equipment and facility modifications to increase the efficiency and quality of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the eight-year period beginning January 1,
2016 and ended December 31, 2023, we funded our operations, constructed an FDA-regulated Drug Substance (DS) manufacturing facility for
<b>Re-Tain</b><sup>&#174;</sup> and invested capital to increase our production capacity for the <b>First Defense</b><sup>&#174; </sup>product
line. We have also initiated another capital investment (which investment is currently paused) to bring the formulation and aseptic filling
capabilities for <b>Re-Tain</b><sup>&#174;</sup> in house in order to end our present reliance on an outside contractor. From the first
quarter of 2016 through the second quarter of 2021, we issued an aggregate of 4,553,017 shares of common stock, raising gross proceeds
of approximately $26.7 million in six separate transactions. In order to minimize the dilutive effects of these transactions on our existing
stockholders, we chose not to issue any form of convertible or preferred securities and issued these common shares without any warrants.
Net of debt issuance and debt discount costs, we had approximately $12 million in outstanding debt as of December 31, 2023 compared to
approximately $3.2 million as of December 31, 2015. This equity and debt capital has been, and is being, used to increase the production
capacity for the <b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b> product line and
complete the development of <b>Re-Tain</b><sup>&#174;</sup> without relying on funding from a partner or licensee, thereby keeping control
over all product rights and future revenues. During this time, our total assets have increased to $43.8 million as of December 31, 2023
from $14.6 million as of December 31, 2015, and our stockholders&#8217; equity has increased to $25 million as of December 31, 2023 from
$10.6 million as of December 31, 2015. This represents a 200%, or $29 million, increase in total assets and a 135%, or $14.4 million,
increase in stockholders&#8217; equity over this eight-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Production Capacity Increase and Product Contamination</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2018, it became clear that demand for
<b>Tri-Shield First Defense<sup>&#174;</sup></b> was outpacing production. In response to this increasing demand, we began a series of
investments during 2019 to increase our production capacity for the <b>First Defense</b><sup>&#174;</sup> product line to approximately
$30 million per year. The necessary facility expansions and new equipment needed to increase production capacity were in place by the
end of 2022. See <b>PART II: ITEM 7 &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b>,
for more detail about our investments to increase production capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As this increased production capacity was coming
online, a product contamination event was detected by standard in-process quality control testing around the end of the third quarter
of 2022. Scrapped product from contamination events (largely this one around the end of the third quarter) and other production process
losses resulted in a total charge to costs of goods sold of approximately $589,000 during 2022. We took immediate steps to address the
contamination, and production ran without issue during the balance of the fourth quarter of 2022. Then during the first quarter of 2023,
our standard in-process quality control testing detected a second contamination event. We slowed down our production output to take the
necessary steps to assess and remediate the issues and perform a deep sanitization of our facilities and process equipment. After several
months of processing without further contamination, we experienced a third contamination event during the third quarter of 2023. Scrapped
product from contamination events and other production process losses resulted in a total charge to costs of goods sold of approximately
$527,000 during 2023. We believe that the ongoing implementation of our capacity expansion plans and the corrective actions being taken
in response to these contamination events should allow us to operate at the higher level of production output going forward without further
significant contaminations. We worked diligently to address the situation and believe we are taking the appropriate steps to emerge from
this problem stronger with the production capacity in place to produce approximately $30 million of product per year going forward, while
continuing to ensure that any product that is put to market meets all quality standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that our efforts to increase production
capacity for the <b>First Defense<sup>&#174;</sup></b> product line are linked to our product contaminations. It was relatively simple
to run at lower production capacities for the 30 years between 1991 (the original USDA approval of <b>First Defense</b><sup>&#174;</sup>)
and 2021. The contamination events we suffered during 2022 and 2023 were largely the result of us processing more milk (colostrum) than
ever before in order to meet increasing customer demand. As we enter 2024, we believe that we have much improved processes and controls
in place to better support large-scale production from our raw material source farms through liquid processing. Our most important customer-focused
objectives going forward are to fulfill the large backlog of orders and then again be a reliable supplier of a very effective product
to the dairy and beef calf market.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Animal Health Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The <b>First Defense</b><sup>&#174; </sup>product
line is manufactured from hyperimmunized cows&#8217; colostrum (the antibody rich milk that a cow produces immediately after giving birth)
utilizing our proprietary vaccine and milk protein purification technologies. The <b>First Defense</b><sup>&#174;</sup> product line provides
bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. The target disease, calf scours
(bovine enteritis), causes diarrhea and dehydration in newborn calves and often leads to serious sickness and even death. The <b>First
Defense</b><sup>&#174;</sup> <b>product line </b>is the only USDA-licensed, orally delivered scours preventive product on the market
for calves with claims against <i>E. coli</i>, coronavirus and rotavirus (three leading causes of scours). A single dose of our product
provides a measured level of protection proven to reduce mortality and morbidity. Our pre-formed antibody products provide <b>Immediate
Immunity&#8482; </b>during the first few critical weeks of life when calves need this protection most. Studies have shown calves that
scour are more susceptible to other diseases later in life and under-perform calves that do not contract scours. The direct, two-part
mode-of-action of the <b>First Defense</b><sup>&#174;</sup> product line delivers specific immunoglobulins at the gut level to immediately
protect against disease, while also providing additional antibodies that are absorbed into the bloodstream. These circulating antibodies
function like a natural timed-release mechanism, as they are re-secreted into the gut later to provide extended protection. The <b>First
Defense</b><sup>&#174;</sup> product line is convenient to use. A calf needs to receive only one dose of <b>First Defense</b><sup>&#174;
</sup>within the first twelve hours after birth. Our capsule format of this product, which requires no mixing, is stored at room temperature,
while the gel tube formats of this product require refrigeration in accordance with product label indications. We are the market leader
(in terms of both unit volume and dollar sales) when compared to other calf-level scours preventatives and have greater market potential
as we gain market share from the dam-level (pre-calving scour vaccines) competitors. The third quarter of 2023 marked the 32<sup>nd</sup>
anniversary of the original USDA approval of this product in 1991. During the fourth quarter of 2023, our cumulative sales of <b>First
Defense</b><sup>&#174;</sup> since inception exceeded 33 million doses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The product line extension, <b>Tri-Shield First
Defense<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#174;</sup></span></b>, is the first calf-level,
passive antibody product on the market with USDA-approved disease claims providing <b>Immediate Immunity&#8482;</b> against each of the
three leading causes of calf scours (<i>E. coli</i>, coronavirus and rotavirus). This product achieved USDA approval during the fourth
quarter of 2017 and was listed with the Organic Materials Research Institute (OMRI) during the first quarter of 2019, which means it
can be used on organic farms. <b>Tri-Shield</b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#174;</sup></span>
combines the <i>E. coli</i> and coronavirus antibodies contained in our bivalent product with rotavirus antibodies in a single-dose gel
tube delivery format. This unique breadth of claims further differentiates our product from calf-level competitive products on the market
that contain only one or two of these label claims. The unique virus-like particle (VLP) technology that is used in our production process
increases rotavirus titers in colostrum to a level much greater than traditional vaccine technology can. Because it is possible that
some farms may not have (or perceive to have) a rotavirus problem, we are continuing to sell the bivalent formats of the <b>First Defense<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#174;
</sup></span></b>product line as options for customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The <b>First Defense<sup>&#174;</sup></b> product
line continues to benefit from wide acceptance by dairy and beef producers as an effective tool to prevent scours in newborn calves, which
is the leading cause of death in preweaned calves. Our <b>Beyond Vaccination<sup>&#174;</sup></b> marketing campaign focuses on providing
antibodies without vaccination. A 100% vaccine protection rate is biologically impossible. The <b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>
product line removes the variability associated with a scour vaccine response and instead provides a measured level of pre-formed antibodies,
protecting each calf with an equal level of scours protection. There is a strong link between how we sell our product and the challenges
we face in producing it. We know better than most how variable a cow&#8217;s response is to any vaccine. We see this in every batch of
<b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b> that we produce. The value in <b>First
Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b> is that we adjust for this variability by
standardizing the antibody content, as needed, so the newborn is given a steady, equal level of protection with each dose. This technology
removes a producer&#8217;s reliance on variable vaccine responses to generate passive antibody protection and instead protects every calf
equally with a measured dose of <b>Immediate Immunity<span style="font-family: Times New Roman, Times, Serif">&#8482; </span></b><span style="font-family: Times New Roman, Times, Serif">against
the most common scour pathogens.</span> Preventing newborn calves from becoming sick helps them to reach their genetic potential and reduces
the need to use treatment antibiotics later in life. <span style="font-family: Times New Roman, Times, Serif">Plus, an effectively treated
calf is much less likely to</span> require expensive antibiotic treatments or build antibiotic resistance. We are the only manufacturer
within the scour prevention space offering polyclonal multi-pathogen antibodies. The market is learning that the best preventative for
scours may not be a vaccine, and we are continuing to educate the market about the health benefits of a measured dose of pre-formed antibodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Historically, the most common tool to help combat
scours has been to vaccinate the mother cow (dam) with a scours vaccine and deliver the antibodies that she produces in her milk to the
newborn. It is generally believed that only 80% of animals respond to a vaccine, which could leave about 20% of calves unprotected. We
believe that the variability in a cow&#8217;s immune response to vaccines creates a sales opportunity for our product. Additionally, our
research suggests that treatment protocols for dam-level scours vaccine programs are not always followed, leaving even more calves compromised.
We are competing effectively against these dam-level vaccine products. Our marketing campaign, <b>Beyond Vaccination<sup>&#174;</sup></b>,
emphasizes that by delivering <b>Immediate Immunity&#8482;</b> directly to the calf via the <b>First Defense<sup>&#174;</sup></b>
product line, producers can reduce stress-causing injections to the cow. Reliance on a dam-level scours vaccine requires that money be
spent before it is known whether the cow is carrying a viable, valued calf. With the <b>First Defense<sup>&#174;</sup></b>
product line, that investment can be targeted to the calves that are most critical to the operation. This, in turn, can free up space
in the cow&#8217;s vaccination schedule to improve her immune response to vaccines that are critical to her health.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>First Defense Technology</b><sup>&#174;</sup>
is a unique whey protein concentrate that is processed utilizing our proprietary colostrum (first milk) protein purification methods,
for the nutritional and feed supplement markets without the claims of our USDA-licensed product. During 2012, we initiated a limited launch
of a gel tube delivery format of our <b>First Defense Technology</b><sup>&#174;</sup> in a gel solution. We achieved USDA claims for this
product format during the fourth quarter of 2018 and Canadian approval during the first quarter of 2019, and it is now being sold as <b>Dual-Force
First Defense</b><sup>&#174;</sup>. We are selling the same concentrated whey proteins in a bulk powder format (no capsule), which is delivered
with a scoop and mixed with colostrum for feeding to calves. We are working to achieve USDA claims for this product format. During 2011,
Milk Products, LLC of Chilton, Wisconsin launched commercial sales of their product, Ultra Start<sup>&#174;</sup> 150 Plus and certain
similar private label products, which are colostrum replacers with <b>First Defense Technology</b><sup>&#174;</sup> <b>Inside</b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2001, we began to offer our own, internally
developed <b>California Mastitis Test (CMT)</b>. <b>CMT </b>is most often used as a quick on-farm diagnostic to determine which quarter
of the udder is mastitic. This test can be performed at cow-side for early detection of mastitis. <b>CMT </b>products are also made by
other manufacturers and are readily available to the dairy producer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Sales and Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that the long-term growth in sales
of the <b>First Defense</b><sup>&#174;</sup> product line may reflect, at least in part, the success of our strategic decision to invest
in additional sales and marketing efforts to help us introduce the expanding <b>First Defense</b><sup>&#174;</sup> product line to new
customers. Our communications campaign continues to emphasize how the unique ability of the <b>First Defense</b><sup>&#174; </sup>product
line to provide <b>Immediate Immunity&#8482; </b>generates a dependable and competitive return on investment for dairy and beef producers.
Our sales and marketing team consists of one vice president, one commercial research and technical services veterinarian, one commercial
leader of stakeholder engagement, one director of marketing and eight regional sales managers. The <b>First Defense</b><sup>&#174;</sup>
product line and <b>CMT </b>are sold primarily through major animal health distributors who, in turn, sell to veterinary clinics, fleet
stores and direct to farms. Our expanded sales and marketing team has proven to be a worthy investment, validating that our message resonates
well with customers. Now that our increased production capacity is in place, we anticipate being able to escalate our growth curve after
we recover from the brand damage that can come with an extended duration of short supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sales of the <b>First Defense</b><sup>&#174;</sup>
product line are normally seasonal, with higher sales expected during the first quarter, largely driven by the beef calving season, which
runs primarily from January to April, unlike the dairy industry in which operations generally calve year round. Warm and dry weather
reduces the producer&#8217;s perception of the need for a disease preventative product like the <b>First Defense</b><sup>&#174; </sup>product
line. However, heat stress on calves caused by extremely hot summer weather can increase the incidence of scours, just as harsher winter
weather benefits our sales. Other competition for resources that dairy producers allocate to their calf enterprises has been increased
by the many new products (principally feed supplements) that have been introduced to the calf market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate that the total U.S. market for scours
preventative products (including sales of our product) that are given to newborn calves (the calf-level market) is approximately $25.6
million per year. With the additional claim for our new product (<b>Tri-Shield First Defense</b><sup>&#174;</sup>) against rotavirus, we
are now also competing against the dam-level vaccine products that are given to the mother cow to increase the antibody level against
specific scours-causing pathogens in the colostrum that she produces for her newborn. We estimate that the dam-level product category
covers approximately twice as many calves as the calf-level product segment reaches. We estimate that the total domestic addressable market
(both calf and dam levels) is approximately $75.4 million per year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Based
on market share information that we purchase from the leading source of this data for the animal health sector, we believe that we are
gaining market share in the United States year after year. </span>We aim to continue these market share gains in both the dairy and beef
segments. Our share of the dairy and beef market (calculated on the basis of calves treated) of the scour preventative products administered
at the calf-level was approximately:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 21%; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-align: center; text-indent: -10pt"><b>2019</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 21%; border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 18%; border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 19%; border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: center; text-indent: -10pt">36%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">41%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">43%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">44%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">48%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our share of the dairy and beef market (calculated
on the basis of calves treated) of both products administered at the calf-level and vaccines administered to the dam prior to calving
(adjusting for two doses of dam-level scour vaccines required for primary vaccination of first-calf heifers) was approximately:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 21%; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-align: center; text-indent: -10pt"><b>2019</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 21%; border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 18%; border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 19%; border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: center; text-indent: -10pt">11%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">13%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">13%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">14%</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">14%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We continue our efforts to grow sales of the <b>First
Defense</b><sup>&#174;</sup> product line in North America, where there are approximately 40 million dairy and beef cows in the United
States and approximately 4.5 million dairy and beef cows in Canada. We believe that significant market opportunities exist in other international
territories. The majority of our international sales are to Canada. We price our products in U.S. dollars. To the extent that the value
of the dollar declines with respect to any other currency, our competitive position may be enhanced. Conversely, an increase in the value
of the dollar in any country in which we sell products may have the effect of increasing the local price of our products, thereby leading
to a potential reduction in demand. Generally, our international sales have been generated through relationships with in-country distributors
that have knowledge of the local regulatory and marketing requirements. We are initiating our plan to expand the number of countries to
which our <b>First Defense</b><sup>&#174;</sup> product line is approved for export. Generally, it is our intent to be the holder of these
product registrations for each country rather than rely on distribution partners to gain and hold these registrations. This is a long
regulatory process but allows us to maximize the use of our product label claims. Industry practices, economic conditions, cause of disease,
distribution channels and regulatory requirements may differ in these international markets from what we experience in North America,
potentially making it more difficult or costly for us to generate and sustain sales volumes at profitable margins in these markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">We introduced <b>First Defense</b><sup>&#174;</sup>
into South Korea in 2005 through Medexx Co., Ltd of Gyeonggi-do, Korea and its equivalent into Japan in 2007 through NYS Co., Ltd of Iwate,
Japan. We are working with Medexx to expand our business in South Korea to include the registration of <b>Tri-Shield First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span>.</b>
The business in Japan is currently not active, but we are working to resume sales in this territory. We entered into distribution contracts
covering certain Middle Eastern countries with Triplest for Drugs and Trade of Madaba, Jordan during the first quarter of 2017 (no sales
have yet been achieved under this contract) and covering Iran with Senikco, LLC of Laguna Niguel, California during the fourth quarter
of 2016 (sales have been initiated under this contract). We are investigating the requirements to sell the <b>First Defense</b><sup>&#174;</sup>
product line in Mexico, Pakistan and India.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">With
</span><b>Re-Tain</b><sup>&#174;</sup>, <span style="font-family: Times New Roman, Times, Serif">we are working to expand our product portfolio
to include an intramammary infusion for the treatment of subclinical mastitis in lactating dairy cows. Mastitis is inflammation of the
mammary gland typically associated with a bacterial infection. It is estimated to cost the U.S. dairy industry approximately $2 billion
in economic harm per year. It is the most costly and common disease affecting the dairy industry. This illness is categorized as either
clinical mastitis or subclinical mastitis. Clinical mastitis infections cause visibly abnormal milk which cannot be sold. On the other
hand,&#160;subclinical mastitis infections do not cause any visible changes in milk or udder appearance, making it difficult to detect.
Most mastitis cases treated today are those that reach the clinical stage even though it is understood that clinical cases are only the
tip of the mastitis iceberg. Milk from cows with subclinical mastitis can still be sold if not treated with traditional antibiotics. Milk
from cows treated with traditional antibiotics must be discarded for the duration of the treatment and for 1.5 to 4 days after the last
treatment, depending on the antibiotic that was used. The cost of that milk discard along with the stress and risk in moving the cow to
the hospital pen is thought to be a primary reason more subclinical mastitis cases are not treated today. However, the cascade of negative
events triggered by subclinical mastitis for both the dairy producer and the milk processor are significant. These include lower milk
production (some have estimated approximately 1,500 pounds of lost milk, or about $270 at $18.00 per hundredweight per infected cow per
lactation), higher rates of clinical mastitis, lower conception rates, increased abortions, increased cull rates, reduced or foregone
milk quality premiums, shorter shelf life for fluid milk, and both lower yields and less flavor for cheese. C</span>ows with subclinical
mastitis maintain a reservoir of infection within the herd and increase exposure of healthy cows to contagious pathogens. Subclinical
mastitis also increases the risk of various quality defects on a variety of final dairy products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
active ingredient in </span><b>Re-Tain</b><sup>&#174; </sup><span style="font-family: Times New Roman, Times, Serif">is pharmaceutical-grade
Nisin-A. FDA approval for this drug would establish an entirely new class of anti-infective that is different from those currently available
to treat mastitis. This new class, called bacteriocins, are anti-microbial polypeptides with no resistance risk for human health. Bacteriocins
selectively target Gram+ bacteria, the same bacteria that commonly cause mastitis. We expect </span><b>Re-Tain</b><sup>&#174; </sup><span style="font-family: Times New Roman, Times, Serif">will
be the first FDA-approved intramammary treatment for subclinical mastitis without an FDA-required milk discard or meat withhold. This
gives us the opportunity to revolutionize the way mastitis is treated, since </span><b>Re-Tain</b><sup>&#174; </sup><span style="font-family: Times New Roman, Times, Serif">is
specifically designed to treat ahead of clinical signs without an FDA-required milk discard or meat withhold. As a result, we believe
that our product can help cows reach their peak milk production and not be sent to the hospital pen. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Referencing the big picture, we are introducing
an entirely new class of socially-responsible antimicrobials as an animal drug, a bacteriocin, that does not promote resistance against
antibiotics used in human medicine. As the great NHL hockey player, Wayne Gretzky, is known to have said, &#8220;I skate to where the
puck is going to be, not where it has been.&#8221; This is motivational to us. We believe our product fits very well with where the industry
is going to be in the coming years. Sustainability objectives of the industry require that less antibiotics be used in food producing
animals, yet a new product to treat mastitis has not been developed in years (other than new formulations of the same old stuff). The
over-use of antibiotics that are medically important to human healthcare is a growing concern of our society and an active issue with
the FDA, largely because of the growing evidence that this over-use contributes to antibiotic resistance. The industry could keep treating
this very significant disease with traditional antibiotics, but it takes innovation to bring a bacteriocin like Nisin to market. We believe
that societal animal welfare objectives will put more and more pressure on the industry to treat cows with subclinical infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
</span>Nisin is a naturally occurring bacteriocin that is not used in human medicines, it could alleviate some of the social and public
health concerns that the widespread use of antibiotics encourages the growth of antibiotic-resistant bacteria. For example, there is a
fear that the possible overuse of antibiotics in livestock undermines the effectiveness of these drugs to combat human illnesses and contributes
to a rising number of life-threatening human infections from antibiotic-resistant bacteria, commonly known as &#8220;superbugs&#8221;.
The FDA has expressed a commitment to addressing this public health risk. Citing concerns about untreatable, life-threatening infections
in humans, new FDA and European regulations are aimed at restricting the use of antibiotics (such as penicillin and cephalosporins) in
food animals and at improving milk quality. By reducing the risk of antibiotic residues and slowing the development of antibiotic-resistant
organisms, we believe that we can improve food quality and preserve medically important antibiotics for human disease treatment. This
current environment is favorable to the introduction of our new product as an alternative to traditional antibiotics. We believe that
this changing environment of new regulations and public opinion supports the value of our ongoing development and commercialization efforts
for <b>Re-Tain</b><sup>&#174;</sup>. Additionally, we believe that the use of our <b>First Defense</b><sup>&#174;</sup> product line is
consistent with this trend of reducing the use of antibiotics because the prevention of calf scours early in life with our purified colostrum
antibodies can reduce the need to use treatment antibiotics later in a calf&#8217;s life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We estimate that the approximate cost to the U.S.
dairy industry of discarded milk associated with the use of traditional antibiotic products currently on the market may be around $300
million per year. These high milk discard costs associated with traditional antibiotic treatments lead producers to only treat mastitis
after clinical signs develop. The <b>Re-Tain</b><sup>&#174;</sup> <span style="font-family: Times New Roman, Times, Serif">label will be
for subclinical mastitis (not clinical). Without an FDA-required milk discard or meat withhold cost, we expect producers to be more motivated
to identify and treat cows at the subclinical stage. In addition, we expect that</span> <b>Re-Tain</b><sup>&#174;</sup> likely will be
priced at a premium to the traditional antibiotic products currently on the market, which are all sold subject to milk discard and meat
withhold requirements. To validate our confidence in the value proposition of our product, we initiated a stochastic model led by researchers
at Michigan State University. This model simulated the dynamics of subclinical mastitis detected during the first week of lactation. The
study involved assessing probabilities of events, both production and health related, and their associated costs using a model grounded
in pathogen-specific assumptions drawn from peer-reviewed literature. The study indicated that treatment with our product generated a
positive economic benefit and was the optimal economic strategy for treating subclinical mastitis in most herds. The extent of the economic
benefit varies depending on factors such as bacteriological cure rates, parity of the animal and the cost of <b>Re-Tain</b><sup>&#174;</sup>.
These findings, which were subsequently published in the Journal of Dairy Science in January 2024, will guide our pricing strategies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">It
is difficult to accurately estimate the potential size of the subclinical mastitis market because presently this disease is largely left
untreated. We believe that approximately 20% to 40% of the U.S. dairy herd is infected with subclinical mastitis at any given time. This
compares to approximately 2% of the U.S. herd that is thought to be infected with clinical mastitis, where approximately $65 million per
year is spent on drug treatments. Rarely is an industry revolutionized overnight. Getting producers to change protocols to make subclinical
mastitis treatment a standard and routine procedure is going to take initiative, but we believe producers are eager for something new
and better since the FDA has not approved an intramammary treatment within the last 20 years. </span>Similar market opportunities are
likely to exist outside the United States. We believe the use of <b>Re-Tain</b><sup>&#174;</sup> could be expanded, with additional data
and regulatory approval, to support treatment late in lactation. We also believe there may be a market for <span style="font-family: Times New Roman, Times, Serif"><b>Re-Tain<sup>&#174;</sup></b></span>
in small ruminants, where the majority of mastitis cases are caused by strep-like organisms aligned with our effectiveness data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on consultations with industry experts
and key opinion leaders, we have opted to carefully control the launch of this novel product over the first 18 to 24 months after FDA
approval, as we seek to transform the way that mastitis is treated in the dairy industry over the long term, which we refer to as our
&#8220;Controlled Launch&#8221; strategy. Our goal is to help early adopters select treatment candidates, develop easy to use protocols,
optimize treatment results and realize a positive return on their investment. We intend to limit initial distribution of <b>Re-Tain<sup>&#174;
</sup></b>to a level that enables our sales team to select the optimal dairy farms at which to introduce <b>Re-Tain<sup>&#174; </sup></b>and
to limit the initial numbers of participating farms so that the desired levels of support and guidance relating to effective usage of
<b>Re-Tain<sup>&#174; </sup></b>can be provided with our available resources. Our overarching objective is to minimize the risk of early-stage
unsatisfactory outcomes that could harm the longer-term prospects and market acceptance of <b>Re-Tain<sup>&#174;</sup></b>. This strategy
is also prudent since our saleable inventory is fixed until an FDA-approved alternative contract manufacturer for aseptic filling is identified
or our own aseptic filling capability is developed and approved by the FDA. While we are dedicated to increasing our sales revenue, we
must consider the damage a mass market strategy could cause to the long-term value of the product. We have seen products sold by much
larger companies that were substantially damaged by such failed market launch strategies. We continue to develop detailed launch plans,
focusing on the readiness of dairy operators to successfully introduce <b>Re-Tain<sup>&#174;</sup></b> to their herds. We believe that
these prudent steps, while potentially leading to lower initial <b>Re-Tain<sup>&#174;</sup></b> revenues, may create a smooth and successful
launch and could safeguard the longer-term performance of our investment in <b>Re-Tain<sup>&#174;</sup></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect the DS production facility that we
constructed to have initial annual production capacity sufficient to meet approximately $7 million to $10 million in sales of <b>Re-Tain</b><sup>&#174;</sup>
at current production yields without factoring in potential yield improvements, but our supply of finished Drug Product (DP) will be limited
until we find an alternative aseptic formulation and filling capability, as discussed above. This production capacity estimate does not
yet reflect any inventory build strategies or ongoing yield improvement initiatives. We have available space in our existing facilities
to double the production capacity by installing a second equipment train. A decision on whether to use this space for a doubling of the
DS production capacity or for in-house aseptic formulation and filling DP equipment will be made post-approval. Our objective is to supply
initial market launch with approximately 100,000 to 150,000 doses of <b>Re-Tain</b><sup>&#174;</sup> (enough to treat up to 50,000 cows
with three doses per cow) that would be aseptically formulated and filled by our DP manufacturer. The expiry dates on this product would
be 18-24 months after the date of production, meaning that product expiry could be approximately between September of 2025 and March of
2026. We may not reach 50,000 cows during the Controlled Launch. Further, early adopters may be offered discounted or promotional goods
as an incentive to collaborate with us on data collection during the Controlled Launch. <span style="font-family: Times New Roman, Times, Serif">We
are expecting a pause in supply to the market after the Controlled Launch after goods produced by our contract DP manufacturer are consumed
and before we obtain FDA approval of an alternative DP manufacturing option. Although these projections are subject to many risks and
uncertainties (some of which are detailed in this Annual Report), if executed correctly, we believe this strategy will lend itself to
a more gradual adoption curve but higher and more sustainable sales over the long-term. In an effort to provide greater visibility into
the launch of <b>Re-Tain</b><sup>&#174;</sup>, we have expanded Note 17, &#8220;Segment Information&#8221;, to the accompanying audited
financial statements to now display a break-out of our financial results among the following three components of our business: i) Scours,
ii) Mastitis and iii) Other, in order to allow investors to see our progress with both products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Through our anticipated growth in sales of the <b>First
Defense</b><sup>&#174;</sup> product line, and as additional resources are dedicated to production, sales, marketing and technical services,
it is our objective to exceed our total product sales of approximately $17.5 million achieved during the year ended December 31, 2023
as soon as possible. Our longer-term goal is to exceed $35 million of annual total product sales as soon as possible during the four-year
period after the market launch of <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Product Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Most of our product development spending has been
focused on the development of <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>, our purified
Nisin treatment for subclinical mastitis in lactating cows. During the 24-year period that began on January 1, 2000 and ended on December
31, 2023, we invested an aggregate of approximately $28.1 million (excluding depreciation and the capital cost of our DS production facility)
in the development of this product. This estimation reflects only direct expenditures and includes no allocation of product development
or administrative overhead expenses. Approximately $2.9 million of this investment was offset by related product licensing revenues and
grant income, most of which was earned from 2001 to 2007.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2000, we acquired an exclusive license from
Nutrition 21, Inc. (formerly Applied Microbiology Inc. or AMBI) to develop and market Nisin-based products for animal health applications,
which allowed us to initiate the development of <b>Re-Tain<sup>&#174;</sup></b>. In 2004, we paid Nutrition 21 approximately $965,000 to
buy out this royalty and milestone-based license to Nisin, thereby acquiring control of the animal health applications of Nisin. Nisin
is a well characterized substance, having been used in food preservation applications for over 50 years. Food-grade Nisin, however, cannot
be used in pharmaceutical applications because of its low purity. A much less pure preparation of our active ingredient, Nisin, is commonly
used as a food preservative and has been given &#8220;Generally Regarded as Safe&#8221; (GRAS) status by the FDA. We are also investigating
potential applications of Nisin for other animal health applications as well as for humans. Our Nisin technology includes patented processing
and purification methods to achieve pharmaceutical-grade purity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2004, we entered into a product development and marketing agreement with Zoetis (formerly Pfizer Animal Health, a division of Pfizer,
Inc.) covering this product. That company elected to terminate the agreement in 2007. We believe that this decision was not based on any
unanticipated efficacy or regulatory issues. Rather, we believe the decision was primarily driven by a marketing concern relating to their
fear that the milk from treated cows could interfere with the manufacture of certain cultured dairy products. Due to the zero-milk discard
feature, there is a risk that Nisin from the milk of treated cows could interfere with the manufacture of certain (but not all) commercial
cultured dairy products, such as some kinds of cheese and yogurt, if a process tank contains a high enough percentage of milk from treated
cows. The impact of this potential interference ranges from a delay in the manufacturing process (which does happen at times for other
reasons) to the less likely stopping of a cheese starter culture. Milk from cows that have been treated with our product that is sold
exclusively for fluid milk products presents no such risk. We worked with scientists and mastitis experts to conduct a formal risk assessment
to quantify the impact that milk from treated cows may have on cultured dairy products. This study concluded that the dilution of milk
from treated cows through comingling with milk from untreated cows during normal milk hauling and storage practices reduces the risk of
interference with commercial dairy cultures to a negligible level when the product is used in accordance with the product label. Further,
we believe that such a premium-priced product will be used selectively, which reduces the risk of cheese interference and is consistent
with modern &#8220;precision dairying&#8221; practices that discourage the indiscriminate use of drug treatments. Among the measures that
we intend to deploy will be detailed guidance on limiting the portion of a herd that is treated with </span><b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">
at any one time in order to avoid concentration levels in the milk that could lead to the rejection of the contents in a cheese tank.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our second most important product development
initiatives (in terms of dollars invested and, we believe, potential market impact) have been focused on other improvements, extensions
or additions to our <b>First Defense</b><sup>&#174;</sup> product line. During the second quarter of 2009, we entered into a perpetual,
exclusive license with the Baylor College of Medicine covering the underlying rotavirus vaccine technology used to generate the specific
antibodies for use with animals. We achieved product license approval and initiated market launch of this product, <b>Tri-Shield First
Defense</b><sup>&#174;</sup>, during the fourth quarter of 2017. During the third quarter of 2018, we obtained approval from the Canadian
Food Inspection Agency to sell <b>Tri-Shield</b><sup>&#174;</sup> in Canada. We initiated sales in Canada through our in-country distributor
during the fourth quarter of 2019. We achieved USDA approval of our bivalent gel tube formulation (formerly marketed as <b>First Defense
Technology</b><sup>&#174;</sup>) during the fourth quarter of 2018 and have re-branded this product format as <b>Dual-Force First Defense</b><sup>&#174;</sup><b>.
</b>We are currently working to establish USDA claims for our bivalent bulk powder formulation of <b>First Defense Technology</b><sup>&#174;</sup>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also working to expand our product development
pipeline of antimicrobials that can be used as alternatives to traditional antibiotics through expansions of our Nisin technology and
yield improvements. We intend to begin new development projects that are aligned with our core competencies and market focus. We also
remain interested in acquiring, on suitable terms, other new products and technologies that fit with our sales focus on the dairy and
beef industries when we have adequate cash reserves.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our competition in the animal health market includes
other biotechnology companies and major animal health companies. Most, if not all, of these competitors have substantially greater financial,
marketing, manufacturing and human resources and more extensive product development capabilities than we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are several other products on the market
(some with claims and some without) that are delivered to newborn calves to prevent scours. We believe that the <b>First Defense</b><sup>&#174;
</sup>product line offers two significant competitive advantages. First, the <b>First Defense</b><sup>&#174;</sup> product line is the
only calf-level product that provides protection against <i>E. coli, </i>coronavirus and rotavirus, three of the leading causes of calf
scours. Second, being derived from colostrum, our product offers <b>Immediate Immunity<sup>TM</sup></b> through antibodies that both
function at the gut level and are absorbed into the blood stream for future protection. All formats of our product can be administered
immediately after birth and are not negatively affected by maternal colostrum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Zoetis sells a product (Calf-Guard<sup>&#174;</sup>)
that competes directly with the <b>First Defense</b><sup>&#174;</sup> product line in preventing scours via oral delivery to newborn calves.
Their product is a modified-live virus vaccine. Newborn calves respond poorly to vaccines and the immune system must be given time to
develop a response to vaccines. Both our product and Calf-Guard<sup>&#174;</sup> carry claims against coronavirus and rotavirus infections,
but this competing product does not carry a claim against <i>E. coli </i>infections like our product does. It is common practice to delay
colostrum feeding when dosing a calf with Calf-Guard<sup>&#174;</sup> so that the antibodies in the colostrum do not inactivate this vaccine
product. There is no nutritional or health benefit to withholding milk from newborn calves. In contrast, we encourage the feeding of four
quarts of high quality colostrum immediately after birth when dosing a calf with our product, which is standard practice for good calf
health. Because the antibodies in our product would likely work to inactivate a modified-live virus vaccine, rendering it useless or less
useful, our product label historically included a precaution that <b>First Defense</b><sup>&#174;</sup> should not be used within five
days of such a vaccine. During the first quarter of 2015, the USDA granted us permission to remove this precaution from our label, and
we have done so. We believe that this precaution should be required on the Calf-Guard<sup>&#174;</sup> label to prevent inactivation of
that product by <b>First Defense</b><sup>&#174;</sup> antibodies or by colostrum. Our product is priced at a premium to Calf-Guard<sup>&#174;</sup>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the fourth quarter of 2016, Merck launched
a new competing product into this market space. This product (BOVILIS<sup>&#174;</sup> Coronavirus) is a modified-live virus intranasal
vaccine that carries a claim against coronavirus only. <span style="font-family: Times New Roman, Times, Serif">Around the end of 2019,
Elanco Animal Health gave notice to the market that it had discontinued the manufacture of its competing products, Bovine Ecolizer<sup>&#174;</sup>
and Bovine Ecolizer + C20, and subsequently exited the market during the first quarter of 2021. This product was the smallest of our three
significant calf-level competitors. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">When compared to the other USDA-approved calf-level
scours preventatives, we lead in both sales dollars and calves treated within the U.S. market. This product category is comprised of the
three primary brands discussed above that are given either orally or intranasally to newborn dairy and beef calves immediately after birth.
With the rotavirus claim for our product (<b>Tri-Shield First Defense</b><sup>&#174;</sup>), we are now also competing against dam-level
vaccine products that are given to the mother cow to increase the antibody level against scours-causing pathogens in the colostrum that
she produces for her newborn. Those products are sold by Elanco (Scour Bos&#8482;), Merck (Guardian<sup>&#174;</sup>) and Zoetis (ScourGuard<sup>&#174;</sup>).
Despite the best-managed dam vaccine program, colostrum quality is naturally variable and newborn calves do not always get the antibodies
they need from maternal colostrum. We believe that the measured dose of antibodies in our product provides more consistent protection
than such vaccine products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We would consider any company that sells an antibiotic
to treat mastitis, such as Boehringer Ingelheim, Merck Animal Health and Zoetis, to be among the potential competitors with respect to
<b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>. We expect the FDA to grant a period of
five years of market exclusivity for our product (meaning the FDA would not grant approval to a second NADA with the same active drug
for a period of five years after the first NADA approval is granted) under Section 512(c)(2)F of the Federal Food, Drug, and Cosmetic
Act. Our Nisin A is produced from our high-yielding, proprietary <i>L. lactis</i> strain and purified to a high level, providing us with
a level of protection over a competitor that might try to develop a similar product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may not be aware of competition that we face,
or may face in the future, from other companies. Our competitive position will be highly influenced by our ability to attract and retain
key scientific, manufacturing, managerial and sales and marketing personnel, to develop and effectively produce and market proprietary
technologies and products. We need to obtain USDA, FDA or foreign approvals for new products to effectively promote and market our products.
We must have available properly-licensed, efficient and effective raw material and finished product manufacturing resources to continue
to profitably sell our current products. We currently compete on the basis of product performance, price, distribution capability and
customer support. We continue to monitor our network of independent distributors to maintain our competitive position.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 10pt">We own a broad
collection of registered and unregistered intellectual property rights relating to our research, products and processes. These rights
include patents, copyrights, trademarks, trade dress, trade secrets, know-how and other intellectual property rights in the United States
and other countries. We believe the ownership of our intellectual property rights is an important factor in our business and that our
success depends in part on such ownership. We also rely heavily on the innovative skills, technical competence and marketing abilities
of our personnel. The Nisin A that is produced from our proprietary strain of <i>L. lactis</i> is an essential component of our <b>Re-Tain</b></span><b><sup>&#174;
</sup></b><span style="font-size: 10pt">product and related intellectual property. We enter into and rely on confidentiality and proprietary
rights agreements with our employees, contractors and business partners to protect our trade secrets, proprietary developments and confidential
information. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We own U.S. Patent No. 10,023,617 entitled &#8220;Methods
and Systems of Producing Pharmaceutical Grade Lantibiotics&#8221;, which covers key, novel and proprietary aspects of our manufacturing
process for preparing pharmaceutical-grade Nisin and was issued during the third quarter of 2018. In the future, we may file additional
patent applications for certain products under development. There can be no assurance that patents will be issued with respect to any
pending or future applications. In some cases, we have chosen (and may choose in the future) not to seek patent protection for certain
products or processes. In those instances, we have sought (and may seek in the future) to maintain the confidentiality of any relevant
intellectual property and other proprietary rights through operational measures and contractual agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">We own numerous trademarks and trade dress that
are very important to our business and have several trademark and trade dress registrations in the United States, Canada and Iran. We
own the following U.S. trademark registrations: <b>IMMUCELL</b>, <b>FIRST DEFENSE</b>, <b>FD FIRST DEFENSE (&amp; Design), FIRST DEFENSE
TECHNOLOGY</b>, <b>TRI-SHIELD FIRST DEFENSE, TRI-SHIELD FIRST DEFENSE (&amp; Design), YOUR CALF CREW, BEYOND VACCINATION, BEYOND VACCINATION
(&amp; Design), CALF HERO, DUAL-FORCE, TRI-SHIELD and RE-TAIN. </b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">We
also own U.S. registrations claiming rights in the color blue for our blue gel and blue bolus</span> <b>FIRST DEFENSE </b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">products.
</span>We also own common law rights in the <b>IMMEDIATE IMMUNITY</b> trademark and other trademarks.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that we are in compliance with current
regulatory requirements relating to our business and products. The manufacture and sale of animal health biologicals within the United
States is generally regulated by the USDA. We have received USDA and Canadian Food Inspection Agency approval for the bolus format of
<b>First Defense</b><sup>&#174; </sup>and for the gel tube formats of <b>Tri-Shield First Defense</b><sup>&#174;</sup> and <b>Dual-Force
First Defense</b><sup>&#174;</sup>. <b>Re-Tain</b><sup>&#174;</sup> is regulated by the FDA, which regulates veterinary drugs. Regulations
in the European Union will likely require that <b>Re-Tain</b><sup>&#174;</sup> be sold subject to a milk discard requirement in that territory,
although the duration of the milk discard requirement may be shorter than the discard requirement applicable to competing antibiotic products
in that market. Comparable agencies exist in foreign countries, and foreign sales of our products will be subject to regulation by such
agencies. Many countries have laws regulating the production, sale, distribution or use of biological products, and we may have to obtain
approvals from regulatory authorities in countries in which we propose to sell our products. Depending upon the product and its applications,
obtaining regulatory approvals may be a relatively brief and inexpensive procedure or it may involve extensive clinical tests, incurring
significant expenses and an approval process of several years&#8217; duration. We generally rely on in-country experts to assist us with
or to perform international regulatory applications.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently employ 79 employees (including 5 part-time
employees) in comparison to 74 employees (including 7 part-time employees) approximately a year ago. Approximately 51 full-time equivalent
employees are engaged in quality and manufacturing operations, 13 full-time equivalent employees in sales and marketing, 7 full-time equivalent
employees in product development activities (primarily supporting facility maintenance and operation, regulatory filings and commercial
scale-up for <b>Re-Tain</b><sup>&#174;</sup>) and 6 full-time equivalent employees in finance and administration. As needed, we augment
our staff with contracted temporary employees. All of our employees are required to execute non-disclosure and invention assignment agreements
(and some are required to execute non-compete agreements) intended to protect our rights in our proprietary products. We are not a party
to any collective bargaining agreement and consider our employee relations to be excellent.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Public Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a reporting company, we file quarterly and annual reports with the
Securities and Exchange Commission (SEC) on Form 10-Q and Form 10-K, respectively. We also file current reports on Form 8-K, whenever
events warrant or require such a filing. The public may read and copy any materials that we file with the SEC at the SEC&#8217;s Public
Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an internet site that contains reports, proxy and information statements
and other information about us that we file electronically with the SEC at <i>http://www.sec.gov</i>. Our internet address is http://www.immucell.com.
References to our website in this Annual Report are inactive textual references only and the content of our website should not be deemed
incorporated by reference for any purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A&#8212; RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUTLINE TO ITEM 1A &#8211; RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Financial Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Product Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Regulatory Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Economic Risks Pertaining to the Dairy and Beef Industries</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Small Size of the Company</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Global Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Risk Pertaining to Common Stock</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Other Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Gross margin on product sales:</i> One of our goals is to achieve a gross margin (before related depreciation
expenses) as a percentage of total sales of 45% or more after the initial launch of new products. Depreciation expense will be a larger
component of costs of goods sold for <b>Re-Tain<sup>&#174;</sup></b> than it is for the <b>First Defense<sup>&#174;</sup></b> product line.
Gross margins generally improve over time, but this anticipated improvement may not be realized for <b>Re-Tain<sup>&#174;</sup></b>. Many
factors discussed in this Annual Report (including inflation, cost increases, supply-chain disruptions and the rising price of oil and
other commodities and supplies) impact our costs of goods sold. There is a risk that we are not able to achieve our gross margin goals,
which would adversely affect our operating results and could impact our future operating plans. We missed our gross margin goals in 2023
and 2022 with realized gross margins of 22% and 41%, respectively. There is also a risk that our plans to maintain or improve our gross
margin may not be realized due to cost increases, additional manufacturing contamination events, production equipment failures, the inability
to raise our selling prices, or any combination of these factors. In addition, such negative events, depending on their severity, could
deplete our cash resulting in an inability to fund our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Exposure to interest rates and debt service obligations:</i>
Rising interest rates could negatively affect the operating costs of dairy and beef producers and thus put further financial pressure
on an already stressed business sector, which could indirectly, but materially and adversely, affect our business. During the first quarter
of 2020, we removed the direct aspect of this particular exposure to our business by refinancing our bank debt (with the exception of
our line of credit) with fixed rate notes. Our mortgage debt outstanding as of December 31, 2023 was $5.8 million bearing interest at
the fixed rate of 3.53% per annum. Our equipment loans outstanding as of December 31, 2023 were $2.6 million bearing interest at the fixed
rate of 3.5% per annum. The two State of Maine loans aggregating $754,000 as of December 31, 2023 bear interest at the fixed rate of 5%
per annum. The $3 million in debt that we secured during the third quarter of 2023 bears interest at the blended fixed rate of 7.33% per
annum with an outstanding balance of $2.9 million as of December 31, 2023. Our outstanding debt as of December 31, 2023 aggregating $12.1
million bears interest at the blended fixed rate of 4.51% per annum. Increasing interest rates would negatively impact the cost of any
future borrowings. This was experienced on the new debt facilities aggregating $3 million that we closed during the third quarter of 2023.
A decline in sales or gross margin, coupled with this debt service burden, could impair our ability to fund our capital and operating
needs and objectives. The additional debt we incurred to fund our growth objectives has significantly increased our total debt service
costs. We are obligated to make principal and interest payments aggregating approximately $2.0 million during both of the years ending
December 31, 2024 and 2025. See Note 10 to the accompanying audited financial statements for more details about our debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Debt covenants:</i> Our bank debt is subject
to certain financial covenants. We are required to meet a minimum debt service coverage (DSC) ratio of 1.35. Our actual DSC ratios were
0.44, 2.68 and 2.03 for the years ended December 31, 2022, 2021 and 2020, respectively. There can be no assurance that we can exceed that
required level in subsequent years. By negotiation with our lender in connection with a mortgage debt financing during the first quarter
of 2022, the required minimum DSC ratio was reduced to 1.0 for the year ending December 31, 2022. Subsequently, our lender waived the
required compliance with this rate for the year ended December 31, 2022. During the first quarter of 2023, the DSC ratio covenant for
the year ending December 31, 2023 was waived by our lender. Instead, we were required to meet a minimum DSC ratio requirement of 1.35
for the twelve-month periods ending June 30, 2024, September 30, 2024 and December 31, 2024, and then again annually after that. During
the first quarter of 2024, the DSC ratio covenant for the twelve-month period ending June 30, 2024 was preemptively waived by our lenders.
If we are unable to achieve the required DSC ratio going forward or reach a favorable agreement with our lender regarding that requirement
(including an amendment to or waiver of such requirement), we would be in violation of that covenant, which could result in unfavorable
amendments to the terms of our bank debt or have other adverse impacts on our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Currency
exchange fluctuation: </i></span>We do not believe that currency exchange rates have had a significant effect on our revenues and expenses.
However, future increases in the value of the U.S. dollar could affect our customers and the demand for our products. We hope to increase
the level of our future sales of products outside the United States. The cost of our products to international customers could be affected
by currency fluctuations. The decline of the U.S. dollar against other currencies could make our products less expensive to international
customers. Conversely, a stronger U.S. dollar could make our products more costly for international customers. The current devaluation
of the dollar makes Euro-based purchases more expensive for us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Inflation and supply disruptions:</i> Inflation
is having a material and adverse impact on almost all supplies we purchase and labor we hire and retain. Continuing or increasing inflationary
trends could materially reduce our gross margin on product sales if we are unable or unwilling to impose offsetting price increases on
our customers. The Consumer Price Index for All Urban Consumers (CPI-U) during the year ended December 31, 2023, improved to 3.4% for
all items before seasonal adjustment. This is down from 6.5% and 7.0% during the years ended December 31, 2022 and 2021, respectively.
We are facing significant production constraints, supply disruptions and inflationary increases which were initially triggered, in large
part directly or indirectly, by the COVID-19 pandemic. The extent and duration of the negative impact of the pandemic on the economics
of our customers and on the demand for our products going forward are very difficult to assess. The dairy market, similar to many others,
has been unstable as a result of the pandemic. The price paid to producers for milk has been very volatile. The Class III milk price has
been extremely volatile since the onset of the pandemic. Market conditions have improved somewhat, but this volatility remains a concern.
Additionally, like most input costs, the cost of grain and other feed is rising, which puts a strain on the profitability of our customers.
There is also economic uncertainty for beef producers, as the supply chain is interrupted or otherwise adversely affected due to closures
of processing plants and reduced throughput. This is a very unusual situation for farmers who work so hard to improve production quality
and efficiency in order to help feed a growing population with high-quality and cost-effective proteins. The pandemic created risk and
continues to create uncertainty and challenges for us and has created or contributed to global supply-chain disruptions and has affected
international trade, while creating a worldwide health and economic crisis. Stock market valuations have declined and recovered somewhat
but remain very volatile. Inflation has increased significantly, and tax rates may increase. There is a risk of a period of economic downturn,
the severity and duration of which are difficult to know. Prior to the pandemic and the responsive federal economic stimulus programs,
many feared the United States had taken on too much national debt. Now the debt load is significantly higher. A combination of the conditions,
trends and concerns summarized above could have a corresponding negative effect on our business and operations, including the supply of
the colostrum we purchase to produce our <b>First Defense<sup>&#174;</sup></b> product line, the demand for our products in the U.S. market
and our ability to penetrate or maintain a profitable presence in international markets. We are experiencing shortages in key components
and needed products, backlogs and production slowdowns due to difficulties accessing needed supplies and labor and other restrictions
which increase our costs and affect our ability to consistently deliver our products to market in a timely manner. Our exposure to this
risk is mitigated to some extent by the fact that our supply chain is not heavily dependent on foreign manufacturers, by our on-going
cross-training of our employees, by qualifying alternate suppliers and components and by our early and continued compliance with recommended
hygiene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Projection of net (loss) income:</i> Generally
speaking, our financial performance can differ significantly from management projections, due to numerous factors that are difficult to
predict or that are beyond our control. Weaker than expected sales of the <b>First Defense<sup>&#174;</sup></b> product line could lead
to less profits or deeper operating losses. The timing of FDA approval of <b>Re-Tain<sup>&#174;</sup></b> will have a material impact on
our net (loss) income until sufficient commercial sales are generated and sustained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Risks associated with our funding strategy
for <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>:</i> The inability to maintain adequate cash and liquidity to support the
commercialization of <b>Re-Tain<sup>&#174;</sup></b> is a risk to our business. Achieving FDA approval of our pharmaceutical-grade Nisin
produced at commercial-scale is the most critical action remaining in front of us on our path to U.S. regulatory approval of <b>Re-Tain<sup>&#174;</sup></b>.
Having completed the construction and equipping of the DS production facility (as described in more detail in <b>ITEM 7</b> of this Annual
Report) at a cost of approximately $20.8 million, we will continue to incur product development expenses to operate and maintain this
facility until commercialization. Absent sufficient sales of <b>Re-Tain<sup>&#174;</sup></b> at a profitable gross margin, we would be
required to fund all debt service costs from available cash and sales of the <b>First Defense<sup>&#174;</sup></b> product line, which
would reduce, and could eliminate, our expected profitability going forward and significantly reduce our cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Uncertainty of market size and product sales
estimates:</i> Estimating the size of the total addressable market and future sales growth potential for our <b>First Defense<sup>&#174;</sup></b>
product line is based on our experience and understanding of market dynamics but is inherently subjective. Estimating the size of the
market for any new product, such as <b>Re-Tain<sup>&#174;</sup></b>, involves more uncertainties than do projections for established products.
We do not know whether, or to what extent, our products will achieve, maintain or increase market acceptance and profitability. Some of
the uncertainties surrounding <b>Re-Tain<sup>&#174;</sup></b> include the product&#8217;s effectiveness against currently prevalent pathogens,
market acceptance, the effect of a premium selling price on market penetration, cost of manufacture, competition from new and existing
products sold by substantially larger competitors with greater market reach and promotional resources and other risks described under
&#8220;Product Risks&#8221; &#8211; &#8220;Sales risks pertaining to <b>Re-Tain<sup>&#174;</sup></b>&#8221; below. Since <b>Re-Tain<sup>&#174;</sup></b>
is a novel approach to treating mastitis, there are many uncertainties with regards to how quickly and to what extent we can develop the
subclinical mastitis treatment market. We believe that polypeptide antimicrobial technology may be viewed positively (relative to traditional
antibiotics). If realized, this may offset some of these risks and result in better overall market acceptance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Net deferred tax assets:</i> The realizability
of our net deferred tax assets is a subjective estimate that is contingent upon many variables. During the second quarter of 2018, we
recorded a full valuation allowance against our net deferred tax assets that significantly increased our net loss in comparison to other
periods. This non-cash expense could be reversed, and this valuation allowance could be reduced or eliminated, if warranted by our actual
and projected profitability in the future. We will continue to assess the need for the valuation allowance each quarter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Product Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Product risks generally:</i> We set objectives
for our products that we believe we can achieve, but the achievement of such goals is not a certainty. The sale of our products is subject
to production, financial, efficacy, regulatory, competitive and other market risks. Elevated standards to achieve and maintain regulatory
compliance required to sell our products continue to evolve. Failure to achieve acceptable biological yields from our production processes
can materially increase our costs of goods sold and reduce our production output, leading to lower margins and/or an order backlog that
could adversely affect our customer relationships and operating results. <b>First Defense<sup>&#174;</sup></b> is sold, and we expect <b>Re-Tain<sup>&#174;</sup></b>
to be sold, at significant price premiums relative to competitive products. There is no assurance that we will continue to achieve market
acceptance of the <b>First Defense<sup>&#174;</sup></b> product line, or achieve and sustain market acceptance of <b>Re-Tain<sup>&#174;</sup></b>,
at a profitable price level or that we can continue to manufacture our products at a low enough cost to result in a sufficient gross margin
to justify their continued manufacture and sale. As we bring <b>Re-Tain<sup>&#174;</sup></b> to market, these risks could be heightened
by the additional uncertainties associated with introducing a new product requiring a shift in customer behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Contamination events and equipment failures
in our production process:</i> During 2023 and 2022, we experienced certain contamination events and equipment failures in our production
process that resulted in scrapped inventory and a slowdown of our production process and had a significant impact on our operating results.
We are at risk of further such production contaminations or equipment failures resulting in more scrapped inventory if we do not continue
to improve our farm operations and implement other necessary improvements from farms to finished goods. The realization of this risk following
the above-mentioned contamination events did result in a slowdown of our production output during 2023 to remediate this problem, which
led to less sales and gross margin during the year. Additional contamination events or equipment failures causing significantly less production
output, depending on their severity, could deplete our cash resulting in an inability to fund our business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Sales
risks pertaining to <b>Re-Tain</b></i></span><sup>&#174;</sup><span style="font-family: Times New Roman, Times, Serif"><i>: </i>Actual
or prospective <b>Re-Tain</b></span><sup>&#174; </sup><span style="font-family: Times New Roman, Times, Serif">customers may decide to
discontinue, reduce or avoid usage of <b>Re-Tain</b></span><sup>&#174; </sup><span style="font-family: Times New Roman, Times, Serif">due
to the following risks:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1)
A rejection of a tank of milk by a positive milk inhibitor test because too much of the milk in a bulk tank is comprised of milk from
cows being treated with <b>Re-Tain</b></span><sup>&#174;</sup><span style="font-family: Times New Roman, Times, Serif">, when tested randomly
for inhibitors by a milk hauler, which could create legal liability. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">2) A failed or stalled cheese tank occurs when
a Nisin susceptible cheese starter culture is impacted by residues in milk that exceed our on-farm treatment recommendations, which aims
to limit concentrations of bulk tanks or tankers to 1% of milk from cows treated with <b>Re-Tain<sup>&#174;</sup></b> or is not effectively
diluted through the milk collection and transportation system. After we study this potential impact during our Controlled Launch of <b>Re-Tain<sup>&#174;</sup></b>,
we may decide to seek a post-approval label change requiring a short discard of milk, which may be limited to just the treated quarter
of the cow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3)
Producers&#8217; current practice generally is to treat only clinical mastitis, which has the visual indicator of abnormal milk. In order
to gain market penetration for <b>Re-Tain<sup>&#174;</sup></b>, we will need to change that practice and increase awareness of the importance
of treating subclinical disease. This will require the producers&#8217; ability and willingness to diagnose without visual indicators.
Users of <b>Re-Tain<sup>&#174;</sup></b> could have unsatisfactory treatment outcomes if they lack the equipment needed to measure and
monitor somatic cell counts (SCC) of the herd or individual cows (for which data is needed). This risk limits our access to treatment
cows because about 40% of farms do not presently have access to this kind of testing at the cow level, and thus are not good candidates
for the use of <b>Re-Tain</b></span><sup>&#174;</sup><span style="font-family: Times New Roman, Times, Serif">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">4) Lower than anticipated treatment cure rates
could be experienced because the product is administered to cows that we would not identify as the best treatment candidates based on
SCC data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">5) Lower than anticipated treatment cure rates
could be experienced because the product is administered to cows that are infected with pathogens outside of our label claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">6) Off-label use of our product in cows infected
with clinical mastitis before we have run the required studies and achieved a label claim extension for this disease state, resulting
in negative treatment outcomes and potential legal liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">7) Producers either do not choose to use it or
might use it improperly, rather than follow our label instructions to administer one dose after each of three consecutive milkings, or
they may limit use within the herd in an abundance of caution to avoid the negative outcomes described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Reliance on sales of the <b>First Defense<sup>&#174;</sup></b>
product line:</i> We are reliant on the market acceptance of the <b>First Defense<sup>&#174;</sup></b> product line to generate product
sales and fund our operations. Our business would not have been profitable during the years ended December 31, 2012, 2013, 2015 and 2016,
during the nine-month periods ended September 30, 2017 or during the three-month periods ended March 31, 2019, December 31, 2020, June
30, 2021, September 30, 2021, December 31, 2021 and March 31, 2022 without the gross margin that we earned on sales of the <b>First Defense<sup>&#174;</sup></b>
product line. Our anticipated return to more consistent profitability is contingent upon the gross margin we earn from <b>First Defense<sup>&#174;</sup></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Concentration of sales:</i> Sales of the <b>First
Defense<sup>&#174;</sup></b> product line aggregated 99% of our total product sales during both of the years ended December 31, 2023 and
2022. Our primary customers for the majority of our product sales (91% and 92% during the years ended December 31, 2023 and 2022, respectively)
are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated
9% and 8% of our total product sales during the years ended December 31, 2023 and 2022, respectively. The concentration of our sales from
one product into just two markets (the dairy and beef markets) is a risk to our business. The animal health distribution segment has been
aggressively consolidating over the last few years, with larger distributors acquiring smaller distributors. A large portion of our product
sales (79% and 73% during the years ended December 31, 2023 and 2022, respectively) was made to two large distributors. A large portion
of our trade accounts receivable (79% and 69% as of December 31, 2023 and 2022, respectively) was due from these two distributors. We
have a good history with these distributors, but the concentration of sales and accounts receivable with a small number of customers does
present a risk to us, including risks related to such customers experiencing financial difficulties or altering the basis on which they
do business with us in a manner unfavorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Production capacity constraints:</i> We invested
$3.7 million from 2019 to the first quarter of 2022 to increase our production capacity (in terms of annual sales dollars) for the <b>First
Defense<sup>&#174;</sup></b> product line from approximately $16.5 million to approximately $23 million based on current selling prices
and estimated production yields. During the fourth quarter of 2021, we reached this new, higher level of production output on an annualized
basis. During 2021, we initiated three additional investments aggregating $4.7 million to increase our estimated annual production capacity
for the <b>First Defense<sup>&#174;</sup></b> product line to approximately $30 million, which we completed at the end of 2022. We are
making initial plans and investments to further increase our production capacity in 2024 and after. While this capacity expansion investment
has proceeded very close to budget, there is a risk of cost overruns in our ongoing projects and any future production expansions that
we may undertake, and a risk that we will not be able to achieve our production capacity growth objectives on a timely basis, resulting
in a continuing or increasing shortfall in supply to the market. The inability to meet market demand for our products is a risk to our
business. The historically large backlog of orders, as well as any ongoing order backlog, presents a risk that we could lose customers
during this period that are not easily regained thereafter, when our production capacity is expected to meet or exceed sales demand. Our
long-term capital plan to continue to expand the <b>First Defense<sup>&#174;</sup></b> product line requires ongoing review of equipment
capacity and utilization across the manufacturing value stream at the 56 Evergreen Drive facility and our leased facilities at 175 Industrial
Way, as well as assessment of costs, functional obsolescence and reliability of equipment. This review and assessment could identify a
need to fund unexpected equipment maintenance or replacement costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Product liability:</i> The manufacture and
sale of our products entails a risk of product liability. Our exposure to product liability is mitigated to some extent by the fact that
our products are directed towards the animal health market. We have maintained product liability insurance in an amount which we believe
is reasonable in relation to our potential exposure in this area. We have no history of claims of this nature being made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Regulatory Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Regulatory requirements for the <b>First Defense<sup>&#174;</sup></b>
product line:</i> <b>First Defense<sup>&#174;</sup></b> is sold in the United States subject to a product license from the Center for Veterinary
Biologics, USDA, which was first obtained in 1991, with subsequent approvals of line extensions in 2017 and 2018. As a result, our operations
are subject to periodic inspection by the USDA, and we are at risk of an unfavorable outcome from such inspections. The potency of serial
lots is directly traceable to the original serial used to obtain the product performance claims (the Reference Standard). Due to the unique
nature of the label claims, host animal re-testing is not required as long as periodic laboratory analyses continue to support the stability
of stored Reference Standard. To date, these analyses have demonstrated strong stability. However, if the USDA were not to approve requalification
of the Reference Standard, additional clinical studies could be required to meet regulatory requirements and allow for continued sales
of the product, which could interrupt sales and adversely affect our operating results. Territories outside of the United States may require
additional regulatory oversight that we may not be able to meet with our current facilities, processes and resources. During July 2023,
the USDA issued a Voluntary Stop Distribution and Sale (VSDS) and a Hold Release on <b>First Defense<sup>&#174;</sup></b> preventing us
from shipping product (while not restricting us from continuing to produce inventory) until two inspectional observations were resolved.
We promptly responded to the inspectional observations involved. On August 1, 2023, the USDA verbally rescinded the VSDS, and on August
4, 2023, the USDA verbally rescinded the Hold Release, allowing us to resume normal shipping during the week of August 7, 2023. There
is a risk that we will become subject to similar or additional regulatory actions in the future. In these cases, the resulting interruption
in sales could have a material and adverse effect on our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Regulatory requirements for <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>:
</i>The commercial introduction of this product in the United States requires
us to obtain FDA approval. Completing the development through to approval of the NADA by the FDA involves risk. While four of the five
required Technical Sections have been approved, the regulatory development process timeline has been extensive (approximately 16 years
from when the product rights were returned to us by a former partner in 2007) and has involved multiple commercial production strategies
and multiple submissions of the Chemistry, Manufacturing and Controls (CMC) Technical Section. Most recently, we received an Incomplete
Letter from the FDA regarding this CMC Technical Section during the third quarter of 2022. This clarifies the required path to product
approval. To reduce the risk associated with this process, we are working with a qualified contract manufacturer (Norbrook) for alignment
of the required validations and DP manufacture and have met with the FDA to clarify filing strategy and requirements. Our CMC Technical
Section submission is currently under review by the FDA as discussed in greater detail in <b>ITEM 7</b> of this Annual Report under the
caption, <b>&#8220;Product Development Expenses and Strategy&#8221;</b>, below. Early during the first quarter of 2024, the FDA conducted
another pre-approval inspection of our DS facility. This resulted in the issuance of one deficiency as identified on the FDA&#8217;s Form
483. Since then, we have fully responded with data addressing the inspectional observation. However, our efforts continue to be subject
to inspection and approval by the FDA and other factors outside of our control, and there remains a risk that the required FDA approvals
of our product and facilities could be delayed or not obtained. The facility of our contract manufacturer is subject to similar inspectional
obligations. International regulatory approvals would be required for sales of <b>Re-Tain<sup>&#174;</sup></b> outside of the United States,
and there is a risk that these approvals would be or become too costly to pursue or be delayed or not obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Regulatory requirements limiting access to
suppliers and customer base</i>: Maine, where our principal executive office and manufacturing facilities are located, has adopted product
reporting and phase-out requirements for per- and polyfluoroalkyl substances (&#8220;PFAS&#8221;). Maine&#8217;s statute requires that
effective as of January 1, 2025 manufacturers of products with intentionally-added PFAS report the presence of such substances (and requires
that such products cannot be sold in Maine unless the required reporting is made) and specifies that (subject to certain exceptions to
be promulgated by the Maine Department of Environmental Protection) no product containing intentionally-added PFAS may be sold in Maine
after January 1, 2030. This reporting requirement may limit our ability to access supplies from companies which are not in compliance
with the state reporting requirements and may limit those customers to whom we may sell our products. The U.S. Environmental Protection
Agency also has adopted a PFAS reporting law, which requires that importers of articles that contain PFAS report the presence of such
substances to the extent such information is known or reasonably ascertainable. This reporting requirement may limit our ability to import
supplies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Economic Risks Pertaining to the Dairy and Beef Industries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The industry data referred to below is compiled
from USDA databases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Cattle count:</i> The January count of all
cattle and calves in the United States had steadily declined from 97,000,000 as of January 1, 2007 to 88,500,000 as of January 1, 2014.
Then this figure increased each year, reaching 94,800,000 as of January 1, 2019 before declining to 93,800,000 as of both January 1, 2020
and January 1, 2021. This count continued to decline to 92,100,000 as of January 1, 2022 and to 88,800,000 as of January 1, 2023. This
count dropped to 87,200,000 as of January 1, 2024. Reflecting seasonal trends, this figure was equal to 102,000,000, 101,000,000, 98,600,000
and 95,900,000 as of July 1, 2020, 2021, 2022, and 2023, respectively. A significant decline in the cattle count could negatively affect
the size of our addressable market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Herd size:</i> Prior to 1957, there were over
20,000,000 cows in the U.S. dairy herd. Prior to 1986, there were over 10,000,000 cows in the U.S. dairy herd. From 1998 through 2021,
the size (annual average) of the U.S. dairy herd ranged from the low of 9,011,000 in 2004 to the high of 9,448,000 in 2021. This average
declined to 9,402,000 during the year ended December 31, 2022 and then declined to 9,386,000 during the year ended December 31, 2023.
A significant decline in the herd size could negatively affect the size of our addressable market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Milk cow price:</i> The all-time high value
(annual average) for a milk cow was $1,993 during 2015. Since then, this annual average value steadily declined to $1,205 during 2019
before increasing to $1,300 during 2020 and to $1,363 during 2021. This price for 2022 increased significantly to an average of $1,598,
which is a 17% increase over 2021. The 2023 average price of $1,763 represents a 10% increase over prior year. A significant decline in
the milk cow price could negatively affect the size of our addressable market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Milk price:</i> The dairy market, similar
to many others, has been unstable for several reasons including as a result of the pandemic. The price paid to producers for milk has
been very volatile. This market volatility, and the resulting impact on our primary end users, could negatively impact our ability to
maintain and grow sales at a profitable level. The Class III milk price (an industry benchmark that reflects the value of product used
to make cheese) is an important indicator because it defines our customers&#8217; revenue level. This annual average milk price level
(measured in dollars per hundred pounds of milk) reached its highest point (since these prices were first reported in 1980) during 2014
at $22.34 (peaking at $24.60 in September 2014), which price level has never been repeated. During the year ended December 31, 2020, this
average milk price was equal to $18.16, but it was extremely volatile during the year due largely to disruption in demand related to the
COVID-19 pandemic. The one-month fluctuation of 73% from a low of $12.14 in May 2020 to $21.04 in June 2020 set an all-time record for
variability. The average price for 2021 decreased by 6% to $17.08. This price average increased by 29% to $21.96 during the year ended
December 31, 2022. The average price decreased by 22% to $17.02 during the year ended December 31, 2023. The annual fluctuations in this
milk price level are demonstrated in the following table:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Average Class III Milk Price During the Years
    Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2015</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2016</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2017</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2018</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Feed Costs:</i> The actual level of milk prices
may be less important than its level relative to feed costs. One measure of this relationship is known as the milk-to-feed price ratio,
which represents the amount of feed that one pound of milk can buy. An increase in feed costs also has a negative impact on the beef industry
and therefore could have a resulting negative impact on our business and results of operations. This ratio varies farm-to-farm based on
individual operating parameters. Since this ratio reached 3.24 in 2005, it has not exceeded 3.00. This ratio averaged 1.74 for 2021, amounting
to a significant decline of 25% from the 2020 average of 2.32. This average has not been lower since 2012. During 2022, this ratio improved
by 10% to 1.91. This ratio dropped to 1.69 during the year ended December 31, 2023. The following table demonstrates the annual volatility
and the low values of this ratio recently:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Average Milk-To-Feed Price Ratio During the
    Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2015</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12</td><td style="text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Market volatility</i>: While the number of
cows in the U.S. herd and the production of milk per cow directly influence the supply of milk, the price for milk is also influenced
by very volatile international demand for milk products. Given our focus on the dairy and beef industries, the volatile market conditions
and the resulting financial insecurities of our primary end users are risks to our ability to maintain and grow sales at a profitable
level. These factors also heighten the challenge of selling premium-priced animal health products (such as <b>Tri-Shield<sup>&#174;</sup></b>
and <b>Re-Tain<sup>&#174;</sup></b>) into the dairy market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Small Size of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Dependence on key personnel: </i>We are a
small company with approximately 79 employees (including 5 part-time employees). As such, we rely on certain key employees to support
multiple operational functions, with limited redundancy in capacity. The loss of any of these key employees could adversely affect our
operations until a qualified replacement is hired and trained, which could be even more challenging in the present difficult labor market.
Our competitive position will be highly influenced by our ability to attract, retain and motivate key scientific, manufacturing, managerial
and sales and marketing personnel. We will require increased staffing levels to operate our expanded <b>First Defense<sup>&#174;</sup></b>
production capacity and to operate our <b>Re-Tain<sup>&#174;</sup></b> production facility. The cost of attracting and retaining the needed
additional personnel in this current job market and inflationary environment could adversely affect our margins and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Reliance on outside party to provide certain
services under contract for us: </i>We are exposed to additional regulatory compliance risks through the subcontractors that we choose
to work with to produce <b>Re-Tain<sup>&#174;</sup></b>, who also need to satisfy certain regulatory requirements in order to provide us
with the products and services we need. One example of this outside reliance is Norbrook, our DP contract manufacturer. Because Norbrook
notified us of its intent to terminate its supply agreement with us, we initiated an investment of approximately $4 million during 2022
to construct and equip our own DP formulation and aseptic filling capability for <b>Re-Tain<sup>&#174;</sup></b> in our existing DS facility.
Due to the loss in gross margin during 2023 caused by the slowdown in production output necessary to remediate product contamination events,
we have decided to defer spending of approximately $2 million of these funds for the near term. The objective of this investment is to
end our reliance on an outside party to perform these services for us. Actual project costs could exceed our current estimates. Completion
of this project could be delayed due to a number of factors outside our control, including delays in equipment fabrication, equipment
delivery or facility construction. In addition, there is a risk that we fail to achieve regulatory approval of the new facility or that
such approval is delayed or requires significant additional expenditures to obtain. We are evaluating alternatives for DP supply going
forward, which include the resumption of the investment in our own in-house DP services (when prudent based on our cash reserves) or another
contract manufacturing agreement or a further extension with Norbrook. We face a supply interruption and adverse effects on the Controlled
Launch of <b>Re-Tain<sup>&#174;</sup></b> after the DP supply provided from our contract manufacturer is consumed and until new supply
from a new contract manufacturing agreement or our own formulation and aseptic filling facility is implemented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Competition from others:</i> Many of our competitors
are significantly larger and more diversified in the relevant markets than we are and have substantially greater financial, marketing,
manufacturing and human resources and more extensive product development and sales/distribution capabilities than we do, including greater
ability to withstand adverse economic or market conditions and declining revenues and/or profitability. Merck and Zoetis, among other
companies, sell products that compete directly with the <b>First Defense<sup>&#174;</sup></b> product line in preventing scours in newborn
calves. The scours product sold by Zoetis sells for approximately half the price of our product, although it does not have an <i>E. coli</i>
claim (which ours does). With <b>Tri-Shield<sup>&#174;</sup></b>, we can compete more effectively against vaccines that are given to the
mother cow (dam) to improve the quality of the colostrum that she produces for the newborn calf. Elanco, Merck and Zoetis provide these
dam vaccine products to the market. There are many companies competing in the mastitis treatment market, most notably Boehringer Ingelheim,
Merck and Zoetis. The subclinical mastitis products sold by these large companies are well established in the market and are priced lower
than what we expect for <b>Re-Tain<sup>&#174;</sup></b>, but all of them involve traditional antibiotics and are sold subject to a requirement
to discard milk during and for a period of time after treatment (unlike our product which does not carry an FDA-required milk discard
or meat withhold. There is no assurance that our products will compete successfully in these markets. We may not be aware of other companies
that compete with us or intend to compete with us in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Global Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Russia&#8217;s unprovoked military invasion
of Ukraine and the war in the Middle East: </i>Russia&#8217;s unprovoked military invasion of Ukraine (and attack on its people) and the
war in the Middle East are having a significant negative impact on the world economy, worsening trends that were already moving in an
unfavorable direction. Among other exposures, the increasing price of oil is already impacting our transportation-related expenses materially,
and we expect this supply stress to increase the cost of petroleum-based products that we purchase (mostly plastics). Both of these military
actions could cause more stress on the global economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Climate change:</i> Our business, and our
activities and the activities of our customers and suppliers, could be disrupted by climate change. Potential physical risks from climate
change may include altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and
other natural disasters, rising sea levels, and a rising heat index, any of which could cause negative impacts to our and our customers&#8217;
and suppliers&#8217; businesses. Increased temperatures and rising water levels may negatively impact our dairy and beef livestock customers
by increasing the prevalence of parasites and diseases that affect food animals. The physical changes caused by climate change may also
prompt changes in regulations or consumer preferences which in turn could have negative consequences for our and our customers&#8217;
businesses. Climate change may negatively impact our customers&#8217; operations, through climate-related impacts such as increased air
and water temperatures, rising water levels and increased incidence of disease in livestock. In addition, concerns regarding greenhouse
gas emissions and other potential environmental impacts of livestock production have led to some consumers opting to limit or avoid consuming
animal products. If such events affect our customers&#8217; businesses, they may purchase fewer of our products, and our revenues may
be negatively impacted. Climate driven changes could have a material adverse impact on the financial performance of our business and on
our customers. In addition, increased frequency of natural disasters and adverse weather conditions may disrupt our manufacturing processes
or our supply chain. These disruptions may have a material adverse effect on our business, financial condition, results of operations
and/or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Bovine diseases: </i>The potential for epidemics
of bovine diseases such as Foot and Mouth Disease, Bovine Tuberculosis, Brucellosis and Bovine Spongiform Encephalopathy (BSE) presents
a risk to us and our customers. Documented cases of BSE in the United States have led to an overall tightening of regulations pertaining
to ingredients of animal origin, especially bovine. The <b>First Defense<sup>&#174;</sup></b> product line is manufactured from bovine
milk (colostrum), which is not considered a BSE risk material. Future regulatory action to increase protection of the human food supply
could affect the <b>First Defense<sup>&#174;</sup></b> product line, although presently we do not anticipate that this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Pertaining to Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal"><i>Stock market
valuation and liquidity:</i> Our common stock trades on The Nasdaq Stock Market (Nasdaq: ICCC). Our average daily trading volume (which
was 7,950 shares per day during the 20-day period ended March 8, 2024) is lower, our bid/ask stock price spread can be larger and our
share price can be more volatile than what other companies experience, which could result in investors facing difficulty selling their
stock for proceeds that they may expect or desire. Our share price as of March 8, 2024 was $5.20. Most companies in the animal health
sector have market capitalization values that greatly exceed our market capitalization of approximately $40 million as of March 8, 2024.
Our product sales during the year ended December 31, 2023 were $17.5 million. This means that our market capitalization as of March 8,
2024 was equal to approximately 2.3 times our sales during the year ended December 31, 2023. Before gross margin from the sale of new
products is achieved, our market capitalization may be heavily dependent on the perceived potential for growth from our product under
development and may therefore be negatively affected by the related uncertainties and risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal"><i>Certain
provisions might discourage, delay or prevent a change in control of our Company or changes in our management:</i> Provisions of our certificate
of incorporation, our bylaws, our Common Stock Rights Plan or Delaware law may discourage, delay or prevent a merger, acquisition or other
change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium
for their shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove
our management. These provisions include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">limitations
on the removal of directors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">advance
notice requirements for stockholder proposals and nominations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
ability of our Board of Directors to alter or repeal our bylaws;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the
ability of our Board of Directors to refuse to redeem rights issued under our Common Stock Rights Plan or otherwise to limit or suspend
its operation that would work to dilute the stock ownership of a potential hostile acquirer, potentially preventing acquisitions that
have not been approved by our Board of Directors; and</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Section
203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation from engaging in a business combination
with an interested stockholder (generally defined as a person which together with its affiliates owns, or within the last three years
has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested
stockholder) unless the business combination is approved in a prescribed manner.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal">The existence
of the foregoing provisions and anti-takeover measures could depress the trading price of our common stock or limit the price that investors
might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby
reducing the likelihood of obtaining a premium for our common stock in an acquisition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal"><i>No expectation
to pay any dividends or repurchase stock for the foreseeable future:</i> We do not anticipate paying any dividends to, or repurchasing
stock from, our stockholders for the foreseeable future. Instead, we expect to use cash to fund product development costs and investments
in our facilities and production equipment, and to increase our working capital and to reduce debt. Stockholders must be prepared to rely
on market sales of their common stock after price appreciation to earn an investment return, which may never occur. Any determination
to pay dividends in the future will be made at the discretion of our Board of Directors and will depend on our financial condition, results
of operations, contractual restrictions, restrictions imposed by applicable laws, current and anticipated needs for liquidity and other
factors our Board of Directors deems relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Possible
dilution:</i> We may need to access the capital markets again and issue additional
common stock in order to fund our growth objectives, as described elsewhere in this Annual Report. Such issuances could have a dilutive
effect on our existing stockholders.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Risks</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Access to raw materials and contract manufacturing
services: </i>Our objective is to maintain more than one source of supply for the components used to manufacture and test our products
that we obtain from third parties. However, we are experiencing difficulty in efficiently acquiring essential supplies. We have significantly
increased the number of farms from which we purchase colostrum for the <b>First Defense<sup>&#174;</sup></b> product line. A significant
reduction in farm capacity could make it difficult for us to produce enough inventory to meet customer demand. The specific antibodies
that we purify from colostrum for the <b>First Defense<sup>&#174;</sup></b> product line are not readily available from other sources.
We are and will be dependent on our manufacturing facilities and operations in Portland for the production of the <b>First Defense<sup>&#174;</sup></b>
product line and <b>Re-Tain<sup>&#174;</sup></b>. We will be dependent on one manufacturer for the supply of syringes for <b>Re-Tain<sup>&#174;</sup></b>.
We are currently dependent on a contract with Norbrook for the DP formulation and aseptic filling for supply of our Nisin DP through 2024.
The facility we may resume constructing to perform these services in-house will be subject to FDA inspection and approval, the outcome
and timing of which are not within our control. We expect to achieve FDA approval for use of our DP facility approximately two years from
when this project is restarted. The potential alternative options for these services are narrowed considerably because our product cannot
be formulated or filled in a facility that also processes traditional antibiotics (i.e., beta lactams). Any significant damage to or other
disruption in the services at any of these third-party facilities or our own facilities (including due to lack of financing, regulatory
issues or non-compliance) would adversely affect the production of inventory and result in significant added expenses and potential loss
of future sales. We face the risk of potential supply interruption and adverse effects on the market launch of <b>Re-Tain<sup>&#174; </sup></b>if
we do not effectively manage the end of the DP supply provided from our contract manufacturer for orders scheduled for delivery through
the end of 2024 (with product expiries that could be approximately between September of 2025 and March of 2026) to align with the new
supply from a new contract manufacturing agreement or our own formulation and aseptic filling facility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Failure to protect intellectual property:
</i>The protection and enforcement of our intellectual property rights may require the expenditure of significant financial, managerial
and operational resources. We rely on trademark, copyright and patent law, trade secret protection, agreements and other methods with
our employees and others to protect our proprietary rights. However, we may be unable to adequately protect our intellectual property
rights or prevent third parties from infringing or misappropriating our intellectual property rights. We may not be able to obtain registration
for all intellectual property we seek to register, and effective intellectual property protection may not be available in every country
in which our products are sold. In some cases, we have chosen (and may choose in the future) not to seek patent protection for certain
products or processes. Instead, we have sought (and may seek in the future) to maintain the confidentiality of any relevant proprietary
technology through trade secrets, operational safeguards and contractual agreements. Reliance upon trade secret, rather than patent protection
may cause us to be vulnerable to competitors who successfully replicate (knock off) our manufacturing techniques and processes. Further,
our confidentiality agreements may not effectively prevent disclosure of our proprietary information, technologies and processes and may
not provide an adequate remedy in the event of unauthorized disclosure of such information. Others may independently develop similar trade
secrets or technology or obtain access to our unpatented trade secrets or proprietary technology. Others may have filed patent applications
and may have been issued patents involving products or technologies potentially useful to us or necessary for us to commercialize our
products or achieve our business goals. If that were to be the case, there can be no assurance that we will be able to obtain licenses
to such patents on terms that are acceptable to us. Any of our intellectual property rights may be challenged by others or invalidated
through administrative process or litigation. Third parties may claim in the future, that we have infringed their intellectual property
rights, which could result in significant costs and potential damages and license requirements. We may initiate claims or litigation against
others for infringement, misappropriation or violation of our intellectual property rights or other proprietary rights or to establish
the validity of such rights. However, we may be unable to discover or determine the extent of any infringement, misappropriation or other
violation of our intellectual property rights and other proprietary rights. In addition, we may be unable to prevent third parties from
infringing upon, misappropriating or otherwise violating our intellectual property rights and other proprietary rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Increasing dependence on the continuous and
reliable operation of our information technology systems: </i>We rely on information systems throughout our company. Any disruption of
these systems or significant security breaches could adversely affect our business. Although we maintain information security policies
and employ system backup measures and engage in information system redundancy planning and processes, such policies, measures, planning
and processes, as well as our current disaster recovery plan may be ineffective or inadequate to address all eventualities. As information
systems and the use of software and related applications by us, our business partners, suppliers, and customers become more cloud-based,
we become inherently more susceptible to cyberattacks. There has been an increase in global cybersecurity vulnerabilities and threats,
including more sophisticated and targeted cyber-related attacks that pose a risk to the security of our information systems and networks
and the confidentiality, availability and integrity of data and information. There are reports of increased activity by hackers and scammers
since the COVID-19 pandemic. Russia&#8217;s unprovoked military invasion of Ukraine may elevate the risk of such cyberattacks. Any such
attack or breach could compromise our networks and the information stored thereon could be accessed, publicly disclosed, lost, or stolen.
While we have invested in our data and information technology infrastructure (including working with an information security technology
consultant to assess and enhance our security systems and procedures, and periodically training our employees in such systems and procedures),
there can be no assurance that these efforts will prevent a system disruption, attack, or security breach and, as such, the risk of system
disruptions and security breaches from a cyberattack remains. We have not experienced any material adverse effect on our business or operations
as a consequence of any such attack or breach but may incur increasing costs in performing the tasks described above. Given the unpredictability
of the timing, nature and scope of such disruptions and the evolving nature of cybersecurity threats, which vary in technique and sources,
if we or our business partners or suppliers were to experience a system disruption, attack or security breach that impacts any of our
critical functions, or our customers were to experience a system disruption, attack or security breach via any of our connected products
and services, we could potentially be subject to production downtimes, operational delays or other detrimental impacts on our operations.
Furthermore, any access to, public disclosure of, or other loss of data or information, including any of our (or our customers&#8217;
or suppliers&#8217;) confidential or proprietary information or personal data or information, as a result of an attack or security breach
could result in governmental actions or private claims or proceedings, which could damage our reputation, cause a loss of confidence in
our products and services, damage our ability to develop (and protect our rights to) our proprietary technologies and have a material
adverse effect on our business, financial condition, results of operations or prospects. While this exposure is common to all companies,
larger companies with greater resources may be better able to mitigate this risk than we can.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1B &#8212; UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>ITEM 1C &#8211; CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Risk Management and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We regularly assess risks from cybersecurity threats, monitor our information
systems for potential vulnerabilities and test those systems pursuant to our process. Our cybersecurity risk assessment is part of our
overall risk management program. We also regularly engage outside consultants to assess, identify and manage material risks from cybersecurity
threats, including those threats associated with our use of third-party service providers. These consultants recommend and help implement
systems to protect against cybersecurity threats. Based on the information available as of the filing date of this Annual Report, we are
not aware of any risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect our business
strategy, results of operations or financial condition. However, despite our cybersecurity risk management processes, there can be no
assurance that we, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially
affect us. Refer to the risk factor captioned <i>&#8220;Increasing dependence on the continuous and reliable operation of our information
technology systems&#8221;</i> under <b>PART I, ITEM 1A &#8211; RISK FACTORS</b> for additional description of cybersecurity risks and
potential related impacts on the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Board of Directors has overall oversight
responsibility with respect to our approach to risk management, including risks relating to cybersecurity. Although the Board of Directors
has the ultimate responsibility for risk oversight, our management team, including our President and CEO, has operational responsibility
for cybersecurity matters, including the day-to-day management of our cybersecurity risks, and oversees processes for the prevention,
detection, mitigation and remediation of any cybersecurity incidents. While our management team does not have cybersecurity expertise,
we coordinate with expert consultants to assess and manage risks. Our Board of Directors reviews cybersecurity threats and risk controls
at quarterly meetings based on information provided by management and outside consultants.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2 &#8212; PROPERTIES</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Building 56:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 1993, we purchased a 15,000 square foot
facility (that included 5,000 square feet of unfinished office space on the second floor) at 56 Evergreen Drive in Portland, Maine. We
currently use this space for substantially all of our: i) office and laboratory needs, ii) vaccine manufacturing operations, iii) liquid
processing operations and iv) freeze-drying operations for our USDA-regulated product line. All of our powder milling and filling operations,
gel formulation operations and assembly services have been relocated out of this building. During 2001, we completed a construction project
that added approximately 5,200 square feet of new manufacturing space on the first floor and approximately 4,100 square feet of storage
space on the second floor. During 2007, we built out the 5,000 square feet of unfinished space on the second floor into usable office
space. After moving offices from the first floor into this new space on the second floor, we modified and expanded the laboratory space
on the first floor and added approximately 2,500 additional square feet of storage space on the second floor. During 2009, we added 350
square feet of cold storage space connected to our first floor production area and added an additional 600 square feet to the second floor
storage area. During 2015, we completed construction of a two-story addition connected to our facility to provide us with approximately
7,100 additional square feet for cold storage, production and warehouse space for our operations. These additions increased the size of
the facility to approximately 34,850 square feet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Building 33:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2015, we exercised an option to acquire
land at 33 Caddie Lane in Portland, Maine which is near our facility at 56 Evergreen Drive, on which we initiated construction of our
DS production facility for <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b> during the third
quarter of 2016. During the fourth quarter of 2017, we obtained a Certificate of Occupancy from the City of Portland for our 16,202 square
foot (9,803 on the first floor and 6,399 on the second floor) DS production facility. Our FDA-regulated operations are conducted in this
building.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Building 14:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2017, we purchased a 4,080 square foot
facility adjacent to the DS production facility for <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>
at 14 Wedge Way in Portland, Maine. We are using this warehouse space primarily for storage of inventory, materials and equipment. During
the middle of 2023, we completed modifications to this facility for packing, shipping and cold storage for <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;
</sup></span></b>and other warehousing needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Building 175A:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2019, we entered into a lease covering
approximately 14,300 square feet of office and warehouse space at 175 Industrial Way in Portland, Maine to expand our USDA-regulated manufacturing
operations. We have renovated this space (a Certificate of Occupancy was issued during the second quarter of 2020) to help us expand our
production capacity and improve quality for the <b>First Defense<sup>&#174;</sup></b> product line. This space is being used for all of
our powder milling and filling, gel formulation and assembly services. The original lease term was ten years with a right to renew for
a second ten-year term and a right of first offer to purchase. During the third quarter of 2022, we entered into a new 20-year lease covering
a facility that has been constructed for us by our landlord (<b>Building 175B</b>, described below), which is adjacent to (and has been
connected to) <b>Building 175A</b>. In connection with this new lease, the lease to <b>Building 175A</b> was extended by approximately
13 years to match the expiration of the other lease to <b>Building 175B</b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Building 175B:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2022, we committed to lease an additional
15,400 square feet of space at 175 Industrial Way in Portland, Maine, which has been constructed and connected to <b>Building 175A</b>,
over a 20-year term. The lease commencement date was April 1, 2023. Lease payments began four months after this date. In connection with
the lease commitment for space in <b>Building 175B</b>, the term of the original lease for <b>Building 175A</b> was extended by approximately
13 years. We intend to use this space for the following three purposes: 1) improve product quality by moving powder milling out of <b>Building
56</b>, 2) provide much needed additional warehouse space and 3) provide space for additional freeze-drying equipment to increase our
production capacity to approximately $40 million per year. Due to the loss in gross margin on product sales during 2023 caused by the
slowdown in production output necessary to remediate product contamination events, we reduced the scope of the investment to build out
<b>Building 175B </b>at least for the time being. The objective of moving our powder milling operations out of <b>Building 56</b> has
been achieved by moving powder milling to <b>Building 175A</b> for the time being. We have completed Phase I of this build out plan, which
included pouring a concrete floor and bringing utilities and heat to the space. Upon issuance of a Certificate of Occupancy by the city,
we plan to relocate all shipping and receiving operations from <b>Building 56</b> to <b>Building 175B</b> and benefit from the new warehouse
space. When we have adequate cash, we will initiate Phase II of the build out plan, which includes construction of process rooms and installation
of production equipment necessary to further increase our production capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Other:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During March of 2021, we entered into a renewable,
two-year lease for approximately 1,300 square feet of office, storage and parking space in New York. Subsequently, we entered into a new
two-year lease to the same property through March of 2025 that includes an option to renew for an additional two-year term. We are renting
approximately 960 square feet in Winona, Minnesota for a sales office. This lease automatically renews with 4% increases for one-year
terms unless we or the landlord give 60-days&#8217; notice of a change. The current term expires in June 2024. We do not expect to provide
notice of cancellation at this time. We also maintain access to cows (as a source of colostrum used in the production of the <b>First
Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b> product line) through contractual relationships
with commercial dairy farms. We maintain property insurance in amounts that approximate replacement cost and a modest amount of business
interruption insurance.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3 &#8212; LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the ordinary course of business, we may become
subject to periodic lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such
lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or
could become a party will have a material adverse effect on our business, results of operations, or financial condition.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4 &#8212; MINE SAFETY DISCLOSURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><b>ITEM 5 &#8212; MARKET FOR
REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock trades on The Nasdaq Capital
Market tier of The Nasdaq Stock Market under the symbol ICCC. As of March 8, 2024, we had 15,000,000 common shares authorized and 7,750,864
common shares outstanding, and there were approximately 642 shareholders of record. We have not paid dividends on our common stock and
do not have any present plan or expectation to pay dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal"><i>Purchase of Equity Securities
</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal">During 2023,
we accepted $18,760 in cash in consideration for the exercise of 4,000 stock options. During 2022, we accepted $30,670 in cash in consideration
for the exercise of 5,000 stock options. In all cases, new shares were issued from treasury stock. </span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6 &#8212; [RESERVED]</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><b>ITEM 7 &#8212; MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following discussion and analysis of our
financial condition and results of operations should be read together with our audited financial statements and the related notes and
other financial information included in <span style="font-family: Times New Roman, Times, Serif"><b>Part II: ITEM 8</b></span><b> &#8212;
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b> of this Annual Report. Some of the information contained in this discussion
and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business,
includes forward-looking statements that involve risks and uncertainties. One should review <b>Part I: ITEM 1A </b>&#8212; <b>RISK FACTORS
</b>of this Annual Report for a discussion of some of the important factors that could cause actual results to differ materially from
the results, objectives or expectations described in or implied by the forward-looking statements contained in the following discussion
and analysis.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUTLINE TO ITEM 7 &#8211; MANAGEMENT&#8217;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTES OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Liquidity and Capital Resources</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Results of Operations</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 18pt">-</td><td><b>Critical Accounting Policies</b></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used for operating activities was $4.7
million during the year ended December 31, 2023 in comparison to net cash used for operating activities of $1.5 million during the year
ended December 31, 2022. The $3.1 million increase in cash used for operating activities during the year ended December 31, 2023 compared
to the year ended December 31, 2022 was largely caused by the $3.3 million increase in the net loss which was, in turn, largely the result
of $3.8 million less gross margin being earned during 2023, due to the production contamination events discussed below. Approximately
$1.4 million less cash was received from the collection of accounts receivable, which was largely offset by $1.2 million less cash being
invested in inventory during the year ended December 31, 2023 compared to the prior year. Our inventory balance increased by $1.8 million
to $7.8 million as of December 31, 2023 from $6 million as of December 31, 2022. Our total depreciation and amortization expense was approximately
$2.7 million and $2.5 million during the years December 31, 2023 and 2022, respectively. We anticipate that depreciation expense, while
not affecting our cash flows from operations, will be a significant factor in creating annual net operating losses until and unless product
sales increase sufficiently to offset these non-cash expenses. Net cash used for investing activities was $1.9 million during the year
ended December 31, 2023 in comparison to net cash used for investing activities of $4 million during the year ended December 31, 2022
consisting primarily of cash spent to fund the purchase of property, plant and equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash provided by financing activities increased
to $1.8 million during the year ended December 31, 2023 in comparison to net cash provided by financing activities of $1.1 million during
the year ended December 31, 2022. We received gross debt proceeds of $3 million and $2 million during the years ended December 31, 2023
and 2022, respectively. We had aggregate debt outstanding (net of debt issuance and debt discount costs) of approximately $12 million
and $10.2 million as of December 31, 2023 and 2022, respectively. This debt bears interest at fixed rates. The blended interest rate on
the debt outstanding as of December 31, 2023 and 2022 is 4.51% and 3.65% per annum, respectively. Debt principal repayments aggregated
$1.2 million and $897,000 during the years ended December 31, 2023 and 2022, respectively. We anticipate that debt principal repayments
will aggregate approximately $1.5 million during both of the years ending December 31, 2024 and 2025. Interest expense (including amortization
of debt issuance and debt discount costs) was $476,000 and $349,000 during the years ended December 31, 2023 and 2022, respectively. We
anticipate that interest expense (including amortization of debt issuance and debt discount costs) will be $563,000 and $492,000 during
the years ending December 31, 2024 and 2025, respectively. During the first quarter of 2024, the availability of our $1.0 million line
of credit, which bears interest at the National Prime Rate per annum, was extended until September 11, 2025. There was no outstanding
balance under this line of credit as of December 31, 2023 or 2022. See Note 10 to the accompanying audited financial statements for more
information about our bank debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From the first quarter of 2016 through the second
quarter of 2021, we raised gross proceeds of $26.7 million (net proceeds were $24.8 million) from six different common equity transactions
priced between $5.25 and $8.25 per share with a weighted average price of $5.87 per share. No warrants were issued in connection with
any of these transactions, and no convertible or preferred securities were issued. This capital, together with our bank debt and gross
margin from product sales, has allowed us to transform the Company. Based on our best estimates and projections, we believe that our cash
and cash equivalents, together with gross margin anticipated to be earned from ongoing product sales will be sufficient to meet our currently
planned working capital and capital expenditure requirements and to finance our ongoing business operations for at least 12 months (which
is the period of time required to be addressed for such purposes by accounting disclosure standards) from the date of this filing. The
table below summarizes the changes in selected, key accounts (in thousands, except for percentages):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/>
December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/>
December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">979</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,813</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(83</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net working capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,272</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,053</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,993</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Common shares outstanding<sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&lt;1</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><sup>&#160;</sup></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(<span style="font-size: 10pt">1)</span></sup></td><td style="text-align: left"><span style="font-size: 10pt">There </span>were 618,500 and
605,000 shares of common stock reserved for issuance for stock options that were outstanding as of December 31, 2023, and 2022, <span style="font-size: 10pt">respectively.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have invested and continue to invest in several different capital
expenditure projects to increase our estimated annual full production capacity for the <b>First Defense</b><sup>&#174;</sup> product line
from approximately $16.5 million to approximately $40 million and to complete the development of <b>Re-Tain<sup>&#174;</sup></b>. When
we describe the production capacity for the <b>First Defense</b><sup>&#174;</sup> product line in this Annual Report, it should be noted
that the actual value of this capacity varies based on biological and process yields, product format mix, selling price and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the three-year period ended December 31,
2016, we invested the aggregate of $4.2 million to construct a 7,100 square foot facility addition at 56 Evergreen Drive and related equipment
(primarily Freeze-Dryer #2) and cold storage capacity increasing our freeze-drying capacity by 100% and making other improvements to our
liquid processing capacity, which increased our annual production capacity (in terms of annual sales dollars) to approximately $16.5 million.
During the first quarter of 2016, we completed this investment, which also included the construction and equipping of a pilot plant for
small-scale DS production for <b>Re-Tain<sup>&#174;</sup></b> within our <b>First Defense</b><sup>&#174;</sup> production facility at 56
Evergreen Drive. After construction of the DS production facility for <b>Re-Tain<sup>&#174;</sup></b> at 33 Caddie Lane (described in the
next paragraph) was completed, this space was converted for use in the production of the gel tube formats of the <b>First Defense</b><sup>&#174;</sup>
product line. After construction of <b>Building 175A</b> (described below) was completed, this space was converted to double our liquid
processing capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><sup>&#160;</sup></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the four-year period ended December 31,
2018, we invested the aggregate of $21.6 million to construct a DS production facility for <b>Re-Tain<sup>&#174;</sup></b> at 33 Caddie
Lane. During the fourth quarter of 2017, we completed construction of the DS production facility. We began equipment installation during
the third quarter of 2017, and we completed this installation during the third quarter of 2018. The total cost of this investment for
the DS production facility and related processing equipment was $20.8 million plus $331,000 for the land and $472,000 for the acquisition
of an adjacent 4,080 square foot warehouse facility at 14 Wedge Way, which will be used for packing, shipping and cold storage of <b>Re-Tain<sup>&#174;</sup></b>
and other warehousing needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2019, we initiated several additional
capital expenditure investments in <b>First Defense</b><sup>&#174;</sup> and <b>Re-Tain<sup>&#174;</sup></b> as detailed in the following
table (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Paid During</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Year Ended December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">574</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,391</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Year Ended December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,073</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Year Ended December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,609</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Year Ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,097</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">796</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Total Paid through December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,941</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Estimate to Complete<sup>(1)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total Project Cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,306</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,075</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,341</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><sup>&#160;</sup></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
investment of approximately $5.5 million of these funds for <b>First Defense</b><sup>&#174;</sup> and <b>Re-Tain<sup>&#174; </sup></b>projects
has been deferred for the time being. These figures are rough estimates for the work to be completed that have not been put out to bid
for firm cost quotations or contracts at this time.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The primary purpose of the additional investment
in <b>First Defense</b><sup>&#174;</sup> is to fulfill the current backlog and materially reduce the risk of another order backlog. Operating
at very close to 100% of available capacity is not efficient or sustainable. Our objective is to be in position to operate without significant
contaminations at the capacity level we choose to cover sales with adequate buffer stock, which would allow more time for necessary preventative
maintenance, and to have redundancy in place for when equipment failures occur. In addition to running without significant product contaminations
or equipment failures, we need to meet or exceed our production yield assumptions to succeed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The first phase of the additional investments
in <b>First Defense</b><sup>&#174;</sup> included significant renovations to a 14,300 square foot leased facility at 175 Industrial Way
(<b>Building 175A</b>), some facility modifications at 56 Evergreen Drive and the necessary production equipment (including Freeze-Dryer
#3) to increase our freeze-drying capacity by 50% and our liquid processing capacity by 100%. This resulted in increasing the annual production
capacity of the <b>First Defense<sup>&#174;</sup></b> product line (in terms of annual sales dollars) from approximately $16.5 million
to approximately $23 million. Renovations of <b>Building 175A</b> to enable this expansion were completed during the second quarter of
2020. By moving our powder and gel filling and assembly services from 56 Evergreen Drive into this new space, we created space at 56 Evergreen
Drive for the installation of the expanded freeze-drying capacity. The new facilities are built to contemporary current Good Manufacturing
Practices (cGMP) standards with efficient material and people flows. A site license approval for this new facility was issued by the USDA
during the third quarter of 2020. During the second quarter of 2021, we completed the relocation of our gel formulation equipment from
56 Evergreen Drive to <b>Building 175A</b>, which created the space necessary to double our liquid processing capacity at 56 Evergreen
Drive. We obtained site license approval of the expanded freeze-drying capacity (Freeze-Dryer #3) at 56 Evergreen Drive from the USDA
during the third quarter of 2021, and we obtained site license approval of the expanded liquid processing capacity at 56 Evergreen Drive
from the USDA during the third quarter of 2022. This investment also included equipment and vehicle investments necessary to expand and
improve our colostrum collection capabilities and logistics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
second phase of the additional investments in <b>First Defense</b><sup>&#174; </sup>included the installation of Freeze-Dryer #4 to further
increase the estimated annual production capacity of the <b>First Defense</b><sup>&#174;</sup> product line (in terms of annual sales dollars)
by an additional 33% from approximately $23 million to approximately $30 million. Due to supply disruptions affecting key components and
equipment, this investment was not completed until the end of 2022. This investment also includes equipment and facility modifications
to scale-up and upgrade our vaccine manufacturing capacity, improve our quality laboratories and install new equipment for our gel filling
operations for </span><b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">
at 56 Evergreen Drive and <b>Building 175A</b>. This phase included the automation of our gel filling operations. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The third phase of the additional investments
in <span style="font-family: Times New Roman, Times, Serif"><b>First Defense<sup>&#174;</sup></b></span> involves the initiation of a <span style="font-family: Times New Roman, Times, Serif">new
investment in building modifications and equipment to further increase our estimated annual <b>First Defense<sup>&#174;</sup></b> production
capacity from approximately $30 million to approximately $40 million with options for further expansion. Given the long lead time required
for investments like this, we initiated this project by entering into a lease amendment during the third quarter of 2022 covering a to-be-constructed
15,400 square foot building shell connected to <b>Building 175A</b> for approximately $250,000 per year. Construction of the building
shell by our landlord was substantially complete as of April 1, 2023, and rent payments commenced as of August 1, 2023. We made this lease
commitment because of the unique proximity of the land adjacent to our currently leased space and the high level of demand for properties
of this type in the Portland market. We did not want to risk losing this opportunity to others. The anticipated benefits to us from this
new lease include: i) space for the potential to install Freeze-Dryers #5, #6, #7 and #8 if justified by market demand in the future,
ii) improved space and quality for our powder milling operations by separating our upstream processes (liquid processing) at 56 Evergreen
Drive from our clean downstream processes (milling, formulation, filling and packaging) and iii) much needed additional warehouse space.
Freeze-Dryer #5 is the key piece of equipment required to allow us to increase our estimated annual production capacity to above $30 million.
Based on past experience, we are planning for approximately 18 to 24 months of lead time for fabrication, installation, qualification
and implementation of Freeze-Dryer #5. We have been running our equipment and staff close to 100% of capacity in order to fill the backlog
of orders. One of our objectives is to create a more sustainable production schedule. However, due to the loss in gross margin during
2023 caused by the slowdown in production output necessary to remediate the product contamination events discussed below, we have decided
to defer most of this investment, for the time being. During the third quarter of 2023, we initiated the initial steps of this project
with a budget of approximately $700,000. We completed this work during the first quarter of 2024, which will provide additional warehousing
space and allow us to move all shipping and receiving functions out of 56 Evergreen Drive to create more space for liquid processing.
In consideration for our landlord agreeing to pay for the cost of those certain tenant improvements, we are obligated to make additional
rent payments of $20,000 per month from November 2023 through June 2024 and a one-time additional rent payment of $488,743 in July 2024.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The purpose of the additional investments in
<b>Re-Tain<sup>&#174; </sup></b>is to bring the formulation and aseptic filling capabilities for <b>Re-Tain<sup>&#174;</sup></b> DP into
available space in our DS facility to end our reliance on third-party DP manufacturing services as well as to build out warehouse space
at 14 Wedge Way for packing and shipping facilities for <b>Re-Tain<sup>&#174;</sup></b>. We began initial installation of the filling equipment
during the first quarter of 2022. Then we paused this installation work pending concurrence with the FDA pertaining to our third submission
of the Chemistry, Manufacturing and Controls (CMC) Technical Section, which is discussed in greater detail below. Due to the loss in gross
margin during 2023 caused by the slowdown in production output necessary to remediate the product contamination events discussed below,
we have decided to defer the spending of approximately $2 million of these funds, for the time being. At the same time, we are investigating
other potential relationships with contract manufacturers that might do this work for us so that we can avoid this use of funds. If we
decide to resume the in-house strategy, we would anticipate FDA approval of this facility (which is a requirement for commercial manufacturing)
at least two years after we resume spending on this project.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the third quarter of 2016, the City of
Portland approved a Tax Increment Financing (TIF) credit enhancement package that reduces the real estate taxes on our DS production facility
for <b>Re-Tain<sup>&#174;</sup></b> by 65% over the eleven-year period beginning on July 1, 2017 and ending June 30, 2028 and by 30% during
the year ending June 30, 2029, at which time the rebate expires. During the second quarter of 2017, the TIF was approved by the Maine
Department of Economic and Community Development. The value of the tax savings will increase (decrease) in proportion to any increases
(decreases) in the assessment of the building for city real estate tax purposes or the City&#8217;s tax rate. The following table discloses
how much of the new taxes we have generated is being relieved by the TIF and how much we are paying:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Assessed Value</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Twelve-Month<br/> Period Ended</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total New Taxes<br/> Generated by<br/> the Project</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less:<br/> TIF Credit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Amount<br/> Paid by<br/> ImmuCell</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">$1.7 million @ April 1, 2017</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">June 30, 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">$4.0 million @ April 1, 2018</td><td>&#160;</td>
    <td style="text-align: center">June 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">32,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">$4.0 million @ April 1, 2019</td><td>&#160;</td>
    <td style="text-align: center">June 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">94,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">$4.0 million @ April 1, 2020</td><td>&#160;</td>
    <td style="text-align: center">June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">94,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">$4.3 million @ April 1, 2021</td><td>&#160;</td>
    <td style="text-align: center">June 30, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">$4.3 million @ April 1, 2022</td><td>&#160;</td>
    <td style="text-align: center">June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">$4.3 million @ April 1, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">488,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">312,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">176,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations </b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Segments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-weight: normal">As detailed
in Note 17, &#8220;Segment Information&#8221;, to the accompanying audited financial statements, we operate in two business segments.
The Scours segment is dedicated to manufacturing and selling </span>First Defense<sup>&#174;</sup><span style="font-weight: normal">, a
product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis
segment is focused on developing and commercializing</span> Re-Tain<sup>&#174;</sup><span style="font-weight: normal">, a product to treat
subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA).</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Production Capacity Increase, Product Contamination and Related
Events</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2018, it became clear that demand for
<b>Tri-Shield First Defense<sup>&#174;</sup></b> was outpacing production. In response to this increasing demand, we began a series of
investments during 2019 to increase our production capacity for the <b>First Defense</b><sup>&#174;</sup> product line to an estimate of
approximately $30 million per year. Over recent years, we have invested more than $12.4 million to increase our production capacity to
meet the still-growing demand. This investment in equipment and facilities represents approximately 50% of our stockholders&#8217; equity
as of December 31, 2023. Although we have not yet been able to achieve our production output goals, we remain deeply committed to continuing
to supply <b>First Defense<sup>&#174; </sup></b>to the market over the long term, despite the current short supply. Our production process
is a very complicated one, which makes it difficult to scale-up quickly. We can&#8217;t just flip a switch and pump out more widgets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The past year or so has been considerably challenging
for us. As of July 2022, we had completed almost all of the facility expansion work and new equipment installations needed to significantly
increase our production capacity. However, the most critical piece of new equipment (being Freeze-Dryer #4) was delivered six months late
by the fabricator. As this increased production capacity was coming online, a product contamination event was detected by standard in-process
quality control testing around the end of the third quarter of 2022. Scrapped product from contamination events and other production process
losses during 2022 (largely due to the contamination event around the end of the third quarter) resulted in a total charge to costs of
goods sold of $589,000 during 2022. We took immediate steps to address the contamination, and production ran without issue during the
balance of the fourth quarter of 2022. By the end of 2022, we had Freeze-Dryer #4 approved for use by the USDA. Just as we began to operate
at this higher level of capacity at the beginning of 2023, we were forced to slow down production to remediate a second contamination
event related to our incoming raw material. In response to this contamination event, we slowed down our production output as we took the
necessary steps to assess and remediate the issues to ensure that any product that is released to market continues to meet all quality
standards. At the same time, Freeze-Dryer #2 stopped operating requiring a six-month repair, netting us back to three operating freeze
dryers. As of early July 2023, we were back to four operating freeze dryers, and we believed that the contamination events were largely
behind us. We subsequently experienced a third contamination event in September 2023 impacting two lots of work-in-progress inventory.
Although all of the incoming material utilized in this production phase had passed quality control testing, the product failed the quality
control tests later in the production process. The production pause necessary to remediate the problem reduced our production output during
September and October of 2023. Scrapped product from contamination events and other production process losses during 2023 resulted in
a total charge to costs of goods sold of $527,000 during 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The production slowdown during the first ten
months of 2023, has, in part, caused an increase in the amount of our order backlog from approximately $2.5 million as of December 31,
2022 to approximately $9.4 million as of December 31, 2023. This backlog increased further to $10.3 million as of March 8, 2024. We cannot
be certain that this backlog will be converted to sales because it includes orders that were placed months ago, redundancy in demand and
orders that may be cancelled. We believe that the ongoing implementation of our capacity expansion plans and the corrective actions being
taken in response to these contamination events should allow us to operate without further significant contaminations going forward with
estimated annual production capacity of approximately $30 million during the latter part of the fourth quarter of 2023 and into 2024.
While we produced far less than we needed during 2023, we believe that our remediation efforts are allowing us to steadily ramp back up
to full production capacity. With the positive trend in our quality control test results described above, we are building back production.
As we resume full production, our goal is to be able to produce at least $6 million or more worth of product per quarter, which would
annualize to about 80% or more of our estimated $30 million annual production capacity. Finished goods produced increased steadily from
approximately $3.3 million to $4 million and further to $5.3 million during the first, second and third quarters of 2023, respectively,
before dropping modestly to $5.1 million during the fourth quarter of 2023. The output levels achieved during the months of November and
December of 2023 annualize to approximately $26.8 million, which equates to an average quarterly production of approximately $6.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since February of 2023, we have been pursuing
an insurance claim under our business interruption policy to offset a small portion of the losses that we have incurred related to at
least three different product contamination events. While our financial losses are far larger, we are seeking a $750,000 insurance benefit.
To date, we have received $250,000. The balance of this claim is under review by our underwriter. We cannot estimate the likelihood of
our success with this claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The increase in sales demand for <b>First Defense<sup>&#174;</sup></b>
is both exciting and challenging for us. The learnings from the remediation of the contamination events have improved our production processes
going forward. We have implemented several important improvements at the source farm level including more product and environmental testing,
more training of farm staff and better enforcement of our protocols. While we never release product to the market that does not pass our
final quality control release tests, we had allowed product to advance in the production process at risk, while the in-process quality
control tests were being performed. We no longer advance product to the next stage before the complete quality control test results are
known. While this does add time to the production cycle, we believe that it has helped us reduce further contaminations. Notwithstanding
the challenges that contamination events have posed for us, we are excited to be approaching both our estimated full capacity of approximately
$30 million per year for <b>First Defense<sup>&#174;</sup></b> (with a flex option to increase our estimated full capacity to approximately
$40 million per year in the future) while, at the same time, advancing to the final stages of a very significant FDA product development
initiative with <b>Re-Tain</b><sup>&#174;</sup>.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>Product Sales</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our near-term goal is to increase and stabilize
supply, regain lost business and re-establish our growth curve. However, the 2023 production shortage caused largely by certain contamination
events may prove to be more detrimental to our growth curve than any prior production shortage because it impacted more customers for
a longer period of time. Through continued growth in sales of the <b>First Defense</b><sup>&#174;</sup> product line, and the dedication
of additional resources to production, sales, marketing and technical services, it is our objective to exceed our total product sales
of approximately $17.5 million and $18.6 million achieved during the years ended December 31, 2023 and 2022, respectively, as soon as
possible. Our longer-term goal is to exceed $35 million of annual total product sales as soon as possible during the four-year period
after the market launch of <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>. <span style="font-family: Times New Roman, Times, Serif">We
do not solely benchmark our sales expectations off trailing twelve-month sales results. Instead, we look at the sales of competitive products
to assess the size of the addressable market and plan for growth when projecting our future production capacity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The production slowdown necessary to remediate the
contamination events described above resulted in significantly reduced sales during the first ten months of 2023. During this period of
short supply when we have been selling product as soon as it is produced, our sales are less impacted by the historically high seasonality
during the first quarter of each year. Sales during the three-month period ended March 31, 2023 were $3.45 million, representing a 12%,
or $464,000, decrease from sales of $3.9 million during the fourth quarter of 2022. Sales during the three-month period ended June 30,
2023 were $3.53 million, representing a 2%, or $86,000, increase over sales during the first quarter of 2023. Sales during the three-month
period ended September 30, 2023 were $5.4 million, representing a 53%, or $1.9 million, increase over sales during the second quarter
of 2023. Sales during the three-month period ended December 31, 2023 were $5.1 million, representing a 6%, or $301,000, decrease from
sales during the third quarter of 2023. Sales during the second half of the year were stronger as we were able to increase production.
Sales during the six-month period ended December 31, 2023 were $10.5 million, representing a 50%, or $3.5 million, increase over sales
of $7 million during the six-month period ended June 30, 2023. Quarter to quarter sales over the past two years are displayed in the following
table:</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sales increased by 30%, or $1.2 million, to $5.1
million during the three-month period ended December 31, 2023, in comparison to $3.9 million during the three-month period ended December
31, 2022. Domestic sales during the three-month period ended December 31, 2023 increased by 29%, and international sales increased by
46%, in comparison to the three-month period ended December 31, 2022. International sales aggregated 6% of total sales during both of
the three-month periods ended December 31, 2023 and 2022. The quarterly sales results are summarized in the following table (in thousands,
except for percentages):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Total product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,096</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,911</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,185</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our lack of product supply drove a sales decrease
of 6%, or $1.1 million, to $17.5 million during the year ended December 31, 2023, in comparison to $18.6 million during the year ended
December 31, 2022. Domestic sales during the year ended December 31, 2023 decreased by 6%, and international sales decreased by 2%, in
comparison to the year ended December 31, 2022. International sales aggregated 9% and 8% of total sales during the years ended December
31, 2023 and 2022, respectively. The sales results for the annual periods are summarized in the following table (in thousands, except
for percentages):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Years<br/> Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Total product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,472</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,096</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(6</td><td style="width: 1%; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sales of the <b>First Defense<sup>&#174;</sup></b>
product line aggregated 99% of our total sales during both of the years ended December 31, 2023 and 2022. Our sales are generally seasonal
with highest demand expected during the first quarter of each year. However, as we fulfill our large backlog of orders, we do not expect
to see as much of this seasonal demand swing in our product sales. Most of our growth (when not limited by backlog) is being realized
through increased demand and a deliberate strategy to prioritize production capacity towards <b>Tri-Shield First Defense<sup>&#174;</sup></b>
(the trivalent format of our product delivered via a gel tube), which provides broader protection to calves. The compound annual growth
rate (CAGR) of our total product sales was 10.8%, 9.7% and 6.2% during the twelve-year, five-year, and four-year periods ended December
31, 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We likely lost some business during 2022 and
2023 as a result of the backlog. During the first half of 2023, the impact of tight supplies hit even harder leaving our customers without
product during their busiest calving season. Our inability to timely meet the needs of our customers could result in the loss of some
customers who seek alternative scours management products during this period of short supply and some of these customers may not resume
purchasing our product when we have eliminated the backlog. <span style="font-family: Times New Roman, Times, Serif">While we worked to
allocate product directly to certain large customers during this period of short supply, we likely lost some customers that could not
access product. While backlog is a better problem to have than seeing product expiring on our shelves, it is nonetheless a significant
challenge when we do not get our customers everything that they want. Our sales team is preparing to resume more normal sales growth initiatives
as we expect inventory to become available. We will work to regain end-user customers that we may have lost while we were short on product
and will aggressively compete for new business. As we emerge from an extended period of time on backlog, we anticipate higher than normal
sales fluctuations quarter to quarter. What is most important to us at this time is that we achieve sales growth over the longer periods
of time, even if we experience some quarter-to-quarter fluctuations. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Valuation of the backlog is a non-GAAP estimate
that is based on purchase orders on hand at the time that could not be met because of a lack of available inventory. Quantification of
the backlog during the current periods has become far less comparable to prior periods. At times, customers have placed orders for more
than a month&#8217;s worth of their demand, perhaps in reaction to our ongoing backlog situation, whereas in the past they ordered more
closely in line with their current demand. We are reporting this figure because it reflects the orders on our books presently that we
cannot ship. We are concerned that this backlog amount may not be highly relevant at this time as it includes very old orders, redundancy
in demand and orders that may be cancelled given the time that has passed since they were originally placed. However, when we required
all distributors to replace their orders around November 15, 2023 to reflect an 8% price increase, the amount of the backlog, in fact,
increased rather than decreased. We believe this reflects strong demand for our product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The backlog was reduced from approximately $2.4
million as of December 31, 2021 to approximately $205,000 as of September 30, 2022. In part because of a first contamination event experienced
around the end of the third quarter of 2022, our backlog increased to approximately $2.5 million as of December 31, 2022. In part because
of a second contamination event experienced during the first quarter of 2023, the backlog increased further to approximately $7.5 million
as of March 31, 2023 and increased to approximately $8 million as of June 30, 2023 and increased to approximately $8.9 million as of September
30, 2023 and increased to approximately $9.4 million as of December 31, 2023 (as demonstrated in the table below). As of March 8, 2024,
the backlog of orders was approximately $10.3 million. <span style="font-family: Times New Roman, Times, Serif">As sales demand increased
while our production output was reduced, the value of our order backlog has fluctuated as demonstrated in the following table:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_002.jpg"/><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that we are on the right track to
increase production output, but we still have more work to do to catch up to product demand. We anticipate that we are in good position
to move past the contamination events that materially affected our output during late 2022 and through the first ten months of 2023 and
are positioned to execute on our plan to resume sales growth in 2024. Finished goods produced increased steadily from approximately $3.3
million to $4 million and further to $5.3 million during the first, second and third quarters of 2023, respectively, but then dropped
off slightly to $5.1 million during the fourth quarter of 2023. Our objective is to produce finished goods with an approximate sales value
of $6 million or more per quarter, as we implement and optimize recent investments to increase its production capacity. Fourth quarter
2023 production was limited by lower output during the month of October, which was caused by a contamination event in September 2023.
After remediating this event, we achieved full production during the balance of the quarter. The output levels achieved during the months
of November and December 2023 annualize to approximately $26.8 million, which equates to an average quarterly production of approximately
$6.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We implemented an average price increase of approximately
8% on the <b>First Defense<sup>&#174;</sup></b> product line effective November 15, 2023. The backlog of orders was worth approximately
$9 million just before this price change. We had some concern that the value of the backlog might decrease materially if customers chose
not to replace all orders at the new price given that many of those orders were dated. However, we did not see a decrease in the backlog
after the price increase which validated the strength of the order demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We acquired a private label product in connection
with our January 2016 acquisition of certain gel formulation technology. This product was discontinued during the first quarter of 2022
because it was not a significant contributor to our total sales and it competed for valuable time and space in our production schedule.
We sell our own <b>CMT</b>, which is used to detect somatic cell counts in milk. Sales of these products (other than the <b>First Defense<sup>&#174;
</sup></b>product line) increased by 53%, or $19,000, to $56,000 during the three-month period ended December 31, 2023, in comparison
to the three-month period ended December 31, 2022. Sales of these other products aggregated 1% of our total product sales during both
of the three-month periods ended December 31, 2023 and 2022. Sales of these products increased by 14%, or $22,000, to $178,000 during
the year ended December 31, 2023, in comparison to the year ended December 31, 2022. Sales of these other products aggregated 1% of our
total product sales during both of the years ended December 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective January 1, 2022, we increased our selling
price of the <b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174; </sup></span></b>product line by approximately
5% and <b>CMT</b> by approximately 7%. Effective January 1, 2023, we increased our selling price of the <b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;
</sup></span></b>product line by approximately 4% (range of 2% to 8%) and <b>CMT</b> by approximately 5%. Effective November 15, 2023,
we increased our selling price for the <b>First Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>
product line by an average of 8% and for <b>CMT</b> by approximately 12%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b><i>Gross Margin</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The change in our gross margin (product sales
less costs of goods sold) and our gross margin as a percentage of product sales during the three-month periods and years ended December
31, 2023 and 2022 are summarized in the following tables (in thousands, except for percentages):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase<br/> (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Gross margin</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,258</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">992</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Percent of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Years<br/> Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Gross margin</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,869</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,779</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(49</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Percent of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46</td><td style="text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The very significantly reduced gross margin (on
both a dollar and percentage of sales basis) during the year ended December 31, 2023 was largely the result of the significant decrease
in sales during the first ten months of 2023, which was caused by a reduction in production output, not by a reduction in demand. The
reduction in production output was, in turn, the result of our decision to slow down our production rate while remediating the production
contamination events, while not yet operating at our anticipated increased production output level. During 2023, we did not benefit from
spreading our fixed costs over higher volumes as we normally do. Further, we did not furlough any labor during this production slowdown.
The gross margin as a percentage of product sales was 41%, 45%, 45%, 49%, 47% and 50% during the years ended December 31, 2022, 2021,
2020, 2019, 2018 and 2017, respectively. The gross margin during the year ended December 31, 2023 was significantly less than what we
have experienced historically and significantly less than what we anticipate going forward. The product contamination events and other
production process losses experienced during 2023 and 2022 resulted in scrapped inventory valued at approximately $527,000 and $589,000,
respectively. Absent these write-offs, our gross margin as a percentage of product sales would have been approximately 25% and 44% during
the years ended December 31, 2023 and 2022, respectively. Although these types of losses are expected to happen from time to time in the
production of a biological product such as ours, we believe we have mitigated the risk of reoccurrence of such losses through the implementation
of certain new quality control steps and manufacturing processes and facility improvements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
significant global supply-chain disruptions that almost all industries are experiencing presently are a challenge to us. </span>The costs
of our supplies, components, raw materials, and services increased significantly during 2021 and that trend continued during 2022 and
2023. <span style="font-family: Times New Roman, Times, Serif">Prices for raw materials and critical supplies are increasing significantly,
and it is becoming increasingly more difficult to obtain timely delivery of the orders that we place. Therefore, we have little choice
but to pay the higher prices and try to take on more months of supply than we would have held previously if we could get our orders fulfilled
timely. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While our biological and process yields can be
variable, we have seen a favorable improvement to our finished goods yield recently, but these yields continue to be variable. The <b>Tri-Shield<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>
product format is more complex (i.e., three antibodies versus two antibodies for <b>Dual-Force<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>)
making it more costly to produce, and both the bivalent and trivalent gel product formats are more expensive to produce than the bolus
format. These new formats are creating sales growth for us, and we are focused on increasing total gross margin dollars, even if that
is accomplished with a lower gross margin as a percentage of sales. A number of other factors contribute to the variability in our costs,
resulting in some fluctuations in gross margin percentages from quarter to quarter and from year to year. We also invest to sustain compliance
with current Good Manufacturing Practices (cGMP) in our production processes. Increasing production can be more expensive in the initial
stages. To achieve our inventory production growth objectives, we continue to acquire more raw material (colostrum) from many more cows
at several new farms. During this expansion phase, colostrum quality can be more variable. Additionally, the biological yields from our
raw material are always variable, which impacts our costs of goods sold in a similar way. Just as our customers&#8217; cows respond differently
to commercial dam-level vaccines, depending on the time of year and immune competency, our source cows have similar biological variances
in response to our proprietary vaccines. As is the case with any vaccine program, animals respond less effectively to their first exposure
to a new vaccine, and thereafter the effectiveness of their immune response improves in response to subsequent immunizations. While this
variability impacts our costs of producing inventory, the commercial value of our <b>First Defense<sup>&#174;</sup></b> product line is
that we compensate for the variability in a cow&#8217;s immune response by standardizing each dose of finished product. This ensures that
every calf is equally protected, which is something that dam-level commercial scours vaccines cannot offer. We continue to work on processing
and yield improvements and other opportunities to reduce costs, while enhancing process knowledge and robustness. Over time, we have been
able to reduce the impact of cost increases by implementing yield improvements. We believe that gross margin results going forward should
be viewed over longer periods of time than just one quarter. As we fully integrate and utilize our increased capacity and evaluate our
product costs and selling price, one of our goals is to achieve a gross margin (before related depreciation and amortization expenses)
as a percentage of total sales approaching 48%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>Product Development Expenses
and Strategy</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Overview: <span style="font-style: normal">The
majority of our product development expenses pertain to the development of <b>Re-Tain<sup>&#174;</sup></b>. During the year ended December
31, 2023, product development expenses decreased by 2%, or $99,000, to $4.4 million in comparison to $4.5 million during the year ended
December 31, 2022. Product development expenses aggregated 25% and 24% of product sales during the years ended December 31, 2023 and 2022,
respectively. Product development expenses included non-cash depreciation and stock-based compensation expenses of $1.5 million and $1.4
million during the years ended December 31, 2023 and 2022, respectively. Approximately $1.3 million of these non-cash expenses were comprised
of depreciation expenses pertaining to our DS facility for <b>Re-Tain<sup>&#174; </sup></b>during both of the years ended December 31,
2023 and 2022. We began depreciating this asset when the Certificate of Occupancy for the new construction was issued during the fourth
quarter of 2017, but sales of our new product cannot be realized until we achieve FDA approval. We expect our product development expenses
to decrease modestly during 2024 as we produce less product for commercial launch and somewhat further after <b>Re-Tain<sup>&#174;</sup></b>
is commercialized and some of the costs incurred to maintain and run our DS production facility become part of our costs of goods sold.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Development objective: <span style="font-style: normal">As
we work to change the way that mastitis is managed in the dairy industry, we aim to demonstrate that our bacteriocin, Nisin A, which is
designed specifically for subclinical mastitis, can provide producers the freedom to change when and how mastitis is treated. <b>Re-Tain<sup>&#174;
</sup></b>is not a broad-spectrum antibiotic used in human health. Rather, it consists of a highly targeted active ingredient without
an FDA-required milk discard or meat withhold. While milk prices vary, the cost of the milk discard associated with traditional antibiotics
ranges from approximately $36.00 (for 3.5 days of milk at 60 pounds per day at the Class III milk price average of $17.02 per hundredweight
during 2023) to approximately $150.00 (for 11 days of milk at 80 pounds per day at the Class III milk price average of $17.02 per hundredweight
during 2023) per treated animal. These high milk discard costs associated with traditional antibiotic treatments lead producers to only
treat mastitis after clinical signs develop. We expect that <b>Re-Tain<sup>&#174; </sup></b>will be a first-of-its-kind product that can
be used to economically treat at the earliest stage of infection, giving producers the ability to get ahead of mastitis before clinical
signs develop so the best cows stay at their best performance level and in the herd longer. The final and most critical development objective
for <b>Re-Tain</b><sup>&#174;</sup> is to achieve regulatory approval of our manufacturing operations.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Development status<span style="font-style: normal">:
Approval by the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) of the New Animal Drug Application (NADA) for
<b>Re-Tain<sup>&#174;</sup></b> is required before any sales of the product can be initiated. The NADA is comprised of five principal Technical
Sections plus a sixty-day administrative review at the end. Each Technical Section can be reviewed and approved separately. By statute,
each Technical Section submission is generally subject to one or more six-month review cycles by the FDA. Upon review and assessment by
the FDA that all requirements for a Technical Section have been met, the FDA may issue a Technical Section Complete Letter. The current
status of our work on these submissions to the FDA is as follows:</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">1) Environmental
Impact: During the third quarter of 2008, we received the Environmental Impact Technical Section Complete Letter from the FDA. During
the second quarter of 2021, we received further clarification through a new Environmental Impact Technical Section Complete Letter covering
the current dosage regimen and labeling.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">2) Target
Animal Safety: During the second quarter of 2012, we received the Target Animal Safety Technical Section Complete Letter from the FDA.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">3) Effectiveness:
During the third quarter of 2012, we received the Effectiveness Technical Section Complete Letter from the FDA. The anticipated product
label (which remains subject to FDA approval) carries claims for the treatment of subclinical mastitis associated with </span>Streptococcus
agalactiae<span style="font-style: normal">, </span>Streptococcus dysgalactiae<span style="font-style: normal">, </span>Streptococcus
uberis<span style="font-style: normal">, and coagulase-negative staphylococci in lactating dairy cattle. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">Subclinical
mastitis, and the study required to achieve an effectiveness claim for it, is defined under the FDA/Center for Veterinary Medicine Guidance
#49: Target Animal Safety and Drug Effectiveness Studies for Anti-Microbial Bovine Mastitis Products (Lactating and Non-Lactating Cow
Products).&#160;Trial eligibility requires both pretreatment samples to be positive for the mastitis pathogen (except for </span>Staphylococcus
aureus <span style="font-style: normal">and </span>Streptococcus agalactiae<span style="font-style: normal">, where a single pretreatment
sample qualifies a cow for enrollment).&#160;For all pathogens, both samples taken between 14 and 28 days post treatment (and at least
5 days apart) must be negative to be judged a cure.&#160;These conservative criteria generally result in enrolling cows with chronic subclinical
disease, which rarely self-resolves</span>.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">4) Human
Food Safety: During the third quarter of 2018, we received the Human Food Safety Technical Section Complete Letter from the FDA confirming,
among other things, a zero milk discard period and a zero meat withhold period during and after treatment with our product. Achieving
this critical differentiating feature for our product encouraged us to continue the significant product development investment necessary
to bring <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">to market. It would have been hard to justify an
ongoing investment of this nature in a product without this significant competitive advantage. During the second quarter of 2021, we updated
this Technical Section Complete Letter with FDA approval of the official analytical method to measure Nisin in milk.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">5) Chemistry,
Manufacturing and Controls (CMC): The CMC Technical Section is very complex and comprehensive. Having previously achieved the four different
Technical Section Complete Letters from the FDA discussed above, approval of the CMC Technical Section is the fifth and final significant
step required before <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">product sales can be initiated in the
United States. Implementing Nisin DS (the active pharmaceutical ingredient) production, which is a required component of the CMC Technical
Section, has been the most lengthy part of this project. We previously entered into an agreement with a multi-national pharmaceutical
ingredient manufacturer for our commercial-scale supplies of DS. However, we determined during 2014 that the agreement did not offer us
the most advantageous supply arrangement in terms of either cost or long-term dependability. As a result, we presented this product development
opportunity to a variety of large and small animal health companies. While such a corporate partnership could have provided access to
a much larger sales and marketing team and allowed us to avoid the large investment in a commercial-scale production facility, we concluded
that a partner would have taken an unduly large share of the gross margin from all future product sales of <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">.
However, the regulatory and marketing feedback that we received from prospective partners, following their due diligence, was positive.
During the third quarter of 2014, we completed an investment in facility modifications and processing equipment necessary to produce our
DS at small-scale at our 56 Evergreen Drive facility. This small-scale facility was used to: i) expand our process knowledge and controls,
ii) establish operating ranges for critical process parameters, iii) conduct product stability studies, iv) optimize process yields and
v) determine the cost of production. We believe these efforts have reduced the risks associated with our investment in the commercial-scale
DS production facility. Having raised equity during 2016 and 2017, we were able to move away from these earlier partnering strategies
and assume control over the commercial-scale manufacturing process in our own facility. During the fourth quarter of 2015, we acquired
land near our existing Portland facility for the construction of a new commercial-scale DS production facility. We commenced construction
of this facility during the third quarter of 2016 and completed construction during the fourth quarter of 2017. Equipment installation
and qualification was initiated during the third quarter of 2017 and completed during the third quarter of 2018. Total construction and
equipment costs aggregated approximately $20.8 million. With construction of the facility complete, we continue to work with outside parties
to investigate improvements to our DS production yields as well as potential efficacy enhancements.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">Under
the FDA&#8217;s phased submission process, we made a first-phased submission covering just the DS during the first quarter of 2019. The
first-phased DS submission included data from the DS Registration Batches produced at commercial scale in our new DS manufacturing facility.
This first-phased submission was followed by a second-phased submission covering both DS and DP, during the first quarter of 2021. The
second-phased DS and DP submission responded to comments raised by the FDA regarding the first-phased DS submission and included detailed
information about the manufacturing process and controls for DP. One of the key components of the second-phased DS and DP submission was
also demonstrating stability of the product through expiry. During the third quarter of 2021, the FDA issued a Technical Section Incomplete
Letter with regard to this second-phased DS and DP submission. This response was not unexpected as it is common for the FDA to issue queries
and comments, especially related to an aseptic DP submission. We made a second submission of the DS and DP Technical Section during the
first quarter of 2022. During the third quarter of 2022, we received a Technical Section Incomplete Letter from the FDA with regards to
this second DS and DP submission of the CMC Technical Section. The submission required that internal and external laboratories re-develop
and qualify several analytical tests and associated controls. We made this third DS and DP submission of the CMC Technical Section during
the third quarter of 2023. In late October of 2023, the FDA notified us that it was refusing to review our submission because Norbrook
was identified as the DP manufacturer in our submission, but the FDA was expecting that we would identify our own in-house services as
the DP manufacturer (instead of Norbrook). This miscommunication was due to a statement in our April 2022 response to an FDA 483 inspectional
observation in which we noted that Norbrook was expected to exit the DP manufacturing agreement with us at the end of 2022, which would
have required us to procure and install some long lead time equipment (filler and labeler) in our DS suite in late 2022. Instead, we were
able to extend the agreement with Norbrook to complete the manufacture of DP inventory for the initial commercial sales under our Controlled
Launch strategy. As a result, we continued to identify Norbrook as our DP manufacturer. In fact, Norbrook has recently initiated production
of the launch goods, and this work has been extended into 2024 with labeling and final packaging occurring post-approval. As a result
of this miscommunication, we were required to re-submit the CMC Technical Section. If the FDA issues a Technical Section Complete Letter
in response to this re-submission, we believe that we could commence commercial sales approximately ten months from the November of 2023
re-submission date, allowing for the re-setting of the six-month CMC review period by the FDA followed by a two-month administrative review
period and approximately two additional months for labeling, packaging and shipping.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">While
being prudent with how much cash we invest into inventory that would have short expiry dating if market launch is delayed, we have built
and are building more DS inventory during 2022 and 2023 to support the initial commercial sales of <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">.
As discussed above, our contract manufacturer has agreed to convert this DS to DP during the fourth quarter of 2023 and into 2024 with
associated product expirations of 18 to 24 months from the date of manufacture. We anticipate a pause in the supply of product to market
after the initial launch goods are sold and before the product is re-launched with DP produced by our in-house aseptic filling operations
(if that investment is re-funded) or by an alternative contractor that we have not identified to date. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">Our DS
manufacturing facility and that of our DP contract manufacturer (and our potential future DP manufacturing facility) are subject to ongoing
FDA inspections. During the third quarter of 2019, the FDA conducted a pre-approval inspection of our DS facility. This resulted in the
issuance of certain deficiencies as identified on the FDA&#8217;s Form 483. We submitted responses and data summaries in a phased manner
over the fourth quarter of 2019 and first quarter of 2020. During the first quarter of 2022, the FDA conducted another pre-approval inspection
of our DS facility. This also resulted in the issuance of certain deficiencies as identified on the FDA&#8217;s Form 483. We have responded
to all of the queries. Early during the first quarter of 2024, the FDA conducted another pre-approval inspection of our DS facility. This
resulted in the issuance of one deficiency as identified on the FDA&#8217;s Form 483. Since then, we have fully responded to this inspectional
observation. The facility of our DP contract manufacturer is subject to similar inspectional compliance obligations. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">We have
always believed that the fastest route to FDA approval and market launch is with the services of Norbrook (an FDA-approved DP manufacturer),
reducing our risk by benefiting from their demonstrated expertise in aseptic filling. From 2010 to the present, we have worked with Norbrook
under several amended contract manufacturing agreements covering the DP formulation, aseptic filling and final packaging services. Under
our current agreement, Norbrook will provide DP for the Controlled Launch with production in the fourth quarter of 2023 and into 2024.
We believe this will enable us to commence sales of <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">without
delay upon receipt of the anticipated FDA approval. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-style: normal">Our potential
alternative third-party options for the formulation and aseptic filling services that are presently being performed by Norbrook are narrowed
considerably because our product cannot be formulated or filled in a facility that also processes traditional antibiotics (i.e., beta
lactams). During the first quarter of 2022, we initiated an investment in the installation of equipment to produce DP at our own facility
at 33 Caddie Lane. Given the loss in gross margin during the first ten months of 2023 caused by the slowdown in production output that
was necessary to remediate the production contamination events, we have decided to defer the completion of this investment for the time
being. Subject to the timing of our installation and validation work, we anticipate FDA approval of this facility (which is a requirement
for commercial manufacturing) at least two years from when this project is restarted allowing for two six-month review cycles. This will
be a post-approval submission. If we decide to complete our potential future DP manufacturing facility, such facility will, upon completion,
be subject to FDA inspection and approval. We anticipate it would have enough formulation and aseptic filling capacity to exceed the expected
production capacity of our DS facility, which is approximately $7 million to $10 million in annual sales. This production capacity estimate
is based on our assumptions as to product pricing and does not yet reflect inventory build strategies in advance of product approval or
ongoing yield improvement initiatives. Establishing our own DP formulation and aseptic filling capability provides us with the longer-term
advantage of controlling the manufacturing process for <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">in
one facility, thereby potentially reducing our manufacturing costs and eliminating international cold chain shipping logistics and costs.
The DP formulation and aseptic filling operation, if completed, will be located in existing facility space that we had intended to utilize
to double our DS production capacity if warranted by sales volumes following market launch. As a result, if we decide to complete this
DP facility (rather than utilizing a third party for these services), we would need to explore alternative strategies (in parallel with
ongoing DS yield improvement initiatives) to expand our DS production capacity. This integrated manufacturing capability for <b>Re-Tain</b></span><b><sup>&#174;</sup></b>
<span style="font-style: normal">would substantially reduce our dependence on third parties. Upon completion of our formulation and aseptic
filling facility, the only significant third-party input for <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">would
be the DP syringes. It is anticipated that Hubert De Backer of Belgium (HDB) will supply these syringes in accordance with purchase orders
that we submit. HDB is a syringe supplier for many of the largest participants in the human and veterinary medical industries, and with
whom Norbrook presently works. Based on HDB&#8217;s performance history and reputation in the industry, we are confident that HDB will
be a dependable supplier of syringes in the quantity and of the quality needed for <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other product development initiatives: Our second
most important product development initiative has been focused on other improvements, line extensions or additions to our <b>First Defense<sup>&#174;</sup></b>
product line. We are currently working to establish USDA claims for our bivalent bulk powder formulation of <b>First Defense Technology<sup>&#174;</sup></b>.
Subject to the availability of resources, we intend to begin new development projects that are aligned with our core competencies and
market focus. We also remain interested in acquiring, on suitable terms, other new products and technologies that fit with our sales focus
on the dairy and beef industries, subject to the availability of the needed funding.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>Sales and Marketing Expenses
and Selling Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
see ourselves as the &#8220;non-pharma&#8221; pharma company. Rather than offering variations of &#8220;copy-cat&#8221; technology like
vaccines and antibiotics, we have taken the path less traveled by developing first-of-their kind products fueled by novel active ingredients
such as polyclonal antibodies (for <b>First Defense</b><sup>&#174;</sup>) and bacteriocins (for </span><b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">).
While we expect that </span><b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">
could be a significant market disrupter, we project the <b>First Defense</b><sup>&#174;</sup> market could be larger, especially during
the first years of the commercial launch of </span><b>Re-Tain</b><span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup>.
We anticipate that these category developing innovations will drive greater value for the livestock industry and, in turn, for our stockholders.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2023, sales
and marketing expenses decreased by 3%, or $102,000, to $3.1 million in comparison to $3.2 million during the year ended December 31,
2022, amounting to 18% and 17% of product sales during the years ended December 31, 2023 and 2022, respectively. Sales and marketing expenses
included non-cash depreciation and stock-based compensation expenses of $182,000 and $158,000 during the years ended December 31, 2023
and 2022, respectively. Our budgetary guideline for 2023 and after is to keep these expenses under 20% of total sales. By decreasing sales
and marketing expenses by $321,000 during the fourth quarter of 2023 in comparison to the fourth quarter of 2022, we were able to reduce
sales and marketing expenses by $102,000 for the year ended December 31, 2023. We continue to leverage the efforts of our small sales
force by using animal health distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The <b>First Defense</b><sup>&#174;</sup> product
line serves dairy and beef producers by protecting their calf crop from scours, the leading cause of pre-weaning mortality and morbidity.
When calves are healthy during this crucial development period, they mature into more productive milking cows and more efficient beef
generators. Our primary competition in this category is vaccines that are also regulated for effectiveness and safety by the USDA. However,
vaccine results are inherently variable. COVID breakthrough infections in humans have reminded us that a vaccine does not guarantee immunity.
That is true for our competitors as well. In the most controlled research settings, only 80% of animals respond to a vaccine. This leaves
20% of the calf crop unprotected when the scour prevention program relies on scour vaccines. Those unprotected calves can be disease carriers.
Not only are they more susceptible to death or likely to require life-saving treatment (sometimes with antibiotics), but they also shed
pathogens into the environment creating a greater disease pressure for their herd mates. The <b>First Defense</b><sup>&#174;</sup> product
line removes the inconsistency inherent with vaccine protection. We sell the only USDA-licensed products in the scour prevention category
that are therapeutic multi-valent polyclonal antibodies. This technology eliminates a producer&#8217;s reliance on a variable vaccine
response to generate antibodies and, instead, can protect every calf equally with a measured dose of antibody-driven immunity against
both bacterial and viral scour pathogens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the twelve-month period ended December
31, 2023, we treated more calves than our next largest calf-level competitive product, which is a vaccine administered to the newborn
at birth. Compared to the dam-level competitive products (which are vaccines given to the cow pre-calving), we are second in sales dollars
to the market leader. Despite these successes, there remains significant opportunity to displace more competition within North America.
There is also opportunity to grow our sales by expanding into international markets. We are being strategic in how we invest in international
market development in order not to divert our limited resources away from achieving domestic growth, which is often more efficient to
obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that <b>Re-Tain</b><sup>&#174;</sup> could
revolutionize the way that mastitis is managed by making earlier treatment of subclinical infections (while these cows are still producing
saleable milk) economically feasible by not requiring a milk discard or a meat withhold during, or for a period of time after, treatment.
No other FDA-approved mastitis treatment product on the market can offer this value proposition. We believe we can demonstrate a return
on investment to the dairy producer and the milk processor that will justify a premium over other mastitis treatments on the market today,
which are all sold subject to milk discard and meat withhold requirements. By creating this value for our customers, we believe we can,
in turn, create value for our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>Re-Tain<sup>&#174;</sup></b> could increase the
lifetime profitability of a cow and reduce disease transfer to herd mates. It is common practice to move sick cows from their regular
herd group to a sick cow group for treatment and the related milk discard. This movement causes stress on the cow and a reduction in milk
production. While practices may vary farm-to-farm, there would be no requirement to move cows treated with our product, allowing this
costly drop in production to be avoided. It is generally current practice to treat mastitis only when the disease has progressed to the
clinical stage where the milk from an infected cow cannot be sold, leaving most subclinically infected cows untreated. Without a milk
discard cost, we expect producers to be more motivated to identify and treat cows at the subclinical stage. This creates a substantial
animal welfare benefit. By treating mastitis early at the subclinical level, producers could preserve optimal milk yields. We also know
that animals infected with subclinical mastitis have higher abortion rates and often progress to the clinical disease state requiring
antibiotic treatment and milk discard. We believe that societal animal welfare objectives will put more and more pressure on the industry
to treat cows with subclinical infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The over-use of antibiotics that are medically
important to human healthcare is a growing public health concern of our society and an active issue with the FDA, largely because of the
growing evidence that this over-use contributes to antibiotic resistance and the rise of &#8220;super-bugs&#8221;. Sustainability objectives
require that less antibiotics be used in food producing animals, yet a new FDA-approved drug to treat mastitis has not been developed
in years. Our product improves sustainability by utilizing a bacteriocin as an alternative to traditional antibiotics that are used in
human medicine. In the big picture, we are introducing an entirely new class of antimicrobial as an animal drug, a bacteriocin, that does
not promote resistance against antibiotics used in human medicine making it more socially responsible. The industry could keep treating
this very significant disease with traditional antibiotics, but it takes innovation to bring a bacteriocin like Nisin to market. <b>Re-Tain<sup>&#174;</sup></b>
would, when introduced, offer a needed alternative to these traditional antibiotics, while at the same time improving milk quality and
the quantity of milk produced by treated cows. We believe our product fits very well with where the industry is going to be in the coming
years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
with all new products, the market determines the value. Our objective is to gain market acceptance of this new product concept as we develop
a new product category. Despite our product&#8217;s exciting benefits, it will take time to change this longstanding treatment</span>
paradigm and develop this new market. It will take time for the market to understand, evaluate, implement and adapt to the use and benefits
of <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>. <span style="font-family: Times New Roman, Times, Serif">Based
on consultations with industry experts and key opinion leaders, we have opted to carefully control the launch of this novel product over
the first 18 to 24 months after FDA approval, as we seek to transform the way that mastitis is treated in the dairy industry over the
long term. Our goal is to help early adopters select treatment candidates, develop easy to use protocols, optimize treatment results and
realize a positive return on their investment. We intend to limit initial distribution of <b>Re-Tain<sup>&#174; </sup></b>to a level that
enables our sales team to select the optimal dairy farms at which to introduce <b>Re-Tain<sup>&#174; </sup></b>and to limit the initial
number of participating farms so that the desired levels of support and guidance relating to effective usage of <b>Re-Tain<sup>&#174; </sup></b>can
be provided with our available resources.&#160;We recognize that it will be important to manage expectations from the producer to the
milk processor because it is possible that processors may express reservations with regards to the zero milk discard claim. Our Controlled
Launch strategy reduces the amount of inventory that we would need to build at risk before regulatory approval is achieved. This strategic
choice means that we have elected not to pursue an alternative strategy that might have maximized short-term, initial sales quickly through
a mass market approach where we provide product to distribution and let them sell it to as many farms as possible. While we are dedicated
to increasing our sales revenue, we must consider the damage a mass market strategy could cause to the long-term value of the product.
We have seen products sold by much larger companies that were substantially damaged by such failed market launch strategies. We continue
to develop detailed launch plans, focusing on the readiness of dairy operators to successfully introduce <b>Re-Tain<sup>&#174;</sup></b>
to their herds. We believe that these prudent steps, while potentially leading to lower initial <b>Re-Tain<sup>&#174;</sup></b> revenues,
may create a smooth and successful launch and could safeguard the longer term performance of our investment in <b>Re-Tain<sup>&#174;</sup></b>.
We also believe that the operational adjustments and accommodations that dairy farmers will need to make to effectively use <b>Re-Tain<sup>&#174;</sup></b>
and avoid the potential problems described under <b>PART I: ITEM 1A &#8211; RISK FACTORS</b>, to this Annual Report will not be so burdensome
as to deter its adoption and usage. Our overarching objective is to minimize the risk of early-stage unsatisfactory outcomes that could
harm the longer-term prospects and market acceptance of <b>Re-Tain<sup>&#174;</sup></b>. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Administrative Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2023, administrative
expenses decreased by 6%, or $130,000, to $2.1 million in comparison to $2.3 million during the year ended December 31, 2022. Administrative
expenses included the accrual of $222,000 in deferred compensation expense (consisting of earned and unused paid time off) during the
first quarter of 2022. This accrual was increased by $8,000 during 2023 reflecting current wage rates. Administrative expenses amounted
to 12% of product sales during both of the years ended December 31, 2023 and 2022. Administrative expenses included non-cash depreciation
and stock-based compensation expenses of $210,000 and $148,000 during the years ended December 31, 2023 and 2022, respectively. We strive
to be efficient with these expenses while funding all the legal, audit and other costs associated with being a publicly-held company.
Given the growth in our business, our administrative staff has increased to four employees reporting to our CEO. Prior to 2014, we had
limited our investment in investor relations spending. Beginning in the second quarter of 2014, we initiated an investment in a more active
investor relations program. Given travel restrictions related to the COVID-19 pandemic, this initiative has pivoted to a virtual meeting
format, which is less expensive. Having experienced this efficiency, it is our intent to continue with the same strategy, for the most
part, even as travel restrictions have been largely eliminated. At the same time, we continue to provide full disclosure of the status
of our business and financial condition in three quarterly reports and one annual report each year, as well as in Current Reports on Form
8-K when legally required or deemed appropriate by management. We believe these efforts have helped us access the capital markets to fund
our growth objectives. Considering inflation and all the necessary support services that fit into this category, we believe that approximately
$2 million to $2.5 million per year is an efficient budget goal to fund the administrative expenses of a publicly-held company.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>Net Operating Loss</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2023, our
net operating loss of $5.7 million was significantly larger than our net operating loss of $2.3 million during the year ended December
31, 2022. The $3.4 million increase in our net operating loss during the year ended December 31, 2023 was caused by the $3.8 million decrease
in gross margin, offset, in part, by a $330,000 reduction in operating expenses.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>Other Expenses, net </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2023, other
expenses, net, aggregated $22,000 in comparison to other expenses, net, of $187,000 during the year ended December 31, 2022. <span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2023, other income included insurance recovery income of $365,000 paid under our business interruption policy
related to the product contamination losses previously described and a recovery from a vendor&#8217;s insurance policy related to an equipment
malfunction that were received during the third quarter of 2023. No such insurance recoveries were received during 2022. Interest expense
increased to $476,000 during the year ended December 31, 2023 from $349,000 during the year ended December 31, 2022. Non-cash amortization
of debt issuance and debt discount costs (which is included as a component of interest expense) was $23,000 and $8,000 during the years
ended December 31, 2023 and 2022, respectively. </span>We anticipate that our interest expense will be $563,000 and $492,000 during the
years ending December 31, 2024 and 2025, respectively. <span style="font-family: Times New Roman, Times, Serif">Interest income was $97,000
and $153,000 during the years ended December 31, 2023 and 2022, respectively. </span>The loss (gain) on disposal of <span style="font-family: Times New Roman, Times, Serif">property,
plant and equipment was $8,000 and ($7,000) during the years ended December 31, 2023 and 2022, respectively. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-style: normal"><b>Loss Before Income Taxes
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2023, our
loss before income taxes was $5.8 million in comparison to our loss before income taxes of $2.5 million during the year ended December
31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Income Taxes and Net Loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the years ended December 31, 2023 and
2022, we recorded income tax expense of $5,000 and $8,000, respectively, which is comprised of minimum state tax liabilities. Our net
loss of $5.8 million, or $0.75 per basic share, during the year ended December 31, 2023 was in comparison to net loss of $2.5 million,
or $0.32 per basic share, during the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have substantial net operating loss carryforwards
that largely offset future income tax expense. As of December 31, 2023, our federal net operating loss carryforward was $17.8 million.
As of December 31, 2023, our state net operating loss carryforward was $4.7 million. On December 22, 2017, the Tax Cuts and Jobs Act was
signed into law. This legislation made significant changes in the U.S. tax laws, including a reduction in the corporate tax rates, changes
to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the
U.S. corporate tax rate from 34% to 21%. Our income tax rate differs from this statutory tax rate primarily because we are currently providing
for a full valuation allowance against our deferred tax assets. While we are recording this full valuation allowance, we are not recognizing
the benefit of our tax losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the results discussed above from
our Statements of Operations, we believe it is important to consider our Statements of Cash Flows in the accompanying audited financial
statements to assess the cash generating ability of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Critical Accounting Policies and Estimates	</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The audited financial statements are presented
on the basis of accounting principles that are generally accepted in the United States. All professional accounting standards that were
effective and applicable to us as of December 31, 2023 have been taken into consideration in preparing the financial statements. The preparation
of financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates. Significant
estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold. We base our estimates on
historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions. We have chosen to highlight certain policies that we
consider critical to the operations of our business and understanding of our financial statements. These critical accounting estimates
have been consistently applied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We sell products that provide <b>Immediate Immunity&#8482;</b>
to newborn dairy and beef cattle. We recognize revenue in accordance with the five step model in ASC 606. These include the following:
i) identification of the contract with the customer, ii) identification of the performance obligations in the contract, iii) determination
of the transaction price, iv) allocation of the transaction price to the separate performance obligations in the contract and v) recognition
of revenue associated with performance obligations as they are satisfied. We recognize revenue at the time of shipment (including to distributors)
for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that
collectability is reasonably assured. We do not bill for or collect sales tax because our sales are generally made to distributors and
thus our sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns.	</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. Inventory is a critical accounting
policy because of the estimates and assumptions used by management to determine its cost accounting and because of the variability of
the cost per dose due to fluctuations in the biological yield.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7A &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8 &#8212; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our financial statements, together with the notes thereto and the reports
of the independent registered public accounting firms thereon, are set forth on Pages F-1 through F-25 at the end of this Annual Report.
The index to these financial statements is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 89%; padding-left: 10pt; text-indent: -10pt"><a href="#fin_003">Report of Wipfli LLP, Independent Registered Public Accounting Firm (PCAOB ID#<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-17777">344</ix:nonNumeric>)</a></td> <td style="width: 11%; padding-left: 10pt; text-align: center">F-1</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_001">Balance Sheets as of December 31, 2023 and 2022</a></td> <td style="padding-left: 10pt; text-align: center">F-2</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_002">Statements of Operations during the years ended December 31, 2023 and 2022</a></td> <td style="padding-left: 10pt; text-align: center">F-3</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_004">Statements of Stockholders&#8217; Equity during the years ended December 31, 2022 and 2023</a></td> <td style="padding-left: 10pt; text-align: center">F-4</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_005">Statements of Cash Flows during the years ended December 31, 2023 and 2022</a></td> <td style="padding-left: 10pt; text-align: center">F-5 to F-6</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_006">Notes to Audited Financial Statements</a></td> <td style="padding-left: 10pt; text-align: center">F-7 to F-25</td></tr> </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-indent: -0.65in"><b>&#160;</b></p><div>

</div><div><a id="a_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-indent: -0.65in"><b>ITEM 9 &#8212; CHANGES IN
AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9A &#8212; CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Disclosure Controls and Procedures: </i>Our management,
with the participation of the individual who serves as our principal executive and principal financial officer, evaluated the effectiveness
of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of
1934, as amended (the Exchange Act)) as of December 31, 2023. Based on this evaluation, that officer concluded that our disclosure controls
and procedures were effective as of that date. Disclosure controls and procedures are designed to ensure that information required to
be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within
the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our principal
executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Management&#8217;s Annual Report on Internal
Control Over Financial Reporting:</i> The management of the Company is responsible for establishing and maintaining adequate internal
control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. We conducted an evaluation of the effectiveness of the internal controls over financial reporting based
on the framework in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission. This evaluation included a review of the documentation of controls, evaluation of the design effectiveness of controls, testing
the operating effectiveness of the controls and a conclusion on this evaluation. Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide
only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. This Annual Report does not include an attestation report from our independent
registered public accounting firm regarding internal control over financial reporting. Management&#8217;s internal control report was
not subject to annual or quarterly attestation by our independent registered public accounting firm pursuant to rules of the Securities
and Exchange Commission that permit the Company to provide only management&#8217;s report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Material Weaknesses in Internal Controls Over
Financial Reporting: </i>Management assesses the effectiveness of the Company&#8217;s internal control over financial reporting at the
end of each quarter. During our assessment for the second quarter of 2023, we identified one material weakness where we did not properly
capitalize non-cash depreciation expense as a component of inventory, which would have understated the value of our inventory as of June
30, 2023 by approximately $387,000 if the error had not been detected before we issued our Quarterly Report on Form 10-Q. This error had
no impact on our product sales or cash position. We do believe that the design of our internal controls is effective, but those internal
controls were not effectively operating. We have implemented some changes to our internal controls over financial reporting, including
seeking additional consulting with subject matter experts on this matter. We remediated this material weakness in internal controls during
the third quarter of 2023. Based on our assessment for the fourth quarter of 2023, we have concluded that our internal controls over financial
reporting were effective as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Changes in Internal Controls over Financial
Reporting: </i>Our principal executive and principal financial officer and our Director of Finance and Administration periodically evaluate
any change in internal control over financial reporting which has occurred during the prior fiscal quarter. With the exception of the
improvements to our internal controls described in the previous paragraph, we have concluded that there was no change in our internal
control over financial reporting that occurred during the quarter ended December 31, 2023 that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9B &#8212; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-17778"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-17779"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-17780"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-17781">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9C &#8212; DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10 &#8212; DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEADERSHIP STRUCTURE OF THE BOARD OF DIRECTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With approval from the Board of Directors, the
Compensation and Stock Option Committee determined that the title of President and CEO should be given to an individual not being the
same person holding the title of Chair. The objective of this policy is to avoid a concentration of authority in any one person. Mr. Michael
F. Brigham has served as President and CEO since February 2000. He also serves as the Company&#8217;s Principal Financial Officer. Mr.
Brigham is responsible for the day-to-day operations of the Company and for managing the actions of the two other executive officers,
as well as those of several senior managers. Since February 2013, Dr. David S. Tomsche has served as Chair of the Board of Directors,
leading the Company as its independent non-executive board chair. Dr. Tomsche works with the CEO in preparing the agenda for each board
meeting and presides over all board meetings and meetings of the non-employee directors. He provides advice to the CEO and serves as principal
liaison between the board and the CEO. Ms. Bobbi Jo Brockmann has served as Vice President of Sales and Marketing since February 2015.
Ms. Elizabeth L. Williams has served as Vice President of Manufacturing Operations since April 2016. Dr. Joseph H. Crabb served as Vice
President and Chief Scientific Officer from December 1998 to February 2022, and he also served as Chair of the Board of Directors from
June 2009 to February 2013. It is the policy of the Board of Directors to have a portion of the meeting without the presence of the executive
officers each time that the board or any of its committees meets to assure that candid discussions of business matters are conducted with
and without the influence of the executive officers. The board delegates certain authority and responsibility to its committees, as described
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE BOARD OF DIRECTORS AND ITS COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2023, the Board
of Directors of the Company held four regular meetings and two special meetings and took action by unanimous written consent four times.
The committees of the Board of Directors are the Audit Committee, the Compensation and Stock Option Committee and the Nominating Committee.
During the year ended December 31, 2023, each director attended at least 75 percent of the aggregate of (i) the total number of meetings
of the Board of Directors and (ii) the total number of meetings held by all committees of the board on which he or she served (during
the periods that he or she served). The board has not set a formal policy for required meeting attendance. A high level of attendance
and participation is expected, and to date directors have fulfilled this expectation. At the first meeting of the board following this
year&#8217;s Annual Meeting, executive officers will be appointed and, effective upon the election of directors at this year&#8217;s Annual
Meeting, directors will be appointed to serve on the various board committees until the next Annual Meeting and until their successors
are elected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board of Directors has established an Audit Committee for the purpose
of overseeing the accounting and financial reporting processes of the Company and the audits and reviews of its financial statements.
The Audit Committee engages the Company&#8217;s Independent Registered Public Accounting Firm, consults with such auditors with regard
to audit plans, reviews the annual reports of the independent auditors, oversees the adequacy of the Company&#8217;s internal operating
procedures and controls, meets with management and the auditors to review quarterly and annual financial results, authorizes the public
release of press releases covering financial results, reviews and authorizes quarterly and annual reports filed with the SEC and otherwise
oversees compliance with certain legal, ethical and regulatory matters. The development and manufacture of efficacious products with and
without regulatory approval is subject to considerable risk. The Audit Committee takes the lead on oversight of credit, liquidity and
operational risk, but the entire board, in conjunction with the executive officers, is very involved with reviewing Audit Committee recommendations
and making independent assessments of risks in all areas of the Company&#8217;s business. The Company does not have a specific risk management
department, but the Company&#8217;s Director of Finance and Administration and its President and CEO manage and contract for the Company&#8217;s
insurance coverages in consultation with outside experts, in addition to identifying, managing and monitoring risk in areas not specifically
covered by insurance. The Director of Finance and Administration reports to the President and CEO, who reports to the board. The Audit
Committee&#8217;s current members are Mr. Gathagan, Mr. Rosgen, Dr. Tomsche and Mr. Wainman. Mr. Wainman serves as Chair of the Audit
Committee. All members of the Audit Committee meet the heightened independence and expertise requirements for audit committees under applicable
SEC and NASDAQ Stock Market rules. The Audit Committee held eight meetings during the year ended December 31, 2023. The Audit Committee
Report can be found later in this Annual Report, and the &#8220;Charter and Powers of the Audit Committee&#8221; has been posted on the
Company&#8217;s website (http://immucell.com/wp-content/uploads/2017/05/charter.pdf).&#160;Information on the Company&#8217;s website
does not constitute part of this Annual Report.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-indent: -52pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Mr. Paul R. Wainman, who joined our Board of
Directors in March of 2014 and currently serves as Chair of the Audit Committee, and Mr. Bryan K. Gathagan, who joined our Board of Directors
in June of 2023, both meet the criteria for &#8220;audit committee financial expert&#8221; as defined by SEC rules. It is the opinion
of the Company&#8217;s Board of Directors that the Company addresses its audit functions with a depth of penetration and rigor that meets
the intent of the requirements of the Sarbanes-Oxley Act for the following reasons:</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-indent: -52pt"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-indent: -52pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All four members of the Audit Committee are independent directors, as defined by the SEC and NASDAQ.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The four members of the Audit Committee have knowledge of accounting for both their own businesses as well as for the Company. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal audit work of the Company is performed by its Director of Finance and Administration, two Finance and Administrative Associates and one Manager of Administrative Operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also continuously reviews, at its own initiative, the expertise of the members of its Board of Directors and its Audit Committee.</span></td></tr>
  </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-indent: -52pt"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-indent: -52pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The Board of Directors has
established a Compensation and Stock Option Committee (Compensation Committee) for the purpose of reviewing and recommending salary,
bonus and other benefits for executive officers and directors of the Company. The Compensation Committee is responsible for administering
the Company&#8217;s 2010 Stock Option and Incentive Plan and the 2017 Stock Option and Incentive Plan. The Compensation Committee&#8217;s
current members are Ms. Basse and Mr. Rosgen, each of whom are independent directors. Mr. Rosgen serves as Chair of the Compensation
Committee. The Compensation Committee held six meetings during the year ended December 31, 2023. The Compensation Committee does not
have a charter but instead operates within the authority provided by the Company&#8217;s By-laws and authorizing resolutions adopted
by the board. Its recommendations on executive and director compensation are subject to review and final approval by the Board of Directors,
a majority of whose members are independent directors. The Compensation Committee considers recommendations from Mr. Brigham, the Company&#8217;s
President and CEO, relevant to a determination of executive and director compensation, but neither he nor Ms. Brockmann participates
in votes of the Compensation Committee or the board in this regard. In recent years, the Compensation Committee has not retained or relied
upon outside consultants to assist in its determination of executive or director compensation but does consider available compensation
data. During the end of 2021 and beginning of 2022, the Compensation Committee did consider certain information provided by a consultant.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board of Directors has established a Nominating
Committee for the purpose of recommending to the full board the number of directors to serve on the board, criteria for board membership
and nominees for election to the board. In doing so, the Nominating Committee considers the integrity and relevant business experience
of each nominee. The Nominating Committee values diversity, believing that the Company benefits from decision making that includes a range
of opinions, points of view and experience. For instance, the Nominating Committee would not want a board comprised only of directors
having principally financial expertise or only of directors whose principal experience is in the dairy and beef industries. Likewise,
the Nominating Committee believes that a board consisting of all men or all women would not be as strong as a gender-diverse board. While
there is always room for improvement, the Nominating Committee believes that it has made substantial progress towards achieving these
board diversity goals. To be considered for nomination to the board, a candidate must meet the following minimum criteria: 1) reputation
for integrity and high ethical standards, 2) willingness and ability to contribute positively to the Company&#8217;s decision-making process,
3) absence of any conflict of interest, or appearance of conflict of interest and 4) commitment to understanding the Company&#8217;s business
and associated business risks and to devoting adequate time and effort to create value for the Company and its stockholders. All director
nominees are recommended by the Nominating Committee and then approved by a vote of the board. The Committee&#8217;s current members are
Ms. Basse and Mr. Wainman, each of whom are independent directors. Ms. Basse serves as Chair of the Nominating Committee. The Nominating
Committee held three meetings during the year ended December 31, 2023. Upon recommendation of the Nominating Committee, the Board of Directors
adopted a charter for the Nominating Committee in December 2012. This charter sets forth the policy to be utilized by the Nominating Committee
in considering nominees identified by management to serve as directors for the Company. The Charter of the Nominating Committee has been
posted to the Company&#8217;s website (http://immucell.com/wp-content/uploads/2019/04/Nominating-Committee-Charter.pdf). The Nominating
Committee applies the same evaluation standards in considering nominees for director recommended by stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BOARD OF DIRECTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>GLORIA J. BASSE</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 63</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director since: June 2020</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></td>
    <td style="width: 70%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Basse was first elected to our Board of Directors at the 2020 Annual Meeting of Stockholders. Ms. Basse has been the senior executive director of Tonisity International, an animal nutrition company with offices in Ireland, Brazil and the United States, from 2017 to the present. Since 2016, Ms. Basse has been a Senior Associate at the Context Network, a business management and strategy consulting firm providing services to agriculture, biotechnology and food companies. She held various positions at Zoetis Inc. (formerly Pfizer Animal Health) from 1985 to 2015 and most recently served as Vice President of its U.S. pork business. Ms. Basse is a graduate of the University of Wisconsin and earned her Masters in Business Administration from the University of Rochester.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MICHAEL F. BRIGHAM</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 63</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Officer since: October 1991</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director since: March 1999</p></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Brigham was appointed to serve as President and Chief Executive Officer in February 2000, while maintaining the titles of Treasurer and Secretary, and was appointed to serve as a Director of the Company in March 1999. He previously had been elected Vice President of the Company in December 1998 and had served as Chief Financial Officer since October 1991. He has served as Secretary since December 1995 and as Treasurer since October 1991. Prior to that, he served as Director of Finance and Administration since originally joining the Company in September 1989. Mr. Brigham served as a member of the Board of Directors of the United Way of York County from 2012 to 2019, serving as its Treasurer until June 2016 and as Chair of the Board of Directors for one year and as a member of its Executive Committee. Mr. Brigham served as the Treasurer of the Board of Trustees of the Kennebunk Free Library from 2005 to 2011. He re-joined the Finance Committee of the library in 2012. Prior to joining the Company, he was employed as an audit manager for the public accounting firm of Ernst &amp; Young in New York City. Mr. Brigham earned his Masters in Business Administration from New York University in 1989 and a Bachelor of Arts degree (with a double major in Economics and Spanish) from Trinity College in Hartford, Connecticut in 1983.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BOBBI JO BROCKMANN</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 48</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Officer since: February 2015</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director since: March 2017</p></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Brockmann served as a Director of the Company from March 2017 to September 2017 and from January 2018 to the present. She was promoted to Vice President of Sales and Marketing in February 2015. She joined the Company as Director of Sales and Marketing in January 2010. Prior to that, she had been employed as Director of Sales since May 2008 and Sales Manager from February 2004 to April 2008 at APC, Inc. of Ankeny, Iowa, a developer and marketer of functional protein products for animal health and nutrition. Prior to that, she held other sales and marketing positions at APC,&#160;W &amp; G Marketing Company, Inc. of Ames, Iowa, The Council for Agricultural Science and Technology of Ames, Iowa and Meyocks Group Advertising of West Des Moines, Iowa after graduating from Iowa State University.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>ImmuCell Corporation</b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>BRYAN K. GATHAGAN</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 56</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director since: June 2023</p></td>
    <td style="font-size: 10pt; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix, he was a senior executive and Vice President of IT and Finance for Intervet, Inc. and oversaw various finance, IT, and general business functions between 1998 to 2008, including 3 years in a global role based in The Netherlands. Before entering the animal health industry, he served as a Vice President at MBNA and Norwest Bank responsible for various IT functions and started his career in IT roles at the University of Maryland, Baltimore County (UMBC). He holds a BS in Information Systems Management from UMBC and an MS in Business from Johns Hopkins University.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>STEVEN T. ROSGEN</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 58</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director since: January 2018</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Rosgen joined the Board of Directors in January 2018 and the Audit Committee of the Board of Directors effective April 1, 2018. He is President of Strategem Research Inc., founded in 2005. Strategem&#8217;s mission is to capture and leverage customer insights when launching new technologies and revitalizing brands that have struggled in the market. Mr. Rosgen specializes in value proposition development and pricing strategy. He has worked with global brands across a range of industries including multiple agricultural sectors (ag informatics, animal health, biotechnology, crop protection, fertilizer, equipment, finance, grain marketing, livestock production, retail and seed technology). Before founding Strategem, Mr. Rosgen was a senior partner with Street Smart Strategic Planning and Research Coordinator for Baker Lovick/BBDO Advertising. He holds a Bachelor of Commerce Degree from the University of Calgary.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>David
    S. Tomsche, D.V.M.</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 67</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director since: December 2006</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tomsche was appointed to serve as Chair of the Board of Directors in February 2013. He served on the Nominating Committee of the Board of Directors until September 2017. He served on the Audit Committee from February 2014 through March 2014 and rejoined this committee in June 2021. He is a large animal veterinarian and owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc., an animal health distribution and milking system installation company) and of J-t Enterprises of Melrose, Inc., an exporter of ImmuCell products. He also is a dairy producer. He obtained his degrees from the University of Minnesota.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>PAUL
    R. WAINMAN</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Age: 59</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director since: March 2014</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Wainman was appointed to the Board of Directors on March 31, 2014 and is a member of the Audit and Nominating Committees and serves as Chair of the Audit Committee. He qualifies to serve as a &#8220;financial expert&#8221; given his background in accounting and finance. Mr. Wainman served as Chief Financial Officer of Hancock Lumber, a 725-employee lumber and building products company located in Casco, Maine, from February 2016 and its President and CFO from January 2020 until, most recently, becoming President and CEO in January 2023. From April 2015 until February 2016, he was a business strategy and financial consultant specializing in the paper and greeting card industry. Prior to that, he was President of Kleinfeld, a personalized wedding stationery company, from September 2013 until April 2015. &#160;From 2005 to 2012, he was President and CEO of William Arthur, Inc., a division of Hallmark Cards, where he led a 275-employee manufacturer of luxury stationery products. Prior to that, he served another division of Hallmark Cards as CFO and COO from 1998 to 2004. He obtained a degree in Accounting and Financial Control from Sheffield City University in England and qualified as a Chartered Accountant of England and Wales in 1990.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each of these individuals brings distinct skills, perspectives and
attributes to the Board of Directors. Ms. Basse has extensive animal health marketing experience. Mr. Brigham is an executive officer
who has been employed by the Company since 1989 and has a financial and accounting background. Ms. Brockmann is an executive officer who
has been employed by the Company since 2010 and has extensive experience in the sales and marketing of products to the dairy and beef
industries. Mr. Gathagan has significant experience with information systems and finance as well as relevant animal health industry experience.
Mr. Rosgen has a depth of experience in sales and marketing and product branding. Dr. Tomsche is a veterinarian and owner of a distribution
outlet of products and services for animals, as well as an investor in and owner of dairy farms, and brings to the board substantial expertise
in our industry. Mr. Wainman has extensive managerial and financial training and expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in">Our executive officers as of March 8, 2024 were
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29%; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MICHAEL F. BRIGHAM</b></span></td>
    <td style="width: 71%; padding-bottom: 8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Biography above.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BOBBI JO BROCKMANN</b></span></td>
    <td style="padding-bottom: 8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Biography above.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELIZABETH L. WILLIAMS</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(Age: 68, Officer since April 2016) joined the
Company in April 2016 as Vice President of Manufacturing Operations. Previously, she led the U.S. Region for Zoetis as Vice President,
Global Manufacturing and Supply. Prior to that, she held multiple Site Leader positions at Pfizer Animal Health facilities in Lincoln,
Nebraska (2008-2011), Conshohocken, Pennsylvania (2006-2008) and Lee&#8217;s Summit, Missouri (2003-2006). She led the manufacturing
organization (1999-2003) and the Process and Product Development group (1995-1999), achieving registration, approval and successful scale-up
of five new products at the Lee&#8217;s Summit facility. She earned her Masters of Business Administration from Rockhurst University
in Kansas City, Missouri and her Bachelor&#8217;s degree in Biology from the University of Missouri.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>EXECUTIVE OFFICERS OF
THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no family relationship between any director, executive officer
or person nominated or chosen by the Company to become a director or executive officer. Except for Mr. Brigham and Ms. Brockmann (both
of whom are Company employees), each of the Company&#8217;s existing directors or nominees qualifies as an &#8220;independent director&#8221;
as defined under applicable NASDAQ Stock Market rules. In evaluating the independence of directors, the board did consider related party
transactions described elsewhere in this Annual Report. Any vacancies that may occur during the year may be filled by the Board of Directors
to serve until the next Annual Meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CODE OF BUSINESS CONDUCT AND ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December 2003, the Board of Directors of the
Company adopted a Code of Business Conduct and Ethics (the Code) that applies to all employees of the Company, including the Company&#8217;s
President and CEO and Director of Finance and Administration. This Code is a set of written standards that are designed to deter wrongdoing
and to promote: (i) honest and ethical conduct, (ii) full, fair, accurate, timely and understandable disclosure in reports filed with
the SEC, (iii) compliance with applicable laws, (iv) prompt internal reporting of violations of the Code and (v) accountability for adherence
to the Code. On March 19, 2014, the Board of Directors approved several minor revisions to this Code. This Code has been posted on the
Company&#8217;s website (http://immucell.com/wp-content/uploads/2017/05/2014-Code-of-Business-Conduct-and-Ethics-revision.pdf) and was
filed as Exhibit 14 to the Company&#8217;s Current Report on Form 8-K dated March 20, 2014. The Company will mail a copy of its Code of
Business Conduct and Ethics to any interested party without charge, upon request. Such requests may be made by mail to the Company&#8217;s
Secretary at ImmuCell Corporation, 56 Evergreen Drive, Portland, Maine 04103.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING
COMPLIANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Section 16 of the Securities Exchange Act of
1934 requires the Company&#8217;s directors, executive officers and persons who own more than ten percent of a registered class of the
Company&#8217;s equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of common stock
and other equity securities of the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulation
to furnish the Company with copies of all Section 16(a) reports they file. To the best of the Company&#8217;s knowledge, based solely
on review of the copies of such reports furnished to the Company and written representations that no other reports were required, during
the year ended December 31, 2023, the Company&#8217;s directors, executive officers and greater than ten percent beneficial owners complied
on a timely basis with all applicable Section 16(a) filing requirements.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11 &#8212; EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table contains information as to
the compensation paid by the Company to its non-executive directors for services rendered during the year ended December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Fees </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Earned or </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Paid in&#160;Cash</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option<br/> Awards</b><sup>(1)(2)</sup></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">All Other Compensation</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Gloria J. Basse</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">David S. Cunningham</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bryan K. Gathagan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Steven T. Rosgen</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">David S. Tomsche, D.V.M.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Paul R. Wainman</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
amount represents the total non-cash compensation expense related to stock options granted during the year ended December 31, 2023, which
is being expensed over the three-year vesting period from grant date.</span></td>
</tr>
<tr style="vertical-align: top">
    <td style="width: 4%; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="width: 96%; text-align: left; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, Ms. Basse had 35,000 stock options outstanding; Mr. Cunningham had no stock options outstanding; Mr. Gathagan had 15,000 stock options outstanding; Mr. Rosgen had 20,000 stock options outstanding; Dr. Tomsche had 20,000 stock options outstanding; and Mr. Wainman had 20,000 stock options outstanding.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Officers of the Company, who are also directors, do not receive additional
compensation for attendance at Board of Directors&#8217; meetings or committee meetings (and no such employee directors are members of
any of the Company&#8217;s Committees). Effective January 1, 2022, this annual fee paid to non-employee directors was increased from $24,000
to $28,000. Effective January 1, 2022, compensation for members of the Audit Committee was set at $2,000 per year. Effective January 1,
2013, the additional compensation for the Chair of the Board of Directors was set at $12,000 per year (Dr. Tomsche served as Chair during
2023). All fees paid to directors are paid quarterly. Historically, fees paid to directors were payable on the first day of the quarter
during which they were earned. However, beginning in the first quarter of 2023 fees paid to directors become payable at the end of the
quarter during which they are earned. No other increases in these fees have been made since those noted above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 19, 2018, each of the then serving outside
directors were granted non-qualified stock options to purchase 15,000 shares of common stock under the 2017 Stock Option and Incentive
Plan. These options had an exercise price equal to $7.08 per share, which was the fair market value of the common stock on the date of
grant, and they vested on March 18, 2021. These options expired March 18, 2023. At the time first appointed to the board, Ms. Basse was
granted a non-qualified stock option to purchase 15,000 shares of common stock under the 2017 Stock Option and Incentive Plan with terms
similar to those previously granted to all other directors. Ms. Basse&#8217;s options have an exercise price equal to $4.81 per share,
which was the fair market value of the common stock on the date of grant (June 29, 2020), and vest on June 28, 2023. These options expire
if not exercised by June 28, 2025 or, if earlier, within one month (twelve months if in the case of death or disability) after termination
of service as a director. On June 17, 2021, each of the then serving outside directors were granted non-qualified stock options to purchase
10,000 shares of common stock under the 2017 Stock Option and Incentive Plan. These options have an exercise price equal to $10.04 per
share, which was the fair market value on the date of grant, and they vest on June 16, 2024. These options expire if not exercised by
June 16, 2026 or, if earlier, within one month (twelve months in the case of death or disability) after termination of service as a director.
On December 15, 2022, each of the then serving outside directors were granted non-qualified stock options to purchase 10,000 shares of
common stock under the 2017 Stock Option and Incentive Plan. These options have an exercise price equal to $6.52 per share, which was
the fair market value on the date of grant, and they vest on December 14, 2025. These options expire if not exercised by December 14,
2027 or, if earlier, within one month (twelve months in the case of death or disability) after termination of service as a director.
At the time first appointed to the board, Mr. Gathagan was granted a non-qualified stock option to purchase 15,000 shares of common stock
under the 2017 Stock Option and Incentive Plan with terms similar to those previously granted to all other directors. Mr. Gathagan&#8217;s
options have an exercise price equal to $5.11 per share, which was the fair market value of the common stock on the date of grant (June
28, 2023), and vest on June 27, 2026. These options expire if not exercised by June 27, 2028 or, if earlier, within one month (twelve
months if in the case of death or disability) after termination of service as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 46; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEMNIFICATION AGREEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has entered into indemnification agreements
with its directors and executive officers in substantially the form approved by the stockholders at the 1989 Annual Meeting, as recently
updated. The agreements include procedures for reimbursement by the Company of certain liabilities and expenses which may be incurred
in connection with service as a director or executive officer. The Company expects to enter into indemnification agreements with individuals
who become directors in the future, as well as such executive officers of the Company as the Board of Directors may from time to time
determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the By-laws, executive officers are elected
by the Board of Directors at its first meeting following each Annual Meeting of Stockholders of the Company, and each serves for a one-year
term and until his or her successor is chosen and qualified, but all officers are employees of the Company &#8220;at will&#8221;, and
their service may be terminated at any time without payment of severance or similar benefits, except as described under <b>EMPLOYMENT
AGREEMENTS</b> below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SUMMARY COMPENSATION TABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table contains information as to
the total compensation paid by the Company to its named executive officers for services rendered during the years ended December 31, 2023
and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name and Principal Position</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<sup>(1)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Option<br/> Awards<sup>(2)</sup></b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other<br/> Compensation<sup>(3)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Michael F. Brigham</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">355,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">39,968</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">395,235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 0.125in; text-align: left">President, Chief Executive Officer, Treasurer and Secretary</td><td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">2022</td><td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">342,944</td><td style="vertical-align: top; text-align: left">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">0</td><td style="vertical-align: top; text-align: left">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">4,500</td><td style="vertical-align: top; text-align: left">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">252,500</td><td style="vertical-align: top; text-align: left">&#160;</td><td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">599,944</td><td style="vertical-align: top; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bobbi Jo Brockmann</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">323,521</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Vice President of Sales and Marketing</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">259,522</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">287,681</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Elizabeth L. Williams</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">264,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,899</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">312,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Vice President of Manufacturing Operations</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">2022</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">254,678</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">4,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">20,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">$</td><td style="vertical-align: top; text-align: right">279,938</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus (or variable compensation) is reported in the year earned, even if paid in the beginning of the next year.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This amount represents the total non-cash compensation expense related to stock option awards granted during the year that they were earned, which is being expensed over the three-year vesting period from grant date.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This amount includes Company-paid contributions to a 401(k) Plan, health insurance premiums and life insurance premiums that are available to all employees of similar employment status, if elected. For Mr. Brigham, this amount includes approximately $8,000 and $222,000 worth of earned and unused paid time off described under <b>EMPLOYMENT AGREEMENTS</b> below that was accrued during the first quarter of 2023 and 2022, respectively, and is due to be paid to Mr. Brigham upon his separation from the Company. For Ms. Brockmann, this amount also includes the personal use of a Company-owned vehicle.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Generally during the first quarter of each year,
annual salaries and bonuses for these named executive officers are determined at the discretion of the Compensation and Stock Option Committee.
Effective January 30, 2021, the annual salary for Mr. Brigham was increased by 2% to $332,212. Effective February 26, 2022, the annual
salary for Mr. Brigham was increased by 4% to $345,500. Effective February 25, 2023, the annual salary for Mr. Brigham was increased by
3.5% to $357,592. No such annual increase was provided to Mr. Brigham for 2024. Effective January 30, 2021, the annual salary for Ms.
Brockmann was increased by 2% to $251,400, and she was paid $12,645 in variable compensation related to her 2020 performance. Effective
February 26, 2022, the annual salary for Ms. Brockmann was increased by 4% to $261,456, and she was paid $22,500 and awarded 18,000 stock
options with an exercise price of $8.15 per share in variable compensation related to her 2021 performance. Effective February 25, 2023,
the annual salary for Ms. Brockmann was increased by 3.5% to $270,606, and she was paid a discretionary bonus of $25,000 on March 1, 2023.
Effective February 10, 2024, the annual salary for Ms. Brockmann was increased by 4% to $281,430. Effective January 30, 2021, the annual
salary for Ms. Williams was increased by 4% to $246,707. Effective February 26, 2022, the annual salary for Ms. Williams was increased
by 4% to $256,575. Effective February 25, 2023, the annual salary for Ms. Williams was increased by 3.5% to $265,555, and she was paid
a performance bonus of $25,000 on August 30, 2023. Effective February 10, 2024, the annual salary for Ms. Williams was increased by 4%
to $276,177.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective December 1, 2022 through November 30,
2023, the Company contributed approximately $18,400 per year towards the cost of family health insurance coverage for each full-time employee
electing this coverage. Effective December 1, 2023 through November 30, 2024, this annual contribution is $20,755. Mr. Brigham and Ms.
Brockmann elected this coverage. Effective December 1, 2022 through November 30, 2023, the Company contributed approximately $12,600 per
year towards the cost of employee and spouse health insurance coverage for each full-time employee electing this coverage. Effective December
1, 2023 through November 30, 2024, this annual contribution is $14,250. Ms. Williams elected this coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EMPLOYMENT AGREEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We enter into compensation agreements (which
are publicly filed) with our three executive officers. Effective March 28, 2022, we entered into an Amended and Restated Separation and
Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with Mr. Brigham (our President and CEO) that superseded
and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham. Upon separation from the Company for
any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among other amounts, all earned and unused
paid time off (which expense totaling $222,379 was accrued during the first quarter of 2022 and $230,162 and $222,379 was included in
accounts payable and accrued expenses on the accompanying balance sheets as of December 31, 2023 and 2022, respectively) and to receive
up to an additional $300,000 in deferred compensation (which amount is being accrued over the three-year period ending in January 2025).
This deferred compensation payment vested as to $100,000 on January 1, 2023 and an additional $100,000 on January 1, 2024. An additional
$100,00 will vest on January 1, 2025, provided that Mr. Brigham is employed by the Company as of January 2025. The vested amounts would
be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. As of December 31,
2023 and 2022, $200,000 and $100,000, respectively, was included in accounts payable and accrued expenses on the accompanying balance
sheets. In addition, upon termination of Mr. Brigham&#8217;s employment (a) by the Company other than for cause, (b) due to death or disability
or (c) by Mr. Brigham for good reason, in each case as described and defined in the Deferred Compensation Agreement, the Company agrees
to pay Mr. Brigham 100% of his then current annual base salary and a lump sum payment equal to the employer portion of the costs of continued
health benefits for Mr. Brigham and his covered dependents for a twelve-month period following termination, and certain equity incentive
awards granted to Mr. Brigham would continue to vest following such termination in accordance with the terms of the Deferred Compensation
Agreement. Incentive Compensation Agreements with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(our Vice President of Manufacturing Operations) allow these executives to earn incentive compensation if certain regulatory and financial
objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts related to these incentive
compensation agreements are accrued over the period they are earned (when it is probable that the amounts will be earned) based on our
best estimate of the amounts expected to be earned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OUTSTANDING EQUITY AWARDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stock options are the only outstanding form of
equity awards to the Company&#8217;s employees and directors. The following table contains information on stock options held by the Company&#8217;s
named executive officers that were outstanding as of December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of <br/>
Shares<br/>
 Underlying<br/>
 Unexercised<br/>

    Stock<br/>
 Options -<br/>
 Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
 Shares<br/>
 Underlying<br/>
 Unexercised<br/>
 Stock Options -<br/>
 Unexercisable<sup>(1)</sup></b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Stock<br/>
 Option <br/>
Exercise<br/>
 Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Date of <br/>
Grant</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiration<br/>
 Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Michael F. Brigham</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/10/2017</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 9%">02/09/2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/08/2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">01/07/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/15/2022</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">06/14/2032</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bobbi Jo Brockmann</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/16/2015</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/15/2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/10/2017</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">02/09/2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/08/2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">01/07/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/10/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/31/2022</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">01/30/2032</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Elizabeth L. Williams</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/04/2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">04/03/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/10/2017</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">02/09/2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/08/2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">01/07/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/10/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/15/2022</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">06/14/2032</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stock options become exercisable three years after the date of grant.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-indent: -51.85pt"><b>ITEM 12
&#8212; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth certain information
known to the Company regarding beneficial ownership of the Company&#8217;s common stock as of April 15, 2024 of (i) each person known
to the Company to be the beneficial owner of more than five percent of the Company&#8217;s common stock, (ii) each of the Company&#8217;s
directors, (iii) each of the Company&#8217;s executive officers named in the &#8220;<b>SUMMARY COMPENSATION TABLE</b>&#8221; above, (iv)
the five largest stockholders listed in this table as a group and (v) all directors and executive officers of the Company as a group:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Name of Beneficial Owner</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares
of<br/>
the<br/>
Company&#8217;s<br/>
Common<br/>
Stock<br/>
Beneficially<br/>
 Owned (1)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Percent
of<br/>
the<br/>
Company&#8217;s<br/>
Common<br/>
Stock<br/>
Beneficially<br/>
 Owned</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Sandra F., Norman H. and Brian L. Pessin (2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,182,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Jonathan E. Rothschild (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">514,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Michael F. Brigham (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Joseph H. Crabb. Ph.D. (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">David S. Tomsche D.V.M. (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Elizabeth Williams (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bobbi Jo Brockmann (8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Gloria J. Basse (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Paul R. Wainman (10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Steven T. Rosgen (11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bryan K. Gathagan (12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Directors and executive officers as a group (8 persons) (13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">524,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">The five largest stockholders listed in this table as a group (14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,213,926</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.4</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The persons named in the table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them, subject to the information contained in the footnotes to this table. The figures in the table include shares of common stock covered by stock options which are currently exercisable or will become exercisable on June 16, 2024.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The address for the Pessins is 400 East 51<sup>st</sup> Street, PH31, New York, NY 10022. The Pessins have indicated that each of them has sole voting and dispositive/investment power with respect to the shares of common stock owned by them individually: Norman H. Pessin&#8211;644,019 shares (8.3%), Sandra F. Pessin&#8211;401,819 shares (5.2%) and Brian L. Pessin&#8211;136,882 shares (1.8%).</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The address for Mr. Rothschild is c/o Arterio, Inc., 1061-B Shary Circle, Concord, CA 94518. This figure includes 226,416 shares of common stock held by Arterio Inc., a corporation owned solely by Mr. Rothschild.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 45,000 vested stock options that are described in the &#8220;<b>OUTSTANDING EQUITY AWARDS</b>&#8221; table and 11,000 shares of common stock held by the mother of Mr. Brigham. Mr. Brigham also holds 1,000 unvested stock options that were granted during 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Crabb holds these shares of common stock jointly with his former spouse. He is listed in this table for informational purposes because he is one of the five largest stockholders.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 6,987 shares of common stock held by immediate family members of Dr. Tomsche. This figure includes 10,000 stock options that vest on June 16, 2024. Dr. Tomsche also holds 10,000 unvested stock options.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure is comprised of 52,500 vested stock options that are described in the &#8220;<b>OUTSTANDING EQUITY AWARDS</b>&#8221; table. Ms. Williams also holds 1,000 unvested stock options that were granted during 2022.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 7,466 shares of common stock held by Ms. Brockmann and 1,055 shares of common stock held jointly with her spouse and 37,500 vested stock options that are described in the <b>&#8220;OUTSTANDING EQUITY AWARDS&#8221;</b> table. Ms. Brockmann also holds 18,000 unvested stock options that were granted during 2022.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure is comprised of 15,000 vested stock options and 10,000 stock options that vest on June 16, 2024. Ms. Basse also holds 10,000 unvested stock options. </span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 10,000 stock options that vest on June 16, 2024. Mr. Wainman also holds 10,000 unvested stock options.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 10,000 stock options that vest on June 16, 2024. Mr. Rosgen also holds 10,000 unvested stock options.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gathagan holds 15,000 unvested stock options.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 150,000 vested stock options and 40,000 stock options that vest on June 16, 2024.</span></td></tr>

<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This figure includes 45,000 vested stock options and 10,000 stock options that vest on June 16, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company does not permit employees or directors
to engage in hedging transactions with respect to the Company&#8217;s stock.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity Compensation Plan Information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below summarizes the common stock reserved
for issuance upon the exercise of stock options outstanding as of December 31, 2023 or that could be granted in the future:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration: none"><b>&#160;</b></span></td><td style="font-weight: normal; padding-bottom: 1.5pt"><span style="text-decoration: none"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><span style="text-decoration: none"><b>Number
    of shares<br/> to be issued upon exercise of<br/>
    outstanding options</b></span></td><td style="padding-bottom: 1.5pt; font-weight: normal"><span style="text-decoration: none"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="text-decoration: none"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: none"><b>Weighted-average<br/>
                                            exercise price of <br/> outstanding&#160;options</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="text-decoration: none"><b>&#160;</b></span></td><td style="font-weight: normal; padding-bottom: 1.5pt"><span style="text-decoration: none"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><span style="text-decoration: none"><b>Number
    of shares<br/> remaining available for future issuance<br/> under stock-based compensation plans<br/> (excluding shares reflected in
    first column <br/>
    of this table)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: normal"><span style="text-decoration: none"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="text-decoration: none">Equity compensation
    plans approved by stockholders</span></td><td style="width: 1%"><span style="text-decoration: none">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="width: 9%; text-align: right"><span style="text-decoration: none">618,500</span></td><td style="width: 1%; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="width: 1%"><span style="text-decoration: none">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="text-decoration: none">$</span></td><td style="width: 9%; text-align: right"><span style="text-decoration: none">6.82</span></td><td style="width: 1%; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="width: 1%"><span style="text-decoration: none">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="width: 9%; text-align: right"><span style="text-decoration: none">202,000</span></td><td style="width: 1%; text-align: left"><span style="text-decoration: none">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="text-decoration: none">Equity
    compensation plans not approved by stockholders</span></td><td style="padding-bottom: 1.5pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="text-decoration: none">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="text-decoration: none">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="text-decoration: none">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration: none">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="text-decoration: none">Total</span></td><td style="padding-bottom: 4pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="text-decoration: none">618,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="padding-bottom: 4pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="text-decoration: none">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="text-decoration: none">6.82</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="padding-bottom: 4pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="text-decoration: none">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="text-decoration: none">202,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="text-decoration: none">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53pt; text-indent: -53pt">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53pt; text-indent: -53pt"><b>ITEM 13 &#8212;
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup> </span></b><span style="font-family: Times New Roman, Times, Serif">product
line and <b>CMT</b>). His affiliated company purchased $231,405 and $587,677 of products from us during the years ended December 2023
and 2022, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts receivable (subject
to standard and customary payment terms) due from this affiliated company aggregated $42,507 and $46,426 as of December 31, 2023 and
2022, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The President and CEO of the Company is responsible
for reviewing related party transactions. To assist with this process, each director is asked to complete an annual questionnaire covering
transactions of this nature and other related matters. Regardless of dollar value, all related party transactions are reviewed with the
relevant director and with the entire Board of Directors, if necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except for Mr. Brigham and Ms. Brockmann (both of whom are Company
employees), each of the Company&#8217;s existing directors qualifies as an &#8220;independent director&#8221; as defined under the applicable
NASDAQ Stock Market rules. Each member of the Company&#8217;s Audit Committee, Nominating Committee, and Compensation and Stock Option
Committee are independent under the applicable NASDAQ Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 14 &#8212; PRINCIPAL ACCOUNTANT FEES AND
SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Principal Accounting Fees and Services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 12, 2019, the Company engaged Wipfli LLP
for the first time as its Independent Registered Public Accounting Firm (IRPAF) for the year ended December 31, 2019 beginning with a
customary review of the Company&#8217;s financial statements as of and for the quarter ended March 31, 2019. On March 20, 2020, the Company
engaged Wipfli LLP as its IRPAF for the year ended December 31, 2020. On March 23, 2021, the Company engaged Wipfli as its IRPAF for the
year ended December 31, 2021. On March 23, 2022, the Company engaged Wipfli as its IRPAF for the year ended December 31, 2022. On March
22, 2023, the Company engaged Wipfli as its IRPAF for the year ending December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Set forth below is a summary of the fees incurred
for services rendered by the Company&#8217;s Independent Registered Public Accounting Firm, Wipfli LLP, for the years ended December 31,
2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Audit Fees <sup>(1)</sup></b></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">130,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Audit-Related Fees <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">140,550</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">149,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Audit Fees include fees billed by or accrued for the auditors for their reviews of the quarterly financial statements included in the Company&#8217;s Quarterly Reports on Form 10-Q for the first three quarters of each year and their audits of the annual financial statements included in the Company&#8217;s Annual Reports on Form 10-K and incidental expenses. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees include fees paid to Wipfli LLP related to the issuance of a consent for a registration statement during 2023 and related to the restatement of the Company&#8217;s Quarterly Reports on Form 10-Q for the three-month periods ended June 30, 2022 and March 31, 2022 during 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><i>Pre-Approval
Policy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with the procedures set forth in
its charter, the Audit Committee pre-approves all auditing services and permitted non-audit services (including the fees and other terms
of those services) to be performed for the Company by its Independent Registered Public Accounting Firm. Such approval may be accomplished
by approving the terms of the engagement prior to the engagement of the Independent Registered Public Accounting Firm with respect to
such services or by establishing detailed pre-approval policies and procedures to govern such engagement. The Audit Committee authorizes
management to spend up to $5,000 per year for services that are not anticipated at the time of the engagement, provided that the Audit
Committee is promptly informed of such services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AUDIT COMMITTEE REPORT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee of the Board of Directors reviews
the financial reporting process, the system of internal controls, the audit process and the process for monitoring compliance with certain
applicable laws and regulations. The Audit Committee is responsible for selecting and hiring the Independent Registered Public Accounting
Firm and meets with those accountants (in person or by telephone) before each quarterly press release concerning the Company&#8217;s financial
results. The Audit Committee approves the public disclosure and filing with the SEC of the related press releases. After reviewing the
quarterly and annual reports that are prepared by management, the Audit Committee authorizes the filing of such reports with the SEC.
All members of the Audit Committee meet the heightened independence and expertise requirements for audit committees under applicable NASDAQ
Stock Market rules. Mr. Wainman joined the Audit Committee in March of 2014 and serves as its Chair. Mr. Rosgen joined the Audit Committee
in April of 2018. Dr. Tomsche joined the Audit Committee in June of 2021. Mr. Gathagan joined the Audit Committee in June of 2023. The
Audit Committee currently operates under a charter adopted by the board in 2004. The Company has a January 1st to December 31st fiscal
year. The Audit Committee met eight times during 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee has reviewed the Company&#8217;s
audited financial statements for the year ended December 31, 2023 and discussed such statements with management and Wipfli LLP, the Company&#8217;s
independent registered public accounting firm for 2023. The Audit Committee has discussed with Wipfli LLP various communications that
Wipfli LLP is required to provide to the Audit Committee including the matters required to be discussed by Public Company Accounting Oversight
Board (PCAOB) Auditing Standards No. 1301 (Communication with Audit Committees). The Audit Committee received from Wipfli LLP the written
disclosures and the letter required by applicable requirements of the PCAOB concerning independence and has discussed the auditor&#8217;s
independence with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on the review and discussions noted above,
the Audit Committee recommended to the board that the Company&#8217;s audited financial statements be included in the Company&#8217;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and be filed with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This report of the Audit Committee shall not be
deemed incorporated by reference by any general statement into any filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates this information by reference and shall
not otherwise be deemed filed under such Acts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.8in; font-size: 10pt"><span style="font-size: 10pt">Submitted by:</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Audit Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Bryan K. Gathagan</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Steven T. Rosgen</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">David S. Tomsche, D.V.M.</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Paul R. Wainman, Chair</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 15 &#8212; EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company&#8217;s 1987 Registration Statement No. 33-12722 on Form S-1 as filed with the Commission).</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312509065667/dex32.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective July 23, 1990 (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312509065667/dex33.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective August 24, 1992 (incorporated by reference to Exhibit 3.3 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390016014285/f8k061616a1ex3i_immucellcorp.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective June 16, 2016 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Amended Current Report on Form 8-K/A filed on June 16, 2016).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390018007801/f8k061418ex3-1_immucellcorp.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective June 18, 2018 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 18, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020014682/ea122959ex3-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective June 11, 2020 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 11, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312509065667/dex34.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of the Company as amended (incorporated by reference to Exhibit 3.4 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312509100006/dex41.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights Agreement dated as of September 5, 1995, between the Company and American Stock Transfer and Trust Co., as Rights Agent, which includes as Exhibit A thereto the form of Right Certificate and as Exhibit B thereto the Summary of Rights to Purchase Common Stock (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1A</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312505137205/dex41a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Rights Agreement dated as of June 30, 2005 (incorporated by reference to Exhibit&#160;4.1A of the Company&#8217;s Current Report on Form 8-K filed on July 5, 2005).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1B</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312509065667/dex41a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Rights Agreement dated as of June 30, 2008 (incorporated by reference to Exhibit 4.1A of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1C</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000114420411046680/v231378_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to Rights Agreement dated as of August 9, 2011 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2011).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1D</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390014004257/f8k061614ex4id_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth Amendment to Rights Agreement dated as of June 16, 2014 (incorporated by reference to Exhibit 4.1D of the Company&#8217;s Current Report on Form 8-K filed on June 17, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1E</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390015003520/f10q0315ex4i_immucellcorp.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Amendment to Rights Agreement dated as of April 15, 2015 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Quarterly Report on Form 10-Q for the three-month period ended March 31, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1F</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390017008652/f10q0617ex4i_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixth Amendment to Rights Agreement dated as of August 10, 2017 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2017).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1G</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390022074052/f10q0622a1ex4-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seventh Amendment to Rights Agreement dated as of August 10, 2022 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Amended Quarterly Report on Form 10-Q/A filed on November 21, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1H</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023065595/f10q0623ex4-1_immucell.htm">Eighth Amendment to Rights Agreement dated as of August 9, 2023 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390021018473/f10k2020ex4-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312507067375/dex103a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (updated) entered into with each of the Company&#8217;s Directors and Officers (incorporated by reference to Exhibit 10.3A of the Company&#8217;s Annual Report on Form&#160;10-KSB for the year ended December 31, 2006).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312510069708/dex106.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement between the Company and Michael F. Brigham dated March 26, 2010 (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2009).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312511079611/dex106.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2010 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000119312511079611/dex107.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390017008652/f10q0617ex10i_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2017).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020007650/f10k2019ex10-9_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023024080/f10k2022ex10-7_immucellcorp.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the 2017 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022).</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020227701ex10-8_immucell.htm">Fifth Amended and Restated Incentive Compensation Agreement between the Company and Elizabeth L. Williams dated as of March 27, 2024.</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390022016147/f10k2021ex10-9_immucellcorp.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Separation and Deferred Compensation Agreement between the Company and Michael F. Brigham dated as of March 28, 2022 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Annual Report on Form 10-K filed on March 30, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023024080/f10k2022ex10-13_immucellcorp.htm">Amended and Restated Incentive Compensation Agreement between the Company and Michael F. Brigham dated as of March 28, 2023 (incorporated by reference to Exhibit 10.13 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11+*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020227701ex10-11_immucell.htm">Fourth Amended and Restated Incentive Compensation Agreement between the Company and Bobbi Jo Brockmann dated as of March 27, 2024.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390019017687/f8k090519ex99-2_immucellcorp.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development Services and Commercial Supply Agreement between the Company and Norbrook Laboratories Limited dated as of September 5, 2019 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on September 11, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390024020389/ea0201306ex10-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amending Agreement between the Company and Norbrook Laboratories dated as of March 4, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed March 6, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390019018253/f8k091219ex99-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on September 17, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390022049025/ea164617ex99-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of August 15, 2022 (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023087893/ea188617ex10-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of November 14, 2023 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on November 16, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Note for $5,100,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-4_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement for $5,100,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.4 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390022014793/ea157362ex99-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allonge to and Amendment of Term Note, dated March 23, 2022, between the Company and Gorham Savings Bank (incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on March 24, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390022014793/ea157362ex99-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mortgage Modification Agreement, dated March 23, 2022, between the Company and Gorham Savings Bank (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on March 24, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-3_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Note for $3,500,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.3 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-5_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement for $3,500,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.5 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-6_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Line of Credit Agreement for up to $1,000,000 executed by ImmuCell Corporation in favor of Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/811641/000121390023024080/f10k2022_immucellcorp.htm">Allonge to and Amendment of Line of Credit Loan for up to $1,000,000 between the Company and Gorham Savings Bank dated March 23, 2022 (incorporated by reference to Exhibit 10.23 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022).</a></p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390024017522/ea0200796ex10-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allonge to and Amendment of Line of Credit between the Company and Gorham Savings Bank, dated February 22, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on February 27, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020015079/ea123091ex99-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note Purchase Agreement executed by the Company in favor of the Maine Technology Institute dated June 12, 2020 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020015079/ea123091ex99-3_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subordinated Promissory Note for $500,000 executed by the Company in favor of the Maine Technology Institute dated June 12, 2020 (incorporated by reference to Exhibit 99.3 of the Company&#8217;s Current Report on Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390021035662/ea143716ex99-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note Purchase Agreement executed by the Company in favor of the Maine Technology Institute dated June 30, 2021 (incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390021035662/ea143716ex99-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subordinated Promissory Note for $400,000 executed by the Company in favor of the Maine Technology Institute dated June 30, 2022 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021).</span></a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020043105/ea131766ex10-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Note for $1,500,000 executed by the Company in favor of Gorham Savings Bank dated December 15, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 17, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390020043105/ea131766ex10-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement for $1,500,000 executed by the Company in favor of Gorham Savings Bank dated December 15, 2020 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on December 17, 2020).</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Note for $2,000,000 executed by ImmuCell Corporation in favor of Gorham Savings Bank dated July 17, 2023 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-2_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement, by and between ImmuCell Corporation and Gorham Savings Bank dated July 17, 2023 (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-3_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic Recovery/SSBCI Program Loan Promissory Note for $1,000,000 executed by ImmuCell Corporation in favor of the Finance Authority of Maine dated July 17, 2023 (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-4_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic Recovery Loan Program Loan Agreement, by and between ImmuCell Corporation and the Finance Authority of Maine dated July 17, 2023 (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000110262414000412/exh14.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14 of the Company&#8217;s Current Report on Form 8-K filed on March 20, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020227701ex23-1_immucell.htm">Consent of Independent Registered Public Accounting Firm</a>.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_031">Power of Attorney (incorporated by reference to the signature page of this Form 10-K).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020227701ex31_immucell.htm">Certification Pursuant to Rule 13a-14(a).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020227701ex32_immucell.htm">Certification Pursuant to Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in">97.1*</td>
    <td>&#160;</td>
    <td><a href="ea020227701ex97-1_immucell.htm">ImmuCell Corporation Clawback Policy.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">XBRL Instance Document-the instance document does not appear in
the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File-the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Management contract or compensatory plan or arrangement.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>



</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>ITEM 16 &#8211; FORM 10-K SUMMARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">To the Stockholders and the Board of Directors of ImmuCell
Corporation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">We have audited the accompanying balance
sheets of ImmuCell Corporation (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related statements of operations,
stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States
of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><b>Critical Audit Matter</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">The critical audit matter communicated
below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated
to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way
our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing
a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Valuation of Inventory</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td>
    <td style="width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, the Company&#8217;s inventory was $7,811,841. As discussed in Note 2 of the financial statements, inventory is recorded at the lower of cost or net realizable value.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing management&#8217;s valuation of inventory is complex and highly judgmental because of the estimates and assumptions used by management to determine the cost accounting and because of the variability of the cost per dose due to fluctuations in the biological yield achieved.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the<br/>
 Matter In Our
  Audit</i></span></td>
  <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary procedures we performed to address this critical
audit matter included the following. We obtained an understanding of the cost accounting developed by management and the related assumptions
and estimates used. We tested the cost accounting by examining the underlying data used by the Company to prepare the cost accounting.
We evaluated the effect of the variability of the cost per dose on the inventory value by comparing the biological yield to historical
results and by performing a sensitivity analysis of the potential range in inventory value within a corridor of historical results based
on minimum and maximum outcomes for the biological yield.</span>&#160;</td>
</tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><span style="text-decoration:underline">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-17782">WIPFLI LLP</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">We have served as the Company&#8217;s auditor since 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-17783">Radnor, Pennsylvania</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">April 1, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"></p><div>

</div><!-- Field: Page; Sequence: 56; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BALANCE
SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">CURRENT
    ASSETS:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-17784">978,741</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-17785">5,791,562</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade
    accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-17786">2,185,383</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-17787">1,758,600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-17788">7,811,841</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-17789">6,038,539</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-17790">493,885</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-17791">406,055</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-17792">11,469,850</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-17793">13,994,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-17794">27,575,683</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-17795">28,441,726</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease right-of-use asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-17796">4,571,149</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-17797">2,194,670</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-17798">95,557</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-17799">95,557</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-17800">38,208</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-17801">57,312</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-17802">57,655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-17803">76,628</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-17804">43,808,102</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-17805">44,860,649</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CURRENT
    LIABILITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current
    portion of debt obligations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="0" unitRef="usd" id="ixv-17806">1,428,807</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="0" unitRef="usd" id="ixv-17807">1,039,447</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    portion of operating lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-17808">644,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-17809">31,764</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-17810">2,124,337</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-17811">2,000,862</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-17812">4,197,420</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-17813">3,072,073</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LONG-TERM
    LIABILITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt
    obligations, net of current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd" id="ixv-17814">10,540,496</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd" id="ixv-17815">9,191,109</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liability, net of current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-17816">4,077,109</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-17817">2,217,418</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    long-term liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-17818">14,617,605</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-17819">11,408,527</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-17820">18,815,025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-17821">14,480,600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CONTINGENT
    LIABILITIES AND COMMITMENTS (See Note 11)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">STOCKHOLDERS&#8217;
    EQUITY:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Common stock, $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17822"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17823">0.10</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-17824"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-17825">15,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-17826"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-17827">7,814,165</ix:nonFraction></ix:nonFraction> shares issued as of both December 31, 2023 and 2022 and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17828">7,750,864</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17829">7,746,864</ix:nonFraction> shares outstanding as of December 31, 2023 and 2022, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-17830">781,417</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-17831">781,417</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-17832">36,357,239</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-17833">35,978,364</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-17834">12,007,097</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-17835">6,232,499</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Treasury stock, at cost, 63,301 and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-17836"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-17837">67,301</ix:nonFraction></ix:nonFraction> shares as of December 31, 2023 and 2022, respectively</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-17838">138,482</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-17839">147,233</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stockholders&#8217; equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17840">24,993,077</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17841">30,380,049</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-17842">43,808,102</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-17843">44,860,649</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-17844">17,471,669</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-17845">18,567,962</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-17846">13,602,385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-17847">10,919,183</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-17848">3,869,284</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-17849">7,648,779</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-17850">4,394,852</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-17851">4,493,872</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-17852">3,088,215</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-17853">3,190,033</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-17854">2,134,295</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-17855">2,263,817</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-17856">9,617,362</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-17857">9,947,722</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING LOSS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17858">5,748,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17859">2,298,943</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    expenses, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-17860">21,893</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-17861">187,190</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LOSS
    BEFORE INCOME TAXES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-17862">5,769,971</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-17863">2,486,133</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-17864">4,627</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-17865">7,672</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    LOSS</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17866">5,774,598</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17867">2,493,805</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Basic weighted
    average common shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-17868">7,747,686</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-17869">7,745,122</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Basic net loss per
    share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-17870">0.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-17871">0.32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Diluted weighted
    average common shares outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-17872">7,747,686</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-17873">7,745,122</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Diluted net loss
    per share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-17874">0.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-17875">0.32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF STOCKHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><div style="padding: 0in; border-bottom: Black 0.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Deficit</b></span></p> </div></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    Stockholders&#8217;<br/>
 Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">BALANCE,</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 30%"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17876">7,814,165</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17877">781,417</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17878">35,692,388</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-17879">3,738,694</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17880">72,301</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-17881">158,171</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17882">32,576,940</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17883">2,493,805</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17884">2,493,805</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of stock
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-5; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17885">19,732</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-6; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-17886">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17887">10,938</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17888">30,670</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-17889">266,244</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-17890">266,244</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">BALANCE,</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17891">7,814,165</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17892">781,417</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17893">35,978,364</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-17894">6,232,499</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17895">67,301</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-17896">147,233</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17897">30,380,049</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17898">5,774,598</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17899">5,774,598</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of stock
    options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17900">10,009</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-17901">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17902">8,751</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17903">18,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-17904">368,866</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-17905">368,866</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">BALANCE,</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17906">7,814,165</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17907">781,417</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17908">36,357,239</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-17909">12,007,097</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17910">63,301</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-17911">138,482</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-17912">24,993,077</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17913">5,774,598</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-17914">2,493,805</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used for operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 30.25pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-17915">2,697,897</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-17916">2,468,479</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt"><span style="font-family: Times New Roman, Times, Serif">Amortization
    of intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-17917">19,104</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-17918">19,104</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt"><span style="font-family: Times New Roman, Times, Serif">Amortization
    of debt issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-17919">13,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-17920">7,658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Amortization
    of debt discounts</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-17921">9,547</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-17922">368,866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-17923">266,244</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    (gain) on disposal of property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-17924">8,099</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" unitRef="usd" id="ixv-17925">7,334</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Non-cash
    rent expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="0" unitRef="usd" id="ixv-17926">95,724</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="0" unitRef="usd" id="ixv-17927">28,476</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt"><span style="font-family: Times New Roman, Times, Serif">Trade
    accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-17928">426,783</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-17929">935,629</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-17930">1,773,302</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-17931">2,948,565</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-17932">87,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-17933">110,858</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Other
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-17934">18,973</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" unitRef="usd" id="ixv-17935">50,513</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable and accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-17936">156,995</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-17937">341,614</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used for operating activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-17938">4,674,236</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-17939">1,543,871</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">CASH
    FLOWS FROM INVESTING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-17940">1,892,513</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-17941">3,975,274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from sale of property, plant and equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-17942">2,474</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-17943">11,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used for investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-17944">1,890,039</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-17945">3,964,274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from debt issuance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-17946">3,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-17947">2,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from line of credit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" unitRef="usd" id="ixv-17948">2,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Debt
    principal repayments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-17949">1,185,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-17950">897,125</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Line
    of credit repayments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" unitRef="usd" id="ixv-17951">2,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Payments
    of debt issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-17952">35,425</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-17953">19,306</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Payments
    of debt discounts</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:PaymentsOfDebtDiscounts" scale="0" unitRef="usd" id="ixv-17954">46,107</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from exercise of stock options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17955">18,760</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-17956">30,670</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-17957">1,751,454</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-17958">1,114,239</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">NET
    DECREASE IN CASH AND CASH EQUIVALENTS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-17959">4,812,821</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-17960">4,393,906</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">BEGINNING
    CASH AND CASH EQUIVALENTS</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-17961">5,791,562</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-17962">10,185,468</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">ENDING
    CASH AND CASH EQUIVALENTS</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-17963">978,741</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-17964">5,791,562</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENT
OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">CASH
    PAID FOR:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income
    taxes</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-17965">6,466</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-17966">4,923</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-17967">444,954</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-17968">338,516</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NON-CASH
    ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in capital expenditures included in accounts payable and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-17969">50,086</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" scale="0" sign="-" unitRef="usd" id="ixv-17970">44,998</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in payments of debt discounts included in accounts payable and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-17971">16,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease right-of-use asset and operating lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-17972">2,472,203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-17973">1,184,727</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>The
accompanying notes are an integral part of these financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
to Audited Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NatureOfOperations" id="ixv-10136"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. BUSINESS
OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ImmuCell
Corporation (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was originally incorporated in Maine in
1982 and reincorporated in Delaware in 1987, in conjunction with an initial public offering of common stock. We are an animal health
company whose purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and
beef cattle. As disclosed in Note 17, &#8220;Segment Information&#8221;, <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-17974">one</ix:nonFraction> of our business segments is dedicated to Scours and the
other is focused on Mastitis. We manufacture and market the <b>First Defense<sup>&#174;</sup></b> product line, providing <b>Immediate
Immunity&#8482;</b> to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with
formulations targeting <i>E. coli</i>, coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>&#174;</sup></b>,
a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy
industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks
including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies,
the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable.
A combination of the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary
conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We
are experiencing price increases in key components, supportive services, transportation and other supplies that are causing our costs
of goods sold to increase. We have experienced some contamination events in our production process. We implemented a production slowdown
to remediate this problem, which led to the recognition of lower sales and gross margin during the first ten months of 2023.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-10154"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>2. SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-10161"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(a) Basis
of Presentation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have prepared the accompanying audited financial statements reflecting all adjustments (which are of a normal recurring nature) that
are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set
by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure
we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes
are to the FASB <i>Accounting Standards Codification</i>&#8482; (Codification). We believe that the disclosures are adequate to ensure
that the information presented is not misleading.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-10173"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(b) Cash
and Cash Equivalents</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash
equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal
Deposit Insurance Corporation (FDIC) limits of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-17975">250,000</ix:nonFraction> per financial institution per depositor. See Note 3.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" id="ixv-10184"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(c) Trade
Accounts Receivable</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ReceivablesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Accounts
receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines
the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to
an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance
is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge
interest on past due accounts during the years ended December 31, 2023 or 2022 because the time past due was not significant. There was
no accrual for such interest charges as of December 31, 2023 or 2022. Accounts receivable are written off when deemed uncollectible.
No accounts receivable were written off during the years ended December 31, 2023 or 2022. Recoveries of accounts receivable previously
written off are recorded as income when received. No such recoveries were recorded during the years ended December 31, 2023 or 2022.
As of December 31, 2023 and 2022, we determined that no allowance for doubtful accounts was necessary. See Note 4.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-10222"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(d) Inventory</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or
net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of
completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess
or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it
is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one
vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note
5.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-10234"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(e) Property,
Plant and Equipment, net</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated
to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets.
The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> is being
depreciated over 39 years from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the
equipment for our Nisin DS facility when it was placed in service during the third quarter of 2018. Approximately <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure" id="ixv-17976">87</ix:nonFraction>% of these assets
are being depreciated over <ix:nonNumeric contextRef="c28" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-17977">10</ix:nonNumeric> years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production
facility at 175 Industrial Way (<b>Building 175A</b>) over the remainder of the <ix:nonNumeric contextRef="c29" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-17978">10</ix:nonNumeric>-year lease term beginning when a Certificate of Occupancy
was issued during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with
a new lease covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold
improvements as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property,
plant and equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs
are expensed when incurred. See Notes 2(h) and 7 for additional disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-10252"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(f) Operating
Leases</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We account
for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation
to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use
(ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present
value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease
incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the
total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the
term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term
for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not
recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement
as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements
include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance
and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify
an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the
present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="ixv-10264"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(g) Intangible
Assets and Goodwill</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of
the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible
assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid
in excess of fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting.
We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level)
on an annual basis (as of December 31<sup>st</sup>) and whenever events or changes in circumstances indicate that the carrying value
of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value
of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the
value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance
relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends.
Although we believe intangible assets and goodwill are properly stated in the accompanying financial statements, changes in strategy
or market conditions could significantly impact these judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-34"><span style="-sec-ix-hidden: hidden-fact-35">No</span></span> goodwill
impairments were recorded during the years ended December 31, 2023 or 2022. See Notes 2(h) and 8 for additional disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
                                            Corporation<br/>
                                            Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="iccc_ValuationOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="iccc:ValuationOfLongLivedAssetsPolicyTextBlock" id="ixv-10306"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(h) Valuation
of Long-Lived Assets</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="iccc_ValuationOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset
and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment
of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible
assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not
be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level
for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-36"><span style="-sec-ix-hidden: hidden-fact-37">No</span></span> impairment
was recognized during the years ended December 31, 2023 or 2022.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-10320"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(i) Fair
Value Measurements</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
determining fair value measurements, we follow the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>.
Codification Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about
fair value measurements. The topic provides a consistent definition of fair value which focuses on an exit price, which is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The topic also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific
information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of
an asset or liability as of the measurement date. As of December 31, 2023 and 2022, the carrying amounts of cash and cash equivalents,
accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value
because of their short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying
balance sheets. Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              1 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing
                                            inputs are quoted prices available in active markets for identical assets or liabilities
                                            as of the measurement date.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              2 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing inputs are quoted prices for
            similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
            through corroboration with observable market data.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              3 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing inputs are unobservable for
            the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions
            market participants would use in pricing the asset or liability.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level
of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment
and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash
equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the
event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers
between levels of the fair value hierarchy. During the years ended December 31, 2023 and 2022, there were no transfers between levels.
As of December 31, 2023 and 2022, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and
money market accounts. There were <span style="-sec-ix-hidden: hidden-fact-38"><span style="-sec-ix-hidden: hidden-fact-39"><span style="-sec-ix-hidden: hidden-fact-40"><span style="-sec-ix-hidden: hidden-fact-41">no</span></span></span></span> assets or liabilities measured at fair value on a nonrecurring basis as of December 31, 2023 or
2022. The carrying values of our cash and money market accounts as of December 31, 2023 or 2022 approximated their fair market values.
Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of December 31, 2023
and 2022 differed from their fair market values. <ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="ixv-17979">These values are reflected in the following tables:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_2" id="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-17980">978,741</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-17981">978,741</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-17982">10,431,817</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-17983">10,431,817</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_2"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-17984">5,791,562</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-17985">5,791,562</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-17986">8,897,197</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-17987">8,897,197</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-10817"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(j) Concentration
of Risk</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Concentration
of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To
reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable
credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have
not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic
area. <ix:nonNumeric contextRef="c38" continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c38_cont_1" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-17988">Sales to significant customers that amounted to <ix:nonNumeric contextRef="c30" name="us-gaap:ConcentrationRiskCustomer" id="ixv-17989">10%</ix:nonNumeric> or more of total product sales are detailed in the following table:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c38_cont_1"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17990">47</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17991">40</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17992">32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17993">33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c43" continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c43_cont_1" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-10898"><span style="font-family: Times New Roman, Times, Serif">Trade
accounts receivable due from significant customers that amounted to <ix:nonNumeric contextRef="c31" name="us-gaap:ConcentrationRiskCustomer" id="ixv-17994">10%</ix:nonNumeric> or more of our total trade accounts receivable are detailed in
the following table:</span></ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c43_cont_2" id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c43_cont_1"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_5" id="_ConcentrationRiskCreditRisk-c0_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17995">43</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17996">41</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17997">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17998">28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    C</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-17999">12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p>

<ix:continuation id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c43_cont_2"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">*</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:AccountsReceivablePercentage" scale="-2" unitRef="pure" id="ixv-18000">10</ix:nonFraction>%.</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
                                            Corporation<br/>
                                            Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-11022"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(k) Revenue
Recognition</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
recognize revenue in accordance with Codification Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single
comprehensive model for companies to use in accounting for revenue arising from contracts with customers. The core principle is that
we recognize the amount of revenue to which we expect to be entitled for the transfer of promised goods or services to customers when
a customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and
cash flows arising from contracts with customers. We conduct our business with customers through valid purchase orders or sales orders
which are considered contracts and are not interdependent on one another. A performance obligation is a promise in a contract to transfer
a distinct product to the customer. The transaction price is the amount of consideration we expect to receive under the arrangement.
Revenue is measured based on consideration specified in a contract with a customer. The transaction price of a contract is allocated
to each distinct performance obligation and recognized when or as the customer receives the benefit of the performance obligation. Product
transaction prices on a purchase or sales order are discrete and stand-alone. We recognize revenue when we satisfy a performance obligation
in a contract by transferring control over a product to a customer when product ships to a customer. Amounts due are typically paid approximately
30 days from the time control is transferred. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment
cost in costs of goods sold. We do not bill for or collect sales tax because our sales are generally made to distributors and thus our
sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns. See Note 14 for additional
disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="iccc_ExpenseRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="iccc:ExpenseRecognitionPolicyTextBlock" id="ixv-11034"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(l)
Expense Recognition</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="iccc_ExpenseRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed
when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed
as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are
charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-11046"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(m) Income
Taxes</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
account for income taxes in accordance with Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax
liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects
of temporary differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning
strategies in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine
that it is more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over
a reasonably short period of time, a reduction of the valuation allowance would increase income in the period such determination was
made. Likewise, if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in
the future, an increase to the valuation allowance would be charged to income in the period such determination was made.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2020. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2023 or 2022. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-11063"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(n) Stock-Based
Compensation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
account for stock-based compensation in accordance with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally
requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of
each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded
compensation expense pertaining to stock-based compensation of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-18001">368,866</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-18002">266,244</ix:nonFraction> during the years ended December 31, 2023 and 2022,
respectively. See Note 13.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-11076"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(o) Net
Loss Per Common Share</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
loss per common share has been computed in accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share
has been computed by dividing the net loss by the weighted average number of common shares outstanding during the period. All stock options
have been excluded from the denominator in the calculation of dilutive earnings per share when we are in a loss position because their
inclusion would be anti-dilutive. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-18003">Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-18004">618,500</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-18005">605,000</ix:nonFraction> during the years ended December 31, 2023 and 2022, respectively.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to stockholders</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18006">5,774,598</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18007">2,493,805</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average common
    shares outstanding - Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18008">7,747,686</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18009">7,745,122</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive
    impact of share-based compensation awards</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding - Diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18010">7,747,686</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18011">7,745,122</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18012">0.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18013">0.32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18014">0.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18015">0.32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-11314"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(p) Use
of Estimates</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ
from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become
known. Significant estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold.</span></p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-11325"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(q)
New Accounting Pronouncement Adopted</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments</i>, which was effective for us as of January 1, 2023, using the modified retrospective transition method. This ASU amends
the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including
trade receivables. The amendment requires entities to consider a broader range of information to estimate expected credit losses, which
may result in earlier recognition of losses. Historically, we have experienced a very low level of bad debt expense, and most of our
trade receivables are collected by the due date or within a few days of the due date. Because of this experience, the adoption of ASU
2016-13 did not have a material impact on our financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_1" escape="true" name="iccc:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" id="ixv-11337"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(r) New
Accounting Pronouncements Not Yet Adopted</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_2" id="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which
is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses.
The amendments will require disclosure of significant segment expenses that are regularly provided to our chief operating decision-maker
and included within segment profit and loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim
periods beginning after December 15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented
in the financial statements. We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
December 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments
that further enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine
its impact on our financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="ixv-11358"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. CASH
AND CASH EQUIVALENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents amounted to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-18016">978,741</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-18017">5,791,562</ix:nonFraction> as of December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-11370"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>4. TRADE
ACCOUNTS RECEIVABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Trade
accounts receivable amounted to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-18018">2,185,383</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-18019">1,758,600</ix:nonFraction> as of December 31, 2023 and 2022, respectively. No allowance for bad debt or
product returns was recorded as of December 31, 2023 or 2022. We anticipate no future events or conditions that would impact our ability
to collect our accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our
collection rate is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable
balances included $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-18020">42,507</ix:nonFraction> and $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-18021">46,426</ix:nonFraction> due from a related party as of December 31, 2023 or 2022, respectively. See Note 18.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
                                            Corporation<br/>
                                            Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-11408"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-11416"><span style="font-family: Times New Roman, Times, Serif">Inventory
consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Raw
    materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-18022">1,594,028</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-18023">2,419,982</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Work-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-18024">5,815,194</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-18025">3,468,702</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Finished
    goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-18026">402,619</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-18027">149,855</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-18028">7,811,841</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-18029">6,038,539</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
inventory figures are net of a $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-18030">527,133</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-18031">589,204</ix:nonFraction> write-off of scrapped inventory during the years ended December 31, 2023 and 2022,
respectively, that resulted principally from contamination events and other production process losses.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-11526"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>6. PREPAID
EXPENSES AND OTHER CURRENT ASSETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-11534"><span style="font-family: Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-18032">454,152</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-18033">363,877</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-18034">39,733</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-18035">42,178</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-18036">493,885</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-18037">406,055</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-11621"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>7. PROPERTY,
PLANT AND EQUIPMENT, net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-11629"><span style="font-family: Times New Roman, Times, Serif">Property,
plant and equipment consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>

    Useful Lives<br/> (in years)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory
    and manufacturing equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18038">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18039">10</ix:nonNumeric></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18040">20,953,601</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18041">19,181,960</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Buildings
    and improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c56" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18042">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18043">39</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18044">20,784,565</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18045">20,050,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Office
    furniture and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18046">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c61" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18047">10</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18048">1,036,374</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18049">900,306</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Construction
    in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">n/a</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18050">2,768,224</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18051">3,668,046</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Land</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">n/a</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18052">516,867</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18053">516,867</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18054">46,059,631</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-18055">44,317,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-18056">18,483,948</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-18057">15,875,620</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-18058">27,575,683</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-18059">28,441,726</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, construction in progress consisted principally of payments toward the <b>First Defense<sup>&#174;</sup></b>
production capacity expansion project and equipment needed to bring the formulation and aseptic filling for <b>Re-Tain<sup>&#174;</sup></b>
in-house. Property, plant and equipment disposals were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-18060">100,142</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-18061">127,127</ix:nonFraction> during the years ended December 31, 2023 and 2022, respectively.
Depreciation expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-18062">2,697,897</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-18063">2,468,479</ix:nonFraction> during the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-11857"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>8. INTANGIBLE
ASSETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="0" unitRef="usd" id="ixv-18064">191,040</ix:nonFraction> were valued using the relief from royalty method and are being amortized to costs of goods sold over their useful
lives, which are estimated to be <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-18065">10</ix:nonNumeric> years. Intangible amortization expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-18066"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-18067">19,104</ix:nonFraction></ix:nonFraction> during both of the years ended December 31, 2023
and 2022. The net value of these intangibles was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18068">38,208</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18069">57,312</ix:nonFraction> as of December 31, 2023 and December 31, 2022, respectively. Intangible
asset amortization expense is estimated to be $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-18070">19,104</ix:nonFraction> per year through December 31, 2025.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-11893"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets as of December 31, 2023 consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross&#160;Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Net
    Book<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Developed
    technology</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18071">184,100</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18072">147,280</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18073">36,820</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Customer
    relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18074">1,300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18075">1,040</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18076">260</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-compete
    agreements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18077">5,640</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18078">4,512</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18079">1,128</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18080">191,040</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18081">152,832</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18082">38,208</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_3" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets as of December 31, 2022 consisted of the following:</span></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross&#160;Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Net
    Book<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Developed
    technology</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18083">184,100</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18084">128,870</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18085">55,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Customer
    relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18086">1,300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18087">910</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18088">390</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-compete
    agreements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18089">5,640</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18090">3,948</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18091">1,692</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-18092">191,040</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-18093">133,728</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-18094">57,312</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-12176"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>9. ACCOUNTS
PAYABLE AND ACCRUED EXPENSES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-12183"><span style="font-family: Times New Roman, Times, Serif">Accounts
payable and accrued expenses consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable &#8211; trade</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-18095">874,558</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-18096">726,736</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable &#8211; capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-18097">13,175</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-18098">63,261</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    payroll</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-18099">942,999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-18100">966,553</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-18101">97,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-18102">95,550</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-18103">192,754</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-18104">143,872</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax payable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-18105">3,051</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-18106">4,890</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-18107">2,124,337</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-18108">2,000,862</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-12346"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>10. BANK
DEBT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loans
#1 and #2</b>: During the first quarter of 2020, we closed on a debt financing with Gorham Savings Bank (GSB) aggregating $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-18109">8,600,000</ix:nonFraction>,
which was comprised of a $<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EscrowDeposit" scale="0" unitRef="usd" id="ixv-18110">5,100,000</ix:nonFraction> mortgage note (Loan #1) that bears interest at a fixed rate of <ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18111">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c77" format="ixt-sec:duryear" name="iccc:InterestPaymentsTerm" id="ixv-18112">10</ix:nonNumeric>-year term
and <ix:nonNumeric contextRef="c78" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18113">25</ix:nonNumeric>-year amortization schedule and a balloon principal payment of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-18114">3,145,888</ix:nonFraction> due during the first quarter of 2030) and a $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-18115">3,500,000</ix:nonFraction>
note (Loan #2) that bears interest at a fixed rate of <ix:nonFraction contextRef="c80" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18116">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18117">7</ix:nonNumeric>-year term and amortization schedule). The proceeds from
the 2020 debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working
capital. During the first quarter of 2022, we closed on an additional $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" scale="0" unitRef="usd" id="ixv-18118">2,000,000</ix:nonFraction> in mortgage debt, which bears interest at the fixed
rate of <ix:nonFraction contextRef="c82" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18119">3.58</ix:nonFraction>% per annum. This was accomplished through an amendment of the original mortgage note (Loan #1) that increased the then outstanding
principal balance from $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" scale="0" unitRef="usd" id="ixv-18120">4,233,957</ix:nonFraction> to $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" scale="0" unitRef="usd" id="ixv-18121">6,233,957</ix:nonFraction> bearing interest at the blended fixed rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18122">3.53</ix:nonFraction>% per annum. This increased the balloon
payment from $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-18123">3,145,888</ix:nonFraction> to $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-18124">3,687,479</ix:nonFraction> and extended the due date of the balloon payment from the first quarter of 2030 to the first quarter
of 2032.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Line
of Credit (LOC)</b>: Also during the first quarter of 2020, GSB extended a $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-18125">1,000,000</ix:nonFraction> LOC to us that is available, as needed, through
September 11, 2025. Interest on borrowings against the LOC is variable at the National Prime Rate per annum. There was no outstanding
balance under this LOC as of December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#3</b>: During the second quarter of 2020, we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount
of $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-18126">500,000</ix:nonFraction>. The first <ix:nonNumeric contextRef="c87" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18127">2.25</ix:nonNumeric> years of this loan were interest-free with no interest accrual or required principal payments. Beginning
during the fourth quarter of 2022, Loan #3 became subject to quarterly principal and interest payments at a fixed rate of <ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18128">5</ix:nonFraction>% per annum
over the final <ix:nonNumeric contextRef="c89" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="ixv-18129">five years</ix:nonNumeric> of the loan, through the third quarter of 2027 if not repaid before then.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#4</b>: During the fourth quarter of 2020, we closed on a $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-18130">1,500,000</ix:nonFraction> note with GSB that bears interest at a fixed rate of <ix:nonFraction contextRef="c90" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18131">3.50</ix:nonFraction>% per annum
(with a <ix:nonNumeric contextRef="c91" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18132">7</ix:nonNumeric>-year term and amortization schedule). Proceeds of $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" unitRef="usd" id="ixv-18133">624,167</ix:nonFraction> were used to prepay a portion of the outstanding principal on our
mortgage note (Loan #1), which reduced the outstanding balance to <ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="iccc:LoanToValueRatio" scale="-2" unitRef="pure" id="ixv-18134">80</ix:nonFraction>% of the most recent appraised value of the property securing the
debt, which allowed GSB to release the $<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-18135">1,400,000</ix:nonFraction> that had been held in escrow. The remaining proceeds were available for general working
capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#5</b>: On June 30, 2021, we executed definitive agreements covering a second loan from the MTI in the aggregate principal amount of
$<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-18136">400,000</ix:nonFraction>, proceeds from which were received in July 2021. The first two years of this loan were interest-free with no interest accrual
or required principal payments. Principal and interest payments at a fixed rate of <ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18137">5</ix:nonFraction>% per annum are due quarterly over the final <ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18138">5.5</ix:nonNumeric>
years of the loan, beginning during the third quarter of 2023 and continuing through the fourth quarter of 2028 if not repaid before
then.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#6: </b>During the third quarter of 2023, we closed on a $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-18139">2,000,000</ix:nonFraction> term loan bearing interest at a fixed rate of <ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18140">7</ix:nonFraction>% per annum from GSB.
The Finance Authority of Maine (FAME) provided $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableLoanInProcess" scale="0" unitRef="usd" id="ixv-18141">1,000,000</ix:nonFraction> of loan insurance to GSB. This loan is repayable under a <ix:nonNumeric contextRef="c98" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18142">7</ix:nonNumeric>-year amortization
schedule with a balloon payment of $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-18143">1,285,072</ix:nonFraction> due during the third quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#7:</b> Also during the third quarter of 2023, we closed on a $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-18144">1,000,000</ix:nonFraction> term loan bearing interest at a fixed rate of <ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-18145">8</ix:nonFraction>% per annum from
FAME. The loan is repayable under a <ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-18146">7</ix:nonNumeric>-year amortization schedule with a balloon payment of $<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-18147">649,235</ix:nonFraction> due during the third quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Loans
#1, #2, #4, #6 and #7 are secured by liens on substantially all of our assets and are subject to certain restrictions and financial covenants.
Loan #7 is subordinated to Loans #1, #2, #4 and #6. Reflecting our poor financial performance during 2023, the debt covenant requirements
for the twelve-month periods ended December 31, 2023 and June 30, 2024 were waived pre-emptively by our bank. We are required to meet
a minimum debt service coverage (DSC) ratio of <ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="iccc:MinimumDebtServicesCoverageRatio" scale="0" unitRef="pure" id="ixv-18148">1.35</ix:nonFraction> for the twelve-month period ending September 30, 2024 and then annually after that
beginning with the year ending December 31, 2024. In connection with these credit facilities, we incurred aggregate debt issuance and
debt discount costs of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentGross" scale="0" unitRef="usd" id="ixv-18149">168,268</ix:nonFraction> ($<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="0" unitRef="usd" id="ixv-18150">98,098</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="0" unitRef="usd" id="ixv-18151">19,306</ix:nonFraction> of which were incurred during the years ended December 31, 2023 and 2022, respectively).
The amortization of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other
expenses, net, and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured
and subordinated to our indebtedness to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply
with the terms of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment
in full. These loans may be prepaid without penalty at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDebtTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-12417"><span style="font-family: Times New Roman, Times, Serif">Debt
proceeds received and principal repayments made (excluding our $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd" id="ixv-18152"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd" id="ixv-18153">1,000,000</ix:nonFraction></ix:nonFraction> line of credit) during the years ended December 31, 2023 and
2022 are reflected in the following table by period and by loan:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfDebtTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended<br/>
 December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended <br/>
December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from<br/> Debt&#160;Issuance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Debt&#160;Principal<br/> Repayments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Proceeds&#160;from<br/> Debt Issuance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Debt&#160;Principal<br/> Repayments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18154">223,222</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-18155">2,000,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18156">199,013</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #2</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18157">494,455</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18158">477,237</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18159">91,446</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18160">22,160</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18161">205,884</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18162">198,715</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan #5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18163">32,017</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan #6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-18164">2,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18165">93,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan
    #7</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-18166">1,000,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18167">45,696</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-18168">3,000,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18169">1,185,774</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-18170">2,000,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-18171">897,125</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ixv-12778"><span style="font-family: Times New Roman, Times, Serif">Principal
payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of December 31, 2023 (excluding our $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="0" unitRef="usd" id="ixv-18172">1,000,000</ix:nonFraction>
line of credit) are reflected in the following table by the year that payments are due:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ending December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">Loan #1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18173">230,879</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18174">239,876</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18175">248,604</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-18176">257,649</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="0" unitRef="usd" id="ixv-18177">266,537</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" unitRef="usd" id="ixv-18178">4,598,360</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18179">5,841,905</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #2</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18180">512,103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18181">530,738</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18182">549,881</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-18183">140,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18184">1,733,180</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18185">96,104</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18186">101,001</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18187">106,146</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-18188">83,143</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18189">386,394</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18190">213,217</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18191">220,994</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18192">228,965</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-18193">240,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18194">903,628</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18195">66,470</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18196">69,856</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18197">73,415</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-18198">77,156</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="0" unitRef="usd" id="ixv-18199">81,086</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18200">367,983</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18201">235,369</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18202">253,003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18203">1,418,574</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18204">1,906,946</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loan #7</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18205">114,632</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18206">124,364</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18207">715,308</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18208">954,304</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Subtotal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18209">1,468,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-18210">1,539,832</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-18211">3,340,893</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-18212">798,858</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="0" unitRef="usd" id="ixv-18213">347,623</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" unitRef="usd" id="ixv-18214">4,598,360</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-18215">12,094,340</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt issuance cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2023" scale="0" unitRef="usd" id="ixv-18216">19,076</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2024" scale="0" unitRef="usd" id="ixv-18217">18,976</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2025" scale="0" unitRef="usd" id="ixv-18218">13,579</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2026" scale="0" unitRef="usd" id="ixv-18219">5,420</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2027" scale="0" unitRef="usd" id="ixv-18220">3,513</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCostshereafter" scale="0" unitRef="usd" id="ixv-18221">11,347</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-18222">71,911</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Debt discount cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost" scale="0" unitRef="usd" id="ixv-18223">20,891</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost2024" scale="0" unitRef="usd" id="ixv-18224">20,891</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost2025" scale="0" unitRef="usd" id="ixv-18225">11,344</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCostTotal" scale="0" unitRef="usd" id="ixv-18226">53,126</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2023" scale="0" unitRef="usd" id="ixv-18227">1,428,807</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2024" scale="0" unitRef="usd" id="ixv-18228">1,499,965</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2025" scale="0" unitRef="usd" id="ixv-18229">3,315,970</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2026" scale="0" unitRef="usd" id="ixv-18230">793,438</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2027" scale="0" unitRef="usd" id="ixv-18231">344,110</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebtThereafter" scale="0" unitRef="usd" id="ixv-18232">4,587,013</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" unitRef="usd" id="ixv-18233">11,969,303</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-13503"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>11. CONTINGENT
LIABILITIES AND COMMITMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
bylaws, as amended, in effect provide that the Company will indemnify its officers and directors against any liability arising from their
responsibilities as officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings
with each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make
under such provisions is theoretically unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability
insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the
indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>.
Accordingly, we have recorded no liability for such obligations as of December 31, 2023 or 2022. Since our incorporation, we have had
no occasion to make any indemnification payment to any of our officers or directors for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted
against us during the normal course of business. We are aware of no such claims against us as of the date of this filing. We believe
that we have reasonable levels of liability insurance to support our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties
from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases,
we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We
have not incurred material expenses in discharging any of these indemnification obligations and based on our analysis of the nature of
the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly,
we recorded no liabilities for such obligations as of December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to purchase certain key parts (syringes) and services (formulation, aseptic filling and final packaging) pertaining to <b>Re-Tain<sup>&#174;
</sup></b>Drug Product (DP), our Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from
contractors. The contract for formulation, aseptic filling and final packaging of DP is scheduled to terminate after the supply of product
for our initial controlled market launch. We initiated an investment in the necessary equipment to perform the DP formulation and aseptic
filling services in-house, but this investment has been paused at the present time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
enter into compensation agreements (which are publicly filed) with our <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="iccc:NumberOfExecutiveOfficers" scale="0" unitRef="pure" id="ixv-18234">three</ix:nonFraction> executive officers. Effective March 28, 2022, we entered
into an Amended and Restated Separation and Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with
Mr. Brigham (our President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company
and Mr. Brigham. Upon separation from the Company for any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham
to be paid, among other amounts, all earned and unused paid time off (which expense totaling $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" unitRef="usd" id="ixv-18235">222,379</ix:nonFraction> was accrued during the first quarter
of 2022 and $<ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-18236">230,162</ix:nonFraction> and $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-18237">222,379</ix:nonFraction> was included in accounts payable and accrued expenses on the accompanying balance sheets as of December
31, 2023 and 2022, respectively) and to receive up to an additional $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-18238">300,000</ix:nonFraction> in deferred compensation (which amount is being accrued
over the three-year period ending in January 2025). This deferred compensation payment vested as to $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-18239">100,000</ix:nonFraction> on January 1, 2023 and an
additional $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-18240">100,000</ix:nonFraction> on January 1, 2024. An additional $<span style="-sec-ix-hidden: hidden-fact-74">100,00</span> will vest on January 1, 2025, provided that Mr. Brigham is employed by
the Company as of January 2025. The vested amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following
his separation from the Company. As of December 31, 2023 and 2022, $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-18241">200,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-18242">100,000</ix:nonFraction>, respectively, was included in accounts payable
and accrued expenses on the accompanying balance sheets. In addition, upon termination of Mr. Brigham&#8217;s employment (a) by the Company
other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in
the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" unitRef="pure" id="ixv-18243">100</ix:nonFraction>% of his then current annual base salary and a lump sum
payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month
period following termination, and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination
in accordance with the terms of the Deferred Compensation Agreement. Incentive Compensation Agreements with Mr. Brigham, Ms. Brockmann
(our Vice President of Sales and Marketing) and Ms. Williams (our Vice President of Manufacturing Operations) allow these executives
to earn incentive compensation if certain regulatory and financial objectives are met during the year to which the agreement relates,
as specified in their agreements. Amounts related to these incentive compensation agreements are accrued over the period they are earned
(when it is probable that the amounts will be earned) based on our best estimate of the amounts expected to be earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the commitments discussed above, we had committed $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:CapitalExpendituresCommitted" scale="0" unitRef="usd" id="ixv-18244">41,000</ix:nonFraction> to increase our production capacity for the <b>First Defense<sup>&#174;
</sup></b>product line, $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitment" scale="0" unitRef="usd" id="ixv-18245">2,345,000</ix:nonFraction> to the purchase of inventory, $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:InventoryProduction" scale="0" unitRef="usd" id="ixv-18246">7,000</ix:nonFraction> related to the commercial manufacture of <b>Re-Tain<sup>&#174;
</sup></b>and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:OtherObligations" scale="0" unitRef="usd" id="ixv-18247">307,000</ix:nonFraction> to other obligations as of December 31, 2023.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="ixv-13587"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>12. OPERATING
LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 12, 2019, we entered into a lease covering approximately <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqft" id="ixv-18248">14,300</ix:nonFraction> square feet of office and warehouse space with a possession
date of November 15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland (<b>Building
175A</b>), which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space
to meet our needs in expanding our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line. The original lease
term was <ix:nonNumeric contextRef="c3" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-18249">ten years</ix:nonNumeric> with a right to renew for a second <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-18250">10</ix:nonNumeric>-year term and a right of first offer to purchase. At the time we entered into
this lease, we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that
reason, a 10-year period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter
of 2022, we committed to lease an additional <ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqft" id="ixv-18251">15,400</ix:nonFraction> square feet of space at 175 Industrial Way (<b>Building 175B</b>), which is connected
to the original space, over a <ix:nonNumeric contextRef="c132" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-18252">20</ix:nonNumeric>-year term. The ROU asset and lease liability for the committed space at <b>Building 175B</b> was recorded
as of April 1, 2023 after construction of the building shell was completed in accordance with the lease agreement. Monthly lease payments
commenced as of August 1, 2023. In connection with the lease commitment for space at <b>Building 175B, </b>the term of the original lease
for <b>Building 175A</b> was extended by approximately 13 years. On November 14, 2023, we amended this lease further to provide for certain
tenant improvements on the leased premises to be paid for by our landlord. These improvements will provide heat to an unfinished space,
provide additional warehouse space, and create a new primary shipping and receiving facility. In consideration for the landlord agreeing
to pay for the cost of those certain tenant improvements, we are obligated to make additional rent payments of $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-18253">20,000</ix:nonFraction> per month from
November 2023 through June 2024 and a one-time additional rent payment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-18254">488,743</ix:nonFraction> in July 2024. The total lease liability for both leases
over the amended terms (including inflationary adjustments) aggregates $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-18255">4,739,077</ix:nonFraction> as of November 14, 2023. Because of this modification
to the lease payments, the ROU asset and lease liability associated with the space at <b>Building 175B</b> were remeasured as of the
modification date. Our leases include variable non-lease components. Such payments primarily include common area maintenance charges.
As of December 31, 2023, the balance of the operating lease ROU asset was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-18256">4,571,149</ix:nonFraction> and the operating lease liability was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-18257">4,721,385</ix:nonFraction>.
As of December 31, 2022, the balance of the operating lease ROU asset was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-18258">2,194,670</ix:nonFraction> and the operating lease liability was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-18259">2,249,182</ix:nonFraction>.
The calculated amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for
the present value of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying
assets, and instead to account for them as a single lease component. Variable lease cost primarily represents variable payments such
as real estate taxes and common area maintenance. <ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-18260">The following tables describe our lease costs and other lease information:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Lease Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease cost</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-18261">348,929</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-18262">149,176</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Variable
    lease cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-18263">36,774</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-18264">36,404</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    lease cost</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-18265">385,703</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-18266">185,580</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for operating lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-18267">248,595</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-18268">148,302</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining
    lease term (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-13769"><span style="font-family: Times New Roman, Times, Serif">19.1</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-13778"><span style="font-family: Times New Roman, Times, Serif">20.1</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    discount rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-18269">7.11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-18270">5.54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-13804"><span style="font-family: Times New Roman, Times, Serif">Future
lease payments required under non-cancelable operating leases in effect as of December 31, 2023 were as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>During the years ending
    December 31,</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Amount</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-18271">946,003</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-18272">342,880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-18273">349,744</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd" id="ixv-18274">356,732</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" unitRef="usd" id="ixv-18275">363,870</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" unitRef="usd" id="ixv-18276">5,949,488</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease payments (undiscounted cash flows)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-18277">8,308,717</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: imputed interest
    (discount effect of cash flows)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-18278">3,587,332</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-18279">4,721,385</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-13945"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>13. STOCKHOLDERS&#8217;
EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Common Stock
Issuances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February 2016 to April 2021, we sold the aggregate of <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18280">4,553,017</ix:nonFraction> shares of common stock in six different transactions raising gross proceeds
of $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18281">26,714,403</ix:nonFraction> at the weighted average price of $<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares" id="ixv-18282">5.87</ix:nonFraction> per share. These funds have been essential to funding our business growth plans.
The details of each transaction are discussed below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1)
During February of 2016, we sold <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18283">1,123,810</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18284">5.25</ix:nonFraction> per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18285">5,900,003</ix:nonFraction> and resulting in net
proceeds to the Company of $<ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18286">5,313,224</ix:nonFraction> (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2)
During October of 2016, we sold, in a private placement, <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18287">659,880</ix:nonFraction> shares of common stock to nineteen institutional and accredited investors
at $<ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18288">5.25</ix:nonFraction> per share, raising gross proceeds of $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18289">3,464,370</ix:nonFraction> and resulting in net proceeds to the Company of $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18290">3,160,923</ix:nonFraction> (after deducting
placement agent fees and other expenses incurred in connection with the equity financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">3)
During July of 2017, we sold <ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18291">200,000</ix:nonFraction> shares of our common stock at a price of $<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18292">5.25</ix:nonFraction> per share in a public, registered sale to two related
investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18293">1,050,000</ix:nonFraction> and resulting in net
proceeds of $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18294">1,034,164</ix:nonFraction> (after deducting expenses incurred in connection with the equity financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">4)
During December of 2017, we sold <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18295">417,807</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18296">7.30</ix:nonFraction> per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18297">3,049,991</ix:nonFraction> and resulting in net
proceeds to the Company of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18298">2,734,173</ix:nonFraction> (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">5)
During March of 2019, we sold <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18299">1,636,364</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18300">5.50</ix:nonFraction> per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18301">9,000,002</ix:nonFraction> and resulting in net
proceeds to the Company of $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18302">8,303,436</ix:nonFraction> (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">6)
During April of 2021, we sold <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-18303">515,156</ix:nonFraction> shares of our common stock at a price of $<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-18304">8.25</ix:nonFraction> per share in a public, registered sale to seven
investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18305">4,250,038</ix:nonFraction> and resulting in net
proceeds of $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-18306">4,233,026</ix:nonFraction> (after deducting expenses incurred in connection with the equity financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Stock Option
Plans</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions
of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of
the Company&#8217;s common stock at no less than fair market value on the date of grant. At that time, <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-18307">300,000</ix:nonFraction> shares of common stock
were reserved for issuance under the 2010 Plan and subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements
are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted
under the 2010 Plan expire no later than <ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-18308">10</ix:nonNumeric> years from the date of grant. The 2010 Plan expired in June 2020, after which date no further
options can be granted under the 2010 Plan. However, options outstanding under the 2010 Plan at that time can be exercised in accordance
with their terms. There were <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-18309">188,500</ix:nonFraction> and <ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-18310">202,500</ix:nonFraction> options outstanding under the 2010 Plan as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the &#8220;2017 Plan&#8221;) pursuant to the provisions
of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of
the Company&#8217;s common stock at no less than fair market value on the date of grant. At that time, <ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-18311">300,000</ix:nonFraction> shares of common stock
were reserved for issuance under the 2017 Plan. An amendment to the 2017 Plan increasing the number of shares reserved for issuance under
the 2017 Plan from <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-18312">300,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares" id="ixv-18313">650,000</ix:nonFraction> shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June
2022. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case
basis. All options granted under the 2017 Plan expire no later than <ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-18314">10</ix:nonNumeric> years from the date of grant. The 2017 Plan expires in March 2027,
after which date no further options can be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time
can be exercised in accordance with their terms. As of December 31, 2023 and 2022, there were <ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-18315">430,000</ix:nonFraction> and <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-18316">402,500</ix:nonFraction> options outstanding
under the 2017 Plan, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-14021"><span style="font-family: Times New Roman, Times, Serif">Activity
under the stock option plans described above was as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2010
    Plan</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2017
    Plan</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18317">218,500</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18318">224,500</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18319">6.94</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">468,425</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-18321">210,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18322">7.73</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c172" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">11,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">32,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.34</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercises</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c172" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-18326">5,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18327">6.13</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c174" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18328">202,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c175" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18329">402,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18330">7.19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">661,310</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c177" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-18332">122,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18333">5.16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c176" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">10,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c177" decimals="INF" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">94,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercises</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c176" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-18337">4,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18338">4.69</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c178" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18339">188,500</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18340">430,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18341">6.82</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">1,071,121</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c178" decimals="INF" format="ixt:num-dot-decimal" name="iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" scale="0" unitRef="shares" id="ixv-18343">188,500</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" scale="0" unitRef="shares" id="ixv-18344">92,500</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" scale="0" unitRef="usdPershares" id="ixv-18345">6.43</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" scale="0" sign="-" unitRef="usd">377,712</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected
    to vest as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c178" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-18347">188,500</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-18348">430,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18349">6.82</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" sign="-" unitRef="usd">1,071,121</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Reserved for future grants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-18351">202,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: left"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).</span></ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Terminations and forfeitures are recognized when they occur.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" id="ixv-14507"><span style="font-family: Times New Roman, Times, Serif">The
following table displays additional information about the stock option plans described above:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average <br/> Fair Value at Grant Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-vested
    stock options as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-18352">307,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18353">3.80</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18354">7.71</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-vested stock options
    as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-18355">337,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18356">3.66</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18357">7.14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options granted during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-18358">122,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18359">2.80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18360">5.16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options that vested during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-18361">57,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18362">2.23</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18363">5.59</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options that were terminated or forfeited during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" unitRef="shares" id="ixv-18364">104,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18365">3.30</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-18366">7.12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2023, <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-18367">4,000</ix:nonFraction> stock options were exercised by one employee with $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-18368">18,760</ix:nonFraction> in cash. During the year ended December
31, 2022, one former employee and two employees exercised stock options covering <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:StockOptionsCoveringShares" scale="0" unitRef="shares" id="ixv-18369">5,000</ix:nonFraction> shares with $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:StockOptionsCoveringcash" scale="0" unitRef="usd" id="ixv-18370">30,670</ix:nonFraction> in cash. The aggregate intrinsic
value of options exercised during the years ended December 31, 2023 and 2022 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitRef="usd" id="ixv-18371">1,040</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitRef="usd" id="ixv-18372">10,525</ix:nonFraction>, respectively. The weighted average
remaining life of the options outstanding under the 2010 Plan and the 2017 Plan as of December 31, 2023 was approximately <ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-18373">5</ix:nonNumeric> years and
<ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-18374">8</ix:nonNumeric> months. The weighted average remaining life of the options exercisable under these plans as of December 31, 2023 was approximately
<ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-18375">3</ix:nonNumeric> years and <ix:nonNumeric contextRef="c155" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-18376">6</ix:nonNumeric> months. The exercise prices of the options outstanding as of December 31, 2023 ranged from $<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18377">4.00</ix:nonFraction> to $<ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18378">10.04</ix:nonFraction> per share. The
<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-18379">122,000</ix:nonFraction> stock options granted during the year ended December 31, 2023 had exercise prices between $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18380">4.61</ix:nonFraction> and $<ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18381">5.22</ix:nonFraction> per share. The <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-18382">210,500</ix:nonFraction>
stock options granted during the year ended December 31, 2022 had exercise prices between $<ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-18383">6.52</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-18384">9.39</ix:nonFraction> per share. The weighted-average
grant date fair values of options granted during the year ended December 31, 2023 and 2022 were $<ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-18385">2.80</ix:nonFraction> and $<ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-18386">4.03</ix:nonFraction> per share, respectively.
As of December 31, 2023, total unrecognized stock-based compensation related to non-vested stock options aggregated $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-18387">619,845</ix:nonFraction>, which will
be recognized over a weighted average remaining period of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-18388">1</ix:nonNumeric> year and 8 months. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-18389">The fair value of each stock option grant
has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the
following weighted-average assumptions:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.59</ix:nonFraction>%</span></td><td style="white-space: nowrap; width: 1%; text-align: center"/><td style="white-space: nowrap; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.04</ix:nonFraction>%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%</span></td><td style="white-space: nowrap; text-align: center"/><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">54</ix:nonFraction>%</span></td><td style="white-space: nowrap; text-align: center"/><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">53</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" id="ix_17_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.2</ix:nonNumeric> years</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" id="ix_18_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.9</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.</span></ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_4" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The dividend yield and expected volatility are derived from averages of our historical data.</span></ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td style="text-align: left"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Common Stock
Rights Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
September 1995, our Board of Directors adopted a Common Stock Rights Plan (the &#8220;Rights Plan&#8221;) and declared a dividend of
one common share purchase right (a &#8220;Right&#8221;) for each of the then outstanding shares of the common stock of the Company. Each
Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" unitRef="usdPershares" id="ixv-18398">70.00</ix:nonFraction> per
share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and Equiniti
Trust Company, LLC, as Rights Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="iccc:ExercisableAndTransferableDescription" id="ixv-14843"><span style="font-family: Times New Roman, Times, Serif">The
Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public
announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined
in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement
of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding
common stock (the earlier of such dates being called the Distribution Date).</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Upon
the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount
to the initial purchase price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyPurchasePremiumPerShare" scale="0" unitRef="usdPershares" id="ixv-18399">70.00</ix:nonFraction> per share, effectively equal to one half of the market price of a share of common stock on the
date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with
any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company&#8217;s
common stock were changed or exchanged into the securities of any other entity, or if more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" scale="-2" unitRef="pure" id="ixv-18400">50</ix:nonFraction>% of the Company&#8217;s assets or
earning power were sold, each Right would entitle its holder to purchase, at the Rights&#8217; then-current purchase price, a number
of shares of the acquiring company&#8217;s common stock having a market value at that time equal to twice the Right&#8217;s exercise
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of <ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-18401">50</ix:nonFraction>% or more of the
outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group
which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At
any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board
of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of
$<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="iccc:RightToAcquirePerShare" scale="0" unitRef="usdPershares" id="ixv-18402">0.005</ix:nonFraction> per Right, subject to adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the third quarter of 2011, our Board of Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold
for determining &#8220;Acquiring Person&#8221; status to <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="iccc:AcquiringPersonPercentage" scale="-2" unitRef="pure" id="ixv-18403">20</ix:nonFraction>%. During the second quarter of 2015, our Board of Directors also voted to
authorize an amendment to remove a provision that prevented a new group of directors elected following the emergence of an Acquiring
Person (an owner of more than <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="iccc:AcquiringPersonPercentage" scale="-2" unitRef="pure" id="ixv-18404">20</ix:nonFraction>% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan
with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts. Each time that
we made such amendments we entered into amendments to the Rights Agreement with the Rights Agent reflecting such extensions, threshold
increases or provision changes. No other changes have been made to the terms of the Rights or the Rights Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
various times over the years, our Board of Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments
to the Rights Plan to extend the expiration date of the Rights Plan. <ix:nonNumeric contextRef="c0" name="us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription" id="ixv-18405">Our Board of Directors decided to seek an advisory vote by stockholders
at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of
the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board
of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory
vote by stockholders at the Annual Meeting of Stockholders held in June 2023, as to whether to extend the Rights Plan by another year
to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained.
On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that
there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually
cast on these proposals in deciding whether to extend the expiration date of such plan by one year.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Authorized
Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
the June 14, 2018 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation
to increase the number of shares of common stock authorized for issuance from <ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18406">8,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18407">11,000,000</ix:nonFraction>. At the June 10, 2020 Annual Meeting
of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares
of common stock authorized for issuance from <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18408">11,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18409">15,000,000</ix:nonFraction>.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-14894"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>14.
REVENUE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
primarily offer the <b>First Defense<sup>&#174;</sup></b> product line to dairy and beef producers to prevent scours in newborn calves.
Generally, our products are promoted to veterinarians as well as dairy and beef producers by our sales team and then sold through distributors.
Our primary market is North America. We do sell into select international regions and may expand this international reach in the future.
There were no material changes between the allocation and timing of revenue recognition during the years ended December 31, 2023 or 2022.
We do not have any contract assets for which we have satisfied the performance obligations, but do not yet have the right to bill for,
or contract liabilities such as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur
no material costs to obtain contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-14908"><span style="font-family: Times New Roman, Times, Serif">The
following table presents our product sales disaggregated by geographic area:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">United
    States</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18410">15,949,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-18411">91</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18412">17,020,797</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-18413">92</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18414">1,522,287</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-18415">9</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18416">1,547,165</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-18417">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18418">17,471,669</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-18419">100</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18420">18,567,962</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-18421">100</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenueTableTextBlock-c0_cont_1" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-15058"><span style="font-family: Times New Roman, Times, Serif">The
following table presents our product sales disaggregated by major product category:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisaggregationOfRevenueTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>First
    Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">product line</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18422">17,293,933</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-18423">99</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18424">18,411,949</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-18425">99</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    animal health</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18426">177,736</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-18427">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18428">156,013</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-18429">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18430">17,471,669</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-18431">100</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-18432">18,567,962</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-18433">100</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-15213"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>15. OTHER
EXPENSES, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-15221"><span style="font-family: Times New Roman, Times, Serif">Other
(income) expenses net, consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_2" id="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:InterestExpense" scale="0" unitRef="usd">475,598</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:InterestExpense" scale="0" unitRef="usd">348,536</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    (gain) on disposal of property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" sign="-" unitRef="usd" id="ixv-18436">8,099</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd" id="ixv-18437">7,334</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-18438">96,570</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-18439">153,100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
    recovery<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:InsuranceRecoveries" scale="0" unitRef="usd">365,127</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income-other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-18441">107</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-18442">912</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    expenses, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-18443">21,893</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-18444">187,190</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p>

<ix:continuation continuedAt="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_3" id="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: left"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Interest expense includes amortization of debt issuance and debt discount costs of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-18445">22,619</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-18446">7,658</ix:nonFraction> during the years ended December 31, 2023 or 2022, respectively.</span></ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation id="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: left"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-15414"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>16.
INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
income tax expense aggregated $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18447">4,627</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18448">7,672</ix:nonFraction> (amounting to less than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" unitRef="pure" id="ixv-18449">1</ix:nonFraction>% of our loss before income taxes) during the years ended December
31, 2023 and 2022, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-18450">17,759,519</ix:nonFraction> of which $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="0" unitRef="usd" id="ixv-18451">16,047,612</ix:nonFraction>
do not expire and of which $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-18452">1,711,907</ix:nonFraction> <ix:nonNumeric contextRef="c196" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-18453">expire in 2034 through 2037</ix:nonNumeric> (if not utilized before then) and state net operating loss carryforwards
of $<ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-18454">4,681,644</ix:nonFraction> that <ix:nonNumeric contextRef="c198" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-18455">expire in 2037 through 2038</ix:nonNumeric> (if not utilized before then). Additionally, we had federal general business tax credit
carryforwards of $<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-18456">726,474</ix:nonFraction> that <ix:nonNumeric contextRef="c200" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-18457">expire in 2027 through 2042</ix:nonNumeric> (if not utilized before then) and state tax credit carryforwards of $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-18458">775,473</ix:nonFraction>
that <ix:nonNumeric contextRef="c202" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-18459">expire in 2024 through 2042</ix:nonNumeric> (if not utilized before then).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach,
deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities
and carryforwards to the extent they are realizable. During the second quarter of 2018, we assessed our historical and near-term future
profitability and recorded $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeTaxExpense" scale="0" unitRef="usd" id="ixv-18460">563,252</ix:nonFraction> in non-cash income tax expense to create a full valuation allowance against our net deferred tax
assets (which consist largely of net operating loss carryforwards and federal and state credits) based on applicable accounting standards
and practices. At that time, we had incurred a net loss for six consecutive quarters, had not been profitable on a year-to-date basis
since the nine-month period ended September 30, 2017 and projected additional net losses for some period going forward before returning
to profitability. Should future profitability be realized at an adequate level, we would be able to release this valuation allowance
(resulting in a non-cash income tax benefit) and realize these deferred tax assets before they expire. We will continue to assess the
need for the valuation allowance at each quarter and, in the event that actual results differ from these estimates, or we adjust these
estimates in future periods, we may need to adjust our valuation allowance. Currently, we adjust the valuation allowance at the end of
each quarter to reduce the value of our deferred tax assets to <ix:nonFraction contextRef="c3" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-18461">zero</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue
Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of
net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
file income tax returns in the U.S. federal jurisdiction and several state jurisdictions. We currently have no tax examinations in progress.
We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits
for any of the periods in the accompanying audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-15438"><span style="font-family: Times New Roman, Times, Serif">The
income tax provision consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 11.5pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18462">4,627</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18463">7,672</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Current
    subtotal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18464">4,627</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18465">7,672</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18466">1,179,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18467">576,780</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18468">145,802</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18469">88,533</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    subtotal, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18470">1,325,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18471">665,313</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18472">1,325,276</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18473">665,313</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    subtotal, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18474">4,627</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18475">7,672</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-15677"><span style="font-family: Times New Roman, Times, Serif">The
actual income tax expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-18476"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-18477">21</ix:nonFraction></ix:nonFraction>% to the loss before
income taxes during the years ended December 31, 2023 and 2022 respectively, as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Computed
    expected income tax expense rate</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-18478">1,211,694</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" unitRef="pure" id="ixv-18479">21.00</ix:nonFraction>)</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-18480">522,088</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" unitRef="pure" id="ixv-18481">21.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    income taxes, net of federal expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-18482">117,149</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure" id="ixv-18483">2.03</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-18484">47,643</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure" id="ixv-18485">1.92</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" unitRef="usd" id="ixv-18486">56,214</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-18487">0.97</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" unitRef="usd" id="ixv-18488">36,652</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-18489">1.48</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tax
    credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" unitRef="usd" id="ixv-18490">53,241</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-18491">0.92</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" unitRef="usd" id="ixv-18492">131,361</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-18493">5.28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-18494">1,325,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-18495">0.09</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-18496">665,313</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-18497">26.76</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-18498">5,221</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-18499">22.97</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-18500">6,799</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-18501">0.27</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense/rate</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18502">4,627</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-18503">0.08</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-18504">7,672</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-18505">0.31</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation<br/>
Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-16006"><span style="font-family: Times New Roman, Times, Serif">The
significant components of our deferred tax assets, net, consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-18506">2,121,940</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-18507">2,530,472</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    general business tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd" id="ixv-18508">726,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd" id="ixv-18509">673,233</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-18510">3,729,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-18511">3,258,395</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    tax credits and net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd" id="ixv-18512">886,428</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd" id="ixv-18513">817,617</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#167;174
    R &amp; D expenditures</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="0" unitRef="usd" id="ixv-18514">592,915</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="0" unitRef="usd" id="ixv-18515">341,683</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-18516">50,722</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-18517">23,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-18518">37,124</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-18519">15,587</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">UNICAP</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-18520">32,607</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-18521">32,787</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Incentive
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd" id="ixv-18522">100,200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd" id="ixv-18523">76,554</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-18524">4,034,030</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-18525">2,708,754</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-16250"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>17. SEGMENT
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business operations (being the development, acquisition, manufacture and sale of products that improve the health and productivity of
dairy and beef cattle) are described in Note 1. Pursuant to Codification Topic 280, <i>Segment Reporting</i>, <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-18526">we operate in the following
two reportable business segments:</ix:nonNumeric> i) Scours and ii) Mastitis. The Scours segment consists of the <b>First Defense<sup>&#174;</sup></b>
product line. The core technology underlying the Scours segment is derived around polyclonal antibodies. The Mastitis segment includes
our products, <b>CMT </b>and <b>Re-Tain<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174; </sup></b>is projected to be the driver of this segment
when approved for sale. The core technology underlying the Mastitis segment is derived around a bacteriocin called Nisin. The category
we define as &#8220;Other&#8221; includes unallocated administrative and overhead expenses and other products. The significant accounting
policies of these segments are described in Note 2. Product sales are the primary factor we use in determining our reportable segments.
The governing regulatory authority (USDA for <b>First Defense<sup>&#174;</sup></b> or FDA for <b>Re-Tain<sup>&#174;</sup></b>) is also
a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating income
(loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated to each
segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating segment
is defined as the component of our business for which financial information is available and evaluated regularly by our chief operating
decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our President
and CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18527">17,293,933</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18528">177,736</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18529">17,471,669</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18530">13,453,514</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18531">148,871</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18532">13,602,385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-18533">3,840,419</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-18534">28,865</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-18535">3,869,284</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18536">11,103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18537">4,242,329</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18538">141,420</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18539">4,394,852</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-18540">2,447,137</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-18541">641,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-18542">3,088,215</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-18543">2,134,295</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-18544">2,134,295</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18545">2,458,240</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18546">4,883,407</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18547">2,275,715</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18548">9,617,362</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING INCOME (LOSS)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-18549">1,382,179</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18550">4,854,542</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18551">2,275,715</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18552">5,748,078</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_3" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18553">18,411,949</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18554">154,558</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18555">1,455</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd" id="ixv-18556">18,567,962</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18557">10,754,189</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18558">136,347</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18559">28,647</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-18560">10,919,183</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-18561">7,657,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-18562">18,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-18563">27,192</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-18564">7,648,779</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18565">66,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18566">4,317,921</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18567">109,605</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-18568">4,493,872</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-18569">1,871,926</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-18570">1,318,107</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-18571">3,190,033</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-18572">2,263,817</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-18573">2,263,817</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18574">1,938,272</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18575">5,636,028</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18576">2,373,422</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-18577">9,947,722</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING INCOME (LOSS)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-18578">5,719,488</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18579">5,617,817</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18580">2,400,614</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-18581">2,298,943</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
                                            Corporation<br/>
                                            Notes to Audited Financial Statements (continued)&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets as of December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18582">24,735,413</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18583">17,827,839</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18584">1,244,850</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18585">43,808,102</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets as
    of December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18586">20,539,523</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18587">18,315,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18588">6,005,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-18589">44,860,649</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization expense during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18590">1,365,988</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18591">1,287,600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18592">86,032</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18593">2,739,620</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization expense during the year ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18594">1,169,011</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18595">1,263,318</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18596">62,912</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-18597">2,495,241</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    Expenditures during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18598">1,096,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18599">795,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18600">1,892,513</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    Expenditures during the year ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18601">3,513,336</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18602">414,486</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18603">47,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-18604">3,975,274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-17326"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>18. RELATED
PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense<sup>&#174;</sup> </b>product line and <b>CMT</b>). His affiliated company purchased $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" unitRef="usd" id="ixv-18605">231,405</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" unitRef="usd" id="ixv-18606">587,677</ix:nonFraction> of products from us
during the years ended December 2023 and 2022, respectively, all on terms consistent with those offered to other distributors of similar
status. Our accounts receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTaxExpenseDueFromAffiliatesCurrent" scale="0" unitRef="usd" id="ixv-18607">42,507</ix:nonFraction>
and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTaxExpenseDueFromAffiliatesCurrent" scale="0" unitRef="usd" id="ixv-18608">46,426</ix:nonFraction> as of December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-17342"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>19. EMPLOYEE
BENEFITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate.
Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. We currently match <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryPercentage" scale="-2" unitRef="pure" id="ixv-18609">100</ix:nonFraction>% of the first <ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryPercentage" scale="-2" unitRef="pure" id="ixv-18610">3</ix:nonFraction>%
of each employee&#8217;s salary that is contributed to the Plan and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryContributionPercentage" scale="-2" unitRef="pure" id="ixv-18611">50</ix:nonFraction>% of the next <ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryContributionPercentage" scale="-2" unitRef="pure" id="ixv-18612">2</ix:nonFraction>% of each employee&#8217;s salary that is contributed
to the Plan. Under this matching plan, we paid $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-18613">178,150</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-18614">159,058</ix:nonFraction> into the Plan for the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-17355"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>20. SUBSEQUENT
EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have evaluated subsequent events through the time of filing on the date we have issued this Annual Report on Form 10-K. As of the time
of filing, there were no material, reportable subsequent events.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0px; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell
Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Signatures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ImmuCell
    Corporation</span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 1, 2024</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael F. Brigham</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham President, <br/>
Chief Executive Officer
    and <br/>
Principal Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">POWER
OF ATTORNEY</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We,
the undersigned directors and employees of ImmuCell Corporation, hereby severally constitute and appoint Michael F. Brigham our true
and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for us and in our stead, in any and all capacities,
to sign any and all amendments to this report and all documents relating thereto, and to file the same, with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full
power and authority to do and perform each and every act and thing necessary or advisable to be done in and about the premises, as fully
to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent,
or his substitute or substitutes, may lawfully do or to be done by virtue hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gloria
    J. Basse</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gloria J. Basse</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael
    F. Brigham</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive
    Officer</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer
    and Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bobbi
    Jo Brockmann</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Sales and Marketing and Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bobbi Jo Brockmann</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bryan
    K. Gathagan</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bryan K. Gathagan</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven
    T. Rosgen</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven T. Rosgen</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David
    S. Tomsche</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David S. Tomsche, DVM</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Elizabeth
    S. Toothaker</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth S. Toothaker</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul R.
    Wainman</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul R. Wainman</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-2" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-3" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-4" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-10" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-11" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-12" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-18" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-19" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-20" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-21" name="iccc:PaymentsOfDebtDiscounts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-22" name="iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-23" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-24" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-25" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-26" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-27" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-28" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-29" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-30" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-31" name="us-gaap:ConcentrationRiskPercentage1" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-32" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-33" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-34" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-35" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-37" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-38" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-39" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-40" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-41" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c64" id="hidden-fact-42" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" xsi:nil="true"/>
<ix:nonNumeric contextRef="c66" id="hidden-fact-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-44" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c106" id="hidden-fact-45" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c107" id="hidden-fact-46" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c108" id="hidden-fact-47" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c109" id="hidden-fact-48" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c110" id="hidden-fact-49" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c111" id="hidden-fact-50" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c112" id="hidden-fact-51" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c113" id="hidden-fact-52" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c113" id="hidden-fact-53" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-54" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-55" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c117" id="hidden-fact-56" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c117" id="hidden-fact-57" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-58" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-59" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c120" id="hidden-fact-60" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c120" id="hidden-fact-61" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c121" id="hidden-fact-62" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c121" id="hidden-fact-63" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-64" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-65" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-66" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-67" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c124" id="hidden-fact-68" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c124" id="hidden-fact-69" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c124" id="hidden-fact-70" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-71" name="iccc:DebtDiscountCost2026" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-72" name="iccc:DebtDiscountCost2027" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-73" name="iccc:DebtDiscountCostThereafter" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c127" decimals="0" id="hidden-fact-74" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" unitRef="usd">10000</ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c173" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c176" id="hidden-fact-77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c177" id="hidden-fact-78" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c178" id="hidden-fact-79" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="us-gaap:InsuranceRecoveries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-82" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-84" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-85" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-86" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-87" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-88" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-89" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-90" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c204" id="hidden-fact-91" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c205" id="hidden-fact-92" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c209" id="hidden-fact-93" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c207" id="hidden-fact-94" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c208" id="hidden-fact-95" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c206" id="hidden-fact-96" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-18714">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentAnnualReport" id="ixv-18715">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-18716">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentTransitionReport" id="ixv-18717">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-18718">0000811641</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iccc-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="hidden-fact-31" toRefs="ix_0_footnote"/>
<ix:relationship fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact" toRefs="ix_1_footnote"/>
<ix:relationship fromRefs="ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact" toRefs="ix_2_footnote"/>
<ix:relationship fromRefs="ix_11_fact ix_12_fact" toRefs="ix_3_footnote"/>
<ix:relationship fromRefs="ix_13_fact ix_14_fact ix_15_fact ix_16_fact" toRefs="ix_4_footnote"/>
<ix:relationship fromRefs="ix_17_fact ix_18_fact" toRefs="ix_5_footnote"/>
<ix:relationship fromRefs="ix_19_fact ix_20_fact" toRefs="ix_6_footnote"/>
<ix:relationship fromRefs="ix_21_fact hidden-fact-80" toRefs="ix_7_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:NisinDrugSubstanceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodNineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2027-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2027-01-01</xbrli:startDate>
    <xbrli:endDate>2027-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodTenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodTenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MortgageBankingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZdGbBMqh1FlvS0VWsnDwFtQUQZbcp+8/vjhiWuHx6DwUIXTksBAFLwuaqwe9SJ598smQehWVDvTLT7qrNCSH1oA5lP7ajJARYB4QG9tIps1UVlNmvOwm8Rl3nYWOLUOnwpxz+/hVEldWQ==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:SubtotalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-14</xbrli:startDate>
    <xbrli:endDate>2023-11-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-10-01</xbrli:startDate>
    <xbrli:endDate>2016-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-07-01</xbrli:startDate>
    <xbrli:endDate>2017-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-03-01</xbrli:startDate>
    <xbrli:endDate>2019-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">iccc:AcquiringPersonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>ea020227701ex10-8_immucell.htm
<DESCRIPTION>FIFTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND ELIZABETH L. WILLIAMS DATED AS OF MARCH 27, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FIFTH AMENDED AND RESTATED INCENTIVE COMPENSATION
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Fifth Amended and Restated
Incentive Compensation Agreement, dated as of March 27, 2024, is by and between ImmuCell Corporation, a Delaware corporation (the &ldquo;Company&rdquo;)
and Elizabeth L. Williams (the &ldquo;Executive&rdquo;), and replaces and supersedes in its entirety the Fourth Amended and Restated Incentive
Compensation Agreement, dated as of March 28, 2023, between the Company and the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WITNESSETH:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Company wishes
to provide to the Executive additional incentive compensation opportunities in order to induce the Executive to remain in the Company&rsquo;s
employ and to further incentivize her to continue her leadership efforts toward the successful commercialization of <B>Re-Tain<SUP>&reg;</SUP></B>;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Executive, in
partial consideration of such potential additional compensation, is willing to agree to certain restrictions relating to the solicitation
of Company employees, consultants and independent contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual promises of the parties contained herein and other good and valuable considerations, the receipt and sufficiency of which
are hereby acknowledged, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </FONT><U>Incentive
Compensation</U>. The Company agrees to pay to the Executive (a) $125,000 when the Company receives all FDA approvals needed for the commencement
of sales of <B>Re-Tain<SUP>&reg;</SUP></B> in the United States, and (b) $100,000 when the Company receives all FDA approvals of the Company&rsquo;s
license application for either (i) an in-house Drug Product manufacture, or (ii) a third-party Drug Product manufacture, in each case
with respect to <B>Re-Tain<SUP>&reg;</SUP></B>, provided, however, that any such payment shall be due and payable only if the Executive
is employed by the Company at the time of receipt of the applicable FDA approval(s) (with respect to (a) and (b) above). The applicable
payment under (a) and (b) above shall be made within thirty (30) days of receipt of such FDA approvals, and each such payment shall be
subject to all required tax withholdings. This supersedes paragraph 2 of the letter from the Company to the Executive dated March 2, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, if the Company
undergoes a Change of Control or sells or licenses all or substantially all of the rights to manufacture and sell <B>Re-Tain<SUP>&reg;</SUP></B>,
and at the time of such Change of Control, sale or license the Executive is an employee of the Company, the Company will make the payments
to the Executive described in the first paragraph of this Section 1 to the extent not previously paid. For purposes hereof, &ldquo;Change
of Control&rdquo; means (a) the sale of all or substantially all of the Company&rsquo;s assets, or (b) the sale or issuance of capital
stock of the Company, in a single transaction or series of related transactions, or a merger, consolidation or similar transaction to
which the Company is party, the result of which is one or more persons or entities acting together directly or indirectly acquiring a
majority of the outstanding capital stock of the Company or of the surviving or resulting entity in such transaction. For purposes hereof,
a license of all or substantially all of the rights to manufacture and sell <B>Re-Tain<SUP>&reg;</SUP></B> shall not include a transaction
in which the Company continues to perform manufacturing services to or for the benefit of the licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </FONT><U>Non-Solicitation</U>.
The Executive agrees, during the period in which she is employed by the Company and for one (1) year thereafter, not to solicit, or assist
or induce any other person or entity in soliciting, any person who at that time is (or within the preceding ninety (90) days was) an employee
of, or a consultant or independent contractor to, the Company to leave his or her employment, consultancy or independent contractor status
with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMMUCELL CORPORATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael F. Brigham</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham, its President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Elizabeth L. Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth L. Williams</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>ea020227701ex10-11_immucell.htm
<DESCRIPTION>FOURTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND BOBBI JO BROCKMANN DATED AS OF MARCH 27, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.11</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH AMENDED AND RESTATED INCENTIVE COMPENSATION
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Fourth Amended and Restated
Incentive Compensation Agreement, dated as of March 27, 2024, is by and between ImmuCell Corporation, a Delaware corporation (the &ldquo;Company&rdquo;)
and Bobbi Jo Brockmann (the &ldquo;Executive&rdquo;), and replaces and supersedes in its entirety the Third Amended and Restated Incentive
Compensation Agreement, dated as of March 28, 2023, between the Company and the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WITNESSETH:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Company wishes
to provide to the Executive additional incentive compensation opportunities in order to induce the Executive to remain in the Company&rsquo;s
employ and to further incentivize her to continue her leadership efforts toward increasing sales of the <B>First Defense</B><SUP>&reg;</SUP>
product line and implementing the successful commercialization of <B>Re-Tain<SUP>&reg;</SUP></B>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, the Executive, in
partial consideration of such potential additional compensation, is willing to agree to expand the obligations set forth in the Agreement
in Connection with Employment by ImmuCell Corporation, dated as of November 15, 2009, between the Company and the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual promises of the parties contained herein and other good and valuable considerations, the receipt and sufficiency of which
are hereby acknowledged, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </FONT><U>Incentive
Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a) The Company agrees to
pay to the Executive (i) $50,000 upon the sale by the Company of any doses of <B>Re-Tain<SUP>&reg; </SUP></B>within twelve (12) months
after receipt by the Company of all necessary regulatory approvals to sell <B>Re-Tain<SUP>&reg; </SUP></B>in the United States, and (ii)
an additional $50,000 (if the amount contemplated by clause (i) has been paid to the Executive) on the date that is twenty-four (24) months
after receipt by the Company of all necessary regulatory approvals to sell <B>Re-Tain<SUP>&reg;</SUP></B> in the United States; provided,
however, that such payments shall be due and payable only if the Executive is employed by the Company at the applicable payment date.
Such payments shall be subject to all required tax withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, if the Company
undergoes a Change of Control or sells or licenses all or substantially all of the rights to manufacture and sell <B>Re-Tain<SUP>&reg;</SUP></B>
and at the time of such Change of Control, sale or license the Executive is an employee of the Company, the Company will make the payments
to the Executive described in the first paragraph of this Section 1(a). For purposes hereof, &ldquo;Change of Control&rdquo; means (a)
the sale of all or substantially all of the Company&rsquo;s assets, or (b) the sale or issuance of capital stock of the Company, in a
single transaction or series of related transactions, or a merger, consolidation or similar transaction to which the Company is party,
the result of which is one or more persons or entities acting together directly or indirectly acquiring a majority of the outstanding
capital stock of the Company or of the surviving or resulting entity in such transaction. For purposes hereof, a license of all or substantially
all of the rights to manufacture and sell <B>Re-Tain<SUP>&reg;</SUP></B> shall not include a transaction in which the Company continues
to perform manufacturing services to or for the benefit of the licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b) In addition to the incentive
compensation potentially payable to the Executive pursuant to Section 1(a) hereof, the Company will pay and, if applicable, issue to the
Executive, not later than February 28, 2025, the amount of cash (up to $80,000) earned if certain sales and selling expense control objectives
are achieved in 2024 pursuant to the bonus payout calculations described in <U>Exhibit A</U>; provided, however, that such payment shall
be due and payable or issuable only if the Executive is employed by the Company at the applicable payment date. Such payments shall be
subject to all required tax withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </FONT><U>Non-Solicitation</U>.
The Executive agrees, during the period in which she is employed by the Company and for one (1) year thereafter, not to solicit, or assist
or induce any other person or entity in soliciting, any person who at that time is (or within the preceding ninety (90) days was) an employee
of, or a consultant or independent contractor to, the Company to leave his or her employment, consultancy or independent contractor status
with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">IMMUCELL CORPORATION</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Michael F. Brigham</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Michael F. Brigham, its President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Bobbi Jo Brockmann</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Bobbi Jo Brockmann</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea020227701ex23-1_immucell.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">Exhibit 23.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 107.25pt 0pt 111.15pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 107.3pt 0pt 111.15pt; text-align: center"><B>Consent of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We consent to the incorporation by reference in
the Registration Statements (Nos. 333-207635, 333-214641, and 333-228479) on Form S-3 and the Registration Statements (Nos. 333-02631,
333-65514, 333-167721, 333-237428, and 333-273227) on Form S-8 of ImmuCell Corporation of our report dated April 1, 2024, relating to
the financial statements of ImmuCell Corporation, appearing in this Annual Report on Form 10-K of ImmuCell Corporation for the years ended
December 31, 2023 and 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ WIPFLI LLP</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radnor, Pennsylvania</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">April 1, 2024</P></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>ea020227701ex31_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>




<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO REQUIRED
BY RULE 13a-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">I, Michael F. Brigham, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of ImmuCell
Corporation (the Company);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: left">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: left">designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Company
is made known to me by others within the Company, particularly during the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: left">designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: left">evaluated the effectiveness of the Company&rsquo;s disclosure
controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: left">disclosed in this report any change in the Company&rsquo;s
internal control over financial reporting that occurred during the Company&rsquo;s most recent fiscal quarter (the Company&rsquo;s fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s Board of Directors (or
persons performing the equivalent function):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: left">all significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: left">any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26.65pt 0pt 5.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in">Date: April 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26.65pt 0pt 5.75pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael F. Brigham</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F Brigham</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and<BR>
 Principal Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ea020227701ex32_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 32</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF<BR>
 THE SARBANES- OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report on Form 10-K of ImmuCell Corporation
(the &ldquo;Company&rdquo;) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof
(the &ldquo;Report&rdquo;), I, Michael F. Brigham, President, Chief Executive Officer and Principal Financial Officer of the Company,
certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">the Report fully complies with the requirements of Section
13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">the information contained in the Report fairly presents,
in all material respects, the financial condition, results of operations and cash flows of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This certification is provided pursuant to 18 U.S.C. Section 1350 and
Item 601(b)(32) of Regulation S-K (&ldquo;Item 601(b)(32)&rdquo;) promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed
to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically
incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael F. Brigham </FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and<BR>
 Principal Financial Officer </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section 906
has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and Exchange Commission
or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>7
<FILENAME>ea020227701ex97-1_immucell.htm
<DESCRIPTION>IMMUCELL CORPORATION CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 97.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IMMUCELL CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CLAWBACK POLICY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Introduction</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of ImmuCell Corporation (the &ldquo;<B>Company</B>&rdquo;) has adopted this policy (the &ldquo;<B>Policy</B>&rdquo;) which provides for
the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with
financial reporting requirements under the federal securities laws. This Policy is designed to comply with Section 10D of the Securities
Exchange Act of 1934 (the &ldquo;<B>Exchange Act</B>&rdquo;). This policy is not intended to replace, supersede, modify or amend any other
clawback or similar policies the Company may have in place from time to time.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Administration</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This Policy shall be administered by the Board.
Any determinations made by the Board with respect to the Policy shall be final and binding on all affected individuals.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Covered Executives</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This Policy applies to the Company&rsquo;s current
and former executive officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the listing standards
of the national securities exchange on which the Company&rsquo;s securities are listed, and such other senior executives who may from
time to time be deemed subject to the Policy by the Board (each a &ldquo;<B>Covered Executive</B>&rdquo; and collectively the &ldquo;<B>Covered
Executives</B>&rdquo;).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Recoupment; Accounting Restatement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the event the Company is required to prepare
an accounting restatement of its financial statements due to the Company&rsquo;s material noncompliance with any financial reporting requirement
under the securities laws, the Board will require reimbursement or forfeiture of any excess Incentive Compensation, as defined below,
received by any Covered Executive during the three completed fiscal years immediately preceding the earliest date on which the Company
is required to prepare an accounting restatement, whether by an action of the Board or a court, regulator or some other legally authorized
body (the &ldquo;<B>Recoupment Period</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For these purposes, Incentive Compensation shall
be deemed to be received by a Covered Executive in the Company&rsquo;s fiscal year during which the Financial Reporting Measure (as defined
below) specified in the incentive-based compensation award is attained, even if the payment or grant of the Incentive Compensation occurs
after the end of that fiscal year.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Incentive Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For purposes of this Policy, &ldquo;<B>Incentive
Compensation</B>&rdquo; means any compensation is granted, earned, or vested based wholly or in part on the attainment of a Financial
Reporting Measure, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Annual bonuses and other short- and long-term cash incentives.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<TD>Stock options.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<TD>Stock appreciation rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<TD>Restricted stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<TD>Restricted stock units.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<TD>Performance shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<TD>Performance units.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&ldquo;Financial Reporting Measures&rdquo;</B>
means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s financial
statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also
financial reporting measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing
with the Securities and Exchange Commission.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Excess Incentive Compensation: Amount Subject to Recovery</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The amount to be recovered will be the excess
of the Incentive Compensation paid to the Covered Executive based on the erroneous data over the Incentive Compensation that would have
been paid to the Covered Executive had it been based on the restated results, as determined by the Board, and must be computed without
regard to taxes paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If the Board cannot determine the amount of excess
Incentive Compensation received by the Covered Executive directly from the information in the accounting restatement, then it will make
its determination based on a reasonable estimate of the effect of the accounting restatement. The Board shall document and the Company
shall retain documentation of the determination of such reasonable estimate and provide such documentation to the exchange on which the
Company's securities are listed.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Method of Recoupment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board will determine, in its sole discretion,
the method for recouping Incentive Compensation hereunder reasonably promptly, which method may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(a) requiring reimbursement of cash Incentive
Compensation previously paid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(b) seeking recovery of any gain realized on the
vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(c) offsetting the recouped amount from any compensation
otherwise owed by the Company to the Covered Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(d)) cancelling outstanding vested or unvested
equity awards; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(e) taking any other remedial and recovery action
permitted by law, as determined by the Board.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>No Indemnification</U></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company shall not indemnify any Covered Executives
against the loss of any incorrectly awarded Incentive Compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Interpretation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board is authorized to interpret and construe
this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended
that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable
rules or standards adopted by the Securities and Exchange Commission or any national securities exchange on which the Company&rsquo;s
securities are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Effective Date</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Notwithstanding the Recoupment Period, this Policy
shall be effective as of October 2, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;) and shall apply to Incentive Compensation that is approved,
awarded or granted to Covered Executives on or after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Amendment; Termination</U></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board may amend this Policy from time to time
in its discretion and shall amend this Policy as it deems necessary to reflect final regulations adopted by the Securities and Exchange
Commission under Section 10D of the Exchange Act and to comply with any rules or standards adopted by a national securities exchange on
which the Company&rsquo;s securities are listed. The Board may terminate this Policy at any time.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Other Recoupment Rights</U></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board intends that this Policy will be applied
to the fullest extent of the law. The Board may require that any employment agreement, equity award agreement, or similar agreement entered
into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree
to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies
or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement,
equity award agreement, or similar agreement and any other legal remedies available to the Company.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Impracticability</U></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board shall recover any excess Incentive Compensation
in accordance with this Policy unless such recovery would be impracticable, as determined by the Board in accordance with Rule 10D-1 of
the Exchange Act and the listing standards of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">national securities exchange on which the Company&rsquo;s securities are listed.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Successors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This Policy shall be binding and enforceable against
all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Adopted by the Board on July 27, 2023</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>iccc-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 18:01:46 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:iccc="http://immucell.com/20231231" targetNamespace="http://immucell.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedBalanceSheet" id="iccc_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" id="iccc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedIncomeStatement" id="iccc_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ShareholdersEquityType2or3" id="iccc_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedCashFlow" id="iccc_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BusinessOperations" id="iccc_r_BusinessOperations">
        <link:definition>995306 - Disclosure - Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies" id="iccc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/CashandCashEquivalents" id="iccc_r_CashandCashEquivalents">
        <link:definition>995308 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/TradeAccountsReceivable" id="iccc_r_TradeAccountsReceivable">
        <link:definition>995309 - Disclosure - Trade Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/Inventory" id="iccc_r_Inventory">
        <link:definition>995310 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" id="iccc_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>995311 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet" id="iccc_r_PropertyPlantandEquipmentNet">
        <link:definition>995312 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssets" id="iccc_r_IntangibleAssets">
        <link:definition>995313 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses" id="iccc_r_AccountsPayableandAccruedExpenses">
        <link:definition>995314 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebt" id="iccc_r_BankDebt">
        <link:definition>995315 - Disclosure - Bank Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments" id="iccc_r_ContingentLiabilitiesandCommitments">
        <link:definition>995316 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeases" id="iccc_r_OperatingLeases">
        <link:definition>995317 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquity" id="iccc_r_StockholdersEquity">
        <link:definition>995318 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/Revenue" id="iccc_r_Revenue">
        <link:definition>995319 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNet" id="iccc_r_OtherExpensesNet">
        <link:definition>995320 - Disclosure - Other Expenses, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxes" id="iccc_r_IncomeTaxes">
        <link:definition>995321 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformation" id="iccc_r_SegmentInformation">
        <link:definition>995322 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RelatedPartyTransactions" id="iccc_r_RelatedPartyTransactions">
        <link:definition>995323 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/EmployeeBenefits" id="iccc_r_EmployeeBenefits">
        <link:definition>995324 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SubsequentEvents" id="iccc_r_SubsequentEvents">
        <link:definition>995325 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountingPoliciesByPolicy" id="iccc_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" id="iccc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/InventoryTables" id="iccc_r_InventoryTables">
        <link:definition>996002 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="iccc_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables" id="iccc_r_PropertyPlantandEquipmentNetTables">
        <link:definition>996004 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssetsTables" id="iccc_r_IntangibleAssetsTables">
        <link:definition>996005 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" id="iccc_r_AccountsPayableandAccruedExpensesTables">
        <link:definition>996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebtTables" id="iccc_r_BankDebtTables">
        <link:definition>996007 - Disclosure - Bank Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeasesTables" id="iccc_r_OperatingLeasesTables">
        <link:definition>996008 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquityTables" id="iccc_r_StockholdersEquityTables">
        <link:definition>996009 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RevenueTables" id="iccc_r_RevenueTables">
        <link:definition>996010 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNetTables" id="iccc_r_OtherExpensesNetTables">
        <link:definition>996011 - Disclosure - Other Expenses, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxesTables" id="iccc_r_IncomeTaxesTables">
        <link:definition>996012 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformationTables" id="iccc_r_SegmentInformationTables">
        <link:definition>996013 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BusinessOperationsDetails" id="iccc_r_BusinessOperationsDetails">
        <link:definition>996014 - Disclosure - Business Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" id="iccc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" id="iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable">
        <link:definition>996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable" id="iccc_r_ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0" id="iccc_r_ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" id="iccc_r_ScheduleofNetIncomeLossPerCommonShareTable">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/CashandCashEquivalentsDetails" id="iccc_r_CashandCashEquivalentsDetails">
        <link:definition>996020 - Disclosure - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/TradeAccountsReceivableDetails" id="iccc_r_TradeAccountsReceivableDetails">
        <link:definition>996021 - Disclosure - Trade Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/InventoryDetails" id="iccc_r_InventoryDetails">
        <link:definition>996022 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofInventoryTable" id="iccc_r_ScheduleofInventoryTable">
        <link:definition>996023 - Disclosure - Inventory (Details) - Schedule of Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" id="iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996024 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZdGbBMqh1FlvS0VWsnDwFtQUQZbcp+8/vjhiWuHx6DwUIXTksBAFLwuaqwe9SJ598smQehWVDvTLT7qrNCSH1oA5lP7ajJARYB4QG9tIps1UVlNmvOwm8RljtUg2kkrgr4db6kMDWvO8A==] CSR-->
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" id="iccc_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>996025 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" id="iccc_r_ScheduleofPropertyPlantandEquipmentTable">
        <link:definition>996026 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssetsDetails" id="iccc_r_IntangibleAssetsDetails">
        <link:definition>996027 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable" id="iccc_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996028 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" id="iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable">
        <link:definition>996029 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebtDetails" id="iccc_r_BankDebtDetails">
        <link:definition>996030 - Disclosure - Bank Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" id="iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable">
        <link:definition>996031 - Disclosure - Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable" id="iccc_r_ScheduleofPrincipalPaymentsBankLoansOutstandingTable">
        <link:definition>996032 - Disclosure - Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" id="iccc_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>996033 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeasesDetails" id="iccc_r_OperatingLeasesDetails">
        <link:definition>996034 - Disclosure - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" id="iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable">
        <link:definition>996035 - Disclosure - Operating Leases (Details) - Schedule of Lease Costs and Other Lease Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" id="iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable">
        <link:definition>996036 - Disclosure - Operating Leases (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquityDetails" id="iccc_r_StockholdersEquityDetails">
        <link:definition>996037 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" id="iccc_r_ScheduleofActivityUndertheStockOptionPlansTable">
        <link:definition>996038 - Disclosure - Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" id="iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable">
        <link:definition>996039 - Disclosure - Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable" id="iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable">
        <link:definition>996040 - Disclosure - Stockholders' Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" id="iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable">
        <link:definition>996041 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" id="iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable">
        <link:definition>996042 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNetDetails" id="iccc_r_OtherExpensesNetDetails">
        <link:definition>996043 - Disclosure - Other Expenses, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable" id="iccc_r_ScheduleofOtherIncomeExpensesNetTable">
        <link:definition>996044 - Disclosure - Other Expenses, Net (Details) - Schedule of Other (Income) Expenses Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxesDetails" id="iccc_r_IncomeTaxesDetails">
        <link:definition>996045 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable" id="iccc_r_ScheduleofIncomeTaxProvisionTable">
        <link:definition>996046 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Provision</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" id="iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable">
        <link:definition>996047 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Expense Differs from the Expected Tax Computed</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" id="iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable">
        <link:definition>996048 - Disclosure - Income Taxes (Details) - Schedule of Significant Components of Our Deferred Tax Assets Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable" id="iccc_r_ScheduleofSegmentInformationTable">
        <link:definition>996049 - Disclosure - Segment Information (Details) - Schedule of Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails" id="iccc_r_RelatedPartyTransactionsDetails">
        <link:definition>996050 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/EmployeeBenefitsDetails" id="iccc_r_EmployeeBenefitsDetails">
        <link:definition>996051 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:element name="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
  <xs:element name="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
  <xs:element name="ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract"/>
  <xs:element name="ScheduleOfActivityUnderTheStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
  <xs:element name="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
  <xs:element name="ScheduleOfSegmentInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfSegmentInformationAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract12"/>
  <xs:element name="BalanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BalanceAbstract"/>
  <xs:element name="BalanceAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BalanceAbstract0"/>
  <xs:element name="BalanceAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BalanceAbstract1"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_UnlabeledAbstract27"/>
  <xs:element name="PaymentsOfDebtDiscounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_PaymentsOfDebtDiscounts"/>
  <xs:element name="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
  <xs:element name="ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
  <xs:element name="ValuationOfLongLivedAssetsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ValuationOfLongLivedAssetsPolicyTextBlock"/>
  <xs:element name="ExpenseRecognitionPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ExpenseRecognitionPolicyTextBlock"/>
  <xs:element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesTablesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <xs:element name="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <xs:element name="DebtIssuanceCosts2023" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2023"/>
  <xs:element name="DebtIssuanceCosts2024" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2024"/>
  <xs:element name="DebtIssuanceCosts2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2025"/>
  <xs:element name="DebtIssuanceCosts2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2026"/>
  <xs:element name="DebtIssuanceCosts2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2027"/>
  <xs:element name="DebtIssuanceCostshereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCostshereafter"/>
  <xs:element name="DebtDiscountCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost"/>
  <xs:element name="DebtDiscountCost2024" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2024"/>
  <xs:element name="DebtDiscountCost2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2025"/>
  <xs:element name="DebtDiscountCost2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2026"/>
  <xs:element name="DebtDiscountCost2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2027"/>
  <xs:element name="DebtDiscountCostThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCostThereafter"/>
  <xs:element name="DebtDiscountCostTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCostTotal"/>
  <xs:element name="LongTermDebt2023" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2023"/>
  <xs:element name="LongTermDebt2024" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2024"/>
  <xs:element name="LongTermDebt2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2025"/>
  <xs:element name="LongTermDebt2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2026"/>
  <xs:element name="LongTermDebt2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2027"/>
  <xs:element name="LongTermDebtThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebtThereafter"/>
  <xs:element name="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
  <xs:element name="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <xs:element name="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <xs:element name="RevenueSalesObligationPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_RevenueSalesObligationPercentage"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="AccountsReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_AccountsReceivablePercentage"/>
  <xs:element name="TradeAccountsReceivableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_TradeAccountsReceivableDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_IntangibleAssetsDetailsTable"/>
  <xs:element name="BankDebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtDetailsTable"/>
  <xs:element name="InterestPaymentsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_InterestPaymentsTerm"/>
  <xs:element name="LoanToValueRatio" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_LoanToValueRatio"/>
  <xs:element name="MinimumDebtServicesCoverageRatio" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_MinimumDebtServicesCoverageRatio"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="NumberOfExecutiveOfficers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_NumberOfExecutiveOfficers"/>
  <xs:element name="CapitalExpendituresCommitted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_CapitalExpendituresCommitted"/>
  <xs:element name="InventoryProduction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_InventoryProduction"/>
  <xs:element name="OtherObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherObligations"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsTable"/>
  <xs:element name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_NetProceedsFromIssuanceOfCommonStock"/>
  <xs:element name="StockOptionsCoveringShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StockOptionsCoveringShares"/>
  <xs:element name="StockOptionsCoveringcash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_StockOptionsCoveringcash"/>
  <xs:element name="ExercisableAndTransferableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ExercisableAndTransferableDescription"/>
  <xs:element name="RightToAcquirePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_RightToAcquirePerShare"/>
  <xs:element name="AcquiringPersonPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_AcquiringPersonPercentage"/>
  <xs:element name="OtherExpensesNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_OtherExpensesNetDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_IncomeTaxesDetailsTable"/>
  <xs:element name="EmployeeBenefitsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_EmployeeBenefitsDetailsTable"/>
  <xs:element name="EmployeesSalaryPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeesSalaryPercentage"/>
  <xs:element name="EmployeesSalaryContributionPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeesSalaryContributionPercentage"/>
  <xs:element name="AcquiringPersonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_AcquiringPersonMember"/>
  <xs:element name="CompanyAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyAMember"/>
  <xs:element name="CompanyBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyBMember"/>
  <xs:element name="CompanyCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyCMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CustomerMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodNineMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodSixMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodTenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodTenMember"/>
  <xs:element name="EmployeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeeMember"/>
  <xs:element name="EmployeeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeeOneMember"/>
  <xs:element name="FederalGeneralBusinessMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_FederalGeneralBusinessMember"/>
  <xs:element name="FirstDefenseProductLineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_FirstDefenseProductLineMember"/>
  <xs:element name="GorhamSavingsBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_GorhamSavingsBankMember"/>
  <xs:element name="MaineTechnologyInstituteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MaineTechnologyInstituteMember"/>
  <xs:element name="MastitisMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MastitisMember"/>
  <xs:element name="MrBrighamMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MrBrighamMember"/>
  <xs:element name="NisinDrugSubstanceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_NisinDrugSubstanceMember"/>
  <xs:element name="OtherAnimalHealthMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherAnimalHealthMember"/>
  <xs:element name="OtherStatesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherStatesMember"/>
  <xs:element name="ScoursMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScoursMember"/>
  <xs:element name="StateTaxCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StateTaxCreditMember"/>
  <xs:element name="StockOptionPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StockOptionPlansMember"/>
  <xs:element name="SubtotalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_SubtotalMember"/>
  <xs:element name="TwoThousandSeventeenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandSeventeenPlanMember"/>
  <xs:element name="TwoThousandSeventeenPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandSeventeenPlansMember"/>
  <xs:element name="TwoThousandTenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandTenPlanMember"/>
  <xs:element name="TwoThousandTenPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandTenPlansMember"/>
  <xs:element name="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems"/>
  <xs:element name="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems"/>
  <xs:element name="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems"/>
  <xs:element name="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>iccc-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 18:01:46 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofOtherIncomeExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZdGbBMqh1FlvS0VWsnDwFtQUQZbcp+8/vjhiWuHx6DwUIXTksBAFLwuaqwe9SJ598smQehWVDvTLT7qrNCSH1oA5lP7ajJARYB4QG9tIps1UVlNmvOwm8RlY+yNEMhmXsUjTr/gDdYvDw==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="iccc_PaymentsOfDebtDiscounts" xlink:href="iccc-20231231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="iccc_PaymentsOfDebtDiscounts" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InsuranceRecoveries" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="6" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>iccc-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 18:01:46 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ShareholdersEquityType2or3" roleURI="http://immucell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BusinessOperations" roleURI="http://immucell.com/role/BusinessOperations"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_CashandCashEquivalents" roleURI="http://immucell.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_TradeAccountsReceivable" roleURI="http://immucell.com/role/TradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_Inventory" roleURI="http://immucell.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PropertyPlantandEquipmentNet" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IntangibleAssets" roleURI="http://immucell.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_AccountsPayableandAccruedExpenses" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BankDebt" roleURI="http://immucell.com/role/BankDebt"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ContingentLiabilitiesandCommitments" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OperatingLeases" roleURI="http://immucell.com/role/OperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_StockholdersEquity" roleURI="http://immucell.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_Revenue" roleURI="http://immucell.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OtherExpensesNet" roleURI="http://immucell.com/role/OtherExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IncomeTaxes" roleURI="http://immucell.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SegmentInformation" roleURI="http://immucell.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_RelatedPartyTransactions" roleURI="http://immucell.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_EmployeeBenefits" roleURI="http://immucell.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SubsequentEvents" roleURI="http://immucell.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_AccountingPoliciesByPolicy" roleURI="http://immucell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_InventoryTables" roleURI="http://immucell.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PropertyPlantandEquipmentNetTables" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IntangibleAssetsTables" roleURI="http://immucell.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_AccountsPayableandAccruedExpensesTables" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BankDebtTables" roleURI="http://immucell.com/role/BankDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OperatingLeasesTables" roleURI="http://immucell.com/role/OperatingLeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_StockholdersEquityTables" roleURI="http://immucell.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_RevenueTables" roleURI="http://immucell.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OtherExpensesNetTables" roleURI="http://immucell.com/role/OtherExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IncomeTaxesTables" roleURI="http://immucell.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SegmentInformationTables" roleURI="http://immucell.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable" roleURI="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0" roleURI="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIntangibleAssetsTable" roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPrincipalPaymentsBankLoansOutstandingTable" roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofActivityUndertheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable" roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofOtherIncomeExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofSegmentInformationTable" roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BusinessOperationsDetails" roleURI="http://immucell.com/role/BusinessOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_CashandCashEquivalentsDetails" roleURI="http://immucell.com/role/CashandCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_TradeAccountsReceivableDetails" roleURI="http://immucell.com/role/TradeAccountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_InventoryDetails" roleURI="http://immucell.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IntangibleAssetsDetails" roleURI="http://immucell.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BankDebtDetails" roleURI="http://immucell.com/role/BankDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OperatingLeasesDetails" roleURI="http://immucell.com/role/OperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_StockholdersEquityDetails" roleURI="http://immucell.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OtherExpensesNetDetails" roleURI="http://immucell.com/role/OtherExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IncomeTaxesDetails" roleURI="http://immucell.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_RelatedPartyTransactionsDetails" roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_EmployeeBenefitsDetails" roleURI="http://immucell.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#DocumentAndEntityInformation" roleURI="http://immucell.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_PaymentsOfDebtDiscounts" xlink:href="iccc-20231231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iccc_PaymentsOfDebtDiscounts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpenseAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20231231.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20231231.xsd#iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/BusinessOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/CashandCashEquivalents">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/TradeAccountsReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/BankDebt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/OperatingLeases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/Revenue">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/OtherExpensesNet">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/EmployeeBenefits">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ValuationOfLongLivedAssetsPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_ValuationOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iccc_ValuationOfLongLivedAssetsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesTablesTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/BankDebtTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/OperatingLeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/RevenueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/OtherExpensesNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_OtherAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20231231.xsd#iccc_CompanyAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20231231.xsd#iccc_CompanyBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0">
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20231231.xsd#iccc_CompanyAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20231231.xsd#iccc_CompanyBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyCMember" xlink:href="iccc-20231231.xsd#iccc_CompanyCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_NoncompeteAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable">
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:href="iccc-20231231.xsd#iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:to="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:to="us-gaap_RepaymentsOfBankDebt" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable">
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_SubtotalMember" xlink:href="iccc-20231231.xsd#iccc_SubtotalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_SubtotalMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2023" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2023"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtIssuanceCosts2023" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2024" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2024"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtIssuanceCosts2024" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2025" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtIssuanceCosts2025" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2026" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtIssuanceCosts2026" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2027" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtIssuanceCosts2027" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCostshereafter" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCostshereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtIssuanceCostshereafter" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCost" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2024" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2024"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCost2024" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2025" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCost2025" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2026" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCost2026" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2027" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCost2027" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostThereafter" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCostThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCostThereafter" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostTotal" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCostTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_DebtDiscountCostTotal" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2023" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2023"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_LongTermDebt2023" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2024" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2024"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_LongTermDebt2024" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2025" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_LongTermDebt2025" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2026" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_LongTermDebt2026" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2027" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_LongTermDebt2027" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtThereafter" xlink:href="iccc-20231231.xsd#iccc_LongTermDebtThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_LongTermDebtThereafter" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZdGbBMqh1FlvS0VWsnDwFtQUQZbcp+8/vjhiWuHx6DwUIXTksBAFLwuaqwe9SJ598smQehWVDvTLT7qrNCSH1oA5lP7ajJARYB4QG9tIps1UVlNmvOwm8Rle5HQxcs9QaUYAq2Szdn88Q==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlanMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandTenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandTenPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlanMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandSeventeenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20231231.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20231231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20231231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable">
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionPlansMember" xlink:href="iccc-20231231.xsd#iccc_StockOptionPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="iccc_StockOptionPlansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:href="iccc-20231231.xsd#iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:to="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherStatesMember" xlink:href="iccc-20231231.xsd#iccc_OtherStatesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="iccc_OtherStatesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueSalesObligationPercentage" xlink:href="iccc-20231231.xsd#iccc_RevenueSalesObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:to="iccc_RevenueSalesObligationPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FirstDefenseProductLineMember" xlink:href="iccc-20231231.xsd#iccc_FirstDefenseProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_FirstDefenseProductLineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherAnimalHealthMember" xlink:href="iccc-20231231.xsd#iccc_OtherAnimalHealthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_OtherAnimalHealthMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofSegmentInformationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ScoursMember" xlink:href="iccc-20231231.xsd#iccc_ScoursMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="iccc_ScoursMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MastitisMember" xlink:href="iccc-20231231.xsd#iccc_MastitisMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="iccc_MastitisMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/BusinessOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CustomerMember" xlink:href="iccc-20231231.xsd#iccc_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NisinDrugSubstanceMember" xlink:href="iccc-20231231.xsd#iccc_NisinDrugSubstanceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iccc_NisinDrugSubstanceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskCustomer" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_AccountsReceivablePercentage" xlink:href="iccc-20231231.xsd#iccc_AccountsReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="iccc_AccountsReceivablePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/CashandCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/TradeAccountsReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_TradeAccountsReceivableDetailsTable" xlink:href="iccc-20231231.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="iccc_TradeAccountsReceivableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/InventoryDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_IntangibleAssetsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="iccc_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_IntangibleAssetsDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/BankDebtDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsTable" xlink:href="iccc-20231231.xsd#iccc_BankDebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_BankDebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_GorhamSavingsBankMember" xlink:href="iccc-20231231.xsd#iccc_GorhamSavingsBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_GorhamSavingsBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MaineTechnologyInstituteMember" xlink:href="iccc-20231231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_MaineTechnologyInstituteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBankingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_MortgageBankingMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iccc_GorhamSavingsBankMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iccc_MaineTechnologyInstituteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodNineMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodNineMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodTenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodTenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodTenMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_EscrowDeposit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_InterestPaymentsTerm" xlink:href="iccc-20231231.xsd#iccc_InterestPaymentsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_InterestPaymentsTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LineOfCredit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LoanToValueRatio" xlink:href="iccc-20231231.xsd#iccc_LoanToValueRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_LoanToValueRatio" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FinancingReceivableLoanInProcess" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MinimumDebtServicesCoverageRatio" xlink:href="iccc-20231231.xsd#iccc_MinimumDebtServicesCoverageRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_MinimumDebtServicesCoverageRatio" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestCostsIncurred" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MrBrighamMember" xlink:href="iccc-20231231.xsd#iccc_MrBrighamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_MrBrighamMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NumberOfExecutiveOfficers" xlink:href="iccc-20231231.xsd#iccc_NumberOfExecutiveOfficers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_NumberOfExecutiveOfficers" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CapitalExpendituresCommitted" xlink:href="iccc-20231231.xsd#iccc_CapitalExpendituresCommitted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_CapitalExpendituresCommitted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_InventoryProduction" xlink:href="iccc-20231231.xsd#iccc_InventoryProduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_InventoryProduction" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherObligations" xlink:href="iccc-20231231.xsd#iccc_OtherObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_OtherObligations" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/OperatingLeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AreaOfLand" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlansMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandTenPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandTenPlansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlansMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandSeventeenPlansMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonMember" xlink:href="iccc-20231231.xsd#iccc_AcquiringPersonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="iccc_AcquiringPersonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:href="iccc-20231231.xsd#iccc_NetProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionsCoveringShares" xlink:href="iccc-20231231.xsd#iccc_StockOptionsCoveringShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_StockOptionsCoveringShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionsCoveringcash" xlink:href="iccc-20231231.xsd#iccc_StockOptionsCoveringcash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_StockOptionsCoveringcash" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ExercisableAndTransferableDescription" xlink:href="iccc-20231231.xsd#iccc_ExercisableAndTransferableDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_ExercisableAndTransferableDescription" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyPurchasePremiumPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_RightToAcquirePerShare" xlink:href="iccc-20231231.xsd#iccc_RightToAcquirePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_RightToAcquirePerShare" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonPercentage" xlink:href="iccc-20231231.xsd#iccc_AcquiringPersonPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="iccc_AcquiringPersonPercentage" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="31" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/OtherExpensesNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentOfOtherExpenseNonoperatingLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherExpensesNetDetailsTable" xlink:href="iccc-20231231.xsd#iccc_OtherExpensesNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="iccc_OtherExpensesNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_IncomeTaxesDetailsTable" xlink:href="iccc-20231231.xsd#iccc_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="iccc_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FederalGeneralBusinessMember" xlink:href="iccc-20231231.xsd#iccc_FederalGeneralBusinessMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="iccc_FederalGeneralBusinessMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StateTaxCreditMember" xlink:href="iccc-20231231.xsd#iccc_StateTaxCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="iccc_StateTaxCreditMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/EmployeeBenefitsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeBenefitsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeeBenefitsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_EmployeeBenefitsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeMember" xlink:href="iccc-20231231.xsd#iccc_EmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_EmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeOneMember" xlink:href="iccc-20231231.xsd#iccc_EmployeeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_EmployeeOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryPercentage" xlink:href="iccc-20231231.xsd#iccc_EmployeesSalaryPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeesSalaryPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryContributionPercentage" xlink:href="iccc-20231231.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeesSalaryContributionPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://immucell.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>iccc-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 18:01:46 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">NET OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">NET OPERATING INCOME (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss attributable to stockholders (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used for operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used for investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BEGINNING CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">ENDING CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract_lbl" xml:lang="en-US">Business Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:to="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Schedule of Net Income Loss Per Common Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrentAbstract_lbl" xml:lang="en-US">Trade Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Bank Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Contingent Liabilities and Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US">Schedule of Lease Costs and Other Lease Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments (undiscounted cash flows)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Option outstanding of exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Non-vested stock options as of beginning balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of Shares, Non-vested stock options as of ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Non-vested stock options as of beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Non-vested stock options as of ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other Expenses, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Schedule of Other (Income) Expenses Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule of Income Tax Provision [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Income Tax Expense Differs from the Expected Tax Computed [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense/rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax expense/rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Significant Components of Our Deferred Tax Assets Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and money market accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents at carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Trade accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract" xlink:to="iccc_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Net Book Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Net value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract0" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract0" xlink:to="iccc_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current portion of debt obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract1" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract1" xlink:to="iccc_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Debt obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract2" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract2" xlink:to="iccc_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract3" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract3" xlink:to="iccc_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract4" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract4" xlink:to="iccc_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.10 par value per share, 15,000,000 shares authorized and 7,814,165 shares issued as of both December 31, 2023 and 2022 and 7,750,864 and 7,746,864 shares outstanding as of December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Total product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1" xml:lang="en-US">Total product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Costs of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract5" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract5" xlink:to="iccc_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Product development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract6" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract6" xlink:to="iccc_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract7" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract7" xlink:to="iccc_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract8" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract8" xlink:to="iccc_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract9" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract9" xlink:to="iccc_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract10" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract10" xlink:to="iccc_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract11" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract11" xlink:to="iccc_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average common shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average common shares outstanding - Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract12" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract12" xlink:to="iccc_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted weighted average common shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average common shares outstanding - Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_BalanceAbstract" xlink:href="iccc-20231231.xsd#iccc_BalanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BalanceAbstract_lbl" xml:lang="en-US">BALANCE,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract" xlink:to="iccc_BalanceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock option cash (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BalanceAbstract0" xlink:href="iccc-20231231.xsd#iccc_BalanceAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BalanceAbstract0_lbl" xml:lang="en-US">BALANCE,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract0" xlink:to="iccc_BalanceAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BalanceAbstract1" xlink:href="iccc-20231231.xsd#iccc_BalanceAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BalanceAbstract1_lbl" xml:lang="en-US">BALANCE,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract1" xlink:to="iccc_BalanceAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Intangible amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract13" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract13" xlink:to="iccc_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract14" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract14" xlink:to="iccc_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Debt Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract15" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract15" xlink:to="iccc_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract16" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract16" xlink:to="iccc_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract17" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract17" xlink:to="iccc_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpenseAbstract_lbl" xml:lang="en-US">CASH PAID FOR:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract18" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract18" xlink:to="iccc_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NON-CASH ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20231231.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Change in capital expenditures included in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20231231.xsd#iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Change in payments of debt discounts included in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right-of-use asset and operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Treasury stock, at cost, 63,301 and 67,301 shares as of December 31, 2023 and 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Stock options shares exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss (gain) on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Debt principal repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Line of credit repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_PaymentsOfDebtDiscounts" xlink:href="iccc-20231231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_PaymentsOfDebtDiscounts_lbl" xml:lang="en-US">Payments of debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PaymentsOfDebtDiscounts" xlink:to="iccc_PaymentsOfDebtDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">BUSINESS OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract19" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract19" xlink:to="iccc_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Bank debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract20" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract20" xlink:to="iccc_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule of Trade Accounts Receivable Due from Significant Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Trade account receivable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract21" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract21" xlink:to="iccc_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Dilutive impact of share-based compensation awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract22" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract22" xlink:to="iccc_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">TRADE ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, Estimated Useful Lives (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">BANK DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt Proceeds Received and Principal Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Debt Principal Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Principal Payments Bank Loans Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US">During the Three-Month Period Ending ,Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">During the Three-Month Period Ending, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2027" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtDiscountCost2027_lbl" xml:lang="en-US">Debt discount cost 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostThereafter" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCostThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtDiscountCostThereafter_lbl" xml:lang="en-US">Debt discount cost Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2023" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2023"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2023_lbl" xml:lang="en-US">Total During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2023" xlink:to="iccc_LongTermDebt2023_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2024" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2024"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2024_lbl" xml:lang="en-US">Total 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2024" xlink:to="iccc_LongTermDebt2024_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2025" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2025_lbl" xml:lang="en-US">Total 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2026" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2026_lbl" xml:lang="en-US">Total 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2027" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2027_lbl" xml:lang="en-US">Total 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtThereafter" xlink:href="iccc-20231231.xsd#iccc_LongTermDebtThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebtThereafter_lbl" xml:lang="en-US">Total Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs and Other Lease Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract23" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract23" xlink:to="iccc_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Activity Under the Stock Option Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Shares, Stock options granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Grants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise prices per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercises (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20231231.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20231231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20231231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved for future grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common stock outstanding under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Additional Information About the Stock Option Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Stock options that vested (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options that vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options that vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Stock options that were forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options that were forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options that were forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Geographic Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueSalesObligationPercentage" xlink:href="iccc-20231231.xsd#iccc_RevenueSalesObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_RevenueSalesObligationPercentage_lbl" xml:lang="en-US">Percentage of product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueSalesObligationPercentage" xlink:to="iccc_RevenueSalesObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Major Product Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Percentage of product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">OTHER EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Other (Income) Expenses Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Expense Differs from the Expected Tax Computed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred subtotal, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Expense Differs from the Expected Tax Computed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed expected income tax expense rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal expense, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Share-based compensation, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Significant Components of Our Deferred Tax Assets Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Federal general business tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Federal net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State tax credits and net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xml:lang="en-US">&#167;174 R &amp; D expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">UNICAP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Incentive compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract24" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract24" xlink:to="iccc_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract25" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract25" xlink:to="iccc_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract26" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract26" xlink:to="iccc_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_UnlabeledAbstract27" xlink:href="iccc-20231231.xsd#iccc_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract27" xlink:to="iccc_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2023" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2023"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2023_lbl" xml:lang="en-US">Debt issuance costs During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2023" xlink:to="iccc_DebtIssuanceCosts2023_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2024" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2024"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2024_lbl" xml:lang="en-US">Debt issuance costs 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2024" xlink:to="iccc_DebtIssuanceCosts2024_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2025" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2025_lbl" xml:lang="en-US">Debt issuance costs 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2026" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2026_lbl" xml:lang="en-US">Debt issuance costs 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2027" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2027_lbl" xml:lang="en-US">Debt issuance costs 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCostshereafter" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCostshereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCostshereafter_lbl" xml:lang="en-US">Debt issuance costs Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost_lbl" xml:lang="en-US">Debt discount cost During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost" xlink:to="iccc_DebtDiscountCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2024" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2024"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2024_lbl" xml:lang="en-US">Debt discount cost 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2024" xlink:to="iccc_DebtDiscountCost2024_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2025" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2025_lbl" xml:lang="en-US">Debt discount cost 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2026" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2026_lbl" xml:lang="en-US">Debt discount cost 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostTotal" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCostTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCostTotal_lbl" xml:lang="en-US">Debt discount cost Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest (discount effect of cash flows)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Terminations/forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss (gain) on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InsuranceRecoveries_lbl" xml:lang="en-US">Insurance recovery</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Income-other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred subtotal, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Computed expected income tax expense rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Company A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20231231.xsd#iccc_CompanyAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyAMember_lbl" xml:lang="en-US">Company A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyAMember" xlink:to="iccc_CompanyAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20231231.xsd#iccc_CompanyBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyBMember_lbl" xml:lang="en-US">Company B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyBMember" xlink:to="iccc_CompanyBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyCMember" xlink:href="iccc-20231231.xsd#iccc_CompanyCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyCMember_lbl" xml:lang="en-US">Company C [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyCMember" xlink:to="iccc_CompanyCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US">Laboratory and manufacturing equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl" xml:lang="en-US">Non-compete agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US">Loan #1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US">Loan #2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US">Loan #3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl" xml:lang="en-US">Loan #4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl" xml:lang="en-US">Loan #5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl" xml:lang="en-US">Loan #6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Six [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl" xml:lang="en-US">Loan #7 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Seven [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_SubtotalMember" xlink:href="iccc-20231231.xsd#iccc_SubtotalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_SubtotalMember_lbl" xml:lang="en-US">Subtotal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubtotalMember" xlink:to="iccc_SubtotalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlanMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandTenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandTenPlanMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlanMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionPlansMember" xlink:href="iccc-20231231.xsd#iccc_StockOptionPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StockOptionPlansMember_lbl" xml:lang="en-US">Stock Option Plans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionPlansMember" xlink:to="iccc_StockOptionPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherStatesMember" xlink:href="iccc-20231231.xsd#iccc_OtherStatesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherStatesMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FirstDefenseProductLineMember" xlink:href="iccc-20231231.xsd#iccc_FirstDefenseProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FirstDefenseProductLineMember_lbl" xml:lang="en-US">First Defense&#174; product line [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FirstDefenseProductLineMember" xlink:to="iccc_FirstDefenseProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherAnimalHealthMember" xlink:href="iccc-20231231.xsd#iccc_OtherAnimalHealthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherAnimalHealthMember_lbl" xml:lang="en-US">Other animal health [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherAnimalHealthMember" xlink:to="iccc_OtherAnimalHealthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScoursMember" xlink:href="iccc-20231231.xsd#iccc_ScoursMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ScoursMember_lbl" xml:lang="en-US">Scours [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScoursMember" xlink:to="iccc_ScoursMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MastitisMember" xlink:href="iccc-20231231.xsd#iccc_MastitisMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MastitisMember_lbl" xml:lang="en-US">Mastitis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MastitisMember" xlink:to="iccc_MastitisMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Asset depreciated percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">impairment of recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Fair value of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value of liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xml:lang="en-US">Concentration customer risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_AccountsReceivablePercentage" xlink:href="iccc-20231231.xsd#iccc_AccountsReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_AccountsReceivablePercentage_lbl" xml:lang="en-US">Receivable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AccountsReceivablePercentage" xlink:to="iccc_AccountsReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive amounted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Trade accounts receivable related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write off</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US">Property, plant and equipment disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset amortized, useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bearing interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_InterestPaymentsTerm" xlink:href="iccc-20231231.xsd#iccc_InterestPaymentsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_InterestPaymentsTerm_lbl" xml:lang="en-US">Interest payments, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Loan amortization, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Balloon principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl" xml:lang="en-US">Mortgage debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl" xml:lang="en-US">Outstanding principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Interest fixed rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from issuance of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LoanToValueRatio" xlink:href="iccc-20231231.xsd#iccc_LoanToValueRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LoanToValueRatio_lbl" xml:lang="en-US">Loan to value ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancingReceivableLoanInProcess_lbl" xml:lang="en-US">Finance loan provided</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableLoanInProcess" xlink:to="us-gaap_FinancingReceivableLoanInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MinimumDebtServicesCoverageRatio" xlink:href="iccc-20231231.xsd#iccc_MinimumDebtServicesCoverageRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MinimumDebtServicesCoverageRatio_lbl" xml:lang="en-US">Minimum debt service coverage ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MinimumDebtServicesCoverageRatio" xlink:to="iccc_MinimumDebtServicesCoverageRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Incurred costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xml:lang="en-US">Outstanding amount of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl" xml:lang="en-US">Bank loans outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NumberOfExecutiveOfficers" xlink:href="iccc-20231231.xsd#iccc_NumberOfExecutiveOfficers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NumberOfExecutiveOfficers_lbl" xml:lang="en-US">Number of executive officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NumberOfExecutiveOfficers" xlink:to="iccc_NumberOfExecutiveOfficers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Total accrued amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl" xml:lang="en-US">Deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Deferred compensation agreement annual base salary percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CapitalExpendituresCommitted" xlink:href="iccc-20231231.xsd#iccc_CapitalExpendituresCommitted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CapitalExpendituresCommitted_lbl" xml:lang="en-US">Capital expenditures committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Construct and equip commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_InventoryProduction" xlink:href="iccc-20231231.xsd#iccc_InventoryProduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_InventoryProduction_lbl" xml:lang="en-US">Purchase of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InventoryProduction" xlink:to="iccc_InventoryProduction_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherObligations" xlink:href="iccc-20231231.xsd#iccc_OtherObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherObligations_lbl" xml:lang="en-US">Other obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherObligations" xlink:to="iccc_OtherObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Square feet (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renew term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Additional rent payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Common stock shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:href="iccc-20231231.xsd#iccc_NetProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock option expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionsCoveringShares" xlink:href="iccc-20231231.xsd#iccc_StockOptionsCoveringShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StockOptionsCoveringShares_lbl" xml:lang="en-US">Exercised stock options covering shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionsCoveringShares" xlink:to="iccc_StockOptionsCoveringShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionsCoveringcash" xlink:href="iccc-20231231.xsd#iccc_StockOptionsCoveringcash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StockOptionsCoveringcash_lbl" xml:lang="en-US">Stock options covering cash (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionsCoveringcash" xlink:to="iccc_StockOptionsCoveringcash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZdGbBMqh1FlvS0VWsnDwFtQUQZbcp+8/vjhiWuHx6DwUIXTksBAFLwuaqwe9SJ598smQehWVDvTLT7qrNCSH1oA5lP7ajJARYB4QG9tIps1UVlNmvOwm8Rlaz/sGzJ54BuS05h2U4vWzQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining life of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining life of the options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise prices (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Stock options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Stock-based compensation related to non-vested stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" xml:lang="en-US">Common stock purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ExercisableAndTransferableDescription" xlink:href="iccc-20231231.xsd#iccc_ExercisableAndTransferableDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ExercisableAndTransferableDescription_lbl" xml:lang="en-US">Exercisable and transferable, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExercisableAndTransferableDescription" xlink:to="iccc_ExercisableAndTransferableDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyPurchasePremiumPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl" xml:lang="en-US">Purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl" xml:lang="en-US">Common stock were changed percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Acquisition percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RightToAcquirePerShare" xlink:href="iccc-20231231.xsd#iccc_RightToAcquirePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_RightToAcquirePerShare_lbl" xml:lang="en-US">Price per Right (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RightToAcquirePerShare" xlink:to="iccc_RightToAcquirePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonPercentage" xlink:href="iccc-20231231.xsd#iccc_AcquiringPersonPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_AcquiringPersonPercentage_lbl" xml:lang="en-US">Percentage of acquiring person</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonPercentage" xlink:to="iccc_AcquiringPersonPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl" xml:lang="en-US">Extend the rights plan, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Loss income before income taxes, rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards not expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Expiration term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl" xml:lang="en-US">Non-cash income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Value of our deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Related party products purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" xlink:to="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryPercentage" xlink:href="iccc-20231231.xsd#iccc_EmployeesSalaryPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeesSalaryPercentage_lbl" xml:lang="en-US">Employee&#8217;s salary percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryContributionPercentage" xlink:href="iccc-20231231.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl" xml:lang="en-US">Employee&#8217;s salary contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xml:lang="en-US">Employee benefits paid (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets and Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ValuationOfLongLivedAssetsPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_ValuationOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ValuationOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ValuationOfLongLivedAssetsPolicyTextBlock" xlink:to="iccc_ValuationOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Expense Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncement Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NisinDrugSubstanceMember" xlink:href="iccc-20231231.xsd#iccc_NisinDrugSubstanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NisinDrugSubstanceMember_lbl" xml:lang="en-US">Nisin Drug Substance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NisinDrugSubstanceMember" xlink:to="iccc_NisinDrugSubstanceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CustomerMember" xlink:href="iccc-20231231.xsd#iccc_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CustomerMember" xlink:to="iccc_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_GorhamSavingsBankMember" xlink:href="iccc-20231231.xsd#iccc_GorhamSavingsBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_GorhamSavingsBankMember_lbl" xml:lang="en-US">Gorham Savings Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_GorhamSavingsBankMember" xlink:to="iccc_GorhamSavingsBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MaineTechnologyInstituteMember" xlink:href="iccc-20231231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MaineTechnologyInstituteMember_lbl" xml:lang="en-US">Maine Technology Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MaineTechnologyInstituteMember" xlink:to="iccc_MaineTechnologyInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodNineMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodNineMember_lbl" xml:lang="en-US">Loan #3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodNineMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodNineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodTenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodTenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodTenMember_lbl" xml:lang="en-US">Loans #4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodTenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodTenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBankingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MortgageBankingMember_lbl" xml:lang="en-US">Mortgage Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBankingMember" xlink:to="us-gaap_MortgageBankingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MrBrighamMember" xlink:href="iccc-20231231.xsd#iccc_MrBrighamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MrBrighamMember_lbl" xml:lang="en-US">Mr. Brigham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MrBrighamMember" xlink:to="iccc_MrBrighamMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlansMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandTenPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandTenPlansMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlansMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandSeventeenPlansMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlansMember" xlink:to="iccc_TwoThousandSeventeenPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonMember" xlink:href="iccc-20231231.xsd#iccc_AcquiringPersonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_AcquiringPersonMember_lbl" xml:lang="en-US">Acquiring Person [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonMember" xlink:to="iccc_AcquiringPersonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FederalGeneralBusinessMember" xlink:href="iccc-20231231.xsd#iccc_FederalGeneralBusinessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FederalGeneralBusinessMember_lbl" xml:lang="en-US">Federal General Business [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FederalGeneralBusinessMember" xlink:to="iccc_FederalGeneralBusinessMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StateTaxCreditMember" xlink:href="iccc-20231231.xsd#iccc_StateTaxCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StateTaxCreditMember_lbl" xml:lang="en-US">State Tax Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StateTaxCreditMember" xlink:to="iccc_StateTaxCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeMember" xlink:href="iccc-20231231.xsd#iccc_EmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeMember" xlink:to="iccc_EmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeOneMember" xlink:href="iccc-20231231.xsd#iccc_EmployeeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeeOneMember_lbl" xml:lang="en-US">Employee One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeOneMember" xlink:to="iccc_EmployeeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesTablesTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesTablesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems_lbl" xml:lang="en-US">Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:to="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:href="iccc-20231231.xsd#iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable_lbl" xml:lang="en-US">Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems_lbl" xml:lang="en-US">Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:to="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems_lbl" xml:lang="en-US">Schedule of Principal Payments Bank Loans Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) - Schedule of Activity Under the Stock Option Plans [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Activity Under the Stock Option Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems_lbl" xml:lang="en-US">Schedule of Additional Information About the Stock Option Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:href="iccc-20231231.xsd#iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable_lbl" xml:lang="en-US">Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:to="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Schedule of Segment Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TradeAccountsReceivableDetailsTable" xlink:href="iccc-20231231.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TradeAccountsReceivableDetailsTable_lbl" xml:lang="en-US">Trade Accounts Receivable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TradeAccountsReceivableDetailsTable" xlink:to="iccc_TradeAccountsReceivableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Trade Accounts Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_IntangibleAssetsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_IntangibleAssetsDetailsTable" xlink:to="iccc_IntangibleAssetsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsTable" xlink:href="iccc-20231231.xsd#iccc_BankDebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtDetailsTable_lbl" xml:lang="en-US">Bank Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtDetailsTable" xlink:to="iccc_BankDebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Bank Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="iccc_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="iccc_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherExpensesNetDetailsTable" xlink:href="iccc-20231231.xsd#iccc_OtherExpensesNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherExpensesNetDetailsTable_lbl" xml:lang="en-US">Other Expenses, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherExpensesNetDetailsTable" xlink:to="iccc_OtherExpensesNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentOfOtherExpenseNonoperatingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems_lbl" xml:lang="en-US">Other (Income) Expenses, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_IncomeTaxesDetailsTable" xlink:href="iccc-20231231.xsd#iccc_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_IncomeTaxesDetailsTable" xlink:to="iccc_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeBenefitsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeBenefitsDetailsTable_lbl" xml:lang="en-US">Employee Benefits (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeBenefitsDetailsTable" xlink:to="iccc_EmployeeBenefitsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Employee Benefits [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_AccountsReceivablePercentage_lbl0" xml:lang="en-US">Accounts receivable percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AccountsReceivablePercentage" xlink:to="iccc_AccountsReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_AcquiringPersonPercentage_lbl0" xml:lang="en-US">Percentage of acquiring person.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonPercentage" xlink:to="iccc_AcquiringPersonPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_CapitalExpendituresCommitted_lbl0" xml:lang="en-US">Capital expenditures committed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl0" xml:lang="en-US">Change in capital expenditures included in accounts payable and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl0" xml:lang="en-US">Amount of change in payments of debt discounts included in accounts payable and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost_lbl0" xml:lang="en-US">Debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost" xlink:to="iccc_DebtDiscountCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2024_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2024" xlink:to="iccc_DebtDiscountCost2024_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2025_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2026_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2027_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCostThereafter_lbl0" xml:lang="en-US">Amount of debt discount cost thereafter.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCostTotal_lbl0" xml:lang="en-US">Amount of total debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2023_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2023" xlink:to="iccc_DebtIssuanceCosts2023_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2024_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2024" xlink:to="iccc_DebtIssuanceCosts2024_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2025_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2026_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2027_lbl0" xml:lang="en-US">Amount of debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCostshereafter_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl0" xml:lang="en-US">Employee&#8217;s salary contribution percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_EmployeesSalaryPercentage_lbl0" xml:lang="en-US">Employee&#8217;s salary percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ExercisableAndTransferableDescription_lbl0" xml:lang="en-US">Exercisable and transferable, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExercisableAndTransferableDescription" xlink:to="iccc_ExercisableAndTransferableDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Entire disclosure of accounting policy for expense recognition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_InterestPaymentsTerm_lbl0" xml:lang="en-US">Amount of interest payments term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_InventoryProduction_lbl0" xml:lang="en-US">Production of inventory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InventoryProduction" xlink:to="iccc_InventoryProduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LoanToValueRatio_lbl0" xml:lang="en-US">The ratio of loan to value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2023_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2023" xlink:to="iccc_LongTermDebt2023_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2024_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2024" xlink:to="iccc_LongTermDebt2024_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2025_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2026_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2027_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebtThereafter_lbl0" xml:lang="en-US">Long term debt thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_MinimumDebtServicesCoverageRatio_lbl0" xml:lang="en-US">Minimum debt service coverage ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MinimumDebtServicesCoverageRatio" xlink:to="iccc_MinimumDebtServicesCoverageRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">The net proceeds incurred from issuance of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Include, but is not limited to, quantification of the expected or actual impact.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_NumberOfExecutiveOfficers_lbl0" xml:lang="en-US">Number of executive officers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NumberOfExecutiveOfficers" xlink:to="iccc_NumberOfExecutiveOfficers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_OtherObligations_lbl0" xml:lang="en-US">Other obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherObligations" xlink:to="iccc_OtherObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_PaymentsOfDebtDiscounts_lbl0" xml:lang="en-US">Payments of debt discounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PaymentsOfDebtDiscounts" xlink:to="iccc_PaymentsOfDebtDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_RevenueSalesObligationPercentage_lbl0" xml:lang="en-US">Percentage of product sales is an act of selling a product or service in return of money or compensation or service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueSalesObligationPercentage" xlink:to="iccc_RevenueSalesObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_RightToAcquirePerShare_lbl0" xml:lang="en-US">Right to Acquire, Per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RightToAcquirePerShare" xlink:to="iccc_RightToAcquirePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award options exercisable weighted average vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_StockOptionsCoveringShares_lbl0" xml:lang="en-US">Stock options covering shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionsCoveringShares" xlink:to="iccc_StockOptionsCoveringShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_StockOptionsCoveringcash_lbl0" xml:lang="en-US">The amount of stock options covering cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionsCoveringcash" xlink:to="iccc_StockOptionsCoveringcash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ValuationOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for valuation of long-lived assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ValuationOfLongLivedAssetsPolicyTextBlock" xlink:to="iccc_ValuationOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_OtherStatesMember_lbl0" xml:lang="en-US">Continent of Other States.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl0" xml:lang="en-US">Two thousand seventeen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TwoThousandTenPlanMember_lbl0" xml:lang="en-US">Two thousand ten plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems_lbl0" xml:lang="en-US">Schedule Of Trade Accounts Receivable Due From Significant Customers Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:to="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl0" xml:lang="en-US">Developed Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CapitalExpendituresCommitted_lbl1" xml:lang="en-US">Capital Expenditures Committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl0" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl0" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl1" xml:lang="en-US">Employees Salary Contribution Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Change Due to Subsequent Interim Measurement, Weighted-Average Expected Long-Term Rate of Return on Plan Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FederalGeneralBusinessMember_lbl0" xml:lang="en-US">Federal General Business Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FederalGeneralBusinessMember" xlink:to="iccc_FederalGeneralBusinessMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl0" xml:lang="en-US">Other Commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StateTaxCreditMember_lbl0" xml:lang="en-US">State Tax Credit Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StateTaxCreditMember" xlink:to="iccc_StateTaxCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion_lbl0" xml:lang="en-US">Cost, Depreciation, Amortization and Depletion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl0" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract18" xlink:to="iccc_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCostTotal_lbl1" xml:lang="en-US">Debt Discount Cost Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract19" xlink:to="iccc_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract16" xlink:to="iccc_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract17" xlink:to="iccc_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsIncurred_lbl0" xml:lang="en-US">Interest Costs Incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherAnimalHealthMember_lbl0" xml:lang="en-US">Other Animal Health Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherAnimalHealthMember" xlink:to="iccc_OtherAnimalHealthMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfSegmentInformationAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfSegmentInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfSegmentInformationAbstract_lbl" xml:lang="en-US">Schedule Of Segment Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfSegmentInformationAbstract" xlink:to="iccc_ScheduleOfSegmentInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodNineMember_lbl0" xml:lang="en-US">Debt Instrument Redemption Period Nine Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodNineMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodNineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract21" xlink:to="iccc_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl0" xml:lang="en-US">Escrow Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract22" xlink:to="iccc_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract20" xlink:to="iccc_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract25" xlink:to="iccc_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract26" xlink:to="iccc_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract23" xlink:to="iccc_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract24" xlink:to="iccc_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract27" xlink:to="iccc_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule Of Activity Under The Stock Option Plans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:to="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MortgageBankingMember_lbl0" xml:lang="en-US">Mortgage Banking [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBankingMember" xlink:to="us-gaap_MortgageBankingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Current, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2027_lbl1" xml:lang="en-US">Debt Issuance Costs2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2026_lbl1" xml:lang="en-US">Debt Issuance Costs2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2025_lbl1" xml:lang="en-US">Debt Issuance Costs2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2024_lbl1" xml:lang="en-US">Debt Issuance Costs2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2024" xlink:to="iccc_DebtIssuanceCosts2024_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2023_lbl1" xml:lang="en-US">Debt Issuance Costs2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2023" xlink:to="iccc_DebtIssuanceCosts2023_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl0" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl0" xml:lang="en-US">Treasury Stock, Common, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_GorhamSavingsBankMember_lbl0" xml:lang="en-US">Gorham Savings Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_GorhamSavingsBankMember" xlink:to="iccc_GorhamSavingsBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl2" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl0" xml:lang="en-US">Lessor, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract10" xlink:to="iccc_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract11" xlink:to="iccc_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract14" xlink:to="iccc_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract15" xlink:to="iccc_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract12" xlink:to="iccc_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract13" xlink:to="iccc_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2024_lbl1" xml:lang="en-US">Debt Discount Cost2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2024" xlink:to="iccc_DebtDiscountCost2024_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2025_lbl1" xml:lang="en-US">Debt Discount Cost2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2026_lbl1" xml:lang="en-US">Debt Discount Cost2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2027_lbl1" xml:lang="en-US">Debt Discount Cost2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BalanceAbstract_lbl0" xml:lang="en-US">Balance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract" xlink:to="iccc_BalanceAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract2" xlink:to="iccc_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract1" xlink:to="iccc_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract4" xlink:to="iccc_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract3" xlink:to="iccc_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract0" xlink:to="iccc_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract9" xlink:to="iccc_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract6" xlink:to="iccc_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandTenPlanMember_lbl1" xml:lang="en-US">Two Thousand Ten Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract5" xlink:to="iccc_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract8" xlink:to="iccc_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract7" xlink:to="iccc_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NisinDrugSubstanceMember_lbl0" xml:lang="en-US">Nisin Drug Substance Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NisinDrugSubstanceMember" xlink:to="iccc_NisinDrugSubstanceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandSeventeenPlansMember_lbl0" xml:lang="en-US">Two Thousand Seventeen Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlansMember" xlink:to="iccc_TwoThousandSeventeenPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RightToAcquirePerShare_lbl1" xml:lang="en-US">Right To Acquire Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RightToAcquirePerShare" xlink:to="iccc_RightToAcquirePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ValuationOfLongLivedAssetsPolicyTextBlock_lbl1" xml:lang="en-US">Valuation Of Long Lived Assets Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ValuationOfLongLivedAssetsPolicyTextBlock" xlink:to="iccc_ValuationOfLongLivedAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2025_lbl1" xml:lang="en-US">Long Term Debt2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2024_lbl1" xml:lang="en-US">Long Term Debt2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2024" xlink:to="iccc_LongTermDebt2024_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2023_lbl1" xml:lang="en-US">Long Term Debt2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2023" xlink:to="iccc_LongTermDebt2023_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2027_lbl1" xml:lang="en-US">Long Term Debt2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2026_lbl1" xml:lang="en-US">Long Term Debt2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl0" xml:lang="en-US">Participating Mortgage Loans, Unamortized Debt Discount, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_UnlabeledAbstract" xlink:to="iccc_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl0" xml:lang="en-US">Intangible Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NumberOfExecutiveOfficers_lbl1" xml:lang="en-US">Number Of Executive Officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NumberOfExecutiveOfficers" xlink:to="iccc_NumberOfExecutiveOfficers_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information About The Stock Option Plans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:to="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FirstDefenseProductLineMember_lbl0" xml:lang="en-US">First Defense Product Line Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FirstDefenseProductLineMember" xlink:to="iccc_FirstDefenseProductLineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ExercisableAndTransferableDescription_lbl1" xml:lang="en-US">Exercisable And Transferable Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExercisableAndTransferableDescription" xlink:to="iccc_ExercisableAndTransferableDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockOptionPlansMember_lbl0" xml:lang="en-US">Stock Option Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionPlansMember" xlink:to="iccc_StockOptionPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebtThereafter_lbl1" xml:lang="en-US">Long Term Debt Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherStatesMember_lbl1" xml:lang="en-US">Other States Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Debt Proceeds Received And Principal Repayments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:to="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockOptionsCoveringShares_lbl1" xml:lang="en-US">Stock Options Covering Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionsCoveringShares" xlink:to="iccc_StockOptionsCoveringShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl1" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl0" xml:lang="en-US">Concentration Risk, Customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandTenPlansMember_lbl0" xml:lang="en-US">Two Thousand Ten Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeesSalaryPercentage_lbl1" xml:lang="en-US">Employees Salary Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MinimumDebtServicesCoverageRatio_lbl1" xml:lang="en-US">Minimum Debt Services Coverage Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MinimumDebtServicesCoverageRatio" xlink:to="iccc_MinimumDebtServicesCoverageRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl1" xml:lang="en-US">Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl0" xml:lang="en-US">Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Assets Or Liabilities Measured At Fair Value On ANonrecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:to="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl1" xml:lang="en-US">Two Thousand Seventeen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfIntangibleAssetsAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfIntangibleAssetsAbstract" xlink:to="iccc_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl0" xml:lang="en-US">Other Noncash Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_InventoryProduction_lbl1" xml:lang="en-US">Inventory Production</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InventoryProduction" xlink:to="iccc_InventoryProduction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract_lbl" xml:lang="en-US">Schedule Of Trade Accounts Receivable Due From Significant Customers Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" xlink:to="iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl1" xml:lang="en-US">Expense Recognition Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl0" xml:lang="en-US">Other Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingFacilityMember_lbl0" xml:lang="en-US">Manufacturing Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl0" xml:lang="en-US">Investment Company, Purchase Premium, Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherObligations_lbl1" xml:lang="en-US">Other Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherObligations" xlink:to="iccc_OtherObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost_lbl1" xml:lang="en-US">Debt Discount Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost" xlink:to="iccc_DebtDiscountCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl1" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract_lbl" xml:lang="en-US">Schedule Of Product Sales Disaggregated By Major Product Category Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:to="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent_lbl0" xml:lang="en-US">Related Party Tax Expense, Due from Affiliates, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" xlink:to="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodTenMember_lbl0" xml:lang="en-US">Debt Instrument Redemption Period Ten Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodTenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodTenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_PaymentsOfDebtDiscounts_lbl1" xml:lang="en-US">Payments Of Debt Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PaymentsOfDebtDiscounts" xlink:to="iccc_PaymentsOfDebtDiscounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_AcquiringPersonMember_lbl0" xml:lang="en-US">Acquiring Person Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonMember" xlink:to="iccc_AcquiringPersonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeOneMember_lbl0" xml:lang="en-US">Employee One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeOneMember" xlink:to="iccc_EmployeeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl0" xml:lang="en-US">Long-Term Debt, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_InterestPaymentsTerm_lbl1" xml:lang="en-US">Interest Payments Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BalanceAbstract1_lbl0" xml:lang="en-US">Balance Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract1" xlink:to="iccc_BalanceAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BalanceAbstract0_lbl0" xml:lang="en-US">Balance Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract0" xlink:to="iccc_BalanceAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceRecoveries_lbl0" xml:lang="en-US">Insurance Recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SubtotalMember_lbl0" xml:lang="en-US">Subtotal Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubtotalMember" xlink:to="iccc_SubtotalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0" xml:lang="en-US">Short-Term Debt, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RevenueSalesObligationPercentage_lbl1" xml:lang="en-US">Revenue Sales Obligation Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueSalesObligationPercentage" xlink:to="iccc_RevenueSalesObligationPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl0" xml:lang="en-US">Loan, Managed and Securitized or Asset-Backed Financing Arrangement, Principal Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyBMember_lbl0" xml:lang="en-US">Company BMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyBMember" xlink:to="iccc_CompanyBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl0" xml:lang="en-US">Leases, Operating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl0" xml:lang="en-US">Area of Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyCMember_lbl0" xml:lang="en-US">Company CMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyCMember" xlink:to="iccc_CompanyCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract_lbl" xml:lang="en-US">Schedule Of Product Sales Disaggregated By Geographic Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:to="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LoanToValueRatio_lbl1" xml:lang="en-US">Loan To Value Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl1" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableLoanInProcess_lbl0" xml:lang="en-US">Financing Receivable, Loan in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableLoanInProcess" xlink:to="us-gaap_FinancingReceivableLoanInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MastitisMember_lbl0" xml:lang="en-US">Mastitis Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MastitisMember" xlink:to="iccc_MastitisMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MaineTechnologyInstituteMember_lbl0" xml:lang="en-US">Maine Technology Institute Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MaineTechnologyInstituteMember" xlink:to="iccc_MaineTechnologyInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Noncash Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl1" xml:lang="en-US">Change In Payments Of Debt Discounts Included In Accounts Payable And Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl1" xml:lang="en-US">Debt Instrument Redemption Period Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_AccountsReceivablePercentage_lbl1" xml:lang="en-US">Accounts Receivable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AccountsReceivablePercentage" xlink:to="iccc_AccountsReceivablePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl0" xml:lang="en-US">Noncompete Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockOptionsCoveringcash_lbl1" xml:lang="en-US">Stock Options Coveringcash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionsCoveringcash" xlink:to="iccc_StockOptionsCoveringcash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCostshereafter_lbl1" xml:lang="en-US">Debt Issuance Costshereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_AcquiringPersonPercentage_lbl1" xml:lang="en-US">Acquiring Person Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonPercentage" xlink:to="iccc_AcquiringPersonPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CustomerMember_lbl0" xml:lang="en-US">Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CustomerMember" xlink:to="iccc_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl0" xml:lang="en-US">Interest Income, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Principal Payments Bank Loans Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:to="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyAMember_lbl0" xml:lang="en-US">Company AMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyAMember" xlink:to="iccc_CompanyAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScoursMember_lbl0" xml:lang="en-US">Scours Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScoursMember" xlink:to="iccc_ScoursMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MrBrighamMember_lbl0" xml:lang="en-US">Mr Brigham Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MrBrighamMember" xlink:to="iccc_MrBrighamMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0" xml:lang="en-US">Property, Plant and Equipment, Salvage Value, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl1" xml:lang="en-US">Debt Instrument Redemption Period Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCostThereafter_lbl1" xml:lang="en-US">Debt Discount Cost Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeMember_lbl0" xml:lang="en-US">Employee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeMember" xlink:to="iccc_EmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllOtherSegmentsMember_lbl0" xml:lang="en-US">Other Segments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>iccc-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 18:01:46 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ShareholdersEquityType2or3" roleURI="http://immucell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BusinessOperations" roleURI="http://immucell.com/role/BusinessOperations"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_CashandCashEquivalents" roleURI="http://immucell.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_TradeAccountsReceivable" roleURI="http://immucell.com/role/TradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_Inventory" roleURI="http://immucell.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PropertyPlantandEquipmentNet" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IntangibleAssets" roleURI="http://immucell.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_AccountsPayableandAccruedExpenses" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BankDebt" roleURI="http://immucell.com/role/BankDebt"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ContingentLiabilitiesandCommitments" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OperatingLeases" roleURI="http://immucell.com/role/OperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_StockholdersEquity" roleURI="http://immucell.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_Revenue" roleURI="http://immucell.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OtherExpensesNet" roleURI="http://immucell.com/role/OtherExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IncomeTaxes" roleURI="http://immucell.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SegmentInformation" roleURI="http://immucell.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_RelatedPartyTransactions" roleURI="http://immucell.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_EmployeeBenefits" roleURI="http://immucell.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SubsequentEvents" roleURI="http://immucell.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_AccountingPoliciesByPolicy" roleURI="http://immucell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_InventoryTables" roleURI="http://immucell.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PropertyPlantandEquipmentNetTables" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IntangibleAssetsTables" roleURI="http://immucell.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_AccountsPayableandAccruedExpensesTables" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BankDebtTables" roleURI="http://immucell.com/role/BankDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OperatingLeasesTables" roleURI="http://immucell.com/role/OperatingLeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_StockholdersEquityTables" roleURI="http://immucell.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_RevenueTables" roleURI="http://immucell.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OtherExpensesNetTables" roleURI="http://immucell.com/role/OtherExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IncomeTaxesTables" roleURI="http://immucell.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SegmentInformationTables" roleURI="http://immucell.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable" roleURI="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0" roleURI="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIntangibleAssetsTable" roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofPrincipalPaymentsBankLoansOutstandingTable" roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofActivityUndertheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable" roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofOtherIncomeExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ScheduleofSegmentInformationTable" roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BusinessOperationsDetails" roleURI="http://immucell.com/role/BusinessOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_CashandCashEquivalentsDetails" roleURI="http://immucell.com/role/CashandCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_TradeAccountsReceivableDetails" roleURI="http://immucell.com/role/TradeAccountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_InventoryDetails" roleURI="http://immucell.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IntangibleAssetsDetails" roleURI="http://immucell.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_BankDebtDetails" roleURI="http://immucell.com/role/BankDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OperatingLeasesDetails" roleURI="http://immucell.com/role/OperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_StockholdersEquityDetails" roleURI="http://immucell.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_OtherExpensesNetDetails" roleURI="http://immucell.com/role/OtherExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_IncomeTaxesDetails" roleURI="http://immucell.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_RelatedPartyTransactionsDetails" roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20231231.xsd#iccc_r_EmployeeBenefitsDetails" roleURI="http://immucell.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsOfDebtDiscounts" xlink:href="iccc-20231231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfDebtDiscounts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpenseAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashIncomeExpenseAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20231231.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20231231.xsd#iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/BusinessOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/CashandCashEquivalents">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/TradeAccountsReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/BankDebt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/OperatingLeases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/Revenue">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/OtherExpensesNet">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/EmployeeBenefits">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationOfLongLivedAssetsPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_ValuationOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValuationOfLongLivedAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ExpenseRecognitionPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="iccc-20231231.xsd#iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesTablesTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesTablesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesTablesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesTablesTable" xlink:to="SummaryofSignificantAccountingPoliciesTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesTablesLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/BankDebtTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/OperatingLeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/RevenueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/OtherExpensesNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_OtherAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CompanyAMember" xlink:href="iccc-20231231.xsd#iccc_CompanyAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyBMember" xlink:href="iccc-20231231.xsd#iccc_CompanyBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CompanyAMember" xlink:href="iccc-20231231.xsd#iccc_CompanyAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyBMember" xlink:href="iccc-20231231.xsd#iccc_CompanyBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyCMember" xlink:href="iccc-20231231.xsd#iccc_CompanyCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ManufacturingFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelationshipsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_NoncompeteAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:href="iccc-20231231.xsd#iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:to="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalMember" xlink:href="iccc-20231231.xsd#iccc_SubtotalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="SubtotalMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_LongTermDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2023" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2023"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtIssuanceCosts2023" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2024" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2024"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtIssuanceCosts2024" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2025" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtIssuanceCosts2025" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2026" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtIssuanceCosts2026" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2027" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCosts2027"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZdGbBMqh1FlvS0VWsnDwFtQUQZbcp+8/vjhiWuHx6DwUIXTksBAFLwuaqwe9SJ598smQehWVDvTLT7qrNCSH1oA5lP7ajJARYB4QG9tIps1UVlNmvOwm8RlrtBuODSahTdroqGiZ6HF5A==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtIssuanceCosts2027" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCostshereafter" xlink:href="iccc-20231231.xsd#iccc_DebtIssuanceCostshereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtIssuanceCostshereafter" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCost" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2024" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2024"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCost2024" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2025" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCost2025" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2026" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCost2026" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2027" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCost2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCost2027" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCostThereafter" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCostThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCostThereafter" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCostTotal" xlink:href="iccc-20231231.xsd#iccc_DebtDiscountCostTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="DebtDiscountCostTotal" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2023" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2023"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="LongTermDebt2023" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2024" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2024"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="LongTermDebt2024" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2025" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="LongTermDebt2025" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2026" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="LongTermDebt2026" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2027" xlink:href="iccc-20231231.xsd#iccc_LongTermDebt2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="LongTermDebt2027" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebtThereafter" xlink:href="iccc-20231231.xsd#iccc_LongTermDebtThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="LongTermDebtThereafter" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:to="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenPlanMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandTenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenPlanMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20231231.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20231231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20231231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:to="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockOptionPlansMember" xlink:href="iccc-20231231.xsd#iccc_StockOptionPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="StockOptionPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:href="iccc-20231231.xsd#iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:to="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherStatesMember" xlink:href="iccc-20231231.xsd#iccc_OtherStatesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="OtherStatesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueSalesObligationPercentage" xlink:href="iccc-20231231.xsd#iccc_RevenueSalesObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems" xlink:to="RevenueSalesObligationPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstDefenseProductLineMember" xlink:href="iccc-20231231.xsd#iccc_FirstDefenseProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="FirstDefenseProductLineMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherAnimalHealthMember" xlink:href="iccc-20231231.xsd#iccc_OtherAnimalHealthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherAnimalHealthMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRecoveries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ScheduleofSegmentInformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentInformationAbstract" xlink:href="iccc-20231231.xsd#iccc_ScheduleOfSegmentInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentInformationAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScoursMember" xlink:href="iccc-20231231.xsd#iccc_ScoursMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ScoursMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastitisMember" xlink:href="iccc-20231231.xsd#iccc_MastitisMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="MastitisMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_AllOtherSegmentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/BusinessOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20231231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NisinDrugSubstanceMember" xlink:href="iccc-20231231.xsd#iccc_NisinDrugSubstanceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="NisinDrugSubstanceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="iccc-20231231.xsd#iccc_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskCustomer" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivablePercentage" xlink:href="iccc-20231231.xsd#iccc_AccountsReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="AccountsReceivablePercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/CashandCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/TradeAccountsReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="TradeAccountsReceivableDetailsTable" xlink:href="iccc-20231231.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="TradeAccountsReceivableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/InventoryDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="IntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/BankDebtDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtDetailsTable" xlink:href="iccc-20231231.xsd#iccc_BankDebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="BankDebtDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GorhamSavingsBankMember" xlink:href="iccc-20231231.xsd#iccc_GorhamSavingsBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GorhamSavingsBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaineTechnologyInstituteMember" xlink:href="iccc-20231231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="MaineTechnologyInstituteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GorhamSavingsBankMember_0" xlink:href="iccc-20231231.xsd#iccc_GorhamSavingsBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="GorhamSavingsBankMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaineTechnologyInstituteMember_0" xlink:href="iccc-20231231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MaineTechnologyInstituteMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBankingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_MortgageBankingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodNineMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodNineMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodTenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodTenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodTenMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20231231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtConversionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_EscrowDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestPaymentsTerm" xlink:href="iccc-20231231.xsd#iccc_InterestPaymentsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="InterestPaymentsTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LineOfCredit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanToValueRatio" xlink:href="iccc-20231231.xsd#iccc_LoanToValueRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="LoanToValueRatio" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FinancingReceivableLoanInProcess" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumDebtServicesCoverageRatio" xlink:href="iccc-20231231.xsd#iccc_MinimumDebtServicesCoverageRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="MinimumDebtServicesCoverageRatio" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsIncurred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestCostsIncurred" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrBrighamMember" xlink:href="iccc-20231231.xsd#iccc_MrBrighamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrBrighamMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfExecutiveOfficers" xlink:href="iccc-20231231.xsd#iccc_NumberOfExecutiveOfficers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="NumberOfExecutiveOfficers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalExpendituresCommitted" xlink:href="iccc-20231231.xsd#iccc_CapitalExpendituresCommitted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CapitalExpendituresCommitted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryProduction" xlink:href="iccc-20231231.xsd#iccc_InventoryProduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="InventoryProduction" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherObligations" xlink:href="iccc-20231231.xsd#iccc_OtherObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="OtherObligations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/OperatingLeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AreaOfLand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="iccc-20231231.xsd#iccc_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AcquiringPersonMember" xlink:href="iccc-20231231.xsd#iccc_AcquiringPersonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="AcquiringPersonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenPlansMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandTenPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenPlansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenPlansMember" xlink:href="iccc-20231231.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenPlansMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromIssuanceOfCommonStock" xlink:href="iccc-20231231.xsd#iccc_NetProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="NetProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsCoveringShares" xlink:href="iccc-20231231.xsd#iccc_StockOptionsCoveringShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="StockOptionsCoveringShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsCoveringcash" xlink:href="iccc-20231231.xsd#iccc_StockOptionsCoveringcash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="StockOptionsCoveringcash" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisableAndTransferableDescription" xlink:href="iccc-20231231.xsd#iccc_ExercisableAndTransferableDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="ExercisableAndTransferableDescription" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentCompanyPurchasePremiumPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightToAcquirePerShare" xlink:href="iccc-20231231.xsd#iccc_RightToAcquirePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="RightToAcquirePerShare" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquiringPersonPercentage" xlink:href="iccc-20231231.xsd#iccc_AcquiringPersonPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="AcquiringPersonPercentage" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/OtherExpensesNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherExpensesNetDetailsTable" xlink:href="iccc-20231231.xsd#iccc_OtherExpensesNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentOfOtherExpenseNonoperatingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="OtherExpensesNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesNetDetailsTable" xlink:to="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="iccc-20231231.xsd#iccc_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederalGeneralBusinessMember" xlink:href="iccc-20231231.xsd#iccc_FederalGeneralBusinessMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="FederalGeneralBusinessMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StateTaxCreditMember" xlink:href="iccc-20231231.xsd#iccc_StateTaxCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="StateTaxCreditMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://immucell.com/role/EmployeeBenefitsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsDetailsTable" xlink:href="iccc-20231231.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeMember" xlink:href="iccc-20231231.xsd#iccc_EmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeOneMember" xlink:href="iccc-20231231.xsd#iccc_EmployeeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsDetailsTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalaryPercentage" xlink:href="iccc-20231231.xsd#iccc_EmployeesSalaryPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="EmployeesSalaryPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalaryContributionPercentage" xlink:href="iccc-20231231.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="EmployeesSalaryContributionPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/dei/role/document/Cover"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &[ M # 2(  A$! Q$!_\0
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M;\3](CUGQAXE\6>#_B/;:+H?@^"$7^JR>M?M%^-OV@_A/\,O$OQDM_BA\"/
M_ACP#\-AXC\7>%];^ ?Q'^+VK7WB[3[&674=,\)^)]'_ &B_@R+ZSUW5I++0
MO"FG7G@>'4Y+N:"2\NW>^%I9 'U'_P (5X-_Z%+PS_X(=*_^1*/^$*\&_P#0
MI>&?_!#I7_R)7SYXC^.'C3X*?L?7OQ]^/&@Z#-\1?!GPA@\;^//"/@M+_0=
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M\96$W@J>YBT77TO_  9$MQ;36(!]8?\ "%>#?^A2\,_^"'2O_D2C_A"O!O\
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MQ'?^'EU)I-3MO#VOW6C#Q%H-CJ4]Y?Z?I&K65E=:CJDL#:G=@'L'_"%>#?\
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M-10!S/\ PA7@W_H4O#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")7344
M<S_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\ P0Z5_P#(E=-10!S/_"%>
M#?\ H4O#/_@ATK_Y$H_X0KP;_P!"EX9_\$.E?_(E=-10!S/_  A7@W_H4O#/
M_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\ PA7@W_H4O#/_ ((=*_\
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MO#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")7344 <S_PA7@W_H4O#/\
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MWT[]-:* /SQTG]DWX@? :_\ V:?%/[/1\ ^/->^"/P)UO]G+Q;H?Q9\3Z_\
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MI>&?_!#I7_R)7344 <S_ ,(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\
M!#I7_P B5TU% ',_\(5X-_Z%+PS_ ."'2O\ Y$H_X0KP;_T*7AG_ ,$.E?\
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MD4V<7B3;^Y- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM? MM;? [XN?LX^!/BMK]W\0WLM4U?QX?A&S>"?#_C7X4^.[.SU+P4]]XM\
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MU.5KEXVG=)DB9S'#&J_Q]6C-8W+6,I)BD.^V<^K?P>F2>"./G&0/G%?U<?\
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M.OB;_P !/!O_ ,R5']@ZK_T.OB;_ ,!/!O\ \R5=-10!S/\ 8.J_]#KXF_\
M 3P;_P#,E1_8.J_]#KXF_P# 3P;_ /,E7344 <S_ &#JO_0Z^)O_  $\&_\
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M.OB;_P !/!O_ ,R5']@ZK_T.OB;_ ,!/!O\ \R5=-10!S/\ 8.J_]#KXF_\
M 3P;_P#,E1_8.J_]#KXF_P# 3P;_ /,E7344 <S_ &#JO_0Z^)O_  $\&_\
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M%-'3X(3^(E^%GA2#XM2_!EO#@'A:3PN/&$"PZ^_@\MX7'Q A\7QVQ_MJ/7U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]_V;S\:?_5;>):]/)/\ D=9+_P!CG)__ %;94<&:_P#(JS3_ +%>9_\ JMS
M_A5HHHK_ $=/X>"OZ?\ _@C3X6\/>./V*OC#X-\6Z39Z]X8\4_&[QYH'B#1=
M0C\VSU/2-5^%OPJLK^RN$R&\NXMII(RR,DB$AXG2158?S 5_4]_P0^_Y-0^(
M/_9PWBS_ -5M\)J_'_'2,9>'V+C)*499QDD91DDXRC+$8V,HR3334HMIIIII
MM---GZ=X0U*E'C?"5J-2=*M1R_,ZM*K2G*G4I5:5/!U*56G4A*,Z=2G4ITZE
M.<)1G"<(3C*,HQ:\W_9+\3^(O^">O[5>N_L,?%/5KN[^"/Q<U:;Q7^S/XVU5
MP;>VU/6;IH;?PS<73;(H9M<EC70-4M(Q''#XYL;*_LM/AL_&KWK?NU7P[^WW
M^R/8?M;_  0OO#^E^3IWQ6\$2S^+?A%XD+BUN+#Q/:Q*\NAS:@ICEM=)\4PV
M\6G7DBRK'97\6D:XR32Z-#$W$?\ !.#]KG4/VD?A5J'@SXE^?IG[0OP2ND\%
M?%C1=5B^Q:QJ4UA+/IUAXOEL'"/%<:C)8W.G>)8%CC-CXIT_4MUM965_I,<O
M\&9=)Y3C7DE5OZI653$9)5FV[4DW/$Y9*4F[U,&YNKADVY3P<^57=!G^@?%]
M.GQ[PY#Q+P%.FL^R^>#RCQ+P-"$8.6/J0CA\GXVI4*<8J.$XAIT(8/.9P@J>
M&XAP_M9^SCF<&_T9HHHKZ,_'@HHHH **** "BBB@ HHHH \3^(O[2/P!^$7C
M?X=?#7XG_&+X=^!/B!\6M7BT+X<^#O$WBK2=*\1>+-1N(M0:U73M+N;E+I;.
M]NM-FT6PU2[CMM+O_$]SI/A2SO)_$NNZ+I.H>@:]X]\#>%=;\(^&?$_C3PGX
M<\1^/]1OM(\!^']>\1Z/H^M^-M6TRPDU74M+\(Z5J%Y;W_B34=/TN&;4KZRT
M:WO;FTL(I+R>*.W1I!^6/[8.NOX$_:'U.\^$.C_%S7_VAOB?X'^%.A/\"_$'
M[..J?&+]F']J7P/X(\8^(K>VCUCXAZ9X5DM/@[XA^%6I?$R[N]9\;^(/C#\.
M?"O@IK_PIX@\=>!?'&B7^CR7D/QX^$W[7ES^UO\ "CXN_P#"J?@_\2_#%E^T
MOX&L?AOXELOBY\3=/\1?"WX*:;\(?B+;:_I?BKP18_LW^*O#_A5-?\::QK?B
M;Q=\0+7XB7\'BC6+?X1> M0TZQL=)TG6=' /TO\ BG\<?@K\#-,TS6OC9\7_
M (7?![1M;OGTO1M6^*?Q \)_#[3-7U.*W>[ET[3+_P 6ZMI%K?WT=K')<O:6
MLLMPENCS-&(U9AE>,_VCOV>OAQJ'@S2?B%\>/@SX#U7XCP6MS\/-,\9_%#P1
MX7U#QY;7L]I;65QX,LM<URQN?%$%W<W]C;VLNAQ7T=Q/>VD43/)<0J_YF?MH
M^)M7^+?C_P"&'C7X)^./C1\+=&\+^#_VK?A/>_M&?!K]DSXH?M7ZI-XOL?%7
MASX?>,?@-J?PET;X<^,(]%\+W7CSP18^)]5^*5SH%O'XBB^&FH>"?AW\0/#4
MFN:KKQ\CTG1?&/@3X2_&OP'\3/V2OBQ:ZO\ M"?L*?L]_!OX)_"_P'\,OB#\
M:/#?A^^\+?"KQOX&NO@;XK^)FCV'C6P^%4'A7QUXHM]=EU?XX>,]"T'3[#Q)
M<>(Y/&^L:EI/BJ[TT _9G6/C_P# ?P]\2](^"^O_ !L^$>A_&+Q!':2Z#\)]
M8^)'@W3/B7K<5_'<S6,ND>!+W68/%.I1WL5G=RVCV>E3+<1VMR\)=8)2MOXI
M_''X*_ S3-,UKXV?%_X7?![1M;OGTO1M6^*?Q \)_#[3-7U.*W>[ET[3+_Q;
MJVD6M_?1VL<ER]I:RRW"6Z/,T8C5F'X[OX)^)>C?#GXP?LP^,?A%\6/%O[0G
MQ)_:E^"OQ&\&_$+3/AAX]UOX97OAWPQ<? 6\TGXGZK^TE8>&IOAQX8N/A9X?
M^&VN:=-IGC#QCH7Q$%UX6M-"\/>'-77Q!X9?6_J#QW\7O#%K^T[X>_:!D\'?
M%7XL? RQ^"OQW_9VMM7^%WP$^*WQEOO#GQH\*?&G1].^)7A>[\'>!_ OB+QG
M8Z5XJ'@6?PXGC:#0IOAQK=_X%ETW4O%-L#H!U8 ^T_&?[1W[/7PXU#P9I/Q"
M^/'P9\!ZK\1X+6Y^'FF>,_BAX(\+ZAX\MKV>TMK*X\&66N:Y8W/BB"[N;^QM
M[670XKZ.XGO;2*)GDN(5>UK'Q_\ @/X>^)>D?!?7_C9\(]#^,7B".TET'X3Z
MQ\2/!NF?$O6XK^.YFL9=(\"7NLP>*=2CO8K.[EM'L]*F6XCM;EX2ZP2E?Q"^
M'WP\^(GP2^"'QS^$?QB_9T^+WBOQ)\?/V-?A5\*O@IX3\&?"OQ=\7]$TZ2R\
M+?%+0H/@1XS^(G@K0_$7A#X1#P)XJ\=:;<W6H_$WQ%X2^'NEV>KW7B#0/%-]
M;:/KDFD^@/X)^)>C?#GXP?LP^,?A%\6/%O[0GQ)_:E^"OQ&\&_$+3/AAX]UO
MX97OAWPQ<? 6\TGXGZK^TE8>&IOAQX8N/A9X?^&VN:=-IGC#QCH7Q$%UX6M-
M"\/>'-77Q!X9?6P#]V:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K^%7]KL@?M7?M/$D #]H;XU$D\
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M]=L]QO\ 3?">O7&F(AQ)-JW]FW$>DV\1!4B6YU)[6"+# ^9(H!!Q7X6>%?\
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M P,#I6[7SS_PUU^RA_T<]^SS_P"'I^&W_P TM>A^ OB[\)_BI_:O_"L/B?\
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M&^"?%_QFTCP1??![P;XQ\2V^N^'Y-(\+>*_'6C:]>?\ "2>&ECT\OXBT1;\
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M'_"W?*\G[-HNL>?OS+YF_P"S^5L3;YWF-Y7\_5?T,?\ !!G_ )NK_P"Z&_\
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MO"O+,RE0PM*:J8.=&GQ]Q%EU2K++:7M)4)XGAS)*U;.:U*%3#8S&Y;[>7)^
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MM.T6]UK3-"O=/K:[^RQXU^*7@OPAX1^.G[3WQD\8:(_@7PKX8^-7P\\*:/\
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M%G6PU6E[:6%K\.99[+,\34RZO4Q];+,/BZ5.?O?P:_X)W?$3XI>.(OC_ /\
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MZIXRU;19M!OM3+K+I^A:[-*MVD]G%HNO>()KN('D_P#@K9^U9\?/V8_^&?\
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M2US[<^IV%[=:7K^H6^E:3>W=]X=\+7NN>)-."V\-_I%M<7UC%<^$?LVCQO\
M OPW<?#/Q'X+\<^ M0_:&^//Q1NO@'X,\0ZCX)^+OQ<^%'@^3X>'Q5XA\?\
M[2OCC1_'FOV/CQU^(&A^(M6NO%MS\2_BYXIGB^(?PI\&>*O'FL^)=7>UT3Q_
MX6_L9_'WX9>+_BKHOQ?U#P+^TC\$_$G['K_"[Q=:_#KX6WGPB^)_Q[\6:SXS
M^,'B?QMI-SKWBS]KK5K32?B9XUU#QUJOB3Q;X\U.Z\'^$/$&I^.;.ST74/A\
M?#FHZC( ?8FG_MM?":^^&WB3XM77A+X]^&/ OA>Y\-V-U?\ Q _9_P#BQ\-=
M9US4/&-]9Z5X3TWP%X.^(/A?PSXS^)NI^)-7U'3=&T/3?ASX?\57VJ:UJ>F:
M19V\VI:C96L_>_"/]I+P/\<=#\0:]\/-#\?3P>$O$-WX4\7Z1XO\*7'PP\8^
M$/$=EI^GZO-I'BWP#\3[GP?XX\+WDFC:MI6M6::]X>T]=0T;4]/U>P:YTZ\M
M[F3\WK']GS]I2*RUGQ3X'^&OQW\/?"[X<_&7]E[XI_#+]F']H7]I'1/C%\9=
M?O\ X2:CXH/QB;PC\0]>^.?QK\'>#_#WBSPWK?@B/X=^"/%/QT&@3^,_A]K5
MQJ=I\+M/\0Q:]J/LVCP^/+OQ!\?SX\^&?BSX1^,_V]/$-W\.OA=X%DOOA_XL
M\;_#GPY\._V<K_P]??%SXT:A\._'_B3P?I.AG5M)>V1_!7B_QK+IG]O_  QT
M*[N8_$?BA]*T< ]A\)?\%!_V<O&8\0S:7J'CG2M.\.?#OQ#\79-?\<?#[Q-\
M-/"OB/X5^$WMT\1_$CX=^+?B+9^%O#/Q4\#:0M[IMQ=^*?AIJWBS14L=7T34
M%O6L=:TJXO)-*_;^^ 6J^&O'?BAK7XM>'X/AO'X+F\5>'/''P;^(?P\^(\<7
MQ)U1M"^'4GA_X3^/-#\.?%#QHOC_ ,01R^'/!)\%^$/$ \5^)(9_#V@_VAK,
M$MBGPE\0_P!G']JO]H;X5?"GX;7/P,G^"^M_LW?LV>)_ *>(O'?Q#^&.LZ)\
M8/B5-8_"[1],\/\ PRU+X9^,/&GB+2/ASKUM\-M6N-:\6?%#PM\/]<M[?7/"
MD;?#^]F3Q!;:+W_Q6^%G[37QS^+>F?M/V?[.GBCX:R_!^X_9V_L3X*>-?'WP
M4D^*WQCM_AQ\4?%7Q ^(,&DZ[X!^*'C?X3Z'8V>F>)K*'X=6WC;XAZ,?$7BO
M3-6B\2+X"TB?3O$,X!^@_P (/VC_  5\==&UW6OAQH'Q NT\+>([GPAXKT3Q
M9X2N?AGXT\)^)K6PT[5GT7Q7\/\ XFW'@_QUX9OIM(U?2=8L8M<\.V']I:/J
M>GZMI[76G7MM<R>M?V]JO_0E>)O_  +\&_\ S6U\S_LS^%?B/+X^_:.^-GQ%
M^&]]\'Y/C7XS\#S>%_AQXBUGP3K_ ([TGPW\.OAWHG@F/6O'>H_#;Q3XX\!1
M:UXDU2SU.\T[2_#?C'Q/%IWA>#0?[2U2+5[B_P!'TGZ^H YG^WM5_P"A*\3?
M^!?@W_YK:/[>U7_H2O$W_@7X-_\ FMKIJ* /!=2UK4O"GQ-TO7O^$1\0V^D?
M$6QA\(ZK$USX3P?%^AQWVJ^$[Y/+\3R01/J6BGQ%H]_=74EL;B:P\*Z?')/+
M]E@'JG]O:K_T)7B;_P "_!O_ ,UM5O'GAE_%_A/5]"M[D6.I3107NA:D5+_V
M3XDT>[@U?PWJ^P<R?V7KMCI]^8NDRV[0OE)&!E\$>)T\8^%=&\0_9FL+F^MF
MCU33';?+H^NV$\NFZ_HD[#AKG1=;M+_2[@C@S6CE25() )/[>U7_ *$KQ-_X
M%^#?_FMKF_&/Q.TWX?\ A7Q!XW\9Z)K'AWPIX5TF]US7];U&_P#!T5GINEZ?
M"T]U<S,/%;2.51"L4$*2W%S,T=O;12W$L<;^E5^"/[3OCWQ;_P %)_VD;?\
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M7%8[$SBZDJ.&H17,_P!O:K_T)7B;_P "_!O_ ,UM']O:K_T)7B;_ ,"_!O\
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M[SM[>7]G\_'E/YOE9B\S^?JOZ&/^"#/_ #=7_P!T-_\ >PU^9^,/_)NN(?\
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M]U[P+KFA^"I+\^+-(O-4T^[L+19+-);--0F:ZC:W1)/U 1@ZJZ_==589X.&
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MFV54_CS/+X^N-POZ5Y'M4. >.L5;ZOP5Q=6OHO9\-9X[ZM?:RNEU373;YO\
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MO@K]JWXHV/P:\(:KXOT.?P3\1IM?L/#NJ^&OB7I5KJFIZ#>Z!=ZE#<V=S?\
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M-_R)>&/^QSF'_JIIG[3X*_\ (US[_L5X+_U93/H:BBBOY4/Z'"BBB@#^>?\
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MU^->,\5?ZSQ?Q57OO[3B3/G?;^7.*7\J[;+Y^/Z9^SU\ M%8/H_P.^#^DNL
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M_LX;XT_^K)\2U_=57\*O[77_ "=?^T]_V<-\:?\ U9/B6OZ%^CS_ ,CKB?\
M[$V7_P#JVJ'XMXU?\BK(?^QIC?\ U6P/GFBBBOZK/YX/V2_X(??\G7_$'_LW
MGQ9_ZLGX35_4]7\L/_!#[_DZ_P"(/_9O/BS_ -63\)J_J>K^+O'+_DX&)_[$
MV1_^HV,/ZE\)?^2-H?\ 8TS;_P!/X8****_(#]+"BBB@#_//HHHK_3 _@\*_
MH8_X(,_\W5_]T-_][#7\\]?T,?\ !!G_ )NK_P"Z&_\ O8:_,_&'_DW7$/\
MW2__ %<8 ^\\,O\ DMLE_P"ZA_ZK,8?T,4445_#9_6@5S/C7_D3?%O\ V+.O
M?^FJ[KIJYGQK_P B;XM_[%G7O_35=T '@K_D3?"7_8LZ#_Z:K2NFKF?!7_(F
M^$O^Q9T'_P!-5I734 1S-(D,KQ1>=*D;M%#O6/S9%4E(O,8%8_,8!-[ JN=Q
M& :_FW^.G_!3/]L_P_X-GO\ ]H+_ ()2V+> ++Q!I-HC_$BXU/6O#K^)-1O3
MHN@16-KJ_@J_M+S6;ZZOVLM+%A!/>3"ZE6UW122FOZ3*^!/^"BO[.7Q?_:'^
M#7@V7]G_ ,4:7X;^-?P/^+_@OX]_#2#7TM6\/^)/%'@&#6$L?#^IO?076GV[
MSG5C>Z7-JEM-I$FJV-G9:NUEIMY<ZI8 'Y,Z3^WS^U)\'?$W@6X_X="^!/@A
MJ'Q'\5:)\/\ PSXJU!++X36-]XB\32?9]*\/77C/5?!/AS1M&O-5WRPV=KKV
ML::EU*);==TBR(/Z8%)*J67:Q4%ER&VDCE<C@X/&1P<9%?SB?$?P'_P6@_;E
MTOP[^SW^T+\$?@9^SY\&;_Q?X1UCXE_$3PQK?A;4-;N+#PIKVF^(T71XK7XN
M_%755U -;V=[I@\/:)I45SK=@VGZIXGTO1KG4K!?Z.D4(JH"2%55!8Y8A0!D
MGC).,DX&30!^6?[;WBS5%^*?ASP7\7OBO\1_V;?V98/#/P\\;^$_CEX$^&_A
MOQ5X/3]HW1/C+I%SX5T[XW^/O&'P[^)?AKX9>%/">KZ=\/-?\-+KT/P\\->+
MKC4_$MGXE\=SV&G1Z,.I_:]^)7Q&^'_PPA\=^$_VC/BCH^IVWP5O==\$W'P7
M_9T\.>-_A7XY\>V&EM?#QI\8OBIXL^'WQ4^'7PT^%6L2SZ#<VQU3XC_!?2?#
MOAEO%?B#4OB7K6G1V^H^%?:?CQX,_:K\3>,;'0?A!\2/ &A_"?XC^&]3\(?$
M%/&_PCMO'&J?"X0>'_%;2>,_!=_9_%GX=3:UJ/C"ZU#0/#H\/>)?#?CK1M$O
M-/C\12H-+_M/0-6Q)OV9/BWX0^&OA[X'?!#X_:%X-^#NB_!KP[\'!I'Q(^#?
M_"U/'.G6FBZ1J7AV]\6^%?&^C_$OX7Z=I_B37=$O+)KJV\7>#?'OAFPUK2+.
M]TC0+'2)K[P_= '7?'/X^:U\&OV/O&7[0LEIX7USQ5X:^$%IXPM;32;^;5O!
M&H^+]5TBP33!8:G83O-JGA&;Q#J=J\-[9WBO?Z)B:"^A,RW2?&OQO_:#^._[
M#?VN7Q]\7-1_:+MO%G[,'Q.\?Z#+X[\&_#OPHOASXX?"F_\  ]FMKHT?PE\'
M>!9C\-/&2_$B":ZT/Q1_PDWB/1U\*V\=KX[5]1NS<?1=S^S/XD\3:7XK_9JU
M35M7T3]CG2?V5/"?[/OA;07?PE?^,/$7BU8;K3[OXD67B.&PN=<TFX\&>$M/
M\.:):6NMQ)I>O>)I]2U5/#%O9:3:WNNYNH_L6>(?BS;^(/\ AJ3XOZ5\5]0N
M_@-XG_9_\+WWP[^&5S\(8_#F@>.Y=(NO'7C>]M-:^(WQ:&M_$?7[WPOX0GAU
M2WFT+PMI"Z (K/P<?[1NWH \&^-_[0?QW_8;^UR^/OBYJ/[1=MXL_9@^)WC_
M $&7QWX-^'?A1?#GQP^%-_X'LUM=&C^$O@[P+,?AIXR7XD0376A^*/\ A)O$
M>CKX5MX[7QVKZC=FX^@/ >N_&SX/_M&?"CX._$_XV:[\=M ^-GP7\<^)EU;Q
M5X-^&?A34/"'Q0^$VH>"Y-=C\)K\,?!G@F)? WC'1/'EQ-#HWC"'Q=KNB77A
M:Q$7C*?^T+R&\@U']BSQ#\6;?Q!_PU)\7]*^*^H7?P&\3_L_^%[[X=_#*Y^$
M,?AS0/'<ND77CKQO>VFM?$;XM#6_B/K][X7\(3PZI;S:%X6TA= $5GX./]HW
M;T:C\ _VB-$MO$/Q=UKXH>'/C3^T-X,^ OBCX/?L_/X1^&UE\'O#_A[7/&DF
MDS:SX^\7VGC7XE_%73=?\1:GK?AWP7JFOWL<VE^'['0/#&H66A_#_4]0U7[%
M= #/'7BGXS_&;]H;XV_!KX5_&S7?@5IGP!^$'@'7C?>%/!WPU\4ZGXU^)WQ>
M7QGJ'AYO%,OQ1\#^.+*'P)X0TCP5:"?0_"=KX=\0:[>>)-0DF\864>GV5M#X
M3\&OV@_CO^V[]JB\!?%S4?V=+GP%^S!\(/'_ (@B\!^#?AWXG;Q+\</C/8>+
M[P6NL2?%KP=\088/AIX';P(\,&A^&/['\1ZZWB*ZDN/'<::?9A?I/7/V9/C4
MOB2?X@^ /VA?#WA/XC^/?@AX/^$/QU\0>)?@P/&MCXVU;P3#JPT+XH>"-(T+
MXD?#6T^'WC:QN/%?C(QPZ@OC?P?+;:EHUO)X25="?^T\6#]BSQ#\,;BS_P"&
M7?B_I7P?T^[^ W@S]G_Q=8^-OAE<_%J34M ^&L6KVOP^\;^&KO3_ (C?#$^'
M/B/H-EXH\407>J:S#XS\+:RU]IDMQX.A_LF1-2 /,? ?[2'Q3_:EU']DWP)X
M6\>:C\!M0^)W[,VN_M*_%SQ+\/O#W@O7O$IN]$U;PE\/8/ /@P?%?PI\1_".
MC:)/XU\3:SK.IZIJ/AOQ)K,NE^&],TO3;^Q&H7>J7'U-^R%\3?&GQ,^$EX?B
M1J%GK7Q"^&_Q+^*OP8\8^([#3;;1K?Q9JOPG\>:WX-M_&#:38_\ $MTR]\6:
M/INE^(=5T_25@TFSU74KZVTRRTZRBATZTXV[_9%NO!#_  !U7]G'Q]I'PO\
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MQ_4IS/\ PFO@W_H;?#/_ (/M*_\ DNC_ (37P;_T-OAG_P 'VE?_ "77344
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M_GKQK_R6/%?_ &4>=?\ JQQ!_:7"W_),<._]B/*O_4&B<S_PFO@W_H;?#/\
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MW_H;?#/_ (/M*_\ DNNFHK^>C]I.9_X37P;_ -#;X9_\'VE?_)='_":^#?\
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M^!_[$>&_]3LP"BBBOW(_)3^R3_@E/_R8/\!O^ZH_^KG^(E?H97YY_P#!*?\
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MR<SK_P!5V(#A;_DI^'?^QYE7_J=1/[)****_SU/[2"BBB@ K^%7]KK_DZ_\
M:>_[.&^-/_JR?$M?W55_"K^UU_R=?^T]_P!G#?&G_P!63XEK^A?H\_\ (ZXG
M_P"Q-E__ *MJA^+>-7_(JR'_ +&F-_\ 5; ^>:***_JL_G@_9+_@A]_R=?\
M$'_LWGQ9_P"K)^$U?U/5_+#_ ,$/O^3K_B#_ -F\^+/_ %9/PFK^IZOXN\<O
M^3@8G_L39'_ZC8P_J7PE_P"2-H?]C3-O_3^&"BBBOR _2PHHHH _SSZ***_T
MP/X/"OZ&/^"#/_-U?_=#?_>PU_//7]#'_!!G_FZO_NAO_O8:_,_&'_DW7$/_
M '2__5Q@#[SPR_Y+;)?^ZA_ZK,8?T,4445_#9_6@5S/C7_D3?%O_ &+.O?\
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MGG_P58_Y,'^//_=+O_5S_#NOXVZ_LD_X*L?\F#_'G_NEW_JY_AW7\;=?U]X
M?\D=F7_91XO_ -5V5G\T^,G_ "4^!_[$>&_]3LP"BBBOW(_)3^R3_@E/_P F
M#_ ;_NJ/_JY_B)7Z&5^>?_!*?_DP?X#?]U1_]7/\1*_0RO\ /7C7_DL>*_\
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M^T]_V<-\:?\ U9/B6OZ%^CS_ ,CKB?\ [$V7_P#JVJ'XMXU?\BK(?^QIC?\
MU6P/GFBBBOZK/YX/V2_X(??\G7_$'_LWGQ9_ZLGX35_4]7\L/_!#[_DZ_P"(
M/_9O/BS_ -63\)J_J>K^+O'+_DX&)_[$V1_^HV,/ZE\)?^2-H?\ 8TS;_P!/
MX8****_(#]+"BBB@#_//HHHK_3 _@\*_H8_X(,_\W5_]T-_][#7\\]?T,?\
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M:WB/X62ZW%^U/\'-.^#S1? /Q-^T'X7'@3XFR?%]M9T+P'<Z1:>// >LB_\
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MX1+2O^?OQ-_X6OC+_P"7U'_"):5_S]^)O_"U\9?_ "^H _ W_@O-_P VJ?\
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M^3.GF1EHI-T3NC'&O_)'<5_]DYG7_JNQ <+?\E/P[_V/,J_]3J)_9;17,_\
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M110 4444 %%%% !1110 5\\_M=?\FH?M/?\ 9O/QI_\ 5;>):^AJ^>?VNO\
MDU#]I[_LWGXT_P#JMO$M>GDG_(ZR7_L<Y/\ ^K;*C@S7_D59I_V*\S_]5N8'
M\*M%%%?Z.G\/!7]3W_!#[_DU#X@_]G#>+/\ U6WPFK^6&OZGO^"'W_)J'Q!_
M[.&\6?\ JMOA-7Y!XY?\F_Q/_8YR/_U)QA^E^$O_ "65#_L5YM_Z8PQ^R5%%
M%?Q<?U*%%%% 'YY_\%6/^3!_CS_W2[_U<_P[K^-NO[)/^"K'_)@_QY_[I=_Z
MN?X=U_&W7]?> '_)'9E_V4>+_P#5=E9_-/C)_P E/@?^Q'AO_4[, HHHK]R/
MR4_LD_X)3_\ )@_P&_[JC_ZN?XB5^AE?GG_P2G_Y,'^ W_=4?_5S_$2OT,K_
M #UXU_Y+'BO_ +*/.O\ U8X@_M+A;_DF.'?^Q'E7_J#1"BBBOF3W@K\;?^"X
M/_)J'P^_[.&\)_\ JMOBS7[)5^-O_!<'_DU#X??]G#>$_P#U6WQ9K[GPS_Y.
M!PE_V.:/_J-F1\EQY_R1O$G_ &*ZG_I_ G\L-%%%?WN?QX%?W5?LB_\ )J'[
M,/\ V;S\%O\ U6WAJOX5:_NJ_9%_Y-0_9A_[-Y^"W_JMO#5?SU](;_D2\,?]
MCG,/_533/VGP5_Y&N??]BO!?^K*9]#4445_*A_0X4444 ?SS_P#!>;_FU3_N
MN7_O'J_GGK^AC_@O-_S:I_W7+_WCU?SSU_<G@]_R;KA[_NJ?^KC'G\E^)O\
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M )+;)?\ NH?^JS&']#%%%%?PV?UH%<SXU_Y$WQ;_ -BSKW_IJNZZ:N9\:_\
M(F^+?^Q9U[_TU7= !X*_Y$WPE_V+.@_^FJTKIJYGP5_R)OA+_L6=!_\ 35:5
MTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?//[77_)J'[3W
M_9O/QI_]5MXEKZ&KYY_:Z_Y-0_:>_P"S>?C3_P"JV\2UZ>2?\CK)?^QSD_\
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ML/\ P7!_Y.O^'W_9O/A/_P!63\6:_7_ W_DX&&_[$V>?^HV#/S3Q:_Y(VO\
M]C3*?_3^)/QMHHHK^T3^6CZ&_9%_Y.O_ &8?^SAO@M_ZLGPU7]U5?PJ_LB_\
MG7_LP_\ 9PWP6_\ 5D^&J_NJK^5/I#?\CKAC_L39A_ZMJ9_0_@K_ ,BK/O\
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M>#]DO^"'W_)U_P 0?^S>?%G_ *LGX35_4]7\L/\ P0^_Y.O^(/\ V;SXL_\
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MD=F7_91XO_U796?S3XR?\E/@?^Q'AO\ U.S ****_<C\E/[)/^"4_P#R8/\
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MW/[0/A4)%I^AWNF3+-_PKGXK%9&GN?$.K(\002*T(MD=G='$ZB-HY/N?#/\
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M_P";6C[)XR_Z#WAG_P )+5?_ )M:_P SS^\#IJ*YG[)XR_Z#WAG_ ,)+5?\
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M+O'+_DX&)_[$V1_^HV,/ZE\)?^2-H?\ 8TS;_P!/X8Z:BN9^R>,O^@]X9_\
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M)/QMHHHK^T3^6CZ&_9%_Y.O_ &8?^SAO@M_ZLGPU7]U5?PJ_LB_\G7_LP_\
M9PWP6_\ 5D^&J_NJK^5/I#?\CKAC_L39A_ZMJ9_0_@K_ ,BK/O\ L:8+_P!5
MLPHHHK^>C]I"BBB@#^-O_@JQ_P G\?'G_NEW_JF/AW7YYU^AG_!5C_D_CX\_
M]TN_]4Q\.Z_/.O\ 0K@K_DCN%/\ LG,E_P#5=AS^+>*?^2GXB_['F:_^IU8*
M_0S_ ()3_P#)_'P&_P"ZH_\ JF/B)7YYU^AG_!*?_D_CX#?]U1_]4Q\1*.-?
M^2.XK_[)S.O_ %78@.%O^2GX=_['F5?^IU$_LDHHHK_/4_M(**** "OX5?VN
MO^3K_P!I[_LX;XT_^K)\2U_=57\*O[77_)U_[3W_ &<-\:?_ %9/B6OZ%^CS
M_P CKB?_ +$V7_\ JVJ'XMXU?\BK(?\ L:8W_P!5L#YYHHHK^JS^>#]DO^"'
MW_)U_P 0?^S>?%G_ *LGX35_4]7\L/\ P0^_Y.O^(/\ V;SXL_\ 5D_":OZG
MJ_B[QR_Y.!B?^Q-D?_J-C#^I?"7_ )(VA_V-,V_]/X8****_(#]+"BBB@#_/
M/HHHK_3 _@\*_H8_X(,_\W5_]T-_][#7\\]?T,?\$&?^;J_^Z&_^]AK\S\8?
M^3=<0_\ =+_]7& /O/#+_DMLE_[J'_JLQA_0Q1117\-G]:!7,^-?^1-\6_\
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M110!^>?_  58_P"3!_CS_P!TN_\ 5S_#NOXVZ_LD_P""K'_)@_QY_P"Z7?\
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M?W55_"K^UU_R=?\ M/?]G#?&G_U9/B6OZ%^CS_R.N)_^Q-E__JVJ'XMXU?\
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MQ9U[_P!-5W0 >"O^1-\)?]BSH/\ Z:K2NFKF?!7_ ")OA+_L6=!_]-5I734
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M^$_$%W''(R)=6]SX56"=5.!+$MWXFM;E8W'*B>WAE /SQJ<B@#H*^>?VNO\
MDU#]I[_LWGXT_P#JMO$M>P?V]JO_ $)7B;_P+\&__-;7E?QTT7Q7\3O@E\8_
MAMH/A+5;37?B%\*_B%X'T6[U?4/"UOI-KJWBSPEJ^@Z=<:I/9>(M0O(=.AO-
M0ADO9K2PO;F.V65X+2YE5(7]#*:M.AFN55ZTXTZ-#-,LK5:DKJ-.E1S++JU6
MI)I2:C3I4JDY-1D^6$K1;LGQYC3G5R[,:5.+G4JY?CZ5.$;<TZE7 XVG3A&[
M2YIU*D(1NTN::NTKM?PDT5^MG_#ES]L3_G]^#_\ X6VK_P#S)4?\.7/VQ/\
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MU7_H2O$W_@7X-_\ FMH_M[5?^A*\3?\ @7X-_P#FMH ^&?\ @JQ_R8/\>?\
MNEW_ *N?X=U_&W7]L?[:_P +?B!^TA^S)\2_@OX'\-RZ5XH\9_\ "&_V7?\
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M=2E'EA&47+W[V:LGT_F8HK];/^'+G[8G_/[\'_\ PMM7_P#F2H_X<N?MB?\
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M )DJ_4__ ()G_L>?&S]C3_A=?_"S]+T+7O\ A8__  KC^P_^$"\066J?9?\
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MZYXSU+P=XX\7PZ-XD\42^+[+P)XM77-<T"XNO FIQ6VOZQX7_8&BB@ HHHH
M*_.BR^!'Q6A_9I_;]^'\GA7;XN^-GQ$_:UUWX8Z1_;GAL_\ "3:5\3="GL_
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M !1110 4444 %%%% !1110!\#_M'Z/HWQ4_:E_9F^ ?Q,@CU?X,^)O GQO\
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M9SZ!87'AS0[:ZAL?"%S+J]QX4BT6?Q#K\FIFG?L0_LV:?#XSCF\(>+?$4_Q
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MW5_BUKGA?X9ZOJ-Y\&UF^+GCCPSXN^#GAW5=(_L.\^'7@GXJ?#S5O!?Q<O\
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M8:)!I>CW.HZ-8Q0:5JFI6=T ?'<7[7?[2NI:-\+/"^F>#?"^C>/?'G[55W\
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MU>ZU/5X/+U/5M4NKP ^=/AW^T3^T+\9?C?X;\!Z#X8\$?!CPO#^SC\"/C_\
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M/&7B'3M2\,:GJ7C32;'2?!=K>7LR>([ZXM4'HOPZ^+G[2/QP^$6F>(/!VH?
M;X5^./!GB/XM?#_XUZIXZ\+^//B'X7A^(/PA\6WO@>[M?!_A/2/'OPPU#2?"
M'BRXTO4_&*>)?$/Q!U/4?"&B?V-H7_"->-)-6NO%&C0ZQ\(/CY9^/_@Q\?O
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M^,_!>A:7ITCV6B66A:]JOP_^%]W-:II$%EFS_P"$)T>WTN0OIMI]LMK6*]N
M#N:*** "BBB@#Y(_:H\<_M"?"_P/\0OBM\-M?^ OA_P/\*?AIK7CW5+#XI^&
M_&_B76/'>I:!::OJ^J^'(=:T'QW\/M(^%UC'IFF:?9Z3XDN++XJSZUJ^OSBY
M\,Z!;^'(1XK\QO\ ]H3]H#XM^-->\$_L[V?PK\"ZI\._@#\.OB_X[B^-'A/Q
MAX[O+_QK\8M-US6/ 7PITS3_  EX_P#AA-X5CT[3O"FKR>+_ !MJLGB.XMY]
M4T:#3O TPM[R6;4_:=^%'[2OQ8^)W@*VT#PS\$O'G[-G@^WLO%>M_"SQO\8/
M''PMU3XC_%73-6^V^')_B#/H/[/_ ,8K'7OAEX+^S66N:1X%MI])B\0^-([/
M5_%UQJ>CZ'8^'[EGB#X2?M->'?BIXX^-/PBT/X$MXG^.WP9\#>"?BCX9\:?$
MGQWIFE?#SXB_#K_A)X_"WC+P7XHT3X,ZS??%/08['QOJNG:IX?U_PU\)[Z_3
MPYH=U;ZSIO\ :UY::. 8'BS]I+XZ^)_V7;#]KKX27GP*\!_#VR_9]@^-6J^%
M/BUHOC7QEKVO:Y;:+J6O^)? !\3>'_&GPST?X<0:&FFPZ#IWBRYT?XE7/B#6
MM5N7N_!WAB'P]%;^*.T^.'Q<_:(T#X):G^T)\/+KX(> ?!OA+X&0_&#6?"GQ
MB\.>./$WB7Q%JT?A^\\5:SX&GUS0_&OPUTKX7II6GVMCH]CXENM)^)USK>N:
MS<BZ\)>'(/#D,7BGQ7Q-^R?^T#H.D?LZ?!/P1I7P;^*G[+GP'\!^%%U?P+\0
M_BUXU^$OB#XP_%SPM/%+I/B'XF#P[\ _C/IVK_#O0KVUB\76'@"UO;"+7?',
MUMJGB^_UG2=!LM$O/0?C[\+OVL_C#XR^%8N_ _[/?B/X(>%='T?Q?XY^"VL?
M'OXB^$K?QK\:]/OTOM*A\5^*++]E_P ;GQS\(? 5Q;VNK^'?#+Z!X*D\7>+8
M;#7O&E@^E:-9^%I0#[@\#^(Y?&/@OPAXNFTF[T&;Q3X7T#Q'+H=^6:^T:77-
M)M-3DTF\9X;9S=Z<]T;.X+6\#&:%RT,1RB]161H$VO7.AZ1<>*=-TC1O$DVG
M6DNNZ3H&MWOB70]-U9X$:_LM(\0ZCX?\)W^M:=;7)DBM-4O/#&@7-[ J7$VD
M6$DC6T>O0 4444 %?$'[3WQ<_:(^!%A??%K2[KX(7WPIT7QW\+O"<'PPU#PY
MXXO_ (J_$#3O''BOPIX1U&[T+XBV_C70_#?A;QA_:_B:]A\-^!4^%/Q"@U&U
MT"VO9_%Z7/B671_"WV_7Y]?$WX6_M7^+/VD[/XDW'@G]G[XF_!_X8KIU[\ _
M 'BCX\?$/X:GP_XWN-->V\1_%CQ_HFE_LR?%2Q\5^/[475YHGPZ,/B2VT'P%
MH4^HW]GIMYXLUJ37M- .>^)G[4GQY@B_:H^)OPFL?A-<?"']CW7?^$>\8>$?
M%?AOQ?K7Q&^+FH^"?"N@?$7XQ1>%O&6A>/=!\/\ PQ71O"7B2VT3P<VJ^ ?B
M?-J_BG3-0N-6MM+TZ6"T3M?VA?CE\?/A/X8M_COX:OO@?JGP8_X2CX0:3I/P
MVO\ P[XWU#XJ?$70?B3XA\'^'9[_ $'XC6GC;1?#/A?QA)J'BRYC\-^!8OA7
M\0[;4;70;:^F\8+<^)9=(\+<5X\_9<^/5PG[4WPQ^'ES\);3X/?MA:^/$WC/
MQ?K?BSQ?I/Q(^$M]XW\&^'?AW\8[?PIX,TOX=:QX>^)?]K>'?#$6L>#M2U;X
M@?#.33/$6MWL>K6%_9:=#-J-_P :?!C]J&^^/GA[Q;:^!?V?OB-\#O@OI>@6
MW[.?PZ\3_'?X@_#0^&?%-KH:Z5K/Q4\?Z)I'[,7Q1T_Q5X_L;>2XT'X=&W\0
MVF@> M!FU&_L=+N_%>M/KNF %O\ :0_:7^*'PA^)>G^'?"/C_P#9JU[6-1\4
M_"[2_"G[*YL/$_B/]IOXI^&/%?B+2-)\7^*M&OM+^(^@Q^!HM%L)O%>JV37'
MP@\?^%+'1?!-WXA\2^-M-L]0U*R\*?H97PK^TM\)?VD?V@_"WC_X%W6A? &Q
M^$GCS4_"PLOBE/XS\>'XE^ =$T^Z\,:YJ-WIWPJD^&6H^&?$WCW0/$&E:M<^
M"?%L/Q@\$6EM<2^'=:G\/V5[H=S9ZM]TJNU57+-M4+N8Y9L#&6/=CU)[G)H
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M/B#QUX:M_@WX5MO#-CJE]IMEXMUR#P\GB;Q!R6M_M+_%#0_VF?!7PET[Q_\
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M<(QBCFN(X+J2")Y-JR3):W+Q(6=8)F41M^<_P3^!W[3D?BWXC>(OVEO _P
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MHHHH *YGQK_R)OBW_L6=>_\ 35=UTU<SXU_Y$WQ;_P!BSKW_ *:KN@ \%?\
M(F^$O^Q9T'_TU6E=-7PG:?%7Q[IMI:Z=9:]Y-G86\-E:0_V7HTGE6UK&L$$7
MF2Z=)+)Y<4:+OE=Y&QN=V8DFQ_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B
M-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_
M^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?
M]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\
MY64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW
M_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,
M7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'
M_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_
MY2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64
M?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +
MA^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(
MT+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?
MB-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"
M_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%
M?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W
M_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y
M64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T
M,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E
M90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_
M  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?
M^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\
M+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E
M(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]
MR45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'
MXC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0
MO_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(
MW_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_
M .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\
M-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]
M#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E9
M1_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q
M?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E
M 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\
M"X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y
M2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN
M'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C
M0O\ Y64 ?<E<SXU_Y$WQ;_V+.O?^FJ[KY!_X7#\1O^AB_P#*1H7_ ,K*KW?Q
M5\>ZE:76G7NO>=9W]O-97</]EZ-'YMM=1M!/%YD6G1RQ^9%(Z[XG21<[D=6
$( /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &[ M # 2(  A$! Q$!_\0
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MR_\ E#0 ?\(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\ !#I7_P B4?\
M"6Z5_P ^GB;_ ,(KQE_\H:/^$MTK_GT\3?\ A%>,O_E#0 ?\(5X-_P"A2\,_
M^"'2O_D2C_A"O!O_ $*7AG_P0Z5_\B4?\);I7_/IXF_\(KQE_P#*&C_A+=*_
MY]/$W_A%>,O_ )0T '_"%>#?^A2\,_\ @ATK_P"1*/\ A"O!O_0I>&?_  0Z
M5_\ (E'_  ENE?\ /IXF_P#"*\9?_*&C_A+=*_Y]/$W_ (17C+_Y0T '_"%>
M#?\ H4O#/_@ATK_Y$H_X0KP;_P!"EX9_\$.E?_(E'_"6Z5_SZ>)O_"*\9?\
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M\);I7_/IXF_\(KQE_P#*&C_A+=*_Y]/$W_A%>,O_ )0T '_"%>#?^A2\,_\
M@ATK_P"1*/\ A"O!O_0I>&?_  0Z5_\ (E'_  ENE?\ /IXF_P#"*\9?_*&C
M_A+=*_Y]/$W_ (17C+_Y0T '_"%>#?\ H4O#/_@ATK_Y$KG_ !;X2\*VGA7Q
M-=6OAGP_;75MX?UFXMKFWT7389[>>'3;F2&>":.V62*:*15DCDC97C=596#
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MPG138QZC-YVDHNE)!):[;8@'B7[&\7B72[C]J/PGXD^(GQ!^)S^"_P!I[7-
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M$&B>#?#&D:[=?:I+[[3K.FZ)8V>IW'VV8":\\Z]AGD^U2@27&[S9 &<UV-%
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MIO>>']+UW3KWZ)U+]GKX!:SH_@7P]K'P.^#^JZ!\+YEN/AIH>I?#3P7?:/\
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M>)O_  BO&7_RAKIJ* .9_P"$MTK_ )]/$W_A%>,O_E#1_P );I7_ #Z>)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVIZKJEY;Z?ING6-K&TUS>7U]=R0VMI:V\2-+/<7$L<,4:L\CJH)'XM?M1_\
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M7_/IXF_\(KQE_P#*&@#IJ*YG_A+=*_Y]/$W_ (17C+_Y0T?\);I7_/IXF_\
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MXEGTY;.UMK1;&74VMA;6T$ B$4,:+Z%10 4444 %%%% !1110 4444 %%%%
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M/_IJM*Z:O,.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9/PFK^IZOY8?^"'W_)U_Q!_[-Y\6?^K)^$U?U/5_%WCE_P G Q/_ &)LC_\
M4;&']2^$O_)&T/\ L:9M_P"G\,%%%%?D!^EA1110!_//_P %YO\ FU3_ +KE
M_P"\>K^>>OZ&/^"\W_-JG_=<O_>/5_//7]R>#W_)NN'O^ZI_ZN,>?R7XF_\
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M>MJ%W-;6P!^FU?F!\,?#F@VOQP\6^%OBK+\0?$GBK]I+PM\2]>\%?M"_"_\
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M?[0/P9D2V@,*S7#I\1O#;+!"US-;VZRRD".,SSP0AV!EFC3<Z_/U?0W[(O\
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M9_V);PZC=)I>H[7$=CJ-M\/?#GBZWLY9T.7^).C+&7:Y$$OX#       8 '
M '0 =@*_0_HR9;0XB\4_$3B^JO:4N!LERO@/(VTG"&8Y[6EGO%V+I/5*K&G@
M\CR:4HZJ$,13<K.4#]@^E;CJWA-]#7Z/_A'1OA>(/I$\8Y_]);C^FFZ>)?!7
M"%/%^&?@7E&+BN6?U;%U:GB/Q]1HU5R3GC,NQD:;;HUA:^AOV1?^3K_V8?\
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M'QY_[I=_ZICX=U^Y> '_ "6.9?\ 9.8O_P!6.5GY+XR?\DQ@?^QYAO\ U!S
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M;_P+\&__ #6T =-17,_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\
M-;0!TU%<S_;VJ_\ 0E>)O_ OP;_\UM']O:K_ -"5XF_\"_!O_P UM '345S/
M]O:K_P!"5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6T =-17,_V]JO_ $)7
MB;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;0!TU%<S_;VJ_\ 0E>)O_ OP;_\
MUM']O:K_ -"5XF_\"_!O_P UM '345S/]O:K_P!"5XF_\"_!O_S6T?V]JO\
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M'/!XI_Y)CB+_ +$>:_\ J#6/X]Z***_T*/XM/V2_X(??\G7_ !!_[-Y\6?\
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MV1_^HV,/ZE\)?^2-H?\ 8TS;_P!/X8****_(#]+"BBB@#^>?_@O-_P VJ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /Q*_X+R_'C5/AO\ L90_!7P9]HNOB3^U;XZT+X0>'=*T
M\YU6Z\/+=VNM>,&LHRZ+,FIK!H?@>ZB(<O'XW1552?.A_3#]DWX$:7^S)^S7
M\%?@+I*VYC^&?P_T+0-4N;48@U3Q0UO_ &CXQUQ!A<'7_%M]K6M.-H DOV
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M% ',_P!O:K_T)7B;_P "_!O_ ,UM']O:K_T)7B;_ ,"_!O\ \UM=-10!S/\
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M% ',_P!O:K_T)7B;_P "_!O_ ,UM']O:K_T)7B;_ ,"_!O\ \UM=-10!S/\
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MG&(Q'PX7#Y;P;PWQ%7J8J;C'#RK4*KDI0@G1_P""#OPW\7:?\!_B[^USX_\
M#&N:]\2_VQ_BYXE\>7_B*%_#L)OO"^A:WKEM;RA-7UZPU&%]2\=ZK\0=4E/D
MI;WEA/HT\9F2**9OW:_M[5?^A*\3?^!?@W_YK:YOX-?"[P[\$?A+\-/@]X1B
M\KPU\,/ WA?P+HQ**DL]EX8T>TTF.]NMG$E]J!M6OK^=BTES>W$]Q*[RRN[>
ME4^$\D7#G#>39,Y>TK8/!4_KM:_-+$9CB'/&9GB9S>M2=?,<7C*CJ.[FN63?
MO&7T@_%"7C-XU>)'B5"E]5RSB3B?&?ZM9<J:HT\HX,R:&'X<X'R:AAU[F%P^
M5<&\.\-X2GA*:C3PTG7HPBE3=^9_M[5?^A*\3?\ @7X-_P#FMK_/UK_0PK_/
M/K^NOH[?\U=_W0O_ 'JG\2>-G_--?]U?_P!YP5] _LF2/%^U3^S/+'!+<O'^
MT#\&9$MH#"LUPZ?$;PVRP0M<S6]NLLI CC,\\$(=@99HTW.OS]7T-^R+_P G
M7_LP_P#9PWP6_P#5D^&J_H7._P#D2YU_V)LX_P#53FI^+95_R-<K_P"QIEG_
M *LLO/[A/[>U7_H2O$W_ (%^#?\ YK:/[>U7_H2O$W_@7X-_^:VNFHK_ #B/
M[A.9_M[5?^A*\3?^!?@W_P":VC^WM5_Z$KQ-_P"!?@W_ .:VNFHH YG^WM5_
MZ$KQ-_X%^#?_ )K:_/W_ (*EZM?W7["'QT@G\+Z[IT3_ /"L=UY>7'AI[:';
M\8_AZZ^8NG^(KZ\/F,HB3R;67$CJ9-D0>1/THK\\_P#@JQ_R8/\ 'G_NEW_J
MY_AW7TW!7_)8\*?]E'DO_JQPYX/%/_),<1?]B/-?_4&L?QMT445_H4?Q:?L)
M_P $3KNXLOVJ?'\MMI=]JSM^S]XJC-MI\FF1S(A^(WPI8SLVJZCIEN8E*+&P
M2=YM\B%8602/'_4-_;VJ_P#0E>)O_ OP;_\ -;7\P_\ P0^_Y.O^(/\ V;SX
ML_\ 5D_":OZGJ_B[QR_Y.!B?^Q-D?_J-C#^I?"7_ )(VA_V-,V_]/X8YG^WM
M5_Z$KQ-_X%^#?_FMH_M[5?\ H2O$W_@7X-_^:VNFHK\@/TLYG^WM5_Z$KQ-_
MX%^#?_FMH_M[5?\ H2O$W_@7X-_^:VNFHH _G4_X+JW]U??\,M?:=%U/1_*_
MX7=L_M&71I?M&_\ X5%N\G^R-6U3;Y.Q?,^T>1GS4\KS<2^7_/U7]#'_  7F
M_P";5/\ NN7_ +QZOYYZ_N3P>_Y-UP]_W5/_ %<8\_DOQ-_Y+;.O^Z?_ .JS
M!A7]0W_!$[4[VR_96\?Q6WA[6-61OV@?%4AN=/GT".%'/PY^%*F!EU77-,N#
M*H19&*0/#LD0+,SB1(_Y>:_J>_X(??\ )J'Q!_[.&\6?^JV^$U>9XY?\F_Q/
M_8YR/_U)QAW^$O\ R65#_L5YM_Z8PQ^MG]O:K_T)7B;_ ,"_!O\ \UM']O:K
M_P!"5XF_\"_!O_S6UTU%?Q<?U*<S_;VJ_P#0E>)O_ OP;_\ -;1_;VJ_]"5X
MF_\  OP;_P#-;7344 <S_;VJ_P#0E>)O_ OP;_\ -;7\?'_!4NXENOV[_CI/
M/976G2O_ ,*QW6=X]F]S#M^#GP]1?,;3[N^M#YBJ)4\FZEQ&ZB39*'C3^RVO
MXV_^"K'_ "?Q\>?^Z7?^J8^'=?N7@!_R6.9?]DYB_P#U8Y6?DOC)_P DQ@?^
MQYAO_4',#\\Z***_KX_FD_NG_9!=G_9._9B9HI(2/V?/@V@20Q%BL?P[\.QI
M*#%)*GESHJS1 L)1%(@FCAF$D2>Q^-?^1-\6_P#8LZ]_Z:KNO'_V1?\ DU#]
MF'_LWGX+?^JV\-5[!XU_Y$WQ;_V+.O?^FJ[K_.+._P#D=9U_V.<X_P#5MFI_
M<.5?\BK*_P#L5Y9_ZK<O#P5_R)OA+_L6=!_]-5I735S/@K_D3?"7_8LZ#_Z:
MK2NFKS#O"OR$_P""T.BPWO[-?PJ\2^*?#VN^+?@M\//VG_A!XU_:&\-^'3='
M4=3^#EG)KNE^(8]EK);LT!O]6TF N]]8);W%Q;7!O+<Q">+]>ZK7EG::C:76
MGZA:VU]87UM/9WMC>0175I>6EU$T%S:W5M.KPW%M<0N\,\$R/%+$[1R*R,00
M#^53]LGXV_\ !+KXO?#7X=^!?V!O '@&3]K/6?BW\*9?@Y?_  :_9_UCX4^)
MO#FNVOC+3#->>(==G\!>#TU:V:RMKRRBTF>XU^4ZM<Z9KOV%;>U35HOZL8]^
MQ/,.7V+O(Q@O@;CP .N>@ ]!7A?@#]F/]F;X9^)&\;?"_P#9_P#@=X"\6@WU
MN/%?@7X6^!/#/B"$3H;#4[6#6]"T.RU"VBG$4EOJ%I!<Q132FX^TQ--+.7]W
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_G%^$C-^W-_P71^+'Q3D']J_"'_@GUX*;X<>%)&S/IS_$QI-8
M\-.)(5<VOVS_ (3'5/BOK%AJ*&61XO OAZ0C=% ;7]I?VQOC]I_[+?[+WQO^
M/=\]LLWPY\ ZOJF@P78!MM0\97ZQZ'X&TB8$\QZQXRU30M+?KA;MFVMC!_._
M_@A%\ =0^$W[$.F?%'Q8EQ-\1/VH/%NM?&CQ'J.HDR:K<:#>S-I'@A;JY(W7
M,&I:193^-K:1VD<R>-;IG<,YBC_.N)_^%OB[A#A>/OX; U:W&V=16L70R:?U
M/(,/56UL3GN*EB8QEI-99S)-0;7]E>!O_&L/H[_2,\=:J]AGG%6 R[Z+_AC7
ME[E99MXDT%Q%XMYO@):2]IDGA1D-/):U>B[X>IQQ[*<Z<L1&-3]I:***_13^
M-0K_ #SZ_P!#"O\ //K^F/H[?\U=_P!T+_WJGX/XV?\ --?]U?\ ]YP5]#?L
MB_\ )U_[,/\ V<-\%O\ U9/AJOGFOH;]D7_DZ_\ 9A_[.&^"W_JR?#5?T+G?
M_(ESK_L39Q_ZJ<U/Q;*O^1KE?_8TRS_U99>?W54445_G$?W"%%%% !7YY_\
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MDE?QM_\ !5C_ )/X^//_ '2[_P!4Q\.Z_<O #_DL<R_[)S%_^K'*S\E\9/\
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MAG_PK=5_^8J@#IJ*YG[7XR_Z /AG_P *W5?_ )BJ/M?C+_H ^&?_  K=5_\
MF*H Z:BN9^U^,O\ H ^&?_"MU7_YBJ/M?C+_ * /AG_PK=5_^8J@#IJ*YG[7
MXR_Z /AG_P *W5?_ )BJ/M?C+_H ^&?_  K=5_\ F*H Z:BN9^U^,O\ H ^&
M?_"MU7_YBJ/M?C+_ * /AG_PK=5_^8J@#IJ*YG[7XR_Z /AG_P *W5?_ )BJ
M/M?C+_H ^&?_  K=5_\ F*H Z:BN9^U^,O\ H ^&?_"MU7_YBJ/M?C+_ * /
MAG_PK=5_^8J@#IJ*YG[7XR_Z /AG_P *W5?_ )BJ/M?C+_H ^&?_  K=5_\
MF*H Z:BN9^U^,O\ H ^&?_"MU7_YBJ/M?C+_ * /AG_PK=5_^8J@#IJ*YG[7
MXR_Z /AG_P *W5?_ )BJ/M?C+_H ^&?_  K=5_\ F*H Z:BN9^U^,O\ H ^&
M?_"MU7_YBJ/M?C+_ * /AG_PK=5_^8J@#IJ*YG[7XR_Z /AG_P *W5?_ )BJ
M/M?C+_H ^&?_  K=5_\ F*H Z:BN9^U^,O\ H ^&?_"MU7_YBJ/M?C+_ * /
MAG_PK=5_^8J@#IJ*YG[7XR_Z /AG_P *W5?_ )BJ/M?C+_H ^&?_  K=5_\
MF*H Z:BN9^U^,O\ H ^&?_"MU7_YBJ/M?C+_ * /AG_PK=5_^8J@#\"O^"Y7
MBC6_C9XN_8U_X)R^ ]0F@\2_M)?%W1?%?CI[+YYM&\!:)J+>'])U#4H-DGFZ
M.+^^\4>+IRL;F%_AJTK@JH23]^_"7A;0O WA7PSX*\+Z?#I/AGP?X?T;PMX=
MTNW&(--T+P_IUMI.D:? .T-GI]I;V\8[)&HK^<W]AR;7?VV/^"M_[6_[:O\
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M8^=/9^(K^^N4Q\8_AZ8_+M9_"^G12[I0B/NO(=D;-(OF,@B?Z;@K_DL>%/\
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M;_X*L?\ )_'QY_[I=_ZICX=U_7]]K\9?] 'PS_X5NJ__ #%5_'Q_P5+>\?\
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M?^3K_P!F'_LX;X+?^K)\-5\\U]#?LB_\G7_LP_\ 9PWP6_\ 5D^&J_H7._\
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MP7X]T'Q;)HVN^(/#5M=^%_$?AG6K*_O])\2:QH%Q!:#4M-UF^TN>WO9?SO\
MAQ^S[^VCX!\,_'#Q=\%OAU^SA^R_XU^(>F^&/"?A;]GW1/C5X^\4_L_Z#XAT
M3QGXBA^(G[1OAVWL?@H/"GPR\<?$7PC=65UX4\(>%?A#J>D7^JP:)XU^-O\
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MJ>&].^+>E>"]+NO'?PP\>W&M6GASQQX9B\&>._'+V=HUUH<]OK?ACQD/"?Q
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MQE_T ?#/_A6ZK_\ ,51]K\9?] 'PS_X5NJ__ #%5TU% ',_:_&7_ $ ?#/\
MX5NJ_P#S%4?:_&7_ $ ?#/\ X5NJ_P#S%5TU% ',_:_&7_0!\,_^%;JO_P Q
M5'VOQE_T ?#/_A6ZK_\ ,57344 <S]K\9?\ 0!\,_P#A6ZK_ /,51]K\9?\
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MA\WP-X1M'WDQ/\/+B$O+R]?T0U^?>'<99A@\ZXOK1DJW&6=8G,L+SIJ=/(,
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MK.'9(S1KYBH)7_LMK^-O_@JQ_P G\?'G_NEW_JF/AW7[EX ?\ECF7_9.8O\
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M4?[0_L^^_LG['_:OV.Z_LS^T?/\ [/\ [0\A_L?V[[-_I/V/[3Y?VK[/^_\
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M"]SH_@[09-4U&;2M#M);VY>3WZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M%;JO_P Q5 '345S/VOQE_P! 'PS_ .%;JO\ \Q5'VOQE_P! 'PS_ .%;JO\
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MTPU./X!?\%0?B=X>_:T_X*!?&^'X4^(8=;^$>DZ[X0L=9\7Z2YDT[7M2\&^
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MI(4N;A(W)19Y0HD;F^D-_P B7AC_ +'.8?\ JIIGXKX*_P#(US[_ +%>"_\
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M./\ U;9J?W#E7_(JRO\ [%>6?^JW+PHHHKS#O"BBB@#_ #SZ0@,"K %2"""
M001@@@\$$<$'@BEHK_3!I---)IIIII-----------IIIIIM---I_P@FXM2BW
M&46I1E%M----------)IIIII---)KC_ ?P;\?I\<?A5XF_9CU6'P=\;S\3/
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M!?P[\"Z+HGA[0-'L['2])\,^#-$M3/)J6LZBM_K^LZQJM][?0 4444 %%%%
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ME?QM_P#!5C_D_CX\_P#=+O\ U3'P[K]R\ /^2QS+_LG,7_ZL<K/R7QD_Y)C
M_P#8\PW_ *@Y@?GG1117]?'\TG]U7[(O_)J'[,/_ &;S\%O_ %6WAJOH:OGG
M]D7_ )-0_9A_[-Y^"W_JMO#5?0U?YQ9W_P CK.O^QSG'_JVS4_N'*O\ D597
M_P!BO+/_ %6Y>%%%%>8=X4444 ?YY]%%%?Z8'\'GT-^R+_R=?^S#_P!G#?!;
M_P!63X:K^ZJOX5?V1?\ DZ_]F'_LX;X+?^K)\-5_=57\J?2&_P"1UPQ_V)LP
M_P#5M3/Z'\%?^15GW_8TP7_JMF4-4TO3-<TS4-%UK3K#6-'U:RNM-U72=4L[
M?4-,U/3KZ![:]L-0L+N.:UO;*\MI9+>ZM;F*6"X@D>*6-XW93_/]^T+_ ,$G
M/BO^SM\1-0_:L_X)-^.I?@W\1T#WGC#]G*[OXU^&/Q'LHYI+VYT;0(=9EDT*
MSM[N5I!!X)\4K_PC%K/<+=^%-=\"S:;80R?T(45_+/$'#&4<2T*-/,*-2GBL
M)-ULMS7 UIX+-\JQ.\<1EV84.7$8>::3J4G*KA<1%.GB<+6A*1_9/A!XZ>(?
M@EFF88O@[,<'B\BXAPRRWC7@'BC+Z'$OAWQ_DK]VKDW&7!^9NKE.;X>5*52.
M%Q\*6!SW**LHXO)<\R[$T:=_QR_8>_X*[_#O]H+Q2?V>OVDO"]U^RW^UYH5V
MGA_6OAIXZCN]!\/^+?$$/E0R6_@J_P#$(MKVPUJ]G=9K;P)XB*ZVT5U;Q^']
M2\811W-]#^QM?!'[<'_!./\ 9O\ V\?"\=E\4O#TF@_$31K.2#P7\8O",=MI
M_CWPP^6DM[2XNVB,'B?PVMP6DE\->($N[*/S[NXT:71=6G&JQ?DEX4_:S_;D
M_P""1/B+0OA-^WIHVM_M)_L@W.HP^'?AY^U/X/@N=7\4^%;-LII6F^)9;Z?[
M7?26]K'OE\(^,[M/$T$,>H_\(7XP\::3H=MI;_*0XASW@V<<+QK?-,BYHT\+
MQS@<*XK#QE*,*5/BW+,-"H\NJ>]"$LZP,*N5UIOGQ-' 3FS]_P 1X/\ A5])
M6A7S[Z,7)P)XK>QK8W/OHL<59["M/-ZU.E5Q&-Q?T>>.,YKX./&6#M3Q&(I>
M&7%.*P/'F6T(_5LDS'BNAAZ<3^F2O-?B3JNHZ&O@35;*\GM;2+XE>$M*UF.)
MRL5]IWBR:Z\&06=VN,20?VWXBTB[C1N!>VMI(#OC6H?@Y\:?A5^T#\/]$^*7
MP9\<Z!\0_ 7B&-GTWQ#X>N_M$'GQ!/M6G:A:RI#?Z/K.GNZPZGH>KVECJ^F7
M&;?4+*VF!C$/QQ1Q\)_&NHQ*SS>&M+B\:VZH"TIN? M_9^,K;R0.3<?:-"C-
MOCGSA'CFOT>A7HXFC2Q&&K4L1AZ].%6C7H5*=:C6I5(J4*E*K2G4IU*<XM2C
M.$Y1DG=/=+^+LSRO,\DS+'Y/G678_*,WRO%XC+\SRK-<%BLNS++L?A*LJ&*P
M6/P&.P^%QF#Q>&K0G2KX?$X:C6I3BXSIJ\93]6HIL;I*B2QLKQR(KQNI#*Z.
M RLK#@JRD$$<$$$4ZM3A"BBB@ HKY_\ &O[2?P]\$?%CP;\%YM(^*'BWQOXL
MNM%CU(?#?X1_$?XC>'?AKI?B5=>A\,^)?B]XL\'>&]7\._#7P[XAU?P]=Z+I
MM_XGU&SD,S/KEW;6G@_2?$?B71.?3]LS]G(:O\1M&OO'>I:!-\*_"?C#QWXJ
MU+Q;\._B=X-\,7?@OX?ZO%H'C7Q5X$\8^*_!FC>$OBKH'AG7+BSTC5]4^%VM
M>,;.TU'4=*LWE\_5=.2Z /J"BOD?_AN/]G9O#,'B>'5/BO=B;XC2?"5O!UA^
MS3^TOJ'Q;L_B#%X'E^);:!JOP0L?A%<?&/1@WP_B/C&'5M6\"V6B7'AZ6VU.
M#4I+:[M7F]D\;?&CX>?#CX;VOQ6\:ZEKF@^$;Y?"T=A#/X(\=7/C74-3\:W^
MFZ5X4\,:?\,+'PW=?$R_\;:YJ^KZ=H]EX#M/",WC-M8N1I3Z$FH136T8!ZI1
M7Q[K?[>W[+'A[PAX:\<ZGX_\1+H'B>S\?:G&EA\(/C5K'B+POH_PJ\0Q^$_B
M?KOQ.\&:/\.[_P 8_!_P]\.O$\T6@>.?$'Q6T'P9HOA/5I$L==OK"X8(>[A_
M:L^!%S\7X/@9;>,=0N/B#=:T_A>V-OX%^(<_@.?QBG@@_$E_ D7Q>B\*/\(W
M^(2> !_PF+> %\<'QF/#Q75#H?V5ED(!]#T444 5[R\M-/M+J_O[JWL;&QMY
M[R]O;R>*VM+.TMHFFN;JZN9F2&WM[>%'EGGE=(HHD:21E121_,#XIU'Q'_P7
M+_;03P#X>O-5TW_@FY^R9XFAO_%FN6<MW8P?'/QS&TD2Q64T)A:5_$<,5SIW
MA]U?[3X3^';ZQXG-QIGB'QIIFDM[3_P4_P#VF?B;^U1\9M&_X)/?L::D9?&W
MCID_X:D^(VGM))I'PZ^'@2UN-9\*:EJ=HP:WLX]-O(+WXABWFBGNHKG1OAM;
M27>K>)]:T2+]F/V6?V9_AE^R'\#_  3\"/A1IS6GAKPC8_Z9JETD/]M>+?$E
MYMFU_P 8>([F%$6[US7KX-<W#*%MK&V6TTC3(;32--T^RMOR_,I2X_SNMP_0
ME)\&\/8NG_K/B8-JGQ#G6'G"M1X7H5(M*KEV7U(TL3Q#.$G"M7CA\I<FEBDO
M[LX+I4OHB^%V7>+V:TJ</I)^,'#V+_X@9DF)ITYXSP=\-,XH8K+,Q\=,UPE>
M$Y8'C/C#"5LPR3P?PV*H4\3EN4ULW\08TH2GD-6?N&A:'HWAC1-(\-^'-*L-
M#\/^'],L-%T/1=*M8;'2](TC2[6*QTW3-.LK9([>TL;&S@AM;2V@C2*""*.*
M-510!JT45^GQC&$8QC&,8QC&,8Q2C&,8I1C&,8J,8QC&,8QC&,8QC&,8I**2
M_A>K5JUZM6O7JU:]>O5JUZ]>M4J5JU:O6J5*U:M6K59U:M:M6K5:M6K5JU*E
M6K5JU:M2I4J5*E2?\;?_  58_P"3^/CS_P!TN_\ 5,?#NOSSK]#/^"K'_)_'
MQY_[I=_ZICX=U^>=?Z%\%?\ )'<*?]DYDO\ ZKL.?Q3Q3_R4_$7_ &/,U_\
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M +*/)?\ U8X<\'BG_DF.(O\ L1YK_P"H-8_C;HHHK_0H_BT_9+_@A]_R=?\
M$'_LWGQ9_P"K)^$U?U/5_+#_ ,$/O^3K_B#_ -F\^+/_ %9/PFK^IZOXN\<O
M^3@8G_L39'_ZC8P_J7PE_P"2-H?]C3-O_3^&"BBBOR _2PHHHH _GG_X+S?\
MVJ?]UR_]X]7\\]?T,?\ !>;_ )M4_P"ZY?\ O'J_GGK^Y/![_DW7#W_=4_\
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MM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUK\_?\ @J7;^)4_80^.C:AJVA75F/\
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M[KR;?(K2+Y:N(D_LMK^-O_@JQ_R?Q\>?^Z7?^J8^'=?N7@!_R6.9?]DYB_\
MU8Y6?DOC)_R3&!_['F&_]0<P/SSHHHK^OC^:3^Z?]D$2C]D[]F(2O&[_ /#/
MGP;(:.-HE$1^'?ATPH5:68F2.$QQRR!PLTJO*D4".L,?L?C7_D3?%O\ V+.O
M?^FJ[KQ_]D7_ )-0_9A_[-Y^"W_JMO#5>P>-?^1-\6_]BSKW_IJNZ_SBSO\
MY'6=?]CG./\ U;9J?W#E7_(JRO\ [%>6?^JW+P\%?\B;X2_[%G0?_35:5TU<
MSX*_Y$WPE_V+.@_^FJTKIJ\P[PHHHH **** "BBB@ HHHH **** "BBB@ K^
M-O\ X*L?\G\?'G_NEW_JF/AW7]DE?QM_\%6/^3^/CS_W2[_U3'P[K]R\ /\
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MK_D:Y7_V-,L_]667G]U5%%%?YQ']PA1110 5^>?_  58_P"3!_CS_P!TN_\
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M%TI-5)TZB<N>M"T.5-IMWT:?\CE%?T\?\.-/@%_T5_XP?EX+_P#F:H_X<:?
M+_HK_P 8/R\%_P#S-5_0?_$<O#__ *"<Y_\ #'B?_FP_&/\ B$O&7_/C*_\
MP[4/_F8_3+]D7_DU#]F'_LWGX+?^JV\-5]#5Y/\ #GX>:Y\,?A[X$^&V@^)M
M*N]"^'O@WPOX'T6[U?PQ>7&K76D^$]$L=!TZXU2>R\5:?9S:C-9Z?#)>S6EA
M96TERTKP6EM$R0IV7V3QE_T'O#/_ (26J_\ S:U_'>95Z>*S+,L51<G1Q68Y
MAB:3E%PDZ6)Q^.Q%)RBVW&3I8BFY1;;C)RBVW%M_TW@*,\/@<#AZB2J8? X*
MA446I152A@\)0J*,DDI152C-1DDE**4DDI)+IJ*YG[)XR_Z#WAG_ ,)+5?\
MYM:/LGC+_H/>&?\ PDM5_P#FUKB.HZ:BN9^R>,O^@]X9_P#"2U7_ .;6C[)X
MR_Z#WAG_ ,)+5?\ YM: /\_6BOZ>/^'&GP"_Z*_\8/R\%_\ S-4?\.-/@%_T
M5_XP?EX+_P#F:K^T?^(Y>'__ $$YS_X8\3_\V'\M?\0EXR_Y\97_ .':A_\
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MT'O#/_A):K_\VM'V3QE_T'O#/_A):K_\VM '\@/_  58_P"3^/CS_P!TN_\
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M_'^NZ#_PKC_A*_[#_P"$"TC3]+^U?\)A_P (W_:?]J_\)#<>*?/\C_A%]/\
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M5?T'_P 1R\/_ /H)SG_PQXG_ .;#\8_XA+QE_P ^,K_\.U#_ .9C],OV1?\
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M/%T6A^%=+.IVD>H:M;2R;!MM^T?\'D^)<7PFF\2ZG;>+KEK^"QNKOP1X]L_
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MX2^/6N?"GXG?#7QGXRU>Z\;W_A)-$^/UA!I*>)?#,GPCL8;C3-,UT _5@$$
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MO+\6M%33_#5Q9^(;S4=5\%6>EVVAZAIFK2WJ6&IZ?<7/O?ACQ+H/C3PWX?\
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9V@GB\R+3HY8_,BD==\3I(N=R.K $ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076914576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ImmuCell Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000811641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0382980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,165,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">56 Evergreen Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Portland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">ME<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">04103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">878-2770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.10 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ICCC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,750,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071373232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WIPFLI LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Radnor, Pennsylvania<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078021232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 978,741<span></span>
</td>
<td class="nump">$ 5,791,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">2,185,383<span></span>
</td>
<td class="nump">1,758,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,811,841<span></span>
</td>
<td class="nump">6,038,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">493,885<span></span>
</td>
<td class="nump">406,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total current assets</a></td>
<td class="nump">11,469,850<span></span>
</td>
<td class="nump">13,994,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">27,575,683<span></span>
</td>
<td class="nump">28,441,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">4,571,149<span></span>
</td>
<td class="nump">2,194,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">95,557<span></span>
</td>
<td class="nump">95,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">38,208<span></span>
</td>
<td class="nump">57,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">57,655<span></span>
</td>
<td class="nump">76,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">43,808,102<span></span>
</td>
<td class="nump">44,860,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt obligations</a></td>
<td class="nump">1,428,807<span></span>
</td>
<td class="nump">1,039,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">644,276<span></span>
</td>
<td class="nump">31,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,124,337<span></span>
</td>
<td class="nump">2,000,862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,197,420<span></span>
</td>
<td class="nump">3,072,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Debt obligations, net of current portion</a></td>
<td class="nump">10,540,496<span></span>
</td>
<td class="nump">9,191,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">4,077,109<span></span>
</td>
<td class="nump">2,217,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">14,617,605<span></span>
</td>
<td class="nump">11,408,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">18,815,025<span></span>
</td>
<td class="nump">14,480,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.10 par value per share, 15,000,000 shares authorized and 7,814,165 shares issued as of both December 31, 2023 and 2022 and 7,750,864 and 7,746,864 shares outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="nump">781,417<span></span>
</td>
<td class="nump">781,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">36,357,239<span></span>
</td>
<td class="nump">35,978,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(12,007,097)<span></span>
</td>
<td class="num">(6,232,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 63,301 and 67,301 shares as of December 31, 2023 and 2022, respectively</a></td>
<td class="num">(138,482)<span></span>
</td>
<td class="num">(147,233)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">24,993,077<span></span>
</td>
<td class="nump">30,380,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 43,808,102<span></span>
</td>
<td class="nump">$ 44,860,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078097728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="nump">7,814,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,750,864<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock</a></td>
<td class="nump">67,301<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078343856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">13,602,385<span></span>
</td>
<td class="nump">10,919,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">3,869,284<span></span>
</td>
<td class="nump">7,648,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">4,394,852<span></span>
</td>
<td class="nump">4,493,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">3,088,215<span></span>
</td>
<td class="nump">3,190,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">2,134,295<span></span>
</td>
<td class="nump">2,263,817<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">9,617,362<span></span>
</td>
<td class="nump">9,947,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING LOSS</a></td>
<td class="num">(5,748,078)<span></span>
</td>
<td class="num">(2,298,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">21,893<span></span>
</td>
<td class="nump">187,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(5,769,971)<span></span>
</td>
<td class="num">(2,486,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">4,627<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (5,774,598)<span></span>
</td>
<td class="num">$ (2,493,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in Shares)</a></td>
<td class="nump">7,747,686<span></span>
</td>
<td class="nump">7,745,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in Shares)</a></td>
<td class="nump">7,747,686<span></span>
</td>
<td class="nump">7,745,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075781840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">$ 35,692,388<span></span>
</td>
<td class="num">$ (3,738,694)<span></span>
</td>
<td class="num">$ (158,171)<span></span>
</td>
<td class="nump">$ 32,576,940<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,493,805)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,493,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19,732<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,938<span></span>
</td>
<td class="nump">30,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">266,244<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">266,244<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">35,978,364<span></span>
</td>
<td class="num">(6,232,499)<span></span>
</td>
<td class="num">$ (147,233)<span></span>
</td>
<td class="nump">$ 30,380,049<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,774,598)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (5,774,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,009<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,751<span></span>
</td>
<td class="nump">$ 18,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,866<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 368,866<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">$ 36,357,239<span></span>
</td>
<td class="num">$ (12,007,097)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 24,993,077<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">7,750,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078007488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,774,598)<span></span>
</td>
<td class="num">$ (2,493,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,697,897<span></span>
</td>
<td class="nump">2,468,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">19,104<span></span>
</td>
<td class="nump">19,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">13,072<span></span>
</td>
<td class="nump">7,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
<td class="nump">9,547<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">368,866<span></span>
</td>
<td class="nump">266,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of property, plant and equipment</a></td>
<td class="nump">8,099<span></span>
</td>
<td class="num">(7,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash rent expense</a></td>
<td class="nump">95,724<span></span>
</td>
<td class="nump">28,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(426,783)<span></span>
</td>
<td class="nump">935,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,773,302)<span></span>
</td>
<td class="num">(2,948,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(87,830)<span></span>
</td>
<td class="num">(110,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">18,973<span></span>
</td>
<td class="num">(50,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">156,995<span></span>
</td>
<td class="nump">341,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(4,674,236)<span></span>
</td>
<td class="num">(1,543,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(1,892,513)<span></span>
</td>
<td class="num">(3,975,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">2,474<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(1,890,039)<span></span>
</td>
<td class="num">(3,964,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt principal repayments</a></td>
<td class="num">(1,185,774)<span></span>
</td>
<td class="num">(897,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Line of credit repayments</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(35,425)<span></span>
</td>
<td class="num">(19,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_PaymentsOfDebtDiscounts', window );">Payments of debt discounts</a></td>
<td class="num">(46,107)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">18,760<span></span>
</td>
<td class="nump">30,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,751,454<span></span>
</td>
<td class="nump">1,114,239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(4,812,821)<span></span>
</td>
<td class="num">(4,393,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">5,791,562<span></span>
</td>
<td class="nump">10,185,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">ENDING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">978,741<span></span>
</td>
<td class="nump">5,791,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpenseAbstract', window );"><strong>CASH PAID FOR:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">6,466<span></span>
</td>
<td class="nump">4,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense</a></td>
<td class="nump">444,954<span></span>
</td>
<td class="nump">338,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses', window );">Change in capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">50,086<span></span>
</td>
<td class="num">(44,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses', window );">Change in payments of debt discounts included in accounts payable and accrued expenses</a></td>
<td class="nump">16,566<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset and operating lease liability</a></td>
<td class="nump">$ 2,472,203<span></span>
</td>
<td class="nump">$ 1,184,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in capital expenditures included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of change in payments of debt discounts included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_PaymentsOfDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of debt discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_PaymentsOfDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071674064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract', window );"><strong>Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. BUSINESS
OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ImmuCell
Corporation (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was originally incorporated in Maine in
1982 and reincorporated in Delaware in 1987, in conjunction with an initial public offering of common stock. We are an animal health
company whose purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and
beef cattle. As disclosed in Note 17, &#8220;Segment Information&#8221;, one of our business segments is dedicated to Scours and the
other is focused on Mastitis. We manufacture and market the <b>First Defense<sup>&#174;</sup></b> product line, providing <b>Immediate
Immunity&#8482;</b> to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with
formulations targeting <i>E. coli</i>, coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>&#174;</sup></b>,
a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy
industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks
including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies,
the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable.
A combination of the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary
conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We
are experiencing price increases in key components, supportive services, transportation and other supplies that are causing our costs
of goods sold to increase. We have experienced some contamination events in our production process. We implemented a production slowdown
to remediate this problem, which led to the recognition of lower sales and gross margin during the first ten months of 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075683936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>2. SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(a) Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have prepared the accompanying audited financial statements reflecting all adjustments (which are of a normal recurring nature) that
are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set
by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure
we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes
are to the FASB <i>Accounting Standards Codification</i>&#8482; (Codification). We believe that the disclosures are adequate to ensure
that the information presented is not misleading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(b) Cash
and Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash
equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal
Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor. See Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(c) Trade
Accounts Receivable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Accounts
receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines
the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to
an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance
is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge
interest on past due accounts during the years ended December 31, 2023 or 2022 because the time past due was not significant. There was
no accrual for such interest charges as of December 31, 2023 or 2022. Accounts receivable are written off when deemed uncollectible.
No accounts receivable were written off during the years ended December 31, 2023 or 2022. Recoveries of accounts receivable previously
written off are recorded as income when received. No such recoveries were recorded during the years ended December 31, 2023 or 2022.
As of December 31, 2023 and 2022, we determined that no allowance for doubtful accounts was necessary. See Note 4.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(d) Inventory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or
net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of
completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess
or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it
is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one
vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note
5.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(e) Property,
Plant and Equipment, net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated
to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets.
The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> is being
depreciated over 39 years from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the
equipment for our Nisin DS facility when it was placed in service during the third quarter of 2018. Approximately 87% of these assets
are being depreciated over 10 years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production
facility at 175 Industrial Way (<b>Building 175A</b>) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy
was issued during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with
a new lease covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold
improvements as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property,
plant and equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs
are expensed when incurred. See Notes 2(h) and 7 for additional disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(f) Operating
Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We account
for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation
to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use
(ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present
value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease
incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the
total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the
term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term
for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not
recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement
as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements
include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance
and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify
an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the
present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(g) Intangible
Assets and Goodwill</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of
the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible
assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid
in excess of fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting.
We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level)
on an annual basis (as of December 31<sup>st</sup>) and whenever events or changes in circumstances indicate that the carrying value
of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value
of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the
value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance
relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends.
Although we believe intangible assets and goodwill are properly stated in the accompanying financial statements, changes in strategy
or market conditions could significantly impact these judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-34"><span style="-sec-ix-hidden: hidden-fact-35">No</span></span> goodwill
impairments were recorded during the years ended December 31, 2023 or 2022. See Notes 2(h) and 8 for additional disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(h) Valuation
of Long-Lived Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset
and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment
of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible
assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not
be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level
for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-36"><span style="-sec-ix-hidden: hidden-fact-37">No</span></span> impairment
was recognized during the years ended December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(i) Fair
Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
determining fair value measurements, we follow the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>.
Codification Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about
fair value measurements. The topic provides a consistent definition of fair value which focuses on an exit price, which is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The topic also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific
information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of
an asset or liability as of the measurement date. As of December 31, 2023 and 2022, the carrying amounts of cash and cash equivalents,
accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value
because of their short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying
balance sheets. Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              1 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing
                                            inputs are quoted prices available in active markets for identical assets or liabilities
                                            as of the measurement date.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              2 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing inputs are quoted prices for
            similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
            through corroboration with observable market data.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              3 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing inputs are unobservable for
            the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions
            market participants would use in pricing the asset or liability.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level
of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment
and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash
equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the
event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers
between levels of the fair value hierarchy. During the years ended December 31, 2023 and 2022, there were no transfers between levels.
As of December 31, 2023 and 2022, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and
money market accounts. There were <span style="-sec-ix-hidden: hidden-fact-38"><span style="-sec-ix-hidden: hidden-fact-39"><span style="-sec-ix-hidden: hidden-fact-40"><span style="-sec-ix-hidden: hidden-fact-41">no</span></span></span></span> assets or liabilities measured at fair value on a nonrecurring basis as of December 31, 2023 or
2022. The carrying values of our cash and money market accounts as of December 31, 2023 or 2022 approximated their fair market values.
Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of December 31, 2023
and 2022 differed from their fair market values. These values are reflected in the following tables:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">978,741</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">978,741</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,431,817</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,431,817</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,791,562</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,791,562</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,897,197</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,897,197</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(j) Concentration
of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Concentration
of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To
reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable
credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have
not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic
area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Trade
accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in
the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    C</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than 10%.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(k) Revenue
Recognition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
recognize revenue in accordance with Codification Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single
comprehensive model for companies to use in accounting for revenue arising from contracts with customers. The core principle is that
we recognize the amount of revenue to which we expect to be entitled for the transfer of promised goods or services to customers when
a customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and
cash flows arising from contracts with customers. We conduct our business with customers through valid purchase orders or sales orders
which are considered contracts and are not interdependent on one another. A performance obligation is a promise in a contract to transfer
a distinct product to the customer. The transaction price is the amount of consideration we expect to receive under the arrangement.
Revenue is measured based on consideration specified in a contract with a customer. The transaction price of a contract is allocated
to each distinct performance obligation and recognized when or as the customer receives the benefit of the performance obligation. Product
transaction prices on a purchase or sales order are discrete and stand-alone. We recognize revenue when we satisfy a performance obligation
in a contract by transferring control over a product to a customer when product ships to a customer. Amounts due are typically paid approximately
30 days from the time control is transferred. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment
cost in costs of goods sold. We do not bill for or collect sales tax because our sales are generally made to distributors and thus our
sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns. See Note 14 for additional
disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(l)
Expense Recognition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed
when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed
as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are
charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(m) Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
account for income taxes in accordance with Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax
liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects
of temporary differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning
strategies in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine
that it is more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over
a reasonably short period of time, a reduction of the valuation allowance would increase income in the period such determination was
made. Likewise, if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in
the future, an increase to the valuation allowance would be charged to income in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2020. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2023 or 2022. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(n) Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
account for stock-based compensation in accordance with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally
requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of
each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded
compensation expense pertaining to stock-based compensation of $368,866 and $266,244 during the years ended December 31, 2023 and 2022,
respectively. See Note 13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(o) Net
Loss Per Common Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
loss per common share has been computed in accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share
has been computed by dividing the net loss by the weighted average number of common shares outstanding during the period. All stock options
have been excluded from the denominator in the calculation of dilutive earnings per share when we are in a loss position because their
inclusion would be anti-dilutive. Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to 618,500 and 605,000 during the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to stockholders</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,774,598</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,493,805</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average common
    shares outstanding - Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,747,686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,745,122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive
    impact of share-based compensation awards</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding - Diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,747,686</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,745,122</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(p) Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ
from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become
known. Significant estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(q)
New Accounting Pronouncement Adopted</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments</i>, which was effective for us as of January 1, 2023, using the modified retrospective transition method. This ASU amends
the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including
trade receivables. The amendment requires entities to consider a broader range of information to estimate expected credit losses, which
may result in earlier recognition of losses. Historically, we have experienced a very low level of bad debt expense, and most of our
trade receivables are collected by the due date or within a few days of the due date. Because of this experience, the adoption of ASU
2016-13 did not have a material impact on our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(r) New
Accounting Pronouncements Not Yet Adopted</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which
is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses.
The amendments will require disclosure of significant segment expenses that are regularly provided to our chief operating decision-maker
and included within segment profit and loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim
periods beginning after December 15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented
in the financial statements. We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
December 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments
that further enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine
its impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071601600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. CASH
AND CASH EQUIVALENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents amounted to $978,741 and $5,791,562 as of December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071476608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Trade Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">TRADE ACCOUNTS RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>4. TRADE
ACCOUNTS RECEIVABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Trade
accounts receivable amounted to $2,185,383 and $1,758,600 as of December 31, 2023 and 2022, respectively. No allowance for bad debt or
product returns was recorded as of December 31, 2023 or 2022. We anticipate no future events or conditions that would impact our ability
to collect our accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our
collection rate is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable
balances included $42,507 and $46,426 due from a related party as of December 31, 2023 or 2022, respectively. See Note 18.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071687168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Inventory
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Raw
    materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,594,028</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,419,982</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Work-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,815,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,468,702</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Finished
    goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,619</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,855</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,811,841</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,038,539</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
inventory figures are net of a $527,133 and $589,204 write-off of scrapped inventory during the years ended December 31, 2023 and 2022,
respectively, that resulted principally from contamination events and other production process losses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071531728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>6. PREPAID
EXPENSES AND OTHER CURRENT ASSETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">454,152</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,877</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,733</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,178</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">493,885</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">406,055</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071542912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>7. PROPERTY,
PLANT AND EQUIPMENT, net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Property,
plant and equipment consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>

    Useful Lives<br/> (in years)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory
    and manufacturing equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-10</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,953,601</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,181,960</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Buildings
    and improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-39</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,784,565</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,050,167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Office
    furniture and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-10</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,036,374</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">900,306</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Construction
    in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">n/a</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,768,224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,668,046</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Land</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">n/a</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">516,867</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">516,867</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,059,631</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,317,346</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,483,948</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,875,620</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,575,683</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,441,726</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, construction in progress consisted principally of payments toward the <b>First Defense<sup>&#174;</sup></b>
production capacity expansion project and equipment needed to bring the formulation and aseptic filling for <b>Re-Tain<sup>&#174;</sup></b>
in-house. Property, plant and equipment disposals were $100,142 and $127,127 during the years ended December 31, 2023 and 2022, respectively.
Depreciation expense was $2,697,897 and $2,468,479 during the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078155136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>8. INTANGIBLE
ASSETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets of $191,040 were valued using the relief from royalty method and are being amortized to costs of goods sold over their useful
lives, which are estimated to be 10 years. Intangible amortization expense was $19,104 during both of the years ended December 31, 2023
and 2022. The net value of these intangibles was $38,208 and $57,312 as of December 31, 2023 and December 31, 2022, respectively. Intangible
asset amortization expense is estimated to be $19,104 per year through December 31, 2025.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets as of December 31, 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross&#160;Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Net
    Book<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Developed
    technology</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">147,280</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Customer
    relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,040</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">260</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-compete
    agreements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,640</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,512</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,128</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">191,040</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">152,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,208</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets as of December 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross&#160;Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Net
    Book<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Developed
    technology</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(128,870</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,230</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Customer
    relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(910</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-compete
    agreements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,640</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,948</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,692</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">191,040</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">133,728</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,312</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074454112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>9. ACCOUNTS
PAYABLE AND ACCRUED EXPENSES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Accounts
payable and accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable &#8211; trade</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">874,558</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">726,736</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable &#8211; capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,175</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,261</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    payroll</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">942,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">966,553</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,550</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,754</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">143,872</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax payable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,051</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,890</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,124,337</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,862</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606171069696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">BANK DEBT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>10. BANK
DEBT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loans
#1 and #2</b>: During the first quarter of 2020, we closed on a debt financing with Gorham Savings Bank (GSB) aggregating $8,600,000,
which was comprised of a $5,100,000 mortgage note (Loan #1) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term
and 25-year amortization schedule and a balloon principal payment of $3,145,888 due during the first quarter of 2030) and a $3,500,000
note (Loan #2) that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from
the 2020 debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working
capital. During the first quarter of 2022, we closed on an additional $2,000,000 in mortgage debt, which bears interest at the fixed
rate of 3.58% per annum. This was accomplished through an amendment of the original mortgage note (Loan #1) that increased the then outstanding
principal balance from $4,233,957 to $6,233,957 bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon
payment from $3,145,888 to $3,687,479 and extended the due date of the balloon payment from the first quarter of 2030 to the first quarter
of 2032.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Line
of Credit (LOC)</b>: Also during the first quarter of 2020, GSB extended a $1,000,000 LOC to us that is available, as needed, through
September 11, 2025. Interest on borrowings against the LOC is variable at the National Prime Rate per annum. There was no outstanding
balance under this LOC as of December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#3</b>: During the second quarter of 2020, we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount
of $500,000. The first 2.25 years of this loan were interest-free with no interest accrual or required principal payments. Beginning
during the fourth quarter of 2022, Loan #3 became subject to quarterly principal and interest payments at a fixed rate of 5% per annum
over the final five years of the loan, through the third quarter of 2027 if not repaid before then.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#4</b>: During the fourth quarter of 2020, we closed on a $1,500,000 note with GSB that bears interest at a fixed rate of 3.50% per annum
(with a 7-year term and amortization schedule). Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our
mortgage note (Loan #1), which reduced the outstanding balance to 80% of the most recent appraised value of the property securing the
debt, which allowed GSB to release the $1,400,000 that had been held in escrow. The remaining proceeds were available for general working
capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#5</b>: On June 30, 2021, we executed definitive agreements covering a second loan from the MTI in the aggregate principal amount of
$400,000, proceeds from which were received in July 2021. The first two years of this loan were interest-free with no interest accrual
or required principal payments. Principal and interest payments at a fixed rate of 5% per annum are due quarterly over the final 5.5
years of the loan, beginning during the third quarter of 2023 and continuing through the fourth quarter of 2028 if not repaid before
then.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#6: </b>During the third quarter of 2023, we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from GSB.
The Finance Authority of Maine (FAME) provided $1,000,000 of loan insurance to GSB. This loan is repayable under a 7-year amortization
schedule with a balloon payment of $1,285,072 due during the third quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Loan
#7:</b> Also during the third quarter of 2023, we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from
FAME. The loan is repayable under a 7-year amortization schedule with a balloon payment of $649,235 due during the third quarter of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Loans
#1, #2, #4, #6 and #7 are secured by liens on substantially all of our assets and are subject to certain restrictions and financial covenants.
Loan #7 is subordinated to Loans #1, #2, #4 and #6. Reflecting our poor financial performance during 2023, the debt covenant requirements
for the twelve-month periods ended December 31, 2023 and June 30, 2024 were waived pre-emptively by our bank. We are required to meet
a minimum debt service coverage (DSC) ratio of 1.35 for the twelve-month period ending September 30, 2024 and then annually after that
beginning with the year ending December 31, 2024. In connection with these credit facilities, we incurred aggregate debt issuance and
debt discount costs of $168,268 ($98,098 and $19,306 of which were incurred during the years ended December 31, 2023 and 2022, respectively).
The amortization of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other
expenses, net, and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured
and subordinated to our indebtedness to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply
with the terms of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment
in full. These loans may be prepaid without penalty at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Debt
proceeds received and principal repayments made (excluding our $1,000,000 line of credit) during the years ended December 31, 2023 and
2022 are reflected in the following table by period and by loan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended<br/>
 December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended <br/>
December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from<br/> Debt&#160;Issuance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Debt&#160;Principal<br/> Repayments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Proceeds&#160;from<br/> Debt Issuance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Debt&#160;Principal<br/> Repayments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">223,222</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,013</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #2</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">494,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">477,237</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">91,446</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">205,884</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">198,715</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan #5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,017</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan #6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan
    #7</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,696</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185,774</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">897,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Principal
payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of December 31, 2023 (excluding our $1,000,000
line of credit) are reflected in the following table by the year that payments are due:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ending December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">Loan #1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">230,879</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">239,876</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,604</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,649</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">266,537</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,598,360</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,841,905</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #2</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">512,103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">530,738</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">549,881</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">140,458</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,733,180</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">96,104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101,001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">83,143</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,394</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">213,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">220,994</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,965</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">903,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">69,856</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73,415</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,156</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,086</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">367,983</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">235,369</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">253,003</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,418,574</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,906,946</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loan #7</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,632</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,364</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">715,308</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">954,304</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Subtotal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,468,774</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,539,832</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,340,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">798,858</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">347,623</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,598,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,094,340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt issuance cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,076</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,976</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,579</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,513</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,347</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(71,911</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Debt discount cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,891</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,891</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,344</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,428,807</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,499,965</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,315,970</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">793,438</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">344,110</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,587,013</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,969,303</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074416688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Contingent Liabilities and Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>11. CONTINGENT
LIABILITIES AND COMMITMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
bylaws, as amended, in effect provide that the Company will indemnify its officers and directors against any liability arising from their
responsibilities as officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings
with each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make
under such provisions is theoretically unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability
insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the
indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>.
Accordingly, we have recorded no liability for such obligations as of December 31, 2023 or 2022. Since our incorporation, we have had
no occasion to make any indemnification payment to any of our officers or directors for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted
against us during the normal course of business. We are aware of no such claims against us as of the date of this filing. We believe
that we have reasonable levels of liability insurance to support our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties
from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases,
we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We
have not incurred material expenses in discharging any of these indemnification obligations and based on our analysis of the nature of
the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly,
we recorded no liabilities for such obligations as of December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to purchase certain key parts (syringes) and services (formulation, aseptic filling and final packaging) pertaining to <b>Re-Tain<sup>&#174;
</sup></b>Drug Product (DP), our Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from
contractors. The contract for formulation, aseptic filling and final packaging of DP is scheduled to terminate after the supply of product
for our initial controlled market launch. We initiated an investment in the necessary equipment to perform the DP formulation and aseptic
filling services in-house, but this investment has been paused at the present time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
enter into compensation agreements (which are publicly filed) with our three executive officers. Effective March 28, 2022, we entered
into an Amended and Restated Separation and Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with
Mr. Brigham (our President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company
and Mr. Brigham. Upon separation from the Company for any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham
to be paid, among other amounts, all earned and unused paid time off (which expense totaling $222,379 was accrued during the first quarter
of 2022 and $230,162 and $222,379 was included in accounts payable and accrued expenses on the accompanying balance sheets as of December
31, 2023 and 2022, respectively) and to receive up to an additional $300,000 in deferred compensation (which amount is being accrued
over the three-year period ending in January 2025). This deferred compensation payment vested as to $100,000 on January 1, 2023 and an
additional $100,000 on January 1, 2024. An additional $<span style="-sec-ix-hidden: hidden-fact-74">100,00</span> will vest on January 1, 2025, provided that Mr. Brigham is employed by
the Company as of January 2025. The vested amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following
his separation from the Company. As of December 31, 2023 and 2022, $200,000 and $100,000, respectively, was included in accounts payable
and accrued expenses on the accompanying balance sheets. In addition, upon termination of Mr. Brigham&#8217;s employment (a) by the Company
other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in
the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual base salary and a lump sum
payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month
period following termination, and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination
in accordance with the terms of the Deferred Compensation Agreement. Incentive Compensation Agreements with Mr. Brigham, Ms. Brockmann
(our Vice President of Sales and Marketing) and Ms. Williams (our Vice President of Manufacturing Operations) allow these executives
to earn incentive compensation if certain regulatory and financial objectives are met during the year to which the agreement relates,
as specified in their agreements. Amounts related to these incentive compensation agreements are accrued over the period they are earned
(when it is probable that the amounts will be earned) based on our best estimate of the amounts expected to be earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the commitments discussed above, we had committed $41,000 to increase our production capacity for the <b>First Defense<sup>&#174;
</sup></b>product line, $2,345,000 to the purchase of inventory, $7,000 related to the commercial manufacture of <b>Re-Tain<sup>&#174;
</sup></b>and $307,000 to other obligations as of December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074251824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>12. OPERATING
LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 12, 2019, we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession
date of November 15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland (<b>Building
175A</b>), which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space
to meet our needs in expanding our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line. The original lease
term was ten years with a right to renew for a second 10-year term and a right of first offer to purchase. At the time we entered into
this lease, we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that
reason, a 10-year period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter
of 2022, we committed to lease an additional 15,400 square feet of space at 175 Industrial Way (<b>Building 175B</b>), which is connected
to the original space, over a 20-year term. The ROU asset and lease liability for the committed space at <b>Building 175B</b> was recorded
as of April 1, 2023 after construction of the building shell was completed in accordance with the lease agreement. Monthly lease payments
commenced as of August 1, 2023. In connection with the lease commitment for space at <b>Building 175B, </b>the term of the original lease
for <b>Building 175A</b> was extended by approximately 13 years. On November 14, 2023, we amended this lease further to provide for certain
tenant improvements on the leased premises to be paid for by our landlord. These improvements will provide heat to an unfinished space,
provide additional warehouse space, and create a new primary shipping and receiving facility. In consideration for the landlord agreeing
to pay for the cost of those certain tenant improvements, we are obligated to make additional rent payments of $20,000 per month from
November 2023 through June 2024 and a one-time additional rent payment of $488,743 in July 2024. The total lease liability for both leases
over the amended terms (including inflationary adjustments) aggregates $4,739,077 as of November 14, 2023. Because of this modification
to the lease payments, the ROU asset and lease liability associated with the space at <b>Building 175B</b> were remeasured as of the
modification date. Our leases include variable non-lease components. Such payments primarily include common area maintenance charges.
As of December 31, 2023, the balance of the operating lease ROU asset was $4,571,149 and the operating lease liability was $4,721,385.
As of December 31, 2022, the balance of the operating lease ROU asset was $2,194,670 and the operating lease liability was $2,249,182.
The calculated amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for
the present value of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying
assets, and instead to account for them as a single lease component. Variable lease cost primarily represents variable payments such
as real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Lease Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease cost</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">348,929</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,176</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Variable
    lease cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,774</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,404</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    lease cost</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">385,703</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,580</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for operating lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,595</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,302</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining
    lease term (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    discount rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.54</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Future
lease payments required under non-cancelable operating leases in effect as of December 31, 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>During the years ending
    December 31,</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Amount</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">946,003</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">342,880</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">349,744</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">356,732</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,949,488</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease payments (undiscounted cash flows)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,308,717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: imputed interest
    (discount effect of cash flows)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,587,332</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,721,385</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078150624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>13. STOCKHOLDERS&#8217;
EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Common Stock
Issuances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February 2016 to April 2021, we sold the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds
of $26,714,403 at the weighted average price of $5.87 per share. These funds have been essential to funding our business growth plans.
The details of each transaction are discussed below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1)
During February of 2016, we sold 1,123,810 shares of common stock at a price to the public of $5.25 per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $5,900,003 and resulting in net
proceeds to the Company of $5,313,224 (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2)
During October of 2016, we sold, in a private placement, 659,880 shares of common stock to nineteen institutional and accredited investors
at $5.25 per share, raising gross proceeds of $3,464,370 and resulting in net proceeds to the Company of $3,160,923 (after deducting
placement agent fees and other expenses incurred in connection with the equity financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">3)
During July of 2017, we sold 200,000 shares of our common stock at a price of $5.25 per share in a public, registered sale to two related
investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $1,050,000 and resulting in net
proceeds of $1,034,164 (after deducting expenses incurred in connection with the equity financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">4)
During December of 2017, we sold 417,807 shares of common stock at a price to the public of $7.30 per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $3,049,991 and resulting in net
proceeds to the Company of $2,734,173 (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">5)
During March of 2019, we sold 1,636,364 shares of common stock at a price to the public of $5.50 per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $9,000,002 and resulting in net
proceeds to the Company of $8,303,436 (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">6)
During April of 2021, we sold 515,156 shares of our common stock at a price of $8.25 per share in a public, registered sale to seven
investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $4,250,038 and resulting in net
proceeds of $4,233,026 (after deducting expenses incurred in connection with the equity financing).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Stock Option
Plans</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions
of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of
the Company&#8217;s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock
were reserved for issuance under the 2010 Plan and subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements
are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted
under the 2010 Plan expire no later than 10 years from the date of grant. The 2010 Plan expired in June 2020, after which date no further
options can be granted under the 2010 Plan. However, options outstanding under the 2010 Plan at that time can be exercised in accordance
with their terms. There were 188,500 and 202,500 options outstanding under the 2010 Plan as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the &#8220;2017 Plan&#8221;) pursuant to the provisions
of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of
the Company&#8217;s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock
were reserved for issuance under the 2017 Plan. An amendment to the 2017 Plan increasing the number of shares reserved for issuance under
the 2017 Plan from 300,000 shares to 650,000 shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June
2022. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case
basis. All options granted under the 2017 Plan expire no later than 10 years from the date of grant. The 2017 Plan expires in March 2027,
after which date no further options can be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time
can be exercised in accordance with their terms. As of December 31, 2023 and 2022, there were 430,000 and 402,500 options outstanding
under the 2017 Plan, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Activity
under the stock option plans described above was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2010
    Plan</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2017
    Plan</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">218,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.94</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">468,425</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">210,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercises</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(661,310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(94,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercises</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.69</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.82</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,071,121</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.43</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(377,712</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected
    to vest as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.82</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,071,121</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Reserved for future grants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Terminations and forfeitures are recognized when they occur.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table displays additional information about the stock option plans described above:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average <br/> Fair Value at Grant Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-vested
    stock options as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">307,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.80</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.71</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-vested stock options
    as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">337,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options granted during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options that vested during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options that were terminated or forfeited during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2023, 4,000 stock options were exercised by one employee with $18,760 in cash. During the year ended December
31, 2022, one former employee and two employees exercised stock options covering 5,000 shares with $30,670 in cash. The aggregate intrinsic
value of options exercised during the years ended December 31, 2023 and 2022 was $1,040 and $10,525, respectively. The weighted average
remaining life of the options outstanding under the 2010 Plan and the 2017 Plan as of December 31, 2023 was approximately 5 years and
8 months. The weighted average remaining life of the options exercisable under these plans as of December 31, 2023 was approximately
3 years and 6 months. The exercise prices of the options outstanding as of December 31, 2023 ranged from $4.00 to $10.04 per share. The
122,000 stock options granted during the year ended December 31, 2023 had exercise prices between $4.61 and $5.22 per share. The 210,500
stock options granted during the year ended December 31, 2022 had exercise prices between $6.52 and $9.39 per share. The weighted-average
grant date fair values of options granted during the year ended December 31, 2023 and 2022 were $2.80 and $4.03 per share, respectively.
As of December 31, 2023, total unrecognized stock-based compensation related to non-vested stock options aggregated $619,845, which will
be recognized over a weighted average remaining period of approximately 1 year and 8 months. The fair value of each stock option grant
has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the
following weighted-average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.59%</span></td><td style="white-space: nowrap; width: 1%; text-align: center"></td><td style="white-space: nowrap; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.04%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td style="white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">54%</span></td><td style="white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">53%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 years</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The dividend yield and expected volatility are derived from averages of our historical data.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Common Stock
Rights Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
September 1995, our Board of Directors adopted a Common Stock Rights Plan (the &#8220;Rights Plan&#8221;) and declared a dividend of
one common share purchase right (a &#8220;Right&#8221;) for each of the then outstanding shares of the common stock of the Company. Each
Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per
share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and Equiniti
Trust Company, LLC, as Rights Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public
announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined
in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement
of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding
common stock (the earlier of such dates being called the Distribution Date).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Upon
the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount
to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the
date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with
any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company&#8217;s
common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company&#8217;s assets or
earning power were sold, each Right would entitle its holder to purchase, at the Rights&#8217; then-current purchase price, a number
of shares of the acquiring company&#8217;s common stock having a market value at that time equal to twice the Right&#8217;s exercise
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the
outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group
which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At
any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board
of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of
$0.005 per Right, subject to adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the third quarter of 2011, our Board of Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold
for determining &#8220;Acquiring Person&#8221; status to 20%. During the second quarter of 2015, our Board of Directors also voted to
authorize an amendment to remove a provision that prevented a new group of directors elected following the emergence of an Acquiring
Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan
with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts. Each time that
we made such amendments we entered into amendments to the Rights Agreement with the Rights Agent reflecting such extensions, threshold
increases or provision changes. No other changes have been made to the terms of the Rights or the Rights Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
various times over the years, our Board of Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments
to the Rights Plan to extend the expiration date of the Rights Plan. Our Board of Directors decided to seek an advisory vote by stockholders
at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of
the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board
of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory
vote by stockholders at the Annual Meeting of Stockholders held in June 2023, as to whether to extend the Rights Plan by another year
to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained.
On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that
there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually
cast on these proposals in deciding whether to extend the expiration date of such plan by one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Authorized
Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">At
the June 14, 2018 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation
to increase the number of shares of common stock authorized for issuance from 8,000,000 to 11,000,000. At the June 10, 2020 Annual Meeting
of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares
of common stock authorized for issuance from 11,000,000 to 15,000,000.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074438992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>14.
REVENUE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
primarily offer the <b>First Defense<sup>&#174;</sup></b> product line to dairy and beef producers to prevent scours in newborn calves.
Generally, our products are promoted to veterinarians as well as dairy and beef producers by our sales team and then sold through distributors.
Our primary market is North America. We do sell into select international regions and may expand this international reach in the future.
There were no material changes between the allocation and timing of revenue recognition during the years ended December 31, 2023 or 2022.
We do not have any contract assets for which we have satisfied the performance obligations, but do not yet have the right to bill for,
or contract liabilities such as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur
no material costs to obtain contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents our product sales disaggregated by geographic area:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">United
    States</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,949,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">91</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,020,797</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,522,287</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,547,165</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,471,669</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,567,962</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents our product sales disaggregated by major product category:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>First
    Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">product line</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,293,933</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,411,949</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    animal health</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">177,736</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,013</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,471,669</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,567,962</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075727568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">OTHER EXPENSES, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>15. OTHER
EXPENSES, NET</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
(income) expenses net, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">475,598</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">348,536</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    (gain) on disposal of property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,099</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(96,570</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(153,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
    recovery<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365,127</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income-other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(107</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(912</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    expenses, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,893</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187,190</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense includes amortization of debt issuance and debt discount costs of $22,619 and $7,658 during the years ended December 31, 2023 or 2022, respectively.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074416688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>16.
INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
income tax expense aggregated $4,627 and $7,672 (amounting to less than 1% of our loss before income taxes) during the years ended December
31, 2023 and 2022, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $17,759,519 of which $16,047,612
do not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards
of $4,681,644 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit
carryforwards of $726,474 that expire in 2027 through 2042 (if not utilized before then) and state tax credit carryforwards of $775,473
that expire in 2024 through 2042 (if not utilized before then).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach,
deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities
and carryforwards to the extent they are realizable. During the second quarter of 2018, we assessed our historical and near-term future
profitability and recorded $563,252 in non-cash income tax expense to create a full valuation allowance against our net deferred tax
assets (which consist largely of net operating loss carryforwards and federal and state credits) based on applicable accounting standards
and practices. At that time, we had incurred a net loss for six consecutive quarters, had not been profitable on a year-to-date basis
since the nine-month period ended September 30, 2017 and projected additional net losses for some period going forward before returning
to profitability. Should future profitability be realized at an adequate level, we would be able to release this valuation allowance
(resulting in a non-cash income tax benefit) and realize these deferred tax assets before they expire. We will continue to assess the
need for the valuation allowance at each quarter and, in the event that actual results differ from these estimates, or we adjust these
estimates in future periods, we may need to adjust our valuation allowance. Currently, we adjust the valuation allowance at the end of
each quarter to reduce the value of our deferred tax assets to zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue
Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of
net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
file income tax returns in the U.S. federal jurisdiction and several state jurisdictions. We currently have no tax examinations in progress.
We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits
for any of the periods in the accompanying audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
income tax provision consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 11.5pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Current
    subtotal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,179,474</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(576,780</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(145,802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(88,533</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    subtotal, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,325,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(665,313</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,276</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">665,313</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    subtotal, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
actual income tax expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before
income taxes during the years ended December 31, 2023 and 2022 respectively, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Computed
    expected income tax expense rate</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">1,211,694</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.00)</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">522,088</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    income taxes, net of federal expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(117,149</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(47,643</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,214</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tax
    credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53,241</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(131,361</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">665,313</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26.76</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,221</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22.97</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,799</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.27</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense/rate</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.31</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
significant components of our deferred tax assets, net, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,121,940</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">2,530,472</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    general business tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">726,474</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">673,233</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,729,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,258,395</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    tax credits and net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">886,428</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">817,617</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#167;174
    R &amp; D expenditures</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">592,915</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">341,683</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,722</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,124</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,587</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">UNICAP</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Incentive
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,554</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,034,030</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,708,754</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606081157584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>17. SEGMENT
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business operations (being the development, acquisition, manufacture and sale of products that improve the health and productivity of
dairy and beef cattle) are described in Note 1. Pursuant to Codification Topic 280, <i>Segment Reporting</i>, we operate in the following
two reportable business segments: i) Scours and ii) Mastitis. The Scours segment consists of the <b>First Defense<sup>&#174;</sup></b>
product line. The core technology underlying the Scours segment is derived around polyclonal antibodies. The Mastitis segment includes
our products, <b>CMT </b>and <b>Re-Tain<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174; </sup></b>is projected to be the driver of this segment
when approved for sale. The core technology underlying the Mastitis segment is derived around a bacteriocin called Nisin. The category
we define as &#8220;Other&#8221; includes unallocated administrative and overhead expenses and other products. The significant accounting
policies of these segments are described in Note 2. Product sales are the primary factor we use in determining our reportable segments.
The governing regulatory authority (USDA for <b>First Defense<sup>&#174;</sup></b> or FDA for <b>Re-Tain<sup>&#174;</sup></b>) is also
a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating income
(loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated to each
segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating segment
is defined as the component of our business for which financial information is available and evaluated regularly by our chief operating
decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our President
and CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,293,933</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">177,736</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,471,669</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,453,514</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,871</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,602,385</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,840,419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,869,284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,242,329</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,394,852</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,447,137</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">641,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,088,215</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,295</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,295</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,458,240</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,883,407</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,275,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,617,362</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING INCOME (LOSS)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,382,179</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">4,854,542</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">2,275,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">5,748,078</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,411,949</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">154,558</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,455</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,567,962</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,754,189</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,347</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,647</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,919,183</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,657,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,648,779</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,346</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,317,921</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">109,605</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,493,872</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,871,926</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,318,107</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,190,033</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,263,817</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,263,817</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,938,272</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,636,028</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,373,422</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,947,722</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING INCOME (LOSS)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,719,488</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,617,817</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,400,614</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">2,298,943</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets as of December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,735,413</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,827,839</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,244,850</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,808,102</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets as
    of December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,539,523</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,315,492</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,005,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,860,649</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization expense during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,739,620</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization expense during the year ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169,011</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,263,318</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">62,912</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,495,241</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    Expenditures during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,096,819</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,694</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,892,513</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    Expenditures during the year ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,513,336</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">414,486</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,975,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074435808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>18. RELATED
PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense<sup>&#174;</sup> </b>product line and <b>CMT</b>). His affiliated company purchased $231,405 and $587,677 of products from us
during the years ended December 2023 and 2022, respectively, all on terms consistent with those offered to other distributors of similar
status. Our accounts receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $42,507
and $46,426 as of December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074256368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>19. EMPLOYEE
BENEFITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate.
Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. We currently match 100% of the first 3%
of each employee&#8217;s salary that is contributed to the Plan and 50% of the next 2% of each employee&#8217;s salary that is contributed
to the Plan. Under this matching plan, we paid $178,150 and $159,058 into the Plan for the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074258608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>20. SUBSEQUENT
EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have evaluated subsequent events through the time of filing on the date we have issued this Annual Report on Form 10-K. As of the time
of filing, there were no material, reportable subsequent events.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071611584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (5,774,598)<span></span>
</td>
<td class="num">$ (2,493,805)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075776640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078672736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(a) Basis
of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have prepared the accompanying audited financial statements reflecting all adjustments (which are of a normal recurring nature) that
are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set
by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure
we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes
are to the FASB <i>Accounting Standards Codification</i>&#8482; (Codification). We believe that the disclosures are adequate to ensure
that the information presented is not misleading.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(b) Cash
and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash
equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal
Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor. See Note 3.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(c) Trade
Accounts Receivable</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Accounts
receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines
the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to
an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance
is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge
interest on past due accounts during the years ended December 31, 2023 or 2022 because the time past due was not significant. There was
no accrual for such interest charges as of December 31, 2023 or 2022. Accounts receivable are written off when deemed uncollectible.
No accounts receivable were written off during the years ended December 31, 2023 or 2022. Recoveries of accounts receivable previously
written off are recorded as income when received. No such recoveries were recorded during the years ended December 31, 2023 or 2022.
As of December 31, 2023 and 2022, we determined that no allowance for doubtful accounts was necessary. See Note 4.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(d) Inventory</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or
net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of
completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess
or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it
is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one
vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note
5.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(e) Property,
Plant and Equipment, net</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated
to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets.
The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> is being
depreciated over 39 years from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the
equipment for our Nisin DS facility when it was placed in service during the third quarter of 2018. Approximately 87% of these assets
are being depreciated over 10 years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production
facility at 175 Industrial Way (<b>Building 175A</b>) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy
was issued during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with
a new lease covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold
improvements as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property,
plant and equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs
are expensed when incurred. See Notes 2(h) and 7 for additional disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(f) Operating
Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We account
for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation
to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use
(ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present
value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease
incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the
total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the
term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term
for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not
recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement
as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements
include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance
and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify
an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the
present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional disclosures.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(g) Intangible
Assets and Goodwill</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of
the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible
assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid
in excess of fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting.
We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level)
on an annual basis (as of December 31<sup>st</sup>) and whenever events or changes in circumstances indicate that the carrying value
of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value
of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the
value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance
relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends.
Although we believe intangible assets and goodwill are properly stated in the accompanying financial statements, changes in strategy
or market conditions could significantly impact these judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-34"><span style="-sec-ix-hidden: hidden-fact-35">No</span></span> goodwill
impairments were recorded during the years ended December 31, 2023 or 2022. See Notes 2(h) and 8 for additional disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ValuationOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(h) Valuation
of Long-Lived Assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset
and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment
of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible
assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not
be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level
for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-36"><span style="-sec-ix-hidden: hidden-fact-37">No</span></span> impairment
was recognized during the years ended December 31, 2023 or 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(i) Fair
Value Measurements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
determining fair value measurements, we follow the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>.
Codification Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about
fair value measurements. The topic provides a consistent definition of fair value which focuses on an exit price, which is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The topic also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific
information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of
an asset or liability as of the measurement date. As of December 31, 2023 and 2022, the carrying amounts of cash and cash equivalents,
accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value
because of their short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying
balance sheets. Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              1 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing
                                            inputs are quoted prices available in active markets for identical assets or liabilities
                                            as of the measurement date.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              2 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing inputs are quoted prices for
            similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
            through corroboration with observable market data.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.65in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                              3 &#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pricing inputs are unobservable for
            the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions
            market participants would use in pricing the asset or liability.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level
of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment
and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash
equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the
event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers
between levels of the fair value hierarchy. During the years ended December 31, 2023 and 2022, there were no transfers between levels.
As of December 31, 2023 and 2022, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and
money market accounts. There were <span style="-sec-ix-hidden: hidden-fact-38"><span style="-sec-ix-hidden: hidden-fact-39"><span style="-sec-ix-hidden: hidden-fact-40"><span style="-sec-ix-hidden: hidden-fact-41">no</span></span></span></span> assets or liabilities measured at fair value on a nonrecurring basis as of December 31, 2023 or
2022. The carrying values of our cash and money market accounts as of December 31, 2023 or 2022 approximated their fair market values.
Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of December 31, 2023
and 2022 differed from their fair market values. These values are reflected in the following tables:</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">978,741</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">978,741</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,431,817</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,431,817</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,791,562</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,791,562</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,897,197</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,897,197</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(j) Concentration
of Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Concentration
of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To
reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable
credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have
not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic
area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Trade
accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in
the following table:</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    C</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than 10%.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(k) Revenue
Recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
recognize revenue in accordance with Codification Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single
comprehensive model for companies to use in accounting for revenue arising from contracts with customers. The core principle is that
we recognize the amount of revenue to which we expect to be entitled for the transfer of promised goods or services to customers when
a customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and
cash flows arising from contracts with customers. We conduct our business with customers through valid purchase orders or sales orders
which are considered contracts and are not interdependent on one another. A performance obligation is a promise in a contract to transfer
a distinct product to the customer. The transaction price is the amount of consideration we expect to receive under the arrangement.
Revenue is measured based on consideration specified in a contract with a customer. The transaction price of a contract is allocated
to each distinct performance obligation and recognized when or as the customer receives the benefit of the performance obligation. Product
transaction prices on a purchase or sales order are discrete and stand-alone. We recognize revenue when we satisfy a performance obligation
in a contract by transferring control over a product to a customer when product ships to a customer. Amounts due are typically paid approximately
30 days from the time control is transferred. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment
cost in costs of goods sold. We do not bill for or collect sales tax because our sales are generally made to distributors and thus our
sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns. See Note 14 for additional
disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ExpenseRecognitionPolicyTextBlock', window );">Expense Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(l)
Expense Recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed
when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed
as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are
charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(m) Income
Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
account for income taxes in accordance with Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax
liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects
of temporary differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning
strategies in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine
that it is more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over
a reasonably short period of time, a reduction of the valuation allowance would increase income in the period such determination was
made. Likewise, if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in
the future, an increase to the valuation allowance would be charged to income in the period such determination was made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2020. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2023 or 2022. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(n) Stock-Based
Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
account for stock-based compensation in accordance with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally
requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of
each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded
compensation expense pertaining to stock-based compensation of $368,866 and $266,244 during the years ended December 31, 2023 and 2022,
respectively. See Note 13.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(o) Net
Loss Per Common Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
loss per common share has been computed in accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share
has been computed by dividing the net loss by the weighted average number of common shares outstanding during the period. All stock options
have been excluded from the denominator in the calculation of dilutive earnings per share when we are in a loss position because their
inclusion would be anti-dilutive. Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to 618,500 and 605,000 during the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to stockholders</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,774,598</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,493,805</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average common
    shares outstanding - Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,747,686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,745,122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive
    impact of share-based compensation awards</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding - Diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,747,686</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,745,122</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(p) Use
of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ
from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become
known. Significant estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncement Adopted</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(q)
New Accounting Pronouncement Adopted</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments</i>, which was effective for us as of January 1, 2023, using the modified retrospective transition method. This ASU amends
the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including
trade receivables. The amendment requires entities to consider a broader range of information to estimate expected credit losses, which
may result in earlier recognition of losses. Historically, we have experienced a very low level of bad debt expense, and most of our
trade receivables are collected by the due date or within a few days of the due date. Because of this experience, the adoption of ASU
2016-13 did not have a material impact on our financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(r) New
Accounting Pronouncements Not Yet Adopted</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which
is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses.
The amendments will require disclosure of significant segment expenses that are regularly provided to our chief operating decision-maker
and included within segment profit and loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim
periods beginning after December 15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented
in the financial statements. We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
December 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments
that further enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine
its impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ExpenseRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of accounting policy for expense recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ExpenseRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Include, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ValuationOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for valuation of long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ValuationOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606072879584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SummaryofSignificantAccountingPoliciesTablesLineItems', window );"><strong>Summary of Significant Accounting Policies (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</a></td>
<td class="text">These values are reflected in the following tables:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">978,741</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">978,741</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,431,817</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,431,817</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and money market accounts</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,791,562</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,791,562</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Bank
    debt</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,897,197</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,897,197</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income (Loss) Per Common Share</a></td>
<td class="text">Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to 618,500 and 605,000 during the years ended December 31, 2023 and 2022, respectively.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to stockholders</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,774,598</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,493,805</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average common
    shares outstanding - Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,747,686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,745,122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive
    impact of share-based compensation awards</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average common shares outstanding - Diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,747,686</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,745,122</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SummaryofSignificantAccountingPoliciesTablesLineItems', window );"><strong>Summary of Significant Accounting Policies (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Trade Accounts Receivable Due from Significant Customers</a></td>
<td class="text">Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SummaryofSignificantAccountingPoliciesTablesLineItems', window );"><strong>Summary of Significant Accounting Policies (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Trade Accounts Receivable Due from Significant Customers</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Trade
accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in
the following table:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    A</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    B</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Company
    C</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than 10%.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_SummaryofSignificantAccountingPoliciesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_SummaryofSignificantAccountingPoliciesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075330944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Inventory
consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Raw
    materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,594,028</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,419,982</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Work-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,815,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,468,702</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Finished
    goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,619</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,855</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,811,841</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,038,539</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074251824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">454,152</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,877</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,733</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,178</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">493,885</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">406,055</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075328064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Property,
plant and equipment consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>

    Useful Lives<br/> (in years)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Laboratory
    and manufacturing equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-10</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,953,601</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,181,960</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Buildings
    and improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-39</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,784,565</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,050,167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Office
    furniture and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-10</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,036,374</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">900,306</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Construction
    in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">n/a</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,768,224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,668,046</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Land</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">n/a</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">516,867</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">516,867</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,059,631</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,317,346</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,483,948</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,875,620</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,575,683</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,441,726</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075182112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets as of December 31, 2023 consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross&#160;Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Net
    Book<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Developed
    technology</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">147,280</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Customer
    relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,040</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">260</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-compete
    agreements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,640</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,512</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,128</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">191,040</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">152,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,208</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span style="font-family: Times New Roman, Times, Serif">Intangible
assets as of December 31, 2022 consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross&#160;Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Net
    Book<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Developed
    technology</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">184,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(128,870</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,230</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Customer
    relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(910</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-compete
    agreements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,640</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,948</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,692</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">191,040</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">133,728</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,312</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075729664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Accounts
payable and accrued expenses consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable &#8211; trade</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">874,558</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">726,736</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable &#8211; capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,175</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,261</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    payroll</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">942,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">966,553</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,550</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,754</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">143,872</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax payable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,051</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,890</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,124,337</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,862</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071569408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt Proceeds Received and Principal Repayments</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Debt
proceeds received and principal repayments made (excluding our $1,000,000 line of credit) during the years ended December 31, 2023 and
2022 are reflected in the following table by period and by loan:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended<br/>
 December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended <br/>
December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from<br/> Debt&#160;Issuance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Debt&#160;Principal<br/> Repayments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Proceeds&#160;from<br/> Debt Issuance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Debt&#160;Principal<br/> Repayments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">223,222</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,013</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #2</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">494,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">477,237</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">91,446</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loan #4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">205,884</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">198,715</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan #5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,017</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan #6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Loan
    #7</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,696</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185,774</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">897,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal Payments Bank Loans Outstanding</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Principal
payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of December 31, 2023 (excluding our $1,000,000
line of credit) are reflected in the following table by the year that payments are due:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ending December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">Loan #1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">230,879</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">239,876</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,604</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,649</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">266,537</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,598,360</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,841,905</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #2</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">512,103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">530,738</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">549,881</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">140,458</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,733,180</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">96,104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101,001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">106,146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">83,143</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,394</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">213,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">220,994</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,965</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">903,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">69,856</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73,415</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,156</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,086</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">367,983</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Loan #6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">235,369</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">253,003</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,418,574</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,906,946</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loan #7</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,632</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">124,364</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">715,308</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">954,304</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Subtotal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,468,774</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,539,832</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,340,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">798,858</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">347,623</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,598,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,094,340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Debt issuance cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,076</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,976</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,579</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,513</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,347</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(71,911</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Debt discount cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,891</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,891</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,344</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,428,807</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,499,965</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,315,970</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">793,438</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">344,110</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,587,013</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,969,303</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078030944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs and Other Lease Information</a></td>
<td class="text">The following tables describe our lease costs and other lease information:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Lease Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease cost</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">348,929</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">149,176</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Variable
    lease cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,774</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,404</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    lease cost</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">385,703</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,580</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for operating lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,595</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,302</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining
    lease term (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    discount rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.54</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Future
lease payments required under non-cancelable operating leases in effect as of December 31, 2023 were as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>During the years ending
    December 31,</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Amount</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">946,003</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">342,880</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">349,744</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">356,732</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,870</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,949,488</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease payments (undiscounted cash flows)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,308,717</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: imputed interest
    (discount effect of cash flows)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,587,332</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,721,385</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071490288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity Under the Stock Option Plans</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Activity
under the stock option plans described above was as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2010
    Plan</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2017
    Plan</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">218,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">224,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.94</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">468,425</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">210,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.34</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercises</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">402,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(661,310</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(94,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercises</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.69</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.82</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,071,121</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.43</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(377,712</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected
    to vest as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">188,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.82</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,071,121</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Reserved for future grants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">202,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Terminations and forfeitures are recognized when they occur.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Additional Information About the Stock Option Plans</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table displays additional information about the stock option plans described above:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average <br/> Fair Value at Grant Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-vested
    stock options as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">307,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.80</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.71</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Non-vested stock options
    as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">337,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options granted during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options that vested during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options that were terminated or forfeited during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions</a></td>
<td class="text">The fair value of each stock option grant
has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the
following weighted-average assumptions:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.59%</span></td><td style="white-space: nowrap; width: 1%; text-align: center"></td><td style="white-space: nowrap; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.04%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td style="white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">54%</span></td><td style="white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">53%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 years</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The dividend yield and expected volatility are derived from averages of our historical data.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071571568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Product Sales Disaggregated by Geographic Area</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table presents our product sales disaggregated by geographic area:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">United
    States</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,949,382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">91</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,020,797</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,522,287</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,547,165</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,471,669</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,567,962</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Sales Disaggregated by Major Product Category</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table presents our product sales disaggregated by major product category:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>First
    Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">product line</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,293,933</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,411,949</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    animal health</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">177,736</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,013</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,471,669</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,567,962</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074178352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other (Income) Expenses Net</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Other
(income) expenses net, consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">475,598</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">348,536</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    (gain) on disposal of property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,099</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(96,570</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(153,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
    recovery<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365,127</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income-other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(107</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(912</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other
    expenses, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,893</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187,190</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense includes amortization of debt issuance and debt discount costs of $22,619 and $7,658 during the years ended December 31, 2023 or 2022, respectively.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071677056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense Differs from the Expected Tax Computed</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
income tax provision consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended<br/>
 December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 11.5pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Current
    subtotal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,179,474</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(576,780</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(145,802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(88,533</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    subtotal, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,325,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(665,313</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,276</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">665,313</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    subtotal, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Expense Differs from the Expected Tax Computed</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
actual income tax expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before
income taxes during the years ended December 31, 2023 and 2022 respectively, as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Computed
    expected income tax expense rate</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">1,211,694</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.00)</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">522,088</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    income taxes, net of federal expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(117,149</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(47,643</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">56,214</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tax
    credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53,241</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(131,361</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,325,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">665,313</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26.76</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,221</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22.97</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,799</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.27</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax expense/rate</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,627</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,672</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.31</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Our Deferred Tax Assets Net</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
significant components of our deferred tax assets, net, consisted of the following:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,121,940</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">2,530,472</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    general business tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">726,474</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">673,233</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal
    net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,729,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,258,395</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State
    tax credits and net operating loss carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">886,428</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">817,617</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#167;174
    R &amp; D expenditures</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">592,915</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">341,683</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,722</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,124</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,587</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">UNICAP</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Incentive
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">76,554</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,034,030</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,708,754</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071586528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text">we operate in the following
two reportable business segments:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,293,933</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">177,736</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,471,669</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,453,514</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,871</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,602,385</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,840,419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,869,284</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,242,329</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,394,852</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,447,137</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">641,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,088,215</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,295</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,295</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,458,240</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,883,407</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,275,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,617,362</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING INCOME (LOSS)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,382,179</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">4,854,542</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">2,275,715</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">5,748,078</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">During
    the Year Ended December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Product
    sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,411,949</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">154,558</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,455</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,567,962</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Costs
    of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,754,189</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136,347</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,647</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,919,183</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,657,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27,192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,648,779</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Product
    development expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,346</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,317,921</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">109,605</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,493,872</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Sales
    and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,871,926</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,318,107</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,190,033</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif">Administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,263,817</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,263,817</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,938,272</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,636,028</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,373,422</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,947,722</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">NET
    OPERATING INCOME (LOSS)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,719,488</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,617,817</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,400,614</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">2,298,943</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Scours</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Mastitis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets as of December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,735,413</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,827,839</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,244,850</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,808,102</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Assets as
    of December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,539,523</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,315,492</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,005,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,860,649</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization expense during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,600</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,032</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,739,620</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization expense during the year ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169,011</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,263,318</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">62,912</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,495,241</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    Expenditures during the year ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,096,819</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">795,694</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,892,513</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    Expenditures during the year ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,513,336</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">414,486</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,975,274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074216080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract', window );"><strong>Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075812704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation limits</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Asset depreciated percentage</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">impairment of recognized</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_AccountsReceivablePercentage', window );">Receivable percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 368,866<span></span>
</td>
<td class="nump">$ 266,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive amounted (in Shares)</a></td>
<td class="nump">618,500<span></span>
</td>
<td class="nump">605,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Concentration customer risk percentage</a></td>
<td class="text">10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Concentration customer risk percentage</a></td>
<td class="text">10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember', window );">Nisin Drug Substance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_AccountsReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_AccountsReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078607056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="nump">$ 978,741<span></span>
</td>
<td class="nump">$ 5,791,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="nump">10,431,817<span></span>
</td>
<td class="nump">8,897,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="nump">978,741<span></span>
</td>
<td class="nump">5,791,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="nump">10,431,817<span></span>
</td>
<td class="nump">8,897,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076804128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers - Revenue Benchmark [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Company A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Company B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076242576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers - Accounts Receivable [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Company A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems', window );"><strong>Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade account receivable percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Company B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems', window );"><strong>Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade account receivable percentage</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Company C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems', window );"><strong>Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade account receivable percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than 10%.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076245488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Schedule of Net Income Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders (in Dollars)</a></td>
<td class="num">$ (5,774,598)<span></span>
</td>
<td class="num">$ (2,493,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - Basic</a></td>
<td class="nump">7,747,686<span></span>
</td>
<td class="nump">7,745,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive impact of share-based compensation awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - Diluted</a></td>
<td class="nump">7,747,686<span></span>
</td>
<td class="nump">7,745,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074456112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at carrying value</a></td>
<td class="nump">$ 978,741<span></span>
</td>
<td class="nump">$ 5,791,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074176688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Trade Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">$ 2,185,383<span></span>
</td>
<td class="nump">$ 1,758,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Trade Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Trade accounts receivable related party</a></td>
<td class="nump">$ 42,507<span></span>
</td>
<td class="nump">$ 46,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074340160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write off</a></td>
<td class="nump">$ 527,133<span></span>
</td>
<td class="nump">$ 589,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075754704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of Inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,594,028<span></span>
</td>
<td class="nump">$ 2,419,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">5,815,194<span></span>
</td>
<td class="nump">3,468,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">402,619<span></span>
</td>
<td class="nump">149,855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 7,811,841<span></span>
</td>
<td class="nump">$ 6,038,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075809280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 454,152<span></span>
</td>
<td class="nump">$ 363,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">39,733<span></span>
</td>
<td class="nump">42,178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 493,885<span></span>
</td>
<td class="nump">$ 406,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071682896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposals</a></td>
<td class="nump">$ 100,142<span></span>
</td>
<td class="nump">$ 127,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,697,897<span></span>
</td>
<td class="nump">$ 2,468,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076964192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 46,059,631<span></span>
</td>
<td class="nump">$ 44,317,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(18,483,948)<span></span>
</td>
<td class="num">(15,875,620)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">27,575,683<span></span>
</td>
<td class="nump">28,441,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 20,953,601<span></span>
</td>
<td class="nump">19,181,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Laboratory and manufacturing equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Laboratory and manufacturing equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 20,784,565<span></span>
</td>
<td class="nump">20,050,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,036,374<span></span>
</td>
<td class="nump">900,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,768,224<span></span>
</td>
<td class="nump">3,668,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 516,867<span></span>
</td>
<td class="nump">$ 516,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078114176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset amortized, useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense</a></td>
<td class="nump">$ 19,104<span></span>
</td>
<td class="nump">$ 19,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net value</a></td>
<td class="nump">38,208<span></span>
</td>
<td class="nump">$ 57,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense</a></td>
<td class="nump">$ 19,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078242576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(152,832)<span></span>
</td>
<td class="num">(133,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">38,208<span></span>
</td>
<td class="nump">57,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">184,100<span></span>
</td>
<td class="nump">184,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(147,280)<span></span>
</td>
<td class="num">(128,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">36,820<span></span>
</td>
<td class="nump">55,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,640<span></span>
</td>
<td class="nump">5,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,512)<span></span>
</td>
<td class="num">(3,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 1,128<span></span>
</td>
<td class="nump">$ 1,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076239616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable &#8211; trade</a></td>
<td class="nump">$ 874,558<span></span>
</td>
<td class="nump">$ 726,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable &#8211; capital</a></td>
<td class="nump">13,175<span></span>
</td>
<td class="nump">63,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll</a></td>
<td class="nump">942,999<span></span>
</td>
<td class="nump">966,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">97,800<span></span>
</td>
<td class="nump">95,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued other</a></td>
<td class="nump">192,754<span></span>
</td>
<td class="nump">143,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">4,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,124,337<span></span>
</td>
<td class="nump">$ 2,000,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606069061568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2027</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount', window );">Mortgage debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Incurred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,098<span></span>
</td>
<td class="nump">$ 19,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Bank loans outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="nump">$ 3,145,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Debt Instrument, Redemption, Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Debt Instrument, Redemption, Period Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableLoanInProcess', window );">Finance loan provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Debt Instrument, Redemption, Period Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member] | Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow account</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_InterestPaymentsTerm', window );">Interest payments, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member] | Loans #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember', window );">Maine Technology Institute [Member] | Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember', window );">Maine Technology Institute [Member] | Debt Instrument, Redemption, Period Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 624,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LoanToValueRatio', window );">Loan to value ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,145,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,687,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member] | Debt Instrument, Redemption, Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member] | Loans #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_MaineTechnologyInstituteMember', window );">Maine Technology Institute [Member] | Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_MinimumDebtServicesCoverageRatio', window );">Minimum debt service coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Debt Instrument, Redemption, Period Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,285,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Debt Instrument, Redemption, Period Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Mortgage Note [Member] | Debt Instrument, Redemption, Period Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LoanToValueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio of loan to value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LoanToValueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_MinimumDebtServicesCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum debt service coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_MinimumDebtServicesCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479359/835-30-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableLoanInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undisbursed portion of financing receivable balance. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableLoanInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total interest costs incurred during the period and either capitalized or charged against earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the related debt discount at the end of the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481212/470-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_GorhamSavingsBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_GorhamSavingsBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_MaineTechnologyInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_MaineTechnologyInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_MortgageBankingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_MortgageBankingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606077570624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">1,185,774<span></span>
</td>
<td class="nump">897,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">223,222<span></span>
</td>
<td class="nump">199,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">494,455<span></span>
</td>
<td class="nump">477,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">91,446<span></span>
</td>
<td class="nump">22,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loan #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">205,884<span></span>
</td>
<td class="nump">198,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">32,017<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">93,054<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">$ 45,696<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606186340656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2023', window );">Debt issuance costs During the Three-Month Period Ending December 31, 2024</a></td>
<td class="num">$ (19,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2024', window );">Debt issuance costs 2025</a></td>
<td class="num">(18,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2025', window );">Debt issuance costs 2026</a></td>
<td class="num">(13,579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2026', window );">Debt issuance costs 2027</a></td>
<td class="num">(5,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2027', window );">Debt issuance costs 2028</a></td>
<td class="num">(3,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCostshereafter', window );">Debt issuance costs Thereafter</a></td>
<td class="num">(11,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, Total</a></td>
<td class="num">(71,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost', window );">Debt discount cost During the Three-Month Period Ending December 31, 2024</a></td>
<td class="num">(20,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2024', window );">Debt discount cost 2025</a></td>
<td class="num">(20,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2025', window );">Debt discount cost 2026</a></td>
<td class="num">(11,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2026', window );">Debt discount cost 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2027', window );">Debt discount cost 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCostThereafter', window );">Debt discount cost Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCostTotal', window );">Debt discount cost Total</a></td>
<td class="num">(53,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2023', window );">Total During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">1,428,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2024', window );">Total 2025</a></td>
<td class="nump">1,499,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2025', window );">Total 2026</a></td>
<td class="nump">3,315,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2026', window );">Total 2027</a></td>
<td class="nump">793,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2027', window );">Total 2028</a></td>
<td class="nump">344,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebtThereafter', window );">Total Thereafter</a></td>
<td class="nump">4,587,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">11,969,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">230,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">239,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">248,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">257,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="nump">266,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="nump">4,598,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">5,841,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">512,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">530,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">549,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">140,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">1,733,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">96,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">101,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">106,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">83,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">386,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loan #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">213,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">220,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">228,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">240,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">903,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">66,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">69,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">73,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">77,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="nump">81,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">367,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">235,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">253,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">1,418,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">1,906,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">114,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">124,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">715,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">954,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember', window );">Subtotal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">1,468,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">1,539,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">3,340,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">798,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="nump">347,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="nump">4,598,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">$ 12,094,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCostThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCostThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCostTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCostTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCostshereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCostshereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebtThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebtThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075757008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NumberOfExecutiveOfficers', window );">Number of executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Total accrued amount</a></td>
<td class="nump">$ 222,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Deferred compensation agreement annual base salary percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_CapitalExpendituresCommitted', window );">Capital expenditures committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Construct and equip commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_InventoryProduction', window );">Purchase of inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_OtherObligations', window );">Other obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember', window );">Mr. Brigham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CapitalExpendituresCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditures committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CapitalExpendituresCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InventoryProduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Production of inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InventoryProduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_NumberOfExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of executive officers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_NumberOfExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_OtherObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_OtherObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606077540272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 12, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renew term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Additional rent payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 488,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">$ 4,739,077<span></span>
</td>
<td class="nump">4,077,109<span></span>
</td>
<td class="nump">$ 2,217,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,571,149<span></span>
</td>
<td class="nump">2,194,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,721,385<span></span>
</td>
<td class="nump">$ 2,249,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076518304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details) - Schedule of Lease Costs and Other Lease Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 348,929<span></span>
</td>
<td class="nump">$ 149,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">36,774<span></span>
</td>
<td class="nump">36,404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">385,703<span></span>
</td>
<td class="nump">185,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 248,595<span></span>
</td>
<td class="nump">$ 148,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">19 years 1 month 6 days<span></span>
</td>
<td class="text">20 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.11%<span></span>
</td>
<td class="nump">5.54%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076930160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 946,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">342,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">349,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">356,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">363,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,949,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments (undiscounted cash flows)</a></td>
<td class="nump">8,308,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest (discount effect of cash flows)</a></td>
<td class="num">(3,587,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating liabilities</a></td>
<td class="nump">$ 4,721,385<span></span>
</td>
<td class="nump">$ 2,249,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606069582080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 10, 2020</div></th>
<th class="th"><div>Jun. 14, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="nump">515,156<span></span>
</td>
<td class="nump">1,636,364<span></span>
</td>
<td class="nump">417,807<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="nump">$ 4,250,038<span></span>
</td>
<td class="nump">$ 9,000,002<span></span>
</td>
<td class="nump">$ 3,049,991<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, per share (in Dollars per share)</a></td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds (in Dollars)</a></td>
<td class="nump">$ 4,233,026<span></span>
</td>
<td class="nump">$ 8,303,436<span></span>
</td>
<td class="nump">$ 2,734,173<span></span>
</td>
<td class="nump">$ 1,034,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,313,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,760<span></span>
</td>
<td class="nump">$ 30,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_StockOptionsCoveringShares', window );">Exercised stock options covering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_StockOptionsCoveringcash', window );">Stock options covering cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,040<span></span>
</td>
<td class="nump">$ 10,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option outstanding of exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise prices per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 7.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation related to non-vested stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Common stock purchase price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ExercisableAndTransferableDescription', window );">Exercisable and transferable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public
announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined
in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement
of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding
common stock (the earlier of such dates being called the Distribution Date).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyPurchasePremiumPerShare', window );">Purchase price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets', window );">Common stock were changed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RightToAcquirePerShare', window );">Price per Right (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription', window );">Extend the rights plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Our Board of Directors decided to seek an advisory vote by stockholders
at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of
the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board
of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory
vote by stockholders at the Annual Meeting of Stockholders held in June 2023, as to whether to extend the Rights Plan by another year
to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained.
On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that
there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually
cast on these proposals in deciding whether to extend the expiration date of such plan by one year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock outstanding under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,500<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life of the options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock outstanding under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life of the options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise prices per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_AcquiringPersonPercentage', window );">Percentage of acquiring person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option outstanding of exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise prices per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_AcquiringPersonPercentage', window );">Percentage of acquiring person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option outstanding of exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,464,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,160,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,714,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=iccc_AcquiringPersonMember', window );">Acquiring Person [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Acquisition percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Stock options granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_AcquiringPersonPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of acquiring person.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_AcquiringPersonPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ExercisableAndTransferableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercisable and transferable, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ExercisableAndTransferableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net proceeds incurred from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_RightToAcquirePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Acquire, Per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_RightToAcquirePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_StockOptionsCoveringShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options covering shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_StockOptionsCoveringShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_StockOptionsCoveringcash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of stock options covering cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_StockOptionsCoveringcash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, used to determine net periodic benefit cost (credit) of defined benefit plan, in subsequent interim measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyPurchasePremiumPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of premium paid by investor to purchase shares of investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480737/946-205-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyPurchasePremiumPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=iccc_AcquiringPersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=iccc_AcquiringPersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606081148384">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (661,310)<span></span>
</td>
<td class="nump">$ 468,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,071,121)<span></span>
</td>
<td class="num">$ (661,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested', window );">Weighted Average Exercise Price, Vested (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (377,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Weighted Average Exercise Price, Vested and expected to vest (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,071,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Grants (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">$ 7.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">7.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercises (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember', window );">2010 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">202,500<span></span>
</td>
<td class="nump">218,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,500<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested', window );">Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Terminations/forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">402,500<span></span>
</td>
<td class="nump">224,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">402,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested', window );">Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">210,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Terminations/forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(94,500)<span></span>
</td>
<td class="num">(32,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Terminations and forfeitures are recognized when they occur.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exercisable weighted average vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078365488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans - Stock Option Plans [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems', window );"><strong>Schedule of Additional Information About the Stock Option Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Non-vested stock options as of beginning balance (in Shares) | shares</a></td>
<td class="nump">307,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Non-vested stock options as of beginning balance</a></td>
<td class="nump">$ 7.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Non-vested stock options as of ending balance (in Shares) | shares</a></td>
<td class="nump">337,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Non-vested stock options as of ending balance</a></td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Stock options granted (in Shares) | shares</a></td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options granted</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options granted</a></td>
<td class="nump">$ 5.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Shares, Stock options that vested (in Shares) | shares</a></td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options that vested</a></td>
<td class="nump">$ 2.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options that vested</a></td>
<td class="nump">$ 5.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Shares, Stock options that were forfeited (in Shares) | shares</a></td>
<td class="nump">104,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options that were forfeited</a></td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options that were forfeited</a></td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=iccc_StockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=iccc_StockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078146640">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The dividend yield and expected volatility are derived from averages of our historical data.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075878032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RevenueSalesObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 15,949,382<span></span>
</td>
<td class="nump">$ 17,020,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RevenueSalesObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=iccc_OtherStatesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 1,522,287<span></span>
</td>
<td class="nump">$ 1,547,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RevenueSalesObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_RevenueSalesObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of product sales is an act of selling a product or service in return of money or compensation or service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_RevenueSalesObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=iccc_OtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=iccc_OtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606077883920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember', window );">First Defense&#174; product line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 17,293,933<span></span>
</td>
<td class="nump">$ 18,411,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember', window );">Other animal health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 177,736<span></span>
</td>
<td class="nump">$ 156,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606074456112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentOfOtherExpenseNonoperatingLineItems', window );"><strong>Other (Income) Expenses, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 22,619<span></span>
</td>
<td class="nump">$ 7,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentOfOtherExpenseNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentOfOtherExpenseNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606077945872">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Details) - Schedule of Other (Income) Expenses Net - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Schedule of Other (Income) Expenses Net [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 475,598<span></span>
</td>
<td class="nump">$ 348,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,099<span></span>
</td>
<td class="num">(7,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(96,570)<span></span>
</td>
<td class="num">(153,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recovery</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(365,127)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Income-other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,893<span></span>
</td>
<td class="nump">$ 187,190<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Interest expense includes amortization of debt issuance and debt discount costs of $22,619 and $7,658 during the years ended December 31, 2023 or 2022, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606075824928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 4,627<span></span>
</td>
<td class="nump">$ 7,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Loss income before income taxes, rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,729,500<span></span>
</td>
<td class="nump">$ 3,258,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeTaxExpense', window );">Non-cash income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Value of our deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,759,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not expire</a></td>
<td class="nump">16,047,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 1,711,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in 2034 through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 4,681,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in 2037 through 2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember', window );">Federal General Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 726,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in 2027 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember', window );">State Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 775,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in 2024 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606077956064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Tax Provision - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4,627<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current subtotal</a></td>
<td class="nump">4,627<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,179,474)<span></span>
</td>
<td class="num">(576,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(145,802)<span></span>
</td>
<td class="num">(88,533)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred subtotal, gross</a></td>
<td class="num">(1,325,276)<span></span>
</td>
<td class="num">(665,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Valuation allowance</a></td>
<td class="nump">1,325,276<span></span>
</td>
<td class="nump">665,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred subtotal, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 4,627<span></span>
</td>
<td class="nump">$ 7,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606076933984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Tax Expense Differs from the Expected Tax Computed - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of Income Tax Expense Differs from the Expected Tax Computed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed expected income tax expense rate</a></td>
<td class="num">$ (1,211,694)<span></span>
</td>
<td class="num">$ (522,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Computed expected income tax expense rate, percentage</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal expense</a></td>
<td class="num">$ (117,149)<span></span>
</td>
<td class="num">$ (47,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal expense, percentage</a></td>
<td class="num">(2.03%)<span></span>
</td>
<td class="num">(1.92%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based compensation</a></td>
<td class="nump">$ 56,214<span></span>
</td>
<td class="nump">$ 36,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based compensation, percentage</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">1.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">$ (53,241)<span></span>
</td>
<td class="num">$ (131,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits, percentage</a></td>
<td class="num">(0.92%)<span></span>
</td>
<td class="num">(5.28%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 1,325,276<span></span>
</td>
<td class="nump">$ 665,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance, percentage</a></td>
<td class="nump">0.09%<span></span>
</td>
<td class="nump">26.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 5,221<span></span>
</td>
<td class="nump">$ 6,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other, percentage</a></td>
<td class="nump">22.97%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/rate</a></td>
<td class="nump">$ 4,627<span></span>
</td>
<td class="nump">$ 7,672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense/rate, percentage</a></td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606078045712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Significant Components of Our Deferred Tax Assets Net - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Schedule of Significant Components of Our Deferred Tax Assets Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">$ (2,121,940)<span></span>
</td>
<td class="num">$ (2,530,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Federal general business tax credits</a></td>
<td class="nump">726,474<span></span>
</td>
<td class="nump">673,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">3,729,500<span></span>
</td>
<td class="nump">3,258,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State tax credits and net operating loss carryforwards</a></td>
<td class="nump">886,428<span></span>
</td>
<td class="nump">817,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">&#167;174 R &amp; D expenditures</a></td>
<td class="nump">592,915<span></span>
</td>
<td class="nump">341,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred compensation</a></td>
<td class="nump">50,722<span></span>
</td>
<td class="nump">23,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Prepaid expenses and other</a></td>
<td class="nump">37,124<span></span>
</td>
<td class="nump">15,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">UNICAP</a></td>
<td class="nump">32,607<span></span>
</td>
<td class="nump">32,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Incentive compensation</a></td>
<td class="nump">100,200<span></span>
</td>
<td class="nump">76,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(4,034,030)<span></span>
</td>
<td class="num">(2,708,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606199667808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - Schedule of Segment Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">13,602,385<span></span>
</td>
<td class="nump">10,919,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">3,869,284<span></span>
</td>
<td class="nump">7,648,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">4,394,852<span></span>
</td>
<td class="nump">4,493,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">3,088,215<span></span>
</td>
<td class="nump">3,190,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">2,134,295<span></span>
</td>
<td class="nump">2,263,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">9,617,362<span></span>
</td>
<td class="nump">9,947,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(5,748,078)<span></span>
</td>
<td class="num">(2,298,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">43,808,102<span></span>
</td>
<td class="nump">44,860,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,739,620<span></span>
</td>
<td class="nump">2,495,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">1,892,513<span></span>
</td>
<td class="nump">3,975,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember', window );">Scours [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">17,293,933<span></span>
</td>
<td class="nump">18,411,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">13,453,514<span></span>
</td>
<td class="nump">10,754,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">3,840,419<span></span>
</td>
<td class="nump">7,657,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">11,103<span></span>
</td>
<td class="nump">66,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">2,447,137<span></span>
</td>
<td class="nump">1,871,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">2,458,240<span></span>
</td>
<td class="nump">1,938,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="nump">1,382,179<span></span>
</td>
<td class="nump">5,719,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">24,735,413<span></span>
</td>
<td class="nump">20,539,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,365,988<span></span>
</td>
<td class="nump">1,169,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">1,096,819<span></span>
</td>
<td class="nump">3,513,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember', window );">Mastitis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="nump">177,736<span></span>
</td>
<td class="nump">154,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">148,871<span></span>
</td>
<td class="nump">136,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">28,865<span></span>
</td>
<td class="nump">18,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">4,242,329<span></span>
</td>
<td class="nump">4,317,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">641,078<span></span>
</td>
<td class="nump">1,318,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">4,883,407<span></span>
</td>
<td class="nump">5,636,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(4,854,542)<span></span>
</td>
<td class="num">(5,617,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">17,827,839<span></span>
</td>
<td class="nump">18,315,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,287,600<span></span>
</td>
<td class="nump">1,263,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">795,694<span></span>
</td>
<td class="nump">414,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(27,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">141,420<span></span>
</td>
<td class="nump">109,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">2,134,295<span></span>
</td>
<td class="nump">2,263,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">2,275,715<span></span>
</td>
<td class="nump">2,373,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(2,275,715)<span></span>
</td>
<td class="num">(2,400,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,244,850<span></span>
</td>
<td class="nump">6,005,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">86,032<span></span>
</td>
<td class="nump">62,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 47,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDepreciationAmortizationAndDepletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDepreciationAmortizationAndDepletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606071537248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party products purchased</a></td>
<td class="nump">$ 231,405<span></span>
</td>
<td class="nump">$ 587,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 42,507<span></span>
</td>
<td class="nump">$ 46,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of any current tax-related balances due from affiliates as of the date of each statement of financial position presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140606077898576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryPercentage', window );">Employee&#8217;s salary percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryContributionPercentage', window );">Employee&#8217;s salary contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Employee benefits paid (in Dollars)</a></td>
<td class="nump">$ 178,150<span></span>
</td>
<td class="nump">$ 159,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryPercentage', window );">Employee&#8217;s salary percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember', window );">Employee One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryContributionPercentage', window );">Employee&#8217;s salary contribution percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeesSalaryContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee&#8217;s salary contribution percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeesSalaryContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeesSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee&#8217;s salary percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeesSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)4.?43+S>6*Z+_0X<S(Q2#(4BU4"/<\)UU8ES&=>0)G5D!V67A2$K$U\T5K
MT&X! ^)KO5RG0L.TSN5=$B?.71VU%<F @(8*<&2-KL/4IXSRJ(T&:_5"N_?U
MLQS8;YT_;=>VT"A6A>XCG_49)N52\8/R<KN@?WU1V=O] 6$A#YL;,J<AA]EL
M$6VL5B^L6[UL6+/,>:'2N<R+;4LS9S%N4<]L+6)F &1D<[X<E@S#GA.W;219
M+5M8MVRQJ+/DHO;>[$R$6*>P+3MBEZ5[1SS<^UA@OM1<B/P^R0H05W?@BM\'
M$"/??/S8W&BU*K\?0,O3:EE>+J2 F3 &\/N= CJM;LPGB=TGJ-'_4$L#!!0
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M!6$*]/T5YVK7,1OZ<'[G_P!02P,$%     @ LH"!6$Z<M1!^!   _ \  !@
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M*\]C49*\U%L%4*GI[0&S<4VJQH'OU>/+( 9^\%M2$JWHG![IJ=^9$!C\623
MAH]O:"Y2"*#C9$@-].R[F+GUY6P2Q!@*T):&CN[MD!]A\M$#NAD-[T>#V0AJ
M2E10XV!R4UZ,_OH^_C'X.IH\S(SX#13- DP"@NL&F"1I2,/6M5"1.;5WT->C
M/\:3B2;OT[ W6V37#Z$EJ?>J!D'L0-)E7DNS1RL&IG8&'DUN3L?=9-?0#WS6
MF/&F7-V^0]05"U/O>/4T'8QOT.W=O?GSR2?HU/+]Y$S:#LVM&)K:&7J<QMF*
M(Q6]MBSB)M5ZK+$]:9!B(6EIQVG%QM3.QN-4<3#:NIM'FR3,& N;2<;0>=/
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MT2AO5+8NCCD\9DIEJ^)RP:.$YUH ?I]GF7J_T2_8G93I_Q]02P,$%     @
MLH"!6)(5:O9\ P  2P<  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R-
M55EOVS@0?O>O&*A T06REB6[C1L?@)VDJ!]R(.[QL-@'6AI9;'AH22JJ__T.
M*5G-!JFQ+Q)G.//QFX/#>:/-HRT1'?R40ME%5#I77<2QS4J4S YUA8IV"FTD
M<R2:?6PK@RP/3E+$Z6CT(9:,JV@Y#[I[LYSKV@FN\-Z K:5DYK!&H9M%E$1'
MQ0/?E\XKXN6\8GO<HOM:W1N2XAXEYQ*5Y5J!P6(1K9*+]<3;!X-O'!O[; T^
MDIW6CU[8Y(MHY FAP,QY!$:_)[Q$(3P0T?BGPXSZ([WC\_41_5.(G6+9,8N7
M6GSGN2L7T32"' M6"_>@F\_8Q?/>XV5:V/"%IK4=TXE9;9V6G3/)DJOVSWYV
M>7CF,!W]QB'M'-+ NSTHL+QBCBWG1C=@O#6A^44(-7@3.:Y\4;;.T"XG/[=<
MUY8TUL)=A8;Y1-EY[ C8;\=9![)N0=+?@"0IW&CE2@O7*L?\OP Q,>III4=:
MZ_0DXA5F0Q@G9Y".TO$)O'$?YCC@C?]_F/#7:F>=H;;X^[6(6[S)ZWC^JES8
MBF6XB.@N6#1/&"W?ODD^C&8GV$YZMI-3Z,OUU^WF]GJ[A;O[ZX?5E\W=[?8U
MBJ=!DB$<<0:_<& C9>TOP>!2FTJWN8!WKD1X^V::IJ/9I9854X<@);.SH[K!
MEYK:OM3HVG2J/Z!A%K3A>ZZ8$ ?@*NO.PYP$N*%Y@;08)!^G*3"5TPU_:7.%
M@C7,>#,@L_,SO\BT^E&K]DHWW)7D2VKN.!-0U3O!,]!%@8:K/2W(7$JRI'N4
M/0[A.X+'(Q>FN"2/$IEPY2!K8X:FU!8)AEC0GUMP&C*:=0[!9AR5XP7/0CR5
MT4^H O'*]Y!7>V5>9X[<2N: RV $/K?M.9UY,.)/W!T\PYQQ<_ [@QTB$6;.
M"1S"RD+.;2:(2$C&K282R7F?ZRWN:38ZV*AV,E,^^G)H2BTA4SE@=VQ\V]I;
M'Q7=4>+KLTSQ;3.RLX$:,1UH^AAO5&@:/V2B?;&LHPS;D$#)5%U0Q'5(9$ZR
M>:3'PT?YB1OKJ&P%#6W?3\GY9.8;CHZCTP:^]:A2OK4FTW0&UT,JC^#P@']^
MH7;H'%Z[/_&S 2?1[,,8M^1=*]?.NE[;OQ2K=D#^,F^?F1MFJ"<M""S(=30\
M?Q^!:4=W*SA=A7&YTXZ&;UA2]7(TWH#V"TV5Z 1_0/]^+O\%4$L#!!0    (
M +* @5B3<:AJJ18  /0\   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MO5MM;]M(DO[.7]'PS1RD!2W+\FLR20#;269]R(L1)Q,L#O>!(EL2QQ2IZ2:M
M:'_]/575338E.<G>'0[8G<ADO]1[/57=?+&NS(-=:%VK;\NBM"\/%G6]>GYT
M9-.%7B9V5*UTB3>SRBR3&G^:^9%=&9UD/&E9'$W&X_.C99*7!Z]>\+,[\^I%
MU=1%7NH[HVRS7"9F<ZV+:OWRX/C /_B4SQ<U/3AZ]6*5S/6]KK^L[@S^.FI7
MR?*E+FU>E<KHV<N#J^/GUZ<TG@?\D>NU#7XKXF1:50_TQVWV\F!,!.E"IS6M
MD."?1WVCBX(6 AE_N34/VBUI8OC;K_Z6>0<OT\3JFZKXFF?UXN7!Y8'*]"QI
MBOI3M?Z[=OR<T7II55C^KUK+V+/3 Y4VMJZ6;C(H6.:E_)M\<W(()ER.GY@P
M<1,F3+=LQ%2^3NKDU0M3K96AT5B-?C"K/!O$Y24IY;XV>)MC7OWJ7I2AJIFZ
MS^=E/LO3I*S559I635GGY5S=546>YMJ^.*JQ'\TZ2MW:U[+VY(FUCR?J?576
M"ZO>E)G.^@L<@="6VHFG]GKRW15?ZW2D3HYC-1E/3KZSWDG+_0FO=_*_YE[]
MY]74U@9&]%_[!"';G.[?AASKN5TEJ7YY ,^QVCSJ@U?__F_'Y^/?OL/$:<O$
MZ?=6?W7_Y?W[JT__4!_?JOO;WS_<OKV]N?KP65W=W'S\\N'S[8??U=W'=[<W
MMV_N]U'^_;4G(^66CWZ\O!HD0W6=V-Q&$.@=<5K6"3O?5QTMDD>MP/XJ,3I3
M]4+#(]-JN4K*#0DZ:;*\QHM97B9EFB>%LIBKX?^U)>]G-Z9Q1:&2[$]XAKP:
MK!=YNE!8E+28J))\M<",M#&&)I1)W1@]Q(Y)'6%8K/)258U1U2HO05NL2IUJ
M:\D.Z(W)M%%UI1!X,(^G,;5[":-MRZJ&9]H"(1'[C<"KFE4%HATSZ.P(<\HL
M,9E55M?1=,-+OFV7#"SNOAUY7>$?-7A[=7\]'*G/- $_:0&K?M>E-I#%AJ;J
M%4DNM%IPGN:K G8[^/WJZDZX5^N6LI:_:,UZ: Q8PF)03V5J%D_';UJ5T V+
M"CI%N+,D:N0%P\JUL=*)*;&O57BF[(*D B94FMB%FF$_.U*?]$P;74+2M#D1
M1=*&%"P15=60HK:D'WI=>U[WRN6FRMA3V;(&TZ&ZP3X1;4@_U)N_FOPQ*5@_
ML#M0;W/2*5G. D$:;!8YQF0@X%&+'>$GO+L1I;*LEFPVB,;U@NDT6JNE1#,P
M#P)SHU:-21=("2J#])BOJ1:F=4?#2,@+GK#5K$1%K$*A0Q-!T"Z4 6ECO6F2
M/N"A,Y8OH_N1FE>/VI1$)MO9HBHRV)_L69F=O6E!_8VLFXA^JS.RF>@UE&SS
M6MV2!4#'&A(UT+L3Z-O7MS=#B&B9BZ)_F9R-X_%XS,KMK((DEM<-SZ$WF:Q:
M&80,R.H#]*E.1FJ0#M5GDV0Z<KJT,(54@\)IH;U^;62Z9R2=-('S@G?G>Y7)
MY]B8-GVL<A"<+&F:*HBS!#R"%"@,&L)&,"=04S73>M:0\18> :P7&C!@M4)$
MIXU&ZGU2 GBP_C-=:X/\"AODT$1>PJ+I+99X%@A/B#E ?5,*>:0FF!EL=<;Q
MK#:85! +?@X9* 8UEEXO<J1V T(** CBR\DUA#B*CA7,625S&DE1+5RB GT&
MCECH1\I5,Z2DRL#*6O%NB]+9/R]+!KI*+/AMM,HI7I*_DW#$J,/)TZ0@"43@
M#6B. QC10P)95A(92W4RAO%OL/V=7S5Y@@[;3/^$(H@(S,M+R!MJ4W @,X<N
M;A&>$LO!M(O'&"OOHW8\6=O.5EG#H9X8V" 6600W  X%N*"74TC+0P;R$?P[
M@1C2I+&:9\!T J%X(FR'!SCV&GX5P=FPJVF@-Q*$;9![MGB!FMAOGMS]:5VM
MX?FU)F7,Q%HS#?/,5%-Z,R:[C3Y4>Z6\UEM+_*MBH2B=4H2AZ!/:7; ),OAC
M7C6VV$3A5D0]1E'VS(A_!+<*8F4F9+;.1@@*(C'3;<-$MS/_98JCJR=D3:Y"
M(V+*>JUW9Q+<28L_\'"V V^(04@[14C+AHB=C_#U"C;:_H*-ID63@2>3K"E_
M@,&D0':DNN0P+P]7IDHE8#',R8':,T3T*I-'N0TD*'$/)((G\)=6MH[)]@6)
M&%MCP=C]@G>JI:X7588A)BI1RJ$^*_)_LL*0"F#6@T $B>5E?-#,D'.*@L2.
MG 1Y2%KV0 KB,):QU90B%^B/)>QB"UN5V&)#-I'E:<W;$:6DDHBP7:$%-F2Y
M17+ :L0G4'1I*>QPO@&R^?IC^>1.R&0Q3LRAA(MD"B72O&52-A02Q8[(R!;
M93"3&B %EN>"FI**E_(V&X@F*5$"(>2C)="%>Y*-N$3Z5X.0( F:P_'45I!'
M2O%[U!H#O?60JP4@LD"$I612W7?ZK%J7#,Q:O>S3Y$A]+%E)WOY@-KT5B"C
M8-3#I J7G/ _+(M56*B P#6%=8IS?BZ!#=6L&%9,-;+0H\.^MN&D)-SV+)NE
M0J8"Q65-ZM,(B= ]$:B3/"9YP1S,3+4,DD=5Z@AL9"010(O$+,$=S::BBSF#
M.*BS4./__7G*8IN4[9()W+3$D-UA /DP(GSFT7Y+$8>D&8R78VGKV-$9'!ME
MPITA8%MOXNBNH/Q*7!.B7!%,B%DE )4 ._#5G"QFY2>H53M!^PG>9:ETI/[
M(158SED)#/B, 3X[/"W8V?F1<P!+2 ^L"/"QG9%$9#% $*7+9JQTE\P3R[4"
M2YW^)G.G'QM6"P</8%@"OUB$RE)R?P>_-=GV;"M00* 4) M$<]O?9!11?0+/
MRXN\WI#9<[U'M@]<G=82TTY. (:S+-?J75+R5J(6(?U#C@"C7IL&8+^9$N#
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M,Q"X3%J0<0@"9G-F<KBTI*JL:TFX/-6VF"$5I-2HE;_W!FP1N@%1&2H_4:T
MU[IX[/H,QA>X[&IN8S'1H@@3'24&QQD*YZ24HC;B\$*QBW'9<LKHKW4WF8P,
MN  6.V02MLSP)XUII&Z<7EWV=Y3,C98VF4?&0#  #@0$#'FYWR<6B&1KAT&7
M&%5P4]9GNU629UNQKXT.DO ,K]$LG?EPE9%8 0^ZY#I6HET7W.ODF[8<$)[R
M'F=@5)Y7_)<$>S;!-E23B7<N?NT*RU8,*$XK*2@1C/+9A@I[6#-UE1%(/?ZD
M*5P5IX9%!BJ!:$VUYCC<BX9Y*4<Q?*;1(JL?Q%+(KBT V&5=/%6]>+KM&U^W
M@'$7-\D&R2=SPWLPIM*/$GX-H9IRSDA=I;E)FZ7D<GJ04=^NZZI&U.AAI^L1
M(IM0X"')3;4O&),>9+-J,E@,V3V.)^(6F30J.03;M*BHQ0E&!G.JV$#$G$ ?
M:L8V2?T.=,51"* .UF9J<MN\'=IZ\$_#N)_%;6H_;HO^OW$;MQ$)JK6U9\=]
MY @)\KT<24D#2M#J(E_!@\NJ/*28PD5-Z_@LX@R&42#M8;Y.%V555/--+-48
MA[],SS@PA42.U%7@^E&OC3F#U?7-A4"Y(W4@H8;!3O(-;E&;?-K 5H8[+8JY
M5SV'?G<B >!NV82\=KLV"#7WHZ\B.&O;M.1< .-VS8;-G*4+RR<V<P*5K(7!
M5C=2[+BE:> <6AKRQ$Z#R?!0R'(8D>O3_TKJ0TE"'^PTG6"MU' A%_F#G9AP
M)8:\J\KYX3O&+,X18/L2XZ@?B<C;<_J"AA<"<5PV[(?KMHV-M;];#,7;X*</
MJ'EUCM+.$3FP[0@U9D]?P?]+QEJ=#JC\9F69C$L'MBY6:ROE,'O/FSQK&T#<
M"$1VX-, DM(>MM>DCD<Z:6:'W8E<>Z5%\5#"V=Q4S4I, OI:Z$(P(Q6IL>K,
M=M?]PLZIDXQDN3U16!.N<Y&8R\COQ]\]7 0!R 7@:#L ?VD=AKD@,EB!*Z@?
M;AT',7R;>^Y U[K%V@'Y=E$U!:5HGYM\!\PZNV=X)RG8==H%3'3'3.SC!<5B
M/E5!E4[]P[(%CL%(TA=WTIFP .Q)[=+!->Y:#O*A>@M"HS]83.]AO8UQ,>ZV
MC'HXLPM/RV!8')Z^2<_D,;<,IK%U[TCK<[7*4W4Y&<>\I]JS)]'XNLMP*&=)
M/L>H@R\GQY/?Z  PI3(W+Y$G1"Q_-14)G7M\-D .N;\: 76;!\X[I!<6,!U/
M[,6P4=+FD8!)3E0C1\QDFQCU)#'8,++Y$@29_=M17]-/E_J:CGNGE/J(!V23
MG'4I=1>%(L.V+G_%KE7/+06*&<7&E8\(M%PWU L8P7S!]6\U]2=A'#^Z79Q\
MB,G$,WGR/2:;,IA,/ :NM<V?"PMQCTMW[+V5"$@Q]8;WO?@-*U'/SWKHBYVG
MU ]V6_FGD:-]E6 -BM?<XF9_(\^%#:P<_3W7]21N*+1&OGI+I4+D!"C4<J.-
M6A9B"ST?0 R94;G"8 56SL? SJ-;(PHF+'*$&9,N>$\!\L&&$@C(6<L]9';'
MM?N7I,#;:RN$X452^(J%)S$Z. /R\*I;-0H,7TIG 0;+(-YT"Z3N>H(HH"%+
M=WMMK]MSJ)R*:,LJ-[JF\WDD4SB\^K/)YE+C<:]0.LS6GP:Z8@-1Q"W?G70S
MX..>!Q\>H]0$K'36T1Y^N)[I-"D?_$/?Z>(C12J0L;S@J'3G>)OZ\,($-WDZ
MWJ3]L@/@;$B@W582!E.<8[31N YV!_G\PE\E73I@UK>N</'$'01LAZVX.YN8
MD22G&L4X$)I;:;<4%KQ8$P+S;3XJ:#CW=D70;@W$QL5%8N90AVPI@;@/7D@)
MN_T&H^>)R;RS.JK:0US/0;3%P7<][?7/GKMUQVJUG(EJO@'SI.!^YH".N.1P
MJHY;Y+'7?*C4ZF>.W>3EL*EFY,[Y'AM%>\V\/=<5'D!IM(_2-KGZO.9#_V?J
MOKEB\GG47D+9[U*_J&<7E_'%Z3%^^9P1_G)OHW==5G@>7<,! 2ZF=6_H\3@^
M!7&7QQ=//'Z"D\G_%2=G\<6SX_CL?/($+^W[G^'F,KY\=A$?/[MXXNG@SR'@
M$3=<35O#?,KMP^[3E,XAD3;I)?L/-;,]<MYSEHU $]8O?.7%E;D^U;ERETO[
M]0+U.'<"'W0()Y1%X"-KJB(00*<91('4"\C%*&ZQ>!"<PIMDR(5S<G2I'KKM
M(/Y8)=*3+RVB*_5SXO[)7! =0K:B4 SZVXHA(O'J^.,,T)ZJ41[M'85WE95;
M![&76Y7!?83V8!P4(8=UEUF*]N@GHLY-=[4EZR73_LI!>X%[8%G^F&<45]MF
M0Q7"]$Y(3/ZFGU,SO#4, .>ZFIMDA:Q%U\J2D;HG-=$N/5(Z#3.PY+:#$',\
M_E7YRRX4/;G9[LX11>><%@#^@:6[=J& ?.E 0!W/(PFNC/[^P<&5K\-&' 79
M+6_D&F1TI4XOU*_J=*Q^;9]=JY,)GIV<X#]RCVJ?)=/-%6X7_<]8(TL2]FK#
M;>XG[J<$K$9[697 P_\-N2+B$?EZ7)WCV>0R>':C_D9]O%^COR$NT\&,W/$B
MPQ7/@7& [I$:/ S5)\JS &&?@NP'"-"UWHT,V)=5]Q1;Y^/SV*\I@D1PX>N^
MKD=_T\IR<'5_0^.':E ,HS>NA;=%A^OY<E^X/08B5R[]731:M&]+07<MJ'+@
M\-+]F/']OE5>\WT 6F2DKC+4Y'7.V*CK8+NV8A:QR_K>M =PD.>\O3P:G OR
MH4._R9VXY1T6M1W^PM9%YPNNP\>CW.9;E"0VH"-QUP**HG7]54)!1WC@^-1R
MZEOSP5EQ=_<A(#^X@Y!NTL+CN7YS/Y)&;?94HY8%YA%C>[V"7U%PZ@4DO'#1
M4)H:08^RN^ !8UU2ZYDN0T6?Z<"!@6IPDN,N2O%AQ$\:Z\7I.'9K*EDS'!2U
M@PZ/QP35#2%UJ_R-:X<E=_:>\CT>FYI\*J?=U,]8-LL>P*1[L)8+!S%0;K+R
MO4]NF4(\@&Z:6O987P."\OG%SHG*OKO47.[)94]@6[K]M^_JD:!.OB9,B#-)
M@QL324%)0!ZL>1R?A1?2!8^(5*1C9AG*:TJ7Y*5MF/DKSNN=ZXJ^-RIWU&4S
M_2V!?-QF[H;N+=T#I+,''TCN76N^N[8)&B@5)$V]J(QK+WTE-<_TFLUGY6Y4
M.RJ K*FCJ$U(3Z>V73*HY]TMSEH60"\:H7PS;GO^D6_T2B7B]0A; <*A:S;N
M(CA%?%H9)6ACG+3]]0X^V.NNU;52[5D&ZHEO LIWKT9&6U<C"U!/O9BUWD4[
M_D3#UV/N8)F<72HQ?S\]Y=:&=!O:<Q3;'8G8X$;?\3F\M!RJ^[I*'PZOJ?+D
MG(3(U7Z\$'JLY7%2H:;AN)_TWN/+6(7K'_+&O4=J4 W5!UU'[X"0U!UXP%L$
M:'7/=^OI#6$GOG>=RANY=4\W2J94?1%AC;M2_A-$3<XI6L3JC;_(3WOR9C]&
M+RTU_K"%X0+!+.*+@@4EM%_4 &7!Q6E\]NQ2#>G/27SZ["2^')^I8?25OYXB
M^Z F\UP[KB+FJG__^) _,8$<42Y=Q.>7Y_SK+#X&*:_SHJ%J,.KN"_ *^[25
MK/EC E]RN'];2J(^)6HO);P?%MY'"\2B6B7Q;*J B'+P/AY=G(D4QB/@NV'D
M5]KS3@U60_7%:D)6;UH'^"R'N,"^B2_]]WZA(K"#CHQ]?TP^OF@[2<ON$KR_
M=!2X69GUFHL2]>%5O:XD2<L=USW91I>CP+9E+;>B.!71SD_-Z5^C>BIU^%0?
M>7)40(X#@CYL.W02(@<.[_W(8_2<ZHE>W1:&CS;@^(W"@!.Y@%/9'5'V$TO7
M(I)33!0P<A'GICM WPYYNQ>E]UQ/V- %=X(<#V6U1H(+/V[K%FPO]3327VD-
MJ44_\;YCL(R^Y#$N)02*VP.H$%C_&L(3UOV/DZJR:OSUA*NLXJ^7;LOH/YJ2
M$M3QN;1Z^0.@',9'!Y7W7_C-X?%)''PV==M]M7-X(S7E.ZDI!Q+73B;GP^?A
MT0D?MO1&@N5VP2A84 T,Q>!U]!3IEM('8F*/AP_5HV0VBH]/\3$Y.1Q?Q,A
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M? !^;[5V1\<GF/XCUO\!4$L#!!0    ( +* @5A6-8Z$F0(  ,@%   9
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MUP[J?L>8/&UT@'9XA[\ 4$L#!!0    ( +* @5@H,1]7@P,  &L'   9
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)U5;6_;-A#^KE]QT(9A!9CH_<6I
M;<!)7*Q DWINNF$8]H&6*)NH)*HD%=?_?D?*5KTA\8!]D7CD/<^]\8[3O9!?
MU(XQ#=^:NE4S=Z=U=^-YJMBQAJIKT;$63RHA&ZI1E%M/=9+1TH*:V@M]/_4:
MREMW/K5[*SF?BE[7O&4K":IO&BH/MZP6^YD;N*>--=_NM-GPYM..;MDGIC]W
M*XF2-[*4O&&MXJ(%R:J9NPAN;F.C;Q5^XVROSM9@(MD(\<4([\N9ZQN'6,T*
M;1@H_I[9':MK0X1N?#URNJ-) SQ?G]C?V=@QE@U5[$[4O_-2[V9N[D+)*MK7
M>BWVO[!C/(GA*T2M[!?V@VZ<NE#T2HOF"$8/&MX.?_KMF(<S0.Z_ @B/@-#Z
M/1BR7MY33>=3*?8@C3:RF84-U:+1.=Z:HGS2$D\YXO1\);&^4A\(K&K::J!M
M"<NO/>\P\9K (]-33Z,=H^T51\[;@3-\A3,(X4&T>J=@V9:L_">!APZ.7H8G
M+V_#BXSWK+B&*" 0^F%T@2\:HXXL7_2_HX8_%QNE)5Z:OUY*P$ ?OTQO&NE&
M=;1@,Q<[13'YS-SY3S\$J?_V@O/QZ'Q\B7V^6G]<+==/?Z#S'Q:/3[!XO(?E
MKY_?KQZ6CT\$VI=+=IDSNX:1UGF-%L:T.=V8-G9*&Q0"6U5I5H*H0.\85*+&
MGN?M]L99*LVQA?!LH1P\ME_G ]T(2;60!\=0-;3M*\QX+Q%S1AQ=!3[\B+4G
MDR0BJ1^@$$Q(D =DDOK.;<_K$A'*DO"FD^*9&:""P+^*)@:8Y3%)TL0L_<0G
M09HY'ZN*%\RI>MER-,G^%8TU&A _2DF4Q3#Q?1+YJ7.'06K9VY'B\!;0V!9+
MK*#U*(0D2W,2AC&@F[CRXQ1C1%ISF 0IR=/L]'<N)I/ 5@IDC5/T=T+2*( X
M)E&0D0@Y%T71-WUM\NF4#*]8P:F=<3\'.8GSB$SB'-Z@E) \2T@:^O#FO^R9
M^F*.,Y(81!X9 <GB@&1A>JP:MB%K-DR.K6A)<!$26_U38N \,=^O18=U+7A'
MZ_I@KDA'#T.5M-A36=HK\XY+I=%.A6.? ;9,%K^%-;MZPN?E*+[40=[9 &R8
MW-HQ;TSWK1YFX;@[OB2+88!^5Q^>H0<JM[Q54+,*H?YUEK@@A]$^"%IT=IQN
MA,;A;)<[? V9- IX7@FA3X(Q,+ZO\[\!4$L#!!0    ( +* @5BU6'0'T@,
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MCH,S&^;%S_!AZG[D<ENU"FHL">K=Q!,;Y##)AH4673\]-D+3+.K-'0U_E":
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MIJS5SGIUK]LO_XM29:YCI38._01%CZ15OGP'N775JK:$)59V7S7&:$@!@2(
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M&J>H(0&\7W>X^(P3VF#ZW\KY[U!+ P04    " "R@(%8O3P5VP((   ]$@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RE6%MSV[82?N>OP*B>3CRC
MZF;G<N++C&]I?29.,K';/IPY#R"YE# &"08 I>C?]UN I*C4=A_Z8(ND@,7N
MM]]^N]3IQMA'MR+RXGNI*W<V6GE?OY].7;:B4KJ)J:G"-X6QI?2XM<NIJRW)
M/&PJ]70QF[V9EE)5H_/3\.R+/3\UC=>JHB]6N*8LI=U>DC:;L]%\U#WXJI8K
MSP^FYZ>U7-(]^=_K+Q9WT]Y*KDJJG#*5L%2<C2[F[R^/>7U8\(>BC1M<"XXD
M->:1;V[SL]&,'2)-F6<+$A]KNB*MV1#<^-;:'/5'\L;A=6?]0X@=L:32T971
M?ZK<K\Y&[T8BIT(VVG\UF]^HC><UV\N,=N&_V,2UKV<CD37.F[+=# ]*5<5/
M^;W%8;#AW7,;%NV&1? ['A2\O)9>GI]:LQ&65\,:7X10PVXXIRI.RKVW^%9A
MGS^_,I57U9(J+SXJF2JMO"(G9)6+*U.6RB,!WIU./<[B'=.LM7L9[2Z>L3M?
MB#N87CEQ4^64[QN8PLG>TT7GZ>7B18O7E$W$T7PL%K/%T0OVCOK(CX*]HW\5
MN?C?1>J\!7G^_Q0(\8CCIX_@@GKO:IG1V0@5X\BN:73^\T_S-[.3%P(X[@,X
M?LGZ^=7G3P^WGWZ]^?0@/MY>7-Y^O'VXO;D7%Y^NQ=7GN[O;ASM\=?^4UR_;
MG<\G8F<[><&V^-S8)-UJN7%C(8$=($.RQT)5@HH"A2=J:]8J)^%7TN,?,;:U
MK+:@N=98EU-9J6(K%* V1:$RLC$'N;+8;_AN"6UQ7O NW69J*Z15#ND3A34E
M&U8V <2U@5SL<OFL36^",R@D53:EH.^>>5"31=X]Y2+=BFM"7-*2P,=$W$)
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M4IFRV+B7@8.-RNU?\<7IH?7"?'3BA<B]$!'?=B'B\K4HQ8MGNMASC4\#-?Q
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M>>Y2P%Z!-7%-2?'/5BH'EX<W!T,>U89ZEY3%$M8^M%- ND4[[-#=P2L24DS
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MOP:Z"<4<OL<3L,#5\NX*_^*80!G05I;5AG*&8WV20S@ ,;*(*.DN7(2;=U(
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M@4=B9H6^S4 [;-.4,A9\W%PZP1JSW&.9B9=[TIK%20J@[ Y5V\V+QC]!<*1
M^XGPDA_<=)]=[!'/_-)B&7 %T&X'U*UG/,+8MG$P9.@C;0>B9=I.)"B#)L5M
MKOX%7.S75C!HH!-HP AEF0ULRHMBF=$H&X#@SK2+<)7;;4#*(DN G7N"QQ/V
M,^59+&P\1K ;-[>O+_Q<Y%<[\A#6)FF<QGX0.<W/O6/$HYESB'@X=T 0MHAT
M^(+R_X1_Q?',^6L\G$YM7(V9W10YS&NI[?91:$Q;7.)N5Y_/UL$=6=8HQKLT
M*7$X3N]+=S*KR48QD9TL^LA2QBB=1V"9I[T[/$2(T;A63.PP+>)VX,&^]G;
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M^+Q6WM;HNX(;"=X<\504%E7<*8/BBJWDAX:STEH$BK"6A5Q LML+N84@"4H
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M<9L;I[?\X72AG=,;OEPKG"D,+<#[I=:NNR$%_9?TJ_\!4$L#!!0    ( +*
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MJ+3;N3P/0#>^;@*K*N^EE;+D3#_,Z2I$[1)H/5/*[@*W07NYQK\!4$L#!!0
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M!V=HE5.<FR]E)?0>$1:H<,.=G<:.L'XQS@^(18O(?H)(,[C3RI46EJK XO^
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M;;C2G6F7N9Z=($R!WM]RK@Z!.:"?QLEO4$L#!!0    ( +* @5AD.J)K0P(
M (H&   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;)V56V^;,!2 _XK%
MI#VUX9;+E@%2TFY:'CI%:;<].W  J\9FM@GMOZ]M",NFA$IY =N<\_D[1ARB
MEHMG60(H]%)1)F.G5*I>NJY,2ZBPG/ :F'Z2<U%AI:>B<&4M &<VJ:)NX'ES
MM\*$.4EDU[8BB7BC*&&P%4@V587%ZQHH;V/'=XX+.U*4RBRX253C AY!_:RW
M0L_<@9*1"I@DG"$!>>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/
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M#VQJ=F%1T3P/0P!R3G9GL4'@*<6&B.&%L(LCULV"XV)O;O(P8H,UHM139N%
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M7EY/9B^OG[@Z%!ZVX\2SP4'?U_<E%^6-3_X^9M67WN#PWQ@8'OTQ5IT%(KO
M\=6$Q@3@V.E'MG#JJ+CTHV?0!5 8)H$\L6<K&,X9VTH&5VUVZW(CY>@O.@QX
M5 5H)GTO(S! ;3WB0)(N1 O8)(@'\!E.Y<);KPB*) 5KEX."3%0LC:&B OY3
M47'2;9P'^!5N*PK%H+]N.8BEO=K]L8_R36_R])TYF38]M73@';A>'@PK^:D9
M< 0OVTZZY;X'&E'YL)U[2SONODLYJ!QQ(3;-'K.4D-_7D<HPUVF%Q.SONUX_
MQ:^&0]25+E<FWL*OTHAN?*8>Z)AHE0XK[0ESZ,L5)6%F-OU.N4DXPG?N^-@V
MOYPY.RZD)XCVVYJUI"%27,)QO(H$_CD^_2^&?WXO(&*<9N"XEY'RZ%9=7*OO
MU,54?>>OW:GS.:Z=G^,_,F39I\DTUL:5P']O:Z1)LKV:9T6?&O +MAKU;E6@
MD?\;[HJ8!S9W=G6%:_.;X-J]^CL5D[^+_@[/0=U!&0 EQ17+@7* [\'AK%G[
M]L!L>.[_(X42D-K'UL'W(M8S;P]\&2M+*0HH4;S4MJ*,7:HG!.G)3*^F5Q-'
M4\X4.,>O8-B>U;T_UM'MPSW=/QZ22#M2/AL>!/_)%IJ?D\@SX^3Y..JAQ-,C
MTHWACHUOT!*^%6YZE[;7-;"@FAPDIT!!J:LM>69[F]4\PT1$SM1M^@CTSCBD
M;7M+MHR>1HQCKFODXFXHV<J_G1!T[+D=V&T_Q9:\32&J-FS&TGD+$+:BS7?9
MQ0\XB:N C]B.,N6YQ\-M3$@L>V#0]CMU3;-@DJ2=UPK8#^:FDGV2NS"\VW:+
MI#&1/M688(&Y0-^/A/%/A-@=E,8/UD5(N2RHR;=#:8--H7:H?38\U?Y.QD]_
MIU9BKYX./S[:4+>'2$1,@E.<H,UKIUNY4_F-EGM],9VHD*W.39&_Z70VI23/
M4(Y7*?=6D<U"CM9>\/ACE9AL(:,P5 G;-)M.:D*O5U2<<HJ-<%^#7R?@+@5.
M"$&_IGX>Z&LD+]S</&JW]KTOQ(4"F=!'5D0CVWT3FY*O\*LPE*O$23#2%>?D
MG.7"CN_C09E<&D\1L8HPB;<,_6D*&WQ)33QUK_'LCF;,7>%?WL.2Q?37&/*Q
MB]D7/][1\#8U)AVJ/MAN6#MK#Q[(1<=-O2Z-K9U^IF->ZAUK\-:^-62Y0$Y&
MY7)M0G[:8SMF@]I,+7$^94D%Y40H#ICZ-EODNAB2P[ISA*X@\J3I1/NR$WEB
MHFQTW1@K;3=_QEW_=A;:2[6C&<A$OTHZ=SS/'AW,L^?@GJIX.WT<A;HFHLOD
M[=0)X8WD\.X=K(2+8E*G\JW+JNU"5L$8]NQJ$"C:.>S9\#3U0UTF7T[ON.9!
ML0; ]\EW!9\A-2K&*B 7A>0. :3B^Z34DH3W?2.8S&XF'79/>>&!'73%TPZ4
MSH:G/W\%++Q'(*X^X$A '2Y//=#K<+WR>6:2M!PKT(MZZ?$O%/+SVTZ)_"(O
MWM$TWH+*&B2HQK[(]0U"FE\1F$[43^Y=/EJ3%WL^Z/;<N/8O1[F4'9"<"4LI
MY/BK&B'?OKZ87+Z\46/Z.I]<O#R?W$POU3CZS"\_D_E0@VFE[:XBWE7WG9I3
M?LL4YSJYOKB>7-U<\:?+R0RLO,GRALHL43MKQ13ZM"?>\?N$+I>W_WI.HBXG
MJI<37@^$^W@A=?"'Q$]3:8$XQ]ZG9]>7(H7I&=*2<>0H]?PVI)SMZ.EL>'+T
MD_B9GQP\].KD,\.GV[$"F2@D0Z6I2-[K]36+WG=E)3ZEJ1]7_Y;70'VE>-.^
M7^;F1@,P+-).\T!\,["OTW6@0[-S#$]V\F1&PK>D9+"5 P9:^:EGNI.P3SEX
M%Q-&CAT5L&-S%^=<;1@;AICLA+O^P>@59>.=JD<(\MXMN(5"MQ!9MU!61Z+L
MNO^V!"SC'4C_99;ROIV!.G1,Q^\@]4R8[>G=,0H,OQ3E#F%(^(Y\2]#/9392
M/_6*Y,/D25\G/J5WBHUUW,'!]43>0^YOW@Y/S8>'IWY%!--YS;HLRL9-J-VF
M);V'W6=6SY =_3F.OH4TM;;^LRDHPIE=29>)WY+.8!<TQO'PB7\YG9U/@G?+
MW[5O$Y_>2['HO12+1H+\Y_.K\:NP:\M]WLZ=. U/, H(#DFUG769#X^F#&V]
MHO@%7F=8O,^,OACRI+OHF]<@.?]:/DKX1E[N*5G/ST^GUQ.$6=SA0DSL.I]6
MLO.;*23[;D,M=.U'W^4V=I'NR:!#3FE/Y(/'YU9_J0[2I)%/C7I6;N\,5^P[
MQ!?!GP-!/KKB/WK"X%+4\I=!_%7_AU5NY<^)M+?+7V7Y!1EQ5E#E:8E'R;6=
MR,2/^U*76_[C(HNR1O++'^D],&WH!OQ.?Q[ ?:$%_)^;>?V_4$L#!!0    (
M +* @5@M&>)M1 4  # 0   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;,58;6_;-A#^KE]Q<)>B+=18DE\DNXF!.%FQ DD7)%F+H=@'6J)M(I3HDE3<
M_/O=4;;B;+(:%%GW):8H\;E[CL_=D3E:*WUKEIQ;^);+PAQWEM:NQMVN29<\
M9^90K7B!;^9*Y\SBHUYTS4ISEKE%N>Q&03#LYDP4G<F1F[O4DR-56BD*?JG!
ME'G.]/V42[4^[H2=[<256"PM370G1RNVX-?<_K&ZU/C4K5$RD?/""%6 YO/C
MSDDXGH9N@?OBD^!KLS,&HC)3ZI8>/F3'G8 \XI*GEB 8_MSQ4RXE(:$?7S>@
MG=HF+=P=;]'?._)(9L8,/U7RL\CL\KB3="#C<U9*>Z76O_$-H0'AI4H:]Q?6
MFV^##J2EL2K?+$8/<E%4O^S;)A!/61!M%D3.[\J0\_*,638YTFH-FKY&-!HX
MJFXU.B<*VI5KJ_&MP'5V<EWM!J@Y7(M%(>8B986%DS1596%%L8!+)44JN(%7
M-VPFN7E]U+5HF)9WTXV1:64DVF,DC.!"%79IX-<BX]EC@"YZ7+L=;=V>1JV(
M9SP]A%[H0Q1$O1:\7AV&GL/K/5\8X,LY@L 'RW/S5U-,*HO]9HN4;6.S8BD_
M[F Z&:[O>&?R\D4X#-ZU\.G7?/IMZ)-KS-ZLE)P(G1C#K0&EX5RPF9#"$HT+
MSDRI>0;,PGLF-'QBLL3O,5'@HRHT3TNMB?B4&6&:^+5ZT,SO9HDCN"-+!ICF
ME->4G^B&*, N.<R5Q$)!=JT+\]@[,1Z2P WG^8SK>M.]<W['I1="]1MM?GMP
MHRR37D5Z[)TRL_18D4&N"GZ/F:-OL=2Q:E\-_ *C./'C?HBCER^2*(S>/1IM
MWGH[D1M[4U;<>AF?V4>?AH'?1^>2,-XSO8=)]%Q,!GX\"OW!,-K#I7[_%#:)
MGXQB/QS%>V9;-#JH-3IXLD8_(I4/1:IR#J_.E<'LNL0(G:H<R<+U$J72I,!V
M_-]+:RP&C,2$=32]!;6B3F!0:"CZ-4?]%<JB\E)99EL)"@,IDVDIF>L:,YZR
M$C5+VN3S.6H5VTPI,WP!6"'$VTS(DAJ+QW+:"(2Q"H9AX@^" &B[AL' #W"<
ME2Z=".B>,VV 4RW\M[#=(M*%C]EA5MRU+7E_Z)TY (\ _G0 KIAZ;HW3$0;1
MDQ@\3&FKQ:QT&43N./9+)3.N22BO4 EQWQ^,$GA-CY'?'_7\)!C :^^S:V-4
M%NZXQK8,J=L#S] >8!'9B>E;5QI2B#%#8G^8#-UHX(?HRMDV*B+'&F!IBQW"
M6^J@&8'BL<)4(69KIC-3JVSS6WOB/?8$&CUQ]A"XR1?2E@O+"J/L5I/HR7/D
M'AS&@RH*P6$OP@!LD1K>M6A^6&M^V*K)*TSM LOLE!?IDE(8OERX[6_L(*U8
M/]A!XMK3^*=WQ/@_X)/4?)(G5YL;S3*^I6+@"E-0W+ED.<.]F6N5/^)\ZHYA
MF#M-G+YCE6%@7 KNX*5;O*H0[1:.,#B@1ITK[1RUU %@I5568A(9!T9M,^.6
M";FW:XZ_7RNPM*Y8<>^=0#^& ^@'<%#/30'5?@"]'ART!'Y4!W[4&H*F,+>)
MOA7M!T42!@_'X>"GRWYC\IDI[9SPP_]%^>UF]QP R;Y7'UKT@_UL:__',D65
M>I,MUE%L,O&/S/$:,Z<ZI+F_NTG2HR0)'R?)$.>B9&?N%-X WG4.O#=P0P>)
MRE_ $>K$<2C([\/&TU-WYQ*'E!?NJHJ'$8*H[G/U;'T=/JDN@0^?5W?I"Z87
MHB"K<UQ*;:P#NKJ>5@]6K=R5<*8LQM<-EWBEYYH^P/=SI>SV@0S4_R28_ U0
M2P,$%     @ LH"!6&RS&"N& @  6 4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&ULA911;YLP$,??^106FZ9-H@4,I"1+D))NU?I0J6J[]6':@P.7
M8-78S'::]MOO# G+I#1[@;-]]_/_P']/MTH_F1K DI=&2#/S:VO;21B:LH:&
MF7/5@L25E=(-LSC4Z]"T&EC5%34BI%$T"AO&I5],N[E;74S5Q@HNX583LVD:
MIE\7(-1VYL?^?N*.KVOK)L)BVK(UW(/]WMYJ'(4#I>(-2,.5)!I6,W\>3Q:I
MR^\2?G#8FH.8N$Z62CVYP74U\R,G" 24UA$8OI[A$H1P()3Q>\?TARU=X6&\
MIU]UO6,O2V;@4HE'7MEZYN<^J6#%-L+>J>TWV/63.5ZIA.F>9-OG4NJ3<F.L
M:G;%J*#ALG^SE]UW."C(HS<*Z*Z =KK[C3J57YAEQ52K+=$N&VDNZ%KMJE$<
ME^ZGW%N-JQSK;'$MGT%:I5_)QP>V%& ^34.+7+<:ECO&HF?0-Q@Q)3=*VMJ0
MK[*"ZE] B((&572O:D%/$K] >4Z2." THLD)7C)TF72\Y+]=_IPOC=5X%GX=
MZ[.GI,<ISA\3T[(29CX:P(!^!K_X\"X>19]/:$P'C>DI>G&/?JLV HA:D4'O
M,9$G,<=%#CRO5.@G8Z%RV]@:R$H)-":7ZXDW-QY.=D_OCFT]//.@.1.&O"=Q
MD(W3(*(YQC1(XW$PSJGWB(X[X_*LU:H$8T@6Y'$6Q..4)$$ZRH.+B'I77'(\
MGY6W5JHR)(UH,(K')$['09YEWH.R3"#T DOC($]CC$=!E.1!EHS)L>\:'ISV
M!O2Z\[0AI=I(VQ_\87:X-N:]6_ZF]W?.#=-K+@T1L,+2Z/PB\XGN?=P/K&H[
M[RR512=V88U7'VB7@.LKI>Q^X#88+M/B#U!+ P04    " "R@(%8!QQ+JWP"
M  "P!0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RE5-]OTS 0?N]?
M<0H(@50MO]NNM)':#00/$]4VX 'QX":7QIIC!]M9QW^/[:2AB*Y"XB6YL^_[
MOKM+[A9[(1]4A:CAJ69<+;U*ZV;N^RJOL";J0C3(S4TI9$VT<>7.5XU$4CA0
MS?PH""9^32CWLH4[V\AL(5K-*,>-!-76-9$_U\C$?NF%WN'@ENXJ;0_\;-&0
M'=ZA_MQLI/'\@:6@-7)%!0>)Y=);A?-U8N-=P!>*>W5D@ZUD*\2#=3X62R^P
M"2'#7%L&8EZ/>(6,62*3QH^>TQLD+?#8/K"_=[6;6K9$X95@7VFAJZ4W\Z#
MDK1,WXK]!^SK22U?+IAR3]AWL6GB0=XJ+>H>;#*H*>_>Y*GOPQ%@%CP#B'I
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M2P.$-'YM,>T^I0G<7^_0/[6U8RTKIF IRN]%JO.9'=DDA35K2GTC-E]@6\_
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M<VAE971S+W-H965T,S8N>&ULI55-;]LP#+WG5Q!N46R 4=OR=YL$2-L-ZZ%
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MC]($T'TAA-X=3(+AKV/Z&U!+ P04    " "R@(%8-;/H_S@%  !F#   &0
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M7E14UH#V"RG-<6(/Z-_H];]02P,$%     @ LH"!6-6):A9T!0  + T  !D
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M2$"MPU=>MMQV%H_;XGF="7@R[>WVP=;8:H>2AX*[K?;L,HM^JX_Z$H^Z(N$
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M@[0#S/NI$'IS8R<H?_\8_@=02P,$%     @ LH"!6"#7C.>< P  &A0  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULK5C1CMHX%/T5*UM5K;2=Q D0
MF$*D&4955^JL1D7M/E1],,D%K'%LUG:@_?NU$R8A.YD(!K^ G=QSN,?7N3EX
MNA?R46T -/J5,ZYFWD;K[;7OJW0#.5%78@O<W%D)F1-MIG+MJZT$DI6@G/EA
M$(S\G%#N)=/RVH-,IJ+0C')XD$@5>4[D[UM@8C_SL/=TX2M=;[2]X"?3+5G#
M O2W[8,T,[]FR6@.7%'!D835S+O!U_,PL( RXCN%O3H:(RME*<2CG?R5S;S
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M<&XE')&UQ,:UV/BU;2!VJ=$164OCN-8X=MP&QL]V5F<;>![6VP8F=;Z3B]K
MQ&5A')&UA.*@>:T'KV\$_=CNW%#GF_5RHK:^(]N"3^@E86\OZ:<XMYZNV-J"
M&U>!7VTKL%-?X8JMK;-Q%MBUM>@G/&<W7T[4%MW8$WR9/\%.#8HKMK;8QJ+@
M"SP*/MFD=$3VNA3<V!1\BD^)^GN+4Z/BBJTMN+$J^-5>!3LU*Z[8VCH;NX)=
M^Y5^PG-ZR^5$;=&-Y\&7F1[LU/6X8FO_]6YL3WB![>G'GE%,!T25/O_HX,:>
MFMT3N:9<(08KPQQ<Q:;'R>H@JIIHL2W/<I9":Y&7PPV0#*0-,/=70NBGB3T>
MJH\#D_\ 4$L#!!0    ( +* @5@X6W?$Y@(  !X*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;,56VX[:,!#]%2N5JE9J24BX=0N1N+3J2ET)02\/
MJSZ89$*L3>S4-K#[]QT[(0L(Z%:*U!?P9<[)G.-)/,.=D \J!=#D,<^X&CFI
MUL6-ZZHHA9RJEBB XTXB9$XU3N7:584$&EM0GKF^Y_7<G#+NA$.[-I?A4&QT
MQCC,)5&;/*?R:0*9V(V<MK-?6+!UJLV"&PX+NH8EZ._%7.+,K5EBE@-73' B
M(1DYX_;-=&#B;< /!CMU,"9&R4J(!S.YC4>.9Q*"#")M&"C^;6$*66:(,(W?
M%:=3/]( #\=[]L]6.VI94053D?UDL4Y'SL A,21TD^F%V'V!2D_7\$4B4_:7
M[*I8SR'11FF15V#,(&>\_*>/E0\'@';O L"O /XIH',!$%2 P HM,[.R9E33
M<"C%CD@3C6QF8+VQ:%3#N#G%I9:XRQ"GPV5Y>D0D9,G6G"4LHER3<12)#=>,
MK\E<9"QBH,B;&6C*,O66O"=+K*9XDX'!?9,TACU"D05$P+9TA9NS#9!$BOR(
M>FI%@51(LX M< R: (]2S..!W-]!O@+Y"S?W@60J> 1<2VH/?L'4<]C0U6B"
MD>)&E>!)*=B_(+CMDSO!=:K()QY#?$S@HGNUA?[>PHE_E7$&48L$[7?$]_S@
M3$+3E\/]*^D$]8D&EJ]S@6\J\H+R)S*^:M)5#O/IN%$%C6#DX+=!@=R"$[Y^
MU>YY'\\);(CL2&ZGEMNQ[,&E FZB$N^_(BNYU9"KLVYUFG2K(;(CM[JU6]V_
M%,?AJR3-JU2 -$OXR3ZGO*3[8.G,C; -O5:G/W2WAXK.!M4Q1XGVZD1[+ZKB
MR=4JOLKQK^?2$-F1W'XMM___J[C?I%L-D1VY-:C=&C1;Q8,S!1KX)U5\-B@X
M*6/WX*I%T]>V U'$GE5Y9=2K=9,SMG?[R?H$FY^R5WFF*3NG.RK7C"N208*4
M7JN/KY<LNY%RHD5A+_25T'CR=IAB P?2!.!^(H3>3\P#ZI8P_ -02P,$%
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MUH*M6$&%(?=%(;?",+$F<\E9P4"3JQD8RKA^2Z[) LNIW'*P?I^QV#Z*0M9
MKOZ2&M_/09&IK&M,TZ*B"M#AZV)&KEZ_'84&2=NCPZ(E.&D()F<(Q@GY)(6I
M-'DO2BB/ 4)4VTE.'B5/DHN(,RAN2!J_(TF4I!Y"T^>[)Q?HI%T&4H>7GLN
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M971S+W-H965T-3 N>&ULK51M;],P$/XKED%HDZ#.2U^VDD3:6B;X@%2M&GQ
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MTU*U2> Z0>T7C,ECH _H&V_Z&U!+ P04    " "R@(%8@*>BZHD"  #8!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6RM55UOFS 4_2L6FZ966@KF
MJ] 1I#91U3Y,BIIU?9CVX,!-8M5@9CNA_?>S@;(T(5$?]@*^]CWGGF/L2U)S
M\2S7  J]%*R48VNM5'5EVS);0T'D!:^@U"M++@JB="A6MJP$D+P!%<QV'2>T
M"T)+*TV:N9E($[Y1C)8P$TANBH*(UQM@O!Y;V'J;>*"KM3(3=II49 5S4(_5
M3.C([EER6D I*2^1@.78NL97D]#D-PD_*=1R9XR,DP7GSR:XS\>68P0!@TP9
M!J)?6Y@ 8X9(R_C3<5I]20/<';^QWS;>M9<%D3#A[(GF:CVV(@OEL"0;IAYX
M?0>=G\#P99S)YHGJ-C?P+91MI.)%!]8*"EJV;_+2[<,. !\#N!W _2C ZP!>
M8[15UMB:$D721/ :"9.MV<R@V9L&K=W0TGS%N1)ZE6J<2N_++92*BU=T-@5%
M*)/G:(3F^K#D&P:(+]&_C!%ZG$_1V>?SQ%:ZM"&PLZ[,35O&/5)F"MD%\O!7
MY#JN-P"??!SNOH?;VG#OVNU=NPV?=X1OV-^OZX540A^LWT,&6T9_F-%<MBM9
MD0S&EKY-$L06K/3+)QPZWX;L_B>R=^:]WKQWBCU](+4^00H$)4P..6WA00,W
M76";XB#V'3=*[.VNB<,\U\=Q'+E]WCM]?J_//ZGO2=_[$2U'E> 9R$&%+4&X
M4SF(<(!C?T_A89[GA]&E<T1AT"L,3BJ\I2755RY'*\[S08'!06&]?R&.]_0=
MIF$_CH)@6%[8RPM/ROO!%6%#JL*##W8981SY>$_685[H>%'@Q7NZ[)V^8WK^
M=R)6M)2(P5(CG8M+32':/MH&BE=-*UIPI1M;,USK7P\(DZ#7EYRKM\!TM_YG
MEOX%4$L#!!0    ( +* @5@1!PXR;P(  )8&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;*U576_:,!3]*U8V3:VTDF^@+$1J8=7V, V5=7N8]F"2
M"['JQ)EM/O;O9SLA"A 0FO:2^-KW')][[-Q$6\9?108@T2ZGA1A;F93ER+9%
MDD&.18^54*B5)>,YEBKD*UN4''!J0#FU/<?IVSDFA15'9F[&XXBM)24%S#@2
MZSS'_,\C4+8=6ZZUGW@FJTSJ"3N.2KR".<B7<L959#<L*<FA$(05B,-R;#VX
MHTFH\TW"=P);T1HC7<F"L5<=?$['EJ,% 85$:@:L7AN8 *6:2,GX77-:S98:
MV![OV9],[:J6!18P8?0'264VMH862F&)UU0^L^TGJ.LQ A-&A7FB;9WK6"A9
M"\GR&JP4Y*2HWGA7^] "N,$9@%<#O&L!?@WP3:&5,E/6%$L<1YQM$=?9BDT/
MC#<&K:HAA3[%N>1JE2B<C&<<2DQ2]'&G[H4 @7"1HJ\R XXF:\ZAD.A!") "
MW4Q!8D+%+;I#<W69TC4%Q);H>H8[]#*?HINWMY$ME70MP$YJF8^53.^,S"DD
M/>2[[Y'G>'X'?'(]W#N$V\JPQC6O<<TS?/X9OG^K_^?#0DBN+NZO+@.J'8/N
M'?7'/!(E3F!LJ:]5 -^ %;][X_:=#UUV_">R W/\QAS_$GMSI: VI*O8BB$T
M#+K1;.(@#-Q0G<VF7<9IFM_WAX-!DW8@,&@$!A<%5H?#(0&RP0O:K;"BZ+>W
MOA_X_I' TZS <P?#;GUAHR^\J.\;DYAV:0I/7;OWA\/P2%1'FM-WPO!(E=WJ
M&KIC?\%\10J!*"P5T.D-% .ONF 52%::1K)@4K4E,\S4CP.X3E#K2\;D/M"]
MJ?D5Q7\!4$L#!!0    ( +* @5B=E7Q7@@(  '$&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;*U576_3,!3]*U9 :$AC^6ZWT49:VR%X&*HV#1X0
M#VYRVUAS[,QVV^W?<^VDH2M9A1!2U=C./>>>>VV?C+92/>@2P)"GB@L]]DIC
MZDO?UWD)%=5GL@:!;Y925=3@5*U\72N@A0-5W(^"8.!7E DO&[FUN<I&<FTX
M$S!71*^KBJKG"7"Y'7NAMUNX9:O2V 4_&]5T!7=@[NNYPIG?L12L J&9%$3!
M<NQ=A9?3U,:[@&\,MGIO3&PE"RD?[.1+,?8"*P@XY,8R4'QL8 J<6R*4\=AR
M>EU*"]P?[]@_N=JQE@75,)7\.RM,.?;./5+ DJZYN97;S]#6XP3FDFOW3[9-
M;)IZ)%]K(ZL6C HJ)IHG?6K[L <(!Z\ HA80'0*25P!Q"XA=H8TR5]:,&IJ-
ME-P29:.1S0Y<;QP:JV'"[N*=4?B6(<YD<X4'0IGG4S+G5!A"14&N']>LQITR
MI^0KGJ.3&1C*N'Y//I#[NQDY>?M^Y!O,;1G\O,TS:?)$K^0)(W(CA2DUN18%
M%"\)?!3=*8]VRB?14<89Y&<D#D])%$1QCZ#IW\.C(W+BKI&QXXO_O9$_KA;:
M*#RX/_OZU] G_?3V,E_JFN8P]O"V:E ;\+)W;\)!\+&O]O]$]J(32=>)Y!C[
M7B?JKA.PZP0IF*ZEIESW]: A3AVQ]9]-%@9!F.#^;/:KZPF+AOCKPE[H3CO=
MZ5'=,\!FY(PZ>X$G]$D-?2+3/[)'@XOA^<7P0&5/7#(X3X87!S+]O=M;@5HY
M4],DEVMAFNO0K7:^>>7LXF!]@G[:V-]OFL:,;ZA:,:$)AR52!F=#5*4:@VLF
M1M;.(Q;2H..X88G?!% V -\OI32[B4W0?66R7U!+ P04    " "R@(%8;4NP
M1YH%  "7*@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R]FEUOXC@4
MAO^*Q:Y6':E38CL)H0M(TW9&.U*[6TW5W8O17KA@()I\,+;3#VE__#HAC9,V
MG )UN&D)^+SG^(U/\F R>DC%#[GD7*''.$KDN+=4:G7:[\OIDL=,GJ0KGNA/
MYJF(F=*'8M&7*\'9K B*HSYQ'+\?LS#I34;%>]=B,DHS%84)OQ9(9G',Q-,9
MC]*'<0_WGM_X%BZ6*G^C/QFMV(+?<'6[NA;ZJ%^IS,*8)S),$R3X?-S[A$_/
M72</*$;\'?('67N-\JG<I>F/_.#K;-QS\HIXQ*<JEV#ZWST_YU&4*^DZ?I:B
MO2IG'EA__:S^I9B\GLP=D_P\C?X)9VHY[@4]-.-SED7J6_KP!R\GY.5ZTS22
MQ5_T4(YU>FB:297&9;"N( Z3]7_V6!I1"\#NA@!2!I!M V@90(N)KBLKIG7!
M%)N,1/J 1#Y:J^4O"F^*:#V;,,E/XXT2^M-0QZG)M= K0JBG8W0=L40AELS0
MYY]9N-*G2AVC/_5".KK@BH61_( ^HAN]C&99Q%$Z1V"H'GM[<X&.?OTPZBM=
M9YZM/RUK.EO71#;4=,&G)XCB8T0<0EO"S[</)\WPOG:GLHA4%I%"CV[0VW[.
MWR]U*/JJ>"S_;9OV.H_;GB=OV%.Y8E,^[NF.E%S<\][DMU^P[_S>9H(EL88E
MM+*$0NJU5;.J;.!FU2Q$*F6; 6M5KU#-+S#W$]=WO*%/\:A_7Y]<RT"7X@%U
M_6I@HW"W*MP%"_\TG69Q%C'%9[K9M3/3D.67D[9BUTI^K8:/.' #.G2#%]6V
MC?2"@><3I[U<KRK7>X_/"5=MA7NORB$#3U<3T!=UMPP,7!</R :7_:IL'RS[
MDMVE@JE4/!45QRS)YOIZG8DP69CZT?<K'M]QT=HJ8()=6\626,.+0>7%X$!7
MCX%-2RR)-2P)*DN"3JX>P:N+ G&&'O6=EU>/X-6ZQD,<X*&_H1V'5>%#F^L:
M_8>NPB2,LQA<ZF#.7<^K);&&/=@Q,.$<:+&7B2RY8DNM:4N-L?![%OQGJ<*X
MN"7=2C[/(G2IR5:BHS!!3YP)V8Y0<$JZ#FTU XS<UPQ#4Q@DDWV:B#V^V41P
MTIW72Q=PA0U=87JH-@(Y;F=;+*DU;3'LAF%XZZ2-X)38 ?H(#-W7#8.&&&;#
MLRR,9KIG9.%#&*]$>L]S)R3<**#JSBO"DEK3 \.9V#]4HU@%3EMJ35L,<F(0
MW_8&K%*V25B#P/5\[P5AE2,;7QT<QW.P/VA'+&S@$,-TN,6ZWA*LX$0[GU-+
M:DU;#'KBX:&6NE7@M*76W)HQQ$E =.ODGO!&2NB> (?NZX8!30)3WY:]LP5/
MP8EVWJOJ CE);0/O8#MX=K?PNL!,8C"3O&L7;[_>@5/2(= [7= E,71)8-3[
M:SX/IQS-,Y&$^ML(;]H!-XLE$BQ]Z((KB>%*XAVJ6:RBIBVUIBT&-0F\I[DO
M4Y6R=:;"#O7IP'V!5.7 .E(-'8<Z&_9BB:%! M/@E@M[2ZB"D^U\4KO8AR2&
M-4EPJ+5NE35MJ35M,:Q)X'W.3FX,<$I@OPJ.W/>7+D.8%,:]'=IG"ZZ"D^VZ
M3FRI-:TQN$GQ@=J'6L5-6VI-6PQN4GB'LXOV>2,E])T$#MW7C=I/Q3#RG:>)
M5");/[6AYZB_DRQT'GB7"M;<>3UT09;4D"5U#]4F5D'3EEK3%@.:]%T_;N_7
M)GM (FKUI@O:I(8V:3>T25_3)AGX 2$O:9.^IDWJ^X&SZ0$+:G"3PKAYF=<*
M]K95@K2EUIRM(4AZ*(*D5@G2EEK3%D.0]/ $":?<I;>[ $K7 *7[KBW+C;U=
MRM9[V\-^4-MQ+Y]&>G/<NO!^[:G!_)'-*R8682)1Q.<ZT#D9: 6Q?@IR?:#2
M5?$@X5VJ5!H7+Y><S;C(!^C/YVFJG@_R9Q.K9U$G_P-02P,$%     @ LH"!
M6(E-+R#K @  RPH  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULK59=
M;]HP%/TK5C9-K=0V7Q"@@T@%5K52.U6MNCU,>S#)!:PZ-K,=:/?K9SLA!9:F
M'^*%V([/N>=<XYO;7W'Q(.< "CUFE,F!,U=J<>JZ,IE#AN4)7P#3;Z9<9%CI
MJ9BY<B$ IQ:443?PO,C-,&%.W+=K-R+N\UQ1PN!&()EG&19/0Z!\-7!\9[UP
M2V9S91;<N+_ ,[@#=;^X$7KF5BPIR8!)PAD2,!TX9_[IR/<,P.[X06 E-\;(
M6)EP_F FE^G \8PBH) H0X'U8PDCH-0P:1U_2E*GBFF F^,U^[DUK\U,L(01
MIS])JN8#I^N@%*8XI^J6KRZ@--0V? FGTOZB5;&WI2,FN50\*\%ZGA%6//%C
MF8@-@!^]  A*0+ +:+T "$M :(T6RJRM,58X[@N^0L+LUFQF8'-CT=H-8>88
M[Y30;XG&J?B2*<QF9$(!G4D)2J*#,2A,J#Q$Q^C^;HP./A_V7:5#&8";E+3#
M@C9X@=8/T#5G:B[1-Y9"NDW@:HV5T& M=!@T,HXA.4&A?X0"+PAK!(W>#@\:
MY(15WD++%[XY;[^N]!9TJ2"3O^L25O"UZOG,;3V5"YS P-'748)8@A-_^>1'
MWM<ZLWLBV[+>JJRWFM@WK6-KO<YM0=&V%*:4+&._YWLMK^\N-WTT1OJ@CW;E
MH_TN'PAG7"CR%](CE$N8YA1176)J[34S^QYZ BSJD*-&Y <=1Y7CZ,V."Z_8
MUE)XU%\%"75&H_ISW#G&UW9MJ>U4:CN-:K_K(UEBFM?J*J#11L2P&WC='5V=
M_W2U.Z$?U.OJ5KJZC;K."2,*CJ_T?R-%-77@&K()B-H:T$C\WAJP)[*M'/2J
M'/3V7/YZ^[2^)[(MZ[[W_,GT]GV-2L;7[E%SX/<:<S?:@@S$S'9+$B4\9ZKX
M\%:K54=V9ON0G?6AZ=1LN_%,4[1YUUC,").(PE13>B<=[5 4G5,Q47QAFX\)
M5[J5L<.Y[C9!F WZ_91SM9Z8 %7_&O\#4$L#!!0    ( +* @5@G!?^$Q ,
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M<FMS:&5E=',O<VAE970V,BYX;6S%FVMOVS84AO^*X W#!K2U>">[Q,"Z;-B
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MW9W1#?$C'&.LU1[<$:2?@1\Z!A0U0%%'.$6"\\-=DVSPH95OZFR <28"XU"
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M?8I1-P0MJUWWD@JYAZ\NMP0GA*D ^7Q-J7AMJ!]HSY+&_P%02P,$%     @
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MH?L_%,9 [R\Y5_<3<T#?4<[_ E!+ P04    " "R@(%8S4793$4#  #1"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6RMEEV/FS@4AO^*Q5:KJ=09
MOC\RFR"U&56MU&U',SO;BVHO'#@D5@VFMIFT_WZ/@= T8<@HZDV"P>_+\Q[
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M&<9/^39>BD]GY2E$+K)'<7;UIS_HL]&?^VJ-Q$P2LTC,)C&'Q%P2\TC,)[&
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M49H\)+1!O_$K7XY]ZBKN:F=PM:-!/U2S4,U&-0?5W$:3SNL-HV?V#HWPH5J
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M_)NCF4%4,U'-0C4;U1Q4<U'-0S4?U0)4"U$MHC1Y3&@S@W/UBG^'GP1X_B!
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M@@8  !HD   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;+V:6V_;-A2
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M-<'2#U'2$Q&ODD\S[F,AXC Y7%(B2Z0$Y/UY'(O=B1H@_QQH\C]02P,$%
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M("MZ^V(@:):WQTLJ9+.=OX;R/@1,&<CO*TK%;J 6J&Y8[E]02P,$%     @
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M-$B $];@S-0(C NVKER%@C>U%ERS(D\W"%U0A8Q.BCPB94VJM%:2XBS2!J?
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M\ /4'11J9_/"7+TZ5T^;ZV?*.4C*A.^)-'IRV!)J!;T##(O!]$O9:2LS9^3
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MW!!T6SR_OZ="T*SXNB%8EIIJ@#R^HE0<-M0)ZG=&%O\#4$L#!!0    ( +*
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MH41B52%6=01=Z%IF0H6LC'1S+HM78"I /I]2*K8=-4%3#L?_ %!+ P04
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M6O2+-L7B/BI7^:V;*@6D^_21.)*E*0T\_&PK-XO*/9]: !2UJ?(&?5&EF:<
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M.[,-M/]^MA-28&E$47H#L>/S^GV<8^=DL&;\22P )'I.$RJ&UD+*[-RV1;2
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M*GW-Y4)]G0#7 ]3]&6-RT] 3E-\[X3]02P,$%     @ LH"!6#R08"8\ P
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M>TJB*$G\"&!^!5&$(? TX@BF #1@2!35[\&=]U&X>D^%Z__OC9X!4$L#!!0
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MS7?J/8R?AS+<>K[6>/WOI'J\G%MNE[\NOW9.;L(5Y_J^8GC^"U!+ P04
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ LH"!6"-_)<+N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MLH"!6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "R@(%8VA2GQZ0'  "G,P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MLH"!6'Y2I8LQ @  I04  !@              ("!YP\  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +* @5A0]G'VQ@8  (X:   8
M          " @4X2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "R@(%86:CQ_[$"  #+!P  &               @(%*&0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ LH"!6$Z<M1!^!   _ \
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M965T.2YX;6Q02P$"% ,4    " "R@(%8A!WM*E4"   O!0  &0
M    @(%H2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M +* @5B^4RQ 7P,  &8'   9              " @?1*  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ LH"!6+8DG(,+ P  +P8  !D
M             ("!BDX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "R@(%85C6.A)D"  #(!0  &0              @(',40  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +* @5@H,1]7@P,
M &L'   9              " @9Q4  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ LH"!6+58= ?2 P  [0@  !D              ("!
M5E@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "R@(%8
M-O!ZAND"  !:!@  &0              @(%?7   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( +* @5BF;9$%N0<  &<1   9
M      " @7]?  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ LH"!6+T\%=L""   /1(  !D              ("!;V<  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "R@(%8PM?+MU\$   ?"0
M&0              @(&H;P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( +* @5C"??LU#Q,  -T]   9              " @3YT  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ LH"!6)HUF(P6
M P  [08  !D              ("!A(<  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "R@(%8[3F!2L$#  "J!P  &0
M@('1B@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +*
M@5@,88T/M0D  %47   9              " @<F.  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ LH"!6",:K-:N!0  $0T  !D
M         ("!M9@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "R@(%8/KZM_H<"  !H!0  &0              @(&:G@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +* @5BI??#R,P,  -(&
M   9              " @5BA  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ LH"!6 T9J*%T @  ;04  !D              ("!PJ0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "R@(%8P9ER
MBD("  "9!0  &0              @(%MIP  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( +* @5AD.J)K0P(  (H&   9
M  " @>:I  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MLH"!6*%-"3CF%P  >D8  !D              ("!8*P  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "R@(%8+1GB;40%   P$   &0
M            @(%]Q   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( +* @5ALLQ@KA@(  %@%   9              " @?C)  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ LH"!6 <<2ZM\ @
ML 4  !D              ("!M<P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "R@(%8$/=2 BX#  #?!@  &0              @(%H
MSP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +* @5CX
MM7+#\0(  .X&   9              " @<W2  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ LH"!6$=L9I/. @  1@8  !D
M     ("!]=4  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* @5A0)07^O ,  *\'   9              "
M@6GL  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ LH"!
M6-6):A9T!0  + T  !D              ("!7/   'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "R@(%8@4I91QX%   !#   &0
M        @($']@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( +* @5A!%;S[$@(  (L$   9              " @5S[  !X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ LH"!6),ING[(!   "QD
M !D              ("!I?T  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " "R@(%8(->,YYP#   :%   &0              @(&D @$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +* @5@X6W?$
MY@(  !X*   9              " @7<& 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ LH"!6&YACJAB P  40X  !D
M ("!E D! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "R
M@(%8,)K^8'$#  #Z"@  &0              @($M#0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +* @5C<JGQ$'P(  !@%   9
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M970U-"YX;6Q02P$"% ,4    " "R@(%8G95\5X("  !Q!@  &0
M    @(&K'0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M +* @5AM2[!'F@4  )<J   9              " @60@ 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ LH"!6(E-+R#K @  RPH  !D
M             ("!-28! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " "R@(%8)P7_A,0#  !*$@  &0              @(%7*0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +* @5B*S:3-\P(
M "X)   9              " @5(M 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ LH"!6,P5.FU?$@  ]$8! !D              ("!
M?# ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "R@(%8
M+L!)9L,$  "P(   &0              @($20P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( +* @5CM1DQ"10@  .T_   9
M      " @0Q( 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ LH"!6(:"I;4!!0  N",  !D              ("!B% ! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "R@(%8+6!:*L(#  !7$@
M&0              @(' 50$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( +* @5CO]MT3/0,  %T*   9              " @;E9 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ LH"!6,U%V4Q%
M P  T0L  !D              ("!+5T! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " "R@(%8 S5'WNX7   S70$ &0
M@(&I8 $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( +*
M@5B2"S:"@@8  !HD   9              " @<YX 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ LH"!6*0.AF'7 P  ,P\  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( +* @5CI;@.=,@0   $,   9
M  " @7>1 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
MLH"!6"X<U7TQ!0  /R(  !D              ("!X)4! 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " "R@(%8N G-DR0#   :"P  &0
M            @(%(FP$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( +* @5C&,RPD"P0  (8/   9              " @:.> 0!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ LH"!6#N.7EC5 P
M@ P  !D              ("!Y:(! 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    " "R@(%8[GNGM*('  #D*0  &0              @('Q
MI@$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( +* @5@U
MH-_J=P(  %4&   9              " @<JN 0!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ LH"!6(MLFDX, P  ^PP  !D
M     ("!>+$! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
M" "R@(%8/)!@)CP#  #L$P  #0              @ &[M $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( +* @5B7BKL<P    !,"   +              "
M 2*X 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +* @5@KC=?1P 4  ,<T   /
M              "  0NY 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "R
M@(%8JYPQ2VX"  #:+P  &@              @ 'XO@$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "R@(%81.3?6!X"  "7+@  $P
M            @ &>P0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     60!9
+ &88  #MPP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>218</ContextCount>
  <ElementCount>402</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BusinessOperations</Role>
      <ShortName>Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/CashandCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Trade Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/TradeAccountsReceivable</Role>
      <ShortName>Trade Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Bank Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebt</Role>
      <ShortName>Bank Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Other Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNet</Role>
      <ShortName>Other Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Bank Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebtTables</Role>
      <ShortName>Bank Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/Revenue</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Other Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNetTables</Role>
      <ShortName>Other Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Business Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BusinessOperationsDetails</Role>
      <ShortName>Business Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BusinessOperations</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/CashandCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/CashandCashEquivalents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Trade Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/TradeAccountsReceivableDetails</Role>
      <ShortName>Trade Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/TradeAccountsReceivable</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Inventory (Details) - Schedule of Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of Inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/InventoryTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssetsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssetsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Bank Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebtDetails</Role>
      <ShortName>Bank Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable</Role>
      <ShortName>Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable</Role>
      <ShortName>Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeasesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Operating Leases (Details) - Schedule of Lease Costs and Other Lease Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable</Role>
      <ShortName>Operating Leases (Details) - Schedule of Lease Costs and Other Lease Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeasesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Operating Leases (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable</Role>
      <ShortName>Operating Leases (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeasesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable</Role>
      <ShortName>Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable</Role>
      <ShortName>Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Stockholders' Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable</Role>
      <ShortName>Stockholders' Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable</Role>
      <ShortName>Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RevenueTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable</Role>
      <ShortName>Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RevenueTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Other Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNetDetails</Role>
      <ShortName>Other Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNetTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Other Expenses, Net (Details) - Schedule of Other (Income) Expenses Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable</Role>
      <ShortName>Other Expenses, Net (Details) - Schedule of Other (Income) Expenses Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNetTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Provision</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIncomeTaxProvisionTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Tax Provision</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Expense Differs from the Expected Tax Computed</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Tax Expense Differs from the Expected Tax Computed</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Income Taxes (Details) - Schedule of Significant Components of Our Deferred Tax Assets Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Significant Components of Our Deferred Tax Assets Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Segment Information (Details) - Schedule of Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofSegmentInformationTable</Role>
      <ShortName>Segment Information (Details) - Schedule of Segment Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformationTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RelatedPartyTransactions</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0202277-10k_immu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/EmployeeBenefits</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentAnnualReport, dei:DocumentTransitionReport, us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent -  ea0202277-10k_immu.htm 9832, 9856, 9858</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0202277-10k_immu.htm">ea0202277-10k_immu.htm</File>
    <File>iccc-20231231.xsd</File>
    <File>iccc-20231231_cal.xml</File>
    <File>iccc-20231231_def.xml</File>
    <File>iccc-20231231_lab.xml</File>
    <File>iccc-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="924">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>104
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0202277-10k_immu.htm": {
   "nsprefix": "iccc",
   "nsuri": "http://immucell.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0202277-10k_immu.htm"
     ]
    },
    "schema": {
     "local": [
      "iccc-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_def.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_pre.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iccc-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iccc-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iccc-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iccc-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 357,
   "keyCustom": 45,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 28,
   "hidden": {
    "total": 102,
    "http://fasb.org/us-gaap/2023": 92,
    "http://immucell.com/20231231": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 218,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 829,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 924,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://immucell.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Balance Sheets (Parentheticals)",
     "shortName": "Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://immucell.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://immucell.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Statements of Stockholders\u2019 Equity",
     "shortName": "Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://immucell.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://immucell.com/role/BusinessOperations",
     "longName": "995306 - Disclosure - Business Operations",
     "shortName": "Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://immucell.com/role/CashandCashEquivalents",
     "longName": "995308 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://immucell.com/role/TradeAccountsReceivable",
     "longName": "995309 - Disclosure - Trade Accounts Receivable",
     "shortName": "Trade Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://immucell.com/role/Inventory",
     "longName": "995310 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "995311 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNet",
     "longName": "995312 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://immucell.com/role/IntangibleAssets",
     "longName": "995313 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://immucell.com/role/AccountsPayableandAccruedExpenses",
     "longName": "995314 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://immucell.com/role/BankDebt",
     "longName": "995315 - Disclosure - Bank Debt",
     "shortName": "Bank Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://immucell.com/role/ContingentLiabilitiesandCommitments",
     "longName": "995316 - Disclosure - Contingent Liabilities and Commitments",
     "shortName": "Contingent Liabilities and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://immucell.com/role/OperatingLeases",
     "longName": "995317 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://immucell.com/role/StockholdersEquity",
     "longName": "995318 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://immucell.com/role/Revenue",
     "longName": "995319 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://immucell.com/role/OtherExpensesNet",
     "longName": "995320 - Disclosure - Other Expenses, Net",
     "shortName": "Other Expenses, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://immucell.com/role/IncomeTaxes",
     "longName": "995321 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://immucell.com/role/SegmentInformation",
     "longName": "995322 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://immucell.com/role/RelatedPartyTransactions",
     "longName": "995323 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://immucell.com/role/EmployeeBenefits",
     "longName": "995324 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://immucell.com/role/SubsequentEvents",
     "longName": "995325 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c27",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c27",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://immucell.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://immucell.com/role/InventoryTables",
     "longName": "996002 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNetTables",
     "longName": "996004 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://immucell.com/role/IntangibleAssetsTables",
     "longName": "996005 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://immucell.com/role/AccountsPayableandAccruedExpensesTables",
     "longName": "996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://immucell.com/role/BankDebtTables",
     "longName": "996007 - Disclosure - Bank Debt (Tables)",
     "shortName": "Bank Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://immucell.com/role/OperatingLeasesTables",
     "longName": "996008 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://immucell.com/role/StockholdersEquityTables",
     "longName": "996009 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://immucell.com/role/RevenueTables",
     "longName": "996010 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://immucell.com/role/OtherExpensesNetTables",
     "longName": "996011 - Disclosure - Other Expenses, Net (Tables)",
     "shortName": "Other Expenses, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://immucell.com/role/IncomeTaxesTables",
     "longName": "996012 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://immucell.com/role/SegmentInformationTables",
     "longName": "996013 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://immucell.com/role/BusinessOperationsDetails",
     "longName": "996014 - Disclosure - Business Operations (Details)",
     "shortName": "Business Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable",
     "longName": "996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c39",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c39",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Trade Accounts Receivable Due from Significant Customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c44",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c44",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://immucell.com/role/CashandCashEquivalentsDetails",
     "longName": "996020 - Disclosure - Cash and Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://immucell.com/role/TradeAccountsReceivableDetails",
     "longName": "996021 - Disclosure - Trade Accounts Receivable (Details)",
     "shortName": "Trade Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c50",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://immucell.com/role/InventoryDetails",
     "longName": "996022 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://immucell.com/role/ScheduleofInventoryTable",
     "longName": "996023 - Disclosure - Inventory (Details) - Schedule of Inventory",
     "shortName": "Inventory (Details) - Schedule of Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996024 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNetDetails",
     "longName": "996025 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
     "longName": "996026 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://immucell.com/role/IntangibleAssetsDetails",
     "longName": "996027 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://immucell.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996028 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets",
     "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable",
     "longName": "996029 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://immucell.com/role/BankDebtDetails",
     "longName": "996030 - Disclosure - Bank Debt (Details)",
     "shortName": "Bank Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
     "longName": "996031 - Disclosure - Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments",
     "shortName": "Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RepaymentsOfBankDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable",
     "longName": "996032 - Disclosure - Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding",
     "shortName": "Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "iccc:DebtIssuanceCosts2023",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "iccc:DebtIssuanceCosts2023",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "longName": "996033 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iccc:NumberOfExecutiveOfficers",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iccc:NumberOfExecutiveOfficers",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://immucell.com/role/OperatingLeasesDetails",
     "longName": "996034 - Disclosure - Operating Leases (Details)",
     "shortName": "Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c132",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c132",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable",
     "longName": "996035 - Disclosure - Operating Leases (Details) - Schedule of Lease Costs and Other Lease Information",
     "shortName": "Operating Leases (Details) - Schedule of Lease Costs and Other Lease Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable",
     "longName": "996036 - Disclosure - Operating Leases (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
     "shortName": "Operating Leases (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://immucell.com/role/StockholdersEquityDetails",
     "longName": "996037 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c147",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c147",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
     "longName": "996038 - Disclosure - Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans",
     "shortName": "Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
     "longName": "996039 - Disclosure - Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans",
     "shortName": "Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c180",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c180",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable",
     "longName": "996040 - Disclosure - Stockholders' Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions",
     "shortName": "Stockholders' Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
     "longName": "996041 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area",
     "shortName": "Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iccc:RevenueSalesObligationPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable",
     "longName": "996042 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category",
     "shortName": "Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://immucell.com/role/OtherExpensesNetDetails",
     "longName": "996043 - Disclosure - Other Expenses, Net (Details)",
     "shortName": "Other Expenses, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable",
     "longName": "996044 - Disclosure - Other Expenses, Net (Details) - Schedule of Other (Income) Expenses Net",
     "shortName": "Other Expenses, Net (Details) - Schedule of Other (Income) Expenses Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://immucell.com/role/IncomeTaxesDetails",
     "longName": "996045 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable",
     "longName": "996046 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Provision",
     "shortName": "Income Taxes (Details) - Schedule of Income Tax Provision",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable",
     "longName": "996047 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Expense Differs from the Expected Tax Computed",
     "shortName": "Income Taxes (Details) - Schedule of Income Tax Expense Differs from the Expected Tax Computed",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable",
     "longName": "996048 - Disclosure - Income Taxes (Details) - Schedule of Significant Components of Our Deferred Tax Assets Net",
     "shortName": "Income Taxes (Details) - Schedule of Significant Components of Our Deferred Tax Assets Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://immucell.com/role/ScheduleofSegmentInformationTable",
     "longName": "996049 - Disclosure - Segment Information (Details) - Schedule of Segment Information",
     "shortName": "Segment Information (Details) - Schedule of Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://immucell.com/role/RelatedPartyTransactionsDetails",
     "longName": "996050 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://immucell.com/role/EmployeeBenefitsDetails",
     "longName": "996051 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iccc:EmployeesSalaryPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iccc:EmployeesSalaryPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202277-10k_immu.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountsPayableandAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable \u2013 capital",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable \u2013 trade",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable",
        "verboseLabel": "Trade accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293"
     ]
    },
    "iccc_AccountsReceivablePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "AccountsReceivablePercentage",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable percentage",
        "documentation": "Accounts receivable percentage.",
        "label": "Accounts Receivable Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r163"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r193",
      "r551"
     ]
    },
    "iccc_AcquiringPersonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "AcquiringPersonMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquiring Person [Member]",
        "label": "Acquiring Person Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_AcquiringPersonPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "AcquiringPersonPercentage",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of acquiring person",
        "documentation": "Percentage of acquiring person.",
        "label": "Acquiring Person Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r593",
      "r886",
      "r887",
      "r888",
      "r951",
      "r972"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r785",
      "r801",
      "r829"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r788",
      "r804",
      "r832"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r789",
      "r805",
      "r824",
      "r833",
      "r837",
      "r845"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "label": "Other Segments [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r439"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discounts",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r93",
      "r127",
      "r360"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r360",
      "r491",
      "r880"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r491",
      "r722",
      "r723",
      "r880"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Intangible amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r63"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive amounted (in Shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet (in Square Feet)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r197",
      "r223",
      "r262",
      "r277",
      "r283",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r465",
      "r467",
      "r481",
      "r543",
      "r632",
      "r740",
      "r752",
      "r908",
      "r909",
      "r957"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankDebtDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "BankDebtDetailsTable",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and improvements [Member]",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r735",
      "r736"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r464",
      "r735",
      "r736"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition percentage",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r781"
     ]
    },
    "iccc_CapitalExpendituresCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "CapitalExpendituresCommitted",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures committed",
        "documentation": "Capital expenditures committed.",
        "label": "Capital Expenditures Committed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/CashandCashEquivalentsDetails",
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and money market accounts",
        "netLabel": "Cash and cash equivalents at carrying value",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r191",
      "r708"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/CashandCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENTS",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r546"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "BEGINNING CASH AND CASH EQUIVALENTS",
        "periodEndLabel": "ENDING CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r131",
      "r220"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r131"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation limits",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in capital expenditures included in accounts payable and accrued expenses",
        "documentation": "Change in capital expenditures included in accounts payable and accrued expenses.",
        "label": "Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in payments of debt discounts included in accounts payable and accrued expenses",
        "documentation": "Amount of change in payments of debt discounts included in accounts payable and accrued expenses.",
        "label": "Change In Payments Of Debt Discounts Included In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r198",
      "r199",
      "r200",
      "r223",
      "r244",
      "r248",
      "r250",
      "r252",
      "r256",
      "r257",
      "r294",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r481",
      "r584",
      "r585",
      "r586",
      "r587",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r619",
      "r641",
      "r663",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r863",
      "r881",
      "r890"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r99",
      "r545",
      "r618"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r323",
      "r324",
      "r692",
      "r905"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved for future grants",
        "verboseLabel": "Common stock outstanding under the plan",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r886",
      "r887",
      "r951",
      "r970",
      "r972"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r619"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r111",
      "r619",
      "r638",
      "r972",
      "r973"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.10 par value per share, 15,000,000 shares authorized and 7,814,165 shares issued as of both December 31, 2023 and 2022 and 7,750,864 and 7,746,864 shares outstanding as of December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r547",
      "r740"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "iccc_CompanyAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "CompanyAMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company A [Member]",
        "label": "Company AMember"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_CompanyBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "CompanyBMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company B [Member]",
        "label": "Company BMember"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_CompanyCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "CompanyCMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company C [Member]",
        "label": "Company CMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFITS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r149",
      "r150"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentOfOtherExpenseNonoperatingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentOfOtherExpenseNonoperatingLineItems",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (Income) Expenses, Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Provision [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r91",
      "r92",
      "r291",
      "r691"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r91",
      "r92",
      "r291",
      "r581",
      "r691"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r91",
      "r92",
      "r291",
      "r691",
      "r869"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r174"
     ]
    },
    "us-gaap_ConcentrationRiskCustomer": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCustomer",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration customer risk percentage",
        "label": "Concentration Risk, Customer",
        "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r51"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "verboseLabel": "Trade account receivable percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r91",
      "r92",
      "r291"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r51",
      "r52",
      "r91",
      "r160",
      "r691"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r91",
      "r92",
      "r291",
      "r691"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress [Member]",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostDepreciationAmortizationAndDepletion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostDepreciationAmortizationAndDepletion",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Cost, Depreciation, Amortization and Depletion",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of goods sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r524"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r884",
      "r949"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current subtotal",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r453",
      "r459",
      "r884"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r884",
      "r949"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r291"
     ]
    },
    "iccc_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "CustomerMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Member]",
        "label": "Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships [Member]",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_DebtConversionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionLineItems",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BANK DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r222",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r354",
      "r361",
      "r362",
      "r364"
     ]
    },
    "iccc_DebtDiscountCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCost",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost During the Three-Month Period Ending December 31, 2024",
        "documentation": "Debt discount cost.",
        "label": "Debt Discount Cost"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCost2024",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost 2025",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2024"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCost2025",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost 2026",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCost2026",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost 2027",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCost2027",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount cost 2028",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2027"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCostThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCostThereafter",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount cost Thereafter",
        "documentation": "Amount of debt discount cost thereafter.",
        "label": "Debt Discount Cost Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCostTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtDiscountCostTotal",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost Total",
        "documentation": "Amount of total debt discount cost.",
        "label": "Debt Discount Cost Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r107",
      "r108",
      "r162",
      "r164",
      "r227",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r492",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r882"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r365"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payment",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r96",
      "r339",
      "r492",
      "r720",
      "r721"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r227",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r492",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r882"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balloon principal payment",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #5 [Member]",
        "label": "Debt Instrument, Redemption, Period Five [Member]",
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #4 [Member]",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "iccc_DebtInstrumentRedemptionPeriodNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtInstrumentRedemptionPeriodNineMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #3 [Member]",
        "label": "Debt Instrument Redemption Period Nine Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #1 [Member]",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "iccc_DebtInstrumentRedemptionPeriodSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtInstrumentRedemptionPeriodSevenMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #7 [Member]",
        "verboseLabel": "Debt Instrument, Redemption, Period Seven [Member]",
        "label": "Debt Instrument Redemption Period Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtInstrumentRedemptionPeriodSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtInstrumentRedemptionPeriodSixMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #6 [Member]",
        "verboseLabel": "Debt Instrument, Redemption, Period Six [Member]",
        "label": "Debt Instrument Redemption Period Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtInstrumentRedemptionPeriodTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtInstrumentRedemptionPeriodTenMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans #4 [Member]",
        "label": "Debt Instrument Redemption Period Ten Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #3 [Member]",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #2 [Member]",
        "verboseLabel": "Debt Instrument, Redemption, Period Two [Member]",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r68",
      "r69",
      "r93",
      "r94",
      "r96",
      "r100",
      "r143",
      "r144",
      "r227",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r492",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r882"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amortization, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2023": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtIssuanceCosts2023",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs During the Three-Month Period Ending December 31, 2024",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2023"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtIssuanceCosts2024",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2025",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2024"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtIssuanceCosts2025",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2026",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtIssuanceCosts2026",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2027",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtIssuanceCosts2027",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2028",
        "documentation": "Amount of debt issuance costs.",
        "label": "Debt Issuance Costs2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank loans outstanding",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "iccc_DebtIssuanceCostshereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "DebtIssuanceCostshereafter",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs Thereafter",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costshereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation agreement annual base salary percentage",
        "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage",
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r948",
      "r949"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred subtotal, gross",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross, Current",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt financing",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, Total",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r911"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred subtotal, net",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r157",
      "r180",
      "r458",
      "r459",
      "r884"
     ]
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOtherTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Other Tax Expense (Benefit)",
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r156",
      "r884"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r948",
      "r949"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of our deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Components of Our Deferred Tax Assets Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails",
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards not expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax credits and net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNICAP",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property, plant and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal general business tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u00a7174 R &amp; D expenditures",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r947"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock were changed percentage",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Change Due to Subsequent Interim Measurement, Weighted-Average Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, used to determine net periodic benefit cost (credit) of defined benefit plan, in subsequent interim measurement."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits paid (in Dollars)",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r915"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794",
      "r808"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r65"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r610",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r676",
      "r677",
      "r678",
      "r679",
      "r743",
      "r745"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest fixed rate",
        "label": "Derivative, Fixed Interest Rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r608",
      "r610",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r676",
      "r677",
      "r678",
      "r679",
      "r711",
      "r743",
      "r745"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology [Member]",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Sales Disaggregated by Major Product Category [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://immucell.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Sales Disaggregated by Major Product Category",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794",
      "r808"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781",
      "r825"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781",
      "r825"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Income Loss Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "verboseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r254",
      "r476",
      "r477",
      "r540",
      "r555",
      "r714"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in Dollars per share)",
        "verboseLabel": "Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r244",
      "r250",
      "r251",
      "r252",
      "r254",
      "r476",
      "r477",
      "r540",
      "r555",
      "r714"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense/rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal corporate tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r445",
      "r460"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r950"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r944"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r944"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal expense, percentage",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r950"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r950"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss income before income taxes, rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r950"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Computed expected income tax expense rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r950"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "iccc_EmployeeBenefitsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "EmployeeBenefitsDetailsTable",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee [Member]",
        "label": "Employee Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "EmployeeOneMember",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee One [Member]",
        "label": "Employee One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation related to non-vested stock options (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee Stock Option [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPPlanDescription",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extend the rights plan, description",
        "label": "Employee Stock Ownership Plan (ESOP), Plan Description",
        "documentation": "Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase price (in Dollars per share)",
        "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased",
        "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeesSalaryContributionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "EmployeesSalaryContributionPercentage",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s salary contribution percentage",
        "documentation": "Employee\u2019s salary contribution percentage.",
        "label": "Employees Salary Contribution Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeesSalaryPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "EmployeesSalaryPercentage",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s salary percentage",
        "documentation": "Employee\u2019s salary percentage.",
        "label": "Employees Salary Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r186",
      "r209",
      "r210",
      "r211",
      "r228",
      "r229",
      "r230",
      "r232",
      "r238",
      "r240",
      "r255",
      "r295",
      "r296",
      "r373",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r506",
      "r576",
      "r577",
      "r578",
      "r593",
      "r663"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r785",
      "r801",
      "r829"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r782",
      "r798",
      "r826"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow account",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r693"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "iccc_ExercisableAndTransferableDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ExercisableAndTransferableDescription",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable and transferable, description",
        "documentation": "Exercisable and transferable, description.",
        "label": "Exercisable And Transferable Description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "iccc_ExpenseRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ExpenseRecognitionPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense Recognition",
        "documentation": "Entire disclosure of accounting policy for expense recognition.",
        "label": "Expense Recognition Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r480"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r89",
      "r159"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r479",
      "r518",
      "r519",
      "r520",
      "r720",
      "r721",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r392",
      "r479",
      "r518",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r392",
      "r479",
      "r519",
      "r720",
      "r721",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r479",
      "r520",
      "r720",
      "r721",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r518",
      "r519",
      "r520",
      "r720",
      "r721",
      "r732",
      "r733",
      "r734"
     ]
    },
    "iccc_FederalGeneralBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "FederalGeneralBusinessMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal General Business [Member]",
        "label": "Federal General Business Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableLoanInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableLoanInProcess",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance loan provided",
        "label": "Financing Receivable, Loan in Process",
        "documentation": "Amount of undisbursed portion of financing receivable balance. Excludes financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset amortized, useful lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r318"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r525",
      "r526"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r526"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMember",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Member]",
        "label": "Finite-Lived Intangible Assets [Member]",
        "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Net Book Value",
        "netLabel": "Net value",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r525"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_FirstDefenseProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "FirstDefenseProductLineMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Defense\u00ae product line [Member]",
        "label": "First Defense Product Line Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r833"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r833"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r833"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r833"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r833"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r792"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r902",
      "r903"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r644"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r303",
      "r539",
      "r718",
      "r740",
      "r900",
      "r901"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairments",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r304",
      "r310",
      "r314",
      "r718"
     ]
    },
    "iccc_GorhamSavingsBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "GorhamSavingsBankMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gorham Savings Bank [Member]",
        "label": "Gorham Savings Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross margin",
        "terseLabel": "Gross margin",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r223",
      "r262",
      "r276",
      "r282",
      "r285",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r481",
      "r716",
      "r908"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r768",
      "r781"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "impairment of recognized",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r64",
      "r139"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r120",
      "r166",
      "r262",
      "r276",
      "r282",
      "r285",
      "r541",
      "r553",
      "r716"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r441",
      "r446",
      "r447",
      "r451",
      "r456",
      "r461",
      "r462",
      "r463",
      "r589"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/IncomeTaxesDetails",
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable",
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense/rate",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r181",
      "r239",
      "r240",
      "r270",
      "r444",
      "r457",
      "r557"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Expense Differs from the Expected Tax Computed [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r442",
      "r443",
      "r447",
      "r448",
      "r450",
      "r452",
      "r583"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computed expected income tax expense rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal expense",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "iccc_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r42"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total accrued amount",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive impact of share-based compensation awards",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r252",
      "r400"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r789",
      "r805",
      "r824",
      "r833",
      "r837",
      "r845"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r849"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r849"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r849"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance recovery",
        "label": "Insurance Recoveries",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible Assets, Current",
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "iccc_IntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "IntangibleAssetsDetailsTable",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_InterestCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred costs",
        "label": "Interest Costs Incurred",
        "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r168",
      "r212",
      "r266",
      "r489",
      "r648",
      "r751",
      "r971"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r219"
     ]
    },
    "iccc_InterestPaymentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "InterestPaymentsTerm",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payments, term",
        "documentation": "Amount of interest payments term.",
        "label": "Interest Payments Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r709",
      "r740"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r190",
      "r202",
      "r297",
      "r298",
      "r300",
      "r523",
      "r712"
     ]
    },
    "iccc_InventoryProduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "InventoryProduction",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of inventory",
        "documentation": "Production of inventory.",
        "label": "Inventory Production"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write off",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_InvestmentCompanyPurchasePremiumPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentCompanyPurchasePremiumPerShare",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in Dollars per share)",
        "label": "Investment Company, Purchase Premium, Per Share",
        "documentation": "Per share amount of premium paid by investor to purchase shares of investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r739"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs and Other Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments (undiscounted cash flows)",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest (discount effect of cash flows)",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renew term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r223",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r466",
      "r467",
      "r468",
      "r481",
      "r617",
      "r715",
      "r752",
      "r908",
      "r957",
      "r958"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r165",
      "r549",
      "r740",
      "r883",
      "r899",
      "r952"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r189",
      "r223",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r466",
      "r467",
      "r468",
      "r481",
      "r740",
      "r908",
      "r957",
      "r958"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r103",
      "r104",
      "r105",
      "r109",
      "r223",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r466",
      "r467",
      "r468",
      "r481",
      "r908",
      "r957",
      "r958"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LimitedLiabilityCompanyOrLimitedPartnershipBusinessOrganizationAndOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r967"
     ]
    },
    "iccc_LoanToValueRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LoanToValueRatio",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan to value ratio",
        "documentation": "The ratio of loan to value.",
        "label": "Loan To Value Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE ACCOUNTS RECEIVABLE",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending, Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r351",
      "r366",
      "r720",
      "r721",
      "r967"
     ]
    },
    "iccc_LongTermDebt2023": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LongTermDebt2023",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total During the Three-Month Period Ending December 31, 2024",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2023"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LongTermDebt2024",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2025",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2024"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LongTermDebt2025",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2026",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LongTermDebt2026",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2027",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LongTermDebt2027",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2028",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt obligations, net of current portion",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r544"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of debt obligations",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending ,Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r227",
      "r912"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r227",
      "r356"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r227",
      "r356"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r227",
      "r356"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r227",
      "r356"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r227",
      "r356"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bearing interest percentage",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "iccc_LongTermDebtThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "LongTermDebtThereafter",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Thereafter",
        "documentation": "Long term debt thereafter",
        "label": "Long Term Debt Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_MaineTechnologyInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "MaineTechnologyInstituteMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maine Technology Institute [Member]",
        "label": "Maine Technology Institute Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r727",
      "r913",
      "r968",
      "r969"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and manufacturing equipment [Member]",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "iccc_MastitisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "MastitisMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mastitis [Member]",
        "label": "Mastitis Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r395",
      "r522",
      "r575",
      "r609",
      "r610",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r703",
      "r704",
      "r717",
      "r724",
      "r737",
      "r742",
      "r910",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "iccc_MinimumDebtServicesCoverageRatio": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "MinimumDebtServicesCoverageRatio",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum debt service coverage ratio",
        "documentation": "Minimum debt service coverage ratio.",
        "label": "Minimum Debt Services Coverage Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r395",
      "r522",
      "r575",
      "r609",
      "r610",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r703",
      "r704",
      "r717",
      "r724",
      "r737",
      "r742",
      "r910",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_MortgageBankingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageBankingMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage Note [Member]",
        "label": "Mortgage Banking [Member]",
        "documentation": "Origination or servicing of loan secured by real property."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "iccc_MrBrighamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "MrBrighamMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Brigham [Member]",
        "label": "Mr Brigham Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r727",
      "r913",
      "r968",
      "r969"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://immucell.com/role/BusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS OPERATIONS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable",
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss",
        "netLabel": "Net loss attributable to stockholders (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r133",
      "r167",
      "r188",
      "r206",
      "r207",
      "r211",
      "r223",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r249",
      "r262",
      "r276",
      "r282",
      "r285",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r477",
      "r481",
      "r554",
      "r640",
      "r661",
      "r662",
      "r716",
      "r751",
      "r908"
     ]
    },
    "iccc_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds (in Dollars)",
        "documentation": "The net proceeds incurred from issuance of common stock.",
        "label": "Net Proceeds From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Include, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Not Yet Adopted Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncement Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "iccc_NisinDrugSubstanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "NisinDrugSubstanceMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nisin Drug Substance [Member]",
        "label": "Nisin Drug Substance Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r824",
      "r833"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH ACTIVITIES:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-compete agreements [Member]",
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "iccc_NumberOfExecutiveOfficers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "NumberOfExecutiveOfficers",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of executive officers",
        "documentation": "Number of executive officers.",
        "label": "Number Of Executive Officers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://immucell.com/role/BusinessOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating expenses",
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET OPERATING LOSS",
        "terseLabel": "NET OPERATING INCOME (LOSS)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r276",
      "r282",
      "r285",
      "r716"
     ]
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Costs and Other Lease Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r739"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails",
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating liabilities",
        "verboseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r500"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r739"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r739"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING LEASES",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_OtherAnimalHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "OtherAnimalHealthMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other animal health [Member]",
        "label": "Other Animal Health Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r740"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construct and equip commitment",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Member]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDeferredCompensationArrangementsLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Other Deferred Compensation Arrangements, Liability, Current",
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r147"
     ]
    },
    "us-gaap_OtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_OtherExpensesNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "OtherExpensesNetDetailsTable",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income-other",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r642",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash rent expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpenseAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH PAID FOR:",
        "label": "Other Noncash Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash income tax expense",
        "label": "Other Noncash Income Tax Expense",
        "documentation": "The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER EXPENSES, NET",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofOtherIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses, net",
        "negatedTotalLabel": "Other expenses, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other (Income) Expenses Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_OtherObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "OtherObligations",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other obligations",
        "documentation": "Other obligations.",
        "label": "Other Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r627"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable related party",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "iccc_OtherStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "OtherStatesMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "documentation": "Continent of Other States.",
        "label": "Other States Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r787",
      "r803",
      "r831"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParticipatingMortgageLoansUnamortizedDebtDiscountAmount",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage debt",
        "label": "Participating Mortgage Loans, Unamortized Debt Discount, Amount",
        "documentation": "The amount of the related debt discount at the end of the accounting period."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional rent payment",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "iccc_PaymentsOfDebtDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "PaymentsOfDebtDiscounts",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of debt discounts",
        "documentation": "Payments of debt discounts.",
        "label": "Payments Of Debt Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r301",
      "r302",
      "r710"
     ]
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrincipalAmountOutstandingOnLoansManagedAndSecuritized",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance",
        "label": "Loan, Managed and Securitized or Asset-Backed Financing Arrangement, Principal Outstanding",
        "documentation": "This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt issuance",
        "verboseLabel": "Proceeds from Debt Issuance",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of loan",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r584"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from line of credit",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r882"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property, plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r524",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r706",
      "r725",
      "r741",
      "r870",
      "r906",
      "r907",
      "r913",
      "r968"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r524",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r706",
      "r725",
      "r741",
      "r870",
      "r906",
      "r907",
      "r913",
      "r968"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r175",
      "r178",
      "r179"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment disposals",
        "label": "Property, Plant and Equipment, Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r192",
      "r552"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, net",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r542",
      "r552",
      "r740"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r175",
      "r178",
      "r550"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset depreciated percentage",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, Estimated Useful Lives (in years)",
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r386",
      "r395",
      "r426",
      "r427",
      "r428",
      "r521",
      "r522",
      "r575",
      "r609",
      "r610",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r703",
      "r704",
      "r717",
      "r724",
      "r737",
      "r742",
      "r745",
      "r904",
      "r910",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r386",
      "r395",
      "r426",
      "r427",
      "r428",
      "r521",
      "r522",
      "r575",
      "r609",
      "r610",
      "r669",
      "r671",
      "r673",
      "r674",
      "r680",
      "r703",
      "r704",
      "r717",
      "r724",
      "r737",
      "r742",
      "r745",
      "r904",
      "r910",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r896",
      "r897",
      "r898"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r782",
      "r798",
      "r826"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/EmployeeBenefitsDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r510",
      "r511",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r637",
      "r639",
      "r668"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r510",
      "r511",
      "r512",
      "r513",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r637",
      "r639",
      "r668"
     ]
    },
    "us-gaap_RelatedPartyTaxExpenseDueFromAffiliatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTaxExpenseDueFromAffiliatesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Related Party Tax Expense, Due from Affiliates, Current",
        "documentation": "The amount of any current tax-related balances due from affiliates as of the date of each statement of financial position presented."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party products purchased",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/EmployeeBenefitsDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r510",
      "r511",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r637",
      "r639",
      "r668",
      "r956"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r511",
      "r514",
      "r590",
      "r591",
      "r592",
      "r645",
      "r646",
      "r647",
      "r666",
      "r667"
     ]
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Principal Repayments",
        "label": "Repayments of Bank Debt",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt principal repayments",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Line of credit repayments",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r882"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development expenses",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r440",
      "r965"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r799",
      "r827"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r784",
      "r800",
      "r828"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r791",
      "r807",
      "r835"
     ]
    },
    "us-gaap_ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResultsOfOperationsForOilAndGasProducingActivitiesByGeographicAreaLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Sales Disaggregated by Geographic Area [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r145",
      "r548",
      "r579",
      "r580",
      "r588",
      "r620",
      "r740"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r228",
      "r229",
      "r230",
      "r232",
      "r238",
      "r240",
      "r295",
      "r296",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r469",
      "r471",
      "r472",
      "r474",
      "r475",
      "r576",
      "r578",
      "r593",
      "r972"
     ]
    },
    "iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r275",
      "r280",
      "r281",
      "r287",
      "r289",
      "r291",
      "r382",
      "r383",
      "r524"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "verboseLabel": "Total product Sales",
        "netLabel": "Total product sales",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r275",
      "r280",
      "r281",
      "r287",
      "r289",
      "r291",
      "r382",
      "r383",
      "r524"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://immucell.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://immucell.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Sales Disaggregated by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r705",
      "r713"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of product sales",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "iccc_RevenueSalesObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "RevenueSalesObligationPercentage",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of product sales",
        "documentation": "Percentage of product sales is an act of selling a product or service in return of money or compensation or service.",
        "label": "Revenue Sales Obligation Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset and operating lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r739"
     ]
    },
    "iccc_RightToAcquirePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "RightToAcquirePerShare",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per Right (in Dollars per share)",
        "documentation": "Right to Acquire, Per share.",
        "label": "Right To Acquire Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares sold",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "verboseLabel": "Company A [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r868"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r396",
      "r889"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r396",
      "r864",
      "r889"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfActivityUnderTheStockOptionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Activity Under The Stock Option Plans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information About The Stock Option Plans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfAdditionalInformationAboutTheStockOptionPlansLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information About the Stock Option Plans [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets Or Liabilities Measured At Fair Value On ANonrecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Expense Differs from the Expected Tax Computed",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Principal Payments Bank Loans Outstanding",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r68",
      "r69",
      "r93",
      "r94",
      "r96",
      "r100",
      "r143",
      "r144",
      "r720",
      "r722",
      "r885"
     ]
    },
    "iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Debt Proceeds Received And Principal Repayments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt Proceeds Received and Principal Repayments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt Proceeds Received and Principal Repayments",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Components of Our Deferred Tax Assets Net",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Income (Loss) Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Expense Differs from the Expected Tax Computed",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r525"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "iccc_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://immucell.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r117",
      "r118",
      "r119"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other (Income) Expenses Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Principal Payments Bank Loans Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfPrincipalPaymentsBankLoansOutstandingLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Principal Payments Bank Loans Outstanding [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Product Sales Disaggregated By Geographic Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Product Sales Disaggregated By Major Product Category Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "iccc_ScheduleOfSegmentInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfSegmentInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Segment Information Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://immucell.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Under the Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information About the Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Trade Accounts Receivable Due From Significant Customers Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScheduleOfTradeAccountsReceivableDueFromSignificantCustomersLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofTradeAccountsReceivableDuefromSignificantCustomersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Accounts Receivable Due from Significant Customers [Line Items]",
        "label": "Schedule Of Trade Accounts Receivable Due From Significant Customers Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Accounts Receivable Due from Significant Customers",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r51",
      "r52",
      "r91",
      "r160"
     ]
    },
    "iccc_ScoursMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ScoursMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scours [Member]",
        "label": "Scours Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r291",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r321",
      "r322",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r718",
      "r870",
      "r968"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r605",
      "r606",
      "r607",
      "r670",
      "r672",
      "r675",
      "r684",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r707",
      "r726",
      "r745",
      "r913",
      "r968"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r274",
      "r279",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options that were forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Non-vested stock options as of beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, Non-vested stock options as of ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model With the Weighted-Average Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Activity Under the Stock Option Plans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested (in Dollars per share)",
        "documentation": "Share based compensation arrangement by share based payment award options exercisable weighted average vested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Terminations/forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "verboseLabel": "Number of Shares, Stock options granted (in Shares)",
        "netLabel": "Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance",
        "periodEndLabel": "Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)",
        "terseLabel": "Option outstanding of exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested (in Dollars)",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercises (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Grants (in Dollars per share)",
        "verboseLabel": "Exercise prices per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r404",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelWiththeWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life of the options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Non-vested stock options as of beginning balance (in Shares)",
        "periodEndLabel": "Number of Shares, Non-vested stock options as of ending balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options that were forfeited (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options that were forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance",
        "periodEndLabel": "Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options that vested (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price (in Dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r150"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank debt",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r162",
      "r740",
      "r966"
     ]
    },
    "us-gaap_ShorttermDebtAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShorttermDebtAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding amount of loan",
        "label": "Short-Term Debt, Average Outstanding Amount",
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r648"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r221"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StateTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StateTaxCreditMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Tax Credit [Member]",
        "label": "State Tax Credit Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r291",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r718",
      "r870",
      "r968"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r198",
      "r199",
      "r200",
      "r223",
      "r244",
      "r248",
      "r250",
      "r252",
      "r256",
      "r257",
      "r294",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r481",
      "r584",
      "r585",
      "r586",
      "r587",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r619",
      "r641",
      "r663",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r863",
      "r881",
      "r890"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r34",
      "r186",
      "r209",
      "r210",
      "r211",
      "r228",
      "r229",
      "r230",
      "r232",
      "r238",
      "r240",
      "r255",
      "r295",
      "r296",
      "r373",
      "r432",
      "r433",
      "r434",
      "r454",
      "r455",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r506",
      "r576",
      "r577",
      "r578",
      "r593",
      "r663"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r605",
      "r606",
      "r607",
      "r670",
      "r672",
      "r675",
      "r684",
      "r690",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r707",
      "r726",
      "r745",
      "r913",
      "r968"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r255",
      "r524",
      "r582",
      "r604",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r746"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r396",
      "r864",
      "r865",
      "r889"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r255",
      "r524",
      "r582",
      "r604",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r746"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r786",
      "r802",
      "r830"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of stock options (in Shares)",
        "negatedTerseLabel": "Exercises",
        "terseLabel": "Stock options shares exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r110",
      "r111",
      "r145",
      "r410"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "verboseLabel": "Stock option cash (in Dollars)",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r34",
      "r145"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise prices (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "iccc_StockOptionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StockOptionPlansMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plans [Member]",
        "label": "Stock Option Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockOptionsCoveringShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StockOptionsCoveringShares",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised stock options covering shares",
        "documentation": "Stock options covering shares.",
        "label": "Stock Options Covering Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockOptionsCoveringcash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StockOptionsCoveringcash",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options covering cash (in Dollars)",
        "documentation": "The amount of stock options covering cash.",
        "label": "Stock Options Coveringcash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r115",
      "r135",
      "r621",
      "r638",
      "r664",
      "r665",
      "r740",
      "r752",
      "r883",
      "r899",
      "r952",
      "r972"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) - Schedule of Activity Under the Stock Option Plans [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r516"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r516"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r516"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://immucell.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r517"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SubtotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "SubtotalMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtotal [Member]",
        "label": "Subtotal Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesTablesLineItems",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "SummaryofSignificantAccountingPoliciesTablesTable",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "iccc_TradeAccountsReceivableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "TradeAccountsReceivableDetailsTable",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 63,301 and 67,301 shares as of December 31, 2023 and 2022, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r70",
      "r71"
     ]
    },
    "iccc_TwoThousandSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "TwoThousandSeventeenPlanMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "documentation": "Two thousand seventeen plan.",
        "label": "Two Thousand Seventeen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandSeventeenPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "TwoThousandSeventeenPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "label": "Two Thousand Seventeen Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandTenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "TwoThousandTenPlanMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan [Member]",
        "documentation": "Two thousand ten plan.",
        "label": "Two Thousand Ten Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandTenPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "TwoThousandTenPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan [Member]",
        "label": "Two Thousand Ten Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r172",
      "r173",
      "r176",
      "r177"
     ]
    },
    "iccc_ValuationOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://immucell.com/20231231",
     "localname": "ValuationOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for valuation of long-lived assets.",
        "label": "Valuation Of Long Lived Assets Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r739"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average common shares outstanding (in Shares)",
        "verboseLabel": "Weighted average common shares outstanding - Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r252"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average common shares outstanding (in Shares)",
        "verboseLabel": "Weighted average common shares outstanding - Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r252"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481212/470-30-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-30/tableOfContent"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>105
<FILENAME>0001213900-24-028718-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-028718-xbrl.zip
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MOZYANLN$-&P^KDP6*D5:>)F#<9(9O2.W/N8SDIEV,3J!_GH:+>RO[">!'4,
MJ3+ERI^2Z<KOP%N8Q2N_OLSG:;S\RU';+\MS_[=V8)C7\B=G:92MO&AHTL1<
MK([5E!43U:S\H0(S<;7RZUF1_Z-MA6!%C*)R]0NE,9^<<&$KRF2:I%&AZX_?
MT**C+RNLN4WR*\'07@N';E<G',XK9AB#"*3TC(J9V3O,"W:U6(NT, ]8_B+,
MYT7(RR,CJ9!=FT"0 >'&'X=:-OLRU(ERPIL$>CR'Y>T1XN$+%NU)/](_&>W
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MK2*:NNBI4S4:,XEFE+(KQKE[L#;-AZ,TX389),STR2J12>I2%J7*;9CB^;*
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M!>@Y0FF&B6?-,_DWV2&?2OW-2+ >K"=XS<G%(SFTC0Z4SI7FY%0W6R&=*SV
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M@BTX%S?:2_,"+<OHI#A*B@7GS(?&D%#00J62U$%R%%DJ 4LDA2"$^%,DGW.
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M'@/1[<D6KI]6E#-]*HT8$D"SD#T;Y9?E)MIP>^<T*9V<:-*<T\N05&B*69$
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M.IU!&RH:B*(U8 P8LF@ )6@"^5#)<1.K>:Q6^@99A-_)1%X^0#Y:J=V2N4W
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MS2_+9KPOT'@?HR&;3]G<N>DQ#/>.5@GJ?<IVM5+K"J:$TYZ)@&,D:*_ 54E
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M6Z9?%H;NL4G2C?..?DOJ%*6?E1*;\9/_$LW8<,,S=]TSC_]^VGC@T26I\$[
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M),&RA']\NN/3 0;,($>/ED9C0#8"#%#;-YOA2<29LJ04T*C+K7@IW9C#B1F
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M;,3("HYY?U-NAO2_ Y6>S6ZG?BF PA5_ALM>:,4C.U5&;H3*L%C8/)1^_!.
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M]BS8/84C\FO6ZE4O0J1CE*:PM"HN%TJX/XLLL,9$I$V(I'>>9-H7*&%PBA
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M-TIC%S<<!#?UN69J']DC/!96)RI>('AK0;)FZ&WZ--@6>O0%:+F,:5.)]2!
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M;$%5-EFP24>;4'/ZBN ^I'Z:S!:7HK)US-H:(#T8V:RBTK=LEM7<DY#7:NF
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MRIP=L(CD\7%)&*B*"Z,HFE-NW/7YQNIXL+<#O'/R]9-I]'MR'>X[-;YJRZ)
M+)\M\K&HUF)DK-6T&EOT#(K).M1D.T]->/,*T%%TCQ:2,9N0C+2:@0*MB]SN
MK,O84Q,B&$JX>+),S?:-4WD:"+^>K=_B&E;M2KMV]$8K6-3909KF0A1FE>^\
M^<0V\F?K*W=" (W"/KA2^2SIEU?<9=H*NWC8">3):^.I,T'\T>3:<"BIF1E<
M=7>12G=N1$)(4/O0]]3%*A#($@AR23H[?64\-^-.W'#RP@85<#8H*6LK]?.$
MV0!3!J.8/&*>Y[$$DJ0152 6R.L!^\.?7D[+SMIC5JI:)OQ=4UMW:O:UD>$
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M<'&.W)<E'+*+;+9W)!1+U3CC)YO/L)@]9;;A'T?;J_[87_T>B[^LD0 9S+"
M5.ILU]=+05VA'-Z(JXQY3SF@"3LBREI>)'GHHY0TMG<5*&L.<AZ=HIV,=:$"
M<)^37%31&/1$RC3J.O[D6!)[EI8<!*0+G3Q:(>5"^\P^.]-O-3OH;DBZ$;[
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MQ6#8'VQS6.R:[Q!,P"CR3?HK\%3XSQ71G[H[DLG<<'HC)H*S&=ZTH?KENAE
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M8S/6T0)E1[G+5&>Y-U*O;-;1*KA4)%[E0U=?NQZD,\9W]]JX72ZSXTD!P:M
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MS_KQJZDY)T9"FW)BS74R9"+S;AVJ)R0M!O22#R<AISG(;]$$+BXX2RIHD I
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M*.P;:NB#^.LL1"1?K3/C+!/$@<7<9.PA'_ KS1D((4?8M& \IEF*4ALIB1?
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ML#8[*3UKLC";!A6+P1.@DTG(N13R/ZS\:46Z)XID)Y&\JCBKKS3:K"V?OF6
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MBAKJ[[_\;3VX&)O!#E]KXB/JE2"GLV,L=##%<:4SN7SOHJ:7>P[#3,$Y%5>
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MS)C5$K5Z;NH2UE524!<XJ5SDQ#@FY%&<74MBF(JZK+^_;-DBNVP>TAC-7#[
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MFJ7OXLK#8I*=95**8Z[9A!#Y&8_-BC@](EJVGAW[-.SMF/E[/D/W B\?F[_
M!^P"TVNV=C:CQK/&Q&H=/-!E@,6@],?LI7;-8Q)_#KD_Y-W&#KJZ(SO*2%^+
M!WE#-LHOE/- R@F=LKXJ-BINYI-7=HS:=DH6MI1^(?YLL-[1'DGQDO4FX]);
MI%ZP!,3;6*;<".L482-O+5$3?8//_DB+0H7E5)88C#J4BJWMWOY.L*C/VO>S
M9L#6UM=@!EBQ3_] LT'%!XI;B[G7F6K1HRFS79M5B8\@3VG\2Y)WW=8>JQRX
M0H(3T7GC]V*+/DF!'BYS;Y\^Q#N/3_U38)_;;(*_)Z1G1_>\(#^-?O1)4"A0
M%8F3P9VA@UVK2!B(#04C<?@5OG*XFX)NT2-',8&OO!V/%W,JJ;7WPY&4,P8@
M!5C2P:ZY4X=R*",8:O':06\?6*3=^GZWMW5PT&V'=2\J^V.O VO%MRX(I#3'
MK[C>#S=79*V'YZLA[E0ML/7U5 L,OE4+_%G4I4\LR\^O:. S6P2#[:_$(MAK
M!0:V>YO[2^("R>3?R3C-K:G]^>YHA/X&V_'OZ<0<YM\9Q+<CED!WUT)XZ,$,
MVS"DYZ4Q?<M,P*S46?"A/'H-5"V+>*I& )G4LVPR8<HSL*,U? OVX+2+1#V_
M8+7,8#Y223+0\><:!0@<IT^_J%%K55U_F2X4%3PC?O*,KWG_V._M''XE!Y^=
M=E+)9-7! 8BG*0.;&;.=NK8"[W"PW=MJ!TV\F%OS=.&,[NW$)\9T! 2M\7J[
M3ZH4ERMQ=R-N%L+7^2ZO=BR4:5Y<TG>]8.':#48W2!&EJ]NS]<54#BSYX2:A
M(%#)P:+R1AEYBL]"M%%H<$;(\GB,/=[WQ8;[X*:#>%U*+:65P.-P[#.Z.8+8
MBYMAP\Y8(6-/,4DY<(A(#-"12TM5&_^-8:PXLL$5U RI@0"6>7R4Z/*9+V\0
M=23]G-XFWR?H):R $1G.ONNU$SA47!L0[L*P2UCQZN$FOZPIN T0*]LM9SU-
M6<2%99^#/$Z-R1VO-13"3]B8GM=G,DJGQ97/J>Y?BVM<-<ZOB_R(T7K<U#0,
M#7=B TO8'H$:DM @38M[?61/BLZG,,TGNJ8G%MS9BSX-MF3_N')$^!0(,,FF
M# DRC=L8EKR)%N*1[H''4HL=%\!/7\<%(&<*A559+3%-WOD@RAH-=GK;'0'X
M.REX/2N=QU#P7EQDM4O >U3_9@Z]'GAH%]9:>O11(":84%2LA2-Q: R\:6Q)
M:W^AK\Z3:\9:&:7G24X!'!3_U1>.D<0</SRCZW!&=?#.C*'DR7QD19UWGAL^
MQ*03];"%VE;LN_L>;;H-43K%$/L=F3,.5DV-[F)-"QX6HX#1N5L9^5JW-Y?>
M07J#(6/.28W&/2/))&_4T<XN3W:X;@/B,W34P89,)WX O&4LF(%ON5^Y<7N_
M"5-NUA1O\@YTWLVM8+=/XPSR;BPC+J)4O1OJ0T+'D\]QS$FP-K4ST3=3!Y/R
M!D>566KTIE'KH@<4N*CG9N$<#@S=HUR^X18?-0Z)$@]P1SLWQC%Y@D3UM6N1
M"QDML0& 8+ C>%?4E,:8+/V:Q*ZVDH$&.K8PQ!:PH,#F\9K3:IL:?DUA2QIB
ME@8<^XA[U87_>;E(+;O?NH:IYI_SM-X1+N])F.&D@0%'0+109//:\T* ^K#:
M@!!*O2CJR&)XU'Z-[T6:N$P3Y_U^FQ>YA<#GY-%2RU,HI2&15$=#^ 9,<D$9
M6K+J B>0R7B;*69$C3M6>LFES1,RMMI95KN(,PP,>PHUB?D[,$JUR=L"+( _
MI&<!@RP^C:SWB8I@YWIK'4'5"O,K?D]9%#,E'ZEJLP)<)<G?:%&-A"?GC-LU
M0]Z1CO/_K/U70K?Z&LP6'Z!ST.43D$-"%-@1$KB>;T!72>C/+G=G>S;LPO"-
MC%!@+WA,Y5]%^1'T%R/N;J^GUTM\E.9 5'F Q,P"_"C"E3_!G=@OPZG"9)WU
MO!I)<?LR-I!^5PP,XD]L./0'N^'TS<Q^SW+S&&.V9<;HJ8HZ$0(W9=W!XHA?
M*L;BHBY08L<@"C0J<1.W7]I#*34Q>4I#BQA"3%C:N N>ZQG$ SO'M;.[B2)*
M;7Z.A927M"L3H_,]I= Q9%F11\.@#?]8Y"GC4'ML3 [76<R,R#UV#.T]52>Y
MY@L$UXWKK+"8.PZ/;ER8Z:Y1/[7#QW=(Z60.2&7Z<K#QR(8$'B*;Z8<4UJV@
MA7Q!/&W<.Q5S"SI$.F,(9P"K Q*^()3)*ECA-5I;ZORQ-C/@82I"G),WI7.W
M=%,2&Y@5$[3-\,^P,K:)(8 TMN]X*J69>P]4FKEE2S-_>?7SX2\HT#QZ]>KX
MY,W/S[I+\207IPA5Q8RJ6G*WD&NNMSALA.ON@T$(D L162TR;DN"-2PET@(J
M2L@$(8P6XZ''@A/"BDN05.OK5NEYP0Q-/HY)M,(K;3_2@B<AVFB43@G7D4^*
M>1Z!$C,\'-<\IR@>F!HO=>J#*6#&MHB"VHW*2$%]"$XJB;FWBHRU!H+!+0@N
M2QJ&>LLZAI[(8=Q_H,.X;0_CKR=O7L6GAZ]???A7?'QR>O3+V]/?WJ]8-/V%
M'LG':1S^$I @MK^>VH[AM]J.;T@0GQD)XN F;?XI.E!XT+10W&-Y\H#-+_2_
MV_O]@QTL2\CY+G^^XW4WV/ST"[3J*.E:W''7XN'[_WWU(7[]]GWT_M7/)Z<?
MWA^^^2 ^VRG!:[Q]$[_ZOWX[^?"O7OS^U2^''PA[X^W1__[][2_'K]Z;!WSX
M\.K]:7SXYC@^.3W]S?SIW6_OC_Y^>/KJ-'[[6GX;"V3#JFU*7^BM]+9)\TSX
MYM2/"U_W35)-DO_$1TP &OW*5"YUQFE2[QO$J1O+Y]Q.3"&'ZYD1COCDZ.B(
M4%'-CSC>L$\)DFTA!YA(;Q"U2.APF!';@X"'>;O7V]O9[.WO;D?AU]!15R=D
MS/840 _\N 3)&80@=K>'_"-E #9C0K=_.0D!">=)-O%)F96SR2?_S2>16-9L
M\^:$G%]1DSK"K$7ILSTK^[=]Z..A7K7]?/KO1R-W7Y$6]YT2W9D]>?6?!9(H
MI]R3"63A!Z7+766$#[Q(]R84=AG6+0KQ,T*^.3$O!ON]O=U-!$F(CSO+'5^7
MI?'@Q#S7YV/AM[E1B2GNYU+XTDSBNE=L;?9V]Y:_(NIZQ4[7*P" #L0Y)BNA
M-B4^VW2(I7B&4PDEP3U?\Q/Z\:H[\BB>X6#PZ:]*=P_NVGOP_S&^X*OW_WQU
M_/]^69;$\#-;$GN>)?'F\.=70.-2\R&"G_W;Z>F),2%@'I@O_/*OTQ,R"UZ?
MO#E\<W1R^(NQ,=X<&\- OF.VX;=?/M!7T-=\B ^>M<GP(<CJ YD4V-1:YY4G
MT^LJJ[2GIB."XU'5-4%BJ@M%B@9;I[DOSU.N#54XGV1AG@$U8!]K;OW:X[ B
M=!7!%C'W,J=0F;C"^Y'?IF]SLRBCN'<XW)CU0$XZ.?F>L5/V60)8+XU^5)F+
MG!2=?C"6*4'!D1B=_O;NW2_T[\/W_XJ/#S]P%KH3_Z<?GR+H9K/P;C*4PZ<&
M("5/=_L3A?L#W%5*Q@-+X6;.=1]QPG];%TX'[!Y!2Q5$(-M69"-^D4TPF8^N
MDG*R,2T*SG>YW91,%#"04P<A8VQ+#982TOY;T 1?"& LH!QBNQ7?6Q0;K*0>
M>A0T>V V$3[K7&1)0WGR39#]WKK/\#5B<$L83,*C 11D6<UVL+ 3 PE5(GI@
M2D3@P6)+W^JY0HBJ84#ZT-,969? I,IL_<=-R]F0C.XC'(C($XFT#K8>Z#Y]
M^]N'7Q!B_? V]B^&0=?%$(<70[3ZQ?#J46X&O@$'_;V.&_"V:X*IE)")G".K
MFY__[;O-[^C?R#[KO^\YOIO#,T:#3.J+OWTWV-Q\:?:D+O4UEZAF&2=3#9^8
MIWSW8_37>J)?H!_:.^DO/[8_&NSCUM_XZU_J"3[%CO]"( M:-BU.K3GN@ES,
M6X.O_J4N\3]8F&\;]1DVZKVS#MY:Z^#;]CR5[3E2#/_#,5%1XA)Y)UP\]]BE
M![I&/MU;5M(;S]/8?Y/6[-?;)A QUU$KR(PVA*>85/&+[?Y>I.6M7I,+U09Q
M+?%Q.F8*Y"TID.9PP6R>& ./ V3Y:B\TFN'%H+\3+WE?U/V^(5?PO-CJ#^PO
M?2JC%5Z\ZL1X5F 2+&[[\I"6C^#UI]=A12^&NM4Y5"ZGK+ED6'+S"94$Q/6B
M-'NMSW.F)<H;S?/V[?.H&BJH->:&'S/4W#4J<7_AQ%4I^[6.'37#:D]JWTH_
M/@SJQ\V^;8=#H&7'&G#EJ0WS$-@E4=-I"03K&_TB5=VYR=LI%V=G\&W,$IIW
M#3O>1=.,?$(A1Z1^UPUVJY(56M+]EM W]8FC9"JE2HJ/PB.S&P$9>;'G;0QC
MP;;?2<OR8O>6[PUY '51$S+GW"Q6YG5BS8S7DOU7=HQ9X6GUPBK_%\/^GGN/
M^9WYP]+C5G6,%;_A<*%XB,0LRZ5MYLH89W-F@S N4S!&&1+MZU0@;IF$3>K!
M:0?/IBB#8YYWKV;$LHN&#-N,M(H#CAH7KG,F5P\GR!USG*4498)U-A5GDV1&
M!#[BDD1["JL%BA,S!@Z#^\MBQ_Q+>9%OT$AE/L97;>M2J=_IT*6#_L$===M*
MNK3SA5 +V\O>MDQG$2E6QL]R/<U4U6A>:#:<FP+.%A*4F7NA?2WC8[:^NM'E
M_.RO4A\84F)2X89814&*P5,4G^!:O?7E?+,.&J^,;I,'H:47_<V7RB0=U5I&
MQ@_>:JB4Y0IER<RB&]0*\HC)^7F9$L\,O=Q+"\9K.==;TP>V>0+/H[\0-^Q"
MB737Z;H)NW<&=K@TBA>#3>]R6::REXV7"IKIQ2.:+Y6>4EFJT5?9'V;NB)Y)
MFZRYYW(.4<J72FKSR&E76A.];2AH(-WN[PQ><@=4?W?G);4C02?.FN,\YCT$
MF.N<0EFVE\TN]20*KEE:F_V#/<KQK+JO=[LNE@PI(O7O1*"Y?^T+S#A1%QK/
ML^/#!\T!;NL =Y"HDEW0V].C%O1OUVAU86/[>6^7UHP6<&O[X%,M8-1<P&S%
M"=SAM.C%^V)G=\M-8OM@Z$TBNL,JM\30@[^BCNZP6WN;FQT#VD[!NC3;[KKN
M4)&.;1FC^K96V[%] FNJ;) &AW<@<8O?4Z^<.R9!DR2;#*=(B=)\!CR?'64%
MQ9?SPC^ED5J%6BR!_@8@$]C1+3W'YAYGC7N:FE$69EB#3;5"82$3A#KMY4W9
M$I@#H)R+ CJ"D1(-CY+\(VWUL[V/[U:0N?/U%&1N?2O(_%:0^=@%F0]TR%^'
M8+@-6$7;F^3 6$+D16GY*Q/"KF2K-C!HA[N>FTP6IOV8RE9>#+>=^;[.#FN5
M_2%Y0&Y,HHJRE,N=ZC+)*^&XC(R-,Z8H2GV%7N87.V928E[AOW 948F,@J1P
M71 JY<"P<$XQ">X/,S_=WW,_,+YH@4;<DF#S_?J:K(T^(.2A[-;ZX^-"NQPM
M:3D%F@F@&+VPX#I!:*2RQ5O^2\3X'7,<M=>1YK>7#[V!ECV2"!6M8- /STP*
M";*9N(D9[PK#Q+46L(HX&AYZ"5E %??:6)KE?Z<Z.2)+]_IE-/9 QC^[]F;/
M+LT0J%$^G$4057/V%T6+C)DD$3:.7^3G!7O1?I._&E0NR$!0*M0SZOCKI]<1
M$=Z#\DA(K659N1E(_IOL/&,++*@QDS!7O9*)0@P$[F36X3B&Y1!GW/;QPQUB
M#(LUZ7)GY@QNC2*1@=TD[].9)Y-)21S@@JUNS"^%A""H"9=1\#AOR6A*RDFU
M[B*# 3T24R:1M15Q'H9"C^;Y,T0F_IORT+B-DRFVTRG!?_3BC^FU"RRN46BU
M6%3FA693TS]0YL: :6D)16>.5;7^_6>WB>Z4;!)3 ['49%Z9.UG_ZX=8DSR;
MFR]7OP>_P^5[0Y:)%?YW<D77$SL+3B%UUC(B/?-#+)-Q9D%_Q[\TS._UF9@#
MJFO^]MW0SM.(89UN4,\TBB.ORF2^Y)$\U\;+N^KUJ6;YKZ/R+S]&:HCS8(PU
MWIS/JF_Z[MMZ/.9Z['YWPP.[[)C;+?,U,W>*T*W'0M65?IK)(V?Z-,_6)UL[
MN+!/5%(>9K;#KV>VA]12__7,]^7CGGHS)#,$8UHN\@EN\Z+\/B[/1VO#S>W>
M<&N_-]S967>:H5''L3-\&4YSFIZU:EP&Y+?I+/ -M@>^^_$(!F^7Y=M< K4H
M7G9O1_-;[3%]]^.+)<\\:'R;0!Z_^_%@[V#I(+H>WRUECS_NG=[>04LY?!$C
M7]ON[0]:6OS&-ZP_P*AO7(YE0]^_X[A?WO6,MD_@_4\=<H8-Q\X68MVP:BML
M<,?2[/6&>RUYO&W5/_TP!IN]@[:)\/CC6-OJ[>YLWCZ.]?L-H5MX.\>QPF+<
M74SO<Y7<7Y _4#$*4(#=C?'IMVQ[J[>_N?_Y16?;Z,?=P><?Q]J@M[FSBO0\
MM BOH%8^KZ*E_F7I"%8 , [)/MSN#+=[!P=/0-%M;?:V]E=0= \NK3MF''M/
M0%H'*ZB01U2XJUCGRYKA":=M;;"N(&T/NG!HSG]@K7>7L6RO($N/,I;M)S*.
M_V-:_[#"_C0D^T$:+3IA1053D'OL25R?3H]%$"J_K<=B"0]P5^/%DJX+CO]W
M.21\HCL ';+_IJH.Z+QS2[Q_[)=O^<V/XQH6>20E\G8'^TSGF4^BW4UIYQ?E
M<Q:"9  /H[S4^E,M)!+R&]?_SSDV>O@*M6P]K]SIYK$'941V57"N'K"-Z&D4
MN"B:B:US%]S[.LNYF)\_X&P8,L93/RTMD"]^ZE#2HU43_=QF42=:5WVVF$Z[
M,)&7<Y.@,*&)*1H B4:4^6N6].UZ-7TWXJU+IE.1NSF%:&8]+1CBF7'$+==1
M!U,*(U4#7T.[<%O=$']^EDL;L&NO.1Z-[1-F1.::+^HROD1YDLV(VK%<)B7R
M[Y:B?I09X^.<VK<DY4W(LM<HGZDL#VS,-6%F^?[H(5<ZE3IOJ0&4AGKN>WZV
M%6(!14R9,I:PYK?;=9@12DIZS#,J)XZVQ]:C4J&]5RE+\B@ Y7$2[P6\TV#=
M]&C0%#NAD]:<$148]< 6TD=KKB[_-=,8')?79JC_,UQODWU9>9&#K=T6(0&"
M_=;HFBY">LXLH?@4RX10.D@//V$"1$QNKJ+F/\<#;)?6&$)Y8-GO.EF4GR<P
M9T)$I>\)*P)RVF6UWJ$&?"W1CVXN)94== C_=)H<TX&.F."9+78$MRIY6/.V
MI8%0]0E#>IY-BUHZ'L!?5,V2Z72C,@>Q16O7(%[KHFU"E4G&A2QWTC(!;1Y)
M4]20)J45;V+GWX%^KVO ;7K?M0#- /P5N3F%0))-SLMD?L%ET78G>CZ]"']"
M94>65\GVQ;5QKT%)52]&J:BUJHF'?>/21?. (JM[=3HY)-::%$XKSPA0$<6"
M"JK %$4'*.HX0(\)(7:K=?[P:AC,.2MHX?W;M/!PT-]=IH8_D8Q'D/%5>9N7
MT\(O/W74&\&$0HZIPJ>S\,ON.RC.\&KBT.O0=JV'+.-)&^QSAPHW&Q+(NEH@
M'CL,U-T-ZL._OCP9=[.B]HCAIM<(-9\NS)^VS'[#]3CS\/RE\V!O&'Q"3.-5
MIFT9Q& @%&HM]E&/*,C7E#[YI^TZE2H]VV"W JWF[99F]'E9,9\&3Z3C:E?G
MQ*,(ZRIL=/)6"276"K<B5OK64XU&K3K)IAW@.5)M&)0-?BL/O%L)4V,<2^LM
M;BU2XUC&.P!WLC1].94D;:[.!R#F^'H*<QZ8"_KK64CB>?IZIDMIZB^RJ&N%
M)-&_8#>_ZFH?'2POH'JTFJ+AEUK%M=7*%GX9X]YKI:6^B'$/>EL'K236RB/_
MT]4%WCGK#[I.&OYZTUD;VDS[ V7YAKV#MDA^IHSCSOY3R0?O[#R5+*SQ-_?N
M6/7QN$4&]Y3KP0.OVZ"WNTHEW*/LX<'>[A,9R<83&<>PM[O9NL"?O"X>/O"J
M;/5VVG72GTOO#':>RDB>2F'.5N]@[XZ+\K"J>(FK\8FD?;6^JQLMN=MC-*MN
MQ]V>9.^ S8.6\-RT:"L,Y(M;A+V#UN7SM2U!Z];[VA9@T-MOEP[?:Q$>^A8>
M;O:'K@. @K.*NK%4/SV4U=;;WGW@.N<[7#U;FT_%AAST!G>]!A]N+.9.WKZC
MT_C832^?X)9^)15S2#X?2?:UNU;[BU516Z@0_=KU-&6AO_9%./BV!+N][4^T
M")^V/ZHYA.U5%5GC6N?*8*/*JEO;_[?OLU/F1U(0M5((^4[/T)MGV#MHFP?+
M%^@>8OI4I[[398Q\%3,W^KEM^GP=,]_L;;4-K7M,_5N?T!/N$UIF3:[2 K1B
MH00PU[Q:OS9N]H[7HV&!! $,7VE1Y9\IU(I=I9;VIT0 !!RAH'FB2(1:!TB0
M=$3_0'6+&$AVOB"B86#CD5OJ, 'U5X!@$/PZOU0RJ1U=,+UN3N"YA-0WRB9$
M?7J6E3.NB_S/HE :MX+JA^LR03,-=7$ .\\,[;-U*#UFP=_=P7=WOQ[PW>WG
M#+[[F,+:M6V?&.CWH4%VG\R)]9A?N:?H6D$[M43=U>9Z=;C1RF6X6<5D(=,S
M%%13-PT#G%+$9EJ<2Z.19<TT.GTQY@8\<(-R-Q"73-/1UM_UE4 N/X^,HC5W
M\'4,5%$*O% '$W[)L/%3OPNJ(JV>6O!5 BNM0*&)+S+#CB7JE/&/J /%+$NF
M=.^,G<H O;@8/%::*.!.JA1UWHY@BN9$*LZ_*&2\X^(2"+Z"#PO(WXG1#WC^
M:$&THM11:VO3J5V0<'$)Z)WO/MQ)>8H2>]K%DCB;$DPBFH%5-24DV)[V2]+]
MAL7.)^;OUS2_:2(-O%<7J=][<&96D:[28FQVCPF]M6_-/*I<Y#DJO#O6PG8=
MAFL2@?ZT]7BJ#D<MO /$+0FH5;K'O X#:FH$ZLQBIEW&!3!G\=UG6TC_P3:V
MS95P9^D)K>YP1+77S=\W<T2+R\0N;1(/MHTK&7933+FQ+VBEV-LQTC$QYPG'
M&0T5T5I7 ]5ZCQEW[6]GQ81>;8_,DF9(9D=S4FXEPHF3QWGA=T=&_[.UWNIO
M7MX$N2,]D*Y+JZO-4=LE!?F:Z=B4>,RV6](N-5L?(_N,92UKG3T+04_Q"DV3
MMS571^VNRJ$E\^G'[STY6-8,9YZ0DO)D<S?]PQBZQ*M,3?_.KO8:CAB2W>LX
MBE _UX]_@B1<:HOJO+B:$"_'A/K\<(5HXPT IV8C,UI@$&3C5"C#.J3&J+Z"
M!Y:;PT<M>=R9!<8P2#TUZ34D+N+?JIL0]$W)=M$T)X3UW25#W#V%5XJ,9^**
MC,SZU=*:5J>@FH8DZZWX<U%,XE^3?($6;.[R>@=O@J:X-O[YUW?KL07-YKO"
M765ZC7+_=UJ8=6<^M7Y\:$ZWN4ZFYCG@A:$=OT0_?U&ZQ;&G$6U9@ALO=(6_
MG1X?1C=WC&'_CF_88H>Z[[M:Q.I>C.W28M]ILXMRMI 5]ZX*<&IW;+)9SB[1
MU!M3]YK&1?OM=$A70V;G4>\4$>K5*T;"P-V]QJL)3+P6]G(;;=6M!BU0^BI[
M,K"M@'<<Y.H+P<.*@F'=TES(?)UA*V'8=^VV',._3,TV3L-.L& '>=B$6B)]
MZ@RF7QB+L"X7,Y]N$O,8V1-I?@74A,J<L.?;@O>G0D!RD%>P.5;HSI.@3M!?
MW]2NX3G89@>BA L0V<N;9+4)3M*%*W"7?O"[7JX1> UR?S&VMEYVWKCN2NU
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M>C'!EL!U?<%21#5\F=711,N7R$Y7XAE:A2/=&;D357;I.$R[/9R.<\/CPX#
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MQ.1FLF_ZW.?22'_R [BSGIZQBY"H,CG-1GES%1W KI.PO;-\ N5!:?2@NY[
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M)Q$L#"W<:,&*-;ZZ,4+W9M%PHV383-P9%?X@CPV(EG*4Y\,^-[/7@B^?%,*
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M9D^**U(]Q#[8<+OZP'E#AT-.-^P"3W"K:6D'5UJ<ZBB/ODP7Y,MVD'Y#;LA
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M)M8ZM"R>V,FDJ#)!128"ASD$,X.1:H@8"O"5U!*J$]81N?)<BQ#-=@#=")4
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MB>O%7-F:],/Z.[:LW=6R<VW,:>$1,RXH _RQ%XV^RS#2[?S:O#*9F;FE>$X
M1386:IM)S3U5T> \'675=*,I-_#_IJHO+88]*\-3[>;/4S=#J-UA(B"B83 E
M4*:(?<,WB\'^TK6)6:K1=5?6W#=ELDJE</E;3;K9(W!.GFTJ$#_LW^5U[:RD
MQ+?R9OBO-+UR,D7T[DSE.4<-+X.Z#XB"'KN=$KI XVVO!9@]R7\/T3M='2$Z
M!8FA2/ D;%[>"Q(H43_ROEI 4W+R+HQ1SQ$]\9GA=1 E(TF*4"G5TF[B3"(E
MN?HJ ?8RT9 8V;XC,7:X,HZE5F-2RZURSN6H'>]AH[,7C%TN)8/Y*CHG3+4,
MVPHK+%RK'NL#+FCURM3A=VO(1ZJS(2('+M *'CJ!S&(^1Y5,D$%Y,(IL[YU]
M:X^Q \($:EZ[)EU]XD7 1]>Q;7N *B%O,L?];JOIFI9KD@30TFFII&8:C%(_
MNXSABHD[XK[[6+>U\?7*_3O!B9Y\.W"B_6\33O31<$0?\1S??^.O8R/ZG /[
M#.D)V.<;BR!BI361+E"G\/')5>*QOC#3&&HN28%!IOX_^\=<M+/H UWDVG#0
M%:E<P8 (["O%D#AD!Y/;NFHA\H9Z$L,)JT$YRIS86W(4&<T&+E\.4\2FPX%N
MY)=R:<+A=0L)_0(:>)![NZ^0ARL*AJQ;")_%>:TX&)0=UG#HG3'K=$MB46,>
MPT02"7X9^[DT8T#'"#0M<QZHJ=L>UW<)+W[D 0[1='79UAHK:S!CJ37(P73-
MDB:U+(GR[PBT&EP,T?"1DPMJ: +H"[(&+0H='D-WX:P[)#K'1$[%5/O+NM1#
MOZ C43 M@(MJ%4A$N+5 [YR"FW=R@X!)5M=V(J>NLZR.3=0\UJ<7#[XG T+:
M),$:T>3)=LNC'9?8:S0+VZ!X\!9[*-1J8$8FSYG!$0*)Q3M<A=A=DD=6\TU8
MB3EH'$;<S 22X]Z]NI)4 ']F]IZK'PSTD;I&;?'6(9.AG9."EFLW>' )>QD]
M,=]M3U!/)D&%S"#5[1/!X965(Y<8C-FJI$,E^B'GD:U:F'16M0$D>E39 ?XJ
M#3$XHBAS=&"2149@6").UK.N-G<2X.7U+H;;*#@XI2(H^HX(B_Q,[)C<HZ_6
ML+LO:.FP3B330>L:XOQ[80#'M6V1-!,'3$0D.8FI: O<0_L6FBS-&RM=E3Y_
M_@VB/FA*G-!,'<EV_!E-,/GX=W L7%HH_S 0XA'UM-"+1B-7N&1R2%&'.$;'
M&QD)RE8A/(91.E#A40DJ!8?%N?1]TJ'Y&81M#^.7^+;4&O@2J F_J$>*C1:.
MV60+ZXHFVG*8S5ULC@G3&!P@<TEB?HZ' /UM=E3:W?*Q7$F6"$L TN<.OM:,
M_;T4WA=Q(M$T ' W"#S);00H4W)IE70O QTYQRFT+T[CB9+=86($J8N?7F@3
M# '_M9GT!!(4,@/T].35>?Y>M>&L1@'0ZA"V":LB+&IQTS0JKH39M'%CY(Z<
MEW N:XF"3>;F\0\QVPK<]EP#[GWC 4XE>.MH9>SLD5KAO,NBE@QN.4!K)]]N
MR7_;P1AFB,QGJ/P5.H%":841^U37N A[);'T]25)G$)Q_( .U^,KHY;53^KU
M#P?G)&W&=!-"0%,'*2-NJP82*9W^V$<T9%T1,^, C,2-):>DW!HWO3X+Y]!X
MGL-DMC"F9U=HJ:74>%E=.HPFK7S-G-<\B5HR$\)>B8<#>,:2C6.+5G!FP!/:
M)BV"OVF@M->HDG2-Z5R\3\N@)KG/86G3]=^YOT)YKMD69?#7,O'(F)>,BP;!
M]&8Z1DD7_=<(7BOX;[:Y-*Z@XR.Y$WZ?^Y1$.NGY'!"2P%0H 7P;!W[E<@M>
MKLF36[*:HUW#RJ)[!":)I6T3G+8+PH5*@?XB#%5"8QFVIG,,;K5K\FD=V"PQ
MF0S&)8*CTQS GHAJDH]M/K3DXWQ1P=%I&=EN"B)*BO-Q(]^>9A_XX@Z%C97I
M$WKNMLD-(0=D\)[+D!ELA%:%F;#"L';%\+.!&4*7[A"%?)_1M64._YQ/]U1P
M'P5_**NE$EDOG-]M"VRK:3]DE[$19CW-#1B#@HR8D2$+<0:F"\$E,?F/9=)Q
M'.-IN!52'G<^='I>?+=)2='$;6$872V$MGGN0M^U)):09 SZ.KJ.D;:'PBX9
M5,O+X(3R0'A1T"^G19[F^00B]"0S*ZB@MDX[]I7YA$Y.3XHA>;%FFI( >"\7
M=TCDG5! E!*DU@2_Z, ;Y%Y@]<O"*;"H7@ZJBGUO),)H&NNL^I <PZ"%$*'E
M)??PD(-Y4]Y(#T#=2R 8-+^6I?6T++5UK9^8K9"093!_03;*@8D;NMW'R<'^
MA[7ICA0H9&6Z86""Q$=@O+T<GGD#SLX0F4Y)8;)A-N DU5!EFKBA3CE!>;/<
M-8DS93LPT .3*U;8-^T:O\JU$_44/G2DZ19. 4BO!W2-@29DY#(]\.WAN[/T
M^.?T^.S%ZW3[D&,<V]M_2=\=G_X]?7EX=';R[A0/[SD*R$/AMWF7LQ*3@5O^
MA81E14<"6+A$N&O8Y$_A=[&A8O*#%9N:_H +5P/ADVFY 0#:3 T-P/(7+%FP
M>S8D0;1@R'@]8@Y?T 4W X Q9(D'VL!$3;& 8<:U" UAT"U'XZ:C<&N*N3_L
MFVFF-:R?_$2O/(Q[25B-WJ<9PV='G5U?^A'WV4BZJSX>6]7'[I:O^MBYMNIC
M9W/W#E4?VBSG<,5@7!4&VSR#0;40*K-'.SL"\1>FW+RR-MCM&HQT3:&@RJ-&
MHYCE JQ8S#@T-L\*;?=3CD;KMVC])3R^.A9IB!FLV*.HP(-K'I3>BM'@FFZ^
MQ.6O! ;0.J1N[F+BB9FQO;.Z (:!EFH3W*X09O4[KZ]Z26Y?];*SO154O>S=
MK>IE9<7.[VQ*XH1(:,N#TBRR'I:WB$)7M@2.[$B]P#D[O8MA(3Z,P'>4[:K5
M1E< >IE&_$ELCW/ILL.EIXEG+!3HG+6$ZL/(X1Z3[,/$BTV2?S3B2+<_.#2=
M$3>=G<XGY57.-B3TDUH?W+SIQ<EF^K8J2G957!/G<39,#.:W; _(3V6E_AFT
M=PT:&B8;? :VC9E %264*5#,KE[1US!!9IIWYEU*.MZH,'A'\,CULDP.6!4*
M:PN:^F$@7&*PL?TT!98RGQ:#7JKLB1'CRKRX**T5(,#%#6[D-.>*H$0:/ 9@
M1LY>R.% CVSK<<Q1F4*:\/)+[% -KGKJ]LFZ-HI.<<5"GD 8(6"SX'L^^D5'
M"B&TIL=TD5S8W#%WZ2D!V]T20@[]38[882O*O-2IUMP=V,CL4$[*>N'[H0.&
ML*B-D-P.IF/RG0VD^<1L&%2;5'ENAX S O/2PE8@E%."0/DU"51:7=SF7MCA
MEAYSI*+NG7Z='@[.[N1@X^\2CN>+R,_7MEHE&+I ORE.W;QB&D[&2<*!=\&9
M:QIC([ DQ2;6VI[+-N;@ S#T+5\V$@K,5*SWUF>\@'P69TTNQBCD_E(1X@E#
M+1824\2.BL:J(H+"G>6V71$K8_)H)V)EW-G<=S_3"14%RF1>8141EP!*:$VG
M):IRA7QGF%JW,/O.)K,"_G'P[< _'G^;\(\_!YO,%]$BZFMI=?6I)<XMQO.&
M!/F)1&%(\[PJZ_H;H(VYM;M*RCJ9Y8W%J9AG5L*&C_8W/9\Q_+$ BH @GH0^
M@_*ISH?<WFU-O-L*?,2CW<V]P!U6J'BQ\F6W\XEW>28QG3F]Z<"/4=WTI$63
MSM"&.F^8 D.,3VZP^6A77/@8PNW'9B;"0]H!>K;^A'=3^",M?M3C??U^.X/;
MB?5Q81M>'_('SL^1^8*']LB':^)PD3C?K2\*;<:3KIC!ZA#2O7/WSSUASBTF
MR<7%T]Q'2HH9N5N: ^5F*E?V$4QC]_$^3X.C3+X3L_/#N+H/E$!LYI/U-[A*
M6LYP !0)&A! EN0U5R$7Y:)&ZL9%QZU60X<C90<IN:##TA<1^W'+:T,?'#Z&
M]7)(Z Z07Z'5%"YMY'K;#Z_M/ :"C3>EY)*65@J)J,Z'60=M8>BTXY%$\9)'
M>T\>W^&$[,HR/-K=>WJW<_7&(F$9R"2*?V76X&N8]QO?PDH0,GT&OPTX-RL1
M)=]FP9T8 /WX&I W;3G<>*;K+/T?T:%S,;3N"%IRUPB:"JP.0B8+<H3C</GT
M1_N/@['L/=UIC29Q\3RF$F\-9\^&L[\TG/M>6G<V]*[Q>CUED9$HT\[NQXDY
MZHJ=65N2-6"[UA'.0"5Q64M ^MX30: CKYJK7H(4J40D?1\5GM:!6_FU1SS#
M]8\VJV_)Z;_%>&!TI\\$(G$L!^LL^Y#7R7=='UOB?!,42Z(WL,%"R8'=#^S4
M98V/NO157Q=+?/_.EOC7G,0,#R+?9SB*WCW\)D[CM0(N<6QAL"LJ,<KL4#E5
MQIYB2Y_&4C'(%>#(HFQB*&#M63%=3+6B#\^<%%)KP B8$_'SDL ?=<=?LJ=;
MFT_V.8;;SVH27O4X0Z7 71S!I5L$!R3P7=V-Z27RPMV=^[[P4URFST;K(#@I
MCWCJ<M#!M71%HND2F#TI'K7$C+C6UE-J^9!Q QC:D6ZIF8[R(7=GO.&E(D2W
MG_ACQ*V[5S]7#N:MGKKG8R5T<F?^B;A!.UO;3P3P3L(F/5IHTN=O9;].#P=L
MC22U,.]S>F.273JNK/.BUDS)-!OF43F(X,T=?=)OFZ>;<HNR2T#4V2R6-&L4
MFY"B!0DQRBI7 @;6YR5Z#:[;/D%5X3?];/!>6X/@/?,\<RUQ_4M"S*+=>GJQ
M!'K".0H4DW,M"<]G>:#B;^SN_<CIVNT?15 $9X8_-"Q0B.+PJ RZS)J%X#GM
M0T(+5P2E8M9PQ/5[D"R@YCW1*1#90,'9<_8*U?)1B9#TPU'D!-Z4D3_)U#0A
MUE$$JJ.76/545_8DA"*"RC6G6A'\!ECCG6?G]:L5-,<SU]7#G'B#H\,[7#!C
M0-8'RP'VG1.1I[C#RAHRLCAP.8NI.R0='8&;';1T^2%'\%I?3E#DK=>)@7S(
M]O%U P(B#]+ 2>V_SGC8VF=0Z4E*)<9?[4=]DGTC^Z_:$#NJ:$M1(7\X&!A)
M[5O$3I14#;WE.)E;_Y^OV32#+%PZ.VEP=H(.J5(4PU* +!')/_O%([E&7YY/
M0B)+3\TA<$9?9O+;C%_)9QRP*6$\&N7<#Q*H5?]@+C02R+T%K!)?E:#M&FGC
MC%AVP7CO+@4;H#.$^YT5GVOF:KJ*I@OCS+4G75X5T2'R.1="ZEP^Q4-XG#WC
M::W?HIRT?RZ&YWI1>>%X;BIH(!P@7Q@^)DO.HKT7FJT]AU'F<(D/P I_C40"
M8S2)@$[.N5J+'RA(^L@4!DXB+6<;4G_(>RX$)%KRQ>+"306]VYV9D/@9:J0L
M%:Y,TS9AK4-/0/$3#AK:]#K4F6]!B*^?E^50@/&"(\GJUH!HZ(GT_.)[[J%!
M"GYAKL623HN$@L-6E[99)JI%>V9DKDO+Z9G!_P=%-5A,I6!7RPM-.= 0Q0,!
M=BGQMT::I'&]KM]XTA_"RBGVC30]F"SR8,?;&^1OF>CI; B;@JY"QD@=MD%D
M9E9J [-O09K!1@@XNY@LKH*F#L^F3%,^H0?%K1#WE56<D6#R^6X-0('*>A*4
M*Q.N#1GD%0JZ)3(=E"NX+LKIP&2QZE>O@M(NJ),O/RQ\/]V5UQ0%]O;\0*JX
M:29>*#BBT496DC9_^-7:-7?#S3S]=G S3[YFW,PG/K*?@*7EH1E2OL"K:Q3'
MKCS,*A@9.RH+HGW/CY7)]]__[6#O8.<O5E"E%+%MWO9!UC03Z4#HRS'5MNAJ
M%2KV$<.@\WDZ+8<Y&*?2P].C]/'68Q._9@'PIZW9[L])L6X,9:C <WW5E0\E
M&W@<N.,^[*7%RF]%Y51].G*9XS /'XI'T#.L^M]9;YSR1+5T-E"Z[P*N<'&Q
MSIYQ_*ZE#YKFJL4BO/5HA$EYW5;;!F-+WD:PKWJJ=%D2&G&I02KRX8IMU!(Q
M+9+@3L]"&NYC-V&195G5ZQR&B$L+L^#X,5BX*9J)6%96&L4!G'D6L*KI+G*Z
M+8>Y5UUY1F$F3E1J=*UL!YN"#0D%UP.4T@X<32,WI5>C[(JMDTIG/2RE# P)
M3^; Q+/XNU:H34:E8^IQI9ZQR\*AK]92*/_'(BKZ+J7ZU$RQ@/_3O8Q'Y1\M
MQ;8!5CUCSNW,Z+5=/;#!!:3"O=[\/U^K2#MVA<\J+6AOL\O4E@2.1UF]IZ]M
M:*%VHJ#W @3VZ@S@5WPH-'&@1UW*/=GI 86B^K#2T@L8*VWN!<Z]O!FC(40I
M8"^A&E Z=A3KKCG2D*'>.>?H#%DDJR,\<$0MDH],N<4%WS=?33*1^G)W@.?H
M%C:05J7.R_$]K'L^12U\CB2".'2$/Z+!5KP^:<?ZF,=5!&Y9L,(3\"-J#6+8
MYAOHCC'Y%P!QN%UBV,.R79TH_B2FP6HYO*$C89@X7Q;@*C6QSERMB=4(;7?1
M5]$+A#?? EF)B)2:6WP(R_U0"BQ&DP6<H$@8]PMN^XJ),.7DS2;_K7M!MM/6
MUX>Z^#\9Z;?__"'[GZWM/1CIV5\_^A"XO/:)EM?N_"7]K]\.WYP=GQV>'?_C
M17KXYCE^\<I^?GY\>O3JY/2W=R].T\-G)[^=):\/W_W]Q1D7Y7[-1M:;<I9_
M(0=A_R$/PH$[!R^/WQR^.3H^?)6>TN:_>/WBS=DIGX?3W]Z^?<4_'[[[[_3Y
MX=GAU[SQ)RNB":B7/<\YHN(,4]+WPN%!"KH,N)FY2LK,2KP =7K"9'-NW1J4
M>#"0:Z2(IOHTR'MIJ("6U^AA0&H+OEV=OMS8-OH,^O?.OJFYW'K,M^OBN>T!
MC^*#YT/KC%86;$J*C5[__-DW6'4AZ=4Y4C"S\__\8>L'_KF>9P/[^<Y#NBR&
MS1@?W?K1Q2%@'F;SFAQV^]</?TW_HZGLZ>C"  UASJRXH'\!J=U[T'3/AGA$
M6?V<5N?]M9VMO=[.[D%O9W]_G9\SM.?HNP^>TJMU4AN3?*0C;ZW/AG;SS=)Q
ME8_^\X=_HTW[GZVMW1_^JH0'M-V_%_/1I$A?O7K;(_7L#]H[?]#>RD$+$ATO
MZ:"E:V^/#D^>I<?/_^T_B@\_S\K9FP6WR6#GA(;Q#J\<T +/LBF-?)@7/Q\B
M4U!6^/KQ\ >63\6'BXWM)_2_'_ZZN[?W'S]%C_KKNLBM9MBU"-O;URU"%#7X
MX:]TZODY])_J5CL3K_M]UWH;=& 3=KA.QSF'85?D%@R<USGCV\]RYVZSO.OY
MN^\Z[/SPUU5)S;OC%__@$NU^CH.PUUZ TZ"G@N*PTQ?_NX !>LL%V;$%V?V#
M"[+W99Z9_?:2!3GL3WUF]J'Y7FX\_AQ'YS&,227W/=1<ZTNG?OT2_<$I/I$I
M[NR'<_R)=:CJU8]I0,I_-Q^3 F^O@OSVKD;NXX]OY-YNC&P%/W56\-&OAV]^
M(6?G^$T"VY?\G\-?WKU0:_CWX[-?T\.CHY/?R!;&+T[>V(_';WYA8]E;T=YU
M^IK-Y2_(3WKRD'[24^\P'YV\.7MW\DJ<H[?O3HY>/(=__$EW^3\*MS+%)WWK
M<X\C4'I#">J\1=R)Q'I>_YQB3'"C?%"GESB?*2"I]!%U>E%Q40R9A6=<6EO9
MK%9N7(:6<!(_'RP<[L/_WGLS)>@4N(NZHA3$)8OZIQJ!1@")&(13F;NII&L9
M2)1&A< DTQ<?E&\7",IW"T1WMW>SC>W]M7Q=FEOO#_4GG=@I#;B2A'WTY7*4
M;#_=W>/8.=G7K/W6\(7P4^OKJ\S-S919:B68"9X3!ZU09G%=!XNA\S)H85#'
MM)/6M+F0*P#9:,MYIHIK\LWT^<TK)^R*BC %@=R,/R[DGC,A=!'TI3*&-&4B
M35+Q9 D*+ER,SGA+#)DQ JY1LA*@0_6(C&B1:6'6BG47$.X9RR?^62^FP&'^
M2TOL#&K3T\Z!B4N22%LTYMH9%$BLV)A.7QSY+IX+:V.-F<F_UI!H(O=^,=5&
MOH)?X8S<P*KSROB:! C:Z.0G=SCY.%$!YPH"$W#H>39<6C@H:B7J 94IWN4V
MP9^-3XCH_$RR["X B+VM;P< <? U R ^!2+AHQ_GCTB=<:M*1EF2C9JDHPPP
M@EDD]^0*>=B9?BY[Z+43WDX9Q*RDI...I>TK5DZ8WT] J^Y]P'?&#_<S1L_@
MTB ?II;$D:"])</I^GI(=_@:;EY1CRT[AL:Y -WQST.T?VYR:SX[28Q_GLG=
MO0)Q+'56W2 ?3V_Z.$84:GH#H@2(24[.:[6XZIQ$U/HD2-MU/MR"Z@':-OYH
M$+_FM?B@PYXOZ)0*#^(2<,6EXA,'3.Z$,ALE,I+PDJ;/(PSKDFGI[=EX\>K5
MJ]>W=@.<E:Y(&B/5C5';L3%#VQ'BX@_G%9L0+_T7T)7(\8O0:2'#J,DY0WJ*
MTU)RQ.6D.L]F6OCN1GL&^.AE=I7PMQB#K;5 P71]R3NP) 5=&_WVL"03A];?
MK8K-N=>Q6G)0EA?-?Z?)Z\;.1T!ITK7*D>V9J:U;\]N6[&)0)+J4<<$-X+65
M/#,N6H%&>^.2E?L&^*RT[N'>\<)XQYW7L80Q"+5B9:C4@0U LFE]53?"@^P@
M!8X'4\UN[>:.RY1PX\K.&Z6L]%SZR"GNY9L171ZQ'QG1KPMS.*E+MHW_:9V)
MN9_156O[8A^*&>JX=,X,Y$P(R W\TAA-LO(?ZU9AV?JYTFXXV12D\X,*,P\Q
M9DQ&T,?@O.*3G3 ^HH@1:0YH7%:A0\)PYYQ;$%7LQ)PM,TBC'Q-OJL$CP'W?
MX$2:L\(?$W URTB7<4EN3.T%]O:M9>MFVJ%?EKZMPT))7PN!I/R.M!*> S*<
M4/^J/8^;4Y32%T!+EL3Q67)VV:%TOI@7*PI5Q(EO(JT6Z T^ZM/E:<LLOWJW
M!":% L%^)T,:ETUN0UL=U&Q&)%UF!$=@_,G1\B]M-]$I2G4?5I^QE7)0[F2B
MZ6>F$-6SMIEJY3<3Y_(0>#3&J=I%48LR6%#4*L8S%YI2!XV[U!7Q'2*&Q5#%
M,)0%:71E" 7FL9/XV!61=U&WN)(4J=V0[AL,U[.J XLHN?8-1M0KP"@)E?QM
M,<N3W2W-8?2O8G;0]-&N$B(5:D)4%2W).!N&_?(:Z<6AS J7N2EXO.^_W&7V
M1B8(6>D4;OR7J6Y[*,D$E!EFTI ][$$F^$2@([%(41_V84=; =7=;LYM$T?X
M=N5L24LX475MPU/C2YAKV%; *7M?3^)Z2@%?!Y5ARD$C)[<WLX+(2H+N2&(9
MNY9PVNH)O[4>NBQ"IQ"6E>OV9&:%_%H1MHJU'KH_M8XJ4S>WQSGT1%4KF)9<
M@&_%[0''=#/NO#U2B[,<^;MIN1)_JSLC@,MAR*]?&!]Y<V19 )>1'Y>T!/#)
M_6+74I]&WWU>D- "_38MO;Q$OAL2O@NA,-E?VE;<PMX)E*JJWXX#N%J<B^ #
M(W<YX)+TB!5LSISE([0ZFG@Q_[N97OD'>%/>W$^TK:>K0^X^A9[M3$.KQH2&
M9$%&GLY\O/)<-Z((N-=H,.'P13<ZO'I#.N9KMVM5>IJ_.,[\M8=]-9*NY&RS
M1B#U!'TO)U?25Z7U^5[GVJPV#+^0G-O!@^;<GKF<V\G9KR_>I<=O7IZ\>WUX
M=GSRYFO.J5X'R-IY\D,JV1. KYJ?1\6'?+@QRB9U;E"M?##\^4TY0WYJ>ZN_
MOWU856?5=-8,7TZR\QBV=?!17G:;-SU]B&D=<L/!Y;<=;'WT>:U\U;;EP&/H
MV]U__B+N\],'O<]'[CY[<$3Z[L4OA^^> S]!E_O%\2]OTK_]]N[X]/GQ$>[Y
M:7+VZ^%9^O;=BW^\>'-&$N#T[0OYP]<L =Z434!K\/%?^^"T&W?-KVU_._FU
MIU]S?NW>Q^6!+U@++O='JH;O)P57CN/VPGEGZ^,+YY7#DF9\Q\</N"2K-[TU
M[^WKYJTE=G] +6UO!6KIW0ON,]A+7_S?%T>_H08J.7GY\OCHQ3O!>QV=O'M[
M\N[P[$7ZR\D_7KP#V.]V^+X'TM\?ZRV?[N*]>G'XG%;SU^.WZ>G9N]^.SF $
MG+Q,R<)/GYV0*8 ?W$8\J);7P:%#9C&Z^N1<5%;/S\WJK76OZV;\K 33'\(N
M&@<0AADDZ7RC-L0#&(J>GHCC[1-_869I[,J^4:9-SWQ;Y34'6?D)1R].T+07
MP<Y^GIY+:Z]2VH,Y8)[$)HTDFIM8S?,*'): P3O><'O#T3@K*F%*\JTTK4!)
MRT2ELZ;T"97\73YK?)(W6S3CLN):[QDGI! +EG=NIJ_IX:\+\OCS2?)R,WU6
M%>?C;,K..,,'N42W8YH%E.W+O%\MT/1I9VMK:S/]53NI>MQA5TS\K8O9^)C[
MB<1L>#B)C:$C1<_QT^R*-/0&_5^+XB9,A"B&3!(@MJC9(/IL<^G)]BVHI,&C
MNI<$K;LD_HHR__R"V2KK?%;8P^G#(&UJ+<?V;B]]CM!]1MN>GM(&EM-Z,,Y;
M"\N[:^/I.*F)Z[<;SJW6S*O/-B%$[R?1YP<-Y.1@%/9R9+AKG^+#1BXQ==&,
M9L-,0 #(0O##$FTAY]*>!6K+.:H"#@-YH7Y&&[#:#SHY'J&V\DN'-D$^,YJQ
M0C_9BX % J/C[HKN-'D<WZ3(F/:UGS>7N?8;E$$8T(%[ [ZF%SPK^_TB_5M)
M1YON-VW9K+4'_\ [_0E'HC\S&.)K[H_&_&E+.[R_F>#Y+[BX/:<E?840WH2&
M-JUO?,7KJ#8\* .2]QS25"=XR6/9P+_1 9R/TU\WTR.RA_NM1R>M^SDN<IH$
MMT,#P8?=+I&)+OJV_?3I 1<[^#F!\11/&(<7^38'54@;D:^!*'C:>NSV[F9Z
MS#A2EUB^NN99X+U"B#)+.4KG40]V"'& C>E+<O #7R-OMR"QJRS'F$&H3H#+
M6>$Z_2M#,@Q,Y-?\(B-\='#; :BRAD97:8+$<6I),D/R]Q[K@J%R%C<<,UKH
M+3H'[>2/2'P9YC"?<,^0VI& >8DNH%L5DH( 0@OV:#J,977!X:2?3\K+ATLY
MQ,; DJ[^%&& 96.IVRAB2_3X[)2LT=>OC\_.7CQP]4';3OI2Z>S=O4RB>]E2
ML=PJD5NT5OGY8D(/C!0 M"N#O7T#4OU#6;Y75<SH=+(!BBFR%)<5SJL0R$F*
M#MRXF*;47@<7=+7PR"JA2.(2,6_&]=S0;V/SF1)Y4PJY$:V:^^-F<NMU9,%C
MNHX!(S,E5"&U7C>I4* / G2BZP^$7P!TSW9*B5:=LP4_'>3KNIK)-:M@P/GK
MOB\[V!<:HN7%51DYLUR65 HPX("UPEJ0?#7PDB1R6I]<#X79.!-H$$KR,XD>
M3TPEC+A'KF+HG<7!RX:LW69ZR(2(M'KH& O+UOU-2B^BFIA"6MM*#DD.'M==
M>.M#U,QH,1F1VG:];OD[ANEJ/,N-&U&T/HZ*B[_-35_:"-;7\KU>AYAWW63(
M;RF+F98W](*4\6*NF,9\(K RO-[/@/49C;KCO8E[K__X\NL:U?)&Z&-TGFI#
M^E,!Z)+U>OW0M.:FC)+ZB0(5)=QLEMZ9X$;RX!^$!O*S</UVW#B<:P<@%I!K
M2P0Y!T8AM5P_119TG>?>08G8>;IRK%9[T^GQ\#/PUEH- P!,:S-P.LD]6;*V
M1YK/SIDDH\M]NQ,]0L\@(;4!0DB29,)_4!OF$G ^ "&E_SAZ_@@7+X^=IQ2V
M5P[ P7X@]LB>K:A^D8&1WMA<"<]RH)DDK+WB0B,#U(I-R$,.4.71JJOQJKC>
M "H(7*W,(=Q27I>>&7/_TC$+6A =S[AK(M.7"<<5_P*&W85T8NYXEJT:O]$_
MMW,HMIPH AMZI_#TQ9'O 7]9X)S:DK9AHF:.:O]X\H&$QXJ/'DP"QG*I82Q*
M8 C17<[=VGF.K%S!L?2(@8 6C)>1WP7*.+.A@X>[> _:!'C IF.C1N  \%EY
M>_N<@[]:5AU^-J.$,%<FW 6&%EQB#4BB22<-U=Q.7- !:TB/-HP6KDU#\D!$
M9T^1M_^T/G&7'MVQ%&S Z+5-WD4YN;#MD-W$5K<'CEJ\*>H=Q6M,9"G?"R@V
MN!8.[\2W!J,5(#_B&@!4K+H8YM7(LIF(<;A>=<^TEF\@ &5_*Y(A @J-E.+9
MXK1?<4M8#K/1-5TA*'F?OZ5 YIF(;;TL\7WV^/9D'AF-BY/Y#:+CA=<85(UW
M,6Q<H(C**]:K+KC$RU_.( &X#A#+@2_R$K.UHRO%Q1(\!*DQ<..2A;[EFK@R
M3@F4+"U-CZM_6Y_B4QE<@\2=)K<EVCN#1!U,1;&E$1_\)2.[[ASJ$C^]*^OS
M?-:+ DL<*P&$B<0!K<IF^$,0P(FB"*U1"'V]O3K\3'#N(83Y#V1DT"7-I:#8
M#KRNENP=22XS)GU9BZB8R*I!R:O/$2<F_MX<GCX__"]U$"0,)"CM;DG"IC2/
MR9O7M^QFU/E !<%Q\4*?48K@+0?:2<!=;<Q]SVDB[.;.UE]HJ1ERQ47EH&Y<
MM:;\^>V_L '#F%FR31JKB98P>7AM+_-^79 1O39NFOG//_U43*<+<$EMTJ+^
M=#G?8(#(K/EI,9^4V;#^"0UT?MK:_VD@X]F<#T?KFV*R'0?URVI]KGA;XB0/
M;FQ3-(M&*N!74'4]4'Z'_[N_L\Q8LK^CQ7V?(>V!F_8V6]#<W8V3^__/DI,6
M<*+-7DV\O4JGB$XU66.,>-V6?I2^><YU=S;TJNWB/ZNNZ*3^/905*\;@;6;T
M:>:0H0/=]DM85W;'08P)=!_?7#W6K0L<V$!RZ^TT!X0#)&9QJ?7R^CAD.2>9
MZFF+VT>O*S!IX4-G<P^'E186P.3FL5EC6+-;@)IO>)E)2.6A6JN*<RO'8>,R
ML9(W'P^(!)B5AV15/R/EO''R89)?<86^!S.;,RIHR5NPSWT!-^%AAO 9>/!^
M -SC&D*DIIS_H(B0)1JW-D*J&5[_R56IUX]6JOSO__;T\9.G?W%ER<& /N);
M#IE;&NP-URO^K(H=OJ%/YL97/71A1(=OAE-@0J=[[-*U\=N.O;KMY\/?W75L
M=W[_G^UPG&E]QDV'@]V1][/RDAS9<U8G8:T=R4;6*Q*8*B]GSKL1!6=9WI;O
M$#0$_GYN_ESGQE68B$;FNN[E\G]M Z".6'-;C[3'F8U5?Z>#>&CM!FIMD91K
M]2D_N/7AD[!/W/?C]J<\;F&(A-/FTA9L42YJKC;GD%P/H7J<,@B@ DTJ,BGP
MDY"0>:PNT^T$'KZS(L.#/[5D8?<I>EC^PC^9'7@=?GKGF\%/[VU]S?CIU?Q$
M=SQD-ZS\+7-/MW[I_8_ IT!B_Y'1?8+(B(X,'*]WSMTE4>[NUD"!M>B#[O?K
M[5Q?*NV(-)HO"1*-X#.X+)MDU54OZ9>S1>VS+]8GV"AYEK+'^.1P!3[#A^Z7
MQ]<%K<S4,,E=4K\=$=G9VMZ*%P+O/V:T*8;U=I+-7!@2<;^;/GS=$%WHOC,H
M77-A=^T#SQ:49LA%B::1Y72UT[@9?&=5J"L<5ABEOF95.0A<%Q_N&0)>\52+
M?2::==%(*B=6T+>:,U=L1N:UTBYJ2M) 8@JP#%F-XE#7U08:CT=90PDBD8Y:
M:',L*=Q+]!&:33ANZG8N*F5NB+!(VR%@!M&MBGEN-&EJ:>^)S^SI&[O0L1G)
M@7_*'&7/ZSPZ)RLV_YK%ML3A\K08/"FA3H8G][J6LHW$1"X&B=L+Y7G)XI9I
MG/*\>:TDB3;+"Q8*#*:MY XX2*N'ON0<5[U@JNR.HQQ26E4!CL6R"I*.1Y,B
MK  FPLSB'?BIT/^NM7TJTL$Y RO!24;'A>$KEE2S=)OOIDWRANOJF_JZA0$G
M5.<9PK+P]7!-4+.+K)AH\Z?@_M(F9HY'15*U0PT[;VLC)%(G,T7W"!#VF@D#
M!^K[KFH6/*1C#6]<%LS[(V8F/I$R_@3CP1 Z+3?1Y)\'OA-@_[ST[U;K@2+7
M7.MHX4#Q#)ART+MA"'*.<%<*&HAR'@:K9X$V+N:<YI]A7$A=LDU@H+ XR4N7
M=\CMIL%(M@K(&,@Z2SR<!YAB%5H.W^P;[25&4*1#$8':^0IMOSPL&%;17/64
M#L>Q180Q&6_M0-0:P:[A&I3R6-O:96D%C@K&4$D>AXX!8]I8ZCE=XD>]"6H?
M5I@(W%RS+,)6!'EVB07(/!1N7A5")C.YBC83FCE@/&0ZBG9BBIW[:OF[JK5"
M@A/78;MPQ,VM#J-TJ!=HIXB$UJOB?0Z83B]9.2.E(+)FUVY"W*=995[&R?<9
M8^+IGY<E?O!+T6?R&GIG"?L5ZX\R$?)L96O=R?M]7$QRC*3BX6>3R^R*E$I)
M&XKS&A"97+,#\7@+HP89YF'[3,C8<T9&->4E-[:G(^F.5E[GB:+G[>REYV4V
M@?9G?D [_+G4"<U*IWK"J]2#]&;</X"CTX6B0%O)-AC.T\7475Z25J#+GB\$
M6<*-/^/KQ3!6PTMQ$V[,@(S!=89HTD-=G^[,P_H9YH(>FKFR3%TH#4J746?W
M9T/OCP('>\GN.CW3U4PPP4TY&TV*@9)W <_''1X9%T'*/]./=GV,A[BWKAE9
M:SP8]Q:_#F"4:"=#:]#JQ(U@E0RVFY,]$[&P<CD'7_ 1&GOQZE0Y_B*,8JU@
MO@N7U4&_&4&<V$U,G&"5/O4JU;W5W'E4U=V9J;EJ&A_F5X03=D;GS9";9-F[
M<7G]6[LW[A$KO)M.9'M+C@=ZCSV;9ESE^3U\F]_FC%D*S>GKAA'4'\1P 75!
M A?(=KES:TATNL&0-[JCA&[VW3H7OSJDN[Q2\E R.R?,:7_-UB>*'X,0P1_<
M\0E(]Y8Z<HK*1\;25TZUTTY\4,:.CFSE_ RPDRA@9X4<N =@Y^E/6WL_^7=N
MN'=N'(4HGM7'A?%4BJSD"M>  M5)NW35 HY">[]U$:/[^]&YLL7@O!6WT -%
MM*ZUE5>6-WWF>N\OM//@_<$8NXKEH+\]7(G\+Z].WAT?IG\C27UX>NK8#Q[T
MM7ZG'O0UA^>T$8]W'_P]+F/+5;,_IUJ NK/UX&]>OO_7(':>X* N]P+X: E(
MK^U!X"?%2EIQ8VR!71G$1@.U.UOM:IXR;LP7VA,.)LJR7>K@?:1F&*30S\I9
MP7:WIN,%,M]C,FBRE[DDK:D$63U0,TTPV!S>%JY(\D.Y(.I9E?VKF+CH\F\S
M[O_&7=]H8=AAY(BS*D%EYK;"?!12][HFD=&:\A1<TCYU3BD3G=$N-, /P!$(
M2GVC^@].YN?G5R']J3 \<Q2(_7#2^SPGA+W(#1C0QQ:@,N\79"D.QC/TSC;6
M@G*HZ\'^W>E8S2^KS#*"6=[!_U?2CJ$H9["9KC&< 54>;T=T.FA2LLR_YMFD
M&:_+*FT_/> N?BA@5]QZW6BHSW"?*VK683__MGFZB;+L]T&)@%]7[F=^7F7#
M1>;M7]HK\\!*=%JM6>E+/H#L1L0+$=9\G=5</TU_>68+W<*].TZ/^)'OR@'Y
M>S!+'@A"T8DL6(EIN.ZS=\9./+00>WU\].OABU<IJ#_>'?_RZ^'K[WKHVFI#
MXU)0C7-"TD[)%+8_YFO:FDVPVO26IRN5S4,J&)_V8!7343ZZS!+#+!0OG&JP
MA:/['='&,$GX)(^:K>".,P,.!_/05P,T#%+,<)H/D&< NSCS*JP<3A8!NB+P
MURQ83Z4@$:9<DH#@#V?=8!IT61"VGA4S:G!X)QM&W!E8B26R&Z7Z"$\0CR6F
M#G'3U8^'+Q,!3A_R*]3US+?,-LR:,6MZZ3@/'G_+BB-Y;$E' +DY6B4 ^]N\
M-+04I^@"H\,[>+H9YLN"EV8:[KBFC-_K#FS![QD+^O^&WCD"L//*J?P=569/
M>Z)D)3P)5>4710J3U3C<?FRK=B.G"<=K-;JAWPF'CI?X\QV$4;IGC;?X,;5?
M>U:1T JJ[_^>SV9Y?S%[G[Y$U.55T:]P"'3:6Z;#Y<A4^8966N"KMH]!ID^>
M.=&'T$9)0,2=C([MY(."VZ6L/3+]F6(JE?HH2(AT]KB@%[^H9F1@_'LVG?^%
M-G#!%8HL>F0W28?'"V8F =D2MS4)W-,"NX"^@R.H/6V>960B3.28'U:<;>3>
M)VM6HU$N^BR#_LFAVO0%V2CEM!A(!/(4MEAM%M19!?C>%:W39)(+3?:O6=70
M2I"=2F;C#"F9 2?G,83=[U;)G:V29R?/GAVG?SLAF^3DZ.^O#]^\^>JLDKV#
M!W]/RU2)N*L^N6LN"A<^VF<Q8"*P1*B)5MD( O=P@X:0],J-?\/.&C[UMVQF
MZWJP[("J%"5?<%JJB7([QK'84-K>EV<%<C[@@PMGL>)9P2BWEFP"D+5XPR<0
M^,L/%E/@=<;6FY@[\@<#N?.:A";>'K=L5T8S?*5)#]\>]<1IA4">O<^A;X[+
MRZS'$!GF"%![;\J3$(UIM762_6MR)J]3E@#&L(G#.V:'E[_M0@S=4X9?+5"[
MVJW:U*U:Y&ECR"(@?E=M]DNPP$YINDGQ>90I2>J'QEY,>)B'+@* SO6#PE4N
MG_E00/0(V<W\B@YPG?Y2E8LYZ4$6T;6&:WY'+NXY=@'GPWUMA(53AYR5,O:&
M_\2ADT!A=FBI&#:^%$-V4N 6,-C@LW<#9.\Z0/;>9T!D?XJ.F_?!;F]_S=CM
MNYRK&Y=]>='OBY6^Q;"^YSNN->K>_??A&RX1/SS[]?"7PZ_/IMM__-DR'KNW
MM:K<<7J"/?^X(2*K_7<5]I<S5>*9YTKQ_G._*LGD.!L7L_=,I_+JU5'//BG1
M]79 76(K=;JS+ZA4 ;"$.C_$>_VJ 6DFSXA?+9'QJZ;X@+>ZYWK#$+Y].V[C
MHUJ!GHZ#.0604EB!@)E8O.W0YO)O=TYVMIQ+P>N6+<7C,_Z#^?@P)SB_<I$W
M:GQP^0"T>G;I<@:"1LOI$V<2-M/6O3ZGX6D+C%/7^&%ALP5]W])=77N$\-/S
M2=D'#U))@H];\.+7C O(858A>0/36[KOL8!V7&?1OBFB[:H5GLK:*T"&V.MG
M;PZEO+NL+F'V/,MF[Y?*&6SFM%Y^:I*M 81! @R#K,HE)$D?PQQ<5BS.,)"=
M=Z5Y*!IM,<5D- ZU]MOK9T?K$K@K)T"AI<].I<V9AP.?:I?:H)<D6V+XKE)R
MI:]/HSB'>!;EF$;]:SFG"U)?;ZQ]AI#"G1_PQ<493L_0#B<]VTS?G9S^\N+3
M:*2EU/$G4$P/'VQ84DR!4_R%9.,?.$&BY42!@]X14XX=\0.7T&Y3&JR.2GMJ
M4'&I&6:W?6#J+@XK2&8ZGZ;O\CKG8 941$]4H@AK!),W_2<=;LQ:#4MS@4$V
M9XX^C'>2"X5:.J#U+Z<L0)DSC_O)SM))1@)WS) N6D"7WBYRSTK)G67QB7X%
M#9%J T":%"F!Q?GYQ#<Q%'<\KM@26F&F-D2M"R,^T;E6_?4EED%:J &GX353
M[_(L2.T;VYZJ,AU1-JC*VN',!?)JH.M &4YAGLS123STZ6O=J[7LW)>%#% #
M'BJ]5O8?X/]R+H&-@93]C" =,<^JEX():"[ ::?-R;,O9CY@ :;"BYPA<A87
MX<=P7<Y$R?1Q-MT[UYUN=D:2.PDAVUMLHZ#8")8=+QM]'HCHTRGHN/3+Q8#K
M^V96[.A.WU%9HG4WN!M92S_+WM-S7I47Q>#]3\^>/3\)XQJQ4@TB^+@FX$U.
MGTL4?P4NX"B;G--%^ZXL/X:$#44E?X)V>E;C:/^<+N:@L<[@@Y(DYI87/!C?
M]J*7/M_\Q^;K39'/NAU?D>?W^,DG5[ !MGGKX?W.SZYAHS8F*W/^-Z5T6S'U
M718QZFYH(58GUGKU$R6W'*<&.IZZQ 7="I)O[P%>7R[.QS[IL*?JTED41=#5
M(37R/)0P>E]W0GOI?*N+G/TM\H2T,%L<<AK_*U(#I"?HZRWDV&F#_&N=_L.^
M2A[NHIF8<QFB]]1S&R(9BZ(4J_&F_>6"DYJ='JFXFDRR$.>W+J,9I7_;:-(7
M\ JYM(K]^=?YA#1O'KR/?/K2T/ N<&=Q?]]UB.<OA5+R1_03^A5MD[0J%>LG
M>=]ZE<IX7<S(^RJ;;--.^Q>@.KY*+?'V\+=7/!;05AX>OWEM\<"O3SGL/_U\
MV=:]3[B2G\/I,H[A)96P"E=DT"\I3U(96RQCDD1@2YAI62%H*.E6)*DLA/YW
M0>LV*O*Z!5%36M-5-*;20PZ"JY\-WI]73 .,P%M7HX"\@W;Y6@ :C?=7^A7<
MA5=<HHSPZY.=?=^H:R*5RUQXNBBD/9W+N!IH>U(.N':/QG64U8.2' <(W-ZR
MDGN\BL[[Y4D[E;ZS):JU%P.444 \P(:<=S""1\XU*L]>XIFNE]:^*NMH1$$$
MUL5"': [;L+@R_B]!ZK)=4[Y9Y:RAHKAO1D(LX*$-KN >)=9RV/_^R0GAS&?
M<.6I].C+I!3M,A\*E%R*2L$6/["D,Z]=9(/LZES]Y#=3N:DO6PBRG8Z!V((R
M7IL[F@$U-5Y43BNCK%;*L_D0329P0FG[N8KUDLM_ 3CC:KV=)\&)"@C_^0!.
M%A\6 #?Z67G-OAJX.).D_>I!\+%_*0WDCDY.#/ON(MI[L6F0&2",]O(POEO^
MVAQ)+PA=[3%Z%0 _  A;"WGV8G8^D;#NT-U\C6=K!1W]J._)9./#K_S.6 2&
MCSW=NC>CVY^X@5>[VNZ%EKUR77?03)/$8B6UJ%S(/J"+^9[.*Z@ :#/F$B=C
M69UDC99.UZNU0[O.A8:2SVK)Q80FKT>(A.FF$,18U&*XMAB;$G!BN^(3A[.)
M:7DTE>30BV,^-Z,H#17(?Z\8-EN<,"L&@>+AY):#8,HG&X1?CI"C0"N!.N S
MW+I$=86N><QCD(0\!E$"D9-Q= RY9P)=D."%''0*N59J3:X$BC"D=75,%MT)
MIW +DR#@):ONN+OC&7?-5N*,/%V)(7($*W1;V<I8[9-ED2N5E.QV18MH-@=7
M$GF\DW @VWRYVRQ' :NT:+U"EG^45=-:TH!Z?4+*@XACP7%7H-H9=61>F86F
M1GPZ%!ML9]6?W*92?'_4I>'!6Q%:H>Q#"2W^[T9$R]T2ER>+;OJV6I.+)-T.
MN%I^C[:QRA-F(P:[Q"T(W/^XC+U6HO]I,2T[3W]<H= >T"6YIJ)JF8*V726Z
M30/6179PI8-Y\Z #/B6;YUE1GE?9?$R"N5]>K*"0?9"@QT==^%6@\=4+_WVQ
M[[W8+UX=_[_#9R_.?N6NQ\>O7AT?OCY=M=X?-P#A!!?$UIJ$WTEZQD <WT!Y
M/<C()D&IDO_$W3HTPRVQ8C%!$4\TW<NUL6B)A[H4TKY:F[OT]%[RBZ0:XU<P
MDGHQGT^6/46'57;IQE-0>KS*,Q#013#EKM)?TO@#D A)ZC)]12M43F:]Y TY
MPEG]/DO7@/'90#G1.I>PU.-R3%8D"#7?YK-9?34A"ZJ0SSW>P(<E@OLJ8+(Y
M72#>0;Y_4==D*13\X5U\^/&Z0-=MG:;AM).R(H.O^)?8<FNHR,-W=M==:ORM
M$!?QSV_5P'H>)'C/&0^-;^YOX.LT!<\$57&'0F-N=YR2;$E)B\K18I+6=,/R
MC<4<=&(CJ&@DKKW9)9"@Y<G:NE[)_/X_>V_;GKBQK M_YU=H>R?GLL^1L22$
M@)G$S\78>,):'MO+,,G.IW4):-M:$8A(X!GO7_]45;>$  $")"$\VB\3&R/U
M2]U=75U==5=$,C.\;VWFTB,FV4\Q7W]V@$13ZY_FR,,3+%&F!3-*ACAS@[O0
M$->3?W@%]4)A:2O]V_Q5Y<!?E\6)<O$XEW'YYZT"SO4BX#PBX%Q[SP'GR:)M
M:9?E.Z<10;T97'5D5 5]9X;P=S WNQ$KM?ZG=?6UV_Z])=W?W+2O6H\=^*&$
MU>2O[K\\-._^_%&F;R.I*N=['#D2-RK1[<+MI1=K'(044Q%1X6V+*(==PM@B
M\GG[?(R<2[B/%)FC10\54;7U'>0!#/'.1!RTRU+K>Y^->9FTL)>.LJKF7&:G
M6"FH%";8\UOS'=C>V8R%+XINC7T7G)HA7G9WQFTVNP?BKAIQ_Q-%XR?N@$JA
M^E:+U2K75:ELCP+6-1%Q/5<H,\Q!*H>\/W/4QB1$Q@NKOY7H+M<4H=0#YO5=
MJP=_9+;'N,<_LC)E&7Y]DU[-/CJ!?$[/(2;T]_M3=XE%$/^"!2]Y1?:5W-^E
MX!IM;5WRM"I!IK$8=^[)H97DU?TUZD?IT]=.^Z[5Z8!NO+O^>M65FG?7$AP1
MVU?9TM'E5T^VYR@IE<HJJDNA7(+CZHSY\LH9L+E3!9S6Z$2$NJR%A+*>=,KU
MTH"="<)?GXW1(6K?0),MJ+!PCD<L:GOZ;SP"$<&]2;VW>"0I';*_N7A%'B:%
MY#UVL5(X7@ PP?^*X3_?D'R8>*U+@A=6)%5_D$ZM,^G%&?F$M#ZS;I]/C@Q_
MAR\@*[<,^Y.%]]RH?$"WR<0D*PJCSVAK2;D.+*]O.TC7@9IMN5PZ$2YW6E?T
M>NMLJ3QZ2$]C>07\VNL9]7D\F96>Y^\5]R6O<'P3:4.!< 9\0D_A67'MXU,"
M\[(=J'J1E3O@_QRPLG0_H[CA<0XKH180UWH4UFTCFS'Q;O*K57$Y((07EF/*
M!8.QT^?8T+GS=.[#_5S _1QFY)S#_=SO*9&2^IQ )2XF$QE:7JP>G-55?15#
MZI7@X!4EEV$<-XX[E.KG_Y0&M/WYT31\)N=KHB-=,W(7V<3S/W[SB6'$0BVM
M6ZBX(,D9Q;F4_8U6\NO<(U7M,T!TR@ETX=#E(:/ M/_B_^;Y^R6Q8Q/=+&Z&
MD>,LS:B$8(E%G05DJ6I(+4 !>A- 5;E4H.P!)H4G/U%8AZ3HJE))[])FX5[B
M^,X,H!&Z[?L[235.S3/I4^NN!2>'=O-6NO_C#@X0O[4?I,?6P_UCMWWWN83'
MB-MV\^ZJ56R1).^.*&B@&KX&A$^F+G=>@AW_0ND836(A+ZF-BN[72/:B6=!G
M-NZ*^DG\P$$\_%2;CY+[8!<";8:Z#?,,N$/8%,Y$"M[HVZ:WN$W/S@#0H0ER
M*08=AQ6)"HGO"V+;$%4 [6!GP5H&>%-+1R8>^AO\@8^;W+>S[Q G^W!(I,IP
M *!=D0?&+/=@L3B4<)?#O,P.*B)VB:K,+\U F'E94*33O,\*;+/G*=^\<"MZ
MFKK(F31W8J/1@Y(4_4%C9"9N7"S^@.&A-YHP8NNGPPEN[2N.7$'E5UFDH'J.
M#5MZB90F58(0#\Z:]K@.%3LZ[^H2A3;?2X2% E_FE"YB>R8[!8Z[?+[]5^'M
M;3 QLCC<E#91I$>6$HH!W96RXI4TZ,Z=HT78)FR DV+Z-@_,EN67*;?ML+TR
M+Q:0!/>ESXJ1Y_I@M<Z_6RW\NQ'^W<K[]^^F=KP^(-#I'U.R!K^>F/]6- U[
M:UXFM$%SEW&W]4525?)3J=I':>801<NE===IHJV3CNVR>HIJ88AD[NH,57X1
MT3$.,9=Z<V%IR/CHE/BV$RHB-C:MI5@[V';PR#!R1N?+5-H\TBL(^W*I[ [L
M(C'+;Z070)2"39E2L-'*^**Y.*1-P49<;RU'7VS2_R* XAO#%&FN+I:K3IQ<
MHD[F-[+1@1W^)K 8M$(M1></P3!QHG\]T4[B=S;R5)/Q$>H&O5.^4MDC<&3'
M2Q]^CP^K[F!=>$ M88VX4*],[V4N[7)OA&QX001>TT;=AB6R^@ILCQBF<'7:
M7WKNQ:74I$)B--?>='QYJIZ=:F>@K:;CN;BF7>8_8H@Y%TFL;IQ<8@VM>SH$
MA8ME_D#S%!.Z76=BVNE-R^;00?Z^CZ&$ =P1'?>#Y#[W3C5%E[5*7=:JU;.5
M,;55+3JF]N3R,[S(,JF8#:9/+([3WV9_7IOH&GPK:G_\:<4[%\-\\6X7OJ[5
M94515O8CJH5HE&7?]>/L-6]FVW^/<ZQ[@BO^6HT5ZWO"*3>0;N-J2J0K+^;0
M[UQ<3I(5\Q Q>%6/&OPF827?CZ(+NTHCW;TB$J&?W#<PW/XY2_%*<4:J^<!G
MI2K7\M"/''2AJFP_%8DKR<Z$83)]UT_Q2U'R2CX06'1A5VD<0$,&>_@2959:
M$Z-K!4SSTX5=I)&XCGPPIS8Q\O#$WGPMRG<J^!QT81\5&:=(Q#HR_CVN>%*Z
M+HCEN)V[.%B?L+G"95):/CK.Y9#/S7R"CD_AV8SMUDRZ QA!6#*'&,@XBZK@
MT3L3])'1/5C?]%[F+\Z0+V#DL2 F'0/ R8'KC'E$QK-K$OE3S(LQJCO8?RDA
MMQ+SN3Q&&#Z"Y.F\.UCP_IQ>@H0*1'X$@W)$W1]JD$($Y[)X2WQI[)BVKA\B
M:YT@$>7I7M')AA'AXTBUBTT*VXD08IBQ92!5Z.RW  QG.J&@7I#?1\K_F'E)
MZ*'1(I*6'@CQD@PD-58; 8W(  -'-SP09@F)]P2EKLPQ<&Q^*@:34/ZOB%.Z
MUO?#X99BXC$L$*/=B&(R%)(U<  WG)>,"()@_^&5J4IS6HM"M#& ;, CXR<1
M(=@BXDL:\IP52AB:\7P&GYY2/2N'QZX%?%JAZ#V7"0X['$4) PM6!,S-:.S.
MRE(KX!/WN=/XVM)D'O9M\H2:)\9X[,+$X8$*RQU #C%KU,<2ETRHR)\T<D]A
M0.!/W&FZML&EJ9N-)Y)%]1O5[*"J$#^1^8SZF;1^=#,E9$;CT78S@2VW2G.V
M@4DVW+0ZW[9T&E[/81H^?*6("43M!;./MV=/>-OMS^V\/.G3OZ=$&8:\ +]9
MR.N#>PF2#ZQXD((0Q^8;64>"?Y87A1^8 2;$2TMBMZ2]D,==TN,\EQT:=+YA
M6@#2[L$:&H7H[O@;Q6OPK3BB55T2B7I^IT1&/>,DL!A"Z[]GN3MFJ#=W?KRE
M#S-/] ;4/[5,%/*4E$ !\9P+8H+I@[A:40R"=".[6*4<Z+:%7)#Z? ;C!#G[
M_=JYN%U8 U9:0)-O6^'*GQ':S>\TF(\SA69 +,$>^6*Z/. V'*<LTABQ;2JD
M&+Z'IXVM/<*[4%BZ)621IWP+>*??#FYUG-?,[5L>(W)_AA'/)F4^_%0K*W5:
MB]2Z,/-HO1)L<0URUBY1." (#@[U4*R: 2]C7Z+ARSXCQ1M9@SSC14PL9V]2
M%[L*)B5%2,]]JP*K?B)*7 _]=;3$74K9F&'S!I-:?#&8:P21AAR(S5\$KS-W
MZ)4\"\PX4S"4.-Y< 6V_DR+=S&=J7.;8"_:CF62):F^U:/5R70V)MK2_:(41
M?\JIM&E]:,H9%_4KQ9S[--N!\*)$7+*>R!SP>TXA?N'GJA)F/,.W0)79%BI4
MG$V,YH?O0.=@9D\GWYC]*G[S\+M"TR)G,N7K,A/)Z' R/9$"=B9*/*)4B*06
MB>.>_&A!SCCI3STEA5&?U!J'ZV8]L+BK;*D'2JJ2'/Z6]< &M*A*6=$1+J6X
MFB "&@NK/L #,L<B85LT'J0(/)3"SQG;XV$7,$@KP5"Z#Q>NK_H66,J D!8!
M4<H2$$:YJD7N#*6]\#";1IVO]?B8F'L6;<+:P7&QQ=X4/AGCJDIV>RKMO#U)
M>VU/H5$%J9.Q(58MJVJRQD=XARKYNU#D#L6UNK$%^L+/U6,CK[3G#K4:?)F9
MQ*L8J-9E#AE%YE!$YI#^_C.'<DX_FU^ZIZ6:01F-^^ZZ]>6N?=.^HN0DJ?GY
ML=7ZTKKK9DM#DC%'>IB4@/B81SQ3&79NAZA_AIQ-FV^?F.%/B9PESJ<]\1;R
M@"-23I'X>L8-;?,<)DQXFG%(B,2F^5QA;E 0G_D\.X_,^;EY98?2=$QL"YQ>
M8=9!P4I"!?[Z;#!U!?>URZQA;^IZO)SJ0D85FA+,Q:0LR;;X3N27'Q37/)[8
MF@5_ C2"+! #)%_L.Z.1R'^ER8G<JU8P386E@"T)[G,2QB91^-3F ;L]T<4+
MU]E,.K[_;8HU%.:HO[EG>%EP\VY@21@C$4Y-G S.'(G6'UI/\-\2L:\@?U7J
M3-U9K9V(G)\,\QKSH2^^!M;UI[=SSD\3E6:.WE<;X %+8R49%RYQBZAQ\+@@
M+BQ"69)TJ)Q?^KPZ:4A++-Z[T%+%YT21';I(05N4[F-+B$C!V8/T7WA1 5]
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M^HI^L34^,50K5/L S6AG)(>?#@BG-TV:B10KWMP4S#QU,GK7\ Z"F$.YIPV
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MB5@Y<S7G[IR;L?3"*N(>:%.K--[\>MWN2E?W7[ZTN]U62WIL/=P_=C.-ECA
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M7DP(F48>D D6BU(SJHHX5JL-1.9Y(\4;P:157R,=U?<.[+A:+@!6431=J?L
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M:[?V7L[-E6SOLR/0EYX1&'6#F ,(:IE ,$MFB-3T9^3U]B'U9T6IUHT:'6-
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M]\7QPG\5XH>OF"!PQMTX.*N@EE'G<H%A4X@ IS<QH4$X77C.B'PWIN=-7<*
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MM)3?P@=GM,=&>#/RBGV N;7?\,PF.C,&[0\C08\(N2"MT5)71-B;"1UR76O
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M=&_XJ @?O0$F>"TG\#F<ZW./<73P)HMZ@VG2< +]BV'IW$*_'E:_=IAMX^7
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M49R4WVO(4"&,' EC'T.*FEY-7A[?MN*?[A.[V>S\1KT+,7:W[WYO=0[!V%T
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M-=Q0\?^1D. 5MDPJA>A-7*L_80/\0W,TF/\@],T'Z)PS6*2B;GWOVU,$$OQ
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MC_X,[Z,!Q811(N#.!Y8ACK".!PW>-L6AT"G G^"+>+:I/CQ2/,7Q$CYH1YQ
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MJ(5O(S=96FXJN>0F[-<+%<(0.\^$)A)NFC@W&-(ME"=;;JX0\%QD7RY.)$:
MXH2/B@U'SZ8EJ*/;&9.NLG\%AJB41%8"D-L52E=2;8=MHG!U72H89#0[0Z%O
MA<E7,[D04BDB.$8$1&5%!-8+[7,!'& &B"!X,: H%Y)>:WJS\)54CB6R4I*N
M0 )Q!=1&TM10]Q0G]%E<3UEXZ0_JH6,_";5[ZCI_"1,"*X4DZ^?$@(A+,/FH
M#SZ)*D7)+T>53,**.OB2J/".J-)25:XM.$K!TQBUSC R8O&PI/ O$M#0< 6M
MG'3G2#5.Y6EGI4&KR36$4\>@$5GP*5'11>QZ8D76++3[A.OY+PD7&;PA $-
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M6IR!7=&L%0EG^XT/."IC_E!&G>QP$.JG/0A@[C9RITT<D,N6H-D$--II0=,
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M%-=598]CL)LPN$HFZ(ML?0SW4C"M/MH0#**2NK<SBEY"R?KF<(S)Z)B#+DH
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MQO<BRP(,3A0$LUE3L<S Z;7! _#M+'U6N^C7JIW< 00'#'<IH;--O,D)H=-
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M5T"K84*QVJQWU5;^ALHEL@ZL;+=*9?N,J-4NJ75&U.J4U"H6M8HG8_-)3DH
M[]7::J\H"66'+=F_[Q8-PA3>J O,7K<K5S_Z1'>'XY5CW&PF!SY3S4(;VRTX
MA/6FVF[DC@9<TDWC6+0M<?W&<+V1E8^I[UI3;;1SVV(EG$LX'QW.^=T+&'10
M;ZF-6NX8P1+09PSHE9;77@NEE3!YK3#9:X6V$B:O%":=O19Y*&%RQC IGA:5
M3S?J7O1[+5#V\U=/.PE,CQL@\1 ,_(Q>F*4C=",<MPKMM.G1G6.[JW;*.\<2
M8'OSGM1KB*L6]F',[PXL<?5V<97;C5&O7_0;:J-94[N],OZF1-:^TB? (KGH
M=WI=M5O6\R]AM;?\":W> '[5[*AMK>16):SVV-%0JS>WZ&A88NLU8BL?7O""
M7E-KO2:J3\4 S&'#9/8X=]QE9GI>H-M##E3T_!+X*U]TN1+Y6T2'F</A\!V2
MX592X0:(X&DUC#3+@WZ\S^^IM<XI L2N2K 4!"S-?&#!^O1=M5>"Y4V#I94/
M+%T 2T-M=4Z19%:"I2A@:><#"S6*;FJGT+]*K!0%*YU<6-$P/UMMU4_A."BQ
M4@BLC+G+=?0,Y -,'4.PP;H[15'R$C%'1DSH"/C(1]QUN?'9M"/<W/%\/@$-
MG=YUM5<_17^OJRU= >L-_?=LWV$\9/\;IC=T MO/LO_+^*%CQP\=C@5_E'3&
MHY3O&&$E;+R1S'V,#A\^-,^/2X"^3H#F=FK UTJ0EB ]%4CS.5.TEE1A"Q2(
M68+TZ!'E>VU$5T:4OU:8[+7;10F3UPJ3O;;9*&%RQC IGF;TB!D6^52C]D6_
MU5#K6NY+R6.K1L<M>M+<"?>/&9DMAWG3EB<,7LH,)QA8?*\4^^<F9VO9' X:
M%;7MR4H&1.4."]$ZE "C==5N+;?7/ ,?IQ, )3C/$)PY/39= F>OMTGGQA*<
M)3AW V=.3TV/$G'J+;67O^=2"<X2G+N!,U^83:.&R3P-M=G8NMA-"<T2FIM!
M,U]43P,3&)M-M5XON68)S6- \W&S***&1GE%W8Y:RQ]Z5D*TA.@VH4L#_];V
M?#? =+@;W75G0,?K"3K'\F&U0=>%O79/;>1OQW "L(:NL9]]':C3IYGB+IIV
MH,NI+GQBF,]]1?GE9_S[EVER(N]8O0:D7CF-]VRBNT\FK :_6I,+-&V#X_-:
MH]K9J^-X.C=?08D[(*QK#M.  8+*A7+C&H#RYXTSF9@^941>V\8-_>Z)VT.3
M>^@JM1PO</DC//_!<H;?*\/:G_C\G_4+Q@$C4Y@X((C/@VNS41.P:K2P%</.
M.[[+>1L JJOLYNO=X^W=KY_N'I4OM]<?;K_</MY^>F#7=Q_A5[_]=OOX&_SJ
MX9>?!_T$&8 ">\9*K=HR[7TBI7A3_!JXRF!FZ2_PD>XQP!$,;*C,M!D?C?C0
M9U/7>38-SORQ[L,?G &\X&4S]F):%L-Y3&QS-&.F[S%G-#*'W(5Q;(,9I@O/
M._C3DVX"LV/XE&7J ],R_1G37=,#8+*1ZTQP8--57.Y-'=LSZ1L 5YS2DC%]
MAR8ST7^8DV#"8$]@/]@4)+_I^]Q@@QG[R&%=NLL9_%5EMS9#[H<<1F4O^.1W
MSCP3=DEWPV7 K +XE^OKWV%FGO)B^F/&]>$X>C&\U'6"IS'3F<>GNJO[/-H#
M<TC\"Y;K<H['C]'SM''A\U7VF)BU3(<67Z$YS=B ,Y?_'<#W#5PD3E.A23$O
M@(D0.3QXC<=,#[? <3G=-%@X=PO6@ZO'O8)?FY.IX\%V6AR',KB/VV/S*OL#
MWV7:/OP_WE.Z_NN\IX?#70\_B\BF "4#%^-M81?')LP()QV"Q.7F9!"XGEB^
MI%$(&)"/X8H]> HQY:@,/H0]&_"Q;HW@M>HR@D]AV$"/1E7F=SW>F"H#5"]0
MQ1F B*-_>K#5@(HG6(4QTGU4$@U!=YIN8H>=$4S>B,=X=*; TYOMVB]F7V6_
M!D!_8._< QG6KRK7PR'H)@ <:T8(&^O/N"/X(;S =A+8QZT@<B9G16 'U [Y
M9 !S:=15ANY\W"'X6ZNR!Q-S<!U:'(PZ=5P]@C.];*P;"KS'&0YU7$"('SIX
M"_L58L^A7\.;<>!H\^&E\=[C=/%+H$U[CETM-$<[ Z8++$ Q^#.WG"F20(67
MV0'>V <N,D3$/;S^.T>YC831;=0AV9CK%O"3(;(T *D1#.$<<3S$%AX6H#!"
M&4@*C/6[X"DQXH:6;DX\P;2!Q>B>!VR.&TK(FP./&>+U> 9L5&4MT%;P+.,4
M!@'P:NYYQ#IP H*SPF\ ;X1D^8+$> +/.)R!;)+^#4QI!!.RGVB@ ;=,V <E
MY'_RQ"#(4%L$=10VB4:)%Q+Q'T2N%TSA%/@"NL#\Q4DJ ;KC%/_@"HS#D<\@
M>PCEF1<*--,U@'^X)*)!@B")B?/I[BP#,Y*W"FGQ(N C^9Z0<;$204A*C:^0
M>H!'(D36,R@.#L +42Z$!&BT'O>$:)T"SS+A_2CJ"#DT9"C?<<+/.$NY$$ Z
M5B?A(5"CI9*^,$&>!ZP4=D:!>9-P36D=.AEL(>]<(7%4V P?M\IS)EP,"0,Y
M'D\) "G^EPAU/#$*G1#;P;&& 2:_P$.P5!,.*_\QY;8G*(()&V,"R%/(W6%4
M;U%72<D?V,H!3,U @8P+TFW=FGEF=(RCO5+P)['_IOWL6,^H,KY$YSG6%4>Z
MZ<*&6T&TP^%!1DI,'53:3%IFJ U&<MCC2>#!)$!S039894DYBW3)$K$X_%9"
MMM#G\CQ8Q]322?4 C0U "'0<HD8-J/S.9W2L/7;IS5#6<.^*4 >RZ!G4#O@<
M?2B!)=4:>'8*QP EAA4*QA%P&0M&&7[7$=U7J/+CX"2Y' 8&Y#=>>80/?@'9
M@!O6:;X'TQQ_0'OQHQL\L7LA/-GEQ_LKE9!^A^"K"/ #SW/UB3Z9()_P01J1
M*2U8R6 ($\&#"7OH^0 S.FT6B&Z=A+4!>$<6B.84_S&T@ ."!)N1C:.@[8X.
M&M"H!*\*/R"D;KIR@O$]'@PXZMP(+,%+A8J/\I8<GW3F4$I:Q 2DVJ#@"P7+
M,O'\B9DXEL5#S0/6%-C#,4EI\25A5N!YYY[8$<GY;3A+GH>;A6;+-%0J@2ZX
M)/H*S#.Q/,'-Q0J5<(41!( .8V#O7+!,TA@2[P0\ 9?AJ+X&2"S)9X#K>_1>
MP&+R"!?M="SZCGY.^8OF?$F'=(2%2UEP8/U7I<(^F]PRWK%[_8F_A\'^#C@H
M7.\8AJ?_#W)S>#VK5.2#Y"2.)AS.4KR[XCM3^+*&CD;Y2>A\;.-GZR(;D^ZH
MI*-R2/I)-":]I9;QDAJZ^CY7DHL*E_.>/<ZFL))K%T3&\#V[TR=<+/G.P<75
MV\FG?@X?HW43Y6(29>_  'C']\J  _1AX"GM97*^[8SYXDXEUYR@8(R>I2]/
MSA<7$M/HP" ZD"]U)>DW7<$:D.SBL[R=3((;;EG*36R5_S)P?^XK=Z#BD+/J
M.C#(,R.2E9'G/H#,D-K-9>06O@IW).7:E+MRIE2<\^^3OWE[UW?A5I\VEH;.
M!-7P.4\@D%B8/V2[!Z"/#E$K,$'@7@E;!*7QRMNFVO+;)LP!P!NG%V"F( 93
M]Z$@6$#/_3KZ](,/ Q^TD:_2PY-YS00J&T_?,S4O^C[6*%ZX8@+]1HX8.8VJ
M[!/YC/&SWW10_IC6)?5:(^N =HD;BC J;78MG,VD#GP# 4\JQH/PJH9J0ICC
M3T[$:%^O(P_K)4I_=%)JM?=KODO?JK\7^ZW\YE;9![P>U"?L$C?_'E0($Q%!
M[[WY]/5*F#&@/,'2>#A1EX-Z.R0UD5S>:," L08&3+CDFE8#;>:9"R=%[ P>
M</\%-9>$2U3!$1,SJ;+?IS!E+]Z#T#F><J+&KC@U^;3TU7IK-PT,+M!0DX\J
M0!&P/*>Z"88<6+6H7J)C5%JX>#E@@86IN[;<AL F]0L?(*4+,1!B7!JBC'HH
MH&[WSS7%(-O;7Z3>VD/<"0X&'?U]:X-UZ (CO26P>?".(3>?T9N4MS1$HW71
MUP"RC8RZ5NP%+TG$&Y+^LI'I>C[[.P#CAKL**-H(>MJH=6OO;+]VM(.1./?Z
M#-<';%2N_4ML!-^@D\#VX7=WCO 8Y+U@;L,N-&IJO;U8QC[7PKI%75AG#7E-
M&^PV0YQP7<X$O>7DD2331=(_<K@XXE#CE^F0(BH&ND7GWQMS[L^['93([8#C
M"0:)=U^"=UHS817#F70)O9P%4^&GCZZP0']838 =@A.^XLD/>4B2A5R[P-.>
MA$ +23&[V63ONQ?]1JVFUFJ+(6#DM@H95TJ*AJ)3.-M,- #))A9D4)QG:>:2
MG*K,@$NA\6DZ0"$;W40X\K]TT#[ 1,4HWRNTOF&8[+>%]R)H<B*S(^UM'=A[
MA=QM['&R;+>=>$^26-1M)3?$ZHT5.LGIEMVL;;+L9I5=SQVKW.F5S?!%4O45
MMRL(G,7WM-3PDM00>D52 0$P\LG4<F9T<:TDY;U@'$GX"M]1"$\AG]F+$UA&
M*,*!74B6!&?!,KF;'$*RGA9Z/%$3(B^.Z8(&<]FH73%#GZ'G%#4$.#H*GI,5
MZ@ALWA)_:LS8#L:G#BHFFG4L&K($1>OEWPY-O Z[+&WYX4C+('6M,%2V%(9S
ML1@"K-)M27<2HTRM5IP0H?7K5QC@D=2DA;H*)\LF%7FHDPOQ<@"(#F3T@XYF
M%EYK>^%=(OQT.:2ADJ<1GW]R'"/2L3$8!H- \-X&#Z3!O:%K#J0J#&+$M&F'
MZ."N4;[5E#9/U@%)&-C3U"3RVX+:5D73EK#</X CW(+4!$85Z-:-[HVO7W2P
M*G^E2 ?CGKOH?M&?XDK]%6V5_=C\_]E[W^[$C29O^#V?0NM[<Y^9<V2"A)!@
M)NMS/!X[Z]UD//?8N?+DU74$-$:)D(C^V.-\^J>J6A(""1!( F'WGLTU-A;J
MZJY?55=55U=U"6\9K/V 7)[R#!:8'$<P+"?H*)L.H20?, /JBC FV>$,O/YP
MUHIW9_8W/A@EF$2Z$[9]UXL1%$QYM7)23TEX)3Y#'S('N!;P,Z+TLN-P2-8(
MK0JT\=F<49P@2H*0 NHT=@XN$CB1D9F1J,LTC&5Z5WST@:%Q.KS&Y4.+SJ1E
MI224Z!0T3097YS'9^%?:518#\8/2Q6BM2#Z],0E:<KR9'(,6@";*94Q>_A/1
M 7"*4G! ??S%'?TU ^ZUR)7^EP4D+/QI&/T>H,(/&'^-$QNXC8O?_AV/ $P@
M<\V7?UW*CKA+COG?<T<V.BQ,PA$^.K/HJJ96>\G"LR8)6SSVB(<2;@2T21*<
M<X=_<D7H4\AFQH*TNT<V)HS"#=.E@V-X);P03XQ!4: VM2865Y^4XI8*"<'>
M&6W>_"OC",YT2IM+>"J<1"D8D>I-#. (CO#C"SW _?46V,\,@Q5H9H -,B1'
M)CFB32R(*#.$?^G]\DGP$-$'_UFS))-C\4U4_:.(_N0%XB"U)(FW"TL\UG.C
M1<R43OA#GX[ A@" * =L'#V#W*C<[J)XXI4YMP+3OL;M'J@#?>]?Q4,6LT"P
M>XN2;U=1+@@/Y!#LHN-*(MZ<FZ,X=0X7XZ?AQ0U%75"K@>61?]X;O4&R88NN
MT10E;V81TBZV$!AGDKM:;^U:D$S'A^@@='@.ZJ"RJF$FQ-S;>("OR<(7FXI^
M=F'D3V-9MQ$\P8:PZ 0]5NLTN6TG]]MM[GUG3<R[6^2(%)NR@:&,-9.&R7)[
MM$#F27OU-/AP=R$.=7IWQ -K]2T=6!OBP+HID!<'UN5XN+?HI""W<FB^^6+6
MI@M5D<OA//Z"EHE_-_F%^;[K;;M,U3>.?YE*;4MW7Z^_7>)UJM8OUY?WU_5?
MFZKABEWSS/,[IW7/Y@'?RQ45]W)ED#[FCG*G)9NL68HGT*G%'$S2[^1'V2^;
MHSQ*5RD1101=#D %JRG7G/'_G@3+]@R6W-'D;IXYX^/!)I,FC/%<9SKN)X<9
M+P%0MAZXNF8<=S"E.25DXQ645ISZ_P46@*]5CZ]5%-DA@Q!V*?*=XX=OV-#C
ML?,N&4F=.+<;<_PQC.)+(&T\)3&0%*,GW3KCT \H#_IW$^,LTE?7"VP<XQW(
MP:?0LO$HJ 7/7J( O(]O+\&K3,F?XB4"<*D"BIY0E!O]CRDSQ]&AKA]=RTB'
M(N"GZ"I;(/5TZ1I8C!ZZ(WWVP'>GW$F/.>X3-X IE(ZKA/&)&:TE#.$P-J8D
M4O"B37Y<5<+S69C+4MKSX<OG>M8CY9 2)%L8&J(8[R;-V,TFFHQ#;R71).G,
M"#QG;%E;XEW\N\E5E.FZ#+G!V44 JX71%'\U$3*&$MW@YD>A#L@B#\(!&2YP
M8W?"<:@B5'_#P4P;B5\BN4=G2ZNT\C-'6D\.:DXT )GG!8# ,"^=$=V6+GGP
MA5(G5G1&BY!"/")]0I?5,.4_N1B#IT*X[8R3BX,\7LB^HVN%F1?X!H_/07+G
M/.KE2)2Y0A),S@F\SY9XWDWTD-^6;@AD9M"*@]\FJ-JE0U6$C,<F-H_Y1$G
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M7D/())%7VJ>H# C6]#6IJJD-G3-\<1UWSK!3D/.(K>AF[-(97W^?8_I.[GT
M%6M"'7E9E%Y;NGOX[^MOK>O_[^OUE_OK>UGZ<OU0??^7&KC7C#LE]Z,I&X<V
MNYNL04$,@;TNF>SW]B64X=6FDB=H[RP:ZSUV@,'1?,EA@8P+X5L^WB^).G0G
M]U->8XN'2MFN<A:51X^XNI*\Z/B9U'J#,JG7WUSA;>S$_953057#\O.;>G]%
M<*OYMRD.DMMOZ#_4GEN4D[9_B^QD4=I^9"A1VOX[Y7V<L__JLON:E&.ZTZD
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M(ZLOG3$,]V2-F'^//E@1J>QV0"J[LM;KRCVE02FF.R7/"=P>";<E;-BRN%4
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M+=A9F2W=M*5/F"=FSDKJC3IT0Y/>F;.6V364OH(%:>%.+DN\==?5U&(3L&/
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MB3#R(0A0EKH:?4W&3G.@D)+>8VQU:>PK*D-UZZRA ;8,.QPSP/9EU)42'L3
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MQ](89#,::E^('(MBD,UNJ)V,//G(*,W(FJ%1QQ9:,)A_B+OJ^%,8?'&#/UB
MB;;%W:G<<]U$+L?,^G 9=]N]L<U'3J3U_>E<Z1N*=G8Q 9>'Q2Y(]++T=+>_
M_W/45/?2<4+3_D:]/9>'Z9U=(-TYH^PQS WX@*;-[=4;^,Q?'DL_N[CY(SO2
M[N,\@)7G4Z9RWI2,]2NWPUC73H#.(:5SV;?.F'W_7_:R/%#_[ *=Q+ZBZ)J2
M&:U%GR1W _G0'N[,#$Q4_^(GD/Z_/F UKID)XTO?Z?>IAZ2@5WT.OGM7@?]O
M?R>8T9^#ESG0YUNSN8U8HR%2[XP'\=W0HS'H-YO\'W]JS:4)[,8PF)_-9 M<
M_KGU_=^=?T]<-W#<8,E"7O,>_CR\18*?E.0G-?FIF_RDT4]+0RFK0VT;JY>\
M34]^,I*?^LE/@P5-G>RPZM*P6X94%K-2U.R[NLM3V/:RQ7(HVN+'Q;04/3N$
MMB-#E,6**/WLZWJ[4;Q82C5G*?6=7J9&:[GJR*5>:*SPYOO0LZT/D:"2_(&@
M\E60I.BOC(3U@CY*/J3F&M;$8IY$4@:",PV"^8<??WQ^?F[[;-1^=)]^O+K]
MWV4Q7OUR,M2/*V.EQO__VSO7IK:1)0S_E9Q\35%(\CUUEBH,@9 %3+ )2[;.
M!R%-L!)9,KH8G%]_1C(VLDVPC6>L?L>JVCI[%LFR/&]W3_<SMWX:\F:^/XS,
M($K.*=U+/'E'T_D_XX<\7WOW]/C,;[&?/Z0;W#F?OWET)?LVDV].XLU44^V]
MU'+Z^\D74FXZQ^,-Y$5/#5?=*6F3AS]=6:,-#+@V*.]HO!GJ MN@!-<&,[X@
MH W*<&U@"&^#"D8;3(52XRVAU! >2JNY--USD["[)!7._.BG2S9_D<>^ZUA.
M=,9ZM_Q[;8??&?+^. N9^:]//I],&.5IKM_K^UZZ8.31"=_OO0![1\\:O=C<
M5V3>;G?F]=8T>5VXR=>V0+<_+ U=H"&(@/4M$/"21:;C,?N3&7C)$B9EO*^Q
M!>)U F:&<3 <#9*E(721?B#JZ4GE13Q7D-L ^L8;8"MZ?(H)GFXHKG7>60))
MT4N*BYYG9D%2\++B@N>:C9!4O**XXOE7[>)!53)XJ+1H>7?&<M6K*:X>D7I=
M@G)UQ96C4JQ+D*ZAN'04:E4BX[K&YL',=G6/)$57'4:1J56I"*XZD:)3JU)1
M7'4<E7^M*GYBB:$Z4LJ[,Y:KGNIXB$BM*D$YU1D1E5I5@G2;!T3KY@>Z1B$_
M@,4S?]RYL#GL#/ML9/CI[@+G3NAXAT%\UXYO$T.SF#H1"Q;1+"7?9)L.'K98
MUW?MDUX_\ >C#1@6BXBB8@D.OH1!]/',_.D'X]6X8<;?QG];*-#*1G,PNS]V
M<]ADGM7MF<&O:8MIFVZRI4"Z@OB<1<MDEFN^R+S5CMMA[N:MADXE..A$WMC'
MAUM<,HLY@V33\R4[N,+D-V/RL-AMLBUV<SCYOY_YUR0G0 ]/>7AUI_6?W'3B
M]>,H3._0EW,-@&X:EJ6)D-%01D98NB9"QI(R,L)B-N"@*GZ200F6N0$'50DR
MPD[0 @ZJ$F2$Q8%2T8"ZE0D</WR]&/=[?=,;[A?DJ2C#YXV]K!AF+8R=HK$3
M6:125@RSCHR]61@[*6.G$MGA &MA['C&3B6RPV+H#8QHJ1OBX*@U^>2U&#8E
M;O)PA+\P>523I]*WPXV&D$]D"Y,G'N7A1HX*DT<U>2I1'FZ4;1F3/RA,GJ#)
M4XGR2@XT%B9/T>2)1/D*W'#C\P)/E_]V^X*WVS ]*F=T*E+8'&:OS"X*?;ZB
MRA3#"MP8&K:"$HXG@!P8NDS.F1V)D_9"CN?TXMXB358VDI66X)V97IR<MI.>
M*'MD6NG1QXL['!A7AQM4><E0S,?"4&0;"MPX3*'B"RK"#2W@JRBA=X>DY11[
M]V;LN,E9RJNMKT=Q=DC"3+%O5]M,X*ALH>&<AG"8$5U#\;UZ%8Z;4>W56S]^
M.!:;W**,EU?AN!S5#EU9"X'C?H5\6?G@:!RP?!)Z\.U@9 <^;ZH@3D=63CS^
MT;N A8OR,!0/W Y 1D=""5X(1\?>MC>DZ=FJ##A7X4@5F&02O R6&F4V/MD/
M0Q8=N&8XLU_T$:]B(W;J#)A]XO&6NG-N79;>O+D827$V6Q46,[VB:',XFNXV
M;P:'R1XWW+_M#K.ZGN_Z=\-+YZZ[F#F!A-T:''%:2\[Q=+UTPD\R*ZCK]!?C
M0Q0MX=C06EJ>^Y[E]_HL8OL\=5V.!*,H"<MP% BRXA.E&BS300^R$K2$!3S8
M05:"DG"<)QD[X=6F'5M1*VBS8.!8V<,^COV@:_;:YB YF:AI>GF="J;M:"7!
M4L'Q'$E2K>+OA^PV.DD97_+^E\QFO7X2CB_2MI_M@5^[M^4M6E^#8D=PD*FP
M(Q'L1'L+.YDQ/P'LI 8+S*9U7<, %1<8%HYA.KG4SJ(.B\;$B=EY\!41$Y:-
MB0V]ZIL1Q7ZAOGF>MUZM+=S]X C8FA-;Z3/F.AS(6G,F*8 DFR=2Q'IIU3C/
M67):^/.H1M)#.E$<+94AB^ZJTQ=Z_<9S9V'R_DZ2-W%CJNZ4-)'&! =[%J9\
M;S2G?$N(;L"6?$'Q^1^123-U./"3Q+5VQ']V\MFVQ3R3_^#G?G?\ER,_8)89
M+IZ_O44&F EJ-?$I AQA(F9)PJ*I^&!5>TNPJ@D/5@TX[@4R2+)$ M9A7CZ1
M2A,>J1H%<=L.*Q(!W(3',+@)=&H5DFWG<<M3_@8D\2PLD" 6;,"16O%%W)$S
M6)B72Y%3%\ZE&EB4E\?3AN &@*.\*--@WMCW30DLHN]3A+PB=C["G1427;Z<
MQTSVAO2#Z,Z\8XFC<H==C -@:1>(!4\%L>I;@EA5?! K2.M6V%XF>E:%1T]=
M2V JEAF)5C,Y2'?9$$N_/]0U'4Y190+#QDV)8L>D:\:F+?"__]G9>??O]=FW
MRO_^_<?JQX\W7J5A_ZX-[FZ&WM5A_'!<"QJUOXV?5YUAZ-8&UF_-_1+M1FWV
MY7>M].M1MTXC[?O1D='^>W?PV#RXT09V.[B],8:?6_<V^W ;U<^[7OCSU]G#
MB7?]^Y=CWGSI!<?-?QK[YY]O[\^K?UOV\+RV&[G^A_IO)[*:WUO][_;Q;?/L
MOJL?N8.V]NTZ] X?CJ*O5U^_WUK]#_7=P<^N<QU_?JP>/ER=_-/Y%3;WCTX?
M8O/^@37:7RJ->MC[RKK7WPX'G=-.[3XX/VA_UOW]BGM1,W]^V;^\:9:_'C>B
MDWZH7WUSSWN#UD.O?NF6O)OKUNE5RWOH/_[^L-O]]LFUK[_^]=?_WAVT+W=V
M]JCZ*T)G62I"JPRIRA*D*L-)A;W4A>(8AZY5"BO(SPJ('/:F:]7""O);XD(F
M%M0**\C/"LC$@GIA!<64Y]02&H4EY&L)5&*"KC8#77("@Q\'FYO 0#(BZ'CD
M5"D[(!,/-LXO*=K!1B<TT8P'>+A/*3L@$P_49HGD1KQI!@.U42)M(R 3"=0F
MB?2'N,E$ [5A(GU#(!,1"IZ8VY9ZXE>RZ'H!!7/;5$^"G$9!]G+=7T*&I 6D
MVS2DDRQH0=MR7#XH0U"UL1FY2EFRF@7\RG>!@'A%MX!DM>/;R(],5QTWS($\
MY5*AB][:6#=P44UZ0!6S+WC+#3N!Z85F>AIRV!QFKV3WP B:@7/7-579<%8W
M</$*F'CBSZ_2C1Q@RGKV.Q6Q1#1!"1= \"XT9/<Q?\ GGO]$\T=%S]R0B]66
M)4B6 V!8HPGT1K)X1C>$-D$.)?EZL4OX^J%2#D7LND-CNKZCEU<>&LM^2$2^
M5<JA8%PS:\DV@1#CP:VP)FL%T[,V6S_:D6_]FCD^U>_U?"^]4 P$EW!G!!"6
M6FY14<JA(ES+VO7JCF:L:NVC#QD-H=:>0SFV3FXTTP1"C =WA#A)V!W;,8-A
MVW39BPY_$3@#;B07KFFEH2&W ,^ET[4WF#S_D-@ 7\:NX"CK/>6H4\*)<-0R
M0ATW9?*U':VVLLFG'Q)L\ECEWVP3"#$>M/)/3\]96-UXA"?$9:SR;[8)A!A/
M#N7?>L;32(9=5C6>AOBQFC+"*-<T>Q-\PIQ>1BM.DAVHRRN7XNF'Q&X[5L8J
M3F:;0(CQX!8G/ 7USLU>=D?_SH/?Z?IQ:'K)B2')#:$JXYH5W*J"FE DL6 %
M=Y8J-7WECE%7<&>?OBY4.FLM8DO*M08]_G0?\Q8[\'M]W^/_&:Y!D&&B-]X,
MUS6/"\_7+L7'$=%GIN@5O&FR:QY77IC$(I/ '04FJA?-5 ]W!)BHS)([;]SY
MP/3UDI&AXTT!)I-L*8=-\/@6F2Q+-5NHXB&T->."NCE4%0^7K>G7"FN)2]0.
M63H=QAFPS")#)YR9,Y/"K%:Z[G#;]\.JXH&PL8K[#V9@SR]J^=3KN_Z0L>5%
M5MV=\< 6BL1DO!@75#7CT/%8&.Y;][$3.HF6F>PW_6O@>'<7+ B7B-8XN2\>
M<Z*0^V9F[M03WBMVU4\5#RQ12&(EB[)U]$AT^-)2482.C%2W#N, B%+#XRDK
M@:\\MC34Q7?]-3Q4\H;ABUR<2H9:N#"$EE.1+)QJN/B#I"_2%!D7@-!R8;G#
MQ#5<B$'2%R6KA0<P:#H5269<PR,AI'V1ILAX9(6F"\M%Q34\UD+:%^6J5<>%
M,*\/GH]VY7T><5MNCB).0E/'Q3) PLGP.%Q"0UTXDFE+'8_9)(,-D^5VQ\R_
M"\Q^U[%,=R2TY<=>% P_7K6WM=ZHXR$:LII2P6YU/)ZS0-,T(+>B+@O2F[9^
MX50=CP&!*$S&A_$X4*+P1>#;L16U@C8+!HZ5K3^/G"",#MD/?CM[NNW467CZ
MX3:D57@T"$!JR:4/'AH"T(QD)&[@<24 J>4BI08>4EJ@69H:[7M.SW0_,].-
MNIN<D4VRVVS@T2?*&LOM+QN8Z(BJ6#0[2DR41%5CR3TD'B,:L_L3S_)[K&,^
M[L=1UP^<\4EP$[;/KX:18QV,0* B@]$-/.1#73"::0T>^%E6YY3L[7OVJ6^9
M[I<X<$+;L3:ZAE2RB^*!'!SI:#HK'@9:I/B($#";!:9[S+SD7^.5PNKP.T/#
M@SHHPE%T5$/# T)+Z9W&97[M(&#V^"%_UAG&._'0#FFU:+HDW#E!]3>T'/^0
M^);# RUS6Y^/NZ;VZ'%AUDLL/PX6]5FJ.P<NGEE&XC.3U_N1L^WS> P-%^HL
MD'FRD93KCF;U/%W=]F$K0\/E.]2#-Y&!$$/#Y4 (P9N,S+CP!RUX4Y%<Q\5&
M!(.W7(B@XR(?HE%8LEZXT <@G$K6#F]Z#T9<%#_SP]#5ID?YQD49>BF+@HC%
M11G:X?*=2^9R\>P+GFD/.X'IA68ZWA\VA]DK&<<;[PV^W>!6Q\4[;U:\M<S:
M >5TCSUG)'H<VN^G7[O'S# .V)X3^F5N$1^OVH?CAXPOC5YO_-?D67//#;MF
MP,(_//KIYZ:WS#W[]>?R]TTV=7]^>N;QMC/@]C73X,DGS^,>"\S('WOPJK]U
M2OZ9!\Y]V2'S_)[C/5W]PQ>^V@(O?N7,8[-R3W[W@K;K\Z>_W_NC'LGE%W_]
MZT+?_XA>?&@<!1^3B_./G'G@KO/XD3<#SU(M%H[^L\M,.XVW_%;^Z_;&_WOK
MV\,]_K=NU'/W_@]02P,$%     @ M("!6'P7<RT "@  ^28  !\   !E83 R
M,#(R-S<P,65X,3 M,3%?:6UM=6-E;&PN:'1MW5IM4^+(%OY.%?^A+[4[I55!
MT7FYN\I0A8([WE*T '=J/S9)0WHGI#/='9']]?N<3@*)X(S>TIFI\0/FI?N\
M]3G/>8'VA_'E1:=>:W_H=WOXS^BO/3X?7_0[[?WL/][NYZ_;)U>]O]AH_-=%
M_WUCJF)[Q Y:B65C.1>&#<2"#=6<QU[VP&,CH>6T@8W8>EWLL^+.-GDD9_$1
MTW(6VF,VYWHF<=MJ=-HGG?Y=*"?2@O3>P4%[_P227-^CL=IPS#;(-3JOXHE)
MCA_:U;0J<3OSVXFR5LTW:/DBMD([@<[G\_141!$[53I1FENIXN>4Z[&6+!D*
M2Q^6]^SJ9CC^P+J7_4&OWV/=08\-^Z-Q=XR;\\%I?S ^_[//3J\NK_N#47=\
M?C6HU[I_#/M];!AO5^RY12Q,\6*\(C&U^1,9!X(HMO;>RKC1&8?2L#.5:ANR
M[ES@9<!X'+"A,)9;$=1KYS%)*F\%#GR>B-BX$V?=F18"&ZS' EK(N&%JRBZY
M]D-V^%^/';8.WW@,U"=+1W$B[$*(F&WS'X]QUA,17W MF+]^SG9L*-BK*/B<
MJF-BS^/E*^WN=NLUHGJB)A/)_J?8B5;^)UBENJ=_)_R4A"]V>4X6+9*(^S F
MW9@T$=J( +<R9M(:1OIJ89>,*,%".MAJ&[8R3;WV!-O\YFSSVEM9A+CDRCGZ
M=+\2?.^%7.+OU%@Y77Z[.&S?=#Z>CP?]T:@__G#4WK_I_/3!]?%#?]COCKS*
M"2^D"86IUZQBB5:W,A ,EY4S9SP()'D2C^"21?CY91=3"6+$IC&697ZK=" T
M48(,J2_N$<1S+>:<_+OB;Z^TH;" .&*>1"KW/\6F! B@5W"7_P@69O1]V$S&
M:78?"0ZV)I0)$],I)#)8@B@.:*<6W,AXQ@R/A L 8DR(++6QB/<IM!'N8$8W
MUYU76LQP3'19K\$RT,*R2,;"R20AG@LI(DAT3.HC@,TTC<@P<Z%]B?/X)[?.
ME/@,17,,E>]3)X['1/0%_>&%P^J1+K<Z?^!P#*-R;6$D.D$#M],K6\&6(4N4
M)?/B?<G[RC[GP'PAH\@=@6*<4(XNQ%U2P)::0$"WVC C+".7" N?6\%BO88G
MIRJ.A>]$6$@LZCL'I->4,;9GB3*:#M2MF$_@@P=O"5!;OW]G0/VNQSZX^@@Z
M=/9G5\,^'7?UE.NU//SFJ4UQKHBON33KJ'2N@5L*;H0,C(SH%J!"YE,."F9*
M9>GOED<IGT2BRL%D+J>%+R0DSQ+K="I]*6)_27P6H?1#9&WMH$-06>!_BM4B
M$L%,!%Y%CF*!<S&<]U1%D5J8HY_Q[-IG5X-QF5=SRN<R6AY]C9M;:P#-F7"-
MSL$>:^\3-4JV#Q0GE'A?,@2VZ_B=3+O#=U&_E<" _(E2%('A<C/O[LA=]LO;
MEM=JM5B:J Q)*'T1))51!>Y,_P*5Q]"V;,/6Z88 CD!P(2+B<G"XR^;0/$3>
MY5,4*JNPV<(&& B<1*KC>HEULS3B5N&2)U0^\(C4 =9BV5>$R%'X!C4#XGM$
M):S)RN$=*5TY74;^P@P[,D,(/E<IH)D @DH%!\20UH]X:C+#A8C3"<%OPF6P
M8=M=EIN3,!P7W%(Z@45BNVQ.T8"PG<,WW\PL:ZNP;68Y+DJSP*O70K40MT)[
MF=!9KN0N42''A23(!%JE69V"-PX;51PM66ZZM7]!XZS.RHQ7R5,V,W.21-)W
M)'(FSF![]=IH.V.33OY&&G4)&4^T^)RB=X']^9W+JZ&* B1L\XW["/#Y3[/)
MSJ2(@B-VS6?B&,0^IT@&@*O7K-G,!RSMWOF?A4 35\2N9A GZ-$^L8.]M^!J
M5"2#U93"#2T.#A.[,;=X1SBX90215/"]O0^NVP1 R?JI.1$H6R!EXJ0NLWRW
MA2.)\526)=/LDVTR<SS#V3P'TF[V454CM+88P2G[I.'0=U3P_THEYVMT](K
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M;6UU8V5L;"YH=&W-5FUOVC 0_H[$?SA%ZK1)0-YXZ2"-Q.N*QBB"2%4_FL2
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M?5Y]PT4<.^M_L:_:H#%KR*HQ @QS+W-^QN:Q1_)$/@1MD.EHW"U'WXR!RUZ
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M8C.QLQ-2A4>GO5\7'7C_8,$&W]&S@;'PY<IG;Q.*,N_O?@OX,]@,,4"806&
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M^4;:PY0V&'$O; B=)"@&'=*I;Y'KV^[4\N[(ZFO.[@M2C=>R4G2"X[M<P$W
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M;)=-U)"'=P.;!=;H5U%]@F=NY)?8M%#2CO"F3C2,OZS,5A+_#U!+ P04
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M2$F^NF T@9Z2HU4\[=Z_'G"ED ]QF"Q890P^)>UDF8Y!H1:%D)1=W9<08CU
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M@> L,1=;D( PO=<A9+U<+<<1K"11N^U, 20L"[;,N7Z(L&NV8UR12Y&V& @
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MX+ION1;D9+5<73FAZ22JRL!6;6BW$&KGC@H$9@OW'GB(8X3JRD63JY<K>M\
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M,=KDE,7F"+>CU<D<X>[5P-%T!EY6CQLEBCL5KS*YS$#CQPO,%P"00TRBMNG
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M,<<J*?;HGV%A$/?6H//:'MN8%"(0E6CDOZ?\VUM*YL&)$57!_P]02P,$%
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MO9S?34O0+R=_;_@CK<#> /[JRV?HB5?W']S =+#]L-FW#3]I@P/.-MC8_"S
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M*3B+HD]Y H^O3A G&HU?,<](-T\TEP@6PZ'#XRL1P:FZAB7O.!O^<=UV<IN
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M0JZX&O>![*$JWOG-TT<8X^IDZ- Z3,8(&@7C?A4*$PR H(^.B<<CKJ6ML7T
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M(PQY'-PQMT:D>H*8A6@"89+BCFZ@_NB;9N]6Q-]@@2G^_*M6I)85!%!%TD1
M>U":J@LHEO\X?6_=6NBL_F'?6A H_7'ZON]U1[E5E'>ZH5>YI&<IW QVRR%,
MU[0769@S5BSG_.:86!&T^PL;UQ>R$F[<6DA-AN(A)(]+K+*9$(/%\],,B3<O
MM(LO2IB!485]DPAI(DVD3&>QT\,V-RP4^#B9%>D^W]:*_M'O<P+X T<J-,^X
M"M4+I$KK:IQ]R6#4!GG4,WD$WGR[,=@2T4#.[!ZOC_'.A;(M2+3?!3W'Y:(/
M6*TEHTD6ZO;-'4YX/%_=)_ECS?E#ZO@A)CS]XA(>+Z.X"A^_PC&X9:#M3K/%
MTX<3\Q68U9EE+)[J:Q#@ST&,*1Q'J^,L*9YLD]41'7P6E-W:O;W3 *-&B>>>
MT]OC&GF) \VS>$=N>LY)RG.2V5$SVIEDM$'Y0P[E$*Z=%'H\,+-X82"U_#R_
MUSL"3DJ>%1^!MZ^.7IV<$IB^?4?^6>2*=\A&< %=B/.I@U>G1P!/"/D2_>/E
M$4!?;2&.\('!SJK#J$O\=91RYZT'!$L?9;76&X[*@=S3#&(:+7EQ0/)Y8BE0
MW*BR&HYPEB2;QTHQ(=)<TYQ1#Z0<EA$RV_L)A!:QQ)/(UR*2'HDM&'F$\RH3
M%K.,\QBPH@[D^93--3ZB,C7JJ!#(4=TU94/I%\5D\AWLTG1.^8'=:R>;0FQJ
M)#/'(35.3RGR6S2696$_EL%DGM6$$!9E>JJ^RWQ$)R>< G$>4I[Y#/5@3)"H
MSL '\>U$C#G&%H(;@N_6J(OO011BO]8V2IQ _+68!>3*0:".5HFIZA,RP7CC
M?8<.C/X3=GOICZ/H)JGK7DT<F")L,<_DC@?W_M2X^GYLB2S8LA5[]W\P$^J.
MSS8)?(D7H@8FTE34:5GP^' 98@9UY%_L;.?=$9(<'TV'H]6:B^<VAEO']R[@
M"L9QY:B?A!XY30Z2M%21B5$@3X13YI,#TK1R,>0><N)U<+.8Y(HZ3'8Z"KS*
M((0/9.')TYMM"G=^GL^P(3Q32(YA@VZSQ?5.ME+OC@20;(%V)):B#U]]5R[O
M0Y?1Q$7F90R-I;@0)ZSO>"V./''V6*H2,?7H)')I+:P\T9)&0..MEMP\*>8^
MNX/;QKV][IOPP^[-:[I#%IB9_A]2!"<_=/TM.@3'52O+M]$,^32NF&DC[!%'
M4>ON:L#7QVPZ5ESS3'98[I/&BV,J8"SCA2H\%G#:0U9^>]P 8_DT?H@DYSQ*
M-K<V"C^LO>PPNHR9WMSJ#L81)6W+8HU?)222$5;61!(COI'5UJRSEL>**"PL
M)R,7D405$,@;JJI.R4-2R*7"-8F\T:Q)VOV;OWEJ\<"*327? ?*AY1M>IECJ
M6H$^+O/5B:A\T"Y>ZQ,,_I%_^T^;MQ[JT]RC4A&]_NP@JX]/RT*1/ X[S&IW
M91N O5C'^R<6MO=P(4$VB]!U#;^'!^X.YO&O4R<._7"=#((G!A'S*IW."#L9
M=K;) FQ&@ NX\EW?ZE4K7U+-8P1SE(I>"4HXZB! 8=.Q\""9R4Q7\/(8+(%.
MB75$&Q]H%Z7WK0Y^IS5?%='T4:C[N$DA8"/?19L-5C'L^\7L9KI8E%6*YS<+
MN]DUF0)JO$.E#T\]-M5?AS[2IMAIFM^\XU"E*$#Z%29+^"4]0^T_:8:*(%$;
M\!%CC57>Z/[Z>G+W*YA?@L7LX\WL<G8^N5F"R?GY_/Z&Y$6_G5_-SF?3A6VS
M1T[LC;@V\0E2!N6EX\?D@45^U71-]"'TYN%-%,80W_@BFF=.X@^&4!4.3+_/
M5^"1A5OW$7I9G@H][PQ$,:@5V@!EY_@-$*8+"&$<&.> .CE Z-DTS'I@IPYS
MU<GMF:XJIS9D@JH#"G9J@3698%G\Y".K*2,X,FF]'J&,25]IF@]"'EU:.]OI
M93Z,/[W,A[I,N<-07]TU93K0ZJ91,+ZZ*4PP+PBK+ZTN<8Y@ZDN<-; >SI[%
M8Q2G2QAOSJ(XCCYCWX!N.YM"P3@D*$RP3F1.^(E<Z-@-*N#(I5D-E#XN;4K_
MY8F:TG]Y8EOIOSP9O=+?3RY;Z1?#4%?ZI5V-(P<P@V$:%T6'[_SDT]D._^\E
M(A3%@YVT%3@P?8Y1X%'@'),_E*A**.Z?$X +=' AJ<MK1UEPGB5IM$&LVGX5
MJ@Z9AG)2G%-UK#?(X.YO88Q_X:SAJ?;K: XI&TXC'D/,:^I:$Q"C-F!;-;+J
MAQ019/-FM6/PVB^6A&ZS^4S1+K8;3ZMJ+ZMH@OD*Y'*B86.;K\I;+=1Y61[=
M=R>A=^$'&7X0CB=PZ,U-E@L+MU>*K KL<S<P!446YN_P"\[O >H9E$$:F(+5
MM]3]@$+;TE2F4$^2WY<'&YFP07YJW2!G;4,C,L@;2HP[C)YO07'XG1,4 4'D
M.?XD36/_(4L)<*(24] K8O4F<8Q3D9&P/<TJ3 -#ILWU_BRSWAC@Y>L_0>!O
MMDC8)'<+[N;X ?<#D(K#;]YR@\GY[,2>_=KG6J#4>GG5?W)U%4%Y^5)1X[VT
MKO%>CE_CO130>"_[:SQD&F## %>U(N'&^,8V@]X^@H!LG7EZB_F*_@FR,N:K
MI?,%;;EDMR40',B1;81E:Q4UAAT7*Q4[,A(#G- $]9(KU1\M^SE,XK)=!,2
M$)1C^9WD$3& _X.?,#XY =;JF LDP"P>[# E3M>TP2',&:^2T>3F I!_3/]V
M/_MY<C6]62ZLGN9EQ=PXVDO-2(]+R\A!4(]2F!#?2)EM8.]+-8!+-1YL> &5
M.&5%K]Y-+J9EX-@"W$W/IPBU9U=3NU=CO0#1N$Y5GJL>Z:>*M#;#8Y9+R@8T
M>0RQL@#=_(QTY/SN5\LI5;J%UMS>.P:J'BA;N9\J&D4^#$,^S@ZR5IV:?-X$
MO)CMG%-6G95B(J9[)P7F0KWJ7-'UG?/YVD'R\9U OT>*1L.\DXG"!0-'Z!.P
M*;^Q?JSA2(BJJ%H#['/6+_K\)8H_X911D0N3P?#1)&+^]1B=$09&\#?'?GB\
MS;\:QYY&%1,5).TA*CX=JWJ\]$,_02KK8Q1Y@T&D2<0B1!J,,"!2?@/6^".[
MKF6>D*@ :0]0$2#M1%]#638\2N:APN&&E87B;DK*(T__?CN]64P7Q,4P7_XT
MO0/G]W=W4_SP9[&8+A=VCVP" FV%LG/F01%69=Y"DNVD>#+M_PZ](JUA,X_A
M\ >TWNP8CZ+MR[& #5XFV9S6DVSFZ0P+0!2/@ZSNGKJ05 >]ELGM$0E>T"DF
MOIALS9"GTS!MUU.Y$$SZ:A5V7!$ULCPQ1]CS:5C--S;$3ESOWC0J#AG@IE;=
M!^993C[(DDIK.ST<68^LJ:PDE\-OF5*DC6^/,MPQ[3F<"&#YZQ&XO2*OMI$Y
MAR^+;J^1*7=0T\J.!I*7?5,Q24Y1KPV-0<LX.L>(23FCK$SA>UNE\)V.)H6O
ML)B%@#@\_.X3N,J"*W^EN]"("$4+'GH!MIC&%R=U]!&8)JF_(;F8\I[ E?\$
M\^IJ.^C$UHNK22! ")H'\Z5;EPB\:!!DC?:PH1!1@#[YJL72HT0CD\+'.-+N
M0N\@-B8]03A24Q%KW-2F&U5,ID(XVT^#^M5=BN;.QY7=#?FX1"A:B8+L9(L9
MD;"<W'R<G5U-6XY5*TYZ88$V/?9BPU?%V?X>&E\)I!#OR]XA44,1"^(<V'IR
M+,&C4!!#V4'+46IGN^T!!GIL@]QLJ?LY.'2&V) [R9F_C^IBB0%'\C=P[L3Q
M#F?C(AFLK*I)44DV<F^)C%WQ(JI,"'#K[#!@T2:/?A-GT*LE>!E^;U;EPL)^
MK<@J*Z=7&=%Z._EU0G;RFPL<YGIW/]W?I%H%;$^ -%)%]YBZ_ON_"'5#AH "
M*U;#&>7Y%4FL6*8B*7HEYZ6BW^K.=2391_J@AVXY*$ZI<G[^)CD29#[,O2J/
MDGFS@<,-.Z]Z#LMM <L_?/O^Y>GI'T&*VXY)%=.$R%&WK;'KL1CJ 3+#0JE!
MR3J4ZMS(0HE2Z\$^G&B"Y,"I-7YU.&&UAWI%? =+YPM,!D,3BY#IXS:;%3:2
MR+:XS5O8]")VR^L -+R1JI^(RX[C: 63A-0?N81#0X=!S,XIA,-1%XIJK< *
M0NM^&3%ATG#%&;^JJ92'M@F89T-$'0G1M1*.),)9!^Y(@7++FYZT=-MYK44G
MHK=RR]_F#[\E4NC84VEM9EC7'WF2K]3Y4MI7=N.1.H5&T5^,P:JJKK*"XM#!
MXG0J-A[R,GAA)52>W/P57$S/EI8CMKE2:@9BLX>GX>4N[MZ0RXM"RDHY&PY#
M CXK4O:;/#N#7IE#%Q<!"3WTV[(8^-TX:CN+B)GNFV),C3+@ZH6C<4[S@2O'
M5R0L;&(T/G@EY/FHL;.1\<3%J@?>&&M_7STI"!TF:9R1_LVH)RI!\^4!.GD2
MBI(M8575AB;%!$B:$3#/TB1%.LL/UR/24#QYL_44<X)ZA,M>1>$:%S+ _5_C
M^G+$IJ_#O9K?67B#J"X_P^ )7D=A^JC[5-B/%],GQ5[<LO1D1@IIH:,76*))
MA<?D:YS5UX\\,"4P1ANS2TI"@E>G1P!-XFO;2E0+AIH9@OI.;9^\5Q*T?X5.
MO/P<V5P')0OF+PE4V-2)^S=62P?U@(DRU.N3J'@%(4\/R\,ZP D3YBM:*?&I
M$^-O;>=\ZX.6?CBOIM*4=8.I7B(0V08[X<%.$D,%3G6B_9U5$[T76'IAO9I'
M9;>#/$G_R;I6)SP\#Z C3G4"_?TS WH-+/V 7LZC":!/5@@(]K'>9&/$I]0&
MHWW0?K1\A#%T<'>6;T#[HD41[.V9U',>'1#$EL^//>!V!);108"9;:AUP4?E
M $=J1)1W9/A2'B<LPC93$Q2,*AW4A@;O#)A,\"X,O.);X**/#[9-LT+NG/RJ
MB@=SC#K$O=>K2D*O-3>U#77P(2Y]VI9B&P!M<3!A<#!D:?.'=%I7(5C:0B!H
M-3(J^D/JK)3W6(.#WMYOTX!@":2" 77X6H3_6D7XKZT*_S57^ V'KG51ONX2
MY6M]HGRC(LHW5D7YIDN4EOR6W.EEB?*-/E&^51'E6ZNB?-LERG?C$>7;+E&^
MU2=*,;NZU<BF*%G&="7*]^,19=MRI@ZFOR@E;69&4W.G8PX77/'2?2Y6Q<RQ
MCSD#[''=TPR2*3,A3#;8"M?L.^&2LA4=S&*(!QR[%XPB$CL,$N:.4MFQC$NN
M^BGQY.'R:J3LWQJ&KI&<$)+$C5?ADV*/58IO?K.<W7S$N?&O9I.SV=5L.2LR
MYY_/KZ]GR^M&73X[>%1#0:,^G_Q<]4@.G1>E#-=7T$E@,E]=P22)XN$!*T'8
M0CT'8>98R:9OIW<3#%9P-9TTDI)8><8E+>3&.RZYR5 -*\*=$T?7D$\L6%2L
MW"'3>1$(6"8M :DW4"NSD/]V%JZB>$/JS-J^.N-+M'&UP9D*]8O>LM.!*DVW
M^[=P W;( P,]>\38C1M@B80*AL.*R/WW-]SKH/L8(6!#F;398.U,Y8<@()AP
M&YBPOSO51<3>A:H!*FN'GYW8Q\IF*%RT^S>O'5H\,#!1?D>#A 5 ,$53QP-]
M;"IWI/<A^0EZI;X1O!>CM3,68,SB@"%A&^+LFMS*E<,:1H^0E]Q2+57&D 8
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M\ZZ'P.DC,BF>]I$2^5>CN#@9"(FM93N$(/I>G_;FR<I>;X!K:YD=AA^;[N-
M;6E;W[?-X5G_\I8P_\=E_>?L?WW6O^RXOB;K7W+L>JQ_FB9Y;LZ%H5:+F5.
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M(*V:68>-I$";L5K=L]#_#H94$L-I,A[][4!&)H>2>4<*AYNNFY>XWF0D-H6
M&&DW+JS1*_I-;B(<7KV%*9P@@W5 OPF'D&DEQ6:%@2/4X+AH 9RJR3C<]-T"
MK*.H8^A](N@?TADY >$^[Z"'WR;A,D<D:\\\'.;61Y2J\4L@0<:867><$'Q+
MC3"UM 5*";>Y%8I/1"^KBT=F^3FR +\]U9'!KV*,"S]JB.H(X=<2KCC\FA,Q
M@-=,(+!,@D-:J!E)&+IO?P3V/1R5B<!1)__+9'FB_N"&2P,G6;>A26ITS9_H
M!#GC*A-:Q/+XT-<6KP3^#F9B*%/J$HG8 @1K9"WXBD5YXV+P]2CN%62E*X[
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M,>[YY\ O/AW-G9":Y!LWC_+SHYAKJ.SGUMF1Z"1,5>C>B-K0=-)(&A-LHZA
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MPR_)'W#C%VZYV\U>5$&W8*H-O&/P^H#A.LFC,BQ(8[,A)2PV!!11#0FX!=W
M&P,FZC+A(J(:>)^7M+02C&V%=7:HL I6RD67S K%11[&S,(4\9?X+DE_,L36
M.S3+MAQ3 X^+=?NU7L=P[:00I[+//R^R[-@_!=E :FM+-R$6HDC_]'^/C\$_
M?KG^^<T___%W=YM]^35\\\'[_=W3^M==>'^1??[X+O[P[J\O_WV_W"7!NR?W
M]Y/@+^F+= '_\ON[5Y^^G+I7Z<G_7%Z^7/SUQ=.7L_-?3YZ\1?SPZ\O=3_/?
M//A?#^G[F\<P^?>GZ\^S\)??/_G.KW_9Q!_/_OYA<O/3PV\W;__J>KN;=R_2
M(/JO][_[J7OV/_/M_W@?'\ZN?WL\O0R>%B<__Y*$%Y\OT[_=_^U_'MSM?[U_
M\?3O1_^7[*<O;R\^W\_^OOR4G$TNKSYGSF^?X8?%7]Y\>)]L_@8??_GYXFEY
MM7SW6WQSOOCI-)J\"6[?.?_^R^3NU[/7?_OX(9UMD]/[GX.;S=/\\^;]7>#\
M_B+Y^/M?WKP^RQ8G;QY?WK]^^N7WO_WYS_\$YXN[XV.UEY'*%EHASMK)YL#U
M=P<WCH^]?6641Y9?T+\<R]&CQPA&XZ<?=)BB[OBX[  $_HKX'$L+@_9N_9D=
M<_KC7,N!J*<4E9WL/?DMM#U^9BC(KYG[O6%'\ S5@\(PU=5#^@@K%0'WA$=@
M4-F!NDX-H2I(90VQ/X@U+OO*]_.ZEW,7.0L9ASI8ZO#/Y+?9R5BOLP7%VX"P
MR(0H9O+H>_P@;Q>KLP?YZ0(=]$9]0A?CV738L9%1"?FQUOE[U+&N().(U7E2
M%Q>0NK]MNMD&T0["(A\GG>6;*'R""=[(R/-CXC"H_QVGDKJ)TE\ASLD2K4,<
MP%+W#VI>SF9X-KV<C8R*MYR/B473?*$?P\#!*SN-0!B%QSGM@_L,5NRFA:5N
M%,V-*JG&A#?"I9[K)Q+Q3WZ%O]-]BC3,O(4#I-D1=IP=CZM(SQ'<D-L!KI'E
MS9:-<G7MDE6B.#Z'"':/_A:'CTX7\]N#$VGYS)V<#LJW$N4O=8>HZ.3,YOKL
MS[[(FYQMF8%@S+'6 X"-NNPT3;E2NHN:/V<2>N0!T0H11#]>P,2-_6W[^1DC
M9$&L)\.E"828XGM0JHQ]::WU$?#V[:UF6) 28!7?(#XO/=Z0S<B.@<]]>*-P
MPMT>Q'#C9YN!0NJ%R5I0LZ*\=25N$5.;5C*CRLF\F1-58G)4+8@+N/)#Z)W!
M$/TCQ=IVDB39)C^#W&.CQPG<+""/OW%@=U&UN/@>6SGGC]C#<9'!9;3('A+X
M6X8X)FE;_<TU=)(LSM.;'3Y5V4(7_5A6GL*%SN:K.YAF<3@/"SY@.D 5CW$/
MU\(B'/N<B!A0GV$,@4O8\&C)!.VD$ASUM-)4SMAY[J7JSK($#2[!F?(>_#!_
MB)?"[<3]+?,3<AB;HG^ENS+E-,Y!C7X10SA8#E$M+-F(X=?!.#,]=-4'/2VH
ME8U<)WCJ*T[;1*I%9=_A9;B,BC[I%BCC@,-H:OA$0^>"75W8)5XN0)J-R6 4
MD$9U6N&,6?5)9MX7TNJHMX0\ Z$J/ 84V*U-E_!@<L)"1/4!CI1QRM88#4G]
M)&L:"9WRJ,# '['BO3_?%X/_RW2'#.PY/*0].M_@ 8-,9TH*L0_E$8(8KV:D
M?]#?1^%&Z84!<8<>;9Y4+;O))HI3_W>R>\Y75;524O1H$GH7?I*78-",5&&R
M-G)D"O+&,L)JS;%F]#@U(RWA4U;HC42;,K.C?#FS6J%#C?^$([&B#5PZ7_"Q
M!M_](&*!3XBC7^;UN!+R?EFW*E7@P'@DA#R/S K=20)\T@MX@*LHAN5/J?,%
M)D>XAJ[EJ-<>D&AH5L4Y4P\G*&L7H%[SD_@^(R2:]7,GCG=HPLE5Z$V4HI/_
MOQ&#RVC_L%B_'Z\G/W8<;?V8YF0.B<JN0("7@5OO#(11FC^$'TEUC=XHHI75
MZ#>K/?SGHM1'M2J82V*L*T+C<CA8"N->"/I7 6<)J*R :J.I$QGN>-A)SCR*
MNUABG@&KU"3-;.,6 "DJQ#KDA(:M""IBL^!:>$[R6!DYT[PVH&9 <4E9JT7'
M8(BE\J+PF*25V!N\925%V\<T$4FV*M?P1M^[CERE(H>HDDTA,09+DUU+EKPK
M(*^(LQ@=\XO*;1A #FEI52WQ1,;=_>I%8H<ZNT_22^BA3398I$Z:X6(\C8\M
MG.6[.#*_-6K@FH';^Q\6/X!5WA"X4;R-\/&> /=YG/,%X2-[[A>93<5-^2Y_
M'W+KQ.FNEEN]#$LBV1[KWVA> =+D;6S>LDPRZX7D3W&V^!N<%A07^4JJ.&%K
MI0K[0J&.9J6I4M[]&]0JB^(B@YC,9+4BZZ>JQ#PD=+N)F_;!RK'75=8[KDJU
MCPJEPC)G8E1L9A1+\)6W9<F"5,25O(%GMS9] \_DA'4*+K[_P[?O7YZ^^V/"
MJ0AL/):\2R3[^''NH%5J]1[T2))(^ \949"]H,'HR?1#!!&F)!'CUCH9(7SX
M(F1!B3,S/9XBM.,\]S&6Q2^36\?7_2A,F.PHHJ#IO'6 $CP4WR+3S?=&5>I&
M5NC\P&#.["@'Z#J)G\Q7A2&!0YJBP'=W^?\NX9?T+-!?:4F0J)4@6R'6&( D
MC;%?YQ;QAK7&84R1C2!:*0$WPF3%IT*]JH"3/$Y"#_\'Q]P^.0&N;3<L^L1H
MFO?;"/'%>IB!'='XA2#Y1ZVY55>BE'0;-0:$IT+9K5*>EP8&&X>0^1,GBQ4&
MJ):QXT%0G3'OVF=,*^?++LDUSY+<,:L'Y^R+P0\*'R89X[696)PPL%-];M<I
MW"6FP[>?S!'VJV.)3D;I#EMO*=)J6*-M\8.L8:$C3-9&B5Y!WIAO2O+F1X!T
M0#:^JHLC$,+4LM$E*_*#0I?B<].O7#VI+#WP!LBC9-[&XG##P%H5TP/R5G;U
MF8#<VI7$V<-5M)X^1I'WV0\"A,X9.N6$:Q\G<2 'TV'!)$'8/+;$F6/NF64K
MD#<CBJWLUJHE+R_Q.@PE9T;%=XM#*HJG!?A!\Y7_!#T!1#+\M^*]&:V0),P6
M)^ZD>EZ">S@F711HLUCS4%IZE>M6;DJ4_127CA^3J)W:>WH3GC)QNJ9/D\*<
M,;"(VX,\$*K60V+9<).6<UW-R4V)^MGS'(\#)SC'N+_SDT]Y2"C^EVY7&8>2
M!0<9FQMFOI):"ZST\+=V+3@!X36K;?+'K.S_0F?=#-:2(@[M!NNB9R=PJ(,K
M9J00:0=J#:U:9\+2;+K&1 :OEN*BB-D0A1<SG5]7+R9!(\82^]T!;D='C(V,
M?8+RJ67K$QFXJCNB"I<<VIO*(&/!FTKGA'DR)$\,EOA-K4WG>Y><FNY4SA![
MN%/IN8'S#-[D@(GW2W0,P/ZSXA"@&48J'(RC=@671V[J>M(5J/=E.[2B!PZZ
M:TAT3U2/-/%.C&L4)642H6%U7A<UX[D'^/QPWI>27 .H&2BR$)+F-K6AH" ;
MKPD$1J^.K/L$SE?3)/4W.$!6,Y ..C>^93;ILUZH).1=5?69;25%ET@=$91A
M]=@<;^#G6KQ.'(7HGV[N63'AKI(F;^/4)\LD4R5]!OM^0*,C,/&B;=I\,F(!
M?:IHJ.-3:;;43HT<4GE9AV)6!9#,.%'VHV#4U]^+507()@!U"U"_%.R:/IYJ
M 4)U=.T_DXIP]A,_O(BS-4[*F^(D7M=P\W"8<(J%5%9C8_LNEPT6P/#G '\/
MJ@;@'WF3?UJM4= EC#U:>"-6-\W('?QC%'BSS3:.GG+XT?"@(>""3<E&P 63
M&U9*L;(%J#>AH<A*_$6G&)OQ%_S1J]QTGV=)&FU@+*%,#IJ852%-XJR+FN(C
MRV+F3'"E("CC45<+];>.@V@#"@';3[2Y0"@?89,OK6\=W6)B/5P]1(=2T($?
M^BDD(0V'83.#8*6;G@WH='+%"C @[8H(EW9H51M:-L(-1"7<"#,0FA UF_5C
M%#\ZFX7SA)U49T[X26*78;4U?DG'8(2!D_QK4'P.\/=CV(4Z)%%M1[S!*I5C
MNW;\$"ZA^QA&0;3>S<(D]=,LE3F\='1A^GD\GQT&+$@CL&\%JF9V58>$C"J,
M"$R BB5Z 1]2W%><8;OV#GHPKUJ3EZBY030E,"/<F6GTB#+&S)#LA.#;5V-0
M*;+RJO C-0622$KB]%\+%X8.ZNHRBJ'K)*FX=8-:URP;]-/>JN%T;.P Q.:!
M9;04'UFW?+O%@M'1,3XU&X2/MB4,M6F5?5]FC\2"7'$T2@*^?3U^E=*2E:!&
M:<Z ^NGZ.HK3M;.&V"Q"YM$@AR8Z#=.WZE0N6)9-\2UV^%.]LQ8.0EQ)U0\_
M[($JYH"ZCL]P-1AG(V/?'K0Q;M VZ;/D'/\ BN_&8++2YWEOHU+&I!C<O"^"
M.,4O>@=9]G0:QJ.\:%RPXKBJ;P'YN(T)&T%</%$UPK28(U7?'FYC_\E)<617
M?ATX"% 81,S?Q- 985?MPQ^#ZNN1[!-\D36?43.'JW+677Z.EH]1EC@AMDY(
M,*#$AL%N;7KK8'+" ,++D],3\LK>^HE$3 S5?L(?:$\(+/#;B13V @*U#Z,A
M)AW,L!'QCH$(BVC@282&">: E6]K\I)[Y!0SC,71ZM_\'M+B@1<S#O(/1[)S
M,,73L#*HX]-2T',X8+#IZ-]<GF#\$,F4ZNS&2I7%L0,T-@*\NR3(+KU)P9#\
MCG-09U9BGZ&W-+J[4%G@U1\G18#SC\?@VN)./JL4L(Z-Y"+:P"3UW7,<LA@/
M$Q9"IV'Z^$KE@N49+\I.C$(Q<$74R.'*'*'ZL147F8"3T+M"7P5_R6(_\7QW
M0+.#3\VXRX//#],@<>B^3DNVB) $FY9)][ 5/:#%ROH(0_R?LRSQ0YC('&JX
M'1B/_N!QTZ%;BC:@;#2&;4A$.M5NU#EV)3.$8*^J/"<!#&I#TQX/&A-<+8&^
M!?G'(W";\^:^$CMSB'VJ($C(^:")V<O4)O&N0\8(5C1]@EO%"/HK]K*GN50@
M3KN5I3H5\X[(FDJFZ$/K6SM_PEO"G1^&S*@:@S@[:+K#3]>C$(8ILC<=7W?Y
M5SH-S89?0($#EP$6*LBWH/H8_"/_W.HU%U=*#2<"<Z0]SPOX"F2)\V /<3S8
M=ZY;]?-0T23-V]+S"RSRF=W;3JHD6F9^<TQ]4J64O5TA.W"&_JD[)P"%P #V
MOA (*@ZZ@8 _!>3;<9P$J1*BHJ(Y2/6J&X=)Y<Y@Z#YNG/C3(/M')SGM!@8/
M,5W<"*42Q.U U;"]Q]A!DZA<N0D&:=.A<HY89!O4RRY:+?QUZ*]\%Z<S;]:2
M\6%"]%Q"V9E81TKI7DUL26JL,0-U2#\XCTFMI\;#_:(O\%W>V_>MS<V&]:LL
M\/TY5FD&%4]',L08^Z<&C!K?.-4YU E7QA8\9LA2=^B>LZF:+Y&6:3BI?OF3
M#V,T X^[079S.=KZO7V\O5V*M^[$U%4#DHC_9O(S9:,?29+J3NEW):KF3Y.:
MWUAH75S U/&#9.$^0B\+8+3*G[)&\97O//B!GZ)O"CX])ZVXC$+G)@ICZ&8Q
MOGXEQ>ITFQ':61N?CM<]1 V;1,'2]^ 8E&SA=L6[[2@&-=;*W/$><%)06[G(
M1'= G4.0UV9LVTGCW'*&6A22>]8@Z.B]Z>5,X,O0-A?S\*XDBSYH<3&4(T0O
M;T;/PUI99RU_[>MX1#Z<07!)W:ZU24CAC>Z-LX'SU;7S[R@N,^"(FY<=SW39
M?1M9"5P6.A,6M5T_AI_I=DJF?*G+'Z/&>B1+U,B,)[%&R:X3<<^(N/\0MQFM
MZ[ M0Z[7\&#\BB'3[6X'N+)B$+&,'X[Q3(&.53M63%I\N-2M02U(&<JRXQ R
M> /.YD+ XF+6<087R,3",FT<RLJ]@65EC0%I7'NI8[)4_<7%C,Y79#[+Z=S/
M)IK,2\1U;2JKF93T'VNA9#8*2PO/7S66]8-H?YC7-OE]'E,SRA8/9@R*4#3K
M?A;@B)G3I2K&N6PD*AR+?2@A7J%BUFU[4?I$>H<FBAK8J'0&K?=FR$U[0)83
MN.+C-R1.4*^4:1L8# F49\W#<:FF\J@T&QM)0T2UB9(UJU]$V6(F=<@;'9'G
MVRFYU*H:MH\4-L*A),7=")*2F1Q5'S2SZZ&.'P($3<9<=K,C8,-UX)#NVAW3
MGL<]?0A.48^P3EX"8.+<"YPDP<Z^8>[_):F;O<R08TXI=?01(%T!TA? G=G>
MBWL"0S2Y-&L">^_M'*+#[NZ=A(V"5YPO 27;E?Y\5+N]* #H^[W0;"F"E-/W
M4%N^$$F#OD<1?@0 2<'@:'9Z&2D+:DM=?A5^IM1!=G@AD@8!*,(/ X"X*=BW
M/0+[UD<@;T_=O*TDE9"0="/'A.CT*#J^<:I53*,5#(1_B:Q=%T*O\#5"#]GR
MM[$?NO[6">[@UMF1V$+QP#QMQ(SLW%I99D"8%*0@.&9%QI$_EH1 28D<JRI:
M8$]L!$%PNB%5><*URD+AB';@CJ=1G5"IJMX0J5 PH+K[<RE@44CCGFYOV+P%
MZ@$0RNV/ZC2KIZIJ;#U#G-5H%$PZO"CT!9!)KG.6,-Z  P.$IGQ'8&PP#UFL
MX?=7C14H;PM(8M5-2AO,LQ07WO3\<*VJ%24[-Z\0Y1@4\JF6"J_L,:]DE1>+
MJ'4ZGK=7/:% T7\*LZJL^K![=S ?ZT'G1CW\#=*LFR2<_I?A^;3AJ*?*HN&4
M;X]*687A_)ZXIBN,DSQ=1_N5A)OZ3^@/]R'Z*'VLIP0EZ88EWBGI(F;N.*2+
M95YJX:+[/SC;*/DC*%*^,!\.%=0 (0<0O6:J64*2MB^;S_6E%UFU_& :1=(G
M'\FC$\,S)X$>SG #PX1$Z$WB& <+8(5]MMM_4NCPR6<G]H9RM6I@R* ?K#^W
M(L]SQ%;+:%RW^C#5N%S0,]5]W+ZD?@4ZP9U'.)35'2Z.CDO*<#H?'B],%V_9
M!)1M1I'S2T2"S:-6Q]#5JNF)Z'[/\S&\G6 6KJ)XDV/](<K2P6T7><IF(JZ&
M&X ^LZ8B#6JT 2$N:N2,T<)1!J.4N:,F-Z4\2-7QE$UTV2:JZOI0)&(N2U)/
M3D5,&)65035H[/E$^F&%XAOI,=OR5@RI"PO7V"KZ"*-U[&P?<?RRM@?#[+Z-
M/1AFLL J,U_[T*[71$@X575?[C 5;Y3O</&E#+:T\FT<>9F;+IP )A=^XJS7
M,5P[*?0>=GL&)C%TQ(T03:0,6AUZ.&:@L.B<:5041 "A AIDP,,.[ D!3&D$
M-\EZH53I38U"4 P\NX-)AG3??#7?POPE8W(9Q7,_F(3>1R?)&<')'O+SN@^3
MLP,6AG*:Z.3,[/L)C9R+A;E+K26:!6+AW#H \.K'7-TR4'DY5D@&9U)9P/C)
M=]%BUF6:L/LV9IHP66"_"R) Q8$310/;$>U"4BIM%/YX>_C@]DL6P72^*C:%
M0<(<>*1,^^ XO+!\<(TF6/F5AL8(LJZ+B+'AB.L:OWJX#+WGH3;J3G)&7S=T
M<=-_1\V?Y90?G:-?KZ-X-XJP+UD$"."QM0TJW<CEQ[M![A6:?9NN"U GSH)6
M_DTRF@APJC0:UU*M4:F7*ZX\0T6G=W ;Q3CY8\T_=+8K_CCL,RQQ#DS>MLJS
M)Z#"BL]!U5G=17F$M5CYQ;A>:$F#A/Y42VXJ>]2\8=,9:K<5(FD2OP+\2 "V
M[DD?TXXJ(VF**NV>GD'+"Q0.IH$25YN_,97F3F>^:)L:LZ?,U?(R]\^B]XCC
M66;AGL(T27VT"@8[DXA0-.L4%."H/TC'I#$EA-[(JB<X3ZJI5>Y@@ ]RMTZ<
M#E.X@D+ \*&DS0'SFH9\",B71XQ$L59\PRP9-5V\U&&JQ2^Q,MK);IPB_1C<
M*07886"#G0&1LQ-:N)F3$%RU^XG.BN)V5_9\$Z60I%''3T/V9(;:\X3)FMWX
M1-F2QN%X@H-E!5[78E+3HZFF!269/\G>?Q]&#PF,">%9N,W0L06/W@_\XNA,
MFI/</,/6?-+-IN$->*AQ,)9(GL$SSQ-EMTZ *;QQRE;HG6PU8^(P28NT%<'M
MP&1U)QXC##2V$_",RV 0$4YE*72.WUCZ:]E<0"="HK$>CVHJ-=*)RH,R$IGH
MPM")_>@^3+;018=O*)$-J2N^E-FWN?A2%@M,GVW^_0@*TG1*I@HNY8Y15\ZL
MP5YI,\G82U#1^7*[E1!K3/DKN^3&SDRAZ6WW0?H@Y;15QMT)-/H2^:1&\/B9
M-_6L]$Z]'0*XK_,H?$)[^X W@RPJQM]64MGHA,F8?-<= CM4$*SAJD=-9.BL
M\EN&-,[T:<C:%FPZAC/.L_A@7HF4WP/2@%WCS,I=<9?T&A?$W*$K%43&#WO1
ML9?D J\*.#HA?F.^\5,2BR2]\\CV:2X1B"1G[.)G12^->J$X5KG6T<B.LHJ"
MKO8YE:GKD9=CGC["N-;W4!LAFXY9K<;DHQ\&_Y'7.[%[7N^495W'\2="U:G=
MF3PC867/(/^#-2W.6CAD@JU!6#1Y[!MB "PO-F[ W,C'F/*E![ZDDL"HSG$/
M57V6)6B-)LG$_2WS$_*BF_PSAL,LE&YZAD\QG0RQSC-%.U!K> 3*IN/(8R<L
MW#I*Q29$^<1#+E[F*Y(A8)B:SFT"AB'5YH!E!Y";/!SN11)(C"$BARV>1NP6
M?83JQV"'!'/C[O*BXDND$Q/'Q> ;9K_N)FAT]^UDAW4^=HJHZM$ 2%R4C:U1
M; *TY]C4D'UJ/&FD^N:#&L-)5TQ2W:F9E%VY^![IPD_2V'_(\O=QY25C=5##
M[X);=*7.N!W7A?WH&ZPVVHM1$:1^^_[EZ;L*JK93&FC#1GEAV7_^5#*(D5/Z
M] L^@<#D!LK?3G$[,!FUPF.$ 2_2!)1MC@!J-:8G'R*RJ;1?Y_!5/2[X?!J%
MZ/0Y7]5IW$1AE&?98*;2[V^^RY V::/),,;%WG>ST(TV\/L#$([I6DQ%_HWS
M@>Q<]?!@Y+.Y=+Y,LO0QBOV!7GLPR9C$((L)9H0>_AR@[T'58"0^MRZIU='$
M';7JD:#J5.'1)*NMV8!-*@^=2."_<+1@\7<(HA:AR1ZPZCY7]5G=R+ARAKR*
M J'2LJ)%:)R( &@$)5^D)$A5)LS!JVJ4Z68;1#L(SV (5[["U3NW Y.ZA<<(
M Q]E$U"V&9F6$1%.I6HZQZ^J;RY0=R'TBG[Q30XZ ;I!A!\R#*5WQ&B:3=TD
MPI(PT$83VBXEW69HF>A\:,[WX44N"7<E%Y$T3=!^.WD+$0W48@U9CP^J)WSQ
M_@G?MFKU@U4UP!M/2PUT#U[[JA$0"+Z*PZD;8)R0FKP=TMA_@>\)G+(YE@AJ
M_X,]3P=S)!0Y<,>LVW3JE,&YL_53)R"'6L]/T2)-\IB7%'HL,11M *PU F[9
MRNZBX(VG)8SNP9M?%&4J"0IOR-P+,@^_&2I7\ZVSPTMY$GKH-W$&O=(-PQ0=
MZ1WX(7!I0O0+"O@#IU1]VYP(">ER<C)Y*T3'XIK3,U%M3&B<?_.KN6"^K/&8
ME[W%&S!A5P. )AO<#JM?MX)25408_=;#4?%>2?!9 JK_Y#%!I4LN QR@.K%5
MY_@\2E(60B[J"$#;0I+^8.-^B\IS2S#T0>F_ )>>773T>=V]!CW.7-O8?6FC
MZ)SS_5"-ZTL**V^^BEE_(S+K;\8SZV^_BEE_*S+K;\<SZ^^^BEE_)S+K[T8R
MZ\M'&$-GE<)89>YQA:ZBN45#B3VF3DD<#G\$.^TR0F9^MS!2_!E_.5B7 V:Q
M6P3[\5J:_5F29 X:&N8FP3Y>_NP?@0>XBF*(SPK9)LNS_SD;G)KV]R(U=+E8
M_*)G(IGD!U 8U@GJ(L-_!6&4@L!')WS411H=@0"NG>#H_V_O6W_CQI%]_Q4"
M!SA(@,Z><>:U@_/)=N(<7R2Q83N[6,R'"[F;;6NG+7DEM1/O7W]9?$B45'RH
MN\U2SAU@=I/8),4JONKY*Z.:Y,7=@FVAMN_7*E?_>JQR_7/05BI^!U%."NE7
M?8-4MAUQ$EU]![]GLOH!,??/U8]>?5S4=O![)JL?$+?_7/WHU<=%?@>_9[+Z
M ;'_S]6/7GU<]7#P>R:K'ZM^#-:65N :$1'%^%_GP_A(!>3/LQ>W!?RZCX_S
M!)O!!!S4U]DFJYXA;,B$[(>]KZ:S3F2H62T'$2O2C8(ZQZGB8[Q4.@-E(GB3
M.G)A,+7=EVJ&JQ._(N2^\O??Q SR6CMF9%;?FE<*A+M>5KFL$>Y<DJZSO-0:
MJ_M"W*/M +3VM2@:QRL5SYGD9T<YS@ X]ZZ0&>"R\,3S#?_6G&S*Y1_.!1,O
MD'C^5FWTDHHY:>M7/,IAF'@CC?,2@H3,1PBEE"#%R/)%\2A],,1Y(5Y+7C?&
M;WK#JX>PT)CK7IUC6OS[X2]$T;U.0D;+X*8V^55W7@"N5RDN754QTG.Q=2T4
M[W5'8G:/IH]PVT$BA7,= /1O2HD(?@6-7,R^N1>W##0 7F]$)R%/LR?H1LKO
MX?1'S,;I(Y" /Y;%'9PK$,YC3,]27A?:B=9\A +SRIC_7PLUA3_DVP?YGB.:
MT$(M4G'W!NX?V6*H' TUHP(**I@ &=&D+%;6/\4(@C8(15HPF,\=1$+"+E!X
M6Q""!^]PMA%=A*CW%_;^F_I8&^VUX9EXI\K;3:XJIM:TTL9P-9!]@RT7_;X)
M&JW_W#<)]\W8\(TO%_V^"9J[_]PW"??-V&2.+Q?]O@D:RO_<-PGWS=C8CB\7
M_;X)F-C_W#=)]\W85X O%_&^"<<H06O6+KH5E423B.^AP,MQ)!HI*=,_Y47^
ML)53N>;54[Z$_),G7HEM[]4"=3_%_%KU%*=#]53Z(:DZ&*)KM"AQC$B]/)]Y
M<UF52\Y7]9D@SOAR+M:0)%06$L[(IZ@7O!%7J!H ,B&V526N0>!3=Y%"(H4<
MC=4PW%\(#U ,N:.5B^<1P:7VF7^UZD-792'^NE3HM)_+YA^\.5Z5CU"-55H[
M(^W"[P(&8?$P-9G8SW!#EF(/?.VUZ4U"7)Q9PQZR9Y8_/&9+>9$R\8N\>5:X
M=C5;YX7@)SQYE:G&WKZQ3O_JO\0:-++DLC'+R8&_/?(E-"DK,:5F*\94GZ7=
M='LL$;(;]UYPBFVZ!6CTB_7[;WRY;?(G<7K$VO'*F82E.L"Z<M-%_$/UH15X
MG*2,E\I/='*+M\1VNN@$1Q?O%>[5;"3,X;1'?,;I(MCECMPWIUO!F51(Y[IV
MD##BN9?4]%ZT*_[$BRT'7-JZVPE3T^T?E9L$0@D@4QA4,GA&X%<UWVS@=<O:
M1N*),7)I7HBG2RAU\AT2(@%_AM\N+=1XJS6IV!KBTVB=XQB;6FR]RN_NFYM2
M YV+V4@<?M<BR]8@J>CV"R9ZL!JZT!TTG(0Q_SV4IN9ZL"""JQ["A0R.J*T0
MBK]SH(NOCI4&]#=>>\ 8Y*#L%D;M'ZJL^S2[?58KJMMIOSC+9/6*4DT 9(DV
M0N6KG@++M%+Y)"=!&-7PTOP=;:XT"TKP$.]+F)K^Q;:IFZQ8B7O_^.ZNXN+N
MX^<0,E?4^5(Z>@.!&F)/?KW/E_=,ZL7B!^LLKY0O&UX*&1"Z>89G16K&8GLJ
M15IO4PY!HDJ!7F\WFV>]0]O=7';S(WU44G'[X/MWVC)3!$W(Z=^&*;SU4NB]
M6-]([C![?';<OUCM=OHC3'YEP?1W%DQ]:<$ZQ4WVJLD>V,.P#M]S!UJ1Y!J@
MM%7IB4CKH]CS:IF<6T1>3.;&6>H^ZJFES%-P4S)>L0#1%.\3,J5E5M_[3*U9
M&_Q7XVL" \QL16!*4>O1$4]QR\(EGRE0?_"=R*KU"MW_0 93B*!],A]I78H;
M^ [+Y(=('_!H^D=K.9%S!$=-&H>NQ>]YK>HS.G'#), L5T=,F<!4-]*E&4T?
MMWZ-"4RM'-Y\+6_NRRV4*;T&FT'#>0'0F'ZFBUZLT=U8;?JQ1]&(E.U^:D9K
M$$-\\L?>FM3-Y+5HQJM N 8WL=Q'"$U>9GW-P0D*^/?R(A1_,3_320@]P;$P
M.+*U/,ANR#$UA*H.( =>R+^WO]"#+_J2/*RE^<!"76O$$.![,LA>_8/R/&T-
M8HUY=UF5:UY#A?IL<\9Y?:H,!1ZL7@DE:'=CT$^LNNI)78K$3Q>V>#&<2 IW
M+??$9T&JD$GU[O%[RG1;<P(IR_DA<\=X[B3QP%(#QF:E RSO^6J[494#5WP,
MW?QNRR'8XCJ_*Z27OVA.MT+O>>!5OTHUJK/JP=G%FLGA68MQW7V B2\P^ 2S
MOL':C["/+4HYG07C$$P:JU^'8WWBI]7LVK8HD2H.86W@(]\9;;LQ71WCE>[Y
M>@XG%B?*=WA];$A<'^");\1LA/2UO"_*37GW+-U6 86K[<:Z?DQU9+^KKL15
MCP*$X:)(!"]2%@<) 8!C1\:@G]N=6-N+[#X\*/!Y\C.BQ-$S&>RFP#*TB/.A
M*FOG6R:AADW((3M5,>FR!R;R$8KS+L)\\KJ?&2EJ+$%5S^LE+[(J+\_*B@N!
MJ/'?6J;5^(I*R'SWM&UVAXA+J_%\YLVI$#>%G/^4K_CJY/E+#7#@%^85.UXV
M^9.JHWH+4#A+IQ8$Y1=A*&;& A_5*QB.Y<5KUH[(NB'9[V90XB=E.A>P [0K
M+]/K4>:H.YQE;?G<YX#FJZ2XUMCA\E:*6[$=$=6)J22\J7QP"GZ[,32Q<4,:
M8>RMATD9JA5Z,BD,%[TYHX8*A*H$^G*[^FTI5D@ :Y<9M/ANI5$%J+T/9<_>
M">EZDS(_2!MZ'.(8DG;KCTR15GUP<6M/,N^*]I2::8"4*$,L1CV%U<!9=,2:
MH/_I:4U(EU9I%V./M4:A%2^BB76^+_&<2KR.QQM9K)&O\*BO@*46#6'JGLW%
MR'A+9#Z/(A)]G2:P)^V5:-\![=T<DO&M3O8KA<OQ%"OEI0I;H @V))0F=%S_
M%7]0B7R7O%J7U8-,;)R0/Z&'6;!V(&:-Q+JA9,R]'HSR49M(-[:0.[$N9<%H
M.__[4]9L*[GIKOACF[-S6>7%,G_,-L>0&?X/GE5G^9-SD6&\-S @@Q$73(_Y
M;* 5H#^# 6C?OEW)1@_K7BQ,_#+N' 9]EN65#' 6PMKV047D7>7U'V<5YP:I
M[TJ\*2\8/PQ38'(.S)J$N$_$-!C,@YF),)@)J9;RXGS&=F*BQ4UQ/TW#(,94
MV;8S4[V9W1U[81(+!RFPF9,:'1R&1F6X/Z31MAWQ.S+:>K@PP6@;Y&52HZV8
M3=YP&<<K+@FQ@#DH@5*7UPK\6\PI(GN]D=U8UV\NE@P_4=A:Q; AZ;H,\NL,
MM(#*8[ RF,0SD"]=UZ<9A.E11LDZS!IIP>18M"=O$MG80N[ MZ3KV@$BYRN/
M?; 5@J#=0H."P6VIW=P2ULPT6J N,-J%'-")+17*"A(GO32$W63?M-%$!XL&
M;;?*4 @67-V1O=)=7Y/*K7ZR?'9<'R.2KLP5E]59+K.J>?;[YW5+)IN2.NG=
M<\>M"CB%R<.2;>NOC! ,QR3W#.,+%7,YIXAD%TFH'37$@926')DJ=U]N5KRJ
MW_]KFS?/(3%;M5JPXT:I#])5T91P')SF4PI5VDD8J@,'V)#8WB)T,_%UA:=_
M7@AY_DY\(9Q=UO8!O!C3"XET)%@.'T78@H0YD/;:PI.RE9!WO&WNRPH$I"^
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MAP#&-%N,;'VPW4N\61++47UL<S%K"]W$0CK'Q*L!IKO<@7U@EU%1,7*4=Y1
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M5Q(NE+3!*Y.*OUR+:D/,=FNVZ(4R)"9Y#B>&4F#0"1S.4 =J0Q^K839 #=,
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M76^5,-,3/O)"L#C-ZOO+JGS*5P##_Z6&?)96G3T&:F3I(B=\)8?B!?4],V.
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MRX*="C^'7X8R<S<!V3AT<?Z\(7Y(0BZ'.;>EP6D<"*LZ"T.B)D2E<2#-RDW
M^!J,=C=\*^ ;^$*HSD:8UVNUO:_U>U#Y\M%7E&N-.IBU;R"!R]7YQMD)7>93
MYS\)8K*7G0J'W8, 0GCB^%_.R(.26/>_"VG:6&(UN6Y<4>>!>C2BB89SOWE-
MH[6RG5,8!FY_RW8H?W5%'$6A5C^!8^8N8NZ7DJNAM(G5OP*4ZBWAMC16V@;R
M7P7;DA+;F"\518-5^P;2**0NZKWSK*8IQ5^'9...K,0ZN/3%*33QKY3TI/X5
MJ)YXP@7EQPSN((L3LN,JNXO2;Z&V[W/^NVQ'R D_SR^IFAVJ?0,JP?@A)'_$
M7!SG6U7#6/O&PG97\'I/=LF?E$Q0R]>PJ*FXZ_=BJP5T_[/QH'1Q[YRJ\UG]
M!&['4?%'U?G4& ULCVAS4'4X[QP%3OYEKU5'#1J_!(.RTUM59U5U*"A0<W]6
MG</*%U",5)Q#=7Z:/P2UGC4_4<-2RKZ%PBWS'=4Y*G\ Z,A4'4@-$39_";8^
M"^ZDCM&H?@075ZTYE!H*)?L62J'$O<4B]@A;IL:2!87CY">^QN* +)SHPJ'!
MSXX7$^8[U\P/B,LW*[X*3YR0IH IS0:,&&28=,^4)#YW%I-EP-8%Y^<T#B.N
M+8')S$V) !Z?^_+R;I 9OX.UZGMVN,5)%_L5"\,;[G:Q]9KYR?6%@3@[1X,S
M(WN:93]7C]_*M_!F1-FYU>-;?5@[6B/U?(WFTCJ6C97>Z!/K:D[3$';05O.+
M-;<<M3&M["S"@^92=PE99!:0[W/^XH;O:B[=.-XM5^Y=$K,UF)CNX!8LTI[6
M349)'!NNF..'\S@2&1$B=<1HI2B/:V%6R1'CE(71WMPD/ZDZ8WI34AT4WC)?
MQ!'WKQ)J.9RWA)L>[G-]]OF)A;M:IR(1PA/TF\Y9>A/M3\Z&(9RY$=WR<UG"
M D<_.;'--P)W88[-#(O*D!;T<[984$'%\0K:,WM@<00T,?WQ;8AL?QPHD/P8
M\*WS<R@.!9[C?N&_S.F%&3L!=?D_?&(+XOU"HT?.["^$KAXCLIAMN9JMQ 86
MKY/?-5)L^_Q8V83X'K&(W>C.X9R=T=!9K0*R$A<*#[N/A*T"9_-(W5E '#.7
M1F=L:SZ:C(E/SN\LR/[]E/]H9>8]&U&PL/*3?2,]=U0#*7H3:AO(RLDEB[)P
MH+8T--M!98-8631[8AD\9W2YY"=4<7+ET(D?NES\_-]%VFN<_-%\0GHTX#V$
MXEF<DV*^V+2YDL3!&>$<!0D3J?=OIFXF!.S8"DE@37,ZDD$@LU5J*8)G)'*H
M6I:K_&/ ?5KI<E"#:;T!X2;2G#BHP7C[ %"K519-4^>S8P0X1/>Q)@WF:M\,
ME>6GP:/*,) HEN,N6F V?VHAFT['*E4^ 5S"W3EQ.NM9?32X5*[R.5B#6\F7
M<$Y<[6I3QZ9+/P9,4:Q<*^I@)_D4-'%W?[^HM8!K7PV0BZ;!8-<0D-:[FFFF
MP:;L4WTP!8F0TTA>9X7$_<N*;=\N"'TK.!9_2%A/V'89/]W7N:M]F7"X8&XL
M3 JW.N*K V.;@(3\YXG[=L7Y*'%(GB/B+\@BYU$,9?)"*_%-.#&/N:7Q/?%T
MC07Y\)[S0+R?7L?AFY7C;'[;OT&:+R^HST>CCG?#0IJ&B<(HX,K0@M[2"1^2
M!V[9>"F$Q(O"_"<'++5(OC6;3KI'6F*\,GAFEBORG05E?IW S=G@?RP)M_Y"
M,/N-MYOD!=L;]Y%Z>[T01TDSN45,#A +N#W_Z?4[\3Z43R,]P%VEH$K93'B,
M^#Y DM\\:+JAO/(;0)MBJ]+8*QB"\)JUM"ZF&B[(TA+'HEGM=#2+3IT@V'&W
M)8FH DM/C6;N@F#*4Z+%1;$J @@F9J,E63M5<F\JFQOTRFPC=7 [1B[4=L R
M6;[OOV1-A+D_BB=/2D"%5QIZ(NNO#$<FF@\HRZR<##/+[I%+,P$6F K%XMXP
M9D$JH9?)]QN W=)(Q 6>KIGO6A%J,PU,YT9#L8L2E8#58RMDD>/UEF$I3CBK
M/BH&7I\MI":S&[8#EHGSKSB[83F^=BON[^?+SV$:685>F*VT4,^.RK+LP"L3
MYK=(IY&/C"V>J.<!"VX_[&26W &(3"+?X2RO"^K3B%R)W,7JK06\M>P@-A5'
MI@NS3*+?C\"'L>.52IW0"0BOQ>G\ 6<)YA5%+ 30)A$QZW7>KCJ,)@(H7#-R
MYZ=^9V8IQJE,%MDNFH:MU6&%B[?T5@"[8>T60I@K57<!2*1L,_1M)E?FK^Y)
ML!99#TD(=T.%N1".\?S!HZLT-\O.'JE'&WF)=R^ DLCU8,76@O*)*)_JSI)K
MU$YL4G+N @[;;%=>ELWV+\OJT[1T":)"&=LSUI.Y%J9@P7B@7=OZ;HTN3 .5
M;]^L\:.U!9X.063[_E<#+=0 'Y /U@0A[G6FFK> XGVA+V<EW==WO>!\+D!_
MR]YU6B>]R8E9 4*H10UFLH<PU:BG9&6][C3-D)MN3_G9D]HQ1#1ZN;@@WE'A
MT8.P]_G3"!=>=&V4<%.%3 .0K=BA)A(-%F-NCRI/3J(*0>3>F4.FJY3Y"7=6
M\FFKP^/*3L>8UI'!=$T/E35N'+JX]#/_N< D=*"HFR#RDP0=8:K !Q@4-)'P
MK7AAY)/%N1/XW-J',]>-UW'R6.J,+*E+H2VL L$)25@%/KBHGY&$[X.D8.4N
MF5BJ>C9LKI3,A*0IA\I@L_PQE:&?%E[I98:;&DE8=GO08P!ZDFM"J$<>)NR9
ML?%$-7!R!/J1Q/!$*<&N1UIF6;;BZ>K;ZMO5?Q_N26NUD=_+"]>R$\SAF0<)
MK45BBF](D!2MM7=BD%*<:%J1$IC8.0<%)A..PED</;* _GE88/"2KE'"MI&]
M!5S'#NQX 2+5RS",[4LTHX+OP0#),T<--WV@QE:AM*UMB19)'8U82_C!O>,#
M.B.F/-H_)&9T)KJYM@ ']PP,QTNM]F\V#D!4!K+DC\JH]'!*LIXT%UQ3Q&6(
M&$[4Q<W;/W"*7BQ6KTC+Y_\3-2'!@V7Z'&#&NCM$78Z<&8 +YZ::[8 AMP_B
M)5IR+"7!EKHDO&,>O$<C)301Z;9!A9M>]3$0#5 "M@2/;!='QA13MYJ6'E86
M\8!*LS"SMB'ADQ2U8\ZX;?!8\J(Z>V(/;E?;:*%&K+5,:"MB4,<%HX 4=RN$
M\?87GYS@"Q&)!'8DV4)H(J:R#2K<4\%'XI/ \432]&)-?2KF$-$ML2/)+FH3
M$6<G:",I#W'H>P\JQ?KXN$$U11UN3"8]0 26?MA+9(<&;K:$5J PE4VP$1VH
MZR'C:@+7S&=EQNP8S0YBR%$5'3%VH&90]4-R =\KBB'4*S^R4C_F?!YZ%IR0
M)0M(H13R^3.?+F><^DZPN^08)"G-XK#+DBW_TN<6G81V(B%V.)W()FQ56#W*
ME0#D%52;L&2EHJWH4)T*=O!=6P<:@(*K7F(FP5(K5F"YE<>>D+0JH&0R^A'K
M&4&E\=EUO'X@P7Q9N[@1K9Y=8!GJT9[.%J^):1XF1 KVYAF=>8Z$#4DWT\#<
M8XWTOBAD"6S8^262>9U13_0ILWV?K4L=]\C<?TG+8<T7-5H-C*I^9JQ:7M@Y
M%>P-V7 9M"WP/8"P=?L'N>Y.)E#*++WGPWQ@P3>O3;>-0B+!@(_65&@:[X3[
MX;/.@W9X+_7R-.>1JP1)3F^V^#P0P%[,6JI63I8O"]3\0M;K:X[WK*1<'YIM
MSIZI-1$VTAI'IYO2$FN463-0$"+LF13XB8C-Q%XF8#;^2')TV_15DO67 X3M
M"TM>)5J17SNM<:PY55%VX(:::5U]AVA%F!(B$UN1,J@ GVE"Y>!:D:*<SEAR
M<%4EV8(8;N)$90)G;,TU#OJ(V4AC%$4J5.4G@:F0(#&*Z73[9(5#A[D5V3MB
M+R^$-054._,IO@PV\, V)*!LP2D'$50!E)?'-)TR5'HZ8^!X04GSZ[G14Y-7
M\V6>@4W<DN"!@12/2M_0G<4!5YF;1.S)"]CDW^:;)"7@_)D$+@W!@\'Z],=Q
M+NHVJWJ@8A:<DK";6A-$)6AC8"SNN(D>M )KD $+F\LU6_P>AVFANWLF.=;G
MMY=D(1Q4XH<)]L49W1+N3H0T(MD3BW3FM\1E*S\9$3R6,@S7T]AC!I,A8 <X
M(-?^MW?#./<CUX!F8,S;PZ7>X+G?KU93FZ\*+KA.WW[D(NP"RSS5LE&8@[^A
M%DW0+SSV]+KOM>9\F0]5:Q &?XE<)]4OVU&,=Q.P+>4@GNP^A^)M^3YM?^9&
M=)N6>K(S,0,&QN)YM4B]<MS2AACL$NKEO-PF2G/M[SY/&\BN=IX&\)^%L^2[
MU",E+N\9[JJWPB+JC@JC2G9$A_ND_XQPFBYU+)RY2D/C7G3:7'1%#2FCB9ZL
ML&9!1/],N)DOJ^V#H8U&.S%DMV H!>B"''>QE[G+BC7Y*U'TPJXZ5$AA>Q8X
MVE#%&[/&1)DST>'IC(9)N[>;@*QIO+:J#DWTODZ=:$0>-=C?&/:#/B\W$_DZ
M? 09PL U[_0KECC4%Y.<^W>.1^9+/DT^L6AWXSEI6DI2(0=8$Q2)?BW&054&
M!G%UZ2U0GSH-+I^RW>(,10JH1\BA5* 16O/ /$#$B4]0) N2,Y+^MS"E[*[(
M7EE*5<*X6P=,>$$'9TS?L<YGWBF8+PM"MQ9>.BF11*ZOH;E&VB7?A*A!. &\
MC$N%S4M_RX%A 7R'P'9:V 660&5= M$@0" 3,HR(^:EDXU#1D2EA)=N29OXB
MV:BLA)(,F3@JI5"#W6 ;L*LM"7=9N_>!=*.!Y#'M!$V(PG74 ML)\@WKQMF)
MW4K4#'3=(.:DK/7_-63BJ,R$&NS8H05U_Q@M?P&_;D@/O=#!%ZS[%Z0F"!<H
MQ,QH:6/@.#):6B%&?7_+;5>>BNK^$=. E*)>W*39"CYJ$!YE?$%AU1050P=G
MR+.FD4X$S"5DD92@; B%VE0*#<K886D@O=#!&M52J,\7;=<X"DNA@W./2&3O
M<M$2/O<7[5C>1!L#Q^%-M$(,5@VB[\XAWE:);K'I/;O%C:)""#/^8+XF9'M"
M%47LM+8B;U?4)R%79<X!>!UG.1WD-0POX@J,<%EJA@5Y-IFK:F7AUH:?_G*M
M(X8<&2XR9'.-RND<Q1IM@1$N!MSGS)ZJ6[Y#V$@D;:,T2E];UPRW(0GYVEM'
MS&6F\@3%BFBIZ[J)O-[S_R4R$S_Y3?;M2 _+BN*2(@*7BM4[3C) *89N>M,6
MLP:NJ#E9ZK-$._$>A776P1FJMXW1RWG.I/@_$:G;.AY)4H?XM*B;O:2>^8OR
M#PJ_F19NJ%Y!G3]G783Y'QX=?T5NN;4Z7RX)>!1E8.8G%H$96K0]7A_T[]?7
M:[)C4LMQE%\<0L7ZI!<T%9$S#!KTF@-\<9&^NO.U&*A"I1*#E(1ZI1)#[2EF
MW9>Z)UJZ..BFA^U'ZVJ! H)@'K-YUEK>L5"4NH)/1RN-CNQF*&MT8]^_'"'4
M4B=YVTC!"G?$P>55'GV:\JH@A'L]GW.?7Q/[B_U!*2EC9>L65IGNE)PR#31[
MG#Q[5!4X38X.^X*!B;HN:!1S:+D"\P.&."E+$U2;>ZA+8HI I+#O!'37AU '
M*)11+'G.O"1Z:DM- ,CAEBOJHR@06$-M(T97AZ+-WGSY.4R+ILP?TI8CEWX>
MK+A@P3ZS^4J$,_)<=^BZ_7TXF9[^@. /V AFJ)J3)W$H;E;#0W_SU^9'C"NZ
MIM'A]472H,/Q=_,@^X<;)XA\/M-'NMG3#5:.GQ4$$>^[]FQ8\I:LL&CL,CIB
M)YLO"^ #^X9U M@G:YLZ4G(@&["%\@(&ZS(:K]=.L&/+.[KRZ9*Z(B$YW;]$
MO73F45?<O?2HD58;S%9113DATU(];9#<<Z!/^/=?@*>A2!1[C76+M5221Q%)
MN,S'P0HJ<S? \6L!YEY1]EEM/$M+IH-8O[N"^L#"5?98R&VFK<6C3A<S4*$F
MX^H-@"*>P,G#@RRB^\!9D(:*'.:[SF&04&089*^[[:RB=EJFCML5<_SPFD7<
M/B;H9(4)"L3L+R<S'K"W)B79%U>7(=13<_7R,BB[UZ9EB;+O#VA8JTLEIV3\
MXK%A4%OKII44]O)0$&/Y!J0--L#=9JAED!5^R6-Q3K;:RQ5 S)_5%@<O5Y.Q
MNPOI4.YQQ5O'RM8B:J.$F[]A(.3:1;X,PDDNJ,)C9J?PF%E<F/9ZA=;\1IH/
M:VT-*9 T3R1O'MO^=J1%&C6NKB/S2C:Y!K@37&.U0O>F&]0%]6E$KNA67#B4
MQ[2WKA2)]LH\*@\[A(_731'Y.EQ/UI6TEVXX(2^\!UE$E7M9IWXOVSO,W5HG
M+-_S_86X/[3J#?9FQS1LH4+8_N(TY0*[B0J0$I7:(9@*9'JQ^!/'_Y(\SC9?
MQGE&A]7PAH1(CQ93#P-XD3(JV/&,=I&5FT=)<)J@0WC*DCLT(GJ8[M>QN(AB
MZS5-J^B;]O4L#"'N'')";LE0V+J1TJ+=XX)*A8ZU6RH]XJA752:Z4&VBJP/T
M%*^ORLE:QNLN_=I64E)Y<%/WKC+5^?**A"$+[*\9#<*XP<%F*9;B?QH83G$Y
M-#1LAVPP+R[JK+69;B5FOMTD+:E* W-C>.A3M2\<:BNG2)<\MD^G)O5:TR\M
MA"<7OK@E6^+'Q#RW*!O UA93&]XT/ST=1U0&$?Z"&.H7&CV>QF'$UB2PM4B4
MR2('"612+)>U4H5PBAM,<H&6Q^SR2R;CR\Q\()L/D6LT#)=&_H:1Y2Y$^I!1
MW'BD%*Q>QJH1QG6_6D7:])Q:!<K);16%9\;&BV,_Q@#I/G)*/=)]:H/:NPIJ
M(87M2BF(L?&!^K$$RN[(2GA^E_Z2!>NT$VR/TT@ZV"W9B![#_LK6.41&QO38
M7AW0_II0H8A=)ZI#F*7CA0J T[LQN26>DSV(VMT'CA_RZ6</],P\]^;AK!TX
M.L@9;QZRD>VO&QW*V%N+JKC+)Q,-9">XW9RO-Q[;$7)"?+*D/1)UBKW+D_I.
M$0U(.:7)WAV,,N4>*3L5,A7@1":7M7B8%FG4A#@#+:C<OFA@/+4'#7?Q0TC^
MB/EPY]O]JSLC]Z@RD"VW3D;&V*VK#&C-F9/2P7;A.@17<N'D8$W/<:N_HCW9
M)7_:&2^""3_4/G%"&LZ7E8$S0&PM"D6BV$Z:WD-M521!5PS0\V*[XE:CB1O\
MU).U(HJH%>\*;S#MBK>%$&;^C9Y$V]""*AS4Z^FE71E*R:"Z\'HBE$/5HVPX
M1,\HZ1,;NS)5)CN.U&U%*:N#B=U97.0F$9)F*MF5=!NE*6VKK8CU: [>?S/]
MR-CBB7H>5[CJ Q^[HM4@/"5)Z^")TLSF9\>+$_CFRROFKY*78 KREA3_5!]M
M_!Z3!C(XM7_SZ5PX-!#,DD_<H,1I[&^(TZTZW?$+VP#+3.@_8'C+I\QWB4C:
M$D#>TO!+VI%0_ D\#BZG-"5#W(I8)LH?D<ZO22(>/YBQE4\%>[:/L5WTIA6/
M4L OCT\ W1(JBSA+$U,5K613[1YE&@)30",7%$K1ZWU>D^T0A(3,I$(0,JAR
M"4)4GS9_1Y$D]!=O-M/6D8D7+K8![LLE-YO9?0CP59@!!]/QD(SPS;6B?V3*
M1"7.G<#GLQ.-^!+N[:[O+FK3$74G;KE8^X>>3,3Z.23SY7D8T;43@?=8K0P^
M(=M<A2474O^ DJ%%OB9/A1D$S.=_=).353C$,56;_#2\*7-T<X6 Z &GHP\M
MG%ZSZ%<2S19L(Q+_NI5"XBGWHS!^P]P3P5SP '&J 1.X5)H/W"<7FH8IR1/,
M:M%!)?G_2LM'?U3=K5N' M<<DC3* >?],/(T3+V!M,TS,CS0N.3)[H3X[B-G
M_\OLF8)WA^XBAQ.A-%Z=K0'+&I0 ,@82<L[7&5L[U+<NY HYW#"TJLJWR[:*
M8"%YKD\LQ.$:EL5'KTGTB:P?2  LGF8:N 6)]"4B00HUL:W>[<** *5DD%\U
MZ M1#AA@2[R);2>&'I<Y8%[?<,'^"C:];,\N8A=S_YKY 1'E+#GC21*R]8MM
M#0XP#%XO;[KQUEL'<N"R(/J;F_M(%K$GJF.5C,5\F9H+\?\ON"?-K)6#,>%@
MTGIB!#G8'MI33^;+:CQ;:+0[\Q=GU(LCLD@ L*TKNEP@Y:R"JXPV^A/L8KM/
MS-Z'H_JEPD^SB=)!XOOALX+4 RVP#K+(6>":O974T9S:TUR5)DN'A?32:ZEQ
M@F>9G$]9R,=U-C1R//HG663DRW2'* #>DQWDUC*]FC;UE\7TEK"\K5.O*YFO
MI;'3X$^B1K/2@)LX3;LB3/5I2-]M[T@[.!U\H19: SF9ZAQ@AL+-VSL983W9
M(AGR?D\0F05??<>G@S*IL##0"C9@91P/B$%[/_43S?06?-X JM>ZGF0+J(.D
M]_.WO\@:2&'GW*@W@VI'#-;/["G.2Y]/([;;(:*;(.J9PE2NS= !WUI@-!DJ
MG"+,RCJ,O]=0,HR(MU@U9S(JV):LNX^0%!_ 2)-AO9"RLN8^QNZ3$\4!_Z]E
M@>IS@'F,4Q&T :: -FZP=/!:UY]>CMR1M([:[V?-C_,2PND+O7#F1G1K>WT!
M,(2YW Q:2P%(8"SY-$IS\!?)7V<;SJE+LR2]U6,4SIZ<8#$^)3/B%S>QV+(6
MFDD0:LN 4M"L:5O"<W%Z^^(]LS",U^G/!M?&'LQANY8PRM='.F#Y/\,URDBR
MQXMW-WWJP4RH!=\Y!RKP'2_O'1>>[#X2M@J<S2-U9P'W1:TNO3Z<H$8L--OT
MZ<.,'*(ZHZ&S6@5DE2>)%E:(M0P4)9JX.[N*W!6Q@WR@@M*8L>]5]^3Z,Q[V
M24E[P;RWX##>BA83J-92N6VC*<*33!S9-W'LNY FWLOQ('1QXF&^".>+G-F,
M5";RK*O-0&M+GQ/4!:;9!K(7XN,)=IPOET0<=LF>\ULG2HK4^2[UTH/Q4"]#
M]%E!3V8W5!D3U,<1>\BS?#G+:1+4S$=(7M'C8JI:HHDU8/\*I+ZS_2XSIMIY
M]A YJ@Q=0.9DE_WC  $\+2ZPVYOI=*@U!7IZ:5[Y5-DR-1PL*-B-_'VS$^T?
M/C/?J;]U3M[2Z_L8A92ZA/:\B?;L0'ONSVJTF]>NK/81)$$KE:C.2.10+X23
MBA(L.*S!E3XH[W:'5_FW.=4TR[/,Q%5SV2SHH@@]>4,JS&1A9:H7V8!?!%@5
MH/:\G>SV?_P')0&7P./NBFR)9Z'8ER+1<5=IL64(&ZMY=$@'77L*/3;".J=6
MBHGIT4;V[?2665<;DQ:(:]7&>HGUTM_$49CP]]Y*Q:HV2K@W.P 2:T(/-E$/
M1+(?!I/LAR.4[ <+A<F@)/O-8)+]Y@@E^TU%LG"].+]N7P;F1 10UL[XDCJ;
M@<4KZ@H%U,LD*T?9HF8T8HI]K=3<+WL6G3I!L./32A !%KT:35P;V[( NMN-
MU^ SE_*6! ^L;UW6@B+;>AW50.&X5W,CINB5 Q]9$-V38'W"@H ]B>)UT)<.
M#110!=VBV^4F4 W(@!G?X2\)[@-G0>KE@\]B(N I>$'[W,O]Y8#9S8"<X(6$
MH.&-0 ]"??;!:O7FAJA]_XVOF8AQ"E%M/%NA]!9"*.5A ;6RM<K]2V\*_-X4
M:BMT^$84+_T-$/L;@&S9$ ORGG\VS%K<4YKP,CR@!5*NWTB&V490X\[*6NRB
M-K)56=7FDCB[@$-9FF$0_?;)^9T%APU><37R+PL2Y'\[2$\R*/+E6O?*DX%A
M'MGU3$^D(L/:\7>SIE4E.0)4/D$Y5;:KD\"X.C&D%VL9&R?Z^)Y, M\3:S>)
MHURY*B>Z# F#UL7]LA]J/-V00/S 69'WMMV>(BGL%^;=I^U62990FW)^JF'H
MZ9UV7:^7X-,8@T]]P)+$IRR(I12@>HE0O42HQKW-CR="]=+#$;J'(][=_DNX
MZB5<]1*N>@E7C4->+^&JEW#52[C**KZG^OB>3@+?4VOIYZ.TC$!G;/.(H8W+
MTJ\L; @:)QDBLEA+-46)+EZ3**V^<<5"T7F7&X U\Y,*G87G[28*66WG:RD5
M5DK&="&5$ %FMCPV=H2]2T+%55!!Q4#M?TQ5SR=1WT=)OQ!1AY@L9GP)\55X
M'8N]*BLK&\[C*!2M)K.L8A=8@GJTD7<^'0%K@FKN>$GLGDD]NO3=JN,5C%8X
MBZ* /L114OJ'U4L-!X'CK]+WKL"J < 0YH%?1UD@L$=^V2C1]ZS9?$WMAS$C
M4NJX43T .R+'U3S\ /)8Y["K">]0%"!CXA%C3!99LY2T%C[_APT+'4_,I.E7
M^/[(/4_GF4.46$B;+L\@+$]HZQI&A&"G.Q!OVH9OTTP#<T\:<G$6-4J"-O*[
MPBI7F4VUK 4Y%>S3REAT88\ZJ L\_,G_TM_R05FPR\_Y9KMG-HB]MN&-),S]
MOOUPM\[3)X>;9NIX\">!)AJXAE0NI_)6VH@.]M7ZGJU?6/#ETK\)F$O @S,2
M(KBNM[;@*@AAUD3>\R0ZQ(?<[GQD;&%-:F4B$Y-:!2' 0L6]3+I%4SX6"37J
M9J.,$CQZ6$(6.1YJ)O%-0#8.7>0M,O@!/"F[D7>$3RHW'(+^1@U],D!$1]GP
MU-E0/F7Z)UEDE&<9Q934  W2^W'38\,J0YTA##R]9AJ87@:0^(NK3P(D:$*_
M6;FFP\TB])96&_[(9%J'#RZ-H_]B+<]HB*7;3!$Y "?3<?GBE  'MV/B[)FB
M-U2TN_$<7X2L1=FI35+]OE]]E]*XL\*XAB]INL<#:88C)6/C"8TR6?-H@'3@
M*TNE710((K^@4=;,YLX171H"\M("5M;6\O15*&*W!]%<VF7SKP#H".4MF+-2
M/%R%(K*\-1:!DJB+6):KA)N([)/CQTMN8F)1%/#"$9V^HIV5IQ=ME' C$X82
M:H4.,PIX$O.IBA9"ZTW MFGVAQ61MA#"/$ 9RK,--L#4&;/S[W))7;*?B!5I
M-M.8H" E8 &6_S;-%^?N7.P* )/[@A5'U,[";"6%?:UL*-5V^%!? ESQ8ZH5
M.18&GJ874T0F$]&W Z<?BB<XMR(+$N@AXF$L3--H<HJH( 'RY-=,%.J+1448
MR':M4<%*>#>\3=0.G28OR:A/U_$:#+WR>$@6IA6^RHQQHM;I([YG6.A+XXT2
M^O*,X3S@2=E,G; ER+-NT+C+YY L8^^*+J$#Q2H4Q^JQU +-2G(N0HE[%RIE
M\6, _WZN@]AQR3@#$/=N=.:Z\3KVG(@LS@@G[]($4?YGCR30^HO96O2(_C/Y
MN70RP(H QM9(8WVM&@,G$X-M=/^,<R7H]SNI2CF#3SUK)37:&(29X2@FJIG$
METK7[AB)Z1'W BEW??JDI!W<J^IXAC?LTF%,M?\PM,A!C,@5W9)%\^1MW:MW
M$C;>-UI&KBDU5 =)%9*X_5.Z5+'Y2KU;/= Z-<LY.]FEE68\)U0NN@4C[!IE
M;/.NO]!+'2YU,,:[;6]A\\#DM;.V<_.N2QVYHZS^LE'4B&:H^U_,GXG6M=S=
M6-P3]]%G'EOM;L4[;SL71EW4,$/=/677"23N<2\OB71+O/2YY"/=6+H4;*$T
MZ=79"B%RT8MK)A[1;DA$9JN 6,S%:"$TX<7;!A_<??[Q^2GUJ'2O:SY@]\1&
MH+*3W&A-7&O(H1M%U(9Q+>P58F;%V-AP8I<Q@!RSMJ )4J@-7!O(:&,+R_#Q
MQ@YBQR?U8M#1P+HW%4@9..Z8EPR]<79BCW/\!?])$)/]@]E"0<Q>O1XR K,]
M@4)3[?PQKIT7L28<&)X8*Z22HJQV'M.U4<+=9GL(O*GE12.4J!MNA;/B<W*[
M0BY1.D8AEZ$$"PH8"EE,AS/&1_3NG6=BZ55L"R',0R.<@*4P8M;[R/D*V)*$
M(8?5\2Z(;1%+B"&[1<"2EB&*G?J?OM)6F"NP\-7I'L%RUP 9ZK5 C]6?%M>S
M;]L;Z!S5FF_"$?"E@>UC!]YQ _V2UHX;UPYVIAG?3;&8U!EYB)(J<V21-=D@
M"WYDO@FH[]*-X]V235KU.S3L(W&(1C>1FC62,DSM,2"@?P=SXOA?!*$S$CG4
M"\V15)D;&+$>_6K54:W%G,#E=C62!"!S519&!DZ%8/)$#%,)'J++Y/&D8.B6
M+,AZDZ2IDH"RA854(06"*"57H U".<V@&V2LI+%VWJRD!RF1Q*VRIKHHU*4,
MF?W31F?NV^E9K$H5M86Q#<$5 $4-_+5S>?_$$,1^H'IT8B\ "I8F9$'L7,P8
MZ[U(]]@L=0E3P.@@O/0O6!P@"+] %CE<9$/\15!QN\QT\,D=40SA'\@>H_ +
MH,)%"G6$W\[?'7W6Z'*L.M:$-F]E>'I$\_H8[@[^R);X< (LC#:=35@#H4R&
MW\-<Q4P\F- SE >0ZFOXJ#CA4W2)N@S#V/'=; ; NU8+H:D$&6N!U\K[8BF0
MX&VOM<5\F,1\F2L_L( ;22"Y(.#2;<8/,MXP>*7V#("LVVPH9G7%'+_8;K3W
M7902%>,:[CIC0QWQ;+PP;Z*@&X[0Q,7T#DES<%S+;J1]\K/(RV70:"Z#%-;F
MR_W.R_W.R_W.$0CNY7[GY7[GY7[GY7[GY7[GY7[GY7[GY7[GY7YGQ+<#+_<[
M4Y>@O?L=Q4!6_)"DZVM(J?+)A%93=;(9X#^ +1IT!%JNR70#E4@W9%?,7]V3
M8"WF]<D1'</$JY3BA<!^(I?^-7F.[I^(QW<QYD>/T/&X?KQ,(!K;>@G34Q*X
ME=^UF/^5. $_ &-J3\X"3KD -+79(P]767 @=1&G9G2%29A ;\D[O,:DX&,6
M)M#F69RSL?4EX0'K+2NJQJ3H8]<VT&>;G\_1E4;P\'4J38(^7%#,NM+,EIPD
MOMZ4V?B*W. *_C@1M2:^+>K"D7FLN)&T+)'QE(51*%!7CYK5OISJLI/@8! ;
M@RC/V<3-7XVE\M>CDLI?C0)HMJ3RK;%4OCTJJ7R[E\J/(Y#*=\92^>ZHI/+=
M(<*A$Q"3B:6W7+XWELOWB5S^_C_?O'GUW[]\^OG;__??_^5NXN=?_6]_7/SY
M_7;UZ\[_?!8_??P^^/'[__CP^^?[7>A]OW7_?.?],WH;W9%__OG]-U^>W[M7
MT;M_75Q\N/N/M]OGD]-?WVT7=\'#KQ]V_YC_L2#_]A#]</WHA[]_^?1TZ?_R
MYQ?J_/K/=?#QY+]^G%W_X^&/Z^_^PUWLKK]_&WGLWW[XDT;NR;_FFW\M/CZ<
M?/KC\?V%M[U[]_,OH7_V=!']Y^?__->#N_FW']YN?W^DO\3_>/[N[.GSY7_=
M?PE/9A=73['SQQ/Y\>Z?W_[X0[C^3_+XR\]GV_NK^^__"*Y/[_[QGLV^]6Z^
M=W[_Y^SVUY.__N?''Z/+3?C^\\_>]7H[?UK_<.L%T4D\/[MS'N\7 ?OC(_W7
M=_^X^';VTT__[]7IW>V;-T>DQ=\?M!BB3G8_+7XD 7&$PVVFRH?/C\;.%!#)
MQ031/-$PF2,E>4']/7_PA<QE5(XA7"%%,)>M3A@+; F>T3"I(2?845YXI8^F
MO-S*L\\%H1,:LB((K4-)[4/T1V-P,BF=2M[K!%Z@'. *-^JGDMJ'QR66P['D
MO4YDQ9)8U(\EM0^/2RR%<PE&:*7"C?JII/;A<8FEX&A#)"?UDLN]OJ,M^?Q8
M=O[[!D=;)]C2^Q*ZQI!(:C.33O+ET0@FQ2'/"Q@\TE*\2% .W]<^FJHTZK//
M!=$[JZ>'$-0<X]I'1R*$@S?\8= TF0H;:FYP[:,C$<+!]_W0._6DAQ#4G-[:
M1T<BA(.G^V'07A85-M1<W-I'1R*$@U_[H7=6A*D0-/U9R:?3S7J089$+IG_B
M0__'?Z=.$.Q$M9"U<.W @\8MI(XC<MR&92YGB&=& U=1NB).F ;".0I)#Z/D
M)Y?^D@7KA%9>0LFH\]2&!'P0?Y7VR;EBH:1E1V\-;*-DGN^5@V.)Z?KXN*T-
M%<152O*JPX/[0F7/_YXS6UIV((#=QTBJHZ7F9 W P(G*2%8_.P$5EL66J.KC
MXZXM)3DU@ +WBJ>7!;1E^7#?NBH)I2X,DW-_I8%7#W&$^]5L<UMJH()MZDRV
MIR:PD!_&E8UQ[I):W:GV1$9@ ^7J*]^Q#B A[UIEMGXA=/48D<5LRW^Z(K=$
M%&C+_U$<"-];E:H">>PE:RQQ%6@!US&\,N27*+=.1&Y(X!+P0[<V>6QE,%T\
MREK2B#F@Q4 XGU_$41R0DA&\)7_$E,_A,Q\PN&;^J<AE\Y(F\B5P#HTX^RMW
MH9MISL993&R?Y55(FT;'KD@8$M),:E<@9+L>ABD;F.5Z3'2C[)F98H^\_:LR
M;JGZA2;UD023+"N)C7H7]I7#1JT+;?JH9^]!]0.VNH5U];!1V4*7_+B\1;OZ
M 5O+PKIV6"A%H$O^J](.T*(5-K7#:K4*(QZP]<1T79GH2G.M"JB#IS6E0=(3
M["J/0VI&+^>T?', K@F?_446-B&+\V>7_ZJ5%!$S'H[>?,C1-W!6(=Z0M&^P
MNT%"/;NCD+L40>"::0-')&=N1+>IYI(@>B1W$7._S-,2P9[CA[U;KI4(W-<)
M&'9;4QY6/SR4#/7(/#YP>/Y'S(G4VG*JH:8T(RABQDD!=X]\_9QPG5Z<LO6&
M^&&V,@/'7Q&Q,DYVAU_)%LOLR0D65\T]VWI;$0"&<+.!=54^*4,-IG2(_> $
M&]?.FECH_%8:&BFW&-@NE+JUEI ;@0BM-'JK#(X:L&S2U2:)-/=IT\+V_HG=
M/[)8Y.3>DT01-)H)2#\>)7KRJ:+T2BNPDS22B$@?_)N&0#[V*LBA<>)@L?/C
M,L,0OA! 6XBA/;D4FN+SB>O80B,I>/XPK\WA_&80#93+T#QRN4E;\$1.$/4+
M/P#.ZM*/ NJ'U/W9\<"CG?;X1-VM1Z^J5:&:.PN-*HMO3RNI;>?/)'!I2&X"
MZHY8AUNYQ@[JC5ZIVV5N[B9(5'P4'L-O[\:KS0>?X45K5>1H'MA.-?3<[WEI
M86V#&;.6-O@-+^JJ(UCSS(X&M<6WJVV[R)CUN--W>-%I4Y&;MTUIU'"MNS$Q
MA8?N63Y(9ODS":/#+67[S1@,J:,RH%#P@[5PT=:='BLD6P<B=E=9(;I:99.)
MXPE)V9<75#_G8?4PY;Y@KV>K59 DZ;3%IBSIHS(S1[3E#B= J/[7&#YD.LN9
MOSA_WA"7__&>B1^-/<BOS/81*?3P(C?H@ 3Y\L[^1)5L\@24O<6<OR@_E$Z8
M=)Z">TIF?^(3NGWH.9F790&M'2;]K.#6!I_SFOE)_L:ILZ&1XR63#6^Y=(,M
M65RP(*VID/=Y E9G??I'Z)88",&DO1;H<ZF^R^8C_\4HO/1ODHC9QX"%HTES
M;N'PY4Y6698F3<(&=8%#K5F-:8L'Y/RKO*R%E+Q)"S; BI-]ER[?6I:$BKUE
M/]^1F>$F#E_,L+(L 5O1H5CAADE-R13KLO]BCR%TP*31'Z11%IZ\\-7)XBP.
M^ DPY3EUZ@NY\OD-3O5JK;_:ZC,P]FM<2W:BI*<&8C/(_2Y;U_LAG( N\/()
M3=+$ZC'_HN>#JPO4RS2$Q_N+!14C.EZAP\?L@<51VTM^PW?\4EJ C_J-:!A$
MB53>D.ECJS19*Y0-$KG,0*\Y4C8D>U5\QX_ZD+^/SJN^ZC?0,X#WX68MJ *Z
MY?QMR:%YTBT-OUAX[M]*"JT%E4VK4>Y/U08T3'4 ;7-98%SC^;3D4]QSI(HB
M[Y=OP[RA:L$=GP;WWU8@GD\;'U)ZI-9>,W^;7+6F*3;S97HNLW$:L< E=K?&
M?DY([?1@0X[ SZAQE;1R(DIN%,[X>?_"H8&U1*EA&$>N_30^15:0-?![ZT%O
MBM)][+"1ATG?R_M'QQ^%TF-/Z<@L.S:<X.^V1^2KV'E.:,M;.2:MMB-+T ?<
M(_=7QJN[7YV)'DS>H"^]I^JSC.<-.+C7<DR+8@1: OML_"4I=^Q)N:/29854
M7(-L&*[N#VQTV>*3.6<:<G]4$98AI0[UWGU<OLI$E1]\7D?FQH\"4[ 7^"C'
MUY_'?R'4R.*4TBZLGD>;!3B&Q_.])S6U&R!5KH_.VQY"TG /X,<62$DA.#[G
M1'=>+\Z)!5V!>QN/&UTOYVZ/W&-1Y?IE(S"0-.2[_5&I]-3<G1X3.3)3CZ0-
M@/4!QN41%5[H'(\[I#6IXSK>XN,)660 HP?J?B8%\)-I?@ZIOSKQ'/<+_V7^
M39@))J N_X=/;$&\7VCTR+&K@#0+PWB=(EEHH#JL(=C/JL#,S%]\(M$C6S"/
MK7;-K[3P5KD&QX/?V#?Q)IX,7 1$E),C7#&C6[XJQHQE([\3?=&OK]T@AE-=
M#:#>B(S";N2UX\[HEBZXD1V[IC?R>T2:WF9YK.EYLQ+ Z?EHM/QGYO%A1'?W
MJ>AYA>-IUB <G:)7]0"LA>W0P9&V2=Z38/U^+,&/;D;'7A_#FG);DCM4(^#A
M3VTW 5O$;G3G\'/9&0V=O+CSXF'WD;!5X&P>J3L+B',X@9D52) 2.JD0,JQZ
MH3^^[NGG5K2 CDGMK:\FA"K3 B)E'D&^)6',C=-\.=_PHW@>S)A3CY\./CIA
MRH<H!I[VB*8DK,)<"[D 645(SI#,(,"B$(8-2A\A*B'HZ%@81+_=<: 3HWO@
MR/%4*V#P 0J:PO]VT)+VL7'.+K!V0TB^ T$4@9)5E9DSMG:H#R%0Z=@X E52
MX+V<Y, 4#GW:1S>7Q7X4['[[?-<"<$C<OZS8]FWVRRG&V5\.$!>&0CGR*,-9
MG#/8*4(']"2^G["J4[RE_M7(U;9AFE .[G'87RM>$D#)%C-/+T'G@D-UROS$
MR1"W,:=Q&+$U"2Y]UXN3MB]A2/C_%O?.,[A'I\\!9H<2"[YQ6:D,!&(>/ZP]
M_C$X$B5+:/[@T54"QPT)7"&3E=9A1SX(;LC9DKB[H8,+E(TJK/#)^9T%V;^?
M\A^M6+ K7.^"1Q>:Z,''&%JIF)_#"U2X?.;+3&L:(@G]BP6VD>H1;Y6,:RL^
MT$D..[&KIZJ6*ARV:L?P%0Z%AYFQ/P_N2+"E+@$ZU#<.BUS_4&%MYJ? 9E1
M)&0H(''/GS$3@IW4Y6/C'7G:%+(BGB9,^AS2+V@01F=<KKXHDYV0$'9(X^S8
M/@+:<;T+TXZ) ]8*USN[SWRZ=KQ_$,>+'G5/\ W?8B7'JXA .E_ H_SX;:^Z
M$P)1,=7TKN7E! XB_5$<J_>-/Z*&E6*D&+=$[$1IIY(DT]EW2?=A&THIE*F/
MTAE340EU?*=\(D_V Z[E7-E%\@+?F,-K$AD>O',$DT&OF<_2T(B_*A&PE!FM
M2+3'PLM32;(A@?FOCHZ<C*,GP^+ZJ<$$EL5H(K2/?!%?L3"<^]P6;%A(4T,@
M['D$'61HIX6:.&@NS@X #8R?I,5@OT69SB>9IJ6%6:0P45DV@F7@X@)+,(P#
ML;O>$I=M24#!7T4W49BL!!O ,JA%"RK!@A-A8U//1L8\6I@+K(2-05%5J:!L
MN&:#NF33]7"Z0#0H!EII#,DBQZMD1PQ\,$BGQ(^[-P';TI"/W?>QI<BO9G[R
M(/8P>H;9"?')DD;B"$[]F"-ZN%6U=%SHRTV/-7@:!T(W+PC7$L=+,FIF_N**
M?^/5>+ U>Q,6<(_R0.I37,=F@@!\?-A?>VI\6E64.C7,3;G/.I*K00.BJ ?8
MC+OVZ=F1>@=-9'L *_TN?$&#?*9*(+%[=J0O(X;LMMG;!Z3H]I!]V9$S:PR:
MTLL4?1@54"2*?=]G01=4X0:,FO31BI+9&E8WE$BCAEDLJH<:[MB!F8HR#^I#
MZ-%&WE1,EE.+U5!T)HPND)L#!+W4(RU0-9 ^2(@=GU?1A:YYAR6 4T7.W+!;
M1LLN@;[TVQ=!DV"[S#Y:>:)AA#I6IU!?H#8<_]H2Q8K?9G,ZHTO.?BB@XKCL
M"U4XS\+RQ<D?T_ NH,(U6<S]KXH++-^E'LU*-%J)<P(R9FII)>-*.)L5 QHQ
M'W5W^!Z^7A(L;[CQ('@=;#01,%+$WB'.N3$0#]-(B:_RW))9D?4FLG*S:\(!
MIIM@5[V,Y &7>@-HUYI/4!92.O2H?X6V22X)^%Q_>.LSD![U8@7YS(IODCI5
M#*G NQ+OC=7FSI]=$H;\@WPG7XOJ(AA*I\/>BR)J"1,L\H*LG-DCA-%J9\[?
MU^VW:<K2O),T2'J)! 01*.!\4/"<^6YZV/$D%.>MB+=!"V?06R3%PXD=_= D
M_G6;F@:MT>F';/]T>/HHRNI>^GF,EO]"^I!$5-)-(? \]B02W(>Q,SH,':]N
M04@+K)FP/2.%IWW0W*&F5>#;.1/%[-]1&- .IF48%K_'892TB!K&V-6H'K$:
M*0,/V)[7EMU*F-[_R%\E3]?Q#G^M[!RQ2O47%7)/VZ\[+V @>R/+(3")MO?/
M'F[6V:8Y#V)(&@D?\]V,#OY]NJ*6-&7X;),[NO+IDKJ.'QTRZ=AR'@<U%ZU4
M7J1/ZEIQ1$OI(ZVD !(O]^/>!.(M:;03;4FCF9_T$-VLX;=W#<+(A7L4A-R4
MDZ>":._LVUZ1D1JG^Z#-J1,$NR4+1'<A\/JGBE11W;?>0I=!B5%94,KD/'\U
M+JJJ#"KS%LK8SEEOT;>ABIWOH,%LZ48=3Q_*;(PA/=N"8E2PQDU9:+)E^<\R
MS[1X?<C9SAS5T$;-H[[<3-Z<Z*(/EU(PM/J,1G.^(J4!O>6WI2^W7 #!EHCJ
MUS/7#6+'"Y/_<CZI\R!:M\)7Z@)C:^*G%V-I&.0*0-["U7??(3:GPIXS79&7
M-Q*=:WNK E321"071,K)N$ZQ)73Z+_NRHJ ](1G^$EWU8GR:LF^YND8KKEIC
MLK#7</MF6[X5:J,ZAJH+MHH96#0"(<R?=BV]])."Z&G&F5E1P$/CH_J8AFVX
M6@8R#-W5QKXE&Q:D!1_W1$YVV3_:Z+YEPH'I9.4$KBPUY5(BB;'J=;2SN/:-
M%&;P=D][;O.NKR=QR.$.PXRO4+4YEXZH6VFA^FL]5GE)]NUH#M]VK;+*U+MY
MZ:_@8C<O3$FJ*'1)9F5H^C3UNG-9'.CT?RY]@'MV5<:M/$F49MN?G##BOI0.
MTI5/<(V-*M35>8*WVM8S(OQ0DO;_SMAM@K^W-9$0F<CBZ((*[G[I"#9+)6=S
MG+W/SY^Q.Z\U<H!Y.M8Y.VAT7VM&&BKP95;#/HSFRX^,+8I-0>_8 1BP\O12
M0E,4=!MNF,DY'P,6BE0Q^"SHXLBH1=([-;;4[*F(!^9"$W%O/LE'SO,9-Q(>
M2W+W[+0I::>%ZRX:&]96^)"=R3OB><*J^XM/3O"%B(G9D6P+H2E:T3;<H+Q+
M(RM*?%'L3-Q1+=;4IR) )G+>[0BUB]H4)=N)(%1^D5'/J#R#+N\0"BS0^OBX
M)SY%=2YUA*I#A-HT9,]/^NQ$I#[:$EJ!PB2WRD:HD(NP6.E.>FA#.CD959J-
M]LYN,CWZG1%.U<U>?:W%'/[,4_OX/WE$_-G"05")+'+F0Y^3H1JL@)E19@K@
M;&CD>(F%7] HYAASDR%:QRQ.XNB:1;^2Z,:AX)$ 5;)350!E6 $KC R6.Y$'
MC0_O/,](Y% O?&VXLU_1-8T.29\[D6'L^+MYD/W#C1-$W'T)'^EF3SM8.?YA
M25EOK6B%15-/Z#H6T??Y<K_-YV%YX$G+Z2"O2YL*4US'+4##I2H.EO(4K]=.
ML"L];)ZYKB@?R6=VPSSJ4M)W*=<'M+0@6PAI.D-:N#0D1,GNPO6'[=% ,RL>
M="!P'D:4[U2DMD]!;>$*%)&M1+<N)O?_!N*'2'PQ$;/T ?C)[IY_;B''284B
MDIC-UVW1Q"M!"B!O4'$+SJSD/JE01%[5&FM 2<Y%+,O)4CHBNZ;<S3@+XM5=
MS&V,R'372.:1?HP:?-($6HX 7)M9P^,%<4+RR+S%Y7H3L"VQE^S31@DW_FNX
M:EJA@[IQ,XM<^:+\6.K#W]+PR\GNA/CN(]\1OEC8!CO)X4@79@OLQA(@:<G0
MKZVQEC-F9?OK)(?<'EQ1Z=N%6T6PFB%L>/_M>"3,<I^N263%O#;3P,U$T9>(
M!"F4S./*48FSY1*Z%8;"3C*LC QR2V5](<H!PR[,TS ;2V?#-DI'MA_6CH(&
M.2G06Z&U0V ;I=%M@&W>:RMD,-M>GM9;(V7%?G91&]E6V"J;+N!0]L,PB'[[
MY/S.@IP]Y7>#_,N"!/G?#M*3##K)L)D,(/-<+L]TPQ.L7#MK,E^6&%(WB1TB
MDX^-8P3;=3,73@LBYM&M?"2-F%;E$Q0'KQNQZL0 0U436]A:-TGFJ62]XN&G
M3OAX<79Y>NF',2=HI8]A,PW4C57];J^<@]((%G:)'6D@DA^+M\Z*B)(Q)&LN
MP/\ZU/V&A#JRNVLF>6V(,5\K29G]'))E[%W1Y6 Z4*"(?,<%+?@BEN;QB2T)
M'EC?9Q6,+9ZHYUVN-PX-!&\6\K@E1":YF&6 8;Z-.? R7UXQ?W5%MWR#2?*9
M_T&\Q04+/H._D%&C.4D1*\*)^5PFY>:"LYEL'F<T=#TF_ KH +&4SC0M<@MN
MR,\Q"A7<[(NU@]@T9=N%('+9VEI@+3_KVHX6[^E,4ZPMN"'5L:W?-<G.1Y)8
M3.L V-57-,74#@9RPU91YM05-4IE_=%MO!U6)#HQ.>M"BMH1=<;GLZ!>+%[4
MWA$W#I)=(2WU0A9I*9CU)D[QGB_/G<#G\Q<]%)-960EDP?"$>S%OJ#(PT@!L
MHCK8&P\1]'/\A?B/./QO'4\D[!W>=)A&76>U,2T]Z^@@UL,=:AXX[:K%Q9^X
M;\-,ID(3^<RJ)-UJ8%D!R3X=Z2*,M7,?. M2=R]Z/H@Z#"0J99^*-Z"^K=:.
M[;1T-[=V/-0?0JF,T\/ER@:^9E'24>"*.7Z!2FVC ,YDZR2+? A24C^QNI6D
M#5/PUW =>4[VLG/'>>7NGYL\WSS9%?_%0I:;!F$<2ZZQ3LOEM-0!12OG763%
M2JY; P'L@Y*^ILO$VC_QHVE4*YEM#02.1P['D%UB:&74MV>DPKCU*1WV24L^
M0R,I;&W7]:/:D^&+&)IGG%0OG TWD:1R=:,C!"S@%D*8"41]1-N&'?"[SD$.
M>9?^E@_%@EWA6&=V![X?:'_E8^E4UT;)V+':#_I+0"-RQIZ@':L& M@F3D%D
MI6OY!H@ L^>&TOA24I!32 KB2[EG;$.:;]30)])V\E:1)'0J&M>7#0L=;[#B
M&@>"XZP T-$'5 5(V)6D+>MB>3Y@J9:&'NFK_\Y&KD5TS/?Y9@=NH(V>&[L5
MY3Y+FH-3W._-5.:"^E3</&W)HCJX/7NG2-0@L"8!2#VNVSI CTA?RY1M17.5
M2&*Z\'JZ)Y9RNWBQ"ECM$Z5.=@E;IYX3VFC-)Z>#%#Y166U%"]P"%%[7O3U3
MZ1P^$2=Y6C+W;\4M>T#]U8D3TO"SSQY$AV<QMTM_$T?\GYGO4B_=4(HSLA+3
MM<8F]@&F<_4T:A"XL&HOIX&MO)4 <S>]:4FW&S[@!]1C-I9*'@-V88XJ:W9B
MD#(JZ-JMX=65HS 2U$ +\ *:+VOOUI1(CM1);16Q&I:8CQ2+!?SGR^KDH*^)
MVHDA)Y28"KD+0KAGB18.]X,>ZJ<JX2X(#5XL-B8$#M;FP/&_G)&'OD'R9 C;
M=T02(MK;6V7.ZL&@Q@_[A&<?HE/F\Z4=-O7: $2MB0JVK]2N,F+--<MI\#0M
M46!EWTOZSB6^$U &5#&I>5PLT;0MC+STC@0)'*ED+'SVPPUQZ9*2!5AA)/G8
M>(616K5P+R Y*+UB&L6Q+UA 7"?4*("JB'9E8+2"2EI(5]$ SX#3WU8N?6Y.
M8S$!"W'G!@)CM5AMF(#4>P:0D"AF9B5$+"6#>M\N5T^YP(H058V8C@ ^LN#1
M6=\Y6_$43NB.1JTWV;=C\*/D>$IGC%)Y\A.7(+DG[J///+;:";9I%$<Z;20Z
MAD ^5K8+HVOZ2-V]Q5YV*QZA CFUA[$P G4J3FQAM@"ECHVP!G.=BJ-AV:)&
M#2J!75%Q(^N=5+JD/EW':S#TRN,A68]6^"HSAG,N]4L&/\-"7QIOE-"79PQG
MGG6AOPG8(G:C>7!'@BUUH0QUX[ XQUL5J]V, D119D-YB'<&&2\:21YJ0FD8
M&R_PT*9_%>DT86+!9?_M76^G?91(MDQWA!Z[HA2Z??91RJ)[[D@.>W[:^,2"
M:.6LB- 3KB]64HJ::8Q59!W(8-83+1\-;\F"K#<"M1L24+:P'J9K)(AB!LUB
M=LV  =1HAPGB5=D;(* G(8F9'*.NX^J"AGO?WTYG[MMI!Z9*=41!61C!%0!%
M;?O6SN7]$T,0^X'JT8F] "A@NI.>Z-LYO*;-2UWBO2H/-JK8<Y<PU2&"<IKL
M;+3W7'88AKM(]]BVW!*F4!7909?P/?'!5O!AK G98F5XD"JPM_-W1Y_!Q'<8
MZVC$5X#'O+XZ1".3=C8OZ!;#\A;(3FK'U0<5KA0[X-(5/9WA%F]AM.GLHAH(
MF==JK[O HX[4-"8RFUNO_BE6*;$+ZCN^2TY9N']5!?_4H8/8"*Q42YIY69#M
MJ($]1S,1Z7G(9_QT1C8LI- 2+(\]AI0N18E50 &N5J;?<(?YJWL2K,4,#BTK
M3H@CGF)?T.?DU0SAB$:W3@3>@$>/./9^HRAA74AQLA1R'FZ<G=@30\&QDG_0
M^.'X+6;S? %#)?W=];H(@!WS@JA&+:LV> "C&P B2QU(ZF9:)5@,3QS/8]RW
MS'[$3LB-0Q=6!:O!QD2,J#G,</$3HVI]3A!1EVX<T1<FO]1.2IM^]IWTL3%9
MY"_I1/U3*UUV3+D8OQGOC3-8_SNS6H[4%TQ[*3?S. I%\4L^A;F?,/_)\?D\
M%DE*5MHBZ$\";3H,F4 /UJEJAB'&4+$;(R^<3VB^/.4$P0]*I:%QZS[J^- E
M0)#[YY7WH@O'M=,:34IF*BM/CA-4&SPSZ05TZXBN:[:/LVV4)K/R6N&";#YG
M6@S9)601BG9YEV$8BZ!7VIXZ/W&#;Y:=!*>R/%6PRP4\;.*/V);O65)E[E:
MIQ2'J'TT\I--?9(YV+TC/X:EA;@"<*^HT'*!<WCI)VH26JAEVTYN,@:R&[A<
MKH,GX&0OS\1D\A<=IXS/B;N[ZNNJ<Y#12ZH;AEQ"_:-(P%=='P,&OO0ZR8U>
MH.K Y8*%R)XQ+:>9^$L);Y>^J&D+?H!OIC'R[:\#H%QP_>,R9G*[>V1!%&5^
MT"PU%H70@94#GQK-R:Q.10AS20,DR?0XSF?^;Z*%Q6##+ C$X^+DBLA&WH$&
MZ:F<*_3PS,7?/Y@S5,5%#H,(,O/AKJCS0+VD;[MH9\[6:QHE,RNU\3#1R<)8
MHHEU3M'EE*Q7:=2CK6]BU?%3+^RH.Z;Q?4[2::XP:FTE0#;I:Z2#?"=CI)G"
M/&B+?13M?%^:.!>5P'#IHC9T?FGIK+JTQ]32^5-P$M#5H]-8K486J:A\@VPI
MS>"L31RG7M#>B8\?0O)'S*=Z+OI,WO-/+!@^&16L%0%@YZ3 (760;N#'BEV3
MTT%>CAV:W"$[T*Y"E?&M/,%IIH$9%#(7@"U3."V+TG+T *B!J*?)U[&0R'QY
M_DS<6%P.SY=+ZG*0E39J^=?(-J+S="?DT3)WJ.<59I%F-R!.2,Y(^M]+?^:Z
M05RXLB_VO0</06L1QS1#2C(V!17[^0;G3D15PQMG)WCB)_2,WX+5R6Y(^+]=
MLS3>#A[)-F9C,HIA#C1V@[=DFOG-&9_NAO"320KS(32;SV)GI_V;&0_8YV,M
M!3&$&>P!2I^+: F[O]#H\=)?T"U=Q(YWZH2/LR<G6(0?^6^(X^S^;9.E"^O>
M;.%>G6FI#YPHH![(:(7XG0V-'._\F?.^H%$<B(P+,?&H>ODMB^>W#3 ).] .
M 5)1#\D,[-Y=3,*IER(#]CY$]SFF./BR8)<5S.1P*2V<IN]0+XZ5T&^<+5SQ
M##WH$X[G#QY=)3BI'6EK'XW>DZU/$^Q9Q5 W\?,-"9('7U?B;-;_UCT=QM*U
M>F5P4Q]MQL^A\^65XT-GD14&1C;8S6(HG;X*(.!V6+XB84A(61%%^OQ\*2)^
M5M2HDR"JO>\6G@IDJ/5&FQB\)3YY<CP+3_*[J&%N)&;"+&&%7&$]+^]PP8);
M>$^W.OKH#6<-#KB"%T;GD)+>[*,AUN*2W?2PSY;=(E3 S/S(+ZM9UD>LMW3U
M&,V7G\.TS;95D59IC7PK[ #*/$K0L_QRAZX-LRJGNQ8AJWX.=YJZBYC[Y9%Y
MG//P_(^8SZ-G3_GZ@-<LLI6UW$%,?PU(X5#/2NX80I\GT4'EC/(IT8=8B'R^
M3"Q%6+AT$F4L:F1K 8 >[:WZT<=>TVHZ*=9XE_P!DE.-SO\BSF\I#:\\-I:H
MU!9>*1Q0Q@0F;=CLU1B?U0G?"J0W?B>[P^]DSGC"_6$*_N+&<WQK/:6ML(CJ
M9C6NB/)#-!M2Z=,3+^?L?+WQV(Z01.7G20EB*\F <CK()]9.V;4@9+[,@;SC
MDSCD^UH8SEQNI4*:P 9OE&54IF.>I3@!I$(#BD[\,2!VK&XW/6S'J$.9N^19
M :]B''5$E [%SU0W7,&:[:'$W6[^$C-^J@"J9+K8B81W'*=D;SSUG#"<+Y-5
M;^/EAY0.TLZD;]Y:H!JX-WW.49$1*^:L@0"V_>I4V*+(F@ ">=DA+MV9GXQK
MQ9&KCX^;TZ:'>AT<2!_.]"4.75 GV-TY'K%HYJ1TIF/FY% !=' W$MZ!#W$P
MFR\+KRSMG)V[":*>A#NUN21/!?1J-M&TRO&6FPE^@'836V'%,DJ(()M''8'(
M8()R!?L52RVT2Z*A#1/92FHZA]UVQ&#:7?>39)YE8^T)<"LI;#]11:.;Y=F$
M6X]S;NE&PF+L3Q+SFXP 0"-_O7**Q.W7K8@9JUJ_CINTPU@8,0IUTU:9-T!/
M."/4U5>'"NZE^/?PZ#?J4@GLBK(;W3.(P;+JIV#HE<=#.KZTPE>9,4X!E801
MYQD6^M)XHX2^/&.<5F9[ASJ[L;/@K):&QME/]5W3,A[FSVMZEE>S>KT]IHOI
M)OUKD@> ,WG_Q.X?62PJBMP37PP<:ER<R+]&OAZ6(=@R71QK7V HZ1X<D5Y2
M:!P#\R)+01#-\T9._]_'IU,+*?(_F"\R/FQ>93720K%$/2ZSF@$S?R+8NR)C
MA2$KNT<S#=2B62H*7$J8:8;)O!*C]/;FMW?#7&Z-X7I+%?U&D"PD*HW2A@!D
M)YLW!NOIE!9O0[+Z7DE*8"@JF8MR3X7;$8NW2IVD4;81L+1SV?U3-^)PKWPA
M&XT5ECOX=587/<S(%;@R*,"+%/0M)1$_5).(4XV=Q=$C"T3;T,\^9[(0L4Y\
MX?-G$K@T)#<!=4D2.BDV(4U^+_R%B,=?9)'UR2A]<D)6U/?Y[YXXG@#F/;0!
M&M/4$*-:\"9N3,""'<5Z;J\)>S=\Q@(&>UMIF<Q1;IL5).&><FO6@B61YNXH
M*PNK,A#&80Q4D&IP055M,]SM"KPD=8)2FU4P0?:.?A)Z1^7N*,"+7"&N>>LJ
MO)G*GDP]5)],G3]O:)#\,K=,E$%7*8+CZZ@4"E!<2 7O&I9&5D(Q71RW7$#!
MEBPN6' 1BW**N>&T9XD4Z1^/;V& O?DM8BVV99P\E08,SN+L%0W7XI3M@D^]
M]Z?![9$^ T=UPC' 'ZK,(*"^)%VX$=6EA?[Q6!<#[,W#P;VL2Y&;I%,T9S95
M::5S3,OGDS^]M$&31^@&#](V,>4ZX:.QM)*/I[_RY+CDHL+J*M95D4%6D*%B
M(L++S&V]9]Q9N?0Y;'Y(W<2DV#AXV&;YJ%R#062<*W+_!)-!3\G9' LG_DHP
M]Y:(>WO^\_S509P6U/PPEO-TCQD<G98/K0&YTN-T">D[Y6QAB^P!Q2D/<^%E
M=P8O2M]3 W*E[Q\2Q_!8Y.N\=&TW,J=%E>OCBZ4.(>I<HR%B_"A*G70;VOMG
M'P,6@N?46N#P15F[1)@KILX=P(^I8OHDLGTVE%;K:YS2F*PM(.<X;XYP5!A2
MX+EJ UQ8]'SL76(L[S-J(]S<1NZ8U*@3VESV_1L<C6.[Y7\[<R(RZK"7&L^3
M#XL/+.)<DPTN1B#"M_NBK"38\A76/.EKYF])* QQTIDRB=X5__V4A=$UBWXE
MHH<R6_DB%;(8L(9^VC,(ST>CR .).,])1>K>96V6Z?I-NNPD/Q*_!QW%&ICY
M8PI@#2WW7,UQ^IF5:V@_^7S$1[H1:>;G=_.;BK]\$P?NHY/Y3OF3G/R'T.D0
MD)P=I7Y"2"Q7OF&OR HQ7C[_Y"T7)RS^>D9"-Z#)#J!T0:\VTA&<9!0AR^79
M^_;'Q)9<)C8QJ?C*3:'C[P[:1]8T7EMZV*%,]IBL@#K6N4K@W(V<D26?QN*$
M^/P/D;!2?/+Q.O7Q/HM=U?'<V$L:98G7#\D>2=WL]\4V>OHHSD=G,;EGHF0F
M^2/FD^:''OZ;ZT_\\!X':=?[:FAG0US^UROFK\0ET2T_*<V7MR2* W_N9WQP
M(0#KXNBG>TQK8/1@[]=>_UN</HTLN(5XH'[ZOC BFT+#@13D9,+<FESN6S5P
MJ%RA&2MH6PW"TE%=TL (*5<TB)<96KJ6]*6\9QE/S3N\Q'>3?'H$SIH,E%Q*
M!A<,YMY9I8F(;&FK]4VIK<)I"ZH%FUQ66!<"[<<\\5_I6<GRT;M*^Q@4P1#U
M7$GZQ]I[/H>KU@VP]_"M1ND([+42H/D3>H@7#$.U[4T>$ MWU0])R%W@0M->
M0[-4&M%2N]YF&IK;GF3JZ@UZ6P?HD5BU+Q0V7Q9)7#.?[3M&Z[3DU5O&ZJ11
MRZ.VJIE8LNWBA>GR.OST592V8K T= D$%:.^Q&L61/1/)S74%_R8X[M)'F\8
M"2O-[;C+8A\\&*-,%KF2K8E%*+4X5H87KE+:4#O8I<__2.Z=9Q+VW[SV@PE(
M/";".Y:VL#9*VLNHCH'Z+B;[ML<&MA]2Y.%S/2.^6W>KH'%LI(6Z12DHDUBD
M4N$A]8C?\Y/YMM'.0KEC"1&<HT+'\BG?JC2#,QI96:EL+"4SCO75J*CM4@-L
MP<2'(F%$W5.QA08[*VV8FFE@EI96!U^"#UA%3N/*[MSSN>*_Y?TS#FBXH$FM
M6$M-M-JI34..G9B!5>O7D>@%X40=[R/QQ7_RNQ*-Q@FM V"7$.^63OO\H:HZ
MZM73X'HB'#).BC:VZY36TFCX$/GDU2V YNG"56"<A#?4[.B;&X2>X80]7]E!
M.;O0M^455:B,QFBT';\:Q5B%"RH:8'2]M5P2-VWTF'$GLBA$9JSO4H\F@.Z7
M79B$1: ON0PX&,56KBIW(XB1*ZF?912%24[N<^;["!@+PU,G"'9+%B0YU_"9
M6\J4)V<"M& UM^OUEB26=>":17?QP^]<S>_9H5HIGF9(^!F+EV-!7602@"LX
M;EF%1J4_4N4Y2MUI4QR(XN9&JK/?$8NLVDNUZ20W,?%WPP=8O-P\@^&:^T!.
M^%AUC6TD,LA(3<Z): <.JC0XB+F_)M"GP482D]_7$YS,RW2#/+-5.*7,HBP.
M)J(Q,1]K5_IEA(-A%T<3L]H@0H"JW?UJP/2"6^)QWA<W3A#M"CWE2KD&)EHM
M&]=2ND$G.>/E*1DY?VV6M*DI_LXP$Y.3Q]Y5505?7'WZ& -V/.RM%'L?X"PF
M@M/9<IF8#!*>QH& RZ9*=!/'#-GU5@8%;"$O6@<QN7F*?1:&!DCK*I73\1>W
M)*+INSWK:5XZE V.+!*HU+._6@?H<8:JO[P\3+CF:%A[6MM$$]?Q,M#$Y'%_
MJYPATG8A?9B37?%?+&2/:1#&$;?*NE38X!N11$HU*S)B)<FL@<!8?36Y@LN$
MVIQO9F+J-1(J*I^@)NN905F=-$K26,[$W#<!__ 5[L[33P"%N8.E>4W!,"OZ
M,0"9+B8:&=XYGA/L-%]LR[]&#E=J.8U%[6S  ?0ABZE@DCX$V?O3?D*2C(1K
M4OK*2P8/8(H)T.'E4+(E-QPW#H5^0ZU,=FK+5!]7P&[S%D(6"=F0N']9L>W;
M!:$IY05S8W&2>YLT2TNH__VM^%@T,A$T_S]02P,$%     @ M("!6-),&7KG
M.P$ HHT!  T   !I;6%G95\P,#$N:G!G[+L)5!-;MRX:1$3:"$@OQ!Z5)C8@
MBB'9BHC(QH@(2!L5E4Z,"DB$D"@(H<]6-[(!)2*=@!"53@$3( EL140(C00A
MW1:EDRI%*"'-C>><<=X;^[_OGC/>.>.]=\?[PUB# ;6J:GZSUOSF-U?-R-_+
M!;!51PZY'H(I*2G!3BE^8/(1F-//O_Y+GY\7^:]>0TG>"M-9J=2\[)VRTGK8
M,ATE91TE.1N&@,&45/YU NS?/DK+E)>KK%!=J::NH9A0OPJV3$E9>=ER9165
MY<L51Q,4QV'+=51TU^W8OT+/X[3J^LNK=]ZX5;1RPX&G;?K'>X&-N\Y<2513
M-S T,C;9M-EBR]9MMG:[[??L=7 ZZ'S(Y;#K$<\37MX^)WW]@L^>.Q\2&A8>
M%1US-99P+2[I9G(*)34M_?:=WW/NYOZ1E_^PN*2TK/Q11>6SVKKZAL;G+YK:
M66Q.1^>?KU[W<?L'!H?>#_.$(O%?'\<_?9Z8!+]^F_L^OP#]6/R)2PFF_._0
M_Z>X=!2XEBU?KKQ<]2<NI66Q/R?H+%=9MV.%[GX/U=.7]=;OO+%R]8%;14_;
MU#;L.@[HG[G2JVZPT5:X"?P)[5^0_>> )?[?0O;OP/X/7#R8IK*2XN$IZ\ P
M,-ETRR8A4GT4\F'9^P09 ]+N@1[*7$1&04&6H7M^?-HX-[(D_]KX[>&2NV%G
MS]]VW7C^FEE>7H9NQ ,Y[*9E&W-N*R%$#EONX".'K?<0T'_H$3?)86?>)LEA
M955')AXIY_U/ILEA*WV2R)^/ SVRE=%TV<&:_'38.%FH#N"EZD'&<EB;=HX<
M]N?OY'9] 7]Q=<LN.2S1S%(.NV59]O#Z7AITH,54#CN0FT(&G$K)7S<A@&2"
MO2P9J2F'"2A'Y+"_CD :\X^@;E![2MR9A#F/4R6>AOR7;/E3YD8 AD->3E@2
MU5/3ZN%0$&E?K\PJ#. 150&'SV1=TFK_Q[NZBB8<\&SI>L>0#O--8$B2;,-(
M:!,B27 3-_DL;FC&4(SGP848%E)7<K81*@(VM,J, #CKM AC2,#Y0ZH@0C1?
MG2":07?XQICM:B=9],IAH<RD]8L]@0,ES]ZU;"T/(IB;'75[\>#VUYDQR,\7
MEN#R=W\4RU;15\AA[TJ%-,FJ"9PD#8<F4,64++0ZJ7.(B2"A0ATT^3I$8R %
M;@I]:T=KN$E5?[G3T1>V_0.Y'?&0P7P$48YQ(PN"FNN!A1'\;+WOP]]>Q:U_
M_L,:_M8<):UA[):]GJF0PU@>?I)-8(L??5HLIF>AM7,%LRD2?^"+)=),LKT%
M>)F;3M*9K"4,=?)U[[ ;%M\4HH%F*+BSP:G=9YGU/MSMA=;CU^Y6A2LM;OJ/
M$=QG_+??.&(:IXVVDKU#&T)" 291#JL[H;##;HJ605M)= 'UVA87VK$KH<ZV
MW0PC$,]ZB6V?9Z"A^,<C$%-DR/846WIS6Z**)@N-P)R;8^J%X]:&.#<Y;,7!
M1@/NR>L)I_]C3!N)AR 6.,LAFZ MB*;2>Q=)JT)C^<L9JZ&03I+=@,R:X,89
MVXM;36")4(46N<(%EE39'2"S<12XT TQW:,RV41):XFH&"-41@17AUY=#$FR
MN3OV=5S\"J6_%$B,E#ZZBX'.+>%N,E1S6>1:*HN6A;;/$,,5O@)-_'O,)(&U
MH-9L$D/G,P#MZ^1KT%B#BRB2YA"70W(<T&9>NCWI8!5'OE[PZF48#'.0^9\(
M,&&"WGPM= ,<QPT7M,MAL-, _+K$!^P4G*]><H8Z?:&*!Q%RF&XTC5*HUEL"
M]*3\!513;K98BK')#K0TB><CPA*G87'/@(W$5_ARWY$^XMX:G%OII/V" 2^2
MWHMX)H=U:,6+?=H?29S%UAL.OR.M)?AWX%:A#20N?1*,]72A.;63ID$,?@PA
MV+$R\T#7DOZ9%D?Z:"B+[:>57>KX448K"1_T]O'+KK#2JAB]'J\J61>D)8<5
MN;$PT+H^Y@]=ZM_I(;K_F.JN__!9!MJM5GHCA_W=(5O^D;U\W)UA49A_X!S,
MW[V;P_7X94W//\W[IWG_-.^?YOW_W;P7<I@!Y-;>4*@/V@W04XB8R)A(H?2\
MB#?.=^:>+APC1(_DK2M4*V[P79^_5?]L]N'A('NO<Z=:3>;"QXF*E+,>GT&>
M]AUBS@W$_J*:R/S+'<B59CC 9?G5EF4U(6VXKYLA-QGGOJH<YNZ=PSVFY+SZ
M7X8J"U%_E09R.Q:R +>#D!J $%/:D9D,L^?O<H]!58\)W*-<DC&AV8F+<A6I
M2=Q!PX-/( _0GA6T&>B/S2??M #6CTR9*X,KP<<6[BE?-SC2T^KV?$<.>W;:
MDY2D6:25.,(BET-3ERE-%BX'53L<\;A<SZ=@+"?+3=!#B<0)27DKDO&1E1.=
MO[R J"'%$)^]>Y&9_NO@#@+6J:\?*IC)7?!(&'*&$7U!<1M&AQFFD"!41*W[
M>$XY(43@DHH)F4I R R\2X7=D9(#I-U0U<G^+[8YP(NF_NDYA#[DUA:$X-HF
MX-EI$6$15D'K^NM&UP^QJ;'F]><>$F;9F&%3L<N,3]AC^YE=F'8J;&R"64O/
MEFE YB-"BW24#XAQ)YL2CSX'7BZDHZVF7#HP</1JUQ).R0<(W@Y (:T\HLF'
M5Y$Q] *^Z=W\ <.YP728Y#5$6=I #)56SMBE2,M"( ^!Z:C]? S(;R,KCQ W
M@B[I,HL)NAB?-F1NR !=./=#H4[AI_8TVS_J"FA*4!!"$S+%)OGG6=?4?XL7
M7^'Z/9R-*-21EC^N=V6&8=/-5T%AUT"D(&1Z03RK3#2$@@%<H$)F52$01!\H
M=6S-G1.@2^J*1F!):%,LE-HL>0*Q-^?,[%EQA/XS[^;<_3E^C)>@]MMV?D^C
MU/#A=0QF5K9*-F!N!%%$Y$RFUF.2TB1C'_0)V"!DWI#MG$!;@60J2N\!9"'J
M815@5G%*"%.M]B9(%C_-CY)-M'+)^MYE2E\!I>!5)K$10CZ\)<@663$FAYV_
M'+12>HMA2^I:.$<^;RQ;37C;Q4'4TEF81-GV%PJ52=678/KKJ*;$M8V@-369
M9#61U,:'HS>YB(WJN_ F4YZ$@E9>IDPK[V)TPD9?PIA7_T7^4:F=PF14-&W8
M7J3:JECZP^4<3&TO *?:S29BEL4PA[LX30@.36]*#M.*1,4(1L/%[8S-6,-A
M0E=[D!)$CW\(T;!@S\T-_6=[;8AFE1.+#06BA/.[AVQ'1C2NU2.+%893DWCT
M-FSRE+!';W*1]%),TX,Z._FK2>O#>2B?':&YYBBH2"3%=8QMJG^G\K7L@<R\
M%Q]SYP&!E."\OM\F.G);A^@+[VV8WUL^__.#92^6J&J0]Y=K%VLDNX1+57E_
MA84\?]Y;-U&>[[/WVJ:[;HJRT>BV[VC>'U]=[=[];TA>_S3OG^;]T[Q_FO>_
MIWD^=;5U3QK3^SH&QU[WK?(V]3^\OK$QV3=O^$R*_F&QRO ?-X]I[-KQUYV3
M:#O%1>PYS'FK*?YB>'--_@N:B<+T A%_R2!F5FH7^$[I'S;XJO( 'TD:0U<.
M>QJR7P[C>I5&]\,\G%?_7P[O (?QC,N/^= 5+9P;C>W@75 ZY5"6I%T4MKFV
M;,+DX]OJD(?AC8M^OPX-QEU\&OL@HJ$I\#M;AS=IZ&!3K5)2ZU8V9N60 _DL
MH<,1*A+X$F[*#]XVU3,\-'\;JA9WN\P_&L*C+268IR^!\IDDP.V8^280D_:=
M3I'#&@[EF)?7C$%R6.M5V>:?^QN:*#41-?69Q,+<8*".K +AW:#8*G=K6IHM
M !\]8@DHR]0X8KXRM*N#I--?G^4Y[PC2,NO)P[D=S%7D"&JF3 <*CA=@><'S
M<6!'<B4$]P9]DC&1R&SS+5 %N/,3.U\.2R>ZQXICAR);(A%M!1F!(<*+I8]#
MQ]0SVGF8^9#D<*)W"V180U@0?YQ-$P-VG9+5F_$CNX1GY;!GDM_*;MG/K(L!
M[G+](5LY3/L[)HE^B4LH(]_PP<!/@37EXBJ^:C/1)M>=G.Y#LM]:03-,ALD2
M']$_J1YL@LC6S/9JG-"\0*B&$51ZRV$(9FB@I]B+DGQA[JJT^%3O41HH7KK*
M%\?4=<MA:A?(*TSZ\"F#0<K4CBM4RN/SD <>&//$6R1KQ,EATUF/9:\8QE#!
MT@Y"\SQQ &U,B T"^-,5X 9O*:/%76@Z:GBX@+70X*?*2G".08X8^KZXS??H
M(UGRB$>>@J7?Z_D=&AGDU/FOOI*C+YIOV4Z1]1Q@I-E>7 ^=$]%S(^X3E80.
M@@HQR@'DM@/GI;5H ^P2\I5ZF!ZISQ"G%FG'3,("LYZ0PX*6?7H(I!\%S,--
M)DD.+X'XQO:)Z"&H-%9\)3\/) 0A_UNAP\@N_3["QFE/P^D^O@GF;#-UV ^Y
M')&Z0_9&MC=C?J1 6'(5 ?S6*0J;HZ=@2YV7?% :4@;-I!2JQHL^]8JA1RX<
M"T:2R/66^[V@C2-+=WY16>WQ_]Z(^N^/<=Q:"4E:2O04(/7])3:0-9#;05Z#
MM@K+QR7*-D%3K""#.B#1C^ FX"Q03_6B]E<&X ABD0O+U-JI@V0!R-+$4Y@4
MM!DP7BQR/#++\5L>1: XU[_;X?C)7XSC>1X!WC8+Z"H03DCFT-+YNBV1 A9H
M@DPAK>2B](L(M>VRY:[6%_X"D=DAT$LQ,WEL-7#/R>]E(_"=D5%)*,2L#G?@
MA>_F>2<G:">+-.YO49XPL4P!#=G6RFT([1A\.F)55N=UHKV0OO(#U,69$!ER
MO^!;+,HF>/[A32]K*HEV9)'6[@6/OH?9$;Y"X$MIC7_06/OIWHO?G?,'?657
M@-F9*D 6,G1'1+M.LB2][72!,/'@ETZ9X:$<014><F6L_OQU(WHCJ)W.U"9>
M \VJ[3#J7=<>NH@0RPFE1'OQDB%HGI(FC*"\>.Y_#/[T$3V;N&\I7(+)^_X7
M5"Y I/-KG_;*X&.2^*=R6')O*6';B$P7G^R 2H.GH9P>TEDT<Z)+A#NV_=E8
MZ"V(TF:^%:<%R3@2EZ*'!#_AEXL&0Q60V]*QSW*87DM8&/ M$/($R0)ZIET/
MI4$.TR<:/Y0$<5$:(9ALU$I>5D-.93AO3:$2= -<H;7+ QB8+W_@+,*K$=[B
MU E<%YS.Y[X>(5<SEWI6:6Y&_QN<T\.C.D,XT8Q;:YQA>T\&S:3%7\BD+"!6
MMT05$]=Q6U1CD==;-&UFK>JJ/=FQF%7HM1+4LZ9^B?OEDBEQNVP54-V3AHJH
MY@AG@L:YK!2>:5C-"[(>B<>$SW@>)B?+E*#J):<L)X&,!LYZ*ARP2^$ '.1,
M6CUUJ\L^N<5)M +*%?>D5/)H&:)G@V>!GD3;%4-$<D79C<=-D-_&AK0:&+KC
M(>,4B)P)%+CM0R3U$?<"/=F,?5-,,XE]C)B6,J8#>44*M\1T8X7SM.()WMM2
M\8S?@HB2B38A>+:/&3UQQ[-X9V]#!6S>T?)8.B')[=U<M\W2\8BJ>.PQ:"^(
M;Z>M(9F%(G1;3/)?UMRI(8?Y!8;*UG,5_$UT%])6?3:IGJ5(/(5(O8DS$7],
MHUR$.)V)_+(;U?Z\,=Q)<FC8MU=EX0YW[V\JE?ZI6CZ$+"+L8@49#Z)"Z)_S
M\>^_DU/]I+EI$ES<4.["E?#%P0(A'DZPZ9@Z-S/PQH&X>\P$J*&4.Y\N[3Q7
MOJ+NKH1GII ?'BW-DUL>:'MVFJ\$&MDTM:E"%9!Q.W_A9HM;J.WLJL^>HSB_
MX:DX?_?5C7Z'*J2TJ##K+UD5);@S@W/Q:6>Y=J.;XT<-?>L8?<C9QS4.#Y9=
MKX0=^Y=WGZ=@JC"E5N7K6T,?:")U(0H6*$M+$)GY]P1:_KK*O0*+-[QWX<+9
MIL2Q*<\7@:]JL7T/\KY;'[_D6UTWXM^<D^V=>FB.>%E U2 > >XV"O"F8:YT
MR(4]&'P47$&Q&_A>?;>QU+;7/:HDG#R\X'V;']J4[SQO'>%2Z&O;'>M:N. \
M&(FORUB:LLQ.__IVZ%A=TY.7B?NJ+*?"IK_,E!T#/OA]8+_[L'^;N?G>A['9
MSJB=3U6KKW6V=W55N2,]@<U5J%R33M9])YE.[>5]AK3C /= 8Z':8$D.(R)O
MEKC+.JNL*O;Z)M"\H*9C[_5WJN775ZL<6W;])VQE&&P/3!NV1LGM?Z%K_I\:
M/KO$. 4_^__DYY<_^;E)P<\@7<'/UC_Y.>@G/X_"S-5_TGP[;M[J,V8QO.XG
MS:N0_RP0(I<,HA%2.S\?]W_/"8@\1$,DOZT9GV82\W$F=\8?&)G/JP>LZQM;
M9S-HM=0;:,N(!?*JL:X3 Q("2:>68,&2V4&>XN9]CFYMV 01'T9ZAU;DD)LA
M6&"<&54S[%8^T=C4DUK'+)3L%V#3_? <1WM1^4R@D,:[$"&'Z9#/X&X6FO7;
MP8>7R6'SB;>77*1%)//P(+L6D)94SUK:QK_60+V&I%K'4-4_$#HF,4EWPBDX
MMX@IVO2WJ\RZH7R#M$>3?NC:1Z$\KWFZ< )Y_IV=?S>Z;^KXN_'^Q_RC_>=Z
M9\N3O]2]LM-"^U[ GWUV=T53[:V9D)V_3%.\KV.VH-<U<F8S%/%ID:IP(MEX
M KUM4 Z+J.*_3VKGKY+$5(WT"%^@+#&97Y"F3G7 T6:QJ>/9L/FQW6!N&FIK
M]<BIX4YA5M#KGJ#^QT0GQ_OWNSK'^?6&B2T)2[&\H%&)!709C&@#(=/YPU!O
MT5'T-HD]V--FAL-!Y:#_,2CD$10EW'S'D(.$0T=QJUAX55;@24)M4&_?4FM#
M;!R%<HSPT.=Y3,;\T9X#O;92MY.#%VPCMW6>!#7>OZ)/#L8EE#:4UJ#SPJVB
MAP:11<DV]?;<::\+TW[SOMVECPSFQ_?\<F3@ 9Q#YF6T!:&ES3/(BS(]R1ZH
M7@!)M)8V$D/?E2/T2:;0)T$VG2[QA*H?$7?U*SCQCFN&*)<BL4"FGFY,$M8\
M1OG20R<2!/[[7CJQ'J$\+#\X<&::RCD$5 1(::/56_'AI.T$4R%V^NF2C>0*
MB&07]*21U5LB@0QV+&,#V&^^?%!/.)0RQTSG81)QG"&_%5G 2%!_3+>/RUUQ
M*QC^C>!GU'+R6T .=>[+L_J7&@=!FX++Q03JH;YZJ?G$3$E37\Q+-->+>S'H
M]:3&E/WSIXR4>-_"OD4>[^MP25JFH3<0</!X:'$,3#)(Z>31VWNH-"/&OG#^
M2@8F8DQ7^@@3@K@1M!:*+2,$"^2P;-FZB#B73)G9!,,QXP3D*GZ)$,YGB)X"
M/>S<WPC?6+'>"XS=3;U$PTUS8QNS6DZ8.O=W,]-EW0QU<&%Z4VPEC^C^\ZEV
M'B?NE][&A(QJ',2H_72BV/S6.1 K&*>!&D=!7+O;*Y(91&;?(FPS+@??)A*W
MT@F<.<2R20,:;Q:1OBS,),-?UJ^(N-]PZB0C G_>"32</BW&I,I60Q11I'([
M_^E0FAP6@DT-$;K<($:"=_$4F@Y>XBJ ISF<<5?@2!Y#@+&9%D"U"(IB%^HF
ML?/1216A^3&#MX0CUL<7WVJYN#]O6C*=MP)PZ9(- -EW '7NP:2Y[B!Z*_$,
M- 26P57#WTGO> -WDT!_$2Y5<EIX'^[+3<+,'V(B*/5FNQ?8<4[-V#)"XL*)
MVF:=0 YJ1P+>&:;?\R&4E\GMLB)9@2HE5PZ_O=LP/Z8?NM9[K\[!(9)QTXO0
M=Y?*XM-*UQ*_[GA5D_BSF>-)#&[1C.@NAUTO5%2\XT=:R//)_<1@8$E@V(DP
MAX([&>MJ060B&BYQ \F4FD]<%/R:5LT+(5UE*N[MG2B[^SU)?S4TI6LL65X[
MV_ \^["%\XXC6:8[:455GVB\*9F[TWRA'%9[#5+DV<H1=OWGCZN2 _A;2H_K
M5!RMB<SQK#AZ^7CRD9A=OS;</Q*5>2>SR"'&0JW#M>+ E0QWUW).WML37S^\
M+MFTY6AAX!]']9(N_VZAN<+ATKVSC\5;CJZZ=S;_\N_!&[FNM"ZXQ#%X7E$P
M/OPFA_W1+.B4P_8UB>N1T-;R&18\;2W81+SPPD02EU"3X2AE)I+6\)S0U$B;
M"EL#DY3D$*$E67-J!R?J<5# \.B4GTWQHPE[&W^7EUQQ<__Q;Z(C$95-S_9H
M/E9_XKARPW*?>;HA(9@U+(?!SQM?]+Q[SG@%?LMQ]L>]#(UM;<<+X;M:!U-V
M+0.WEU,:+&VJ4XLT=X<D5ACW<3Y"]]RWMKM[8G^P6$R];]HZ8DV:@T@E0S1F
M7GZ<H9%*B-_9(;+T?'/%B@OWL>D^G5CA_8RP1@Q/Y QT_)5WWYA+SQU_C](B
MG,C<Y$M_]UP.$U21&Q\_>F;16?WGI#%6LFTV":6H Z)GDR;WF5LN9,C4$L!F
ML<_,7D"#(W.$F."^DT,HMQ+BJ2')NN#8<BA"^#99,\Z,DBA#3.T>[ XI@38/
M\ER/RV&X_H\1N5GET7GK0W:P3.C@]]#NX"N#.V^?^6VV(6J2WS9QF["!>N\L
M_)[/]\MRV'*T'';G&*2X<XB6J$?JS5>K AE;V)=D4<*+EMM+6<;VVI<ONK'W
MAL#!H,"D+H!PP=NC\'2$:.NX45Q,:%]RV,<767MZWSQKFCQZU]ZR0QABW!\=
M7K\X9IE2FZT%8K5R>T4!0^E[X&F$6$,. _$)NG=^<X-AZG/LSM(C-3[I54=+
M/AXJO/R[%R&3BFFK-_EQ-3Y'7'&BU/G,%HO%86E2I1SV;DJ$ERP'\'+8SA/D
M4Y/,.0>H0 Y30IG*86]RHOM]ODTLJKV1P_Y^!/'>@2[59FR6PUJQ*^2P;YO^
M;3/GG_/^.>^?\_Y+\X@_EDZ&,8P&R>?QV8OV6>CUX3@UU*;'$BNP\)8(F6[B
M52\=[6'-6)SHM9E&$G&.C/S@ICM'WJU['ND6L'Z\?=36/_X',L9]VRL;.\MC
M<-<^ ^0J/S?R \FO_?7-1G;6P8?R%P[GML;EE#@P*?41HZJXOM+GSP#VN\Z*
MT+CQ@D>?>9R,YTU<NPB-48?Y+4CKD!1'[+29CXR"TR,++)+(/V[3VW$K(?)\
M.%2Z9"4;PJ@^;G%;4B/"(1<A52%%E>QP>K)^\HJY+&,%7(5P&K\ODL/4"5V_
M<K_3DF/EL%62O<"G]C'K BPP=).$()Z"R,7$BV# XDV2%5 _6"SN6NK&'05D
M>?.-TSM 3)N)?1O3Y'.A$3 [W?80BG*#^&($C @'$=,LH:.RP+X5SZOURFCE
M8;,,_2"D,/[G*_IRU^8A\T6$/D&9G>N'R&ZY5AH4\7.?U+?*#TJ>MGWI=O3=
M+YC]F+^G=^K?@'[R]^['A+[<%2"MK:<:RGH09BT:X*R(/HT5( V(YX=H;-P*
MU.'\LU>(/M#]<BCI"!1'TB)> 1>RX$DH)-#V'0<C6BAJ"ORAC,[C5.4@B,YV
M,*"(:*N<*R&*ITA#]GJWS!X\2'N67-[NBCE5L"#][0+YPCYZXF[9&O)P^A9K
MV4["LV\XO*F[((!@9V<D68VRA'=V)( N0/O2 6SF88;^\V\PU3G+_YC*2?ZD
MM^9;(7^!5'F^5PY+.3+ 0$P@5DB\Q&?[,&<3]K7&RO2X,CC4)8XFUX[65(EQ
M<-G;AOR$;GHRT2G"/A.%N1S[>")HN;W)\L(=O1(R:D>&%,,YOO^'N(K9]@=Z
M-;1Y8=ZLMO<B"4F?]@#->^:%^!M7N>Z@KLXC'G$SA1VY=%@.:[=K[%2<2V5;
M@@ZS+*>.<IEAW.0@6>=\WX;;(JUSH<J+/K*V ?+G&-!>MHQ@+X?E;?N'9\0L
MI*<BE[:,0'R.+NFU 4UMHS01SY_?_U3ZY MCY0BDR+KGMSQHA%Z)NKH36B+M
M;UP6]/<' \> QQB$\0('P=*844/O6 ]YB]\@2G!/%!*X&$3.>"MD&"K(D#KO
M\QRJ%JHQ=#"LU;U<P4W9>EQRX>HD43]SA3_K.L$/JT$U^N7)U*S@ZY@A8M4Z
MD'BU<RG<,>$7U3'RWR/995Z[2@YSHJ<Q ;TVIN35O[YC^?_F+)^Z1/]X0E'^
M5Y'L<!L\]FI#VN4=5F],O)[6/ZM3V;\257#2)SSQ-2YJ-SR+_)<[B)=F."S(
M\FNFRFI".IA?-T.-,LY]1>"Y^T3#"):R@WPU\OO:!W+81&5?4_@X4?]GX\M-
MYK3O._+<0%B@'6RUA_/_<NA_ZYF)D<,V%RUAR<,MDC Y;"!2Y+=HPK@FK6'^
MU8\)FUVRIV5A%JM;W((*7>6P#8]S99U[,;+J9\5)/W>&O15GG&GID<.\7MR0
M;.MUUI=ETU@<RRF/&#4OT8D?P@MBK=&H]]N-T)0(LA89BP$.4-<08CVDA>AM
M!+48?T^QNX9X<Y&HVG,_LD&&U(8H;>@5O=$)IPZV&EM?_([1B+A[!>4LZ[E\
MWN#RJA?UW\AY#E(U:8XUR9+435)ZIQ"?11A-YWFFD*XL"1ED:$NB .<7.ONO
M 9-R&(NI_3W>;?B>);PVW(&6^B7ZT\OG</,TD3].97+'R ?GS44?Y3!KZ3J(
M= V]C)B0,Q"]Y<S47R\PIA_[1:.H$14*6Q1R*^1RN3Y^!HV@HYS5<WY/*+/8
MQ#G!>GOEY!$/W'OFH6D998WPG* L8?K3'T(YK &BMFM.Z1W??@VI(WI2AQFT
MT:I*K1RJ_?/YE-:!Y%_MC$^<),(-!$\(?QZ@S1=N/BY[];EF@Y#.QJV4! "&
M-V6;(+A7AC] R8IVLXX_T'^F=:=?D,O=QJ;4779EQ:<=ND]7GCSBW$&K\ \\
M^:$RP/]UQLC0MTP+]=^2CUS)%.[IN'3/[_<0-<Z1G9DYW,SB+:]LI[F_+JTY
M9,XP>$FTV985@+;0\JM!Z%"JU8Y7'WBIGK-EL-C[7G_(T>IM=96>%6J;MKS5
MS? +_-W#V2/UOWL3ZOAVS=*CEUJ3ZO/\EY\2_I[B^?FUD_*?:[^Y*<+&7!W
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M2]V]8C88'SJ:GW$\]M'#]/.G?W;>C7_LF5$#ZS&1GD GFX&"0H!8X<?<C$U
MR V&KN17R$TL55#K_%V@H5Q 5H+RIT38=BPO;@K7 $742-P 6EJ,6=2!)Y"*
M$*\U.;:V$?B2)YIQZIC4&J*T. M7RE1E_1@CE.>2"T05XCMH.@2<\'[]$+LG
M.T@7"@3H_M)L3!B>POO$QJI+' ;KZP%J*M%LR8OP2>0I60EE54[*5+F1LG7A
M06: ?2+>;A\3GN7]I7T(^Z0O1NM03[_=[+ 36[9;^N LV)/-V$L\!L);(Y4Y
M&#AI.P07F T^%;R2V)<1+P$M8^L,_>Z//55(M?8146GY]6CCF18M,4(5LND1
MFPW>0&85<-2J/GM :$<DR\?,NWC)=C*6KVM%0A)RQ?8<7&8<GR7%=HSMA#8!
M3)%C3SM6G;@%PHN9>A Y$."D%)>/$C=#""'2//QIJ,P -&\6W-^\(#KT$O28
MRU+%]=>7]]4SC9Q.5[<J(3N1Z4Q#AAG11UHPA]4*E<.T_H)\03=1-8U%-@E?
M_,A/^XY(U2)70(:BD'1!'<!(/JV=(1Q=T<>2K<K:/8[3#Q];"P;P<D=FZS8"
MZ-R__*$\610X-..^M#]L00XS0EM!5D33YY 2@)A/ <I;Z?I$U&"+GCB"FHG>
M\<RAD\74DCB##<D@&I[&LT]LL8AY$('&-.6R@N ,""OZ3-Q?1CC\ZII(NGF*
MH[-?R \$J=-%(%Q4E@1HXU)Q]<P.J6$G<X5UB[W(4AHE#$DFGW]INA_$<Z1(
M5KX<1JDGI_F86%#EL!!^*O>]*_F<J$<GK(%D_*3?&F415AK@B\I?O?BQ?/X-
M%52==A1@=0B=N,&+) O)V6=0C!B7AC:&6*"A8 6MDNB8(51E(]-D^KFLA88@
M*U Y@&C?!)66E9560R[MC/4@XJ;$&,2T,Y:!-HU%U6_KA6[O8VAZ(Q'7S3$"
M#*]@/A%<40RXB>9+T%J3B-K<3CF,2K*&=@CYRJ$,-;#A#DAI73RH4&(Z<S@8
MX9L_E%,I.=I/7"=6^UZ-%<ZTC&T#(BGM6#4,98;H_62"M 54ALY'T%=%T\R8
MH0B>#;>#7'>1!JP0"TKOIBU92+8 3#9F32A9'Z4CIO_L_=,G[A=9:W#&]I)5
M(!\VPP@J$#A:"!-RF$DMR.!(O-C,GT5;W=V32CS2(6X?=""G\&6ZVL4LYE-\
MDF1')13/(6E#.:!EA[D&H)K6$@S&"EQ:X:L)M-:G1&4 P^XQ'H9NCW/9<>A&
M84_R;8GOR][J&DF(Z!K1OIQ0V\G405D(1LAZ :.0?]MD-%9M)/3%(G/:WIYJ
MFQ0%JLZG0%W!8DPJ7QVE#W3-5S1! 6A#:%\[K:[.W)B+C)XY0-;]S*.SX+J3
M?/B0Y[,AE)NPK4)B-$0R@IX0G+P:^BY*7&)B'H8ZI-Q5^LL0T^#32=?Y;&XO
M?8A&C!#78X>'A+D=& I&HV6_@ET*U<&<H0[ZZC"'::9FM!R&(#0?@8I#0"=7
M!1/;(30G:;H7X13)NAB@JL-@;.T3(.E5E-C,1LS9SA*.45O)]?8S*B(M%T$N
M9^8PT;0?$X)4+#%SB3\0S&*LZ"7JB2,MQ/ ;<ZEXV8;/#!@XW@A:>D'W'T%.
M'7I3?C36R+46+\$(_&:A+AG.@ZI/]TD\1*K FZ&@M=\CW>:UH9!K(O>C[IA.
MO@'1'J"R@]  E8,P(G7'K2@5F)(324AP-E&5LJG7[N4Q''%?/]IRXNKQ2;06
MD%+[<REB]%%V KS.Y)AYNC@(>%MD7BM*M9L:@TM3B2J"61."6T"2"-NAA1?R
M651SJ$I$;>\9EL,"!X@JR'9X"G,5*H!X<(BQ'O@V0=:>HZ<W/0L[3NCLT(5\
M6(5[H&+1[$K"4:S.KV/FP'RA+5Y#"Z8\H_[WCNM N[_W#3Q0_GO+M<^N?_SR
M'^QA^I9_'8Q J4+5AO<H$Y?17'MM;.FKH86.H1[A:.P) ,.:74$\",ZFHG8
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MO?< :FK[VT;CL2 @1J4)"+$!*B4B32G)40XB($1 Z9"#J)2($04)$!*5$HK
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M[:#[\"^5\N";,?1(,CSJ,^B3?!:UB> L1N/X#117T"D=P38/(EQ>N3B0*5Z
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M!=^4_$4H<FX"&K*9155COW=9_PP58H WJ:(PITHXYP>;$]>YBZ@@@I->RV#
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MHBEL&GEY;[YG[&#%@:A'>/V2Z<4^Y?"1O9##D4V]>PSR_O8KJPDXB-=.C.M
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M((RM['[O6'3-DN K)O%[RA90*\_?O/5&S;.\M0!655.\'5I7$U;W#*C! U[
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MD9?1LW:D--<3QUI_T])YNZ/Y!/@NRH^8V3U@GD-I@EELT!;3/27X':KD:-^
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M<>-CESN8)-H'>MXX0UA":CS&_U37\F5@;T1]ST14(,=WK>*M++BE*ORKK*E
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M+10,E%A#6<7'U]*@G1'CGG3RP<K6XF;:<C=(GQM.T[\YH2.C>US3K]@F0UU
M-KCZY#+[5V?#L[&_R59^*%YC=A[,FK0NZ+!MUNN0>1'G^&S?O<,?9M1?--$_
MR<$K.0@F7!3?P9W#A*<>AC0*O @(%>*LB1?<A!*XZ!NE24!$@ J91$1P+D97
M9?]0K0$N4EL7H]K;WUC@T*=B/>1XXYW6"8S1IXFMU>WGS^^XS<A]\NM( 2.P
MP\$S-!QUBYKV2,KJW_=1_K]_['^89_GB,S?T;=_&DY)]&P<HDGT;2_E:5X+5
M17&%!.&FCPNH^=+7<:NZ8&/'+''T%$YL]UD*S)6LD#$ T,M^W"1R3PG.^N;Q
M/AC$X3E5CI*(Q]&E_,Q+%"6+\.*X2SBQ60,F T*HRO8$M%#^,WO>?16ER<I8
M7N0"6(>MM_H)DPI(D&$O\"<R^(L,Z;SS#"2N_+6CI&L !32I/ "Z36,D8&$'
MZ$ (T]MN) 77D8ABRS>+D>G11VW"C\7#*_&2=0>@,CQ"A0N 2$0G$)!Q3@#(
M.-?8LZ< 9)QC]);7"ZC#I"[87%6B%:@2K1"W&6Y%D&/'P2"X+M@>?O0>F7C5
M9V=O_'#W#DJ3/8\H:7BP.,J1+*F2-#PXDQWI+Q"F:"F%T+?/5#C=P[3IXI#H
M=I49,LDJ:// 8D!3<JAZ"*WQ.J'??BSFVSJ/O1)0$"E(K,K)@>5]A3D2@&['
M>4BJG @^YU?I$EB$X\2Y=6"C.,X?+3[5AO,&[6&3%[/B:) P7_A@6A>9TZ\C
MI@]*FLQ$"&#5!#,^=^ F7@"3JO2A5$E%4UM?U),E[M(6\SI$4UVSZJ'LK^?+
M0^ 1VGQY(ZV)L@-!6;\4H!^'^,O]O0B@33,'6=.2#Q)ECMCVT>(?"^4_RZ](
M9$8,B(1FHI$D-,?S/1@$4!^V7*Z,1(TA./U7UENLDP39&.+8_30Q+@JG+,FK
MO,?=HZ9)ED<@?XP$EW?*@V5P'DW6_ENM6&(==<(WZS#)$NO$(]89R9VS&9:5
M(/(&"2*?EB"RYS3N!N/K;A9CS/N&I%XL":)#Z8+?)<>C_;\KFA=\5S2/(?U3
M-/\_N&B^R"5A]AIV98XKZZD/11J\EPX$P.?>CL^&3X=45D;M57R3^IG[VBSS
M:DYNM:G'JR4'%U?T[%P220@'9#M"M9F32S5VK<JK7M]R5&/)[S\K;%RJ^O.F
MT#\*!A"OXDQ2:9N,=-[RG;2[>0)OD!$Z@XMV4P4)-XP.DRJMH!C^8@QJ6(G&
M]*I6-WW")DG5/%=G$J*#KL ,7C-:!LJJ-?C\PA\)A&80<3F#,WX5>]0_C_#!
MH::;_!O4RV_C4$-UB9%&&\4ITP0YR+T&L\J92Z@[R_=L>*M=HS3S^_.V&15"
MG9LLN#P9B35+R"?:JMRY=!GO)..//<4#ZEU&RJ03 NX"ZJ=2D!5-/K*GI*E*
M?Y!1VI$5CGR/+4W6Y1/&0KC46]7[^,L3#G>-=?%C.)-Q1AL@[0:WU5#:(^=1
M5?WV\?&JD'S1$<B;;S-89Z286%.MR-=EQV!E@KCFZ+6.+L#9/@>WD<L@B>#*
M,]I),A64=I(W@LJ"2U BF,S%-!)OSA-J:2LLA#:BXY I#WWC\L!F:)27K]#3
M^FZ6H[.6?!IJ!H-<WQNI^ 9U:A6(3O"SGY7SI:C%V6? P+@$3J\KL2[I[D^8
M$%(1K^QZU490[I0X/3"SPQVZFD'6P4=?:I2_2Z3C'_5Y[?,5V"G, SW'9//9
MS(M^[GY>L]E^XO2+FZP'&I>/ALT]'A5T\C&U38'E#!\@-"FHYG/,(":*X863
MH2XF6\1SA;X&BM<F F+PJB2T(\(.T-4;]H3QM7\JY]N'NI>TZ63R/6\&WNLZ
M+UL6F^:JU3-JR&LF)0NR$(DY^4'()*S* H^,,(I6QW(U6.M)R75.2HXB?2B7
M&VL]+%H"^M8GX6[@.+M:PM.([IP/56;Y(Y35?&JTIDZ^;%ZI@ZO#J-.RB7P>
M0X7AR8HCE*G<>P3K0!8Y,$N]%BA2KT-0%=[06KV55,EA13[A:S<PHLLH4@S%
M4GM@!=:/KZ1!B%!%9&^8OZ^G'IUND4&*<"3*/3@-6A?<G1A4'0H4^I*HG+,5
M?8027,U;P\$I8Q!=QR[&A#5>-]K1Q+]:DB+S*LC .(N*E<J+D2#X*L4C4.(C
M%U)NS?.>X20;4E&M0;-OV?+>AI:">^.!7P 9P N(<F+4X]#D+= 0Z'D$^IG+
MP) UJZ'G( C9<_/8\@%B4TMP(/>QMYLA2(W9HVVT2:0'R)*&:M>1RFH5#W1[
MW2:U,97R"W+)\T",XS1MC_ C+8Y=--2HW1O7?!)0(N_H #SC.;CN>"Z B)%5
MWH2U6%=PJ,Z:E,@CU#LSEK!C>C48-U7UH%AY.I.*S/;:%R5%R?9=F:U51_/*
MHMX\@W;9GPBBS-8-[(">J]_28?1T<1FO6&M%F!9$TTYV-W(?*GE>([OR<.$5
M0Y%&.T4$Z"YV,^L1Z<@41SV&LNLH.L*O\7H^>=<CPNA%1XA61]G,;Z#)4Z^E
M.B_Z?"T$>?@>;:[1;;YZ/5L:7D96:JG>2TKFT)C*F&C,NH]\0KTA+<S)(]Z7
M:YYR";V8=*"V2X\@6[V]CT1KI&C'U*;N>GFCV:H(S J;3CZ,PU^UJ7_V-M=T
M61G-6/*RN %. 8S"+N1E\1;7@^A:0C$F!D]%7A88%7!8AJM;FAT$3KZZ<J@5
MQI!MB6M$YGPM1@36:MO\N1XHJ-9@Z[#=8V%#?8F#G:I?,:L'S>EJP$2R5<G:
M0GTHHC&14=PXMH ";W0Y@T!X]5:R9G$UA./3.*DIW%Z22)]WU92K>*MJD6<N
M:0?<U7BY]!*IZ)7"P.Z.P1=@:M$!2-L/3A LH/9"^X1&Y$OB*&UBVRO<RA)"
MSR:24' 6T@<EYUB2Y;B3$48*5":@!,LZD=[5.K/7]9!/\<NNG\-'J!Y80-V<
M,&RV(-0\@W+K#(Y @$WT:,WQ+H,S!-350_KCP1=YR4 WS!0$0D 6V9Q/')<"
M7PMY'M1,T<_\MXVU-%G2 8YEHCL"?*6C P?X.R(&:3%*3Z[T5:OQ@\*KU#-)
M_DQX75?80+9_=K^K3\7EQ"<EXUTE%!9CHU\UEKRW542N5JD"+Q<G-4:+5'CX
MY01VKT^7ZAK^ @IQ-KF1 6D^*[S+H2AZH->IL+4*GS9RP?M*W^5[4@ZMU<SL
MYDQO?U>S+"?1T4$JXD<18_1\^+6J'IAX+1"@MHKVB^^+C(6Z9+OW1AC?@67@
M;/0R^'D^"<>53Z22M8E\WP9 5J26#9%(E4P# 37' 9EH9EU^^5CCQVSO'I.T
M91GB4MH,<2P1K*QGR%3+$QKYBWM8EI+C+J* ]? !$O-HV^3I]G&L=A[9GO^N
MA+=3M#DIA3ZOD*U_<_JEN04X#F=EA6;Y&,0E!X6X:[W-X[OVH:[J&\NS^DB>
MEA6ISE%[R#\56J@='R5R6?)./^4U;C/V]<YC^BW]5?SA4?3!WR]$/EKTD\JR
M'_69A\)KM31@BL@"01OZ+<;<50*.TDG9T.:'S"EBSQG2!/D(2TI2##[K*'+E
M-M]WY$'^7%,KW9)W)5HOZXX]7?<SUOKH;H]#[@$>-O\A*\8L^<]9L6_U8*_+
M3K2Q?-[<A&>G6H#X$=EVA2NNS@".7VD,^8,9-;Y^&C:%9<'^:LM3N-X/%INT
MKH_3Q?^!O80P-0"A3L_?(4PM^R!SFH%0G,(TR=I;A.+\<IK:DZ,A2>J;GUA
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ME'I:&/OCOG<+W%^N,DUI#6BW/_#7Z9;^O<5^POR!_H$\_FD!-9A]^;8#W+^
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M5<S0OZJ8C_"Y-8H)9@L.VN+M9R(3@JT1:HD^Q3#_7,9_D_VFS<<@0% GH#_
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M<I#B8377ZBZX1?MUQ'@^^PV6Z>*SA:)F&&MFT-XR82?8&?H#;=E\?XW< @"
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MJ=O+F4-L/SIK)>*O.L=! FP[U:S!NU2OA.)L29CEQY,//9(.M&2K8@KTRXX
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MH':_H(D#IZWZ8U)?IS5K"X)"3.TW0XPDEB>7LB_UU,KM]B,J&1[U'W[N?9M
M/M!YK["M**W^QA:7(_7BMAL/"Q9VY'U)*W,^/$E81HZT?[ECS8?2D%3)IVGR
M#8[:P1O@UH)5G47+PX==5_S&\PAU>]#1W^%IVE^+O/0WS$[+[-/Y:.5?S;U&
M*-3_#)H]:<!AY-L):8 ,1H?+#BMU8M-S G% *4[L/X<(I=5'2=3,,3("\#.M
M7G7V[FPJ;(>F%,98&@RHEK!SY.-5T?17$X^4 CES.ZU<>>PK.TH[#IW@VZ-O
M ]@#Z6?N[4O[8=M;F@Q)BN$=8>IWU)8&W2C!9SDN\C;-3OWN2-)#Y_Y;H6^&
M:-;@U-(PZX"&NZ5VF)?;()8QK2C*;-\JM_"'4?;P\Z*4'GOX(Z5RW4Z[>NQG
MW])*VJUPSY& K_@MMZ\9P"GAG^3)4)D#IL]J7RQ0JN7 R(\_&;_OSX.3G?[H
MX8'=L['S9Q5_5,**/\T&GX_ ?S4.H\S^D\)S]'"B7-QC$]DB6(5#@&H>([:+
MJMEJ::XM]HL713W'KR%G.-AXW/9HI_A(DRY%)9(M#?!:/>Q[<JKQX^3->9R$
M]Z4GGSM5)&\29]#:*>O?;&<E)FTZL[K1#IG^0V[JA\^G$WBOPO(>=G/%_OLS
MPS]VIUL=V!-LVE/QSO>]H;".?#OMS&J.FD?=Z9\/OAT]7KZ\ZM&YSRM/N[7G
M^FAN*3\8L=DI3?/.\=J9GF*3]B\_W^?XX,1-C"H3A5(!F_#Z/D_X%@ZF?$WM
MAIE_,O.#C$GD#<['S&8<X(M4AF)7?SW8M U^CG,(T2U&9207G<11I6X8::-L
M?=["1BF.0%'2I.#V[\"DR<:2B#P(WU"SO[:P;^B<'Q2%+\]TRQ#@,^PVA8Z/
MEN0]"[P5]3SP[@?\D.F?5*B]<6#=KU"BU:^FOUU\H&V9&_,*K C3V7JK:&=K
M\>'M,8&',XOHW,K-[JY!FU[^6'(JFRX;6/G;LZH#Z0&6Y6<YVND=O#.KO"M.
MQ-\PVE(AOI*UZ\V:U&*351W!&F.8NZ-=!2Y_1YHD <-_Z\+_Y/#KXV%Y-ZSC
M9ZCMZ JZS ;$2)VN2('%J6+:_)&DP6SZ"0E'I\F?63<_I0V&Y,O([E,R><W^
MVZ5#K1=KDF,BK9@]DSXE<G>? S8W[9I"D*_@[?NS0>Y;LUF"5A$])="WDMF;
M7IV#'FW<EWJBS'++4=Z6.\26%RT%WJG[UBR4%+CFG5YJO"NOO2*ODO;JWKZZ
MXUX)@@F6A\':U\03X"ZVOQ_\9.^+/9*.^WJU%RT&;X;NN'[G_KN3HYV2*MR&
MD:\PT]&O^8<CU 8T\+V@UU].FGV@U*<$@CPJHI."$0F@[SF59O:;)<](E5_@
MZ]=#- EGF5?TU6[/MG!S6X*I6W?(QIJ9_<7$)Z_L[JZ;&/RNY,%.)@^KV@AP
M-$7 /;<[DFW'6(E6W!.%AXOC(DP]F5>8KDE;@H\MV?<F_\!^3==S+I47]P4G
M&XI*S>H'OVPTU?[IC.4YZ*S0@NE7,=1Z*']_FL6=X2.9QUY:K=ICX1Z\_8)K
M:Q2ZY?W?&M].X U._E[?]%>SR"L6M'L"Q?-!LVYENU!^3JA/FSP%I7&>XO^C
MXV!^Z)86*+0.RTNA++!:BN9E+<;'ZF;H\3 )C!6LL/N]P<IM[.K.DG"&+KG:
ML[MB)-I=#8,,UCTWO+5G> 4_2CU_5E81:;IE=^1YK3S!3,#5XXXW@3$BHUNP
MX_N-GDXZJ:)"\?#)]^Z:)1[9IVW;"U3QR+A0M[R.WK"$]Y<.U")?L3Q>GC\[
M;O&RZ/0NJLG6(OKK;4>)CNJK#AXI$J@L.W?ORXC;P>V%]W3N,;;WF..YTZ:3
MY7_"BH5?8Q+*Q#E$W%WQ'&)6YYF-4@-V 1,5"J=91REF>N,$7J'G.(?(3,[\
M^MECK!!P);W5EE^=_4EI#15(\+Q,W)*12[K5 -,'<,@ON*)P0>47.Q4'^YD#
MV-I%#3S]R8+81^VNSCAU M^R5=CT8_7VWO7>!U;>=E&5H?^HTI^8B<\:/;/!
M? K7A']B8LW*)ZS[-\*.!;D>R?)>13E"/.R:KZ_UH6!SW8$HR]NW*O)KE+%
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M8#761/9\V%T^X,U]::D.FW2N&HF*#R\O?92*[90Z,=AR<=-5L=G)&TK/E6>
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M9F66+@&MZOFP=I8-?W>,J2+2/UG:(I_ZLX57JOSK!33UX7GL@?[&H3S/6)'
MK8>H:>XG!2")9D?EI'V:R:@!>5CW3 #E1&-3:][;5-K+.QJO+,Q<1'$PN" J
M-M/!M ZSY0?3I<W"1KR$G:M\4:>.YRXQ-J#/HAZ#OQ%V'M.ECV_&'=X6%3GF
M>5_">C".=2!4BW'!6BR )^"M-"\!SKK'V'0VWU>_:*+E19&:3@ )$32'2/C0
M#QXAYUY(11C$4K-O"3:)B#?+6S![F>Y+L]/HY /'QQ-_0?EA!U*?]$DN]=#V
MO16NH"1R"1!'F]4YO63<J>@&B:YFY/L%2NYR\5' 0\><+^.;:6264<#.-*9H
MT6A*E/W\+^1MLA@3/9>@I=7EI\:5$5"11GK#8.%:%=-+HE6$[[D?:6G!+$>E
M[Z+UOA!%(G#%FK)0(THOM>XW1-1"&SQI4I4M'*Q1X7[3/O<5^U%O?>!DC:S
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M1.]N[/:SOJWW@^W0 S^B#*3RW5.4T,Y<%4EK%ZXT>D(*#3&;_*GA#-J(!3\
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M!<T'JI*(Z-#(4.[:!=[(-[9=W]F\,4+$Z+T=>1L*ZKUVYN[9>C[CV+"_Y>G
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M KR41CHE9?;[4X.&_@@_.PYN=4WF&*,:$7E_%N/?V/=UL*[KG!"2_(H?GNZ
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M4S+EK]M4WT^T?7)F<BD[9V0I/ZCXS$1VU,K 9_J^[C+_D>"1"_<+??PP#D@
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MO*R:I[O&()GXDCHQ-74+/2&JF!J#ULO98J\SVI1F7HO2[9-_7WJVY).9L1:
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M?NS6L(-J_N.04JT&[[SK$V;.MJ?[(RLNS;O>/S-45SXM@EU^?!T)MUN[)]Q
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M"1QG,9)H@"LC2:.PJ.@#7:HS'#QH]N:4<5U;!9M2!U>!&MDG,]2NOJQ_ =&
M[T=?(O0:_?*=SAC3G9;*1+ X(U(WO(8VDP^F\1D9J.T"[[7'J(-8!G#C.#$&
M5&:%>V$/BV!>4 Z'H1"2,SBFU5=\_T1C3!/\-*,V6.##8Z@9^5_IDK1#_O*6
MUC] BOZ/4D*+\'^6$KJ![\T%<<C]W)NNZI<K7'1+,OB^1R"*0:+C@[/II?\7
M>^\9UN2VM0O'BDJ)2%-08@64$@N(TJ(B(B)$1$!J1*0+40$)$A(%I4,6L 2E
M14%$08AT*1(@0$1$.D@00A(%:9)(>R#M>UC[?7]LUWK/]KSGV]\YW[G6CP22
M:^;)S'CF'..^Q[SGF!G.Z5YN6S$]<7J964\3+N0>J]AV,??WGIBP+TGIOL26
MFS/=-LWI\'6<,\8,W9&9[!0QZW<E.K=:<(3/RBF8P$=752@BMEWA:&J/$%)>
M<Z'=JZ$SB?2(,[WQ7,'D 6DOT\?X;7=\DW*^+3"[3;I?^;=:U<LNR+ZV,_SM
MT!OJZMTEDKV?9/5-E$I5LL@]YS7D1$,IG2N+/-=EI:#FFJ^!\XHPZ/T&QOA)
M.^D7SJ]+#W[RDF:6QND<NW.)U;7INQ#R1<G]\6A0GW-L6TEZZZ&/?@X-;\];
M.Z>.+H4CCG[@ 'FDU$+E'8_='DVU'FIF>NE[73WTB&<55%HY>:[3@I\(FAZ&
M;^GGG11"2H(X[H)7Q/N]?*3-#PI(C0Q X$L"PE;64YCM?%O$QOSE3!(+M9W\
M9>0J?LIL9:WGZ$%!"CM%<)8&6]!L(\\)MJID1?/N\M565GH$X%WX:1FK@\J3
M2Q/X6 HF4P2<"4'0)#>I?F9)VT$?1.M(OH-+^Q>R%/Y+^4?R=Z(0DO=AJ\V\
M_G_TX\)*/]S%P7Y8TS?F+SG_]?+48U8*+XV'Y,??0O!-FG<(M@@A+:Z&@J:@
M"L$C"JSXDH417@[6\_2/W4C-=)Z,BP#)8K7SNV;XEC")2>Y>$@LMV 02<&4.
M9TPP'BAX28@(X*;<A?VX/(I:,+\JA,R[/"0F BU"R-YF$0'U$9I_\@.T70>\
M<R3":!(WCY^ _]*#<(-QM8FA].6"&BVG>A9J20IKO[+A_.W*AO,J#NCVY01F
MA@O.*Q9?D>+E#5*LIA1!WYJ@W41>4)ND+WM5DV9C=,$W^@*$$)=TEA!B/?"2
M3WF(?Y>O"J)F)UOP0Y]K]'Z6VO@9;%JY2 -J0>T;8MFKM#"UAE+SGS62_K]Z
MJ"Z=X8CP9 ,7DCC6Z<O(2)P,KFVY(,QT1X.A'P,:M6^Z<&1? >F5[QZ@/$4'
ME^WQI=7UQ:<V=(CK02F[SX8'\@D3H^2/,53<;M0FC+%3?^"!-E?GG27BL4>?
MWC(J"!T9NZ'M=\H!<C96UP72/R60O?+&D"M%>!,66SPE>T2-@<V+O^E4>UA&
M>5Y/5G1=!FMV8]>%)F?+C'/'L2Y;WU]<>)BIF.[@:(1_P-Q>$0=DQ^D=&8%!
M)UT0?>C-F.Q5#=N.BFY4H4XN]6\><T DN$KG580WG=-\&O-1QJ[71?1"@P7U
MZMZ<[7H)<Q5-,\ !N>E>[@7Z!!FJ=XC3WX@2T1,?6:SLTJH4;!MJ>3HTV6#_
M^&F9%4=-5 @1/>!Y]6R @FARC\%>KZ-VY1GHW,]#]AI9:)+6>?BG$@:RP83L
M,7.?!F\B/,!)\I_,U"KQKK!%PK7X>)8L.,(OUY2'-2O".TO5[2U*N^9@.X!
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MSE&@7']]JO^(_>"KXM_VQ+;K;8ZXXIJJ^7ER=CY$_ ]5;K_@ T@2Z.O(\]<
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M+P@YJ&:_8N@O(N/NO]*P0V0$_9- ;WG=?S?5=@NC+X0H34:0OX,FR8\-XJ6
M+BAYH)_?+83,VX9M^DM.@U?3 @U1+U6F.P@?L*=R[#'!EWL3R!XPF;.^_DMS
M&QC&" F<],M[*5;]FJUA!^[;;GT&E6C9K/:!>9KP*_MF_F5ZD1Q#F+!<V6ST
M/\[R>JQY_E=:03[^SS?QCSIA4;Y_U E+:G<-R#WWQW"T'=9/^TRI&!FC]* .
ME7*K)PU'#T19ME2E2%9%'3VGJ,EOK8,NJ?G!N<J'\,M%[]M;L-=6:.T:D'U^
MT!8\&149^RIM@>JGSIKP>W'_6J>"&9L*!7%5<>!48YOT;PE< ZS"B<2M,3($
M!CW"Q>1DM(EE:X:,6Z3LELAG)S5O?-@;I?_OV#:#W0;2&W%^JH$2KHLHHK<+
M5@^5^C8L PRR;9@SH0:Z/)6WG%T)>HA@YLSJC'.J(?!+C]6UUE78I^G;???>
MYJNF\>I:K_JK BU)[UQ'1Q0M9 R5 AK3BBB-M>JN%<7* T'L?*9!"?O.)&ML
MVH@=/!(8+=@/W!&PSO7QY!@(!0=O>,"+RUZW;6A6_(2TB]V:K<&D(J_4ZQ5]
MT, <TR"9S*?^V]<P8 H\<.B&4@5#MW';^)EXS_90^EJ\._EN:D0,3_D5SYY#
MOC\/XF#YONHL &G_FK._2Y-KILV"-HDN^:+WEKXFFL68=LY5*W/6_6Z2ATDR
MZVKZ^CNJ\ZJ*T254573>D9:&N^N1'3:<54SXZDFR&$^;T]VH> C\QKL\#R(3
M-C7/=8;7JQ('E@S4)D#@3H\FBEZO03WUB&/!UQD&,X><)KH=>_TG^?:6Y<X,
MXA9,L#D2.G&(;G*$H(ZO^!9YJ/GDK4V[UB-KSW2V"B$5_)F%DA/05Y,[8&>[
MQGH+2]O@YMV%9=-& 2&W1IN;:5TA[M:..I2SCI;6J<,J7WH"9+K\"^#G[0>;
M4[]XTGP>_/:[O>U@DV*<]*H/$YD2*V??($0Q%=9=+')_S1:M<G;!UZ:F0:.L
MSYCH]^I'K,EEW4UUW?961--XQP-TF\R/CI;F7?,[O,VZ?:?5RJ:]1 6IT2J0
M0G>*DP2['V3M%>T1_F_FEK!63!^;9L4]E=IR@2FI[5%:V1MJ>V9FT-\U"D<#
MRLN*NS6Y?MJ?YD*DS+I*=^P>IAIUE4Z*^J;^.U6L%'XQDG=4".')VBQ8\A/5
M[;F6#,(4(0O?  !-;F^26P5;-DK$L.!3;7;#!SE#EX=I=CPE=HNV&.&ZGE_!
MR:WW6W>]$=SGW63!H5@=MDV,8"=0OJ39O@F0H\@OQNJ9OC2I< V_QR@X,&/;
M!U?PVYW@DSO@<-Y0)ZQD7;@?*I3./D44 <*8;?W3 2MS!HBXTHDA+SP#J(7C
M3E+<DX>/IHS@H1,5=A\+O)\AZ49)C?)E*0_VQ+5NC:!XG^UT.:V.&', X9[H
MMMR--_SU)X+*KY=\'A6UXM]KZ,I^U)-KA6^OP=U4RU[G&5PF?:"AJS2!GS+G
M*(3$^=61SZ*?/0R8.I0)P^#AFWB:C>\[DSA^U-3CA/4CG$?;JK7C& CQ<4Q4
MTR9_5%E]N]3=QMF+M[(MP$!B)0B:%X3+@,_\ZKG;H'^M%GQ#<7L1K>T*B-%4
M(:2*+)@-K0U?20:!]-AM12@82E\NQFJA]/H[Z,5P7@9^I7R/N_A*^1YK9'C^
MLMR*"EHC8"4 @M3?ZOA+H/SOQ.'?B<-_1^*0#(X&;R1P@#"%$4)DL'Y<./8:
M &7-Q!!%!#LP%(J=<C,L6M9NKUU%*'8-*WC'[3Z?PR.?!LY7];P&_)S*O.T+
MS/NXIGT:6N)';+KU$-E ],&7+W 3-C^&6 B1E<WKM?*>J(K<J1DV?4&E&QO(
MSE_(!%A<(Z 8'IE"^QBE5$Z#-E6Z=OI/(\_8(Q5HGV3*.J:O:\4=4+_85/@J
M0.&Q2VWH\=W!'G>/M2)HRB.()C3-F]$^G<29%&RT8K:OY^WES#3"Q3R'Y?DO
MT#6FG#7<C0'[YT7U%>I@DGH^(YS<;ZB-->>+48.V9=-MG;\IN*<R^ZTXM3E/
M/#N\8'T[=\:&_1:TUG]/'_GW]L@$L+_VM7#<.\%6?G09\9.A66<-- =P9XC<
M2VJVQNWNRN+LZJZ5\<))57>1OJ,N *&T[5(34(8]<MK6J4_W;-:;*HSUYPW#
MB(E:F?UB9REB16=>'9;8]&+MM6O;)7NVZ*NL/J?RZEM W&Z656W'DU[-\?DV
MC5:SGC)]>85)SP!'7?,^MYZ"N1CN]/%]WM6FZM8A"C819E5OPH_!GW>5J4Q?
M>SCEF[Q37/[??(@N8@MYI(:LJ(4$QV[1[XAUV&T+,:0H1!DZOA1^7W%'5^EL
MAO4DI370NP!3_RI;(^:PE_?ZB)'@%Y&W.,"0C)7)[%/^07X2;JTGOD1YJI]M
M,Z*16#Z*",=#Y]377*HLVQIVB6,(CF,/@.IP\D%]/\\^I,#;_.C=O>0K$!D@
MA?404:'-D_.N$XB="D#=A[&1T-6YL5I/1-)R3#GGS9Y/GNTXS\@FV(114Q?O
M:7*KSUR8-6:7V&PN_+2W$O5ME*S#0 -VS-J#S,?!P'7U.PXRB:88ON6>M$;W
M1]%(7P<G?'3&MG,:W?&7DVY=,,&[8CAH,1Q(,HQAJUX(6#KMQ>F4\>/,D'48
M:]!K1#_"?!F6_;H5\(1[_X8Q_LUY5N>2JL9U?2?MC+/=.7JG<RZ09MM)<P=7
MGJ?IV16\7OKB*2%D^*7 "1@00C3[^;U"R&*ZS)SVBO!:&?6'\)J"71%>)S'R
MED;_,B9T5/X3Q6PJ)BW)?\4O:()XTS6%.&0%PM\Q27[#'U[JKST\7XS4C@ .
M4'F/$%0B-X>^7"G8T=]]PX:7K >Z>E=%TQ69^/$1#I*7M-T(= =Z_4+(!6]8
M\Q!XZ6\6/#M<"[X>2OXR*=BYHA,'2E:"4H.7(#=_R?F_V#?%"8Q'_;AQ"+&@
M] YD.0I;\1<!\$OV^D"Y\F[T9;P8V%G<"5SR2I_QH#_]28SPS>4O8D'+R"(O
MK1!T_U6Y@L)#8S]04>0?]NZH121H/#<QU>7,?W3E!7:E*^%@5_+1]WMYK_O_
MBZU3_XHE#1Q0R5HA01=6SA#^2XZ3:,.I^ ]K _]I[4M4T-K_DK%D_$\QEE\\
MV&JI*0-\8Q*,PD4?;X(W]'J/@/&>_,7J(1C?2"N1T-=)\>=]497$=?AW:0PX
M5]8?QM>RLS%S<AXVUNP<I*C]*'_W-&[T(;NM_%A/=7FO6%O9I705M9MW-]:1
MHFLV@C\;PL_$!K-!\-7LK6_8)*]]G^R!CCU*7RV0'_36V80L=.2=(/?Q3C[U
M[-,9BHC0@FX^R9C4Y1+$Z8Z4@#RG$QWCLY\<ABD>OEU:W"MWZ_(A[^O"+ZY:
M*QFZ06^S\5K%#:0QV$+#RAT54.](IK'"DS@H1V 5>Z&5*?&8B8H[A*EHMCO+
M/AK&KEV8^(9)0P+>&D]'WKK8=6-OOO *3'5,"7O*D2ACJN\J+$04,SMG-#34
MU#W6+!_/(B?"[M%?Y_(V+[+:&W? &#,-J$'DPH-^;."+SZ=I<A'S@].PND3O
ME*)WBCNTC5>VJ4VU,.S%W2]E)"W*&SP.OIDWI.*"]F*8P/J8.^,DUY\UNK1V
M'B0R-R ?18ZM&3\A0:+$'48/3,PZ\9^!D2[S*/^AGN$SGCM@SS5JY4@ME,<8
M=I02XF 0'STS9F\YD4&?)DB0\VBHB:JSO5@SEV<8\YDF WW \H47JPZ<&1$F
M;%J3WK'A X1%Q9)7_B%[3(G65=V:;W7-J_K+9'KG6],4%+Q-YC-L_2?%=P68
MV7ECLI,L>FQ,NDK?'D*CY;T3<CW+94]9^+BCI:_ TA E1 )6RX4MQPH,$VPA
M#I#/)D*E@<EZ\BK>32X<@!L#NNQ<%IWP'-#W9*T*85<W;,&0FG7<*EE0":^^
MJOYP+2Y1 AAL7@A<5(3TS+3Q$\?OU,8]Q6KGM'*/AL34@XY#[!D0 CY7!C*@
MG[[#!T\M&@>C 1LY ]44JN*!+53NR<\?<&W:L<]ZT9H6G)=Z-Z:9QIW?2QF<
M1I@$$EV]V'^)'1A>1I8$[)NJRE-V"-Z.)!14/$!K:&C0U&59C=86GJEE_,),
MC?6IM%?+#K?&K9=K%FY-I-Y.>3%IYYL6Z.E*\KZ FNM9Q9OV/H1K1WURTGX-
M),%"$8Q3CCQM?L%7_GVULF<Q DE1HG0KQ\OE>0OWF/U._F+<L]19BOL(!=BA
MT 1GQ#Q#K&MAIR\&UT[RG_"0[&#KI 6'+K(783-/LZ=6!@ Q?:,\E#JDS<05
M,+S;(U+EFI<$(C0,H5Y>NZE5_Q03*3:>^H5V.YOI&-A0%1C#"D,F6=>R!2^?
MG0K@DM:;"R&Y5A\ [_IA>39^88G]/461"(^N,<L#*(V!2LSO/V9M.4JESG*T
M#/XTOZGW\\?ROG([-Z*O&U>1D.5991WVS/[3MRKK#.?KJP 11F0-B%XW?+_G
MS#FLBP \6Y&B@J8N05.?DY:)$,*X88^1A6]_69+$V%=>BF"HA!_K:[=#R#FU
MR5U"BM.> CW&X5>*!N?*<GFJ,01:E3B1'=_.O?I),'BG?2'3H%VY610Y\%BP
M!<6/F48%6U< $G3H]SED,7J S:GQ"1!)(D8GM50O' :I(O%-7\!6]V05GC)3
M] TK(4&CX#OVP&OSO!O[HGQY9MZWBMY\/;W ?K]JB669X+@.Y-&_D.]<.3KD
M[W9_M_N_O%V0.Q4:WX=8C9/@F0.M3/I&3#B=0A>K@3*1\EYNWC,;GKPAG.SZ
MCF9T,P]ALCPS)RVKHL6/OM^Z*Y497/UB9^@VMX0]Z"!2'1V !S8A)+U0(@;K
M<4TP\6=<X\;V01@+]H"GJOA8.M8)O1% HSJ^G-5(EAJE->5A3_7I;=B=>6%G
M)L6T/VMP-^6(X6RZ8T;M#L8KUK'[09RM#ML9=[-2-(NV96I<J/N*P1@*G,S+
M76+KFTXZMIVQ*$M#>"SK BC8-JP/FTY)-T/E?1E8W.*<SW%S.9#9'&]1]QEA
M+-.T/3#]ZB&8A!PTF8T6Y\C<>?3R#15ZH.= Y?Y3&SO!&"_!T^;<)K)AS)EI
M/Q88.KQ3%QO)@S#F6!0V",]405%>I\V(?K,;KO1!JYBAG%[W.(>84N^0&G=<
MM/R2\_;K_65-SN-$E>?H(=(_)ZL+T2/]#3,2/$G E-T]LGC_ZH\:+3:E;EB.
MK1%[[H"I?DJX9K"9DNY@0;I)R L%ZUIR1HR)7_!-_<;"'^^_#S]$WO]A1$G7
M3KKVT:FK'+H..5E&:E,[XQ+IU^R&>=PV>3%@=KO3X>P7WT<KK]%K7.?".*><
MCF!ZF<91%W+F'4JBCA&W"0I<WZ=F(U5&/J1NQ6T?P::&[PA^Y&!@55^C2\&<
MPYSSTF1W!7QKV&\9.(K_4P*^O8_<T4!N-R 7UL;39VWP0Z)"R)U<CG(<<=8,
M/X020H+J42<$+8EZJ#+D5+O:#=-;'$$'8OTU4P\Q52U*;B-:O+A>U*$-[5O\
M_D3\$3WVJ1WWDCVZ_4CMO7_-/@0//@HA7TPS\)_2CH'OF'OAU!_BW_6O;+1_
MOK*NHU8C8/QIF8#PD\53HX608X3O4K^F7_Y3J_^%1:NYK+],>IG5HWY<9N?R
M?P^""U[=& MK0OPX?U..'SF+XI]\A5?PMS#"/S7F>')!2+O6O/I-,3\/BU<O
M3PG)U\6U#Q^('?3\X9GP(1*W![O?1?=H_HOQY-%]*D6O389]?NRZ;+N6 )L7
M_]/F!QY%"/EKN@144^%+Q[82N5+7\,MQL8B7*\F7Q*,1_+@C:#XB_!<D]>2=
M"--?4=XC,I" 1@&_=Y%WN)_F[X@T_D%F!%X7=*:<29D&/0[#PO<'OEC+QQ*=
M5(1M+PW:-FOY?O8F/(7'MYD[]%?;H+^P@P5F_5#\D"7(*+?.+L$;Z4OJ)21N
MKA R4;)>YK^]5K44]-\I8%% _ 7%]TJ%B]S_]@X6'A9??_'[OBI^M4 'J?^P
M+P.<!PU%0^Z8!;2?!#V,"+7 -G=_GRF /LK;AU2:<#@SL7= !=/-5?]?+)V1
MR__-D;A@SG_T."MQ"\*]/<QCBZ'DU2*>+GO*4^60R8$@OZQ7G:L;+*0CE>*W
MW4]0+@)^J@J'7S!:X;K\1_BI89PH?J*<W1LL\L_R<1YS9:8'@#-];&6FEWOA
M;WQ%_3CP'J0Z-LGXB0HX]"=6Z-#^TZH6Z>#,)MY]<*YV?'L]+&C#;ZHQ91*A
MWK7J@#I[=H$(G&2A: H4'$B@+'H$$K8MA>.X70375\E3'0I\>Y.[U?3+^]XV
M-975UU0<VLCD!^?U)]].C<OI([ZP&T1=1MDCW8-=@M;:6*<DIUAHRAVML.[.
MI]STN2E:<Z3^L-[%QNGMT>\:-T._6BZTK!317UL%O&7W,^CW\%?0$,QZ)*W=
M%JA@/T>%I0@AZ\GN?!<&,JKF>"$-:#U_Q D3X4BL<X*:V0V\*B"I976YO^G_
MJE/V\7$A_X'/M*5US'(1 =<X*X&Z.K-G*_S>&S9D,O,N]*23W AT@+#@!K@S
MSW J0%XZ +J:P+LU=N+S;SBH>SA90(IBL/.^>3C%LBS,OJ-45_T4;7_C1?L)
MV=\<FJ2[T@BEC=VFQ_&!3U:O9.?_G0]R.NI^+'TE86;,I#8=%UD@-<  Y?[0
M- ;UP=[K[;F(QN:DR^SNJ%TV1\G7A9#[U$L Z=5E+Q77!"8;'O%LC_\%!10-
M-:C 6B!RU06M= 6!/EV_N(T]5J=3^_))_>U5Y3UZKKBB;[CU74IK9Q6+6.J6
MI[KHA;+3:=XN(K-DP08CML@%P(R[>9PHC;V<(H4]S7^A9U^ ]> H9K](4LJ_
M^63X \TX5';B2US_02\[H]\%1\L3:,:',7WC&93CT8B/;X@"6:#Z_C$G X'"
M&NL*!7<+NZ:.EMQYO3"HE<]U\^#H9*5#R4FV[H?-3I;Q'XZ@>=[0;'+7$:I=
M_B?W=*N[K;4Q@JW]*96V;L-[.QR,F,/HN\F)"X^5'VP3UTLNNZ,!W$F_.96K
M<ZOQC!;"TR,KFB\MT-HDA.@M"R&&?_P5/%K6Q;<Y"B'^</X$,>SOM-W?:;O_
M7Z3M9)80X*^ZWZ]E#Q]H9Q#OCW'(D8*M/'4@AVO"4P+<.4(($Q[N^Z7[.V\?
MVZ;QQ^1-H'B!:W%68PO5I/)-F&D).7'B:/=WZTO= <?0_H.3;W5FYT-K#_#?
M&AP"X"-@H*6B(XDEI'@AQ'-F'>\49P<1A#F;L4?8\/OJ/$^]Y$":=0E)B53@
M:7,R.\:TJ)(]MQ&-BZXXJO-AV:HWO6_QYLG#$+RV(A0@LI$C$5,(3@D#44^(
MO>.;SPE;R7-9DJ?I Z9&'7K>.9,";4[\0P9!$GN<+82$8QW]O!FVH&DKL-N8
MB'4T3*AL?U<7I0&WM\=677,I,VAG"6G*[7#3YC>TK])5\9"KJYQ;]"6,+>>U
M>*G8?< X.(ZF@'6<%,9BM!Z(H==F\O-JX!RT+4=N0 !ZR6"4 I![@=CHI7X)
MM@9C3,4=ZU<+$ \^GWB9-%6HF:$X8]]9Z![/,GM3/.CY%6^;-_C07JSZ]Z-]
M6UW??=QZV[DCGKK[KFS)TS[-F#AK[JFP2]VY_9K5ZMH7>^8\T 4YO?[3NK9I
M%RNZX#.E7QX63JN5V<[Y..TX.L'<.E*;=JXGNRS1IJCJ<JDWQ[!.H/N:K=U(
MCED.G,H9(=W#ER&;88H>L*UZ)M F0OAM11$V=5J?76'58[#/<]:4/;/P'!TI
MWY<A42 1$T ROCG2QR$0<+)>BGL0XB)W!QD9H=_,F),WH+1EU1^L!9<^.%:*
M+;=PC[T^:F1&@;>3DXTU!:@,^OT%F!3/DHV;I#HA@*>!([HD*3UYA^$U0 S+
M!]%(E'S6HQF';*K=C_ER=EYUH$S_=E.9@D*('9/"?*N!&BB9<I(@ Z[*E!G
MM96\ 4>]B:/)5>D.XAO>5'(<:H]Q+B0C:!*C+@N>-:Y*^4%9A#@35@1ZBP$A
M(!<:OQ.X%1Q2!^L8DOD_.ELW LN]9#-;_7] HNW-FH7#T:I$T+07VP_0/(9A
MJ0/7G-=6*"KU^+@G[L09)P\C-@Y1Q6(/VFE695QB[[O9\L>Y)M.XPT+($V@X
MGEW0BU^*SO[I]1\5\W']+/@R!' 70C8-V0@AC_(,?G[CCR,K_K[4WY?ZWW$I
M:!T)T+")UB+'96KPX_ CZ;5K>I3"&LFE*4U#<DTXG6!XIH]"G9U2UC"L*T#\
MG'AB4-4Q<BW'."975>$1BI%_;B3O?M+B3(.3;$>-. ,E!J@V+&-UD.%8&(.O
MT#"\HVNZ>6>W/QPZWD<S3\BMTS5TSZ79#S;K[O5276KC1RCUXWT(@"I^&LWU
M F&>QW+_7?#/6SWL6D!WW\>R( G"^EPU'4+8H#W[XPL]1(@^OVSTP3/>R?[O
M+M[B!F=3F"&_MWU1B_(00CK=:3Q7(>0$3 ST&?8@ZYR5067<0/!41[?;-ELN
M/LUP^]'RP_/M1<9WN8?72\0O)O4O7N;U<U&*Z2AUHRGWH.!B1+'@=R&$4P@@
MOG'GKE.&XY4I<(EQ3!SSS+;@8MQ!8,94@Y4^*1H76K(\LY$MQS.LW?*[*MP[
MC+@0+I<<L]!#7)' >G-2^!#L$2'D@2](G#]8P7Y^ Q>-E]^AA<\,P3^Q^7./
MQR91W3!C]%(^^?L#(>2M)1O_"\HF1+'S8[P7<2"C(#O:_@'_"4[LT>Y,]XIP
MDXA&M/BC[%3,2"5F=R"M^'QR/U1^R^3:G-,^?-$5=)2R@HZ.@N@H+[V'9[]R
M^&JAS8J(: 71V@;Q^SL=VO_41>._Z#0(M_U[;(XLD+?A.T0H",!Z@LQKLOCG
MEQ=$S/ZB<%UE[<^C]A^IJL\8$*<Y0^-C7GCJR!0\!JWG,H9T9ZIR)W^G-B,B
MGB,T^O"BXYVF51<BN:1= PJ:,:.'-Q#_WQ-8/^MA\?.P.)I53MQT/9]8<TE1
MW=#B3?>NRWB&"W:_^NYVGYR)CS\B)/,:?!*V[?C\\;E6/')"X:?)16+._%3+
M-.>?:IG^POQ<D7%]_+79SA,'#3>+;\O##]T20H;U4>WZ^!-DMJ-MP&,\(YE<
M-J79NH/,KJYMYV?D.WIE^N(9%D&U@31_1]B[@<B:MT2/V<#:&>56E/;2\K^N
M6O#G,_I(7\/)+]# ;O]E'KZX@M!_KELS>-"/>P)X45,57AG\_'P)OJ$2N"BO
M%3I(H17KG5Q[O43A]]N!_@=5XJXE_8JTFHN*)7];PR#R5 -0@JLO_OEE_DH]
MOY63;/Z'K5[\5ZKJ$%(S:FX5NUT@4T420@Y9_9&E&@:A_8JH.NZ%/8TV1 2L
M#?QE V_1[94,)+#ZDDN!E@.>7:U5.^.YKQ@#>S2]1P]L1"W"(8@O11_(4^E-
M*W4S5!'[.$D"DU@HGW"0OASV"$;\W<((CX*U*2]:_<(Y@2QB\<;?!2WT$LF'
M>XQ7 #MP=#5US[GGN]@SE"PYM<Y3IQ-/[4F\W" 3;HU)M.V4]?SW:*JCN.Z\
MZ\ 2&\:(CV""G(NU<*>'[ F3HV,&S3L"T.O&;1;+;>R0X=]+'>\LL!JK-2?%
MS_P8U?5!FG>54D]72#8'&"7:..83"T9M%;==W(]][*1]^?FGXJ"+AW]+7+I^
MJN5K$;0HTKJYZX89;@^2*XFOM]YMFYLDV)3YV\FMB39!!IL]BJAB*ML&OMR^
M$IGP9-] I-4%DYVK/=:,DF/I4HB1%["*O@<,]-U V&LT[TAS!HBM(P2'JH%V
MUHYS?"7@)CRLQL2U@ :44 *7YVOO'7V</TYT34<B(I[TZ1D'YSB@OE6Y)O,M
M%H40DV^;\O*/CEI=N!PKNQ-R.3;]VFQLNGL!;I.=H(W(MI"I*O=$C!09;,C4
MRI1-7,=&AIJ>#S52WPRCZ3V6EEY3J<7]].3!A;;*T+MM=ZLCMY>+K%%.EUA_
M0V65MP[5N$NS<MZ[X(AI=^ED0;"%(\JALJBHO)1HVYMB_KI+[E+O\XKHXUH[
MC/PS5$V[91<XSROE;Z<Y7]LGVW>;8YQM!/'3R0VKT2H " W#ZKVE;V;F9];&
M^=2H!MV\>;O3HT)Q=W',^5[2M#_GAF9?KWL7*^5<1>]82<JE[M*WQG;=_H/5
MINK!=J%"R/,5Z?%C=C]XK94SJ&<90QKZ!B@93)H5)R+RNUG3T-?1$J:91P.\
M3)<[R(W)K\SP*;A>VF;PN6U!'W:ZV[] Y&Q%4:=_@4[#X/-_@R8.0 DV67#/
M"B&4_8(FF**!QB=Z2$33;8$DL0$&O19OEF)(%>@FZ.UGQ QJB<5IIJX;?8&U
MN+E%I[)[3K=?K/H(RM]F%HP5ZS!5U?P"_/693TC!QI(G#FT&44SHUB8.A17P
M-CU1>Z!F7VXAR<>W6\\\89#NB5O=4;L?147?8N2DV;-G<Q-]U6EX NO#H.3O
M-VI=+2'TA<(K+ZX%J4F5CJ6-E3$>7G&0[]4YW-3?]-Y$>\.5KY9&YF-SZ$Y=
MRA2Q$;4#@*]KNAD](@%-]F;F1CV*+NT];P"CD#85O[)1Y)R_*9GR_:O8QPCH
MUW3]<W$F9XZ],I;LJB]TC_F*OX&OWPH&]@5^FA!R!7'_J$Y.0@DGI>F3K\%Q
MH,,$]O 6&K=K\--GP(WV5>$(Q>\Y#U'$#B<&^^@&O?:R7F2P[@TQD+TZH7U]
MM/>TX?<?-_CXJ.\,!U\-:T6+!GMC^E1VAN[=E& H=K:(*J]RR<CJ F1U+@F]
MY_V-)0FSA]?>& G:'[H"Y\6U?6T0^9WW#U@ECA^8S]PCJ4_7#W(L+Q1"X!S+
MQNVL)L(6@-OXF4^>QNDSIX20Z*+?AXRMCZ&F8ULEHQI<YT:GVPQ56_?\_O58
ML KUD^NE=.<-;:?625LXO62?1(T14=^<5Y[_YQ'.W]KMO[7;_UNUV_O((T5V
MYS-5^$2!&$;!@6.0RX#>1VPF>\/OU8H \Z3Q0+=F4^B#.PLY^89XOR!,AP/-
M[I.=-^>;W'.6144:,E30CTQF[C^W%[W<C0I';26[PP%5>$.[(A;TO'7$.,1&
MLC<RS$"+0XS40[MSCPHZ=6[6)-=Y9^Y)<^S24WA"COE.ZZ*?8!_TU@W98(>]
MQM:(IP^4]]_ V+T_.SWM4X=8C<5S$0(J8GVAP "KWP?7"WHIZ*5O1/B8(M?S
M=@'[7Q*ES!CT&/QJ5)- H:+3O\W;H4-377<J<+D]PK>L.J8@V)QC'!$0D:'I
MDDV3[E7/2>/615X]UCSTZ+3"QKW/I;'/,LV''^NENY$S@Q& 2FX]?1W/A4V*
M!&]TEA#"-G=$+=P$)MU#7)X W@MAE8!E%N]TET;9CMV?]](*PUCY[1*> O48
M9+?2Z;!30LA]J8L 42D-';C[9'Z3[Z*E*5]<5<0JX+CUA?<WSAB*A86%'H:>
M6C7_9%U6-,<;2D.,*.:R2)$(L2F#0[QCE9RQ!H($(@:W#^.J9Y\M;EBON+TB
M=4+<V)JCQ"VKZ)J>VZ]^A.GL=]B,X4$J]>09*::L?YME\@(2;";3C($RM2GT
MZ$S%B":ZF%[02'ND0.I-955Q!0=QEV>1A2%3NH<OMWP9IAD68.YP+;I=*TM2
M%FTN[&LU12NW'-ASTR$\C7M:T$YKC^!Y,H?VL'+KAVP:R.+?U^4V(J4\R5)8
MF1"&$++*\;&3I#?+S*W?/L6,75:?>GSWYLF4HX>W6;!$WYZ%*#89849SN$:X
M]BKM"#T%U@X4BU3?IMJ D/2U:V4L1@? HX8W%K''XF>V6*RA8;0=JOJ8W7K(
M6R62HB>S'%'GBA.VG>#9.+)FHE 2.&E,2(TMQY0JV 3X,"[5E'?3&X<-.-8/
M1F:@.?SQF^Y7:>V1I+GIXVB-#Q=%O5UN*:4W"RX:-->)>!L%Q3_E5(PT)Y$P
MR@U5I*;V<'GW:(-] S0OF(2>]@L,MR'9;K%15)1/OE++-B?XY1N]P!1^7+S%
M3QP[54$.'[NUI+$D<X-G#UPTV$6XK\P,I'1RG$MGIA\ 5[">C"*.V#C"39M,
M"ZM'T5#LQ S=J2M#_#>>1#?NP2-+M1?@)Q0?7)I7X)JI(FM[X5^Y^N%I[@'X
M8$2*6JU93CKTIA_\X283S4R'0]5+-XWWDBJN>WP\E?;P<4%AZ;)&8>;V--,*
MCJAGX.23S]ZW^P-3U>2[[<YI5I8%ZXKF*TP6:*BRUM ';>FV0^T>Q4WH /21
MO>]6_4!3VFFYS9D(((")C+X!(FM%'RS<3SM4"QHJ:RW?7D?<C,EFT</T@G(]
M4^[81,_I'S$'&JN0%*N2X.I\OEL[2SE23\3S.<:YU.?BV&6S.T*('9L8'A(Q
M,D.%;N"Y 8[0)I^CW;9LWX3U3UDA4HW+R@3\Z]*WP76UNP%O9D9P/4Z_ VNO
M%%<(A%&L^W%R'%AX0+XJEZ_<F-I\[^:Z)SVE0VY<T\SA!=1'(20"5C(SG3T"
M$^/=X 36HR-0)1%39!8J\@XZ7$^9@1Y8/ WTLF:D!>W+T$A_Y#8@&A9)+$5'
M^$SA-D$W80]SJ(VH#4.VCAC+!D49P/#EN-SR*WGE.!SHFALLF)Y:,R*#P>N3
MV 2F2(Q <@#7E'D0"'K!DV+'%[!+'-]RQIH(H<2MRL!C?IJ?,D'3NJMT*\^3
M$[/@S2Y/X%@VTQ62!++P2)P6WA>S*:#[%8V#1?H4P**6SV2?4(QZBJ.E0N-P
MDF:<,$9%'9D@A$C.?>.Y,Y&;J RDQ#>ZF"9!NN49X&V2TBB%/5E9#7X;>CV@
M8,1V*GBR0]>Z(XL#B]-$RWOM+_!,=>?MZIBDH[NN^WCARPEAI9.(,-Q^Y .\
M_/_#WIM&-;4VZZ*Q16F,]#U9"HB*@$JG$!,5!1$A(@("0E2D%Z,"$B4D*DWH
MLVP !2%+01!I(M**D @)9"DBT@LJZ51ZF%.Z*23AA/7M.^ZYW[?V66OO>^[9
MXXZQ?Y#!&,FH.6>]->NMYZVJIVAT16% !62$HH)%2#2WS9 W'X-;@@7*N3AU
MH-2&B;LJ0!-*I4G"B]'K!;12B(3I]0/0-P@A>9#3D$^7:K-&V:^E5WL9J,_$
MEB68Z@R&3-U8K\H/@<<@:MS2!9RTP<T0Q4 2,U\(8:S!6Q_JJ&R=@FO*R;18
MZ30 I#F''C.1"7]?]6-M\VAKL?*3B1LO7JGJ; !),5LJ&BKZ9N]RW2<R\\>H
M%>C8V0=T66$TA 8,&I=@\+*J!G>^*AN>A%H!D06,-"O9$Q]'24KU?H6.@($@
MEFC515"]<%9B''A?5RCN,<=!4-O7DFL.6A27C="5&H#G4AT,Q!(LF",G7-G=
M99O-*VQF)&M494IB(R6")QA/!>[: _Z%8< 2C.<>,UE24D73AAX1@@2TE:7?
MLKU]'#8D\TA2Z&34+]##$<\Q?$CC0.7U+?ES0@*C!M<4B+PLBC.(1^F:,!&0
M@XD883FQY0)!!;6:QI(SY36W-QMRUFOOA[X2C@1M GIRVC*%^O9 !QUAS_]X
M'CCMLY.D9+?E'GTOJ,GKF[ &.Z;H1H2]@"H3LV*0< 92!4ES%T'W6+HEU,6^
MOO85MWUE,':CN0'D F8>ZQ3N V@GZ3WU=L_PMDNP4Z!=DE@*7XI<%57X)02E
M#;SC*%0ZVAWJ*S/9NXUT%I$<^:NW<-7+7K%6X^)ND^8VG$".PCJ%M.,'B:TQ
MQC7 ]?E&$ZX7@[P;OY;#$Y5<S;7JC3"1IU$>0>GX/AV%RG+@#71M;7G897[Q
M&7@Y<:6X>T"*G1IR OA!V 75 -F>Y-=T.:B(UV#-'TSG-AB/L4FRR*C+I9[X
M,+:.>G)CKC78VC]@WDO>1Z_A4=3AZX7[@9*^ND,^VP!BZI;B\R]$![!RQ'?8
MU6)KR*O%C8Z&%JCKS4I#FI:I\\3M/JJ==#A4W(+:V2D\X,O]@G'MK;<!X3X-
M8.%-Y)I(7C%#GG-ZY'C@(*QK@N "CRO=$2%%AV+X_5769_.C6__^>#?E'^X3
MD8L'H&RN21Q2'GYKAUC93D!-UK' Q=.E04LV S&*D!%+0=AF=Z(*:)!@YE$?
M+9#39=*W]6J$!D_M]Y9JRE7L#*\U1VA =\2MS+FL7K+^[]V;\T#,W VH!R [
M0]Y1?.Q-E&P#()4H= 3<>5,L$Z5 K,;L/AN6CS84!U):/"-OB)L!]FLV]ZLE
M6@F)X'XA>71>-&]7P.=Y00=HWL.*V-$%]UL7.0ZU+\[ GP_3,B0&CACP( 5$
M*S(51G1D[O+1R?68XKS#O%.S_?66&]*YW@;'.R:0$:"41]]FB:DG9K"/ +5]
M,W+;WZXW>Q<BW@UB8@DF<U^V[[L8&G+LAV Q,.0-> 6SP1'(LZ%P60P$X?"B
MR0A#D=SL.(C,%JC&B[5&<_>]U"ALL@56!EFYW\#1PHV\FC2P"7E0Z5/HQ9B[
M^$TWEC>NL:&D+OVYU&"E>PNZ'#/A$;%XFF!-Y1NR%ZT'^O=EQN%^Z42M(79V
M$CLT:N++Z@\_EKLXU;0$4^:CUZ&4F<!0RX">I8I;GX^&/0&C^UG[D$-D8/4N
M\_D$CB20/C3+@0==P0LDP?>*1U405D"5$7KW2B!/*NX@5*Q2)< E#K"9<(U
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MF:4U;:^<F91Y&#PT]1MS7]UG"'L(J+Y96'_=\0U%K/+J%M^0?(>S8/A/)2^
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MIB"@L.;(.BJS71W*'0TU:2+)? =8J,U080" $GAV$9R-"[G[5)MU=%XD?F^
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MKE;8)>>$OH$%3B(2!W5$I6CN;UA-'N3"5XM@Q%YW>L63T0YH7G!X8#81=0+
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M^(^G)RF5K_TV*.N^P6KO-1GGJ$VG% \+>(/HX:K7#])D$'Q5^79CMF@[-&_
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M$8U#?\HLL_B,QG/_XR*TY8OPZ)*+O %Z2!&NPJ*9>(G4/EG2Q^R=D@>J,EU
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MHF, #'Q6N8.5P]\T'L^;GIPT"PKW]KS\K/FG/@\ST#[W56*WAZ#D@Y#CXO7
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MZ:_PW9<* -W>2(#-;Z80R-7?)]!A=J:@-M-QBXYX)+\T7LA+H"I+%(.C6[1
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MW*0YO&X_T9E+1(6X>9*&N$<H7@7#+W3R/DN+')<1\5>P 3@*5JX8T&DGK9N
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M='@941[V%XES@_3-5A;**SM4.JOD5Q0.91EQ_ 'Y,SJ!\?%0UTIAD=!E1!G
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MR"]Z$>A%G3VDA0?/.I\23J^T3URU$O9B)KD]*C66#\\KE_/)=JF/^)?#PE]
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M%ZL-J2**"-='K+A<F<'HPS"FF\MJJNP'AJ84OH2]Z(SQ?%.]C,C&7V_SZ%2
MI1SIM%-;YR1V$.6^\-*@0(GGOD!]^&ZLQ*E TEYF4M7A'_=)E[3[\[>%_M+'
M9019C?#],N(. XS_".!@LN8R0#"'S=.4H SY@=)/J)LC4:G+"/F9SSQRBR'
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MB;?+3([*UF^3.7'=Q"+#]J#!!>^>\.!=TV4AJ+87BDN6?Z%7?^'R))B(LR[
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ME_16W[]!NQNWT_5Y8-?=I4QIY$%";\G!"QEW3^2Z98UF%-_+S_F$_%:3CNH
MR98@0%H"(T([LJ.5)'[AQB,]9'RX62;Y@X2,HB;Q9.BA,57CGKST.N06G[>0
MT"K^1%]17YV^/+-QHTCT:=R"FG2OYZ@]5L;=5L'0W?Y"@^';IK=/%7YC2BFG
M#.N<IRH"^6>I.E4W.M4M.7JL]KVW'M9OSGG8YLIROO<V^$;J[R>.5\BZ?_0]
M-V$2&@M)_8JGD/&9V0$WNY\PUV^4Q2246*'LY9P&3^T\GJA5<3##?.]CIQSC
MQU6*9WH>?YY6?/Y5&%3MI:_"HL3#1,$_@HIO%CS\[^$WG^S_G_3SV#+\<78,
M5@I4,C)\.992EDC+$NQV?I_8YMSN'#7IM]OD3HE=OMV)]/WY&S)>/"WN]0MY
M:@)@M@(S :P!;>55UP\F@ HU%GLK[AW:JA(8IW+R061QGVU/^:W'4P>[WCN4
MOIV#*9N6L]L<^!?O7?X-'[$D!1/4#MB6%]:_) &<%'C),D$*E$"'"1O&D"'>
M=PS^QF^NX^^C"=!\TN50C#+!!"(!G8Z,QWW&/'*!--!Y>:[YD&COG9;F;K%.
MD<>XA?^+A=:TB'*'DR?/S7=[%2M]\KE9TE!?E]@]J._XU08D..SO6Z!K^/R!
MLW?^%E>_&Z>"S*W;CF;KH#)9)RZDA;8?S=Z:=\WKG"'\GMVP9/9KD25&:A6Y
M_&H%^<E(N?/QX.,N.WX!KNW:\52K1/%$>N_IJR=23]CNU*+\75A#];;RE>HB
M7S]V5D^H65ZUX&P)?CGS05%.02G@XBE%%^?-SP\COK=%.%54LX\/'"_V=SVI
MIH#\$?%;\FF\<",K],1,\GKU?#<M1$P8$Y?!D";N#M3<"KHQ2<H#>"H3H\BM
M0\J&J"TU%U3Z%:UD!D_DON-ZGBFZ^]K=,T2":NSZG*_K^4KL<=N^ O+R??59
MVL')JC]*7?5J!!LR$Y5 ^X3VLPF>BO6/24404QB=*-\N60T<HA6_[1 < M@O
M*950FET?P<Y8D6L<)F4ET%CU$]<D;",ZU21CE^-FJSLA]8V[?"<]US[V*R,$
M62XCE&?I/RX>$N_GMFR 9;MY%;$?6[OV.G\9@<#AFUC4-77V*>)MH-037QF
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M]5,_&8#B1V[&34H<S].[B%X3!+-6=H92DS!(D195AQ2GUF*\+1<RDD70Y1E
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MEP#$[6/'41'7)H0BJW8MS+9%U$!%9:U5A99VHVXW7/NK?E]5]/B*X)*G=U]
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M>*X" &5A,#(P,C(W-S Q97@Q,"TQ,5]I;6UU8V5L;"YH=&U02P$"% ,4
M" "T@(%8QB!?:54)   ()0  '@              @ &UN ( 96$P,C R,C<W
M,#%E>#$P+3A?:6UM=6-E;&PN:'1M4$L! A0#%     @ M("!6)E:DIS, @
M(PD  !X              ( !1L(" &5A,#(P,C(W-S Q97@R,RTQ7VEM;75C
M96QL+FAT;5!+ 0(4 Q0    ( +2 @5CP?H=..P<  .PD   <
M  "  4[% @!E83 R,#(R-S<P,65X,S%?:6UM=6-E;&PN:'1M4$L! A0#%
M  @ M("!6/,H_>A_!0  TA(  !P              ( !P\P" &5A,#(P,C(W
M-S Q97@S,E]I;6UU8V5L;"YH=&U02P$"% ,4    " "T@(%8O7Y8*,T-  "G
M3@  '@              @ %\T@( 96$P,C R,C<W,#%E>#DW+3%?:6UM=6-E
M;&PN:'1M4$L! A0#%     @ M("!6+XL=?RD%@  YA$! !$
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M **- 0 -              "  6)W! !I;6%G95\P,#$N:G!G4$L! A0#%
M  @ M("!6&^CJ8- %@$ %7L!  T              ( !=+,% &EM86=E7S P
;,BYJ<&=02P4&      X #@#* P  W\D&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>ea0202277-10k_immu_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iccc="http://immucell.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iccc-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:NisinDrugSubstanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2027-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MortgageBankingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:SubtotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">iccc:AcquiringPersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-17757">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-17758">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-17759">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-17760">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber contextRef="c0" id="ixv-58">001-12934</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-70">ImmuCell Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-84">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-89">01-0382980</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-17761">56 Evergreen Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-17762">Portland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-17763">ME</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-110">04103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-17764">(207)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-17765">878-2770</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-155">Common Stock, $0.10 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-159">ICCC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-163">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-17766">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-17767">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-17768">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-17769">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-17770">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-17771">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-17772">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-17773">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-17774">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-259">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-17775" unitRef="usd">31165000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-17776"
      unitRef="shares">7750864</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="c0" id="ixv-17777">344</dei:AuditorFirmId>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c27" id="ixv-17778">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c27" id="ixv-17779">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c27" id="ixv-17780">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c27" id="ixv-17781">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:AuditorName contextRef="c0" id="ixv-17782">WIPFLI LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-17783">Radnor, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-17784" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" id="ixv-17785" unitRef="usd">5791562</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-17786" unitRef="usd">2185383</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" id="ixv-17787" unitRef="usd">1758600</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-17788" unitRef="usd">7811841</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" id="ixv-17789" unitRef="usd">6038539</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-17790" unitRef="usd">493885</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-17791" unitRef="usd">406055</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-17792" unitRef="usd">11469850</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="0" id="ixv-17793" unitRef="usd">13994756</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-17794" unitRef="usd">27575683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-17795" unitRef="usd">28441726</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-17796" unitRef="usd">4571149</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" id="ixv-17797" unitRef="usd">2194670</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c3" decimals="0" id="ixv-17798" unitRef="usd">95557</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c4" decimals="0" id="ixv-17799" unitRef="usd">95557</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-17800" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-17801" unitRef="usd">57312</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-17802" unitRef="usd">57655</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-17803" unitRef="usd">76628</us-gaap:OtherAssetsCurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-17804" unitRef="usd">43808102</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-17805" unitRef="usd">44860649</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c3" decimals="0" id="ixv-17806" unitRef="usd">1428807</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c4" decimals="0" id="ixv-17807" unitRef="usd">1039447</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-17808" unitRef="usd">644276</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" id="ixv-17809" unitRef="usd">31764</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-17810" unitRef="usd">2124337</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-17811" unitRef="usd">2000862</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-17812" unitRef="usd">4197420</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-17813" unitRef="usd">3072073</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c3" decimals="0" id="ixv-17814" unitRef="usd">10540496</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c4" decimals="0" id="ixv-17815" unitRef="usd">9191109</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-17816" unitRef="usd">4077109</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" id="ixv-17817" unitRef="usd">2217418</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-17818" unitRef="usd">14617605</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="0" id="ixv-17819" unitRef="usd">11408527</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-17820" unitRef="usd">18815025</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" id="ixv-17821" unitRef="usd">14480600</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="2"
      id="ixv-17822"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="2"
      id="ixv-17823"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-17824"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-17825"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-17826"
      unitRef="shares">7814165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-17827"
      unitRef="shares">7814165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-17828"
      unitRef="shares">7750864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-17829"
      unitRef="shares">7746864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-17830" unitRef="usd">781417</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" id="ixv-17831" unitRef="usd">781417</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-17832" unitRef="usd">36357239</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c4" decimals="0" id="ixv-17833" unitRef="usd">35978364</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-17834" unitRef="usd">-12007097</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-17835" unitRef="usd">-6232499</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c3"
      decimals="0"
      id="ixv-17836"
      unitRef="shares">67301</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c4"
      decimals="0"
      id="ixv-17837"
      unitRef="shares">67301</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c3" decimals="0" id="ixv-17838" unitRef="usd">138482</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c4" decimals="0" id="ixv-17839" unitRef="usd">147233</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-17840" unitRef="usd">24993077</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-17841" unitRef="usd">30380049</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-17842" unitRef="usd">43808102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" id="ixv-17843" unitRef="usd">44860649</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-17844" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-17845" unitRef="usd">18567962</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-17846" unitRef="usd">13602385</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" id="ixv-17847" unitRef="usd">10919183</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-17848" unitRef="usd">3869284</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-17849" unitRef="usd">7648779</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-17850" unitRef="usd">4394852</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-17851" unitRef="usd">4493872</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-17852" unitRef="usd">3088215</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="0" id="ixv-17853" unitRef="usd">3190033</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-17854" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-17855" unitRef="usd">2263817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-17856" unitRef="usd">9617362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-17857" unitRef="usd">9947722</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-17858" unitRef="usd">-5748078</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-17859" unitRef="usd">-2298943</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-17860" unitRef="usd">-21893</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-17861" unitRef="usd">-187190</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-17862" unitRef="usd">-5769971</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-17863" unitRef="usd">-2486133</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-17864" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-17865" unitRef="usd">7672</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-17866" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-17867" unitRef="usd">-2493805</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-17868"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-17869"
      unitRef="shares">7745122</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-17870"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-17871"
      unitRef="usdPershares">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-17872"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-17873"
      unitRef="shares">7745122</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-17874"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-17875"
      unitRef="usdPershares">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-17876"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" id="ixv-17877" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" id="ixv-17878" unitRef="usd">35692388</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-17879" unitRef="usd">-3738694</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c9"
      decimals="0"
      id="ixv-17880"
      unitRef="shares">72301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-17881" unitRef="usd">-158171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-17882" unitRef="usd">32576940</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="0" id="ixv-17883" unitRef="usd">-2493805</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-17884" unitRef="usd">-2493805</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c12" decimals="0" id="ixv-17885" unitRef="usd">19732</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c14"
      decimals="0"
      id="ixv-17886"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c14" decimals="0" id="ixv-17887" unitRef="usd">10938</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c5" decimals="0" id="ixv-17888" unitRef="usd">30670</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c12" decimals="0" id="ixv-17889" unitRef="usd">266244</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="0" id="ixv-17890" unitRef="usd">266244</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c15"
      decimals="0"
      id="ixv-17891"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" id="ixv-17892" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" id="ixv-17893" unitRef="usd">35978364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-17894" unitRef="usd">-6232499</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c18"
      decimals="0"
      id="ixv-17895"
      unitRef="shares">67301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ixv-17896" unitRef="usd">-147233</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-17897" unitRef="usd">30380049</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="0" id="ixv-17898" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-17899" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20" decimals="0" id="ixv-17900" unitRef="usd">10009</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c22"
      decimals="0"
      id="ixv-17901"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c22" decimals="0" id="ixv-17902" unitRef="usd">8751</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="0" id="ixv-17903" unitRef="usd">18760</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c20" decimals="0" id="ixv-17904" unitRef="usd">368866</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" id="ixv-17905" unitRef="usd">368866</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="0"
      id="ixv-17906"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" id="ixv-17907" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-17908" unitRef="usd">36357239</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" id="ixv-17909" unitRef="usd">-12007097</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-17910"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" id="ixv-17911" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-17912" unitRef="usd">24993077</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-17913" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-17914" unitRef="usd">-2493805</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-17915" unitRef="usd">2697897</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" id="ixv-17916" unitRef="usd">2468479</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-17917" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" id="ixv-17918" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="0" id="ixv-17919" unitRef="usd">13072</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c5" decimals="0" id="ixv-17920" unitRef="usd">7658</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" id="ixv-17921" unitRef="usd">9547</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-17922" unitRef="usd">368866</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" id="ixv-17923" unitRef="usd">266244</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-17924" unitRef="usd">-8099</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c5" decimals="0" id="ixv-17925" unitRef="usd">7334</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="0" id="ixv-17926" unitRef="usd">95724</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="c5" decimals="0" id="ixv-17927" unitRef="usd">28476</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-17928" unitRef="usd">426783</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" id="ixv-17929" unitRef="usd">-935629</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-17930" unitRef="usd">1773302</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" id="ixv-17931" unitRef="usd">2948565</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-17932" unitRef="usd">87830</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" id="ixv-17933" unitRef="usd">110858</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="0" id="ixv-17934" unitRef="usd">-18973</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c5" decimals="0" id="ixv-17935" unitRef="usd">50513</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-17936" unitRef="usd">156995</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" id="ixv-17937" unitRef="usd">341614</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-17938" unitRef="usd">-4674236</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" id="ixv-17939" unitRef="usd">-1543871</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-17940" unitRef="usd">1892513</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-17941" unitRef="usd">3975274</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-17942" unitRef="usd">2474</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-17943" unitRef="usd">11000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-17944" unitRef="usd">-1890039</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" id="ixv-17945" unitRef="usd">-3964274</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c0" decimals="0" id="ixv-17946" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c5" decimals="0" id="ixv-17947" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c0" decimals="0" id="ixv-17948" unitRef="usd">2000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="0" id="ixv-17949" unitRef="usd">1185774</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c5" decimals="0" id="ixv-17950" unitRef="usd">897125</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c0" decimals="0" id="ixv-17951" unitRef="usd">2000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c0" decimals="0" id="ixv-17952" unitRef="usd">35425</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c5" decimals="0" id="ixv-17953" unitRef="usd">19306</us-gaap:PaymentsOfDebtIssuanceCosts>
    <iccc:PaymentsOfDebtDiscounts contextRef="c0" decimals="0" id="ixv-17954" unitRef="usd">46107</iccc:PaymentsOfDebtDiscounts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="0" id="ixv-17955" unitRef="usd">18760</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c5" decimals="0" id="ixv-17956" unitRef="usd">30670</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-17957" unitRef="usd">1751454</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" id="ixv-17958" unitRef="usd">1114239</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-17959" unitRef="usd">-4812821</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c5" decimals="0" id="ixv-17960" unitRef="usd">-4393906</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-17961" unitRef="usd">5791562</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c10" decimals="0" id="ixv-17962" unitRef="usd">10185468</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-17963" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-17964" unitRef="usd">5791562</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="0" id="ixv-17965" unitRef="usd">6466</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c5" decimals="0" id="ixv-17966" unitRef="usd">4923</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-17967" unitRef="usd">444954</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" id="ixv-17968" unitRef="usd">338516</us-gaap:InterestPaidNet>
    <iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses contextRef="c0" decimals="0" id="ixv-17969" unitRef="usd">50086</iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses contextRef="c5" decimals="0" id="ixv-17970" unitRef="usd">-44998</iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses contextRef="c0" decimals="0" id="ixv-17971" unitRef="usd">16566</iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-17972" unitRef="usd">2472203</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-17973" unitRef="usd">1184727</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-10136">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;1. BUSINESS
OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ImmuCell
Corporation (the &#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;) was originally incorporated in Maine in
1982 and reincorporated in Delaware in 1987, in conjunction with an initial public offering of common stock. We are an animal health
company whose purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and
beef cattle. As disclosed in Note 17, &#x201c;Segment Information&#x201d;, one of our business segments is dedicated to Scours and the
other is focused on Mastitis. We manufacture and market the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line, providing &lt;b&gt;Immediate
Immunity&#x2122;&lt;/b&gt; to prevent scours in newborn dairy and beef calves. We have expanded this line into four different products with
formulations targeting &lt;i&gt;E. coli&lt;/i&gt;, coronavirus and rotavirus pathogens. We are also in the late stages of developing &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;,
a treatment for lactating dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy
industry. These products help reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks
including dependence on key individuals and third-party providers of critical goods and services, competition from other larger companies,
the successful sale of existing products and the development of new viable products with appropriate regulatory approvals, where applicable.
A combination of the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary
conditions in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We
are experiencing price increases in key components, supportive services, transportation and other supplies that are causing our costs
of goods sold to increase. We have experienced some contamination events in our production process. We implemented a production slowdown
to remediate this problem, which led to the recognition of lower sales and gross margin during the first ten months of 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-17974" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-10154">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2. SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(a) Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
have prepared the accompanying audited financial statements reflecting all adjustments (which are of a normal recurring nature) that
are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set
by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure
we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes
are to the FASB &lt;i&gt;Accounting Standards Codification&lt;/i&gt;&#x2122; (Codification). We believe that the disclosures are adequate to ensure
that the information presented is not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(b) Cash
and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash
equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal
Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor. See Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(c) Trade
Accounts Receivable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines
the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to
an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance
is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge
interest on past due accounts during the years ended December 31, 2023 or 2022 because the time past due was not significant. There was
no accrual for such interest charges as of December 31, 2023 or 2022. Accounts receivable are written off when deemed uncollectible.
No accounts receivable were written off during the years ended December 31, 2023 or 2022. Recoveries of accounts receivable previously
written off are recorded as income when received. No such recoveries were recorded during the years ended December 31, 2023 or 2022.
As of December 31, 2023 and 2022, we determined that no allowance for doubtful accounts was necessary. See Note 4.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(d) Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or
net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of
completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess
or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it
is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one
vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note
5.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(e) Property,
Plant and Equipment, net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated
to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets.
The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; is being
depreciated over 39 years from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the
equipment for our Nisin DS facility when it was placed in service during the third quarter of 2018. Approximately 87% of these assets
are being depreciated over 10 years. We began depreciating the leasehold improvements to our new &lt;b&gt;First Defense&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;production
facility at 175 Industrial Way (&lt;b&gt;Building 175A&lt;/b&gt;) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy
was issued during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with
a new lease covering additional space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;). As a result, the net book value of these leasehold
improvements as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property,
plant and equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs
are expensed when incurred. See Notes 2(h) and 7 for additional disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(f) Operating
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We account
for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation
to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use
(ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present
value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease
incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the
total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the
term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term
for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not
recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement
as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements
include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance
and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify
an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the
present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(g) Intangible
Assets and Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of
the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible
assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid
in excess of fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting.
We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level)
on an annual basis (as of December 31&lt;sup&gt;st&lt;/sup&gt;) and whenever events or changes in circumstances indicate that the carrying value
of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value
of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the
value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance
relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends.
Although we believe intangible assets and goodwill are properly stated in the accompanying financial statements, changes in strategy
or market conditions could significantly impact these judgments and require an adjustment to the recorded balance in the future. &lt;span style="-sec-ix-hidden: hidden-fact-34"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-35"&gt;No&lt;/span&gt;&lt;/span&gt; goodwill
impairments were recorded during the years ended December 31, 2023 or 2022. See Notes 2(h) and 8 for additional disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(h) Valuation
of Long-Lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset
and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment
of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible
assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not
be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level
for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. &lt;span style="-sec-ix-hidden: hidden-fact-36"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37"&gt;No&lt;/span&gt;&lt;/span&gt; impairment
was recognized during the years ended December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(i) Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
determining fair value measurements, we follow the provisions of Codification Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;.
Codification Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about
fair value measurements. The topic provides a consistent definition of fair value which focuses on an exit price, which is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The topic also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific
information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of
an asset or liability as of the measurement date. As of December 31, 2023 and 2022, the carrying amounts of cash and cash equivalents,
accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value
because of their short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying
balance sheets. Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.65in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                              1 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pricing
                                            inputs are quoted prices available in active markets for identical assets or liabilities
                                            as of the measurement date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.65in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                              2 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pricing inputs are quoted prices for
            similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
            through corroboration with observable market data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.65in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                              3 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pricing inputs are unobservable for
            the assets or liabilities, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions
            market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level
of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment
and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash
equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the
event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers
between levels of the fair value hierarchy. During the years ended December 31, 2023 and 2022, there were no transfers between levels.
As of December 31, 2023 and 2022, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and
money market accounts. There were &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; assets or liabilities measured at fair value on a nonrecurring basis as of December 31, 2023 or
2022. The carrying values of our cash and money market accounts as of December 31, 2023 or 2022 approximated their fair market values.
Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of December 31, 2023
and 2022 differed from their fair market values. These values are reflected in the following tables:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;978,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;978,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,431,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,431,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,791,562&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,791,562&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,897,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,897,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(j) Concentration
of Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Concentration
of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To
reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable
credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have
not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic
area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    B&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade
accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in
the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    B&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    C&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;This amount is less than 10%.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(k) Revenue
Recognition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
recognize revenue in accordance with Codification Topic 606, &lt;i&gt;Revenue from Contracts with Customers (ASC 606)&lt;/i&gt;. ASC 606 is a single
comprehensive model for companies to use in accounting for revenue arising from contracts with customers. The core principle is that
we recognize the amount of revenue to which we expect to be entitled for the transfer of promised goods or services to customers when
a customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and
cash flows arising from contracts with customers. We conduct our business with customers through valid purchase orders or sales orders
which are considered contracts and are not interdependent on one another. A performance obligation is a promise in a contract to transfer
a distinct product to the customer. The transaction price is the amount of consideration we expect to receive under the arrangement.
Revenue is measured based on consideration specified in a contract with a customer. The transaction price of a contract is allocated
to each distinct performance obligation and recognized when or as the customer receives the benefit of the performance obligation. Product
transaction prices on a purchase or sales order are discrete and stand-alone. We recognize revenue when we satisfy a performance obligation
in a contract by transferring control over a product to a customer when product ships to a customer. Amounts due are typically paid approximately
30 days from the time control is transferred. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment
cost in costs of goods sold. We do not bill for or collect sales tax because our sales are generally made to distributors and thus our
sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns. See Note 14 for additional
disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(l)
Expense Recognition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed
when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed
as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are
charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(m) Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
account for income taxes in accordance with Codification Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, which requires that we recognize a current tax
liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects
of temporary differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning
strategies in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine
that it is more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over
a reasonably short period of time, a reduction of the valuation allowance would increase income in the period such determination was
made. Likewise, if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in
the future, an increase to the valuation allowance would be charged to income in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2020. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2023 or 2022. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(n) Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
account for stock-based compensation in accordance with Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally
requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of
each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded
compensation expense pertaining to stock-based compensation of $368,866 and $266,244 during the years ended December 31, 2023 and 2022,
respectively. See Note 13.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(o) Net
Loss Per Common Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
loss per common share has been computed in accordance with Codification Topic 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;. The net loss per share
has been computed by dividing the net loss by the weighted average number of common shares outstanding during the period. All stock options
have been excluded from the denominator in the calculation of dilutive earnings per share when we are in a loss position because their
inclusion would be anti-dilutive. Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to 618,500 and 605,000 during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,774,598&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,493,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average common
    shares outstanding - Basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,747,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,745,122&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive
    impact of share-based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average common shares outstanding - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,747,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,745,122&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(p) Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ
from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become
known. Significant estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(q)
New Accounting Pronouncement Adopted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&lt;/i&gt;, which was effective for us as of January 1, 2023, using the modified retrospective transition method. This ASU amends
the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including
trade receivables. The amendment requires entities to consider a broader range of information to estimate expected credit losses, which
may result in earlier recognition of losses. Historically, we have experienced a very low level of bad debt expense, and most of our
trade receivables are collected by the due date or within a few days of the due date. Because of this experience, the adoption of ASU
2016-13 did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(r) New
Accounting Pronouncements Not Yet Adopted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/i&gt; which
is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses.
The amendments will require disclosure of significant segment expenses that are regularly provided to our chief operating decision-maker
and included within segment profit and loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim
periods beginning after December 15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented
in the financial statements. We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December 2023, the FASB issued ASU 2023-09&lt;i&gt;, Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which includes amendments
that further enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine
its impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-10161">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(a) Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
have prepared the accompanying audited financial statements reflecting all adjustments (which are of a normal recurring nature) that
are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set
by the Financial Accounting Standards Board (FASB). The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure
we accurately report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes
are to the FASB &lt;i&gt;Accounting Standards Codification&lt;/i&gt;&#x2122; (Codification). We believe that the disclosures are adequate to ensure
that the information presented is not misleading.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-10173">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(b) Cash
and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash
equivalents are principally invested in securities backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal
Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor. See Note 3.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c3" decimals="0" id="ixv-17975" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0" id="ixv-10184">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(c) Trade
Accounts Receivable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
receivable are carried at the original invoice amount less an estimate made for doubtful collection when applicable. Management determines
the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to
an aging of accounts and other relevant factors. Accounts receivable are considered to be past due if a portion of the receivable balance
is outstanding for more than 30 days. Past due accounts receivable are subject to an interest charge. It was not necessary to charge
interest on past due accounts during the years ended December 31, 2023 or 2022 because the time past due was not significant. There was
no accrual for such interest charges as of December 31, 2023 or 2022. Accounts receivable are written off when deemed uncollectible.
No accounts receivable were written off during the years ended December 31, 2023 or 2022. Recoveries of accounts receivable previously
written off are recorded as income when received. No such recoveries were recorded during the years ended December 31, 2023 or 2022.
As of December 31, 2023 and 2022, we determined that no allowance for doubtful accounts was necessary. See Note 4.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-10222">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(d) Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or
net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of
completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
At each balance sheet date, we evaluate our ending inventories for excess quantities and obsolescence. Inventories that we consider excess
or obsolete are written down to estimated net realizable value. Once inventory is written down and a new cost basis is established, it
is not written back up. We believe that supplies and raw materials for the production of our products are available from more than one
vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products when feasible. See Note
5.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-10234">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(e) Property,
Plant and Equipment, net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
depreciate property, plant and equipment on the straight-line method by charges to operations and costs of goods sold in amounts estimated
to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets.
The facility we have constructed at 33 Caddie Lane to produce the Nisin Drug Substance (DS) for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; is being
depreciated over 39 years from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the
equipment for our Nisin DS facility when it was placed in service during the third quarter of 2018. Approximately 87% of these assets
are being depreciated over 10 years. We began depreciating the leasehold improvements to our new &lt;b&gt;First Defense&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;production
facility at 175 Industrial Way (&lt;b&gt;Building 175A&lt;/b&gt;) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy
was issued during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with
a new lease covering additional space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;). As a result, the net book value of these leasehold
improvements as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property,
plant and equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs
are expensed when incurred. See Notes 2(h) and 7 for additional disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c3" decimals="2" id="ixv-17976" unitRef="pure">0.87</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c28" id="ixv-17977">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c29" id="ixv-17978">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-10252">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(f) Operating
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We account
for our real estate leases using a right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation
to make lease payments to the lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use
(ROU) asset related to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present
value of the future lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease
incentives received and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the
total lease costs are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the
term of the lease. When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term
for purposes of determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not
recognize assets or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement
as a single combined lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements
include variable rent payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance
and real estate taxes. These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify
an implicit rate, we use an incremental borrowing rate based on information available at the lease commencement date to determine the
present value of the lease payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the
carrying value of the asset may not be recoverable. See Notes 2(h) and 12 for additional disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0" id="ixv-10264">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(g) Intangible
Assets and Goodwill&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
amortize intangible assets on the straight-line method by charges to costs of goods sold in amounts estimated to expense the cost of
the assets from the date they are first put into service to the end of the estimated useful lives of the assets. We have recorded intangible
assets related to customer relationships, non-compete agreements and developed technology, each with defined useful lives. Amounts paid
in excess of fair value of the net assets (including tax attributes) are recorded as goodwill under the acquisition method of accounting.
We assess the impairment of intangible assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level)
on an annual basis (as of December 31&lt;sup&gt;st&lt;/sup&gt;) and whenever events or changes in circumstances indicate that the carrying value
of the asset may not be recoverable. We would record an impairment charge if such an assessment were to indicate that the fair value
of such assets was less than the carrying value. Judgment is required in determining whether an event has occurred that may impair the
value of goodwill or identifiable intangible assets. Factors that could indicate that an impairment may exist include significant under-performance
relative to plan or long-term projections, significant changes in business strategy and significant negative industry or economic trends.
Although we believe intangible assets and goodwill are properly stated in the accompanying financial statements, changes in strategy
or market conditions could significantly impact these judgments and require an adjustment to the recorded balance in the future. &lt;span style="-sec-ix-hidden: hidden-fact-34"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-35"&gt;No&lt;/span&gt;&lt;/span&gt; goodwill
impairments were recorded during the years ended December 31, 2023 or 2022. See Notes 2(h) and 8 for additional disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <iccc:ValuationOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-10306">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(h) Valuation
of Long-Lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
periodically evaluate our long-lived assets, consisting principally of property, plant and equipment, operating lease right-of-use asset
and amortizable intangible assets, for potential impairment. In accordance with the applicable accounting guidance for the treatment
of long-lived assets, we review the carrying value of our long-lived assets or asset group that is held and used, including intangible
assets subject to amortization, for impairment whenever events and circumstances indicate that the carrying value of the assets may not
be recoverable. Under the held for use approach, the asset or asset group to be tested for impairment should represent the lowest level
for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. &lt;span style="-sec-ix-hidden: hidden-fact-36"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37"&gt;No&lt;/span&gt;&lt;/span&gt; impairment
was recognized during the years ended December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;</iccc:ValuationOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-10320">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(i) Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
determining fair value measurements, we follow the provisions of Codification Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;.
Codification Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about
fair value measurements. The topic provides a consistent definition of fair value which focuses on an exit price, which is the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The topic also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific
information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of
an asset or liability as of the measurement date. As of December 31, 2023 and 2022, the carrying amounts of cash and cash equivalents,
accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value
because of their short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying
balance sheets. Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.65in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                              1 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pricing
                                            inputs are quoted prices available in active markets for identical assets or liabilities
                                            as of the measurement date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.65in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                              2 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pricing inputs are quoted prices for
            similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
            through corroboration with observable market data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.65in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                              3 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pricing inputs are unobservable for
            the assets or liabilities, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions
            market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level
of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment
and considers factors specific to the investment. We also hold money market accounts in our bank account, which are classified as cash
equivalents and measured at fair value. The fair value of these investments is based on their closing published net asset value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
assess the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the
event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers
between levels of the fair value hierarchy. During the years ended December 31, 2023 and 2022, there were no transfers between levels.
As of December 31, 2023 and 2022, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and
money market accounts. There were &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; assets or liabilities measured at fair value on a nonrecurring basis as of December 31, 2023 or
2022. The carrying values of our cash and money market accounts as of December 31, 2023 or 2022 approximated their fair market values.
Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of December 31, 2023
and 2022 differed from their fair market values. These values are reflected in the following tables:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;978,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;978,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,431,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,431,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,791,562&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,791,562&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,897,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,897,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="c0" id="ixv-17979">These values are reflected in the following tables:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;978,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;978,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.375in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,431,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,431,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,791,562&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,791,562&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,897,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,897,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c32" decimals="0" id="ixv-17980" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-17981" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermBorrowings contextRef="c33" decimals="0" id="ixv-17982" unitRef="usd">10431817</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="0" id="ixv-17983" unitRef="usd">10431817</us-gaap:ShortTermBorrowings>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c35" decimals="0" id="ixv-17984" unitRef="usd">5791562</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" id="ixv-17985" unitRef="usd">5791562</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermBorrowings contextRef="c36" decimals="0" id="ixv-17986" unitRef="usd">8897197</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c4" decimals="0" id="ixv-17987" unitRef="usd">8897197</us-gaap:ShortTermBorrowings>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-10817">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(j) Concentration
of Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Concentration
of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To
reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable
credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have
not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic
area. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    B&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade
accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in
the following table:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    B&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    C&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;This amount is less than 10%.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c38" id="ixv-17988">Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    B&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskCustomer contextRef="c30" id="ixv-17989">10%</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c39" decimals="2" id="ixv-17990" unitRef="pure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c40" decimals="2" id="ixv-17991" unitRef="pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c41" decimals="2" id="ixv-17992" unitRef="pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c42" decimals="2" id="ixv-17993" unitRef="pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c43" id="ixv-10898">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade
accounts receivable due from significant customers that amounted to 10% or more of our total trade accounts receivable are detailed in
the following table:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    B&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company
    C&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;This amount is less than 10%.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskCustomer contextRef="c31" id="ixv-17994">10%</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c44" decimals="2" id="ixv-17995" unitRef="pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c45" decimals="2" id="ixv-17996" unitRef="pure">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c46" decimals="2" id="ixv-17997" unitRef="pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c47" decimals="2" id="ixv-17998" unitRef="pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c49" decimals="2" id="ixv-17999" unitRef="pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <iccc:AccountsReceivablePercentage contextRef="c0" decimals="2" id="ixv-18000" unitRef="pure">0.10</iccc:AccountsReceivablePercentage>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-11022">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(k) Revenue
Recognition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
recognize revenue in accordance with Codification Topic 606, &lt;i&gt;Revenue from Contracts with Customers (ASC 606)&lt;/i&gt;. ASC 606 is a single
comprehensive model for companies to use in accounting for revenue arising from contracts with customers. The core principle is that
we recognize the amount of revenue to which we expect to be entitled for the transfer of promised goods or services to customers when
a customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange
for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing and uncertainty of revenue and
cash flows arising from contracts with customers. We conduct our business with customers through valid purchase orders or sales orders
which are considered contracts and are not interdependent on one another. A performance obligation is a promise in a contract to transfer
a distinct product to the customer. The transaction price is the amount of consideration we expect to receive under the arrangement.
Revenue is measured based on consideration specified in a contract with a customer. The transaction price of a contract is allocated
to each distinct performance obligation and recognized when or as the customer receives the benefit of the performance obligation. Product
transaction prices on a purchase or sales order are discrete and stand-alone. We recognize revenue when we satisfy a performance obligation
in a contract by transferring control over a product to a customer when product ships to a customer. Amounts due are typically paid approximately
30 days from the time control is transferred. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment
cost in costs of goods sold. We do not bill for or collect sales tax because our sales are generally made to distributors and thus our
sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns. See Note 14 for additional
disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <iccc:ExpenseRecognitionPolicyTextBlock contextRef="c0" id="ixv-11034">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(l)
Expense Recognition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
do not incur costs in connection with product sales to customers that are eligible for capitalization. Advertising costs are expensed
when incurred, which is generally during the month in which the advertisement is published. All product development expenses are expensed
as incurred, as are all related patent costs. We capitalize costs to produce inventory during the production cycle, and these costs are
charged to costs of goods sold when the inventory is sold to a customer or is deemed to be in excess or obsolete.&lt;/span&gt;&lt;/p&gt;</iccc:ExpenseRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-11046">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(m) Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
account for income taxes in accordance with Codification Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, which requires that we recognize a current tax
liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects
of temporary differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning
strategies in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine
that it is more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over
a reasonably short period of time, a reduction of the valuation allowance would increase income in the period such determination was
made. Likewise, if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in
the future, an increase to the valuation allowance would be charged to income in the period such determination was made.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2020. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2023 or 2022. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-11063">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(n) Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
account for stock-based compensation in accordance with Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally
requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of
each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded
compensation expense pertaining to stock-based compensation of $368,866 and $266,244 during the years ended December 31, 2023 and 2022,
respectively. See Note 13.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-18001" unitRef="usd">368866</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="0" id="ixv-18002" unitRef="usd">266244</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-11076">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(o) Net
Loss Per Common Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
loss per common share has been computed in accordance with Codification Topic 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;. The net loss per share
has been computed by dividing the net loss by the weighted average number of common shares outstanding during the period. All stock options
have been excluded from the denominator in the calculation of dilutive earnings per share when we are in a loss position because their
inclusion would be anti-dilutive. Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to 618,500 and 605,000 during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,774,598&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,493,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average common
    shares outstanding - Basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,747,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,745,122&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive
    impact of share-based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average common shares outstanding - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,747,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,745,122&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-18003">Outstanding stock options that were not included in this calculation because the effect would be anti-dilutive
amounted to 618,500 and 605,000 during the years ended December 31, 2023 and 2022, respectively.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,774,598&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,493,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average common
    shares outstanding - Basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,747,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,745,122&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive
    impact of share-based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average common shares outstanding - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,747,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,745,122&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-18004"
      unitRef="shares">618500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c5"
      decimals="0"
      id="ixv-18005"
      unitRef="shares">605000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-18006" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-18007" unitRef="usd">-2493805</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-18008"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-18009"
      unitRef="shares">7745122</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-18010"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-18011"
      unitRef="shares">7745122</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-18012"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-18013"
      unitRef="usdPershares">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-18014"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-18015"
      unitRef="usdPershares">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-11314">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(p) Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ
from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become
known. Significant estimates include our valuation of inventory, long-lived assets, deferred tax assets and costs of goods sold.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-11325">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(q)
New Accounting Pronouncement Adopted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&lt;/i&gt;, which was effective for us as of January 1, 2023, using the modified retrospective transition method. This ASU amends
the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including
trade receivables. The amendment requires entities to consider a broader range of information to estimate expected credit losses, which
may result in earlier recognition of losses. Historically, we have experienced a very low level of bad debt expense, and most of our
trade receivables are collected by the due date or within a few days of the due date. Because of this experience, the adoption of ASU
2016-13 did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <iccc:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="c0" id="ixv-11337">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(r) New
Accounting Pronouncements Not Yet Adopted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/i&gt; which
is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses.
The amendments will require disclosure of significant segment expenses that are regularly provided to our chief operating decision-maker
and included within segment profit and loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim
periods beginning after December 15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented
in the financial statements. We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December 2023, the FASB issued ASU 2023-09&lt;i&gt;, Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which includes amendments
that further enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine
its impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</iccc:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c0" id="ixv-11358">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;3. CASH
AND CASH EQUIVALENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
and cash equivalents amounted to $978,741 and $5,791,562 as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-18016" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" id="ixv-18017" unitRef="usd">5791562</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-11370">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;4. TRADE
ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade
accounts receivable amounted to $2,185,383 and $1,758,600 as of December 31, 2023 and 2022, respectively. No allowance for bad debt or
product returns was recorded as of December 31, 2023 or 2022. We anticipate no future events or conditions that would impact our ability
to collect our accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our
collection rate is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable
balances included $42,507 and $46,426 due from a related party as of December 31, 2023 or 2022, respectively. See Note 18.&lt;/span&gt;&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-18018" unitRef="usd">2185383</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" id="ixv-18019" unitRef="usd">1758600</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c50" decimals="0" id="ixv-18020" unitRef="usd">42507</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c51" decimals="0" id="ixv-18021" unitRef="usd">46426</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-11408">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;5. INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw
    materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,594,028&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,419,982&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,815,194&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,468,702&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished
    goods&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,619&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,855&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,811,841&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,038,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
inventory figures are net of a $527,133 and $589,204 write-off of scrapped inventory during the years ended December 31, 2023 and 2022,
respectively, that resulted principally from contamination events and other production process losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-11416">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventory
consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31,&lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw
    materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,594,028&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,419,982&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,815,194&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,468,702&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished
    goods&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,619&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,855&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,811,841&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,038,539&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" id="ixv-18022" unitRef="usd">1594028</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="0" id="ixv-18023" unitRef="usd">2419982</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" id="ixv-18024" unitRef="usd">5815194</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c4" decimals="0" id="ixv-18025" unitRef="usd">3468702</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" id="ixv-18026" unitRef="usd">402619</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="0" id="ixv-18027" unitRef="usd">149855</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-18028" unitRef="usd">7811841</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" id="ixv-18029" unitRef="usd">6038539</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="0" id="ixv-18030" unitRef="usd">527133</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c5" decimals="0" id="ixv-18031" unitRef="usd">589204</us-gaap:InventoryWriteDown>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-11526">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;6. PREPAID
EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;454,152&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,733&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,178&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;493,885&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;406,055&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-11534">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;454,152&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,733&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;42,178&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;493,885&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;406,055&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-18032" unitRef="usd">454152</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="0" id="ixv-18033" unitRef="usd">363877</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" id="ixv-18034" unitRef="usd">39733</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c4" decimals="0" id="ixv-18035" unitRef="usd">42178</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-18036" unitRef="usd">493885</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-18037" unitRef="usd">406055</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-11621">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;7. PROPERTY,
PLANT AND EQUIPMENT, net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
plant and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated&lt;br/&gt;

    Useful Lives&lt;br/&gt; (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Laboratory
    and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,953,601&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,181,960&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Buildings
    and improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10-39&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,784,565&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,050,167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-10&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,036,374&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;900,306&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Construction
    in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,768,224&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,668,046&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;516,867&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;516,867&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,059,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,317,346&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,483,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,875,620&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,575,683&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,441,726&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023 and 2022, construction in progress consisted principally of payments toward the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;
production capacity expansion project and equipment needed to bring the formulation and aseptic filling for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;
in-house. Property, plant and equipment disposals were $100,142 and $127,127 during the years ended December 31, 2023 and 2022, respectively.
Depreciation expense was $2,697,897 and $2,468,479 during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-11629">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
plant and equipment consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated&lt;br/&gt;

    Useful Lives&lt;br/&gt; (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Laboratory
    and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,953,601&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,181,960&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Buildings
    and improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10-39&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,784,565&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,050,167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-10&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,036,374&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;900,306&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Construction
    in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,768,224&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,668,046&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;516,867&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;516,867&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,059,631&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,317,346&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,483,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,875,620&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,575,683&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,441,726&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52" id="ixv-18038">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c53" id="ixv-18039">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c54" decimals="0" id="ixv-18040" unitRef="usd">20953601</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c55" decimals="0" id="ixv-18041" unitRef="usd">19181960</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c56" id="ixv-18042">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c57" id="ixv-18043">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c58" decimals="0" id="ixv-18044" unitRef="usd">20784565</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c59" decimals="0" id="ixv-18045" unitRef="usd">20050167</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c60" id="ixv-18046">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c61" id="ixv-18047">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c62" decimals="0" id="ixv-18048" unitRef="usd">1036374</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c63" decimals="0" id="ixv-18049" unitRef="usd">900306</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c64" decimals="0" id="ixv-18050" unitRef="usd">2768224</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c65" decimals="0" id="ixv-18051" unitRef="usd">3668046</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c66" decimals="0" id="ixv-18052" unitRef="usd">516867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c67" decimals="0" id="ixv-18053" unitRef="usd">516867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-18054" unitRef="usd">46059631</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" id="ixv-18055" unitRef="usd">44317346</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-18056" unitRef="usd">18483948</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" id="ixv-18057" unitRef="usd">15875620</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-18058" unitRef="usd">27575683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-18059" unitRef="usd">28441726</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c0" decimals="0" id="ixv-18060" unitRef="usd">100142</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c5" decimals="0" id="ixv-18061" unitRef="usd">127127</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-18062" unitRef="usd">2697897</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" id="ixv-18063" unitRef="usd">2468479</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-11857">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;8. INTANGIBLE
ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets of $191,040 were valued using the relief from royalty method and are being amortized to costs of goods sold over their useful
lives, which are estimated to be 10 years. Intangible amortization expense was $19,104 during both of the years ended December 31, 2023
and 2022. The net value of these intangibles was $38,208 and $57,312 as of December 31, 2023 and December 31, 2022, respectively. Intangible
asset amortization expense is estimated to be $19,104 per year through December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets as of December 31, 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross&#160;Carrying&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br/&gt;
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    Book&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Developed
    technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184,100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;147,280&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,820&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer
    relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,040&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-compete
    agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,640&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,512&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;191,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;152,832&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,208&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets as of December 31, 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross&#160;Carrying&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br/&gt;
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    Book&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Developed
    technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184,100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(128,870&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,230&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer
    relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(910&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-compete
    agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,640&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,692&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;191,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133,728&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,312&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsCurrent contextRef="c3" decimals="0" id="ixv-18064" unitRef="usd">191040</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c3" id="ixv-18065">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-18066" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" id="ixv-18067" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-18068" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-18069" unitRef="usd">57312</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c68" decimals="0" id="ixv-18070" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-11893">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets as of December 31, 2023 consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross&#160;Carrying&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br/&gt;
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    Book&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Developed
    technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184,100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;147,280&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,820&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer
    relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,040&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-compete
    agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,640&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,512&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,128&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;191,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;152,832&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,208&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets as of December 31, 2022 consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross&#160;Carrying&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br/&gt;
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    Book&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Developed
    technology&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184,100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(128,870&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,230&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer
    relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(910&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-compete
    agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,640&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,692&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;191,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133,728&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,312&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c69" decimals="0" id="ixv-18071" unitRef="usd">184100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c69" decimals="0" id="ixv-18072" unitRef="usd">147280</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c69" decimals="0" id="ixv-18073" unitRef="usd">36820</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c70" decimals="0" id="ixv-18074" unitRef="usd">1300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c70" decimals="0" id="ixv-18075" unitRef="usd">1040</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c70" decimals="0" id="ixv-18076" unitRef="usd">260</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c71" decimals="0" id="ixv-18077" unitRef="usd">5640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c71" decimals="0" id="ixv-18078" unitRef="usd">4512</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c71" decimals="0" id="ixv-18079" unitRef="usd">1128</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-18080" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-18081" unitRef="usd">152832</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-18082" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c72" decimals="0" id="ixv-18083" unitRef="usd">184100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c72" decimals="0" id="ixv-18084" unitRef="usd">128870</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c72" decimals="0" id="ixv-18085" unitRef="usd">55230</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c73" decimals="0" id="ixv-18086" unitRef="usd">1300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c73" decimals="0" id="ixv-18087" unitRef="usd">910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c73" decimals="0" id="ixv-18088" unitRef="usd">390</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c74" decimals="0" id="ixv-18089" unitRef="usd">5640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c74" decimals="0" id="ixv-18090" unitRef="usd">3948</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c74" decimals="0" id="ixv-18091" unitRef="usd">1692</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c4" decimals="0" id="ixv-18092" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="0" id="ixv-18093" unitRef="usd">133728</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-18094" unitRef="usd">57312</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-12176">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;9. ACCOUNTS
PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
    payable &#x2013; trade&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;874,558&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;726,736&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
    payable &#x2013; capital&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,175&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63,261&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    payroll&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;942,999&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;966,553&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,550&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,754&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;143,872&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,890&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,124,337&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,862&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-12183">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
    payable &#x2013; trade&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;874,558&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;726,736&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
    payable &#x2013; capital&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,175&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63,261&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    payroll&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;942,999&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;966,553&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,550&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,754&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;143,872&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,890&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,124,337&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,862&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="0" id="ixv-18095" unitRef="usd">874558</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="0" id="ixv-18096" unitRef="usd">726736</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" id="ixv-18097" unitRef="usd">13175</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="0" id="ixv-18098" unitRef="usd">63261</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c3" decimals="0" id="ixv-18099" unitRef="usd">942999</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c4" decimals="0" id="ixv-18100" unitRef="usd">966553</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="0" id="ixv-18101" unitRef="usd">97800</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c4" decimals="0" id="ixv-18102" unitRef="usd">95550</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="0" id="ixv-18103" unitRef="usd">192754</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="0" id="ixv-18104" unitRef="usd">143872</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" id="ixv-18105" unitRef="usd">3051</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c4" decimals="0" id="ixv-18106" unitRef="usd">4890</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-18107" unitRef="usd">2124337</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-18108" unitRef="usd">2000862</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-12346">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;10. BANK
DEBT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loans
#1 and #2&lt;/b&gt;: During the first quarter of 2020, we closed on a debt financing with Gorham Savings Bank (GSB) aggregating $8,600,000,
which was comprised of a $5,100,000 mortgage note (Loan #1) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term
and 25-year amortization schedule and a balloon principal payment of $3,145,888 due during the first quarter of 2030) and a $3,500,000
note (Loan #2) that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from
the 2020 debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working
capital. During the first quarter of 2022, we closed on an additional $2,000,000 in mortgage debt, which bears interest at the fixed
rate of 3.58% per annum. This was accomplished through an amendment of the original mortgage note (Loan #1) that increased the then outstanding
principal balance from $4,233,957 to $6,233,957 bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon
payment from $3,145,888 to $3,687,479 and extended the due date of the balloon payment from the first quarter of 2030 to the first quarter
of 2032.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Line
of Credit (LOC)&lt;/b&gt;: Also during the first quarter of 2020, GSB extended a $1,000,000 LOC to us that is available, as needed, through
September 11, 2025. Interest on borrowings against the LOC is variable at the National Prime Rate per annum. There was no outstanding
balance under this LOC as of December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan
#3&lt;/b&gt;: During the second quarter of 2020, we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount
of $500,000. The first 2.25 years of this loan were interest-free with no interest accrual or required principal payments. Beginning
during the fourth quarter of 2022, Loan #3 became subject to quarterly principal and interest payments at a fixed rate of 5% per annum
over the final five years of the loan, through the third quarter of 2027 if not repaid before then.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan
#4&lt;/b&gt;: During the fourth quarter of 2020, we closed on a $1,500,000 note with GSB that bears interest at a fixed rate of 3.50% per annum
(with a 7-year term and amortization schedule). Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our
mortgage note (Loan #1), which reduced the outstanding balance to 80% of the most recent appraised value of the property securing the
debt, which allowed GSB to release the $1,400,000 that had been held in escrow. The remaining proceeds were available for general working
capital purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan
#5&lt;/b&gt;: On June 30, 2021, we executed definitive agreements covering a second loan from the MTI in the aggregate principal amount of
$400,000, proceeds from which were received in July 2021. The first two years of this loan were interest-free with no interest accrual
or required principal payments. Principal and interest payments at a fixed rate of 5% per annum are due quarterly over the final 5.5
years of the loan, beginning during the third quarter of 2023 and continuing through the fourth quarter of 2028 if not repaid before
then.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan
#6: &lt;/b&gt;During the third quarter of 2023, we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from GSB.
The Finance Authority of Maine (FAME) provided $1,000,000 of loan insurance to GSB. This loan is repayable under a 7-year amortization
schedule with a balloon payment of $1,285,072 due during the third quarter of 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan
#7:&lt;/b&gt; Also during the third quarter of 2023, we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from
FAME. The loan is repayable under a 7-year amortization schedule with a balloon payment of $649,235 due during the third quarter of 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loans
#1, #2, #4, #6 and #7 are secured by liens on substantially all of our assets and are subject to certain restrictions and financial covenants.
Loan #7 is subordinated to Loans #1, #2, #4 and #6. Reflecting our poor financial performance during 2023, the debt covenant requirements
for the twelve-month periods ended December 31, 2023 and June 30, 2024 were waived pre-emptively by our bank. We are required to meet
a minimum debt service coverage (DSC) ratio of 1.35 for the twelve-month period ending September 30, 2024 and then annually after that
beginning with the year ending December 31, 2024. In connection with these credit facilities, we incurred aggregate debt issuance and
debt discount costs of $168,268 ($98,098 and $19,306 of which were incurred during the years ended December 31, 2023 and 2022, respectively).
The amortization of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other
expenses, net, and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured
and subordinated to our indebtedness to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply
with the terms of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment
in full. These loans may be prepaid without penalty at any time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt
proceeds received and principal repayments made (excluding our $1,000,000 line of credit) during the years ended December 31, 2023 and
2022 are reflected in the following table by period and by loan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended&lt;br/&gt;
 December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended &lt;br/&gt;
December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Proceeds
    from&lt;br/&gt; Debt&#160;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt&#160;Principal&lt;br/&gt; Repayments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Proceeds&#160;from&lt;br/&gt; Debt Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt&#160;Principal&lt;br/&gt; Repayments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;223,222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;199,013&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #2&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494,455&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;477,237&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #3&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;91,446&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #4&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205,884&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;198,715&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,017&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #6&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan
    #7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,696&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,185,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;897,125&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Principal
payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of December 31, 2023 (excluding our $1,000,000
line of credit) are reflected in the following table by the year that payments are due:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;230,879&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;239,876&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248,604&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257,649&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;266,537&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,598,360&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,841,905&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #2&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;512,103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;530,738&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;549,881&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;140,458&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,733,180&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #3&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;96,104&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101,001&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,394&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #4&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;220,994&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228,965&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;903,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,470&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;69,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73,415&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,156&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,086&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;367,983&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #6&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;235,369&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;253,003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,418,574&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,906,946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114,632&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,364&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;715,308&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;954,304&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,468,774&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,539,832&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,340,893&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;798,858&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;347,623&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,598,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,094,340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,976&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13,579&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,513&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,347&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71,911&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt discount cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,891&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,891&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,344&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,428,807&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,499,965&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,315,970&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;793,438&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;344,110&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,587,013&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,969,303&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c75" decimals="0" id="ixv-18109" unitRef="usd">8600000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:EscrowDeposit contextRef="c76" decimals="0" id="ixv-18110" unitRef="usd">5100000</us-gaap:EscrowDeposit>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c76" decimals="4" id="ixv-18111" unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <iccc:InterestPaymentsTerm contextRef="c77" id="ixv-18112">P10Y</iccc:InterestPaymentsTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c78" id="ixv-18113">P25Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c79" decimals="0" id="ixv-18114" unitRef="usd">3145888</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c80" decimals="0" id="ixv-18115" unitRef="usd">3500000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c80" decimals="4" id="ixv-18116" unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c81" id="ixv-18117">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount contextRef="c82" decimals="0" id="ixv-18118" unitRef="usd">2000000</us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c82" decimals="4" id="ixv-18119" unitRef="pure">0.0358</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized contextRef="c83" decimals="0" id="ixv-18120" unitRef="usd">4233957</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized contextRef="c84" decimals="0" id="ixv-18121" unitRef="usd">6233957</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c3" decimals="4" id="ixv-18122" unitRef="pure">0.0353</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c83" decimals="0" id="ixv-18123" unitRef="usd">3145888</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c84" decimals="0" id="ixv-18124" unitRef="usd">3687479</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LineOfCredit contextRef="c85" decimals="0" id="ixv-18125" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c86" decimals="0" id="ixv-18126" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c87" id="ixv-18127">P2Y3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeFixedInterestRate contextRef="c88" decimals="2" id="ixv-18128" unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c89" id="ixv-18129">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c90" decimals="0" id="ixv-18130" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c90" decimals="4" id="ixv-18131" unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c91" id="ixv-18132">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c92" decimals="0" id="ixv-18133" unitRef="usd">624167</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <iccc:LoanToValueRatio contextRef="c92" decimals="2" id="ixv-18134" unitRef="pure">0.80</iccc:LoanToValueRatio>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c93" decimals="0" id="ixv-18135" unitRef="usd">1400000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c94" decimals="0" id="ixv-18136" unitRef="usd">400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeFixedInterestRate contextRef="c95" decimals="2" id="ixv-18137" unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c96" id="ixv-18138">P5Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c97" decimals="0" id="ixv-18139" unitRef="usd">2000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c97" decimals="2" id="ixv-18140" unitRef="pure">0.07</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancingReceivableLoanInProcess contextRef="c97" decimals="0" id="ixv-18141" unitRef="usd">1000000</us-gaap:FinancingReceivableLoanInProcess>
    <us-gaap:DebtInstrumentTerm contextRef="c98" id="ixv-18142">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c99" decimals="0" id="ixv-18143" unitRef="usd">1285072</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c100" decimals="0" id="ixv-18144" unitRef="usd">1000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c100"
      decimals="2"
      id="ixv-18145"
      unitRef="pure">0.08</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c101" id="ixv-18146">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c102" decimals="0" id="ixv-18147" unitRef="usd">649235</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <iccc:MinimumDebtServicesCoverageRatio
      contextRef="c103"
      decimals="2"
      id="ixv-18148"
      unitRef="pure">1.35</iccc:MinimumDebtServicesCoverageRatio>
    <us-gaap:DeferredFinanceCostsCurrentGross contextRef="c3" decimals="0" id="ixv-18149" unitRef="usd">168268</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:InterestCostsIncurred contextRef="c0" decimals="0" id="ixv-18150" unitRef="usd">98098</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred contextRef="c5" decimals="0" id="ixv-18151" unitRef="usd">19306</us-gaap:InterestCostsIncurred>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c0" id="ixv-12417">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt
proceeds received and principal repayments made (excluding our $1,000,000 line of credit) during the years ended December 31, 2023 and
2022 are reflected in the following table by period and by loan:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended&lt;br/&gt;
 December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended &lt;br/&gt;
December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Proceeds
    from&lt;br/&gt; Debt&#160;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt&#160;Principal&lt;br/&gt; Repayments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Proceeds&#160;from&lt;br/&gt; Debt Issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt&#160;Principal&lt;br/&gt; Repayments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;223,222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;199,013&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #2&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494,455&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;477,237&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #3&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;91,446&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #4&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205,884&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;198,715&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,017&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #6&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan
    #7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,696&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,185,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;897,125&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c0" decimals="0" id="ixv-18152" unitRef="usd">1000000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c5" decimals="0" id="ixv-18153" unitRef="usd">1000000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:RepaymentsOfBankDebt contextRef="c104" decimals="0" id="ixv-18154" unitRef="usd">223222</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c105" decimals="0" id="ixv-18155" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c105" decimals="0" id="ixv-18156" unitRef="usd">199013</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c106" decimals="0" id="ixv-18157" unitRef="usd">494455</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c107" decimals="0" id="ixv-18158" unitRef="usd">477237</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c108" decimals="0" id="ixv-18159" unitRef="usd">91446</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c109" decimals="0" id="ixv-18160" unitRef="usd">22160</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c110" decimals="0" id="ixv-18161" unitRef="usd">205884</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c111" decimals="0" id="ixv-18162" unitRef="usd">198715</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c112" decimals="0" id="ixv-18163" unitRef="usd">32017</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c114" decimals="0" id="ixv-18164" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c114" decimals="0" id="ixv-18165" unitRef="usd">93054</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c116" decimals="0" id="ixv-18166" unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c116" decimals="0" id="ixv-18167" unitRef="usd">45696</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c0" decimals="0" id="ixv-18168" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" id="ixv-18169" unitRef="usd">1185774</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c5" decimals="0" id="ixv-18170" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c5" decimals="0" id="ixv-18171" unitRef="usd">897125</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0" id="ixv-12778">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Principal
payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of December 31, 2023 (excluding our $1,000,000
line of credit) are reflected in the following table by the year that payments are due:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;230,879&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;239,876&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248,604&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257,649&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;266,537&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,598,360&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,841,905&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #2&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;512,103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;530,738&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;549,881&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;140,458&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,733,180&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #3&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;96,104&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101,001&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;106,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,394&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #4&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213,217&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;220,994&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228,965&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;903,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,470&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;69,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73,415&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,156&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,086&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;367,983&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #6&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;235,369&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;253,003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,418,574&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,906,946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loan #7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114,632&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;124,364&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;715,308&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;954,304&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,468,774&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,539,832&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,340,893&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;798,858&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;347,623&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,598,360&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,094,340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,976&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13,579&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,513&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,347&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71,911&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt discount cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,891&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20,891&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,344&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,428,807&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,499,965&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,315,970&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;793,438&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;344,110&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,587,013&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,969,303&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c3" decimals="0" id="ixv-18172" unitRef="usd">1000000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c118" decimals="0" id="ixv-18173" unitRef="usd">230879</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c118" decimals="0" id="ixv-18174" unitRef="usd">239876</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c118" decimals="0" id="ixv-18175" unitRef="usd">248604</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c118" decimals="0" id="ixv-18176" unitRef="usd">257649</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c118" decimals="0" id="ixv-18177" unitRef="usd">266537</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c118" decimals="0" id="ixv-18178" unitRef="usd">4598360</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c118" decimals="0" id="ixv-18179" unitRef="usd">5841905</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c119" decimals="0" id="ixv-18180" unitRef="usd">512103</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c119" decimals="0" id="ixv-18181" unitRef="usd">530738</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c119" decimals="0" id="ixv-18182" unitRef="usd">549881</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c119" decimals="0" id="ixv-18183" unitRef="usd">140458</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="c119" decimals="0" id="ixv-18184" unitRef="usd">1733180</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c120" decimals="0" id="ixv-18185" unitRef="usd">96104</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c120" decimals="0" id="ixv-18186" unitRef="usd">101001</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c120" decimals="0" id="ixv-18187" unitRef="usd">106146</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c120" decimals="0" id="ixv-18188" unitRef="usd">83143</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="c120" decimals="0" id="ixv-18189" unitRef="usd">386394</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c121" decimals="0" id="ixv-18190" unitRef="usd">213217</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c121" decimals="0" id="ixv-18191" unitRef="usd">220994</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c121" decimals="0" id="ixv-18192" unitRef="usd">228965</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c121" decimals="0" id="ixv-18193" unitRef="usd">240452</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="c121" decimals="0" id="ixv-18194" unitRef="usd">903628</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c122" decimals="0" id="ixv-18195" unitRef="usd">66470</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c122" decimals="0" id="ixv-18196" unitRef="usd">69856</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c122" decimals="0" id="ixv-18197" unitRef="usd">73415</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c122" decimals="0" id="ixv-18198" unitRef="usd">77156</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c122" decimals="0" id="ixv-18199" unitRef="usd">81086</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebt contextRef="c122" decimals="0" id="ixv-18200" unitRef="usd">367983</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c123" decimals="0" id="ixv-18201" unitRef="usd">235369</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c123" decimals="0" id="ixv-18202" unitRef="usd">253003</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c123" decimals="0" id="ixv-18203" unitRef="usd">1418574</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c123" decimals="0" id="ixv-18204" unitRef="usd">1906946</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c124" decimals="0" id="ixv-18205" unitRef="usd">114632</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c124" decimals="0" id="ixv-18206" unitRef="usd">124364</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c124" decimals="0" id="ixv-18207" unitRef="usd">715308</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c124" decimals="0" id="ixv-18208" unitRef="usd">954304</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c125" decimals="0" id="ixv-18209" unitRef="usd">1468774</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c125" decimals="0" id="ixv-18210" unitRef="usd">1539832</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c125" decimals="0" id="ixv-18211" unitRef="usd">3340893</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c125" decimals="0" id="ixv-18212" unitRef="usd">798858</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c125" decimals="0" id="ixv-18213" unitRef="usd">347623</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c125" decimals="0" id="ixv-18214" unitRef="usd">4598360</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c125" decimals="0" id="ixv-18215" unitRef="usd">12094340</us-gaap:LongTermDebt>
    <iccc:DebtIssuanceCosts2023 contextRef="c3" decimals="0" id="ixv-18216" unitRef="usd">19076</iccc:DebtIssuanceCosts2023>
    <iccc:DebtIssuanceCosts2024 contextRef="c3" decimals="0" id="ixv-18217" unitRef="usd">18976</iccc:DebtIssuanceCosts2024>
    <iccc:DebtIssuanceCosts2025 contextRef="c3" decimals="0" id="ixv-18218" unitRef="usd">13579</iccc:DebtIssuanceCosts2025>
    <iccc:DebtIssuanceCosts2026 contextRef="c3" decimals="0" id="ixv-18219" unitRef="usd">5420</iccc:DebtIssuanceCosts2026>
    <iccc:DebtIssuanceCosts2027 contextRef="c3" decimals="0" id="ixv-18220" unitRef="usd">3513</iccc:DebtIssuanceCosts2027>
    <iccc:DebtIssuanceCostshereafter contextRef="c3" decimals="0" id="ixv-18221" unitRef="usd">11347</iccc:DebtIssuanceCostshereafter>
    <us-gaap:DeferredFinanceCostsNet contextRef="c3" decimals="0" id="ixv-18222" unitRef="usd">71911</us-gaap:DeferredFinanceCostsNet>
    <iccc:DebtDiscountCost contextRef="c3" decimals="0" id="ixv-18223" unitRef="usd">20891</iccc:DebtDiscountCost>
    <iccc:DebtDiscountCost2024 contextRef="c3" decimals="0" id="ixv-18224" unitRef="usd">20891</iccc:DebtDiscountCost2024>
    <iccc:DebtDiscountCost2025 contextRef="c3" decimals="0" id="ixv-18225" unitRef="usd">11344</iccc:DebtDiscountCost2025>
    <iccc:DebtDiscountCostTotal contextRef="c3" decimals="0" id="ixv-18226" unitRef="usd">53126</iccc:DebtDiscountCostTotal>
    <iccc:LongTermDebt2023 contextRef="c3" decimals="0" id="ixv-18227" unitRef="usd">1428807</iccc:LongTermDebt2023>
    <iccc:LongTermDebt2024 contextRef="c3" decimals="0" id="ixv-18228" unitRef="usd">1499965</iccc:LongTermDebt2024>
    <iccc:LongTermDebt2025 contextRef="c3" decimals="0" id="ixv-18229" unitRef="usd">3315970</iccc:LongTermDebt2025>
    <iccc:LongTermDebt2026 contextRef="c3" decimals="0" id="ixv-18230" unitRef="usd">793438</iccc:LongTermDebt2026>
    <iccc:LongTermDebt2027 contextRef="c3" decimals="0" id="ixv-18231" unitRef="usd">344110</iccc:LongTermDebt2027>
    <iccc:LongTermDebtThereafter contextRef="c3" decimals="0" id="ixv-18232" unitRef="usd">4587013</iccc:LongTermDebtThereafter>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c3" decimals="0" id="ixv-18233" unitRef="usd">11969303</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-13503">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;11. CONTINGENT
LIABILITIES AND COMMITMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Our
bylaws, as amended, in effect provide that the Company will indemnify its officers and directors against any liability arising from their
responsibilities as officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings
with each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make
under such provisions is theoretically unlimited and is impossible to determine. We maintain directors&#x2019; and officers&#x2019; liability
insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the
indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460&lt;i&gt;, Guarantees&lt;/i&gt;.
Accordingly, we have recorded no liability for such obligations as of December 31, 2023 or 2022. Since our incorporation, we have had
no occasion to make any indemnification payment to any of our officers or directors for any reason.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted
against us during the normal course of business. We are aware of no such claims against us as of the date of this filing. We believe
that we have reasonable levels of liability insurance to support our operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties
from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases,
we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We
have not incurred material expenses in discharging any of these indemnification obligations and based on our analysis of the nature of
the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly,
we recorded no liabilities for such obligations as of December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
plan to purchase certain key parts (syringes) and services (formulation, aseptic filling and final packaging) pertaining to &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;
&lt;/sup&gt;&lt;/b&gt;Drug Product (DP), our Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from
contractors. The contract for formulation, aseptic filling and final packaging of DP is scheduled to terminate after the supply of product
for our initial controlled market launch. We initiated an investment in the necessary equipment to perform the DP formulation and aseptic
filling services in-house, but this investment has been paused at the present time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
enter into compensation agreements (which are publicly filed) with our three executive officers. Effective March 28, 2022, we entered
into an Amended and Restated Separation and Deferred Compensation Agreement (the &#x201c;Deferred Compensation Agreement&#x201d;) with
Mr. Brigham (our President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company
and Mr. Brigham. Upon separation from the Company for any reason, Mr. Brigham&#x2019;s Deferred Compensation Agreement allows Mr. Brigham
to be paid, among other amounts, all earned and unused paid time off (which expense totaling $222,379 was accrued during the first quarter
of 2022 and $230,162 and $222,379 was included in accounts payable and accrued expenses on the accompanying balance sheets as of December
31, 2023 and 2022, respectively) and to receive up to an additional $300,000 in deferred compensation (which amount is being accrued
over the three-year period ending in January 2025). This deferred compensation payment vested as to $100,000 on January 1, 2023 and an
additional $100,000 on January 1, 2024. An additional $&lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;100,00&lt;/span&gt; will vest on January 1, 2025, provided that Mr. Brigham is employed by
the Company as of January 2025. The vested amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following
his separation from the Company. As of December 31, 2023 and 2022, $200,000 and $100,000, respectively, was included in accounts payable
and accrued expenses on the accompanying balance sheets. In addition, upon termination of Mr. Brigham&#x2019;s employment (a) by the Company
other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in
the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual base salary and a lump sum
payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month
period following termination, and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination
in accordance with the terms of the Deferred Compensation Agreement. Incentive Compensation Agreements with Mr. Brigham, Ms. Brockmann
(our Vice President of Sales and Marketing) and Ms. Williams (our Vice President of Manufacturing Operations) allow these executives
to earn incentive compensation if certain regulatory and financial objectives are met during the year to which the agreement relates,
as specified in their agreements. Amounts related to these incentive compensation agreements are accrued over the period they are earned
(when it is probable that the amounts will be earned) based on our best estimate of the amounts expected to be earned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition to the commitments discussed above, we had committed $41,000 to increase our production capacity for the &lt;b&gt;First Defense&lt;sup&gt;&#xae;
&lt;/sup&gt;&lt;/b&gt;product line, $2,345,000 to the purchase of inventory, $7,000 related to the commercial manufacture of &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;
&lt;/sup&gt;&lt;/b&gt;and $307,000 to other obligations as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <iccc:NumberOfExecutiveOfficers contextRef="c0" decimals="0" id="ixv-18234" unitRef="pure">3</iccc:NumberOfExecutiveOfficers>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c126" decimals="0" id="ixv-18235" unitRef="usd">222379</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c127" decimals="0" id="ixv-18236" unitRef="usd">230162</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c128" decimals="0" id="ixv-18237" unitRef="usd">222379</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c3" decimals="0" id="ixv-18238" unitRef="usd">300000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c129" decimals="0" id="ixv-18239" unitRef="usd">100000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c130" decimals="0" id="ixv-18240" unitRef="usd">100000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-18241" unitRef="usd">200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="0" id="ixv-18242" unitRef="usd">100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage contextRef="c0" decimals="2" id="ixv-18243" unitRef="pure">1</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <iccc:CapitalExpendituresCommitted contextRef="c3" decimals="0" id="ixv-18244" unitRef="usd">41000</iccc:CapitalExpendituresCommitted>
    <us-gaap:OtherCommitment contextRef="c3" decimals="0" id="ixv-18245" unitRef="usd">2345000</us-gaap:OtherCommitment>
    <iccc:InventoryProduction contextRef="c3" decimals="0" id="ixv-18246" unitRef="usd">7000</iccc:InventoryProduction>
    <iccc:OtherObligations contextRef="c3" decimals="0" id="ixv-18247" unitRef="usd">307000</iccc:OtherObligations>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c0" id="ixv-13587">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;12. OPERATING
LEASES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 12, 2019, we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession
date of November 15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland (&lt;b&gt;Building
175A&lt;/b&gt;), which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space
to meet our needs in expanding our production capacity for the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line. The original lease
term was ten years with a right to renew for a second 10-year term and a right of first offer to purchase. At the time we entered into
this lease, we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that
reason, a 10-year period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter
of 2022, we committed to lease an additional 15,400 square feet of space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;), which is connected
to the original space, over a 20-year term. The ROU asset and lease liability for the committed space at &lt;b&gt;Building 175B&lt;/b&gt; was recorded
as of April 1, 2023 after construction of the building shell was completed in accordance with the lease agreement. Monthly lease payments
commenced as of August 1, 2023. In connection with the lease commitment for space at &lt;b&gt;Building 175B, &lt;/b&gt;the term of the original lease
for &lt;b&gt;Building 175A&lt;/b&gt; was extended by approximately 13 years. On November 14, 2023, we amended this lease further to provide for certain
tenant improvements on the leased premises to be paid for by our landlord. These improvements will provide heat to an unfinished space,
provide additional warehouse space, and create a new primary shipping and receiving facility. In consideration for the landlord agreeing
to pay for the cost of those certain tenant improvements, we are obligated to make additional rent payments of $20,000 per month from
November 2023 through June 2024 and a one-time additional rent payment of $488,743 in July 2024. The total lease liability for both leases
over the amended terms (including inflationary adjustments) aggregates $4,739,077 as of November 14, 2023. Because of this modification
to the lease payments, the ROU asset and lease liability associated with the space at &lt;b&gt;Building 175B&lt;/b&gt; were remeasured as of the
modification date. Our leases include variable non-lease components. Such payments primarily include common area maintenance charges.
As of December 31, 2023, the balance of the operating lease ROU asset was $4,571,149 and the operating lease liability was $4,721,385.
As of December 31, 2022, the balance of the operating lease ROU asset was $2,194,670 and the operating lease liability was $2,249,182.
The calculated amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for
the present value of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying
assets, and instead to account for them as a single lease component. Variable lease cost primarily represents variable payments such
as real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;348,929&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,176&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Variable
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,404&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;385,703&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185,580&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248,595&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;148,302&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining
    lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average
    discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Future
lease payments required under non-cancelable operating leases in effect as of December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;During the years ending
    December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;946,003&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;342,880&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;349,744&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,870&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,949,488&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments (undiscounted cash flows)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,308,717&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: imputed interest
    (discount effect of cash flows)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,587,332&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,721,385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="c131"
      decimals="0"
      id="ixv-18248"
      unitRef="sqft">14300</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c3" id="ixv-18249">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c3" id="ixv-18250">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="c132"
      decimals="0"
      id="ixv-18251"
      unitRef="sqft">15400</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c132" id="ixv-18252">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent contextRef="c133" decimals="0" id="ixv-18253" unitRef="usd">20000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" id="ixv-18254" unitRef="usd">488743</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c134" decimals="0" id="ixv-18255" unitRef="usd">4739077</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-18256" unitRef="usd">4571149</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-18257" unitRef="usd">4721385</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" id="ixv-18258" unitRef="usd">2194670</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="0" id="ixv-18259" unitRef="usd">2249182</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-18260">The following tables describe our lease costs and other lease information:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;348,929&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;149,176&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Variable
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,404&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;385,703&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185,580&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248,595&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;148,302&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining
    lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average
    discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" id="ixv-18261" unitRef="usd">348929</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="0" id="ixv-18262" unitRef="usd">149176</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c0" decimals="0" id="ixv-18263" unitRef="usd">36774</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c5" decimals="0" id="ixv-18264" unitRef="usd">36404</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" id="ixv-18265" unitRef="usd">385703</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c5" decimals="0" id="ixv-18266" unitRef="usd">185580</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-18267" unitRef="usd">248595</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c5" decimals="0" id="ixv-18268" unitRef="usd">148302</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-13769">P19Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-13778">P20Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="4" id="ixv-18269" unitRef="pure">0.0711</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="4" id="ixv-18270" unitRef="pure">0.0554</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-13804">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Future
lease payments required under non-cancelable operating leases in effect as of December 31, 2023 were as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;During the years ending
    December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;946,003&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;342,880&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;349,744&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363,870&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,949,488&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease payments (undiscounted cash flows)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,308,717&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: imputed interest
    (discount effect of cash flows)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,587,332&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,721,385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="0" id="ixv-18271" unitRef="usd">946003</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" id="ixv-18272" unitRef="usd">342880</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="0" id="ixv-18273" unitRef="usd">349744</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="0" id="ixv-18274" unitRef="usd">356732</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c3" decimals="0" id="ixv-18275" unitRef="usd">363870</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c3" decimals="0" id="ixv-18276" unitRef="usd">5949488</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" id="ixv-18277" unitRef="usd">8308717</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="0" id="ixv-18278" unitRef="usd">3587332</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-18279" unitRef="usd">4721385</us-gaap:OperatingLeaseLiability>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-13945">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;13. STOCKHOLDERS&#x2019;
EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock
Issuances&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;From
February 2016 to April 2021, we sold the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds
of $26,714,403 at the weighted average price of $5.87 per share. These funds have been essential to funding our business growth plans.
The details of each transaction are discussed below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1)
During February of 2016, we sold 1,123,810 shares of common stock at a price to the public of $5.25 per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $5,900,003 and resulting in net
proceeds to the Company of $5,313,224 (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2)
During October of 2016, we sold, in a private placement, 659,880 shares of common stock to nineteen institutional and accredited investors
at $5.25 per share, raising gross proceeds of $3,464,370 and resulting in net proceeds to the Company of $3,160,923 (after deducting
placement agent fees and other expenses incurred in connection with the equity financing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3)
During July of 2017, we sold 200,000 shares of our common stock at a price of $5.25 per share in a public, registered sale to two related
investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $1,050,000 and resulting in net
proceeds of $1,034,164 (after deducting expenses incurred in connection with the equity financing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4)
During December of 2017, we sold 417,807 shares of common stock at a price to the public of $7.30 per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $3,049,991 and resulting in net
proceeds to the Company of $2,734,173 (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5)
During March of 2019, we sold 1,636,364 shares of common stock at a price to the public of $5.50 per share in an underwritten public
offering pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $9,000,002 and resulting in net
proceeds to the Company of $8,303,436 (after deducting underwriting discounts and offering expenses incurred in connection with the equity
financing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6)
During April of 2021, we sold 515,156 shares of our common stock at a price of $8.25 per share in a public, registered sale to seven
investors pursuant to our effective shelf registration statement on Form S-3, raising gross proceeds of $4,250,038 and resulting in net
proceeds of $4,233,026 (after deducting expenses incurred in connection with the equity financing).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock Option
Plans&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2010, our stockholders approved the 2010 Stock Option and Incentive Plan (the &#x201c;2010 Plan&#x201d;) pursuant to the provisions
of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of
the Company&#x2019;s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock
were reserved for issuance under the 2010 Plan and subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements
are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted
under the 2010 Plan expire no later than 10 years from the date of grant. The 2010 Plan expired in June 2020, after which date no further
options can be granted under the 2010 Plan. However, options outstanding under the 2010 Plan at that time can be exercised in accordance
with their terms. There were 188,500 and 202,500 options outstanding under the 2010 Plan as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2017, our stockholders approved the 2017 Stock Option and Incentive Plan (the &#x201c;2017 Plan&#x201d;) pursuant to the provisions
of the Internal Revenue Code of 1986, under which employees and certain service providers may be granted options to purchase shares of
the Company&#x2019;s common stock at no less than fair market value on the date of grant. At that time, 300,000 shares of common stock
were reserved for issuance under the 2017 Plan. An amendment to the 2017 Plan increasing the number of shares reserved for issuance under
the 2017 Plan from 300,000 shares to 650,000 shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June
2022. Vesting requirements are determined by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case
basis. All options granted under the 2017 Plan expire no later than 10 years from the date of grant. The 2017 Plan expires in March 2027,
after which date no further options can be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time
can be exercised in accordance with their terms. As of December 31, 2023 and 2022, there were 430,000 and 402,500 options outstanding
under the 2017 Plan, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Activity
under the stock option plans described above was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2010
    Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2017
    Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt;
    Intrinsic&lt;br/&gt;
    Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;218,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;468,425&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;210,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.34&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(661,310&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(94,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;430,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,071,121&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(377,712&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected
    to vest as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;430,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,071,121&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reserved for future grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Terminations and forfeitures are recognized when they occur.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table displays additional information about the stock option plans described above:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average &lt;br/&gt; Fair Value at Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-vested
    stock options as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;307,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.71&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-vested stock options
    as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;337,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options granted during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options that vested during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options that were terminated or forfeited during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2023, 4,000 stock options were exercised by one employee with $18,760 in cash. During the year ended December
31, 2022, one former employee and two employees exercised stock options covering 5,000 shares with $30,670 in cash. The aggregate intrinsic
value of options exercised during the years ended December 31, 2023 and 2022 was $1,040 and $10,525, respectively. The weighted average
remaining life of the options outstanding under the 2010 Plan and the 2017 Plan as of December 31, 2023 was approximately 5 years and
8 months. The weighted average remaining life of the options exercisable under these plans as of December 31, 2023 was approximately
3 years and 6 months. The exercise prices of the options outstanding as of December 31, 2023 ranged from $4.00 to $10.04 per share. The
122,000 stock options granted during the year ended December 31, 2023 had exercise prices between $4.61 and $5.22 per share. The 210,500
stock options granted during the year ended December 31, 2022 had exercise prices between $6.52 and $9.39 per share. The weighted-average
grant date fair values of options granted during the year ended December 31, 2023 and 2022 were $2.80 and $4.03 per share, respectively.
As of December 31, 2023, total unrecognized stock-based compensation related to non-vested stock options aggregated $619,845, which will
be recognized over a weighted average remaining period of approximately 1 year and 8 months. The fair value of each stock option grant
has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the
following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.59%&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.04%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54%&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The dividend yield and expected volatility are derived from averages of our historical data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock
Rights Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 1995, our Board of Directors adopted a Common Stock Rights Plan (the &#x201c;Rights Plan&#x201d;) and declared a dividend of
one common share purchase right (a &#x201c;Right&#x201d;) for each of the then outstanding shares of the common stock of the Company. Each
Right entitles the registered holder to purchase from the Company one share of common stock at an initial purchase price of $70.00 per
share, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement between the Company and Equiniti
Trust Company, LLC, as Rights Agent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public
announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined
in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement
of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding
common stock (the earlier of such dates being called the Distribution Date).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Upon
the Distribution Date, the holder of each Right not owned by the Acquiring Person would be entitled to purchase common stock at a discount
to the initial purchase price of $70.00 per share, effectively equal to one half of the market price of a share of common stock on the
date the Acquiring Person becomes an Acquiring Person. If, after the Distribution Date, the Company should consolidate or merge with
any other entity and the Company were not the surviving company, or, if the Company were the surviving company, all or part of the Company&#x2019;s
common stock were changed or exchanged into the securities of any other entity, or if more than 50% of the Company&#x2019;s assets or
earning power were sold, each Right would entitle its holder to purchase, at the Rights&#x2019; then-current purchase price, a number
of shares of the acquiring company&#x2019;s common stock having a market value at that time equal to twice the Right&#x2019;s exercise
price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
any time after a person or group becomes an Acquiring Person and prior to the acquisition by such person or group of 50% or more of the
outstanding common stock, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such person or group
which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment). At
any time prior to 14 days following the date that any person or group becomes an Acquiring Person (subject to extension by the Board
of Directors), the Board of Directors of the Company may redeem the then outstanding Rights in whole, but not in part, at a price of
$0.005 per Right, subject to adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the third quarter of 2011, our Board of Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold
for determining &#x201c;Acquiring Person&#x201d; status to 20%. During the second quarter of 2015, our Board of Directors also voted to
authorize an amendment to remove a provision that prevented a new group of directors elected following the emergence of an Acquiring
Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan
with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts. Each time that
we made such amendments we entered into amendments to the Rights Agreement with the Rights Agent reflecting such extensions, threshold
increases or provision changes. No other changes have been made to the terms of the Rights or the Rights Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
various times over the years, our Board of Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments
to the Rights Plan to extend the expiration date of the Rights Plan. Our Board of Directors decided to seek an advisory vote by stockholders
at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of
the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board
of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory
vote by stockholders at the Annual Meeting of Stockholders held in June 2023, as to whether to extend the Rights Plan by another year
to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained.
On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that
there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually
cast on these proposals in deciding whether to extend the expiration date of such plan by one year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized
Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the June 14, 2018 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation
to increase the number of shares of common stock authorized for issuance from 8,000,000 to 11,000,000. At the June 10, 2020 Annual Meeting
of Stockholders, our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares
of common stock authorized for issuance from 11,000,000 to 15,000,000.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c135"
      decimals="0"
      id="ixv-18280"
      unitRef="shares">4553017</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c135" decimals="0" id="ixv-18281" unitRef="usd">26714403</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c136"
      decimals="2"
      id="ixv-18282"
      unitRef="usdPershares">5.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c137"
      decimals="0"
      id="ixv-18283"
      unitRef="shares">1123810</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c138"
      decimals="2"
      id="ixv-18284"
      unitRef="usdPershares">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c137" decimals="0" id="ixv-18285" unitRef="usd">5900003</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c137" decimals="0" id="ixv-18286" unitRef="usd">5313224</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c139"
      decimals="0"
      id="ixv-18287"
      unitRef="shares">659880</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c140"
      decimals="2"
      id="ixv-18288"
      unitRef="usdPershares">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c139" decimals="0" id="ixv-18289" unitRef="usd">3464370</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c139" decimals="0" id="ixv-18290" unitRef="usd">3160923</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c141"
      decimals="0"
      id="ixv-18291"
      unitRef="shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c142"
      decimals="2"
      id="ixv-18292"
      unitRef="usdPershares">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c141" decimals="0" id="ixv-18293" unitRef="usd">1050000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c141" decimals="0" id="ixv-18294" unitRef="usd">1034164</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c143"
      decimals="0"
      id="ixv-18295"
      unitRef="shares">417807</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c144"
      decimals="2"
      id="ixv-18296"
      unitRef="usdPershares">7.3</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c143" decimals="0" id="ixv-18297" unitRef="usd">3049991</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c143" decimals="0" id="ixv-18298" unitRef="usd">2734173</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c145"
      decimals="0"
      id="ixv-18299"
      unitRef="shares">1636364</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c146"
      decimals="2"
      id="ixv-18300"
      unitRef="usdPershares">5.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c145" decimals="0" id="ixv-18301" unitRef="usd">9000002</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c145" decimals="0" id="ixv-18302" unitRef="usd">8303436</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c147"
      decimals="0"
      id="ixv-18303"
      unitRef="shares">515156</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c148"
      decimals="2"
      id="ixv-18304"
      unitRef="usdPershares">8.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c147" decimals="0" id="ixv-18305" unitRef="usd">4250038</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c147" decimals="0" id="ixv-18306" unitRef="usd">4233026</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c149"
      decimals="0"
      id="ixv-18307"
      unitRef="shares">300000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c150" id="ixv-18308">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c149"
      decimals="0"
      id="ixv-18309"
      unitRef="shares">188500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c151"
      decimals="0"
      id="ixv-18310"
      unitRef="shares">202500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c152"
      decimals="0"
      id="ixv-18311"
      unitRef="shares">300000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c153"
      decimals="0"
      id="ixv-18312"
      unitRef="shares">300000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c154"
      decimals="0"
      id="ixv-18313"
      unitRef="shares">650000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c155" id="ixv-18314">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c156"
      decimals="0"
      id="ixv-18315"
      unitRef="shares">430000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c157"
      decimals="0"
      id="ixv-18316"
      unitRef="shares">402500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-14021">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Activity
under the stock option plans described above was as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2010
    Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2017
    Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt;
    Intrinsic&lt;br/&gt;
    Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;218,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;468,425&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;210,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.34&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;402,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(661,310&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(94,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercises&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;430,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,071,121&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(377,712&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected
    to vest as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;430,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,071,121&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reserved for future grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Terminations and forfeitures are recognized when they occur.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c170"
      decimals="INF"
      id="ixv-18317"
      unitRef="shares">218500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c171"
      decimals="INF"
      id="ixv-18318"
      unitRef="shares">224500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c10"
      decimals="2"
      id="ixv-18319"
      unitRef="usdPershares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c10" decimals="0" id="ix_0_fact" unitRef="usd">468425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c173"
      decimals="INF"
      id="ixv-18321"
      unitRef="shares">210500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-18322"
      unitRef="usdPershares">7.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c172"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c173"
      decimals="INF"
      id="ix_6_fact"
      unitRef="shares">32500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">7.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c172"
      decimals="INF"
      id="ixv-18326"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-18327"
      unitRef="usdPershares">6.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c174"
      decimals="INF"
      id="ixv-18328"
      unitRef="shares">202500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c175"
      decimals="INF"
      id="ixv-18329"
      unitRef="shares">402500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-18330"
      unitRef="usdPershares">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c4" decimals="0" id="ix_1_fact" unitRef="usd">-661310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c177"
      decimals="INF"
      id="ixv-18332"
      unitRef="shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-18333"
      unitRef="usdPershares">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c176"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c177"
      decimals="INF"
      id="ix_9_fact"
      unitRef="shares">94500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ix_10_fact"
      unitRef="usdPershares">7.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c176"
      decimals="INF"
      id="ixv-18337"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-18338"
      unitRef="usdPershares">4.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c178"
      decimals="INF"
      id="ixv-18339"
      unitRef="shares">188500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c179"
      decimals="INF"
      id="ixv-18340"
      unitRef="shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-18341"
      unitRef="usdPershares">6.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="0" id="ix_2_fact" unitRef="usd">-1071121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested
      contextRef="c178"
      decimals="INF"
      id="ixv-18343"
      unitRef="shares">188500</iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested>
    <iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested
      contextRef="c179"
      decimals="INF"
      id="ixv-18344"
      unitRef="shares">92500</iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested>
    <iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested
      contextRef="c3"
      decimals="2"
      id="ixv-18345"
      unitRef="usdPershares">6.43</iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested>
    <iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" id="ix_3_fact" unitRef="usd">-377712</iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c178"
      decimals="INF"
      id="ixv-18347"
      unitRef="shares">188500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c179"
      decimals="INF"
      id="ixv-18348"
      unitRef="shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-18349"
      unitRef="usdPershares">6.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" id="ix_4_fact" unitRef="usd">-1071121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c179"
      decimals="INF"
      id="ixv-18351"
      unitRef="shares">202000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="c0" id="ixv-14507">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table displays additional information about the stock option plans described above:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average &lt;br/&gt; Fair Value at Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-vested
    stock options as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;307,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.71&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-vested stock options
    as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;337,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options granted during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options that vested during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options that were terminated or forfeited during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c180"
      decimals="0"
      id="ixv-18352"
      unitRef="shares">307000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c180"
      decimals="2"
      id="ixv-18353"
      unitRef="usdPershares">3.8</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c180"
      decimals="2"
      id="ixv-18354"
      unitRef="usdPershares">7.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c181"
      decimals="0"
      id="ixv-18355"
      unitRef="shares">337500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c181"
      decimals="2"
      id="ixv-18356"
      unitRef="usdPershares">3.66</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c181"
      decimals="2"
      id="ixv-18357"
      unitRef="usdPershares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c182"
      decimals="0"
      id="ixv-18358"
      unitRef="shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c182"
      decimals="2"
      id="ixv-18359"
      unitRef="usdPershares">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c182"
      decimals="2"
      id="ixv-18360"
      unitRef="usdPershares">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c182"
      decimals="0"
      id="ixv-18361"
      unitRef="shares">57000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c182"
      decimals="2"
      id="ixv-18362"
      unitRef="usdPershares">2.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c182"
      decimals="2"
      id="ixv-18363"
      unitRef="usdPershares">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c182"
      decimals="0"
      id="ixv-18364"
      unitRef="shares">104500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="c182"
      decimals="2"
      id="ixv-18365"
      unitRef="usdPershares">3.3</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c182"
      decimals="2"
      id="ixv-18366"
      unitRef="usdPershares">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      decimals="0"
      id="ixv-18367"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="0" id="ixv-18368" unitRef="usd">18760</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <iccc:StockOptionsCoveringShares
      contextRef="c5"
      decimals="0"
      id="ixv-18369"
      unitRef="shares">5000</iccc:StockOptionsCoveringShares>
    <iccc:StockOptionsCoveringcash contextRef="c5" decimals="0" id="ixv-18370" unitRef="usd">30670</iccc:StockOptionsCoveringcash>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c0" decimals="0" id="ixv-18371" unitRef="usd">1040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c5" decimals="0" id="ixv-18372" unitRef="usd">10525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c150" id="ixv-18373">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c155" id="ixv-18374">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c150" id="ixv-18375">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c155" id="ixv-18376">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c158"
      decimals="2"
      id="ixv-18377"
      unitRef="usdPershares">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c159"
      decimals="2"
      id="ixv-18378"
      unitRef="usdPershares">10.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c150"
      decimals="0"
      id="ixv-18379"
      unitRef="shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c160"
      decimals="2"
      id="ixv-18380"
      unitRef="usdPershares">4.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c161"
      decimals="2"
      id="ixv-18381"
      unitRef="usdPershares">5.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c5"
      decimals="0"
      id="ixv-18382"
      unitRef="shares">210500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c162"
      decimals="2"
      id="ixv-18383"
      unitRef="usdPershares">6.52</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c5"
      decimals="2"
      id="ixv-18384"
      unitRef="usdPershares">9.39</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c163"
      decimals="2"
      id="ixv-18385"
      unitRef="usdPershares">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c164"
      decimals="2"
      id="ixv-18386"
      unitRef="usdPershares">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c3" decimals="0" id="ixv-18387" unitRef="usd">619845</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c0" id="ixv-18388">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-18389">The fair value of each stock option grant
has been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the
following weighted-average assumptions:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.59%&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.04%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54%&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The dividend yield and expected volatility are derived from averages of our historical data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ix_11_fact" unitRef="pure">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="4" id="ix_12_fact" unitRef="pure">0.0304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" id="ix_13_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" id="ix_14_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="2" id="ix_15_fact" unitRef="pure">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="2" id="ix_16_fact" unitRef="pure">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ix_17_fact">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5" id="ix_18_fact">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="c0"
      decimals="2"
      id="ixv-18398"
      unitRef="usdPershares">70</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <iccc:ExercisableAndTransferableDescription contextRef="c0" id="ixv-14843">The
Rights (as amended) become exercisable and transferable apart from the common stock upon the earlier of i) 10 days following a public
announcement that a person or group (Acquiring Person) has, without the prior consent of the Continuing Directors (as such term is defined
in the Rights Agreement), acquired beneficial ownership of 20% or more of the outstanding common stock or ii) 10 days following commencement
of a tender offer or exchange offer the consummation of which would result in ownership by a person or group of 20% or more of the outstanding
common stock (the earlier of such dates being called the Distribution Date).</iccc:ExercisableAndTransferableDescription>
    <us-gaap:InvestmentCompanyPurchasePremiumPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-18399"
      unitRef="usdPershares">70</us-gaap:InvestmentCompanyPurchasePremiumPerShare>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets contextRef="c0" decimals="2" id="ixv-18400" unitRef="pure">0.50</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c165"
      decimals="2"
      id="ixv-18401"
      unitRef="pure">0.50</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <iccc:RightToAcquirePerShare
      contextRef="c0"
      decimals="3"
      id="ixv-18402"
      unitRef="usdPershares">0.005</iccc:RightToAcquirePerShare>
    <iccc:AcquiringPersonPercentage contextRef="c83" decimals="2" id="ixv-18403" unitRef="pure">0.20</iccc:AcquiringPersonPercentage>
    <iccc:AcquiringPersonPercentage contextRef="c84" decimals="2" id="ixv-18404" unitRef="pure">0.20</iccc:AcquiringPersonPercentage>
    <us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription contextRef="c0" id="ixv-18405">Our Board of Directors decided to seek an advisory vote by stockholders
at the Annual Meeting of Stockholders held in June 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of
the votes actually cast on this proposal, 65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board
of Directors voted to extend the Rights Plan by one year to September 19, 2023. Our Board of Directors decided to seek another advisory
vote by stockholders at the Annual Meeting of Stockholders held in June 2023, as to whether to extend the Rights Plan by another year
to September 19, 2024. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained.
On the basis of this vote, our Board of Directors voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that
there might be a substantial number of broker non-votes, our Board of Directors disclosed that it would be guided by the votes actually
cast on these proposals in deciding whether to extend the expiration date of such plan by one year.</us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c166"
      decimals="0"
      id="ixv-18406"
      unitRef="shares">8000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c167"
      decimals="0"
      id="ixv-18407"
      unitRef="shares">11000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c168"
      decimals="0"
      id="ixv-18408"
      unitRef="shares">11000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c169"
      decimals="0"
      id="ixv-18409"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-14894">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;14.
REVENUE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
primarily offer the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line to dairy and beef producers to prevent scours in newborn calves.
Generally, our products are promoted to veterinarians as well as dairy and beef producers by our sales team and then sold through distributors.
Our primary market is North America. We do sell into select international regions and may expand this international reach in the future.
There were no material changes between the allocation and timing of revenue recognition during the years ended December 31, 2023 or 2022.
We do not have any contract assets for which we have satisfied the performance obligations, but do not yet have the right to bill for,
or contract liabilities such as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur
no material costs to obtain contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents our product sales disaggregated by geographic area:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;United
    States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,949,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,020,797&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,522,287&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,547,165&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    Product Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,471,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,567,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents our product sales disaggregated by major product category:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;First
    Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; &lt;span style="font-style: normal; font-weight: normal"&gt;product line&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,293,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,411,949&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    animal health&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;177,736&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;156,013&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    Product Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,471,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,567,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-14908">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents our product sales disaggregated by geographic area:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;United
    States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,949,382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,020,797&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,522,287&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,547,165&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    Product Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,471,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,567,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c183" decimals="0" id="ixv-18410" unitRef="usd">15949382</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c183"
      decimals="2"
      id="ixv-18411"
      unitRef="pure">0.91</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c184" decimals="0" id="ixv-18412" unitRef="usd">17020797</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c184"
      decimals="2"
      id="ixv-18413"
      unitRef="pure">0.92</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c185" decimals="0" id="ixv-18414" unitRef="usd">1522287</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c185"
      decimals="2"
      id="ixv-18415"
      unitRef="pure">0.09</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c186" decimals="0" id="ixv-18416" unitRef="usd">1547165</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c186"
      decimals="2"
      id="ixv-18417"
      unitRef="pure">0.08</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-18418" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage contextRef="c0" decimals="2" id="ixv-18419" unitRef="pure">1</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-18420" unitRef="usd">18567962</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage contextRef="c5" decimals="2" id="ixv-18421" unitRef="pure">1</iccc:RevenueSalesObligationPercentage>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-15058">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents our product sales disaggregated by major product category:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;First
    Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; &lt;span style="font-style: normal; font-weight: normal"&gt;product line&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,293,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,411,949&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    animal health&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;177,736&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;156,013&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    Product Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,471,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,567,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c187" decimals="0" id="ixv-18422" unitRef="usd">17293933</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c188"
      decimals="2"
      id="ixv-18423"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c189" decimals="0" id="ixv-18424" unitRef="usd">18411949</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c190"
      decimals="2"
      id="ixv-18425"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c191" decimals="0" id="ixv-18426" unitRef="usd">177736</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c192"
      decimals="2"
      id="ixv-18427"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c193" decimals="0" id="ixv-18428" unitRef="usd">156013</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c194"
      decimals="2"
      id="ixv-18429"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-18430" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c3" decimals="2" id="ixv-18431" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-18432" unitRef="usd">18567962</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c4" decimals="2" id="ixv-18433" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-15213">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;15. OTHER
EXPENSES, NET&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
(income) expenses net, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
    expense&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;475,598&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;348,536&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    (gain) on disposal of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,099&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(96,570&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(153,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance
    recovery&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(365,127&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income-other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(912&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,893&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest expense includes amortization of debt issuance and debt discount costs of $22,619 and $7,658 during the years ended December 31, 2023 or 2022, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#x2019;s policy related to an equipment malfunction.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-15221">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
(income) expenses net, consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
    expense&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;475,598&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;348,536&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    (gain) on disposal of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,099&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(96,570&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(153,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance
    recovery&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(365,127&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income-other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(912&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,893&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest expense includes amortization of debt issuance and debt discount costs of $22,619 and $7,658 during the years ended December 31, 2023 or 2022, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#x2019;s policy related to an equipment malfunction.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" id="ix_19_fact" unitRef="usd">475598</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" id="ix_20_fact" unitRef="usd">348536</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c0" decimals="0" id="ixv-18436" unitRef="usd">-8099</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c5" decimals="0" id="ixv-18437" unitRef="usd">7334</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:InterestIncomeOther contextRef="c0" decimals="0" id="ixv-18438" unitRef="usd">96570</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c5" decimals="0" id="ixv-18439" unitRef="usd">153100</us-gaap:InterestIncomeOther>
    <us-gaap:InsuranceRecoveries contextRef="c0" decimals="0" id="ix_21_fact" unitRef="usd">365127</us-gaap:InsuranceRecoveries>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" id="ixv-18441" unitRef="usd">107</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c5" decimals="0" id="ixv-18442" unitRef="usd">912</us-gaap:OtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-18443" unitRef="usd">-21893</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-18444" unitRef="usd">-187190</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="0" id="ixv-18445" unitRef="usd">22619</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c5" decimals="0" id="ixv-18446" unitRef="usd">7658</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-15414">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;16.
INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Our
income tax expense aggregated $4,627 and $7,672 (amounting to less than 1% of our loss before income taxes) during the years ended December
31, 2023 and 2022, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $17,759,519 of which $16,047,612
do not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards
of $4,681,644 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit
carryforwards of $726,474 that expire in 2027 through 2042 (if not utilized before then) and state tax credit carryforwards of $775,473
that expire in 2024 through 2042 (if not utilized before then).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach,
deferred taxes represent the estimated future tax effects of temporary differences between book and tax treatment of assets and liabilities
and carryforwards to the extent they are realizable. During the second quarter of 2018, we assessed our historical and near-term future
profitability and recorded $563,252 in non-cash income tax expense to create a full valuation allowance against our net deferred tax
assets (which consist largely of net operating loss carryforwards and federal and state credits) based on applicable accounting standards
and practices. At that time, we had incurred a net loss for six consecutive quarters, had not been profitable on a year-to-date basis
since the nine-month period ended September 30, 2017 and projected additional net losses for some period going forward before returning
to profitability. Should future profitability be realized at an adequate level, we would be able to release this valuation allowance
(resulting in a non-cash income tax benefit) and realize these deferred tax assets before they expire. We will continue to assess the
need for the valuation allowance at each quarter and, in the event that actual results differ from these estimates, or we adjust these
estimates in future periods, we may need to adjust our valuation allowance. Currently, we adjust the valuation allowance at the end of
each quarter to reduce the value of our deferred tax assets to zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue
Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of
net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
file income tax returns in the U.S. federal jurisdiction and several state jurisdictions. We currently have no tax examinations in progress.
We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits
for any of the periods in the accompanying audited financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
income tax provision consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 11.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current
    subtotal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,179,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(576,780&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(145,802&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(88,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    subtotal, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,325,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(665,313&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;665,313&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    subtotal, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
actual income tax expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before
income taxes during the years ended December 31, 2023 and 2022 respectively, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computed
    expected income tax expense rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,211,694&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;522,088&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    income taxes, net of federal expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(117,149&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(47,643&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,214&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,652&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax
    credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53,241&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(131,361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;665,313&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,221&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,799&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.27&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense/rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
significant components of our deferred tax assets, net, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,121,940&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,530,472&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal
    general business tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;726,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;673,233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal
    net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,729,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,258,395&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    tax credits and net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;886,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;817,617&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#xa7;174
    R &amp;amp; D expenditures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;592,915&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341,683&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,722&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,370&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37,124&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,587&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;UNICAP&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Incentive
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,554&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,034,030&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,708,754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18447" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18448" unitRef="usd">7672</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="c0" decimals="2" id="ixv-18449" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c195" decimals="0" id="ixv-18450" unitRef="usd">17759519</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c195" decimals="0" id="ixv-18451" unitRef="usd">16047612</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c195" decimals="0" id="ixv-18452" unitRef="usd">1711907</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c196" id="ixv-18453">expire in 2034 through 2037</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c197" decimals="0" id="ixv-18454" unitRef="usd">4681644</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c198" id="ixv-18455">expire in 2037 through 2038</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c199" decimals="0" id="ixv-18456" unitRef="usd">726474</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c200" id="ixv-18457">expire in 2027 through 2042</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c201" decimals="0" id="ixv-18458" unitRef="usd">775473</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c202" id="ixv-18459">expire in 2024 through 2042</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:OtherNoncashIncomeTaxExpense contextRef="c203" decimals="0" id="ixv-18460" unitRef="usd">563252</us-gaap:OtherNoncashIncomeTaxExpense>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="0" id="ixv-18461" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-15438">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
income tax provision consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended&lt;br/&gt;
 December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 11.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current
    subtotal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,179,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(576,780&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(145,802&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(88,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    subtotal, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,325,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(665,313&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;665,313&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    subtotal, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18462" unitRef="usd">4627</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18463" unitRef="usd">7672</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18464" unitRef="usd">4627</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18465" unitRef="usd">7672</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18466" unitRef="usd">1179474</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18467" unitRef="usd">576780</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18468" unitRef="usd">145802</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18469" unitRef="usd">88533</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18470" unitRef="usd">1325276</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18471" unitRef="usd">665313</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18472" unitRef="usd">1325276</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18473" unitRef="usd">665313</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18474" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18475" unitRef="usd">7672</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-15677">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
actual income tax expense differs from the expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before
income taxes during the years ended December 31, 2023 and 2022 respectively, as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computed
    expected income tax expense rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,211,694&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;522,088&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    income taxes, net of federal expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(117,149&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(47,643&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,214&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,652&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax
    credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53,241&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(131,361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,325,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;665,313&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,221&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,799&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.27&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
    tax expense/rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,672&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-18476" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="2" id="ixv-18477" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" id="ixv-18478" unitRef="usd">-1211694</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome contextRef="c0" decimals="4" id="ixv-18479" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="0" id="ixv-18480" unitRef="usd">-522088</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome contextRef="c5" decimals="4" id="ixv-18481" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="0" id="ixv-18482" unitRef="usd">-117149</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="4" id="ixv-18483" unitRef="pure">-0.0203</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="0" id="ixv-18484" unitRef="usd">-47643</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="4" id="ixv-18485" unitRef="pure">-0.0192</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c0" decimals="0" id="ixv-18486" unitRef="usd">56214</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c0" decimals="4" id="ixv-18487" unitRef="pure">0.0097</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c5" decimals="0" id="ixv-18488" unitRef="usd">36652</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c5" decimals="4" id="ixv-18489" unitRef="pure">0.0148</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c0" decimals="0" id="ixv-18490" unitRef="usd">53241</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c0" decimals="4" id="ixv-18491" unitRef="pure">0.0092</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c5" decimals="0" id="ixv-18492" unitRef="usd">131361</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c5" decimals="4" id="ixv-18493" unitRef="pure">0.0528</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-18494" unitRef="usd">1325276</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="4" id="ixv-18495" unitRef="pure">0.0009</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-18496" unitRef="usd">665313</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="4" id="ixv-18497" unitRef="pure">0.2676</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="0" id="ixv-18498" unitRef="usd">5221</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c0" decimals="4" id="ixv-18499" unitRef="pure">0.2297</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c5" decimals="0" id="ixv-18500" unitRef="usd">6799</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c5" decimals="4" id="ixv-18501" unitRef="pure">0.0027</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-18502" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="4" id="ixv-18503" unitRef="pure">0.0008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-18504" unitRef="usd">7672</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c5" decimals="4" id="ixv-18505" unitRef="pure">0.0031</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-16006">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
significant components of our deferred tax assets, net, consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,121,940&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,530,472&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal
    general business tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;726,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;673,233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal
    net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,729,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,258,395&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State
    tax credits and net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;886,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;817,617&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#xa7;174
    R &amp;amp; D expenditures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;592,915&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341,683&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50,722&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23,370&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37,124&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,587&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;UNICAP&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Incentive
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,200&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,554&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,034,030&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,708,754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-18506" unitRef="usd">2121940</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c4" decimals="0" id="ixv-18507" unitRef="usd">2530472</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c3" decimals="0" id="ixv-18508" unitRef="usd">726474</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c4" decimals="0" id="ixv-18509" unitRef="usd">673233</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-18510" unitRef="usd">3729500</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-18511" unitRef="usd">3258395</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c3" decimals="0" id="ixv-18512" unitRef="usd">886428</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c4" decimals="0" id="ixv-18513" unitRef="usd">817617</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="c3" decimals="0" id="ixv-18514" unitRef="usd">592915</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="c4" decimals="0" id="ixv-18515" unitRef="usd">341683</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="0" id="ixv-18516" unitRef="usd">50722</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="0" id="ixv-18517" unitRef="usd">23370</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c3" decimals="0" id="ixv-18518" unitRef="usd">37124</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c4" decimals="0" id="ixv-18519" unitRef="usd">15587</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="0" id="ixv-18520" unitRef="usd">32607</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="0" id="ixv-18521" unitRef="usd">32787</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c3" decimals="0" id="ixv-18522" unitRef="usd">100200</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c4" decimals="0" id="ixv-18523" unitRef="usd">76554</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" id="ixv-18524" unitRef="usd">4034030</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" id="ixv-18525" unitRef="usd">2708754</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-16250">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;17. SEGMENT
INFORMATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Our
business operations (being the development, acquisition, manufacture and sale of products that improve the health and productivity of
dairy and beef cattle) are described in Note 1. Pursuant to Codification Topic 280, &lt;i&gt;Segment Reporting&lt;/i&gt;, we operate in the following
two reportable business segments: i) Scours and ii) Mastitis. The Scours segment consists of the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;
product line. The core technology underlying the Scours segment is derived around polyclonal antibodies. The Mastitis segment includes
our products, &lt;b&gt;CMT &lt;/b&gt;and &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;. &lt;b&gt;Re-Tain&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;is projected to be the driver of this segment
when approved for sale. The core technology underlying the Mastitis segment is derived around a bacteriocin called Nisin. The category
we define as &#x201c;Other&#x201d; includes unallocated administrative and overhead expenses and other products. The significant accounting
policies of these segments are described in Note 2. Product sales are the primary factor we use in determining our reportable segments.
The governing regulatory authority (USDA for &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; or FDA for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;) is also
a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating income
(loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated to each
segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating segment
is defined as the component of our business for which financial information is available and evaluated regularly by our chief operating
decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our President
and CEO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Scours&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mastitis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,293,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;177,736&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,471,669&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Costs
    of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,453,514&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;148,871&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,602,385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    margin&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,840,419&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,865&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,869,284&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,242,329&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,394,852&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales
    and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,447,137&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;641,078&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,088,215&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,295&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,295&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,458,240&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,883,407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,275,715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,617,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NET
    OPERATING INCOME (LOSS)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,382,179&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,854,542&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,275,715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,748,078&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Scours&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mastitis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,411,949&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;154,558&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,455&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,567,962&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Costs
    of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,754,189&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,647&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,919,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    margin&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,657,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(27,192&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,648,779&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,346&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,317,921&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;109,605&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,493,872&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales
    and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,871,926&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,318,107&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,190,033&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,263,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,263,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,938,272&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,636,028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,373,422&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,947,722&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NET
    OPERATING INCOME (LOSS)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,719,488&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,617,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,400,614&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,298,943&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Scours&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mastitis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    Assets as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,735,413&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,827,839&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,244,850&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,808,102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total Assets as
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,539,523&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,315,492&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,005,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,860,649&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    and amortization expense during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,365,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,032&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,739,620&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    and amortization expense during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169,011&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,263,318&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,495,241&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital
    Expenditures during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,096,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,694&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,892,513&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital
    Expenditures during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,513,336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,486&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,975,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-18526">we operate in the following
two reportable business segments:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Scours&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mastitis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,293,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;177,736&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,471,669&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Costs
    of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,453,514&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;148,871&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,602,385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    margin&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,840,419&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,865&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,869,284&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,242,329&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,394,852&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales
    and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,447,137&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;641,078&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,088,215&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,295&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,295&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,458,240&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,883,407&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,275,715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,617,362&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NET
    OPERATING INCOME (LOSS)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,382,179&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,854,542&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,275,715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,748,078&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Scours&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mastitis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,411,949&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;154,558&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,455&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,567,962&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Costs
    of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,754,189&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;136,347&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,647&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,919,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    margin&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,657,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(27,192&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,648,779&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,346&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,317,921&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;109,605&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,493,872&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales
    and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,871,926&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,318,107&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,190,033&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Administrative
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,263,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,263,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,938,272&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,636,028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,373,422&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,947,722&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NET
    OPERATING INCOME (LOSS)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,719,488&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,617,817&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,400,614&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,298,943&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Scours&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Mastitis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    Assets as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,735,413&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,827,839&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,244,850&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;43,808,102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total Assets as
    of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,539,523&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,315,492&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,005,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,860,649&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    and amortization expense during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,365,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,600&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;86,032&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,739,620&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
    and amortization expense during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169,011&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,263,318&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;62,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,495,241&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital
    Expenditures during the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,096,819&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;795,694&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,892,513&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital
    Expenditures during the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,513,336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,486&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,975,274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c204" decimals="0" id="ixv-18527" unitRef="usd">17293933</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c205" decimals="0" id="ixv-18528" unitRef="usd">177736</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="0" id="ixv-18529" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c204" decimals="0" id="ixv-18530" unitRef="usd">13453514</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c205" decimals="0" id="ixv-18531" unitRef="usd">148871</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-18532" unitRef="usd">13602385</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c204" decimals="0" id="ixv-18533" unitRef="usd">3840419</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c205" decimals="0" id="ixv-18534" unitRef="usd">28865</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-18535" unitRef="usd">3869284</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c204" decimals="0" id="ixv-18536" unitRef="usd">11103</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c205" decimals="0" id="ixv-18537" unitRef="usd">4242329</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c206" decimals="0" id="ixv-18538" unitRef="usd">141420</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-18539" unitRef="usd">4394852</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c204" decimals="0" id="ixv-18540" unitRef="usd">2447137</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c205" decimals="0" id="ixv-18541" unitRef="usd">641078</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-18542" unitRef="usd">3088215</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c206" decimals="0" id="ixv-18543" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-18544" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c204" decimals="0" id="ixv-18545" unitRef="usd">2458240</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c205" decimals="0" id="ixv-18546" unitRef="usd">4883407</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c206" decimals="0" id="ixv-18547" unitRef="usd">2275715</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-18548" unitRef="usd">9617362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c204" decimals="0" id="ixv-18549" unitRef="usd">1382179</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c205" decimals="0" id="ixv-18550" unitRef="usd">-4854542</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c206" decimals="0" id="ixv-18551" unitRef="usd">-2275715</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-18552" unitRef="usd">-5748078</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c207" decimals="0" id="ixv-18553" unitRef="usd">18411949</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c208" decimals="0" id="ixv-18554" unitRef="usd">154558</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c209" decimals="0" id="ixv-18555" unitRef="usd">1455</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c5" decimals="0" id="ixv-18556" unitRef="usd">18567962</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c207" decimals="0" id="ixv-18557" unitRef="usd">10754189</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c208" decimals="0" id="ixv-18558" unitRef="usd">136347</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c209" decimals="0" id="ixv-18559" unitRef="usd">28647</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" id="ixv-18560" unitRef="usd">10919183</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c207" decimals="0" id="ixv-18561" unitRef="usd">7657760</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c208" decimals="0" id="ixv-18562" unitRef="usd">18211</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c209" decimals="0" id="ixv-18563" unitRef="usd">-27192</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-18564" unitRef="usd">7648779</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c207" decimals="0" id="ixv-18565" unitRef="usd">66346</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c208" decimals="0" id="ixv-18566" unitRef="usd">4317921</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c209" decimals="0" id="ixv-18567" unitRef="usd">109605</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-18568" unitRef="usd">4493872</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c207" decimals="0" id="ixv-18569" unitRef="usd">1871926</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c208" decimals="0" id="ixv-18570" unitRef="usd">1318107</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="0" id="ixv-18571" unitRef="usd">3190033</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c209" decimals="0" id="ixv-18572" unitRef="usd">2263817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-18573" unitRef="usd">2263817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c207" decimals="0" id="ixv-18574" unitRef="usd">1938272</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c208" decimals="0" id="ixv-18575" unitRef="usd">5636028</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c209" decimals="0" id="ixv-18576" unitRef="usd">2373422</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-18577" unitRef="usd">9947722</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c207" decimals="0" id="ixv-18578" unitRef="usd">5719488</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c208" decimals="0" id="ixv-18579" unitRef="usd">-5617817</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c209" decimals="0" id="ixv-18580" unitRef="usd">-2400614</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-18581" unitRef="usd">-2298943</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets contextRef="c210" decimals="0" id="ixv-18582" unitRef="usd">24735413</us-gaap:Assets>
    <us-gaap:Assets contextRef="c211" decimals="0" id="ixv-18583" unitRef="usd">17827839</us-gaap:Assets>
    <us-gaap:Assets contextRef="c212" decimals="0" id="ixv-18584" unitRef="usd">1244850</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-18585" unitRef="usd">43808102</us-gaap:Assets>
    <us-gaap:Assets contextRef="c213" decimals="0" id="ixv-18586" unitRef="usd">20539523</us-gaap:Assets>
    <us-gaap:Assets contextRef="c214" decimals="0" id="ixv-18587" unitRef="usd">18315492</us-gaap:Assets>
    <us-gaap:Assets contextRef="c215" decimals="0" id="ixv-18588" unitRef="usd">6005634</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-18589" unitRef="usd">44860649</us-gaap:Assets>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c204" decimals="0" id="ixv-18590" unitRef="usd">1365988</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c205" decimals="0" id="ixv-18591" unitRef="usd">1287600</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c206" decimals="0" id="ixv-18592" unitRef="usd">86032</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c0" decimals="0" id="ixv-18593" unitRef="usd">2739620</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c207" decimals="0" id="ixv-18594" unitRef="usd">1169011</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c208" decimals="0" id="ixv-18595" unitRef="usd">1263318</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c209" decimals="0" id="ixv-18596" unitRef="usd">62912</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c5" decimals="0" id="ixv-18597" unitRef="usd">2495241</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c204" decimals="0" id="ixv-18598" unitRef="usd">1096819</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c205" decimals="0" id="ixv-18599" unitRef="usd">795694</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c0" decimals="0" id="ixv-18600" unitRef="usd">1892513</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c207" decimals="0" id="ixv-18601" unitRef="usd">3513336</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c208" decimals="0" id="ixv-18602" unitRef="usd">414486</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c209" decimals="0" id="ixv-18603" unitRef="usd">47452</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c5" decimals="0" id="ixv-18604" unitRef="usd">3975274</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-17326">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;18. RELATED
PARTY TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the &lt;b&gt;First
Defense&lt;sup&gt;&#xae;&lt;/sup&gt; &lt;/b&gt;product line and &lt;b&gt;CMT&lt;/b&gt;). His affiliated company purchased $231,405 and $587,677 of products from us
during the years ended December 2023 and 2022, respectively, all on terms consistent with those offered to other distributors of similar
status. Our accounts receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $42,507
and $46,426 as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c0" decimals="0" id="ixv-18605" unitRef="usd">231405</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c5" decimals="0" id="ixv-18606" unitRef="usd">587677</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTaxExpenseDueFromAffiliatesCurrent contextRef="c0" decimals="0" id="ixv-18607" unitRef="usd">42507</us-gaap:RelatedPartyTaxExpenseDueFromAffiliatesCurrent>
    <us-gaap:RelatedPartyTaxExpenseDueFromAffiliatesCurrent contextRef="c5" decimals="0" id="ixv-18608" unitRef="usd">46426</us-gaap:RelatedPartyTaxExpenseDueFromAffiliatesCurrent>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-17342">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;19. EMPLOYEE
BENEFITS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate.
Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. We currently match 100% of the first 3%
of each employee&#x2019;s salary that is contributed to the Plan and 50% of the next 2% of each employee&#x2019;s salary that is contributed
to the Plan. Under this matching plan, we paid $178,150 and $159,058 into the Plan for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <iccc:EmployeesSalaryPercentage contextRef="c0" decimals="2" id="ixv-18609" unitRef="pure">1</iccc:EmployeesSalaryPercentage>
    <iccc:EmployeesSalaryPercentage
      contextRef="c216"
      decimals="2"
      id="ixv-18610"
      unitRef="pure">0.03</iccc:EmployeesSalaryPercentage>
    <iccc:EmployeesSalaryContributionPercentage contextRef="c0" decimals="2" id="ixv-18611" unitRef="pure">0.50</iccc:EmployeesSalaryContributionPercentage>
    <iccc:EmployeesSalaryContributionPercentage
      contextRef="c217"
      decimals="2"
      id="ixv-18612"
      unitRef="pure">0.02</iccc:EmployeesSalaryContributionPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c0" decimals="0" id="ixv-18613" unitRef="usd">178150</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c5" decimals="0" id="ixv-18614" unitRef="usd">159058</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-17355">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;20. SUBSEQUENT
EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
have evaluated subsequent events through the time of filing on the date we have issued this Annual Report on Form 10-K. As of the time
of filing, there were no material, reportable subsequent events.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c11"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c11"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c14"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c20"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c19"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c21"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c19"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c21"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c22"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c5"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c5"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="c5"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:PaymentsOfDebtDiscounts
      contextRef="c5"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="c5"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c33"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c34"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c32"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c34"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c36"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c37"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c35"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c37"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c48"
      id="hidden-fact-31"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c0"
      id="hidden-fact-32"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c5"
      id="hidden-fact-33"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c0"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c5"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c5"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c3"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c4"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c3"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c4"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c64" id="hidden-fact-42" xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c66" id="hidden-fact-43" xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c104"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c106"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c107"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c108"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c109"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c110"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c111"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c112"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c113"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c113"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c115"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c115"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c117"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c117"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c119"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c119"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c120"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c120"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c121"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c121"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c122"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c123"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c123"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c123"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c124"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c124"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c124"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2026
      contextRef="c3"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2027
      contextRef="c3"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCostThereafter
      contextRef="c3"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent
      contextRef="c127"
      decimals="0"
      id="hidden-fact-74"
      unitRef="usd">10000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c172"
      id="hidden-fact-75"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c173"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c176"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c177"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c178"
      id="hidden-fact-79"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:InsuranceRecoveries
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c206"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c206"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c206"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c206"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c204"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c205"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c209"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c207"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c208"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c206"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-18714">false</dei:AmendmentFlag>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-18715">true</dei:DocumentAnnualReport>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-18716">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-18717">false</dei:DocumentTransitionReport>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-18718">0000811641</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-31"
          xlink:label="hidden-fact-31"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-weight: normal">This amount is less than 10%.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-31"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Intrinsic value is the difference between the fair market value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise price).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Terminations and forfeitures are recognized when they occur.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected option term.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The dividend yield and expected volatility are derived from averages of our historical data.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The expected life is calculated utilizing the simplified method, which uses the mid-point between the vesting period and the contractual term as the expected life.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Interest expense includes amortization of debt issuance and debt discount costs of $22,619 and $7,658 during the years ended December 31, 2023 or 2022, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-80"
          xlink:label="hidden-fact-80"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The insurance recovery income resulted from insurance benefit proceeds paid to us under our business interruption policy related to the product contamination losses and a recovery from a vendor&#x2019;s policy related to an equipment malfunction.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-80"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
